assay_type,assay_organism,assay_tax_id,variant_id,assay_cell_type,src_id,curated_by,assay_subcellular_fraction,doc_id,assay_strain,relationship_type,assay_id,confidence_score,cell_id,assay_category,tid,assay_tissue,tissue_id,assay_test_type,bao_format,chembl_id,src_assay_id,description
B,,,,,1,Autocuration,,11087,,H,1,8,,,12052,,,,BAO_0000019,CHEMBL615117,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM
F,,,,,1,Autocuration,,684,,U,2,0,,,22226,,,,BAO_0000219,CHEMBL615118,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells
B,,,,,1,Autocuration,,15453,,U,3,0,,,22226,,,,BAO_0000019,CHEMBL615119,,
B,Bos taurus,9913.0,,,1,Autocuration,,17841,,H,4,4,,,104729,,,,BAO_0000249,CHEMBL615120,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680
F,Homo sapiens,9606.0,,143B,1,Intermediate,,17430,,N,5,1,163.0,,80001,,,,BAO_0000219,CHEMBL615121,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
F,Homo sapiens,9606.0,,143B,1,Intermediate,,17430,,N,6,1,163.0,,80001,,,,BAO_0000219,CHEMBL615122,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
F,Mus musculus,10090.0,,143B,1,Intermediate,,13799,,N,7,1,163.0,,80001,,,,BAO_0000219,CHEMBL615123,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
F,Homo sapiens,9606.0,,143B,1,Expert,,17774,,N,8,1,163.0,,80001,,,,BAO_0000219,CHEMBL615124,,In vitro cell cytotoxicity was determined against 143B cell line
F,Homo sapiens,9606.0,,143B,1,Intermediate,,3801,,N,9,1,163.0,,80001,,,,BAO_0000219,CHEMBL615125,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound
F,Homo sapiens,9606.0,,143B,1,Intermediate,,17430,,N,10,1,163.0,,80001,,,,BAO_0000219,CHEMBL615126,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
F,Homo sapiens,9606.0,,143B,1,Intermediate,,17430,,N,11,1,163.0,,80001,,,,BAO_0000219,CHEMBL615127,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
F,Homo sapiens,9606.0,,143B,1,Expert,,17774,,N,12,1,163.0,,80001,,,,BAO_0000219,CHEMBL615128,,In vitro cell cytotoxicity was determined against 143B-LTK cell line
F,Staphylococcus aureus,1280.0,,,1,Intermediate,,11324,,N,13,1,,,50185,,,,BAO_0000218,CHEMBL857900,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
F,Staphylococcus aureus,1280.0,,,1,Intermediate,,11324,,N,14,1,,,50185,,,,BAO_0000218,CHEMBL615129,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
F,Staphylococcus aureus,1280.0,,,1,Intermediate,,11324,,N,15,1,,,50185,,,,BAO_0000218,CHEMBL615130,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
F,Staphylococcus aureus,1280.0,,,1,Intermediate,,11324,,N,16,1,,,50185,,,,BAO_0000218,CHEMBL615131,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
A,Rattus norvegicus,10116.0,,,1,Expert,,11347,,D,17,9,,,100122,,,,BAO_0000357,CHEMBL884521,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
B,,,,,1,Autocuration,,16474,,H,18,8,,,12054,,,,BAO_0000357,CHEMBL615132,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO)
B,,,,,1,Autocuration,,10091,,H,19,8,,,12054,,,,BAO_0000019,CHEMBL615133,,Inhibition of partially purified 15-lipoxygenase from human leukocytes
B,,,,,1,Autocuration,,16474,,H,20,8,,,12054,,,,BAO_0000357,CHEMBL615134,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
B,,,,,1,Autocuration,,16474,,H,21,8,,,12054,,,,BAO_0000357,CHEMBL615135,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO)
B,,,,,1,Autocuration,,16474,,H,22,8,,,12054,,,,BAO_0000357,CHEMBL615136,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
B,,,,,1,Autocuration,,16474,,H,23,8,,,12054,,,,BAO_0000357,CHEMBL615137,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
B,,,,,1,Autocuration,,16474,,H,24,8,,,12054,,,,BAO_0000357,CHEMBL615138,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
B,,,,,1,Autocuration,,14352,,U,25,0,,,22226,,,,BAO_0000219,CHEMBL836324,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M."
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5646,,H,26,8,,,12054,,,,BAO_0000357,CHEMBL615139,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5646,,H,27,8,,,12054,,,,BAO_0000357,CHEMBL615140,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM)
B,,,,,1,Autocuration,,10997,,H,28,8,,,12426,,,,BAO_0000219,CHEMBL615141,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes
B,soya bean,3847.0,,,1,Autocuration,,6309,,H,29,8,,,12054,,,,BAO_0000357,CHEMBL615142,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean
B,Glycine max,3847.0,,,1,Autocuration,,167,,H,30,8,,,12054,,,,BAO_0000357,CHEMBL615143,,Inhibitory activity against soybean 15-lipoxygenase was evaluated
B,Glycine max,3847.0,,,1,Autocuration,,167,,H,31,8,,,12054,,,,BAO_0000357,CHEMBL615144,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM
B,Glycine max,3847.0,,,1,Autocuration,,11087,,H,32,8,,,12054,,,,BAO_0000357,CHEMBL872867,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM
B,Glycine max,3847.0,,,1,Autocuration,,11087,,H,33,8,,,12054,,,,BAO_0000357,CHEMBL615145,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM
B,Glycine max,3847.0,,,1,Autocuration,,13622,,H,34,8,,,12054,,,,BAO_0000357,CHEMBL615146,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean
B,Glycine max,3847.0,,,1,Autocuration,,13622,,H,35,8,,,12054,,,,BAO_0000357,CHEMBL615147,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean
A,Rattus norvegicus,10116.0,,,1,Autocuration,,11347,,U,36,0,,,22226,,,,BAO_0000019,CHEMBL615148,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase
B,Escherichia coli,562.0,,,1,Autocuration,,5926,,U,37,0,,,22226,,,,BAO_0000019,CHEMBL615149,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay
B,,,,,1,Autocuration,,4567,,U,38,0,,,22226,,,,BAO_0000019,CHEMBL615150,,Dissociation constant with dimeric 16S rRNA RNA construct B
B,,,,,1,Intermediate,,3782,,M,39,3,,,22222,,,,BAO_0000225,CHEMBL615151,,Dissociation constant towards 16S rRNA construct A
B,,,,,1,Intermediate,,3782,,M,40,3,,,22222,,,,BAO_0000225,CHEMBL615152,,Dissociation constant towards 16S rRNA construct B
B,Escherichia coli,562.0,,,1,Expert,,4466,,M,41,3,,,100263,,,,BAO_0000225,CHEMBL615153,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli
B,Escherichia coli,562.0,,,1,Expert,,6592,,M,42,3,,,100263,,,,BAO_0000225,CHEMBL615154,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli
B,,,,,1,Autocuration,,898,,H,43,8,,,13053,,,,BAO_0000019,CHEMBL615155,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
B,,,,,1,Autocuration,,898,,H,44,8,,,13053,,,,BAO_0000019,CHEMBL615156,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
B,Homo sapiens,9606.0,,,1,Autocuration,,13163,,H,45,8,,,20001,,,,BAO_0000019,CHEMBL615157,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
B,Homo sapiens,9606.0,,,1,Autocuration,,13163,,H,46,8,,,20001,,,,BAO_0000019,CHEMBL615158,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
B,Rattus norvegicus,10116.0,,,1,Expert,,10691,,D,47,9,,,12971,,,,BAO_0000019,CHEMBL615159,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
B,Rattus norvegicus,10116.0,,,1,Expert,,10691,,D,48,9,,,12971,,,,BAO_0000019,CHEMBL615172,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
B,Rattus norvegicus,10116.0,,,1,Expert,,10691,,D,49,9,,,12971,,,,BAO_0000019,CHEMBL615173,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
B,Rattus norvegicus,10116.0,,,1,Expert,,10691,,D,50,9,,,12971,,,,BAO_0000019,CHEMBL615174,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
B,,,,,1,Autocuration,,898,,H,51,8,,,13053,,,,BAO_0000019,CHEMBL884518,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
B,,,,,1,Autocuration,,912,,H,52,8,,,11512,,,,BAO_0000357,CHEMBL615175,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1)
B,,,,,1,Autocuration,,912,,H,53,8,,,11512,,,,BAO_0000357,CHEMBL615176,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration
B,,,,,1,Autocuration,,912,,H,54,8,,,11512,,,,BAO_0000357,CHEMBL615177,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration
B,Rattus norvegicus,10116.0,,,1,Autocuration,Membranes,15103,,D,55,5,,,104740,,,,BAO_0000249,CHEMBL615178,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,5116,,N,56,1,506.0,,80002,,,,BAO_0000219,CHEMBL615179,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined
F,Rattus norvegicus,10116.0,,Oocytes,1,Autocuration,,14578,,D,57,7,,,104835,,,,BAO_0000219,CHEMBL615180,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype
F,Rattus norvegicus,10116.0,,Oocytes,1,Autocuration,,14578,,D,58,7,,,104821,,,,BAO_0000219,CHEMBL615181,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor
F,Rattus norvegicus,10116.0,,Oocytes,1,Autocuration,,14578,,D,59,7,,,104848,,,,BAO_0000219,CHEMBL615182,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor
F,Homo sapiens,9606.0,,1A9,1,Expert,,4787,,N,60,1,506.0,,80002,,,,BAO_0000219,CHEMBL615183,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,4787,,N,61,1,506.0,,80002,,,,BAO_0000219,CHEMBL615184,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,3547,,N,62,1,506.0,,80002,,,,BAO_0000219,CHEMBL615185,,Cytotoxic activity against human ovarian cancer (1A9) cell line
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,3547,,N,63,1,506.0,,80002,,,,BAO_0000219,CHEMBL615186,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,6726,,N,64,1,506.0,,80002,,,,BAO_0000219,CHEMBL615187,,Effective dose of compound against replication of 1A9 cell line was evaluated
F,Homo sapiens,9606.0,,1A9,1,Expert,,3455,,N,65,1,506.0,,80002,,,,BAO_0000219,CHEMBL885343,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,5726,,N,66,1,506.0,,80002,,,,BAO_0000219,CHEMBL615188,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line)
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,5726,,N,67,1,506.0,,80002,,,,BAO_0000219,CHEMBL615189,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,5726,,N,68,1,506.0,,80002,,,,BAO_0000219,CHEMBL615190,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,3395,,N,69,1,506.0,,80002,,,,BAO_0000219,CHEMBL615191,,Inhibitory activity against Taxol resistant 1A9 cell lines
F,Homo sapiens,9606.0,,1A9,1,Expert,,3415,,N,70,1,506.0,,80002,,,,BAO_0000219,CHEMBL615192,,Cytotoxicity against human ovarian cancer (1A9) cell lines.
F,Homo sapiens,9606.0,,1A9,1,Expert,,3415,,N,71,1,506.0,,80002,,,,BAO_0000219,CHEMBL827083,,Percentage inhibition of human ovarian cancer (1A9) cell lines.
F,Homo sapiens,9606.0,,1A9,1,Expert,,17099,,N,72,1,506.0,,80002,,,,BAO_0000219,CHEMBL615193,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,17099,,N,73,1,506.0,,80002,,,,BAO_0000219,CHEMBL615194,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,17099,,N,74,1,506.0,,80002,,,,BAO_0000219,CHEMBL615195,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL
F,Homo sapiens,9606.0,,1A9,1,Intermediate,,17099,,N,75,1,506.0,,80002,,,,BAO_0000219,CHEMBL615196,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL
F,Homo sapiens,9606.0,,Jurkat,1,Intermediate,,17721,,N,76,1,503.0,,81072,,,,BAO_0000219,CHEMBL615197,,Inhibitory concentration against Jurkat cells
F,,,,,1,Intermediate,,1229,,U,77,0,,,22226,,,,BAO_0000019,CHEMBL615198,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive
A,Rattus norvegicus,10116.0,,,1,Expert,,11347,,D,78,9,,,100121,,,,BAO_0000357,CHEMBL615199,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase
B,,,,,1,Expert,,17117,,H,79,8,,,11231,,,,BAO_0000357,CHEMBL615200,,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
B,,,,,1,Expert,,17117,,H,80,8,,,11231,,,,BAO_0000357,CHEMBL615201,,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
B,,,,,1,Expert,,17117,,H,81,8,,,11231,,,,BAO_0000357,CHEMBL615202,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM."
B,Candida albicans,5476.0,,,1,Autocuration,Microsomes,11375,,H,82,8,,,11231,,,,BAO_0000251,CHEMBL615203,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes"
B,Candida albicans,5476.0,,,1,Autocuration,Microsomes,11375,,H,83,8,,,11231,,,,BAO_0000251,CHEMBL615204,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes"
B,Saccharomyces cerevisiae,4932.0,,,1,Autocuration,Microsomes,11375,,H,84,8,,,11231,,,,BAO_0000251,CHEMBL615205,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes"
B,Saccharomyces cerevisiae,4932.0,,,1,Autocuration,Microsomes,11375,,H,85,8,,,11231,,,,BAO_0000251,CHEMBL615206,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes"
B,Sus scrofa,9823.0,,,1,Autocuration,Microsomes,11375,,H,86,8,,,12083,Liver,2107.0,,BAO_0000251,CHEMBL615207,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,791,,H,87,8,,,11231,,,,BAO_0000019,CHEMBL827084,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,791,,H,88,8,,,11231,,,,BAO_0000019,CHEMBL615208,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,791,,H,89,8,,,11231,,,,BAO_0000019,CHEMBL615209,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,11375,,D,90,9,,,12083,Liver,2107.0,,BAO_0000251,CHEMBL615210,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,11375,,D,91,9,,,12083,Liver,2107.0,,BAO_0000251,CHEMBL615211,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,153,,D,92,9,,,12083,Liver,2107.0,,BAO_0000251,CHEMBL615212,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
B,,,,,1,Expert,,8269,,H,93,8,,,11377,,,,BAO_0000357,CHEMBL615213,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease)
B,,,,,1,Expert,,8269,,H,94,8,,,11377,,,,BAO_0000357,CHEMBL615273,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex
F,Homo sapiens,9606.0,,HepG2,1,Expert,,17653,,N,95,1,726.0,,81020,,,,BAO_0000219,CHEMBL615274,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,14277,,N,96,1,726.0,,81020,,,,BAO_0000219,CHEMBL615275,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,1717,,N,97,1,726.0,,81020,,,,BAO_0000219,CHEMBL615276,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,14091,,N,98,1,726.0,,81020,,,,BAO_0000219,CHEMBL615277,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,14091,,N,99,1,726.0,,81020,,,,BAO_0000219,CHEMBL615326,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined
F,Hepatitis B virus,10407.0,,,1,Expert,,17653,,N,100,1,,,50606,,,,BAO_0000218,CHEMBL883130,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,13105,,N,101,1,726.0,,81020,,,,BAO_0000219,CHEMBL884519,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,1717,,N,102,1,726.0,,81020,,,,BAO_0000219,CHEMBL615327,,Concentration required to inhibit 50% of 2.2.15 cell line
A,Homo sapiens,9606.0,,HepG2,1,Intermediate,,13105,,N,103,1,726.0,,81020,,,,BAO_0000219,CHEMBL615328,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,13600,,N,104,1,,,50587,,,,BAO_0000218,CHEMBL615329,,Cytotoxic activity of compound against uninfected 2.2.15 cells.
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,13467,,N,105,1,,,50587,,,,BAO_0000218,CHEMBL615330,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.
F,Hepatitis B virus,10407.0,,2.2.15,1,Expert,,17477,,N,106,1,,,50606,,,,BAO_0000218,CHEMBL615331,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay"
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,1593,,N,107,1,,,50587,,,,BAO_0000218,CHEMBL615332,,In vitro anti-HBV activity in 2.2.15 cells
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,1593,,N,108,1,,,50587,,,,BAO_0000218,CHEMBL615333,,In vitro anti-HBV activity in 2.2.15 cells; Not determined
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,15089,,N,109,1,,,50587,,,,BAO_0000218,CHEMBL615334,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,15089,,N,110,1,,,50587,,,,BAO_0000218,CHEMBL615335,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,1593,,N,111,1,,,50587,,,,BAO_0000218,CHEMBL615336,,Cytotoxicity in 2.2.15 cells
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,1593,,N,112,1,,,50587,,,,BAO_0000218,CHEMBL615337,,Cytotoxicity in 2.2.15 cells; Not determined
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,13600,,N,113,1,,,50587,,,,BAO_0000218,CHEMBL615338,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,13467,,N,114,1,,,50587,,,,BAO_0000218,CHEMBL615339,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.
F,Homo sapiens,9606.0,,2.2.15,1,Intermediate,,13467,,N,115,1,,,50587,,,,BAO_0000218,CHEMBL615340,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,14764,,N,116,1,726.0,,81020,,,,BAO_0000219,CHEMBL615341,,Antiviral activity against HBV was determined in 2.215 cell line
B,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6531,,U,117,0,,,22226,,,,BAO_0000251,CHEMBL615342,,Inhibition of 20-HETE synthesis in human renal microsomes
B,,,,,1,Autocuration,,17322,,U,118,0,,,22226,,,,BAO_0000019,CHEMBL615343,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.
F,Homo sapiens,9606.0,,2008,1,Intermediate,,17072,,N,119,1,388.0,,80612,,,,BAO_0000219,CHEMBL615344,,Inhibitory concentration against 2008 (ovarian) cells
F,Homo sapiens,9606.0,,2008,1,Intermediate,,16936,,N,120,1,388.0,,80612,,,,BAO_0000219,CHEMBL615345,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.
F,Homo sapiens,9606.0,,2008,1,Intermediate,,16936,,N,121,1,388.0,,80612,,,,BAO_0000219,CHEMBL615346,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008)
F,Homo sapiens,9606.0,,2008,1,Intermediate,,17146,,N,122,1,388.0,,80612,,,,BAO_0000219,CHEMBL615347,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells
F,Homo sapiens,9606.0,,2008,1,Intermediate,,17146,,N,123,1,388.0,,80612,,,,BAO_0000219,CHEMBL615348,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected
F,Homo sapiens,9606.0,,2008/R,1,Intermediate,,10797,,N,124,1,561.0,,80613,,,,BAO_0000219,CHEMBL827085,,In vitro inhibition of 2008/R ovarian cancer cell line
F,Homo sapiens,9606.0,,2008/R,1,Intermediate,,10797,,N,125,1,561.0,,80613,,,,BAO_0000219,CHEMBL615349,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable
F,Homo sapiens,9606.0,,2008/S,1,Intermediate,,10797,,N,126,1,389.0,,80614,,,,BAO_0000219,CHEMBL615350,,In vitro inhibition of 2008/S ovarian cancer cell line
F,Homo sapiens,9606.0,,2008/S,1,Intermediate,,10797,,N,127,1,389.0,,80614,,,,BAO_0000219,CHEMBL615351,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable
B,Homo sapiens,9606.0,,,1,Expert,,4823,,S,128,2,,,100256,,,,BAO_0000220,CHEMBL615352,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome
B,Homo sapiens,9606.0,,,1,Intermediate,,12912,,S,129,2,,,100256,,,,BAO_0000220,CHEMBL615353,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain
B,,,,,1,Expert,,2957,,S,130,2,,,100256,,,,BAO_0000220,CHEMBL615354,,Inhibition of chymotrypsin-like activity of 20S proteasome
B,,,,,1,Expert,,2957,,S,131,2,,,100256,,,,BAO_0000220,CHEMBL615355,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM
B,,,,,1,Intermediate,,3260,,S,132,2,,,100256,,,,BAO_0000220,CHEMBL615356,,Inhibitory activity against 20S proteosome
B,Homo sapiens,9606.0,,,1,Autocuration,,3451,,U,133,0,,,22226,,,,BAO_0000019,CHEMBL615357,,Compound was tested for inhibitory activity against tryptase
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,13885,,N,134,1,726.0,,81020,,,,BAO_0000219,CHEMBL615358,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
F,Homo sapiens,9606.0,,HepG2,1,Intermediate,,13885,,N,135,1,726.0,,81020,,,,BAO_0000219,CHEMBL827086,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
B,,,,,1,Autocuration,,3676,,U,136,0,,,22226,,,,BAO_0000019,CHEMBL615359,,Compound was tested for the inhibition of Alpha-glucosidase
B,,,,,1,Autocuration,,6043,,H,137,8,,,235,,,,BAO_0000357,CHEMBL615360,,Inhibitory concentration against human neutrophil elastase (HNE)
F,Rattus norvegicus,10116.0,,,1,Autocuration,,11140,,U,138,0,,,22226,Heart,948.0,,BAO_0000218,CHEMBL615361,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat
F,,,,,1,Autocuration,,10543,,H,139,8,,,19640,,,,BAO_0000019,CHEMBL615362,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
F,,,,,1,Expert,,10543,,H,140,8,,,19640,,,,BAO_0000019,CHEMBL615363,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
B,,,,,1,Autocuration,,10543,,H,141,8,,,19640,,,,BAO_0000357,CHEMBL615364,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
F,,,,,1,Expert,,10543,,H,142,8,,,19640,,,,BAO_0000019,CHEMBL615365,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
F,Mus musculus,10090.0,,P338,1,Intermediate,,11365,,N,143,1,524.0,,80360,,,,BAO_0000219,CHEMBL615366,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines
F,Mus musculus,10090.0,,P338,1,Intermediate,,11365,,N,144,1,524.0,,80360,,,,BAO_0000219,CHEMBL615367,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines
F,Homo sapiens,9606.0,,PBL,1,Intermediate,,11803,,N,145,1,554.0,,80384,,,,BAO_0000219,CHEMBL615368,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).
F,Ovis aries,9940.0,,,1,Autocuration,,11803,,U,146,0,,,22226,,,,BAO_0000019,CHEMBL615369,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells
F,Ovis aries,9940.0,,,1,Autocuration,,11803,,U,147,0,,,22226,,,,BAO_0000019,CHEMBL615370,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.
B,,,,,1,Autocuration,,12278,,H,148,8,,,191,,,,BAO_0000357,CHEMBL615673,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C)
F,Homo sapiens,9606.0,,,1,Autocuration,,8249,,U,149,0,,,22226,,,,BAO_0000019,CHEMBL615674,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5
F,Homo sapiens,9606.0,,,1,Autocuration,,8249,,U,150,0,,,22226,,,,BAO_0000019,CHEMBL615675,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6
F,Homo sapiens,9606.0,,CCRF-CEM,1,Autocuration,,8249,,U,151,0,635.0,,22226,,,,BAO_0000219,CHEMBL615676,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7
F,Homo sapiens,9606.0,,CCRF-CEM,1,Autocuration,,8249,,U,152,0,635.0,,22226,,,,BAO_0000219,CHEMBL615677,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4
F,Homo sapiens,9606.0,,CCRF-CEM,1,Autocuration,,8249,,U,153,0,635.0,,22226,,,,BAO_0000219,CHEMBL615678,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5
F,Homo sapiens,9606.0,,CCRF-CEM,1,Autocuration,,8249,,U,154,0,635.0,,22226,,,,BAO_0000219,CHEMBL615679,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6
F,Homo sapiens,9606.0,,,1,Autocuration,,8249,,U,155,0,,,22226,,,,BAO_0000019,CHEMBL615680,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.
F,Homo sapiens,9606.0,,,1,Autocuration,,8249,,U,156,0,,,22226,,,,BAO_0000019,CHEMBL615681,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4
B,,,,,1,Autocuration,,16992,,H,157,6,,,104290,,,,BAO_0000249,CHEMBL857972,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain
F,Streptococcus pyogenes,1314.0,,,1,Intermediate,,10543,,N,158,1,,,50264,,,,BAO_0000218,CHEMBL857899,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse
F,Human herpesvirus 3,10335.0,,,1,Intermediate,,17833,,N,159,1,,,50527,,,,BAO_0000218,CHEMBL615371,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV)
F,vericilla zoster virus,10335.0,,HEL,1,Expert,,17290,,N,160,1,468.0,,50527,,,,BAO_0000218,CHEMBL615372,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.
F,vericilla zoster virus,10335.0,,,1,Intermediate,,17290,,N,161,1,,,50527,,,,BAO_0000218,CHEMBL615373,,Antiviral activity against 07/1 strain of VZV; ND: No data
F,vericilla zoster virus,10335.0,,,1,Intermediate,,17290,,N,162,1,,,50527,,,,BAO_0000218,CHEMBL615374,,Antiviral activity against 07/1 strain of VZV; ND=No data
F,escherichia cloac,561.0,,,1,Intermediate,,10932,,N,163,1,,,50145,,,,BAO_0000218,CHEMBL615375,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)"
B,,,,,1,Autocuration,,9707,,U,164,0,,,22226,,,,BAO_0000019,CHEMBL615376,,Ratio of Ki at A2 to Ki at A1 receptors
B,Candida albicans,5476.0,,,1,Expert,,2346,,H,165,8,,,11143,,,,BAO_0000249,CHEMBL615377,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay."
B,Candida glabrata CBS 138,284593.0,,,1,Expert,,2205,,H,166,8,,,18077,,,,BAO_0000357,CHEMBL615378,,"Inhibition of 1,3-beta-glucan synthase"
F,Homo sapiens,9606.0,,1-87 tumor cell line,1,Intermediate,,11900,,N,167,1,832.0,,80609,,,,BAO_0000219,CHEMBL615379,,Inhibition of growth of 1-87 human tumor cell line
B,Rattus norvegicus,10116.0,,,1,Expert,,14864,,D,168,9,,,12166,,,,BAO_0000219,CHEMBL615380,,Inhibition of 1-lipoxygenase (LOX)in RBL cells
B,Glycine max,3847.0,,,1,Autocuration,,16474,,D,169,9,,,100171,,,,BAO_0000357,CHEMBL615381,,Inhibitory activity against soybean 1-lipoxygenase (SLO)
B,Glycine max,3847.0,,,1,Autocuration,,16474,,D,170,9,,,100171,,,,BAO_0000357,CHEMBL615382,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect
B,Glycine max,3847.0,,,1,Autocuration,,16474,,D,171,9,,,100171,,,,BAO_0000357,CHEMBL615383,,% inhibition against soybean 1-lipoxygenase (SLO)
B,Glycine max,3847.0,,,1,Autocuration,,16474,,D,172,9,,,100171,,,,BAO_0000357,CHEMBL615384,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,173,9,,,100171,,,,BAO_0000357,CHEMBL615385,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,174,9,,,100171,,,,BAO_0000357,CHEMBL615386,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,175,9,,,100171,,,,BAO_0000357,CHEMBL615387,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,176,9,,,100171,,,,BAO_0000357,CHEMBL615388,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,177,9,,,100171,,,,BAO_0000357,CHEMBL615214,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,178,9,,,100171,,,,BAO_0000357,CHEMBL827087,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,179,9,,,100171,,,,BAO_0000357,CHEMBL615215,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,180,9,,,100171,,,,BAO_0000357,CHEMBL615216,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,181,9,,,100171,,,,BAO_0000357,CHEMBL615217,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,182,9,,,100171,,,,BAO_0000357,CHEMBL615218,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3
B,Glycine max,3847.0,,,1,Autocuration,,3094,,D,183,9,,,100171,,,,BAO_0000357,CHEMBL615219,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1
B,Mus musculus,10090.0,,,1,Autocuration,,10413,,U,184,0,,,22226,,,,BAO_0000019,CHEMBL615220,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM
F,Mus musculus,10090.0,,C3H 10T1/2,1,Intermediate,,16929,,N,185,1,294.0,,80049,,,,BAO_0000219,CHEMBL615221,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity)
F,,,,,1,Intermediate,,1229,,U,186,0,,,22226,,,,BAO_0000019,CHEMBL615222,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive
B,,,,,1,Autocuration,,16587,,H,187,8,,,11489,,,,BAO_0000357,CHEMBL615223,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
B,,,,,1,Autocuration,,16587,,H,188,8,,,11862,,,,BAO_0000357,CHEMBL615224,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
B,,,,,1,Autocuration,,16587,,H,189,8,,,11862,,,,BAO_0000357,CHEMBL615225,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).
B,,,,,1,Autocuration,,16587,,H,190,8,,,11489,,,,BAO_0000357,CHEMBL615226,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2
B,,,,,1,Autocuration,,16587,,H,191,8,,,11862,,,,BAO_0000357,CHEMBL615227,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition
F,Bos taurus,9913.0,,,1,Expert,,8058,,D,192,9,,,12347,,,,BAO_0000019,CHEMBL615228,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase
B,Rattus norvegicus,10116.0,,,1,Expert,,9065,,D,193,9,,,100120,,,,BAO_0000357,CHEMBL615229,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect
B,Rattus norvegicus,10116.0,,,1,Expert,,8865,,D,194,9,,,100120,Adrenal gland,2369.0,,BAO_0000357,CHEMBL615230,,Inhibition of 11 beta-hydroxylase from rat adrenal gland
B,Rattus norvegicus,10116.0,,,1,Expert,,9066,,D,195,9,,,100120,,,,BAO_0000357,CHEMBL615231,,Inhibition of rat adrenal 11-beta-hydroxylase
B,Rattus norvegicus,10116.0,,,1,Expert,,8394,,D,196,9,,,100120,,,,BAO_0000357,CHEMBL884520,,Inhibition of rat adrenal 11-beta-hydroxylase
B,Rattus norvegicus,10116.0,,,1,Expert,,8394,,D,197,9,,,100120,,,,BAO_0000357,CHEMBL615232,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M
B,,,,,1,Autocuration,,6431,,H,198,8,,,10328,,,,BAO_0000019,CHEMBL615233,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone
B,,,,,1,Autocuration,,6431,,H,199,8,,,11490,,,,BAO_0000357,CHEMBL827088,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
B,,,,,1,Autocuration,,6431,,H,200,8,,,11490,,,,BAO_0000357,CHEMBL615234,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
F,,,,,1,Autocuration,,9295,,H,201,8,,,11134,,,,BAO_0000019,CHEMBL615235,,Compound was tested for the percent of inhibition against 12-LO at 10 uM
B,,,,,1,Autocuration,,10193,,H,202,8,,,12052,,,,BAO_0000019,CHEMBL615236,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
B,,,,,1,Autocuration,,13622,,H,203,8,,,11134,,,,BAO_0000019,CHEMBL615237,,Compound was tested in vitro for inhibition of 12-LO human platelet
F,,,,,1,Autocuration,,12079,,H,204,8,,,11134,,,,BAO_0000019,CHEMBL615238,,Inhibitory concentration against human platelet 12-lipoxygenase
B,,,,,1,Autocuration,,13622,,H,205,8,,,11134,,,,BAO_0000019,CHEMBL615239,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet
F,Homo sapiens,9606.0,,,1,Autocuration,,12079,,D,206,9,,,11134,,,,BAO_0000019,CHEMBL615240,,Inhibitory concentration against human platelet 12-lipoxygenase
B,,,,,1,Expert,,13500,,H,207,8,,,11835,,,,BAO_0000019,CHEMBL615241,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates
B,,,,,1,Expert,,13723,,H,208,8,,,11601,,,,BAO_0000357,CHEMBL615242,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase
B,,,,,1,Autocuration,,16474,,H,209,8,,,11134,,,,BAO_0000019,CHEMBL615243,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO)
B,,,,,1,Autocuration,,1630,,H,210,8,,,11134,,,,BAO_0000019,CHEMBL615244,,Inhibitory activity against human platelet 12-lipoxygenase
B,,,,,1,Autocuration,,167,,H,211,8,,,11134,,,,BAO_0000019,CHEMBL615245,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated
B,,,,,1,Autocuration,,16474,,H,212,8,,,11134,,,,BAO_0000019,CHEMBL615246,,% inhibition against human platelet 12-lipoxygenase (12-HLO)
B,,,,,1,Autocuration,,167,,H,213,8,,,11134,,,,BAO_0000019,CHEMBL615247,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM
B,,,,,1,Autocuration,,16474,,H,214,8,,,11134,,,,BAO_0000019,CHEMBL615248,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition
B,,,,,1,Autocuration,,10091,,H,215,8,,,11601,,,,BAO_0000357,CHEMBL615249,,Inhibitory activity towards porcine 12-lipoxygenase
B,,,,,1,Autocuration,,11966,,H,216,8,,,11601,,,,BAO_0000357,CHEMBL615250,,Tested for inhibition against porcine 12-LO
B,,,,,1,Autocuration,,951,,H,217,8,,,12052,,,,BAO_0000019,CHEMBL615251,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect
B,,,,,1,Autocuration,,10997,,H,218,8,,,12052,,,,BAO_0000019,CHEMBL615252,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma
B,,,,,1,Expert,,10193,,H,219,8,,,12052,,,,BAO_0000019,CHEMBL828340,,In vitro inhibition of rat platelet 12-lipoxygenase
B,,,,,1,Autocuration,,10193,,H,220,8,,,12052,,,,BAO_0000019,CHEMBL615253,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
B,,,,,1,Autocuration,,10193,,H,221,8,,,12052,,,,BAO_0000019,CHEMBL615254,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM
B,,,,,1,Autocuration,,10193,,H,222,8,,,12052,,,,BAO_0000019,CHEMBL615255,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM
B,,,,,1,Autocuration,,10193,,H,223,8,,,12052,,,,BAO_0000019,CHEMBL615256,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
B,,,,,1,Autocuration,,10193,,H,224,8,,,12052,,,,BAO_0000019,CHEMBL615257,,In vitro inhibitory activity against rat platelet 12-lipoxygenase
B,,,,,1,Autocuration,,11087,,H,225,8,,,12052,,,,BAO_0000019,CHEMBL615258,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM
F,Homo sapiens,9606.0,,41M,1,Intermediate,,15569,,N,226,1,621.0,,80007,,,,BAO_0000219,CHEMBL615259,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure
F,Homo sapiens,9606.0,,41M,1,Expert,,12989,,N,227,1,621.0,,80007,,,,BAO_0000219,CHEMBL615260,,In vitro antitumor activity against 41M cell line.
F,Homo sapiens,9606.0,,41M,1,Intermediate,,16745,,N,228,1,621.0,,80007,,,,BAO_0000219,CHEMBL615261,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.
F,Homo sapiens,9606.0,,41M,1,Intermediate,,15569,,N,229,1,621.0,,80007,,,,BAO_0000219,CHEMBL615262,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure
F,Homo sapiens,9606.0,,41M,1,Expert,,12989,,N,230,1,621.0,,80007,,,,BAO_0000219,CHEMBL615263,,In vitro antitumor activity against 41McisR cell line.
F,Homo sapiens,9606.0,,41M,1,Expert,,12989,,N,231,1,621.0,,80007,,,,BAO_0000219,CHEMBL838393,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line
F,Homo sapiens,9606.0,,41M,1,Intermediate,,16745,,N,232,1,621.0,,80007,,,,BAO_0000219,CHEMBL615264,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay
B,Homo sapiens,9606.0,,,1,Expert,,6210,,D,233,9,,,84,,,,BAO_0000357,CHEMBL615265,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I)
B,Homo sapiens,9606.0,,,1,Expert,,6210,,D,234,9,,,68,,,,BAO_0000357,CHEMBL615266,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
B,,,,,1,Expert,,6226,,H,235,8,,,68,,,,BAO_0000357,CHEMBL615267,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
B,,,,,1,Expert,,17855,,H,236,8,,,10201,,,,BAO_0000357,CHEMBL615268,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase
B,,,,,1,Expert,,17855,,H,237,8,,,10201,,,,BAO_0000357,CHEMBL615269,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined
B,,,,,1,Expert,,17855,,H,238,8,,,10201,,,,BAO_0000357,CHEMBL615270,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase
B,,,,,1,Autocuration,,10413,,H,239,8,,,12220,,,,BAO_0000357,CHEMBL615271,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
B,Escherichia coli,562.0,,,1,Autocuration,,10413,,H,240,8,,,11303,,,,BAO_0000357,CHEMBL615272,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
B,Escherichia coli,562.0,,,1,Autocuration,,10413,,H,241,8,,,11303,,,,BAO_0000357,CHEMBL615103,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
B,Escherichia coli,562.0,,,1,Autocuration,,10413,,H,242,8,,,11303,,,,BAO_0000357,CHEMBL615104,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested"
B,,,,,1,Autocuration,,10413,,H,243,8,,,12220,,,,BAO_0000357,CHEMBL615105,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
B,,,,,1,Autocuration,,10413,,H,244,8,,,12220,,,,BAO_0000357,CHEMBL872866,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,245,8,,,11303,,,,BAO_0000357,CHEMBL615106,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,246,8,,,11303,,,,BAO_0000019,CHEMBL615107,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme."
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,247,8,,,11303,,,,BAO_0000357,CHEMBL615108,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,248,8,,,11303,,,,BAO_0000357,CHEMBL615109,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,249,8,,,11303,,,,BAO_0000357,CHEMBL615110,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,250,8,,,11303,,,,BAO_0000019,CHEMBL840105,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,251,8,,,11303,,,,BAO_0000019,CHEMBL615111,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,252,8,,,11303,,,,BAO_0000019,CHEMBL615112,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,253,8,,,11303,,,,BAO_0000019,CHEMBL615113,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,254,8,,,11303,,,,BAO_0000019,CHEMBL615114,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme."
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,255,8,,,11303,,,,BAO_0000357,CHEMBL615115,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,H,256,8,,,11303,,,,BAO_0000019,CHEMBL615116,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
B,,,,,1,Autocuration,,7323,,H,257,8,,,11303,,,,BAO_0000357,CHEMBL615698,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,U,258,0,,,22226,,,,BAO_0000019,CHEMBL615699,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration"
B,Sus scrofa,9823.0,,,1,Autocuration,,7587,,U,259,0,,,22226,,,,BAO_0000019,CHEMBL615700,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme."
B,Saccharomyces cerevisiae,4932.0,,,1,Expert,,13750,,H,260,8,,,100249,,,,BAO_0000357,CHEMBL615701,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis
B,Rattus norvegicus,10116.0,,,1,Autocuration,,7662,,U,261,0,,,22226,,,,BAO_0000019,CHEMBL615702,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
B,Rattus norvegicus,10116.0,,,1,Autocuration,,7662,,U,262,0,,,22226,,,,BAO_0000019,CHEMBL615703,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
B,Rattus norvegicus,10116.0,,,1,Autocuration,,7662,,U,263,0,,,22226,,,,BAO_0000019,CHEMBL615704,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor"
F,,,,,1,Autocuration,,12211,,H,264,6,,,104698,,,,BAO_0000019,CHEMBL615705,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
F,,,,,1,Autocuration,,12211,,H,265,6,,,104698,,,,BAO_0000019,CHEMBL615706,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
F,Cavia porcellus,10141.0,,,1,Intermediate,,12211,,D,266,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL615707,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig
F,,,,,1,Expert,,12211,,H,267,8,,,10623,,,,BAO_0000019,CHEMBL615708,,Stimulatory activity of intragastric pressure was tested in the rat
B,,,,,1,Autocuration,,15453,,H,268,8,,,121,,,,BAO_0000357,CHEMBL615709,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.
F,Rattus norvegicus,10116.0,,,1,Autocuration,,11884,,U,269,0,,,22226,,,,BAO_0000218,CHEMBL615710,,Dose to reduce neuronal firing against 5-HT cells in rats (iv)
F,,,,,1,Autocuration,,7185,,H,270,8,,,12688,,,,BAO_0000019,CHEMBL615711,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
B,Homo sapiens,9606.0,,,1,Expert,,6876,,D,271,9,,,121,,,,BAO_0000357,CHEMBL615712,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine
B,Homo sapiens,9606.0,,,1,Expert,,6876,,D,272,9,,,121,,,,BAO_0000357,CHEMBL836325,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data
F,,,,,1,Autocuration,,11863,,H,273,8,,,12198,,,,BAO_0000019,CHEMBL615713,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM
B,,,,,1,Autocuration,,11863,,H,274,8,,,12198,,,,BAO_0000357,CHEMBL615714,,Inhibition constant of high-affinity 5-HT uptake
F,,,,,1,Autocuration,,11863,,H,275,8,,,12198,,,,BAO_0000019,CHEMBL615715,,Michaelis-Menten constant was reported for high affinity transport of 5-HT
F,,,,,1,Autocuration,,11863,,H,276,8,,,12198,,,,BAO_0000019,CHEMBL615716,,Maximum rate was determined for high affinity transport of 5-HT
F,,,,,1,Autocuration,,4639,,H,277,4,,,104714,,,,BAO_0000019,CHEMBL615717,,Compound was tested for agonistic activity against 5-HT uptake
B,,,,,1,Expert,,15796,,H,278,8,,,10577,,,,BAO_0000019,CHEMBL881818,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay
B,Bos taurus,9913.0,,,1,Expert,,15796,,H,279,8,,,105,,,,BAO_0000357,CHEMBL884540,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12801,,D,280,5,,,104744,,,,BAO_0000224,CHEMBL615718,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,12801,,H,281,4,,,104744,,,,BAO_0000224,CHEMBL615719,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand
B,,,,,1,Autocuration,Membranes,12120,,H,282,4,,,104744,,,,BAO_0000249,CHEMBL615720,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M
B,,,,,1,Autocuration,Membranes,12120,,H,283,4,,,104744,,,,BAO_0000249,CHEMBL615721,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.
B,,,,,1,Autocuration,,11963,,H,284,4,,,104744,,,,BAO_0000019,CHEMBL615722,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
F,,,,,1,Autocuration,,11701,,H,285,8,,,51,,,,BAO_0000019,CHEMBL615723,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%
B,,,,,1,Autocuration,,9995,,H,286,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615724,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,287,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615725,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,288,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615726,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
F,,,,,1,Autocuration,,16394,,H,289,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615727,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52)
F,Cavia porcellus,10141.0,,,1,Intermediate,,11574,,D,290,9,,,105570,,,,BAO_0000019,CHEMBL615728,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.
B,,,,CHO,1,Autocuration,,15779,,H,291,8,449.0,,279,,,,BAO_0000219,CHEMBL857971,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,15363,,H,292,8,,,107,,,,BAO_0000357,CHEMBL615729,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor
F,Rattus norvegicus,10116.0,,,1,Expert,,15363,,D,293,9,,,12687,,,,BAO_0000019,CHEMBL615730,,Efficacy against 5-hydroxytryptamine 2A receptor
F,,,,,1,Expert,,15329,,H,294,8,,,12687,,,,BAO_0000019,CHEMBL615731,,Intrinsic activity towards 5-HT2A receptor of rat tail artery
F,,,,,1,Expert,,15329,,H,295,8,,,12687,,,,BAO_0000019,CHEMBL615732,,Relative potency towards 5-HT2A receptor of rat tail artery
F,,,,,1,Expert,,15329,,H,296,8,,,12687,,,,BAO_0000019,CHEMBL615733,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery
F,,,,,1,Expert,,15329,,H,297,8,,,12687,,,,BAO_0000019,CHEMBL615734,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery
F,,,,,1,Autocuration,,15329,,H,298,8,,,12687,,,,BAO_0000019,CHEMBL615735,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.
F,,,,,1,Expert,,15329,,H,299,8,,,12687,,,,BAO_0000019,CHEMBL615736,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,300,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL615737,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,301,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL615738,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI)
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,302,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL615739,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
B,,,,,1,Autocuration,,12092,,H,303,8,,,10623,,,,BAO_0000357,CHEMBL615278,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.
F,Rattus norvegicus,10116.0,,,1,Expert,,1317,,D,304,9,,,10623,,,,BAO_0000019,CHEMBL615279,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
B,,,,,1,Expert,,12409,,H,305,8,,,168,,,,BAO_0000357,CHEMBL615280,,Binding affinity against 5-hydroxytryptamine 4 receptor
B,Gallus gallus,9031.0,,,1,Autocuration,,11126,,U,306,0,,,22226,,,,BAO_0000019,CHEMBL615281,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine
F,Homo sapiens,9606.0,,,1,Autocuration,,11126,,U,307,0,,,22226,,,,BAO_0000019,CHEMBL615282,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity
F,Homo sapiens,9606.0,,,1,Autocuration,,11126,,U,308,0,,,22226,,,,BAO_0000019,CHEMBL615283,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control
B,Homo sapiens,9606.0,,HL-60,1,Autocuration,,11126,,N,309,1,649.0,,80156,,,,BAO_0000219,CHEMBL615284,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells
B,Homo sapiens,9606.0,,,1,Autocuration,,11126,,U,310,0,,,22226,,,,BAO_0000019,CHEMBL615285,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity
B,Homo sapiens,9606.0,,,1,Autocuration,,11126,,U,311,0,,,22226,,,,BAO_0000019,CHEMBL615286,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control
B,Homo sapiens,9606.0,,Oocytes,1,Autocuration,,17807,,D,312,7,,,104703,,,,BAO_0000219,CHEMBL615287,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes
F,,,,,1,Intermediate,,16575,,S,313,2,,,100256,,,,BAO_0000220,CHEMBL615288,,Chymotryptic inhibitory activity against 26S proteasome
B,,,,,1,Intermediate,,15407,,S,314,2,,,100256,,,,BAO_0000220,CHEMBL615289,,Inhibitory activity against 26S proteasome degradation of IkB
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,10797,,N,315,1,478.0,,81034,,,,BAO_0000219,CHEMBL615290,,In vitro inhibition of 2780/DOX ovarian cancer cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,10797,,N,316,1,478.0,,81034,,,,BAO_0000219,CHEMBL884522,,In vitro inhibition of 2780/S ovarian cancer cell line
F,Homo sapiens,9606.0,,,1,Autocuration,,3469,,U,317,0,,,22226,,,,BAO_0000019,CHEMBL615291,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells
B,,,,,1,Intermediate,,16037,,M,318,3,,,22222,,,,BAO_0000225,CHEMBL615292,,Association constant for binding to AATT 28-mer AATT hairpin
B,,,,,1,Intermediate,,16037,,M,319,3,,,22222,,,,BAO_0000225,CHEMBL615293,,Kinetically Defined Association Constant for 28-mer AATT hairpin.
B,,,,,1,Intermediate,,16037,,M,320,3,,,22222,,,,BAO_0000225,CHEMBL615294,,Reaction Rate Parameter for 28-mer AATT hairpin
B,,,,,1,Intermediate,,16037,,M,321,3,,,22222,,,,BAO_0000225,CHEMBL615295,,Reaction Rate Parameter for 28-mer AATT hairpin
F,Homo sapiens,9606.0,,,1,Autocuration,,16524,,U,322,0,,,22226,,,,BAO_0000019,CHEMBL825021,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1)
F,Homo sapiens,9606.0,,,1,Autocuration,,16524,,U,323,0,,,22226,,,,BAO_0000019,CHEMBL615296,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2)
F,Homo sapiens,9606.0,,,1,Autocuration,,16524,,U,324,0,,,22226,,,,BAO_0000019,CHEMBL615297,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1
F,Cricetulus griseus,10029.0,,,1,Autocuration,,16758,,U,325,0,,,22226,,,,BAO_0000019,CHEMBL615298,,Cytotoxicity against cell line 2SC/20 determined by MTT test
F,Cricetulus griseus,10029.0,,,1,Autocuration,,16758,,U,326,0,,,22226,,,,BAO_0000019,CHEMBL615299,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test
F,Cricetulus griseus,10029.0,,,1,Autocuration,,16758,,U,327,0,,,22226,,,,BAO_0000019,CHEMBL615300,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test
B,,,,,1,Autocuration,,14360,,H,328,8,,,241,,,,BAO_0000357,CHEMBL615301,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase
B,Homo sapiens,9606.0,,,1,Expert,,14360,,D,329,9,,,241,,,,BAO_0000357,CHEMBL615302,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9964,,U,330,0,,,22226,,,,BAO_0000019,CHEMBL615303,,Selectivity ratio of ID50 in liver and heart
B,,,,,1,Autocuration,,9964,,H,331,8,,,12132,,,,BAO_0000019,CHEMBL615304,,"Selectivity, ratio of relative ID50 in liver and heart"
B,,,,,1,Autocuration,,9964,,H,332,8,,,12132,,,,BAO_0000019,CHEMBL615305,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3
B,,,,,1,Autocuration,,9964,,H,333,8,,,12132,,,,BAO_0000218,CHEMBL615306,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
B,,,,,1,Autocuration,,9964,,H,334,8,,,12132,,,,BAO_0000218,CHEMBL615307,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
B,,,,,1,Autocuration,,9964,,H,335,8,,,12132,,,In vivo,BAO_0000218,CHEMBL615308,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
F,,,,,1,Autocuration,,9964,,H,336,8,,,12132,,,In vivo,BAO_0000218,CHEMBL615309,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
B,,,,,1,Autocuration,,9964,,U,337,0,,,22226,,,,BAO_0000019,CHEMBL615310,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine"
B,,,,,1,Autocuration,,9964,,H,338,8,,,12132,,,,BAO_0000019,CHEMBL615311,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3
B,Homo sapiens,9606.0,,,1,Autocuration,,9964,,U,339,0,,,22226,,,,BAO_0000019,CHEMBL615312,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart"
B,,,,,1,Autocuration,,9964,,H,340,8,,,12132,,,,BAO_0000019,CHEMBL615313,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
F,,,,,1,Autocuration,,9964,,H,341,8,,,12132,,,,BAO_0000019,CHEMBL615314,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
B,,,,,1,Autocuration,,9964,,H,342,8,,,12132,,,,BAO_0000019,CHEMBL615315,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9964,,U,343,0,,,22226,,,,BAO_0000218,CHEMBL615316,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration"
B,,,,,1,Autocuration,,9964,,H,344,8,,,12132,,,In vivo,BAO_0000218,CHEMBL615317,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3
B,,,,,1,Autocuration,,9964,,H,345,8,,,12132,,,,BAO_0000218,CHEMBL615318,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9964,,U,346,0,,,22226,,,,BAO_0000218,CHEMBL615319,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration"
B,,,,,1,Autocuration,,9964,,H,347,8,,,12132,,,,BAO_0000019,CHEMBL615320,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
F,,,,,1,Autocuration,,9964,,H,348,8,,,12132,,,,BAO_0000019,CHEMBL615321,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,3796,,U,349,0,,,22226,,,,BAO_0000019,CHEMBL615322,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor"
B,Escherichia coli,562.0,,,1,Autocuration,,4251,,H,350,8,,,19690,,,,BAO_0000357,CHEMBL615323,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
B,Escherichia coli,562.0,,,1,Autocuration,,4251,,H,351,8,,,19690,,,,BAO_0000357,CHEMBL615407,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
B,Escherichia coli,562.0,,,1,Autocuration,,4251,,H,352,8,,,19690,,,,BAO_0000357,CHEMBL857267,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli
B,Escherichia coli,562.0,,,1,Autocuration,,4251,,H,353,8,,,19690,,,,BAO_0000357,CHEMBL615408,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli
B,,,,,1,Autocuration,,166,,H,354,8,,,19690,,,,BAO_0000357,CHEMBL615409,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible
B,,,,,1,Autocuration,,17861,,H,355,8,,,19690,,,,BAO_0000357,CHEMBL615410,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase
B,,,,,1,Autocuration,,166,,H,356,8,,,19690,,,,BAO_0000357,CHEMBL615411,,Inhibition constant against 3-dehydroquinate synthase
B,,,,,1,Autocuration,,166,,H,357,8,,,19690,,,,BAO_0000357,CHEMBL615412,,Association rate constant against 3-dehydroquinate synthase
B,,,,,1,Autocuration,,166,,H,358,8,,,19690,,,,BAO_0000357,CHEMBL615413,,Rate constant against 3-dehydroquinate synthase
B,,,,,1,Autocuration,,3548,,U,359,0,,,22226,,,,BAO_0000019,CHEMBL615414,,Inhibitory activity against fuc-TVII
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,360,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615415,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,361,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615416,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,362,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615417,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,363,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615418,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,364,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615419,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,365,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615420,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,366,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615421,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,367,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615422,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,368,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615423,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,369,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL872868,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,9877,,D,370,9,,,12236,Liver,2107.0,,BAO_0000251,CHEMBL615424,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM
B,,,,,1,Autocuration,,3003,,H,371,4,,,104832,,,,BAO_0000224,CHEMBL825022,,Inhibitory activity against 3-phosphoglycerate kinase.
B,,,,,1,Autocuration,,3003,,H,372,4,,,104832,,,,BAO_0000224,CHEMBL615425,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1
B,,,,,1,Autocuration,,3003,,H,373,4,,,104832,,,,BAO_0000224,CHEMBL615426,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase"
B,Homo sapiens,9606.0,,,1,Expert,,17185,,D,374,9,,,10612,,,,BAO_0000357,CHEMBL615427,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM
F,Homo sapiens,9606.0,,3677 melanoma cell line,1,Intermediate,,6072,,N,375,1,844.0,,80616,,,,BAO_0000219,CHEMBL615428,,Cytotoxicity on 3677 melanoma cells
F,Homo sapiens,9606.0,,3677 melanoma cell line,1,Intermediate,,6072,,N,376,1,844.0,,80616,,,,BAO_0000219,CHEMBL615429,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL
F,Mus musculus,10090.0,,MC-38,1,Intermediate,,5018,,N,377,1,700.0,,80617,,,,BAO_0000219,CHEMBL615430,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay
F,Homo sapiens,9606.0,,,1,Intermediate,,2852,,U,378,0,,,22226,,,,BAO_0000019,CHEMBL615431,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines
F,,,,B16,1,Autocuration,,8663,,U,379,0,798.0,,22226,,,,BAO_0000218,CHEMBL615432,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested
F,,,,B16,1,Autocuration,,8663,,U,380,0,798.0,,22226,,,,BAO_0000218,CHEMBL615433,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.
F,Human rhinovirus 14,12131.0,,,1,Expert,,3245,,D,381,9,,,12464,,,,BAO_0000019,CHEMBL615434,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease
F,Human rhinovirus sp.,169066.0,,,1,Intermediate,,3245,,N,382,1,,,50085,,,,BAO_0000218,CHEMBL615435,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM
F,human rhinovirus type 14,169066.0,,,1,Intermediate,,3877,,N,383,1,,,50679,,,,BAO_0000218,CHEMBL615436,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI
F,human rhinovirus type 14,169066.0,,,1,Intermediate,,3877,,N,384,1,,,50679,,,,BAO_0000218,CHEMBL615437,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact
F,Human rhinovirus 14,12131.0,,,1,Expert,,5861,,D,385,9,,,12464,,,,BAO_0000019,CHEMBL615438,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
F,Human rhinovirus 14,12131.0,,,1,Expert,,5861,,D,386,9,,,12464,,,,BAO_0000019,CHEMBL615439,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
F,Human rhinovirus 14,12131.0,,,1,Expert,,5861,,D,387,9,,,12464,,,,BAO_0000019,CHEMBL615440,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
F,Human rhinovirus 14,12131.0,,,1,Expert,,5861,,D,388,9,,,12464,,,,BAO_0000019,CHEMBL615441,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive
F,Enterovirus,12059.0,,,1,Intermediate,,13748,,N,389,1,,,50665,,,,BAO_0000218,CHEMBL615641,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease
F,Enterovirus,12059.0,,,1,Intermediate,,13748,,N,390,1,,,50665,,,,BAO_0000218,CHEMBL872065,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease
F,Enterovirus,12059.0,,,1,Intermediate,,13748,,N,391,1,,,50665,,,,BAO_0000218,CHEMBL825023,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease
F,Enterovirus,12059.0,,,1,Intermediate,,13748,,N,392,1,,,50665,,,,BAO_0000218,CHEMBL615642,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease
B,Human rhinovirus B,147712.0,,,1,Expert,,13748,,H,393,8,,,12464,,,,BAO_0000357,CHEMBL615643,,Inhibition of human rhinovirus 3C protease
B,Homo sapiens,9606.0,,,1,Autocuration,,17699,,U,394,0,,,22226,,,,BAO_0000019,CHEMBL615644,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,395,1,833.0,,80619,,,,BAO_0000218,CHEMBL615645,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5)
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,396,1,833.0,,80619,,,,BAO_0000218,CHEMBL615646,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16)
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,397,1,833.0,,80619,,,,BAO_0000218,CHEMBL615647,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10)
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,398,1,833.0,,80619,,,,BAO_0000218,CHEMBL615648,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6)
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,399,1,833.0,,80619,,,,BAO_0000218,CHEMBL615649,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg
F,Mus musculus,10090.0,,3EM 37,1,Intermediate,,7145,,N,400,1,833.0,,80619,,,,BAO_0000218,CHEMBL615650,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,5325,,N,401,1,847.0,,80620,,,,BAO_0000218,CHEMBL615651,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,5325,,N,402,1,847.0,,80620,,,,BAO_0000218,CHEMBL615652,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
F,Mus musculus,10090.0,,3LL cell line,1,Expert,,5325,,N,403,1,847.0,,80620,,,,BAO_0000218,CHEMBL615653,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,404,1,847.0,,80620,,,,BAO_0000219,CHEMBL615654,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,405,1,847.0,,80620,,,,BAO_0000219,CHEMBL615655,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,406,1,847.0,,80620,,,,BAO_0000219,CHEMBL825024,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,407,1,847.0,,80620,,,,BAO_0000219,CHEMBL615656,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,408,1,847.0,,80620,,,,BAO_0000219,CHEMBL615657,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,409,1,847.0,,80620,,,,BAO_0000219,CHEMBL615658,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,410,1,847.0,,80620,,,,BAO_0000219,CHEMBL615659,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,411,1,847.0,,80620,,,,BAO_0000219,CHEMBL615660,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,412,1,847.0,,80620,,,,BAO_0000219,CHEMBL615661,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,413,1,847.0,,80620,,,,BAO_0000219,CHEMBL615662,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,414,1,847.0,,80620,,,,BAO_0000219,CHEMBL615663,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,415,1,847.0,,80620,,,,BAO_0000219,CHEMBL615664,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,416,1,847.0,,80620,,,,BAO_0000219,CHEMBL615665,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,417,1,847.0,,80620,,,,BAO_0000219,CHEMBL615666,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,418,1,847.0,,80620,,,,BAO_0000219,CHEMBL615667,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,419,1,847.0,,80620,,,,BAO_0000219,CHEMBL615668,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,420,1,847.0,,80620,,,,BAO_0000219,CHEMBL615669,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,421,1,847.0,,80620,,,,BAO_0000219,CHEMBL615670,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,422,1,847.0,,80620,,,,BAO_0000219,CHEMBL836739,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,423,1,847.0,,80620,,,,BAO_0000219,CHEMBL615671,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,424,1,847.0,,80620,,,,BAO_0000219,CHEMBL615672,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,425,1,847.0,,80620,,,,BAO_0000219,CHEMBL615791,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,426,1,847.0,,80620,,,,BAO_0000219,CHEMBL615792,,spermine levels in 3LL cells after the treatment of 1 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,427,1,847.0,,80620,,,,BAO_0000219,CHEMBL615793,,spermine levels in 3LL cells after the treatment of 10 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,428,1,847.0,,80620,,,,BAO_0000219,CHEMBL615794,,spermine levels in 3LL cells after the treatment of 250 uM of Compound
F,Mus musculus,10090.0,,3LL cell line,1,Intermediate,,16169,,N,429,1,847.0,,80620,,,,BAO_0000219,CHEMBL615795,,spermine levels in 3LL cells after the treatment of 50 uM of Compound
F,Homo sapiens,9606.0,,3LLD122,1,Intermediate,,15547,,N,430,1,971.0,,80621,,,,BAO_0000219,CHEMBL615590,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
F,,,,,1,Autocuration,,8663,,U,431,0,,,22226,,,,BAO_0000218,CHEMBL615591,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity
F,,,,,1,Autocuration,,8663,,U,432,0,,,22226,,,,BAO_0000218,CHEMBL615592,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.
F,,,,,1,Autocuration,,8663,,U,433,0,,,22226,,,,BAO_0000218,CHEMBL615593,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested
F,,,,,1,Autocuration,,8663,,U,434,0,,,22226,,,,BAO_0000218,CHEMBL615594,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,4504,,N,435,1,723.0,,80951,,,,BAO_0000219,CHEMBL615595,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,4504,,N,436,1,723.0,,80951,,,,BAO_0000219,CHEMBL615596,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
F,,,,NIH3T3,1,Expert,,12695,,H,437,8,723.0,,11169,,,,BAO_0000219,CHEMBL615597,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12695,,N,438,1,723.0,,80951,,,,BAO_0000219,CHEMBL615598,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12695,,N,439,1,723.0,,80951,,,,BAO_0000219,CHEMBL615599,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,17642,,N,440,1,723.0,,80951,,,,BAO_0000219,CHEMBL615600,,Effective dose against murine 3T3 fibroblasts cells
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,17642,,N,441,1,723.0,,80951,,,,BAO_0000219,CHEMBL615601,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,12340,,N,442,1,723.0,,80951,,,,BAO_0000219,CHEMBL615602,,Cytotoxic effect on 3T3 cells
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,12340,,N,443,1,723.0,,80951,,,,BAO_0000219,CHEMBL615603,,Cytotoxic effect on 3T3 cells
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12716,,N,444,1,723.0,,80951,,,,BAO_0000219,CHEMBL615604,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,6277,,N,445,1,723.0,,80951,,,,BAO_0000219,CHEMBL615605,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,6277,,N,446,1,723.0,,80951,,,,BAO_0000219,CHEMBL615606,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,6277,,N,447,1,723.0,,80951,,,,BAO_0000219,CHEMBL884526,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,6277,,N,448,1,723.0,,80951,,,,BAO_0000219,CHEMBL615607,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,6277,,N,449,1,723.0,,80951,,,,BAO_0000219,CHEMBL615608,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,6277,,N,450,1,723.0,,80951,,,,BAO_0000219,CHEMBL615609,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,6277,,N,451,1,723.0,,80951,,,,BAO_0000219,CHEMBL615682,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,6277,,N,452,1,723.0,,80951,,,,BAO_0000219,CHEMBL615683,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,17780,,N,453,1,723.0,,80951,,,,BAO_0000218,CHEMBL615684,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models
F,Mus musculus,10090.0,,,1,Autocuration,,12751,,D,454,7,,,104860,,,,BAO_0000219,CHEMBL615685,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,12380,,N,455,1,723.0,,80951,,,,BAO_0000219,CHEMBL615686,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,14892,,N,456,1,723.0,,80951,,,,BAO_0000219,CHEMBL615687,,Inhibitory activity against 3T3 cell line
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12695,,N,457,1,723.0,,80951,,,,BAO_0000219,CHEMBL884523,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured
F,,,,,1,Expert,,12695,,H,458,8,,,11169,,,,BAO_0000019,CHEMBL615688,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12695,,N,459,1,723.0,,80951,,,,BAO_0000219,CHEMBL615689,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12695,,N,460,1,723.0,,80951,,,,BAO_0000219,CHEMBL615690,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured
F,,,,,1,Expert,,12695,,H,461,8,,,11169,,,,BAO_0000019,CHEMBL615691,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells
F,,,,,1,Expert,,12695,,H,462,8,,,11169,,,,BAO_0000019,CHEMBL615692,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,6277,,N,463,1,723.0,,80951,,,,BAO_0000219,CHEMBL615693,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,6277,,N,464,1,723.0,,80951,,,,BAO_0000219,CHEMBL615324,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data
F,Homo sapiens,9606.0,,NIH3T3,1,Expert,,4959,,D,465,9,723.0,,9,,,,BAO_0000219,CHEMBL615325,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells
F,Homo sapiens,9606.0,,NIH3T3,1,Expert,,4959,,D,466,9,723.0,,9,,,,BAO_0000219,CHEMBL615490,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested)
F,Homo sapiens,9606.0,,NIH3T3,1,Expert,,4959,,D,467,9,723.0,,188,,,,BAO_0000219,CHEMBL615491,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells
F,Homo sapiens,9606.0,,NIH3T3,1,Expert,,4959,,D,468,9,723.0,,188,,,,BAO_0000219,CHEMBL615492,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested)
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12082,,N,469,1,723.0,,80951,,,,BAO_0000219,CHEMBL615493,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12082,,N,470,1,723.0,,80951,,,,BAO_0000219,CHEMBL615494,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12082,,N,471,1,723.0,,80951,,,,BAO_0000219,CHEMBL615495,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,12082,,N,472,1,723.0,,80951,,,,BAO_0000219,CHEMBL615496,,Inhibitory concentration was calculated on 3T3 cells by using growth assay
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,2643,,N,473,1,723.0,,80951,,,,BAO_0000219,CHEMBL615497,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,11926,,N,474,1,723.0,,80951,,,,BAO_0000219,CHEMBL615498,,Inhibition of Swiss 3T3 mouse fibroblast proliferation
A,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,15204,,N,475,1,723.0,,80951,,,,BAO_0000219,CHEMBL615499,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,15992,,N,476,1,723.0,,80951,,,,BAO_0000219,CHEMBL835522,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,477,1,723.0,,80951,,,,BAO_0000219,CHEMBL615500,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,478,1,723.0,,80951,,,,BAO_0000219,CHEMBL615501,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,479,1,723.0,,80951,,,,BAO_0000219,CHEMBL615502,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,480,1,723.0,,80951,,,,BAO_0000219,CHEMBL615503,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,481,1,723.0,,80951,,,,BAO_0000219,CHEMBL615504,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,16279,,N,482,1,723.0,,80951,,,,BAO_0000219,CHEMBL615505,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
F,Mus musculus,10090.0,,NIH3T3,1,Expert,,12831,,N,483,1,723.0,,80951,,,,BAO_0000219,CHEMBL615506,,Inhibition of swiss 3T3 mouse fibroblast proliferation
F,Mus musculus,10090.0,,NIH3T3,1,Intermediate,,13497,,N,484,1,723.0,,80951,,,,BAO_0000219,CHEMBL615507,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.
F,,,,3T3-L1,1,Intermediate,,13715,,N,485,1,620.0,,80006,,,,BAO_0000218,CHEMBL615508,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,13618,,N,486,1,620.0,,80006,,,,BAO_0000219,CHEMBL615509,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,11902,,N,487,1,620.0,,80006,,,,BAO_0000219,CHEMBL615510,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,11902,,N,488,1,620.0,,80006,,,,BAO_0000219,CHEMBL615511,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,11902,,N,489,1,620.0,,80006,,,,BAO_0000219,CHEMBL615512,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,14840,,N,490,1,620.0,,80006,,,,BAO_0000218,CHEMBL615513,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr"
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,14840,,N,491,1,620.0,,80006,,,,BAO_0000218,CHEMBL615514,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr"
F,,,,3T3-L1,1,Intermediate,,13715,,N,492,1,620.0,,80006,,,,BAO_0000219,CHEMBL615515,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes
F,,,,3T3-L1,1,Intermediate,,13715,,N,493,1,620.0,,80006,,,,BAO_0000219,CHEMBL615516,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,494,1,620.0,,80006,,,,BAO_0000219,CHEMBL615517,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,495,1,620.0,,80006,,,,BAO_0000219,CHEMBL615518,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,496,1,620.0,,80006,,,,BAO_0000219,CHEMBL615519,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,497,1,620.0,,80006,,,,BAO_0000218,CHEMBL615520,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,498,1,620.0,,80006,,,,BAO_0000218,CHEMBL615521,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,499,1,620.0,,80006,,,,BAO_0000218,CHEMBL615522,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,500,1,620.0,,80006,,,,BAO_0000218,CHEMBL615523,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
F,,,,3T3-L1,1,Expert,,13715,,N,501,1,620.0,,80006,,,,BAO_0000218,CHEMBL615524,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
F,,,,3T3-L1,1,Expert,,13715,,N,502,1,620.0,,80006,,,,BAO_0000218,CHEMBL615525,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,503,1,620.0,,80006,,,,BAO_0000218,CHEMBL615526,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,504,1,620.0,,80006,,,,BAO_0000218,CHEMBL615527,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,505,1,620.0,,80006,,,,BAO_0000218,CHEMBL615528,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.
F,,,,3T3-L1,1,Expert,,13715,,N,506,1,620.0,,80006,,,,BAO_0000218,CHEMBL615529,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
F,,,,3T3-L1,1,Expert,,13715,,N,507,1,620.0,,80006,,,,BAO_0000218,CHEMBL615530,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
F,,,,3T3-L1,1,Expert,,13715,,N,508,1,620.0,,80006,,,,BAO_0000218,CHEMBL615531,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,509,1,620.0,,80006,,,,BAO_0000219,CHEMBL615532,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,510,1,620.0,,80006,,,,BAO_0000219,CHEMBL615533,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,511,1,620.0,,80006,,,,BAO_0000219,CHEMBL615534,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
F,,,,3T3-L1,1,Intermediate,,13715,,N,512,1,620.0,,80006,,,,BAO_0000218,CHEMBL615535,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,513,1,620.0,,80006,,,,BAO_0000218,CHEMBL615536,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,514,1,620.0,,80006,,,,BAO_0000218,CHEMBL615537,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,515,1,620.0,,80006,,,,BAO_0000218,CHEMBL615538,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
F,,,,3T3-L1,1,Intermediate,,13715,,N,516,1,620.0,,80006,,,,BAO_0000218,CHEMBL836166,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
F,,,,3T3-L1,1,Expert,,6411,,H,517,8,620.0,,11214,,,,BAO_0000219,CHEMBL615539,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,6411,,N,518,1,620.0,,80006,,,,BAO_0000219,CHEMBL615540,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data
F,,,,3T3-L1,1,Expert,,6411,,H,519,8,620.0,,11214,,,,BAO_0000219,CHEMBL615541,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,3966,,N,520,1,620.0,,80006,,,,BAO_0000219,CHEMBL615542,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone
F,Mus musculus,10090.0,,3T3-L1,1,Intermediate,,3966,,N,521,1,620.0,,80006,,,,BAO_0000219,CHEMBL615543,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,15556,,N,522,1,620.0,,80006,,,,BAO_0000219,CHEMBL615544,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,5845,,N,523,1,620.0,,80006,,,,BAO_0000219,CHEMBL615545,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,14422,,N,524,1,620.0,,80006,,,,BAO_0000219,CHEMBL615546,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,5845,,N,525,1,620.0,,80006,,,,BAO_0000219,CHEMBL615547,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,14508,,N,526,1,620.0,,80006,,,,BAO_0000219,CHEMBL615548,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,14508,,N,527,1,620.0,,80006,,,,BAO_0000219,CHEMBL615549,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.
F,Mus musculus,10090.0,,3T3-L1,1,Expert,,14508,,N,528,1,620.0,,80006,,,,BAO_0000219,CHEMBL615550,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Intermediate,,6349,,N,529,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615551,,Inhibitory activity against rat fibroblast (3Y1) cell line
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Expert,,15899,,N,530,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615552,,Mean concentration causing inhibition of cell growth in 3Y1 cells.
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Expert,,15899,,N,531,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615553,,Cytotoxicity in 3Y1 cells.
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Expert,,15899,,N,532,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615554,,Cytostatic effect in 3Y1 cells.
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Intermediate,,15899,,N,533,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615555,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect"
F,Rattus norvegicus,10116.0,,3Y1 cell line,1,Expert,,17038,,N,534,1,1118.0,,80622,,,,BAO_0000219,CHEMBL615556,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure
B,,,,,1,Autocuration,,12421,,U,535,0,,,22226,,,,BAO_0000019,CHEMBL615557,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase
B,,,,,1,Autocuration,,12947,,U,536,0,,,22226,,,,BAO_0000019,CHEMBL615558,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
B,,,,,1,Autocuration,,12947,,U,537,0,,,22226,,,,BAO_0000019,CHEMBL872066,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
B,Sus scrofa,9823.0,,,1,Expert,,4896,,D,538,9,,,11607,,,,BAO_0000019,CHEMBL615559,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method
B,,,,,1,Autocuration,,6148,,H,539,8,,,11607,,,,BAO_0000019,CHEMBL615560,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver
B,,,,,1,Autocuration,,16432,,H,540,8,,,11607,,,,BAO_0000019,CHEMBL615561,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme
B,,,,,1,Expert,,4978,,H,541,8,,,11607,,,,BAO_0000019,CHEMBL857062,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver
B,,,,,1,Expert,,4978,,H,542,8,,,11607,,,,BAO_0000019,CHEMBL615562,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value)
B,,,,,1,Autocuration,,3723,,H,543,8,,,11607,,,,BAO_0000019,CHEMBL615563,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method
B,,,,,1,Autocuration,,3518,,H,544,8,,,11607,,,,BAO_0000357,CHEMBL615564,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD)
B,,,,,1,Autocuration,,4164,,H,545,8,,,11607,,,,BAO_0000019,CHEMBL615565,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method
B,,,,,1,Autocuration,,3518,,H,546,8,,,11607,,,,BAO_0000019,CHEMBL615566,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated
B,Sus scrofa,9823.0,,,1,Expert,,4164,,D,547,9,,,11607,,,,BAO_0000019,CHEMBL615567,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method
B,,,,,1,Autocuration,,3518,,H,548,8,,,11607,,,,BAO_0000019,CHEMBL615568,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.
B,,,,,1,Autocuration,,3518,,H,549,8,,,11607,,,,BAO_0000357,CHEMBL615569,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM)
B,,,,,1,Autocuration,,4978,,H,550,8,,,11607,,,,BAO_0000019,CHEMBL615570,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver
B,,,,,1,Autocuration,,4978,,H,551,8,,,11607,,,,BAO_0000019,CHEMBL615571,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value)
B,,,,,1,Autocuration,,6455,,H,552,4,,,104733,,,,BAO_0000224,CHEMBL615572,,Binding affinity against melatonin (MT1) receptor (pC1)
B,,,,,1,Autocuration,,2222,,U,553,0,,,22226,,,,BAO_0000019,CHEMBL615573,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,13020,,U,554,0,,,22226,,,,BAO_0000019,CHEMBL615574,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M
B,,,,,1,Autocuration,,13021,,U,555,0,,,22226,,,,BAO_0000019,CHEMBL615575,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system
B,,,,,1,Autocuration,,14532,,H,556,8,,,10619,,,,BAO_0000357,CHEMBL615576,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration
B,,,,,1,Autocuration,,14118,,H,557,8,,,10619,,,,BAO_0000357,CHEMBL615577,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,11884,,H,558,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615578,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT
B,,,,,1,Expert,,13969,,H,559,8,,,51,,,,BAO_0000357,CHEMBL615579,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13392,,H,560,8,,,51,,,,BAO_0000357,CHEMBL615580,,Binding affinity for 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,14430,,H,561,8,,,51,,,,BAO_0000019,CHEMBL615581,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT
B,,,,,1,Autocuration,,12248,,H,562,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615582,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
B,,,,,1,Autocuration,,12249,,H,563,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615583,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,564,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,565,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL833691,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,566,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615585,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,567,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615586,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,568,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL884524,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,12249,,H,569,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615587,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
B,,,,,1,Autocuration,,11799,,H,570,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615588,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,14331,,D,571,9,,,10576,,,,BAO_0000249,CHEMBL615589,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes
B,Bos taurus,9913.0,,,1,Expert,,11884,,H,572,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615442,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.
B,,,,,1,Autocuration,,14331,,H,573,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615443,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined
B,,,,,1,Autocuration,,11701,,H,574,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615444,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus
B,,,,,1,Expert,,11701,,H,575,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615445,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.
B,,,,,1,Autocuration,,12248,,H,576,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615446,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus
B,,,,CHO,1,Autocuration,,12248,,H,577,8,449.0,,51,,,,BAO_0000219,CHEMBL615447,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells
B,,,,,1,Expert,,12248,,H,578,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615448,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
B,,,,,1,Expert,,12249,,H,579,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615449,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
B,,,,CHO,1,Autocuration,,12248,,H,580,8,449.0,,51,,,,BAO_0000219,CHEMBL615450,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
B,,,,,1,Expert,,11799,,H,581,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615451,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
B,,,,,1,Autocuration,,634,,H,582,8,,,51,,,,BAO_0000357,CHEMBL615452,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
B,,,,,1,Autocuration,,9995,,H,583,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615453,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,584,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615454,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,585,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615455,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,586,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615456,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,9995,,H,587,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615457,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
B,,,,,1,Expert,,12210,,H,588,8,,,51,Hippocampus,10000000.0,,BAO_0000218,CHEMBL615458,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.
B,,,,,1,Expert,,13311,,H,589,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615459,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,Homo sapiens,9606.0,,CHO,1,Expert,,2331,,D,590,9,449.0,,51,,,,BAO_0000219,CHEMBL615460,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells."
F,Cavia porcellus,10141.0,,,1,Autocuration,,1375,,H,591,8,,,51,,,,BAO_0000019,CHEMBL615461,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig
F,Cavia porcellus,10141.0,,,1,Autocuration,,1375,,H,592,8,,,51,,,,BAO_0000019,CHEMBL615462,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested
F,Cavia porcellus,10141.0,,,1,Autocuration,,11574,,H,593,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615463,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,594,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615464,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,595,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615465,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,596,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615466,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,597,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615467,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,598,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615468,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,12867,,H,599,8,,,51,Ileum,2116.0,,BAO_0000221,CHEMBL615469,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,11574,,H,600,8,,,51,,,,BAO_0000357,CHEMBL615470,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,13114,,H,601,8,,,51,,,,BAO_0000357,CHEMBL615471,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,13181,,H,602,8,,,51,,,,BAO_0000357,CHEMBL615472,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,10639,,H,603,8,,,106,Hippocampus,10000000.0,,BAO_0000221,CHEMBL883242,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
F,Cavia porcellus,10141.0,,,1,Autocuration,,10639,,H,604,8,,,106,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615473,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
B,Cricetulus griseus,10029.0,,CHO,1,Autocuration,,11883,,H,605,8,449.0,,11863,,,,BAO_0000218,CHEMBL615474,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
B,,,,,1,Autocuration,,17785,,H,606,8,,,51,,,,BAO_0000357,CHEMBL615475,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor
F,,,,HeLa,1,Autocuration,,1558,,H,607,8,308.0,,51,,,,BAO_0000219,CHEMBL615476,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370
F,,,,HeLa,1,Autocuration,,1558,,H,608,8,308.0,,51,,,,BAO_0000219,CHEMBL615477,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320
F,,,,,1,Autocuration,,15740,,H,609,8,,,51,,,,BAO_0000019,CHEMBL615478,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
F,,,,CHO,1,Autocuration,,17624,,H,610,8,449.0,,51,,,,BAO_0000219,CHEMBL615160,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
F,,,,CHO,1,Expert,,17624,,H,611,8,449.0,,51,,,,BAO_0000219,CHEMBL615161,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
F,,,,CHO,1,Autocuration,,17624,,H,612,8,449.0,,51,,,,BAO_0000219,CHEMBL615162,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined
F,,,,CHO,1,Autocuration,,17624,,H,613,8,449.0,,51,,,,BAO_0000219,CHEMBL615163,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined
B,,,,CHO,1,Expert,,17624,,H,614,8,449.0,,51,,,,BAO_0000219,CHEMBL615164,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
B,,,,CHO,1,Expert,,17624,,H,615,8,449.0,,51,,,,BAO_0000219,CHEMBL615165,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
B,,,,CHO,1,Autocuration,,17624,,H,616,8,449.0,,51,,,,BAO_0000219,CHEMBL615166,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined
F,,,,,1,Autocuration,,14256,,H,617,8,,,51,,,,BAO_0000219,CHEMBL615167,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP
B,Homo sapiens,9606.0,,HeLa,1,Expert,,3445,,D,618,9,308.0,,51,,,,BAO_0000219,CHEMBL615168,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
B,Homo sapiens,9606.0,,HeLa,1,Expert,,3445,,D,619,9,308.0,,51,,,,BAO_0000219,CHEMBL615169,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse
B,Homo sapiens,9606.0,,CHO,1,Expert,,17200,,D,620,9,449.0,,51,,,,BAO_0000219,CHEMBL615170,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,17200,,D,621,9,449.0,,51,,,,BAO_0000219,CHEMBL615171,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined
F,,,,,1,Autocuration,,15180,,H,622,8,,,51,,,,BAO_0000019,CHEMBL615694,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,15180,,H,623,8,,,51,,,,BAO_0000019,CHEMBL615695,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,16026,,H,624,8,,,51,,,,BAO_0000019,CHEMBL615696,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
F,,,,CHO,1,Autocuration,,2759,,H,625,8,449.0,,51,,,,BAO_0000219,CHEMBL615697,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
F,Homo sapiens,9606.0,,CHO,1,Expert,,2759,,D,626,9,449.0,,51,,,,BAO_0000219,CHEMBL859410,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
F,,,,CHO,1,Autocuration,,2759,,H,627,8,449.0,,51,,,,BAO_0000219,CHEMBL615841,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
F,Homo sapiens,9606.0,,CHO,1,Expert,,2759,,D,628,9,449.0,,51,,,,BAO_0000219,CHEMBL615842,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
F,,,,CHO,1,Autocuration,,2759,,H,629,8,449.0,,51,,,,BAO_0000219,CHEMBL835003,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
F,,,,CHO,1,Autocuration,,2759,,H,630,8,449.0,,51,,,,BAO_0000219,CHEMBL615843,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1)
F,Homo sapiens,9606.0,,CHO,1,Expert,,2759,,D,631,9,449.0,,51,,,,BAO_0000219,CHEMBL615979,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
F,,,,CHO,1,Autocuration,,2759,,H,632,8,449.0,,51,,,,BAO_0000219,CHEMBL615980,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
F,Homo sapiens,9606.0,,CHO,1,Expert,,2759,,D,633,9,449.0,,51,,,,BAO_0000219,CHEMBL615981,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
F,Homo sapiens,9606.0,,,1,Expert,,3445,,D,634,9,,,51,,,,BAO_0000019,CHEMBL615982,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,635,9,,,51,,,,BAO_0000019,CHEMBL615983,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,636,9,,,51,,,,BAO_0000019,CHEMBL615984,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,637,9,,,51,,,,BAO_0000019,CHEMBL615985,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,"
F,,,,CHO,1,Autocuration,,17624,,H,638,8,449.0,,51,,,,BAO_0000219,CHEMBL615986,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
F,,,,CHO,1,Autocuration,,17624,,H,639,8,449.0,,51,,,,BAO_0000219,CHEMBL615987,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
F,,,,CHO,1,Autocuration,,17624,,H,640,8,449.0,,51,,,,BAO_0000219,CHEMBL615988,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
F,,,,CHO,1,Expert,,17624,,H,641,8,449.0,,51,,,,BAO_0000219,CHEMBL615989,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
F,,,,CHO,1,Autocuration,,17624,,H,642,8,449.0,,51,,,,BAO_0000219,CHEMBL615990,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
F,,,,CHO,1,Autocuration,,17624,,H,643,8,449.0,,51,,,,BAO_0000219,CHEMBL615991,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined
F,,,,CHO,1,Autocuration,,17624,,H,644,8,449.0,,51,,,,BAO_0000219,CHEMBL615992,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
F,,,,CHO,1,Autocuration,,17624,,H,645,8,449.0,,51,,,,BAO_0000219,CHEMBL615993,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined
F,,,,CHO,1,Expert,,17624,,H,646,8,449.0,,51,,,,BAO_0000219,CHEMBL615994,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
F,,,,CHO,1,Autocuration,,17624,,H,647,8,449.0,,51,,,,BAO_0000219,CHEMBL615995,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined
F,,,,CHO,1,Autocuration,,17624,,H,648,8,449.0,,51,,,,BAO_0000219,CHEMBL615996,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
F,,,,CHO,1,Autocuration,,17624,,H,649,8,449.0,,51,,,,BAO_0000219,CHEMBL615997,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined
F,,,,,1,Autocuration,,6563,,H,650,8,,,51,,,,BAO_0000019,CHEMBL615998,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
F,,,,,1,Autocuration,,6563,,H,651,8,,,51,,,,BAO_0000019,CHEMBL615999,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
F,,,,,1,Autocuration,,6563,,H,652,8,,,51,,,,BAO_0000019,CHEMBL616000,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
F,,,,HEK293,1,Autocuration,,17296,,H,653,8,722.0,,51,,,,BAO_0000219,CHEMBL616001,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
F,Homo sapiens,9606.0,,,1,Expert,,6876,,D,654,9,,,51,,,,BAO_0000019,CHEMBL616002,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine"
F,,,,,1,Expert,,6876,,H,655,8,,,51,,,,BAO_0000019,CHEMBL616003,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,656,9,,,51,,,,BAO_0000019,CHEMBL616004,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,657,9,,,51,,,,BAO_0000019,CHEMBL616005,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data
F,,,,,1,Autocuration,,5548,,H,658,8,,,51,,,,BAO_0000019,CHEMBL616006,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
F,,,,,1,Expert,,5548,,H,659,8,,,51,,,,BAO_0000019,CHEMBL616007,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding"
F,,,,,1,Autocuration,,5548,,H,660,8,,,51,,,,BAO_0000019,CHEMBL616008,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
F,,,,,1,Autocuration,,5548,,H,661,8,,,51,,,,BAO_0000019,CHEMBL616009,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
F,,,,,1,Expert,,5929,,H,662,8,,,51,,,,BAO_0000019,CHEMBL616010,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding"
F,Homo sapiens,9606.0,,,1,Expert,,5929,,D,663,9,,,51,,,,BAO_0000019,CHEMBL616011,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined"
F,Homo sapiens,9606.0,,,1,Expert,,5929,,D,664,9,,,51,,,,BAO_0000019,CHEMBL615740,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined"
F,,,,,1,Autocuration,,16245,,H,665,8,,,51,,,,BAO_0000019,CHEMBL615741,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor"
F,,,,,1,Expert,,5640,,H,666,8,,,51,,,,BAO_0000019,CHEMBL615742,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
F,,,,,1,Autocuration,,5640,,H,667,8,,,51,,,,BAO_0000019,CHEMBL615743,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined"
F,,,,CHO,1,Autocuration,,14509,,H,668,8,449.0,,51,,,,BAO_0000219,CHEMBL615744,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay
F,,,,CHO,1,Expert,,14509,,H,669,8,449.0,,51,,,,BAO_0000219,CHEMBL615745,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.
B,,,,,1,Autocuration,,15331,,H,670,8,,,51,,,,BAO_0000357,CHEMBL615746,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
B,,,,,1,Autocuration,,15331,,H,671,8,,,51,,,,BAO_0000357,CHEMBL615747,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
F,,,,,1,Autocuration,,6563,,H,672,8,,,51,,,,BAO_0000019,CHEMBL615748,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
F,,,,,1,Autocuration,,6563,,H,673,8,,,51,,,,BAO_0000019,CHEMBL615749,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available"
F,,,,,1,Autocuration,,6563,,H,674,8,,,51,,,,BAO_0000019,CHEMBL615750,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
F,Homo sapiens,9606.0,,,1,Expert,,6563,,D,675,9,,,51,,,,BAO_0000019,CHEMBL616259,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,6563,,H,676,8,,,51,,,,BAO_0000019,CHEMBL616260,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,677,9,,,51,,,,BAO_0000019,CHEMBL616261,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,678,9,,,51,,,,BAO_0000019,CHEMBL616262,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,679,9,,,51,,,,BAO_0000019,CHEMBL616263,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,680,9,,,51,,,,BAO_0000019,CHEMBL616264,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,681,9,,,51,,,,BAO_0000019,CHEMBL616265,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,682,9,,,51,,,,BAO_0000019,CHEMBL616266,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,683,9,,,51,,,,BAO_0000019,CHEMBL616267,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
F,Homo sapiens,9606.0,,,1,Expert,,5272,,D,684,9,,,51,,,,BAO_0000019,CHEMBL616268,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,685,9,,,51,,,,BAO_0000357,CHEMBL616269,,Inhibition of human 5-hydroxytryptamine 1A receptor
B,,,,CHO,1,Autocuration,,17624,,H,686,8,449.0,,51,,,,BAO_0000219,CHEMBL884528,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
B,,,,HEK293,1,Expert,,13706,,D,687,9,722.0,,105,,,,BAO_0000219,CHEMBL616270,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells
B,,,,CHO,1,Autocuration,,15250,,H,688,8,449.0,,51,,,,BAO_0000219,CHEMBL616271,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells
F,,,,CHO,1,Autocuration,,17624,,H,689,8,449.0,,51,,,,BAO_0000219,CHEMBL616272,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,6861,,H,690,8,,,51,,,,BAO_0000357,CHEMBL616273,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay
B,Homo sapiens,9606.0,,,1,Expert,,17200,,D,691,9,,,51,,,,BAO_0000357,CHEMBL616274,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
B,,,,CHO,1,Autocuration,,17624,,H,692,8,449.0,,51,,,,BAO_0000219,CHEMBL616275,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells
B,,,,CHO,1,Autocuration,,17624,,H,693,8,449.0,,51,,,,BAO_0000219,CHEMBL616276,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,694,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616277,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,695,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616278,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,696,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616279,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,697,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616280,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,698,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616281,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,699,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616282,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,700,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616283,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,701,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616284,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,702,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616285,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,703,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616286,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,704,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616287,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,705,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616288,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,706,0,,,22226,,,In vivo,BAO_0000218,CHEMBL616289,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,707,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615610,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,708,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615611,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,709,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615612,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,710,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615613,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,711,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615614,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12058,,U,712,0,,,22226,,,In vivo,BAO_0000218,CHEMBL615615,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
B,,,,,1,Autocuration,,11440,,H,713,4,,,105093,,,,BAO_0000019,CHEMBL615616,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.
B,,,,,1,Autocuration,,6238,,H,714,8,,,11923,Hypothalamus,1898.0,,BAO_0000249,CHEMBL615617,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand
B,,,,,1,Autocuration,,10046,,H,715,8,,,10577,,,,BAO_0000019,CHEMBL615618,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data
B,,,,,1,Autocuration,,10046,,H,716,8,,,10577,,,,BAO_0000019,CHEMBL615619,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.
B,,,,,1,Expert,,10046,,H,717,8,,,10577,,,,BAO_0000019,CHEMBL615620,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
B,,,,,1,Autocuration,,167,,H,718,8,,,55,,,,BAO_0000357,CHEMBL615621,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated"
B,,,,,1,Autocuration,,167,,H,719,8,,,55,,,,BAO_0000357,CHEMBL615622,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated"
F,,,,,1,Autocuration,,11520,,H,720,8,,,12166,,,,BAO_0000019,CHEMBL615623,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase)
F,,,,,1,Autocuration,,11520,,H,721,8,,,12166,,,,BAO_0000019,CHEMBL615624,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
F,,,,,1,Autocuration,,11520,,H,722,8,,,12166,,,,BAO_0000019,CHEMBL615625,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
F,,,,,1,Autocuration,,11520,,H,723,8,,,12166,,,,BAO_0000019,CHEMBL767045,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
F,Cavia porcellus,10141.0,,,1,Autocuration,,135,,H,724,8,,,55,,,,BAO_0000019,CHEMBL615626,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN
F,Cavia porcellus,10141.0,,,1,Autocuration,,135,,H,725,8,,,55,,,,BAO_0000019,CHEMBL615627,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity
B,Cavia porcellus,10141.0,,,1,Autocuration,,11311,,H,726,8,,,55,,,,BAO_0000019,CHEMBL615628,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes
B,Cavia porcellus,10141.0,,,1,Autocuration,,10193,,H,727,8,,,55,,,,BAO_0000357,CHEMBL615629,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
B,Homo sapiens,9606.0,,,1,Expert,,12281,,D,728,9,,,55,,,,BAO_0000357,CHEMBL615630,,Inhibitory concentration against 5-lipoxygenase from human whole blood
B,,,,,1,Autocuration,,11311,,H,729,8,,,55,,,,BAO_0000219,CHEMBL615631,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS]
F,,,,,1,Autocuration,,12576,,H,730,8,,,17087,,,,BAO_0000218,CHEMBL615632,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
B,,,,,1,Autocuration,,12281,,H,731,8,,,17087,,,,BAO_0000357,CHEMBL615633,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage
F,,,,,1,Autocuration,,12576,,H,732,8,,,17087,,,,BAO_0000218,CHEMBL615634,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
B,Sus scrofa,9823.0,,,1,Expert,,11089,,H,733,8,,,55,,,,BAO_0000019,CHEMBL615635,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.
B,,,,,1,Expert,,11006,,H,734,8,,,12166,,,,BAO_0000357,CHEMBL615636,,In vitro inhibition of rat 5-Lipoxygenase
B,Rattus norvegicus,10116.0,,,1,Expert,,11481,,D,735,9,,,12166,,,,BAO_0000357,CHEMBL615637,,Inhibitory activity against 5-Lipoxygenase
B,,,,RBL-1,1,Expert,,10864,,H,736,8,702.0,,12166,,,,BAO_0000219,CHEMBL615638,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells
B,,,,RBL-1,1,Autocuration,,3595,,H,737,8,702.0,,12166,,,,BAO_0000219,CHEMBL615639,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
B,,,,RBL-1,1,Autocuration,,11311,,H,738,8,702.0,,12166,,,,BAO_0000219,CHEMBL615640,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
B,,,,,1,Autocuration,,11311,,H,739,8,,,12166,,,,BAO_0000019,CHEMBL615796,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood
B,,,,,1,Autocuration,,11311,,H,740,8,,,12166,,,,BAO_0000219,CHEMBL615845,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS]
B,,,,,1,Autocuration,,11006,,H,741,8,,,12166,,,,BAO_0000357,CHEMBL615846,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
B,,,,RBL-1,1,Autocuration,,3595,,H,742,8,702.0,,12166,,,,BAO_0000219,CHEMBL615847,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
B,,,,,1,Autocuration,,11311,,H,743,8,,,12166,,,,BAO_0000357,CHEMBL615848,,The compound was tested for inhibition of isolated 5-Lipoxygenase
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11481,,U,744,0,,,22226,,,,BAO_0000019,CHEMBL615849,,Ratio of IC50 against 5-LO and COX
B,,,,,1,Autocuration,,11006,,H,745,8,,,12166,,,,BAO_0000357,CHEMBL615850,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
B,,,,,1,Autocuration,,11006,,H,746,8,,,12166,,,,BAO_0000357,CHEMBL615851,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%
B,,,,,1,Autocuration,,11311,,H,747,8,,,12166,,,,BAO_0000219,CHEMBL615852,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration
F,,,,,1,Autocuration,,11006,,H,748,8,,,12166,,,,BAO_0000019,CHEMBL615853,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo
B,,,,,1,Autocuration,,4288,,H,749,8,,,120,Prostate gland,2367.0,,BAO_0000357,CHEMBL884527,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates
B,Columba livia,8932.0,,,1,Autocuration,,7587,,U,750,0,,,22226,,,,BAO_0000019,CHEMBL872871,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration
B,Columba livia,8932.0,,,1,Autocuration,,7587,,U,751,0,,,22226,,,,BAO_0000019,CHEMBL615854,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration
B,Columba livia,8932.0,,,1,Autocuration,,7587,,U,752,0,,,22226,,,,BAO_0000019,CHEMBL767046,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.
B,,,,,1,Autocuration,,11249,,H,753,8,,,10732,,,,BAO_0000357,CHEMBL615855,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM
F,Rattus norvegicus,10116.0,,,1,Expert,,8003,,D,754,9,,,12198,,,,BAO_0000019,CHEMBL615856,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested
F,Rattus norvegicus,10116.0,,,1,Expert,,8003,,D,755,9,,,12198,,,,BAO_0000019,CHEMBL615857,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
F,Rattus norvegicus,10116.0,,,1,Expert,,8003,,D,756,9,,,12198,,,,BAO_0000019,CHEMBL615858,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
B,,,,,1,Expert,,12416,,H,757,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615859,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
B,,,,,1,Autocuration,,16293,,H,758,8,,,51,,,,BAO_0000357,CHEMBL615860,,Binding affinity towards human 5-hydroxytryptamine 1 receptor
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,U,759,0,,,22226,,,,BAO_0000019,CHEMBL615861,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,U,760,0,,,22226,,,,BAO_0000019,CHEMBL615862,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,U,761,0,,,22226,,,,BAO_0000019,CHEMBL615863,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,U,762,0,,,22226,,,,BAO_0000019,CHEMBL615864,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
B,,,,,1,Autocuration,,10085,,H,763,4,,,104744,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615865,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
B,,,,,1,Autocuration,,10085,,H,764,4,,,104744,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615866,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
B,,,,,1,Autocuration,,10085,,H,765,4,,,104744,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615867,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
B,,,,,1,Autocuration,Membranes,9841,,H,766,4,,,104744,,,,BAO_0000249,CHEMBL615868,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8822,,D,767,5,,,104744,,,,BAO_0000249,CHEMBL615869,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9806,,D,768,5,,,104744,,,,BAO_0000019,CHEMBL615870,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9806,,D,769,5,,,104744,,,,BAO_0000019,CHEMBL615871,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates
B,,,,,1,Autocuration,,8868,,H,770,4,,,104744,,,,BAO_0000224,CHEMBL615872,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay
B,,,,,1,Autocuration,,9036,,H,771,4,,,104744,Hippocampus,10000000.0,,BAO_0000221,CHEMBL833492,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT
B,,,,,1,Autocuration,,11374,,H,772,4,,,104744,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615873,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus
B,,,,,1,Autocuration,,10881,,H,773,4,,,104744,,,,BAO_0000224,CHEMBL615479,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.
B,,,,,1,Autocuration,,8822,,H,774,4,,,104744,,,,BAO_0000019,CHEMBL615480,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9806,,D,775,5,,,104744,,,,BAO_0000249,CHEMBL615481,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.
B,,,,,1,Autocuration,,15463,,H,776,4,,,104744,,,,BAO_0000019,CHEMBL872869,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
B,,,,,1,Autocuration,,15463,,H,777,4,,,104744,,,,BAO_0000019,CHEMBL615482,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
B,,,,,1,Autocuration,,14542,,H,778,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615483,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
B,,,,,1,Autocuration,,14542,,H,779,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615484,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
B,,,,,1,Autocuration,,8569,,H,780,4,,,104744,,,,BAO_0000019,CHEMBL615485,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,,10062,,D,781,5,,,104744,,,,BAO_0000224,CHEMBL615486,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,4771,,H,782,4,,,104744,,,,BAO_0000224,CHEMBL615487,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,10062,,H,783,4,,,104744,,,,BAO_0000224,CHEMBL615488,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,10062,,H,784,4,,,104744,,,,BAO_0000224,CHEMBL615489,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,10062,,H,785,4,,,104744,,,,BAO_0000224,CHEMBL615389,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,15463,,H,786,4,,,104744,,,,BAO_0000019,CHEMBL615390,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,15463,,H,787,4,,,104744,,,,BAO_0000019,CHEMBL615391,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,9098,,H,788,4,,,104744,,,,BAO_0000224,CHEMBL615392,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined
B,Rattus norvegicus,10116.0,,,1,Autocuration,,3070,,U,789,0,,,22226,,,,BAO_0000019,CHEMBL615393,,Affinity for 5-hydroxytryptamine 1 receptor
B,,,,,1,Autocuration,,14542,,H,790,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615394,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex
B,,,,,1,Autocuration,,14542,,H,791,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615395,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
B,,,,,1,Autocuration,,6398,,H,792,4,,,104744,,,,BAO_0000224,CHEMBL615396,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding
B,,,,,1,Autocuration,,1344,,H,793,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615397,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay
B,,,,,1,Autocuration,,11963,,H,794,4,,,104744,,,,BAO_0000019,CHEMBL615398,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8908,,U,795,0,,,22226,,,,BAO_0000019,CHEMBL615399,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex
B,,,,,1,Autocuration,,9098,,H,796,4,,,104744,,,,BAO_0000019,CHEMBL615400,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8841,,D,797,5,,,104744,,,,BAO_0000019,CHEMBL615401,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8814,,U,798,0,,,22226,,,,BAO_0000019,CHEMBL615402,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates
B,,,,,1,Autocuration,,11752,,H,799,4,,,104744,,,,BAO_0000019,CHEMBL615403,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex
B,,,,,1,Autocuration,,11642,,H,800,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615404,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue
B,,,,,1,Autocuration,,11642,,H,801,4,,,104744,,,,BAO_0000019,CHEMBL615781,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex
B,,,,,1,Autocuration,,9231,,H,802,4,,,104744,Brain,955.0,,BAO_0000220,CHEMBL615782,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes
B,,,,,1,Autocuration,,11351,,H,803,4,,,104744,Brain,955.0,,BAO_0000221,CHEMBL615783,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.
B,,,,,1,Autocuration,,4639,,U,804,0,,,22226,,,,BAO_0000019,CHEMBL873481,,Compound was tested for binding affinity against 5-HT1 receptor
B,,,,,1,Autocuration,,1205,,U,805,0,,,22226,,,,BAO_0000019,CHEMBL615784,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor
B,,,,,1,Expert,,10025,,H,806,8,,,10576,,,,BAO_0000357,CHEMBL615785,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
F,,,,,1,Autocuration,,13241,,H,807,8,,,10576,,,,BAO_0000249,CHEMBL615786,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
F,,,,,1,Autocuration,,16245,,H,808,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615787,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
F,,,,,1,Autocuration,,16245,,H,809,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615788,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
F,,,,,1,Autocuration,,12438,,H,810,8,,,10576,,,,BAO_0000019,CHEMBL767044,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,16245,,H,811,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615789,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
F,,,,,1,Autocuration,,16245,,H,812,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615790,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
F,,,,,1,Autocuration,,15740,,H,813,8,,,10576,,,,BAO_0000019,CHEMBL615813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats
F,,,,,1,Autocuration,,15535,,H,814,8,,,10576,,,,BAO_0000219,CHEMBL615814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration
F,,,,,1,Expert,,15535,,H,815,8,,,51,,,,BAO_0000219,CHEMBL615815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT
F,,,,,1,Autocuration,,15535,,H,816,8,,,10576,,,,BAO_0000219,CHEMBL615816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect
B,,,,,1,Expert,,9888,,H,817,8,,,10576,,,,BAO_0000249,CHEMBL615817,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values
B,,,,,1,Autocuration,,10085,,H,818,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT
B,,,,,1,Autocuration,,10085,,H,819,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT
B,,,,,1,Expert,Membranes,17331,,H,820,8,,,10576,,,,BAO_0000249,CHEMBL615820,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes
B,Rattus norvegicus,10116.0,,,1,Expert,,10845,,D,821,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615821,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT
B,Rattus norvegicus,10116.0,,,1,Expert,,10845,,D,822,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615822,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
B,,,,,1,Expert,,10845,,H,823,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,10845,,D,824,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615824,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive
B,Rattus norvegicus,10116.0,,,1,Expert,,10845,,D,825,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615825,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
B,,,,,1,Expert,,13730,,H,826,8,,,10576,,,,BAO_0000357,CHEMBL615826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13508,,H,827,8,,,10576,,,,BAO_0000249,CHEMBL615827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13508,,H,828,8,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL615828,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,12073,,H,829,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615829,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Autocuration,,4671,,H,830,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13631,,H,831,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand
B,,,,,1,Autocuration,,12438,,H,832,8,,,10576,,,,BAO_0000357,CHEMBL615832,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,10483,,H,833,8,,,10576,,,,BAO_0000019,CHEMBL615833,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand
B,,,,,1,Autocuration,,10483,,H,834,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand
B,,,,,1,Intermediate,,12352,,H,835,8,,,10576,,,,BAO_0000249,CHEMBL615835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes
B,,,,,1,Autocuration,,14732,,H,836,8,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL615836,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.
B,Rattus norvegicus,10116.0,,,1,Expert,,11049,,D,837,9,,,10576,,,,BAO_0000019,CHEMBL615837,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.
B,Rattus norvegicus,10116.0,,,1,Expert,,11049,,D,838,9,,,10576,,,,BAO_0000019,CHEMBL615838,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined
B,,,,,1,Expert,,13657,,H,839,8,,,10576,,,,BAO_0000249,CHEMBL615839,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)"
B,,,,,1,Autocuration,,11473,,H,840,8,,,10576,,,,BAO_0000019,CHEMBL884525,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,2014,,H,841,8,,,10576,,,,BAO_0000249,CHEMBL615840,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
B,,,,,1,Expert,,3086,,H,842,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615405,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Expert,,15854,,H,843,8,,,10576,,,,BAO_0000019,CHEMBL615406,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
B,,,,,1,Expert,,10922,,H,844,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615900,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
B,,,,,1,Expert,,13346,,H,845,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615901,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.
B,,,,,1,Expert,,15311,,H,846,8,,,10576,,,,BAO_0000357,CHEMBL615902,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.
B,,,,,1,Autocuration,,10922,,H,847,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615903,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
B,,,,,1,Autocuration,,10025,,H,848,8,,,10576,,,,BAO_0000357,CHEMBL615904,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM
B,,,,,1,Expert,,10025,,H,849,8,,,10576,,,,BAO_0000357,CHEMBL615905,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
B,,,,,1,Autocuration,,9742,,H,850,8,,,10576,,,,BAO_0000019,CHEMBL615906,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
F,,,,,1,Autocuration,,9742,,H,851,8,,,10576,,,,BAO_0000019,CHEMBL615907,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
B,,,,,1,Expert,,12304,,H,852,8,,,10576,,,,BAO_0000019,CHEMBL615908,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
B,,,,,1,Autocuration,,15789,,H,853,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615909,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus
B,,,,,1,Autocuration,,9912,,H,854,8,,,10576,,,,BAO_0000019,CHEMBL615910,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand"
B,,,,,1,Autocuration,,9912,,H,855,8,,,10576,,,,BAO_0000019,CHEMBL615911,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand."
B,,,,,1,Autocuration,,9912,,H,856,8,,,10576,,,,BAO_0000019,CHEMBL615912,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand"
B,,,,,1,Expert,,16693,,H,857,8,,,10576,,,,BAO_0000019,CHEMBL615913,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13276,,H,858,8,,,10576,,,,BAO_0000357,CHEMBL615914,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,12678,,H,859,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615915,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
B,,,,,1,Autocuration,,11825,,H,860,8,,,10576,,,,BAO_0000357,CHEMBL615916,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated
B,,,,,1,Expert,,12443,,H,861,8,,,10576,,,,BAO_0000357,CHEMBL615917,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin
B,,,,,1,Expert,,13830,,H,862,8,,,10576,,,,BAO_0000357,CHEMBL615918,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,14286,,H,863,8,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL615919,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.
B,Rattus norvegicus,10116.0,,,1,Expert,,14356,,D,864,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615920,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
B,,,,,1,Autocuration,,15306,,H,865,8,,,10576,,,,BAO_0000357,CHEMBL615921,,Inhibition concentration against 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,15306,,H,866,8,,,10576,,,,BAO_0000357,CHEMBL615922,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration)
F,Rattus norvegicus,10116.0,,,1,Expert,,16616,,D,867,9,,,10576,,,,BAO_0000249,CHEMBL881290,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
B,,,,,1,Autocuration,,3651,,H,868,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615923,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%"
F,,,,,1,Autocuration,,14331,,H,869,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615924,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
F,,,,,1,Autocuration,,14331,,H,870,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615925,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,871,9,,,10576,,,,BAO_0000357,CHEMBL615926,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,10639,,D,872,9,,,10576,,,,BAO_0000019,CHEMBL615927,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,12306,,H,873,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615928,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
B,Rattus norvegicus,10116.0,,,1,Expert,,1348,,D,874,9,,,10576,,,,BAO_0000357,CHEMBL615929,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype
B,,,,,1,Autocuration,,13605,,H,875,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615930,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus
B,,,,CHO,1,Autocuration,,17624,,H,876,8,449.0,,51,,,,BAO_0000219,CHEMBL615931,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
F,,,,CHO,1,Autocuration,,17624,,H,877,8,449.0,,51,,,,BAO_0000219,CHEMBL615932,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
F,,,,CHO,1,Autocuration,,17624,,H,878,8,449.0,,51,,,,BAO_0000219,CHEMBL615933,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15267,,H,879,8,,,51,,,,BAO_0000357,CHEMBL615934,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,16532,,H,880,8,,,51,,,,BAO_0000357,CHEMBL615935,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested
F,,,,,1,Autocuration,,6563,,H,881,8,,,51,,,,BAO_0000019,CHEMBL615936,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
B,,,,CHO,1,Autocuration,,4751,,H,882,8,449.0,,51,,,,BAO_0000219,CHEMBL615937,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM
B,,,,,1,Autocuration,,15463,,H,883,8,,,51,,,,BAO_0000357,CHEMBL615938,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,3805,,H,884,8,,,51,,,,BAO_0000357,CHEMBL615797,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM)
B,,,,,1,Autocuration,,5640,,H,885,8,,,51,,,,BAO_0000357,CHEMBL615798,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,6563,,H,886,8,,,51,,,,BAO_0000357,CHEMBL872870,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration
B,,,,,1,Autocuration,,5548,,H,887,8,,,51,,,,BAO_0000357,CHEMBL615799,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration
B,,,,,1,Autocuration,,6347,,H,888,8,,,51,,,,BAO_0000357,CHEMBL615800,,Percent binding affinity against 5-hydroxytryptamine 1A receptor
F,,,,HEK293,1,Autocuration,,17296,,H,889,8,722.0,,51,,,,BAO_0000219,CHEMBL615801,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
B,,,,,1,Autocuration,,13047,,H,890,8,,,51,,,,BAO_0000019,CHEMBL615802,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium
B,,,,,1,Autocuration,,15740,,H,891,8,,,51,,,,BAO_0000357,CHEMBL615803,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor
F,,,,,1,Expert,,5640,,H,892,8,,,51,,,,BAO_0000019,CHEMBL835002,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
F,,,,,1,Autocuration,,5640,,H,893,8,,,51,,,,BAO_0000019,CHEMBL615804,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined"
B,,,,HeLa,1,Expert,,17211,,H,894,8,308.0,,51,,,,BAO_0000219,CHEMBL615805,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor
B,,,,CHO,1,Autocuration,,4751,,H,895,8,449.0,,51,,,,BAO_0000219,CHEMBL615806,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,896,9,,,51,,,,BAO_0000357,CHEMBL615807,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor
B,,,,,1,Autocuration,,4707,,H,897,8,,,51,,,,BAO_0000357,CHEMBL615808,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,13910,,D,898,9,,,51,,,,BAO_0000357,CHEMBL615809,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,HeLa,1,Autocuration,,16190,,H,899,8,308.0,,51,,,,BAO_0000219,CHEMBL615810,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT
B,,,,,1,Autocuration,,16633,,H,900,8,,,51,,,,BAO_0000357,CHEMBL615811,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,CHO,1,Autocuration,,11898,,H,901,8,449.0,,51,,,,BAO_0000219,CHEMBL615812,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells
B,,,,CHO,1,Autocuration,,11898,,H,902,8,449.0,,51,,,,BAO_0000219,CHEMBL615751,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
B,,,,,1,Autocuration,,14331,,H,903,8,,,51,,,,BAO_0000357,CHEMBL615752,,Binding affinity against human 5-hydroxytryptamine 1A receptor
B,,,,CHO,1,Expert,,17624,,H,904,8,449.0,,51,,,,BAO_0000219,CHEMBL615753,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand
B,,,,CHO,1,Autocuration,,17624,,H,905,8,449.0,,51,,,,BAO_0000219,CHEMBL615754,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined
B,,,,,1,Autocuration,,3307,,H,906,8,,,51,,,,BAO_0000357,CHEMBL615755,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,6563,,D,907,9,449.0,,51,,,,BAO_0000219,CHEMBL615756,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
B,,,,,1,Autocuration,,14165,,H,908,8,,,51,,,,BAO_0000019,CHEMBL615757,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,5732,,H,909,8,,,51,,,,BAO_0000357,CHEMBL615758,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
B,,,,,1,Expert,,13366,,H,910,8,,,51,,,,BAO_0000357,CHEMBL615759,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
B,,,,,1,Autocuration,,17626,,H,911,8,,,51,,,,BAO_0000357,CHEMBL615760,,Binding affinity towards human 5-hydroxytryptamine 1A receptor
B,,,,HeLa,1,Expert,,6588,,H,912,8,308.0,,51,,,,BAO_0000219,CHEMBL615761,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells
B,,,,,1,Autocuration,,16209,,H,913,8,,,51,,,,BAO_0000357,CHEMBL872104,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand
B,,,,,1,Autocuration,,15463,,H,914,8,,,51,,,,BAO_0000357,CHEMBL615762,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,15463,,H,915,8,,,51,,,,BAO_0000357,CHEMBL615763,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,14770,,H,916,8,,,51,,,,BAO_0000357,CHEMBL615764,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.
B,,,,Cell line,1,Autocuration,,16245,,H,917,8,1167.0,,51,,,,BAO_0000219,CHEMBL615765,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La)
B,,,,,1,Autocuration,,16245,,H,918,8,,,51,,,,BAO_0000019,CHEMBL615766,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La)
B,,,,,1,Autocuration,,5548,,H,919,8,,,51,,,,BAO_0000357,CHEMBL615767,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,5548,,H,920,8,,,51,,,,BAO_0000357,CHEMBL615768,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,5548,,H,921,8,,,51,,,,BAO_0000357,CHEMBL615769,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,6876,,H,922,8,,,51,,,,BAO_0000357,CHEMBL615770,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT
B,,,,,1,Autocuration,,2598,,H,923,8,,,51,,,,BAO_0000357,CHEMBL615771,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,17785,,H,924,8,,,51,,,,BAO_0000357,CHEMBL615772,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand
B,,,,,1,Autocuration,,6013,,H,925,8,,,51,,,,BAO_0000357,CHEMBL615773,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,5929,,H,926,8,,,51,,,,BAO_0000357,CHEMBL615774,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,16633,,H,927,8,,,51,,,,BAO_0000357,CHEMBL615775,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,1558,,H,928,8,,,51,,,,BAO_0000357,CHEMBL615776,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
B,,,,,1,Expert,,16026,,H,929,8,,,51,,,,BAO_0000357,CHEMBL615777,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,12469,,H,930,8,,,51,,,,BAO_0000219,CHEMBL615778,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT
B,Homo sapiens,9606.0,,,1,Expert,,15874,,D,931,9,,,51,,,,BAO_0000357,CHEMBL615779,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
B,,,,,1,Autocuration,,15874,,H,932,8,,,51,,,,BAO_0000357,CHEMBL615780,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
B,,,,,1,Autocuration,,3935,,H,933,8,,,51,,,,BAO_0000357,CHEMBL616298,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15818,,H,934,8,,,51,,,,BAO_0000357,CHEMBL616299,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor
B,,,,CHO-K1,1,Autocuration,,13706,,H,935,8,485.0,,51,,,,BAO_0000219,CHEMBL616300,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.
F,,,,CHO-K1,1,Expert,,13729,,H,936,8,485.0,,51,,,,BAO_0000219,CHEMBL616301,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells
B,,,,,1,Autocuration,,15413,,H,937,8,,,51,,,,BAO_0000019,CHEMBL616302,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15413,,H,938,8,,,51,,,,BAO_0000019,CHEMBL616117,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1)
B,,,,,1,Autocuration,,15413,,H,939,8,,,51,,,,BAO_0000019,CHEMBL616118,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2)
B,,,,,1,Autocuration,,15413,,H,940,8,,,51,,,,BAO_0000019,CHEMBL616119,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay
B,Homo sapiens,9606.0,,HeLa,1,Expert,,3445,,D,941,9,308.0,,51,,,,BAO_0000219,CHEMBL616120,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
B,,,,,1,Autocuration,,15740,,H,942,8,,,51,,,,BAO_0000357,CHEMBL616121,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15740,,H,943,8,,,51,,,,BAO_0000357,CHEMBL616122,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor
B,,,,,1,Autocuration,,17626,,H,944,8,,,51,,,,BAO_0000357,CHEMBL616123,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,945,9,,,51,,,,BAO_0000357,CHEMBL616124,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,5640,,H,946,8,,,51,,,,BAO_0000357,CHEMBL616125,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
B,Rattus norvegicus,10116.0,,,1,Expert,,5272,,H,947,8,,,51,,,,BAO_0000357,CHEMBL616126,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT
B,,,,CHO,1,Autocuration,,4622,,H,948,8,449.0,,51,,,,BAO_0000219,CHEMBL616127,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,17085,,H,949,8,,,51,,,,BAO_0000019,CHEMBL616128,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,3025,,H,950,8,,,51,,,,BAO_0000357,CHEMBL616129,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
B,,,,,1,Expert,,15315,,H,951,8,,,51,,,,BAO_0000357,CHEMBL616130,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15267,,H,952,8,,,51,,,,BAO_0000357,CHEMBL616131,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant
B,,,,HeLa,1,Autocuration,,17158,,H,953,8,308.0,,51,,,,BAO_0000219,CHEMBL616132,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells
B,Homo sapiens,9606.0,,HeLa,1,Expert,,14214,,D,954,9,308.0,,51,,,,BAO_0000219,CHEMBL616133,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells
B,,,,,1,Autocuration,,17133,,H,955,8,,,51,,,,BAO_0000357,CHEMBL616134,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,16532,,H,956,8,,,51,,,,BAO_0000357,CHEMBL616135,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT
B,Homo sapiens,9606.0,,,1,Expert,,2391,,D,957,9,,,51,,,,BAO_0000357,CHEMBL616136,,Affinity for 5-hydroxytryptamine 1A receptor subtype
B,,,,,1,Autocuration,,14447,,H,958,8,,,51,,,,BAO_0000019,CHEMBL616137,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes
B,,,,,1,Autocuration,,14447,,H,959,8,,,51,,,,BAO_0000019,CHEMBL872105,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.
B,,,,,1,Autocuration,,15086,,H,960,8,,,51,,,,BAO_0000357,CHEMBL616138,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor
B,Homo sapiens,9606.0,,,1,Expert,,13051,,D,961,9,,,51,,,,BAO_0000357,CHEMBL616139,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,16026,,H,962,8,,,51,,,,BAO_0000019,CHEMBL616140,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active"
B,,,,,1,Expert,,17085,,H,963,8,,,51,,,,BAO_0000019,CHEMBL616141,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined
B,,,,,1,Autocuration,,17133,,H,964,8,,,51,,,,BAO_0000357,CHEMBL616142,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,17133,,H,965,8,,,51,,,,BAO_0000357,CHEMBL616143,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined
B,,,,HeLa,1,Autocuration,,17211,,H,966,8,308.0,,51,,,,BAO_0000219,CHEMBL616144,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
B,,,,HeLa,1,Autocuration,,17211,,H,967,8,308.0,,51,,,,BAO_0000219,CHEMBL616145,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested
B,,,,HeLa,1,Autocuration,,17211,,H,968,8,308.0,,51,,,,BAO_0000219,CHEMBL616012,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
B,,,,HeLa,1,Autocuration,,17211,,H,969,8,308.0,,51,,,,BAO_0000219,CHEMBL616013,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
F,,,,,1,Autocuration,,16394,,H,970,8,,,51,,,,BAO_0000019,CHEMBL616014,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
F,,,,,1,Autocuration,,16394,,H,971,8,,,51,,,,BAO_0000019,CHEMBL616015,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
F,,,,,1,Autocuration,,16394,,H,972,8,,,51,,,,BAO_0000019,CHEMBL616016,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
F,,,,,1,Autocuration,,16394,,H,973,8,,,51,,,In vivo,BAO_0000218,CHEMBL616017,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested
B,,,,,1,Autocuration,,16394,,H,974,8,,,51,,,,BAO_0000019,CHEMBL616018,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested
F,,,,,1,Autocuration,,15740,,H,975,8,,,51,,,,BAO_0000019,CHEMBL616019,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested
F,,,,,1,Autocuration,,15740,,H,976,8,,,51,,,,BAO_0000019,CHEMBL616020,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested
B,,,,,1,Autocuration,,15740,,H,977,8,,,51,,,,BAO_0000357,CHEMBL858018,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
F,,,,HEK293,1,Autocuration,,17296,,H,978,8,722.0,,51,,,,BAO_0000219,CHEMBL616021,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
F,,,,,1,Expert,,5640,,H,979,8,,,51,,,,BAO_0000019,CHEMBL616022,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM."
F,,,,,1,Autocuration,,5640,,H,980,8,,,51,,,,BAO_0000019,CHEMBL616023,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined"
F,,,,,1,Autocuration,,5640,,H,981,8,,,51,,,,BAO_0000019,CHEMBL616024,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined"
F,,,,,1,Autocuration,,5640,,H,982,8,,,51,,,,BAO_0000019,CHEMBL616025,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined"
F,,,,CHO,1,Autocuration,,2759,,H,983,8,449.0,,51,,,,BAO_0000219,CHEMBL616026,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
F,,,,,1,Autocuration,,16394,,H,984,8,,,51,,,,BAO_0000019,CHEMBL616027,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT"
F,Homo sapiens,9606.0,,,1,Expert,,16394,,D,985,9,,,51,,,,BAO_0000019,CHEMBL616028,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT"
F,Homo sapiens,9606.0,,,1,Expert,,3445,,D,986,9,,,51,,,,BAO_0000019,CHEMBL616029,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response
B,,,,CHO,1,Expert,,4316,,H,987,8,449.0,,51,,,,BAO_0000219,CHEMBL616030,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT
B,,,,,1,Expert,,4316,,H,988,8,,,51,,,,BAO_0000019,CHEMBL616031,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.
F,Homo sapiens,9606.0,,,1,Expert,,15180,,D,989,9,,,51,,,,BAO_0000019,CHEMBL616032,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
F,Homo sapiens,9606.0,,,1,Expert,,15180,,D,990,9,,,51,,,,BAO_0000019,CHEMBL616033,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
F,,,,,1,Autocuration,,15042,,H,991,8,,,51,,,,BAO_0000019,CHEMBL616034,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
F,,,,,1,Autocuration,,15042,,H,992,8,,,51,,,,BAO_0000019,CHEMBL616035,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
F,,,,,1,Autocuration,,15042,,H,993,8,,,51,,,,BAO_0000019,CHEMBL616036,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,15042,,H,994,8,,,51,,,,BAO_0000019,CHEMBL616037,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
F,,,,,1,Autocuration,,15042,,H,995,8,,,51,,,,BAO_0000019,CHEMBL616038,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
F,,,,,1,Autocuration,,15042,,H,996,8,,,51,,,,BAO_0000019,CHEMBL616039,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
F,,,,,1,Autocuration,,15042,,H,997,8,,,51,,,,BAO_0000019,CHEMBL616040,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
F,Homo sapiens,9606.0,,HeLa,1,Expert,,15180,,D,998,9,308.0,,51,,,,BAO_0000219,CHEMBL616041,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
F,Homo sapiens,9606.0,,HeLa,1,Expert,,15180,,D,999,9,308.0,,51,,,,BAO_0000219,CHEMBL616042,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
F,Homo sapiens,9606.0,,HeLa,1,Expert,,15180,,D,1000,9,308.0,,51,,,,BAO_0000219,CHEMBL616043,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
F,,,,,1,Autocuration,,16245,,H,1001,8,,,51,,,,BAO_0000019,CHEMBL616044,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor"
F,,,,,1,Autocuration,,16026,,H,1002,8,,,51,,,,BAO_0000019,CHEMBL616045,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
F,,,,HEK293,1,Autocuration,,17296,,H,1003,8,722.0,,51,,,,BAO_0000219,CHEMBL616046,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
F,,,,CHO,1,Autocuration,,2759,,H,1004,8,449.0,,51,,,,BAO_0000219,CHEMBL616047,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
F,,,,CHO,1,Autocuration,,2759,,H,1005,8,449.0,,51,,,,BAO_0000219,CHEMBL616048,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells
F,Homo sapiens,9606.0,,CHO,1,Expert,,2759,,D,1006,9,449.0,,51,,,,BAO_0000219,CHEMBL616049,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1)
F,,,,CHO,1,Autocuration,,2759,,H,1007,8,449.0,,51,,,,BAO_0000219,CHEMBL616050,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
F,,,,,1,Expert,,15419,,H,1008,8,,,51,,,,BAO_0000219,CHEMBL616051,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor
F,,,,,1,Autocuration,,15419,,H,1009,8,,,51,,,,BAO_0000219,CHEMBL616212,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested
F,,,,,1,Autocuration,,16026,,H,1010,8,,,51,,,,BAO_0000019,CHEMBL616213,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
B,,,,,1,Expert,,1414,,H,1011,8,,,51,,,In vitro,BAO_0000219,CHEMBL616214,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells
B,,,,,1,Expert,,1414,,H,1012,8,,,51,,,In vitro,BAO_0000219,CHEMBL616215,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells
B,,,,,1,Autocuration,,12861,,H,1013,8,,,51,,,,BAO_0000357,CHEMBL616216,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,1014,8,,,51,,,,BAO_0000019,CHEMBL616217,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
B,,,,,1,Autocuration,,5104,,H,1015,8,,,51,,,,BAO_0000357,CHEMBL616218,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,5105,,H,1016,8,,,51,,,,BAO_0000357,CHEMBL616219,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,16312,,H,1017,8,,,51,,,,BAO_0000357,CHEMBL616220,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,,1,Expert,,15180,,D,1018,9,,,51,,,,BAO_0000357,CHEMBL833493,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,5033,,H,1019,8,,,51,,,,BAO_0000357,CHEMBL616221,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,16909,,D,1020,9,449.0,,51,,,,BAO_0000219,CHEMBL616222,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
F,,,,,1,Autocuration,,2590,,H,1021,8,,,51,,,,BAO_0000019,CHEMBL616223,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,2590,,H,1022,8,,,51,,,,BAO_0000019,CHEMBL616224,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined
B,,,,,1,Expert,,16394,,H,1023,8,,,51,,,,BAO_0000019,CHEMBL616225,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,1024,9,722.0,,51,,,,BAO_0000219,CHEMBL616226,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand
B,,,,HEK293,1,Autocuration,,17296,,H,1025,8,722.0,,51,,,,BAO_0000219,CHEMBL616227,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells
B,,,,HEK293,1,Autocuration,,17296,,H,1026,8,722.0,,51,,,,BAO_0000219,CHEMBL616228,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,1027,8,722.0,,51,,,,BAO_0000219,CHEMBL616229,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
B,,,,HEK293,1,Autocuration,,15779,,H,1028,8,722.0,,51,,,,BAO_0000219,CHEMBL616230,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data
B,,,,HEK293,1,Autocuration,,15779,,H,1029,8,722.0,,51,,,,BAO_0000219,CHEMBL616231,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.
B,,,,,1,Autocuration,,6166,,H,1030,8,,,51,,,,BAO_0000357,CHEMBL616232,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,1031,8,722.0,,51,,,,BAO_0000219,CHEMBL616233,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
B,,,,HEK293,1,Autocuration,,4199,,H,1032,8,722.0,,51,,,,BAO_0000219,CHEMBL857973,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand
B,,,,,1,Autocuration,,15316,,H,1033,8,,,51,,,,BAO_0000219,CHEMBL616234,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells
B,,,,,1,Autocuration,,14875,,H,1034,8,,,51,,,,BAO_0000357,CHEMBL616235,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor
B,,,,HeLa,1,Expert,,14727,,H,1035,8,308.0,,51,,,,BAO_0000219,CHEMBL616236,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
B,,,,,1,Expert,,14727,,H,1036,8,,,51,,,,BAO_0000019,CHEMBL616237,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
B,,,,HEK293,1,Autocuration,,15146,,H,1037,8,722.0,,51,,,,BAO_0000219,CHEMBL616238,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT
B,,,,HEK293,1,Autocuration,,5213,,H,1038,8,722.0,,51,,,,BAO_0000219,CHEMBL616239,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand
B,,,,,1,Autocuration,,16429,,H,1039,8,,,51,,,,BAO_0000219,CHEMBL616240,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand
B,Homo sapiens,9606.0,,HeLa,1,Expert,,15042,,D,1040,9,308.0,,51,,,,BAO_0000219,CHEMBL616241,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.
B,,,,HEK293,1,Autocuration,,14818,,H,1041,8,722.0,,51,,,,BAO_0000219,CHEMBL616242,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.
B,,,,HEK293,1,Autocuration,,4829,,H,1042,8,722.0,,51,,,,BAO_0000219,CHEMBL616243,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand"
B,,,,,1,Expert,,17200,,D,1043,9,,,51,,,,BAO_0000357,CHEMBL616244,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
B,Homo sapiens,9606.0,,,1,Autocuration,,13051,,D,1044,9,,,51,,,,BAO_0000357,CHEMBL616245,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,5486,,H,1045,8,,,106,,,,BAO_0000357,CHEMBL616246,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
B,,,,,1,Autocuration,,5254,,H,1046,8,,,105,,,,BAO_0000357,CHEMBL616247,,Binding affinity against 5-HT1D receptor
B,,,,,1,Autocuration,,5254,,H,1047,8,,,105,,,,BAO_0000357,CHEMBL616248,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15331,,H,1048,8,,,107,,,,BAO_0000357,CHEMBL616249,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
B,Homo sapiens,9606.0,,,1,Autocuration,,13506,,H,1049,8,,,10576,,,,BAO_0000357,CHEMBL616250,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
B,,,,,1,Autocuration,,15267,,H,1050,8,,,51,,,,BAO_0000357,CHEMBL616251,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,16616,,H,1051,8,,,11863,,,In vivo,BAO_0000218,CHEMBL616252,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound
F,,,,,1,Autocuration,,16616,,H,1052,8,,,11863,,,In vivo,BAO_0000218,CHEMBL616253,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound
F,,,,,1,Autocuration,,16616,,H,1053,8,,,11863,,,In vivo,BAO_0000218,CHEMBL616254,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1054,9,,,11863,,,,BAO_0000218,CHEMBL616255,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1055,9,,,11863,,,,BAO_0000218,CHEMBL832872,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1056,9,,,11863,,,,BAO_0000218,CHEMBL616256,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1057,9,,,11863,,,,BAO_0000218,CHEMBL616257,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1058,9,,,11863,,,,BAO_0000218,CHEMBL616258,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min
F,Mus musculus,10090.0,,,1,Expert,,16616,,D,1059,9,,,11863,,,,BAO_0000218,CHEMBL616384,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min
B,,,,,1,Autocuration,,10297,,H,1060,8,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616385,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
B,,,,,1,Expert,,13704,,H,1061,8,,,11863,,,,BAO_0000357,CHEMBL616386,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.
B,Mus musculus,10090.0,,,1,Expert,,10297,,D,1062,9,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616387,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
B,,,,,1,Autocuration,,10297,,H,1063,8,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616388,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
B,Mus musculus,10090.0,,,1,Expert,,10297,,D,1064,9,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616389,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
B,,,,,1,Autocuration,,10297,,H,1065,8,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616390,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
B,,,,,1,Autocuration,,217,,H,1066,8,,,11863,,,,BAO_0000357,CHEMBL616391,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand
B,Mus musculus,10090.0,,,1,Expert,,10297,,D,1067,9,,,11863,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616392,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
B,Sus scrofa,9823.0,,,1,Autocuration,,4921,,H,1068,8,,,51,,,,BAO_0000357,CHEMBL616393,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,4921,,H,1069,8,,,51,,,,BAO_0000357,CHEMBL616394,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined
B,Sus scrofa,9823.0,,,1,Autocuration,,4996,,H,1070,8,,,51,,,,BAO_0000019,CHEMBL616395,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates
B,Sus scrofa,9823.0,,,1,Autocuration,,12918,,H,1071,8,,,51,,,,BAO_0000357,CHEMBL616396,,Compound was evaluated for the binding affinity at 5- HT1A receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,5333,,H,1072,8,,,51,,,,BAO_0000019,CHEMBL872907,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate
B,Sus scrofa,9823.0,,,1,Autocuration,,4437,,H,1073,8,,,51,,,,BAO_0000019,CHEMBL616397,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate
B,Sus scrofa,9823.0,,,1,Autocuration,,1742,,H,1074,8,,,51,,,,BAO_0000019,CHEMBL616398,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex
B,Sus scrofa,9823.0,,,1,Expert,,16688,,H,1075,8,,,51,,,,BAO_0000357,CHEMBL616399,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,12861,,H,1076,8,,,51,,,,BAO_0000357,CHEMBL857065,,Binding activity radioligand.
B,Sus scrofa,9823.0,,,1,Expert,,12861,,H,1077,8,,,51,,,,BAO_0000019,CHEMBL616400,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
B,Sus scrofa,9823.0,,,1,Autocuration,,12861,,H,1078,8,,,51,,,,BAO_0000019,CHEMBL616401,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
B,,,,,1,Expert,,12490,,H,1079,8,,,10624,,,,BAO_0000019,CHEMBL616402,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex
B,Sus scrofa,9823.0,,,1,Expert,,11828,,H,1080,8,,,51,,,,BAO_0000019,CHEMBL616403,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,11866,,H,1081,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616404,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT
B,Sus scrofa,9823.0,,,1,Autocuration,,12827,,H,1082,8,,,51,,,,BAO_0000249,CHEMBL616405,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT
B,Sus scrofa,9823.0,,,1,Autocuration,,12918,,H,1083,8,,,51,,,,BAO_0000019,CHEMBL616406,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT
F,Sus scrofa,9823.0,,,1,Expert,,12919,,H,1084,8,,,51,,,,BAO_0000019,CHEMBL616407,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,1085,8,,,51,,,,BAO_0000019,CHEMBL616408,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium
B,Rattus norvegicus,10116.0,,,1,Expert,,15796,,D,1086,9,,,10576,,,,BAO_0000249,CHEMBL616409,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays
B,Rattus norvegicus,10116.0,,,1,Expert,,3651,,D,1087,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616410,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active"
B,,,,,1,Autocuration,,188,,H,1088,8,,,10576,,,,BAO_0000357,CHEMBL616411,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity
F,Rattus norvegicus,10116.0,,,1,Expert,Membranes,16616,,D,1089,9,,,10576,,,,BAO_0000249,CHEMBL616412,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
F,Rattus norvegicus,10116.0,,,1,Expert,Membranes,16616,,D,1090,9,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL616413,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
B,,,,,1,Autocuration,,12306,,H,1091,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616414,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
B,Rattus norvegicus,10116.0,,,1,Expert,,17167,,D,1092,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616415,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding
B,,,,,1,Autocuration,,14776,,H,1093,8,,,10576,,,,BAO_0000019,CHEMBL616416,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.
B,,,,,1,Expert,,12158,,H,1094,8,,,10576,,,,BAO_0000357,CHEMBL616417,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,13481,,H,1095,8,,,10576,,,,BAO_0000357,CHEMBL616418,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay
B,,,,,1,Autocuration,,13427,,H,1096,8,,,10576,,,In vitro,BAO_0000219,CHEMBL616419,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
B,,,,,1,Autocuration,,10210,,H,1097,8,,,10576,,,,BAO_0000357,CHEMBL616420,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT
B,,,,,1,Autocuration,Membranes,10205,,H,1098,8,,,10576,,,,BAO_0000249,CHEMBL616421,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
B,,,,,1,Autocuration,Membranes,10205,,H,1099,8,,,10576,,,,BAO_0000249,CHEMBL616422,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
B,,,,,1,Expert,Membranes,10205,,H,1100,8,,,10576,,,,BAO_0000249,CHEMBL616423,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.
B,Rattus norvegicus,10116.0,,,1,Expert,,12280,,D,1101,9,,,10576,,,,BAO_0000357,CHEMBL616424,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT
B,,,,,1,Expert,,17386,,H,1102,8,,,10576,,,,BAO_0000357,CHEMBL616425,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,13654,,H,1103,8,,,10576,,,,BAO_0000357,CHEMBL616426,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.
B,,,,,1,Autocuration,,14423,,H,1104,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616427,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.
B,,,,,1,Autocuration,,15412,,H,1105,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616428,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.
B,,,,,1,Autocuration,,12073,,H,1106,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616290,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
B,Rattus norvegicus,10116.0,,,1,Expert,,4101,,D,1107,9,,,10576,,,,BAO_0000357,CHEMBL616052,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,10062,,H,1108,8,,,10576,,,,BAO_0000357,CHEMBL616053,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,6238,,H,1109,8,,,10576,,,,BAO_0000249,CHEMBL616054,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,16273,,H,1110,8,,,10576,,,,BAO_0000357,CHEMBL616055,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,11139,,H,1111,8,,,10576,,,,BAO_0000357,CHEMBL616056,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay
B,,,,,1,Expert,,16796,,H,1112,8,,,10576,,,,BAO_0000019,CHEMBL616057,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
B,Rattus norvegicus,10116.0,,,1,Expert,,9548,,D,1113,9,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616058,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
B,,,,,1,Autocuration,,10381,,H,1114,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616059,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
B,,,,,1,Autocuration,,13408,,H,1115,8,,,10576,,,,BAO_0000249,CHEMBL616060,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,13825,,D,1116,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616061,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT
B,,,,,1,Expert,,11147,,H,1117,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616062,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand
B,,,,,1,Autocuration,,10552,,H,1118,8,,,10576,,,,BAO_0000249,CHEMBL616063,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,10552,,H,1119,8,,,10576,Striatum,2435.0,,BAO_0000249,CHEMBL616064,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,17136,,D,1120,9,,,10576,,,,BAO_0000249,CHEMBL616065,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,5778,,D,1121,9,,,10576,,,,BAO_0000249,CHEMBL616066,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes
B,,,,,1,Autocuration,,13481,,H,1122,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616067,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,13481,,H,1123,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616068,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested
B,,,,,1,Intermediate,,13630,,H,1124,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616069,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,16245,,H,1125,8,,,10576,,,,BAO_0000249,CHEMBL616070,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
B,,,,,1,Autocuration,,14509,,H,1126,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616071,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,14509,,H,1127,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616072,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,14509,,H,1128,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616073,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined
B,,,,,1,Autocuration,,14509,,H,1129,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616074,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined
B,,,,,1,Expert,,14256,,H,1130,8,,,10576,,,,BAO_0000019,CHEMBL616075,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.
B,,,,,1,Autocuration,,11139,,H,1131,8,,,10576,,,,BAO_0000357,CHEMBL616076,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,11047,,D,1132,9,,,10576,,,,BAO_0000019,CHEMBL616077,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined
B,Rattus norvegicus,10116.0,,,1,Expert,,11047,,D,1133,9,,,10576,,,,BAO_0000019,CHEMBL616078,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes
B,Rattus norvegicus,10116.0,,,1,Expert,,11047,,D,1134,9,,,10576,,,,BAO_0000019,CHEMBL616079,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined
B,Rattus norvegicus,10116.0,,CHO-K1,1,Expert,,2395,,D,1135,9,485.0,,10576,,,,BAO_0000219,CHEMBL616080,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
B,,,,,1,Autocuration,,9699,,H,1136,8,,,10576,,,,BAO_0000357,CHEMBL616081,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12028,,D,1137,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616082,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain
B,,,,,1,Autocuration,,12028,,H,1138,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616083,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain
B,,,,,1,Autocuration,,5815,,H,1139,8,,,10576,,,,BAO_0000019,CHEMBL616084,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex
B,,,,,1,Expert,,16616,,H,1140,8,,,10576,,,,BAO_0000019,CHEMBL616085,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates
B,,,,,1,Autocuration,,5815,,H,1141,8,,,10576,,,,BAO_0000019,CHEMBL616086,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT
B,,,,,1,Autocuration,,2761,,H,1142,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616087,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate"
B,,,,,1,Expert,,13133,,H,1143,8,,,10576,,,,BAO_0000357,CHEMBL616088,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101
B,,,,,1,Autocuration,,10444,,H,1144,8,,,10576,,,,BAO_0000019,CHEMBL616089,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.
B,Rattus norvegicus,10116.0,,,1,Expert,,13278,,D,1145,9,,,10576,,,,BAO_0000357,CHEMBL616090,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides
B,,,,,1,Autocuration,,15874,,H,1146,8,,,10576,,,,BAO_0000357,CHEMBL616091,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
B,,,,,1,Autocuration,Membranes,10552,,H,1147,8,,,10576,Striatum,2435.0,,BAO_0000249,CHEMBL616092,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
B,,,,,1,Autocuration,,11130,,H,1148,8,,,10576,,,,BAO_0000357,CHEMBL616093,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro)
B,,,,,1,Autocuration,,11130,,H,1149,8,,,10576,,,In vivo,BAO_0000218,CHEMBL616094,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo)
B,,,,,1,Autocuration,,14542,,H,1150,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616095,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex
B,Rattus norvegicus,10116.0,,,1,Expert,,13670,,D,1151,9,,,10576,,,,BAO_0000357,CHEMBL616096,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,9888,,H,1152,8,,,10576,,,,BAO_0000249,CHEMBL616097,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,3678,,D,1153,9,,,10576,,,,BAO_0000249,CHEMBL616098,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes
B,,,,,1,Autocuration,,11332,,H,1154,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616099,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,11332,,H,1155,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616100,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,1185,,H,1156,8,,,10576,,,,BAO_0000357,CHEMBL616101,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,2014,,H,1157,8,,,10576,,,,BAO_0000249,CHEMBL616102,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.
B,,,,,1,Autocuration,,1185,,H,1158,8,,,10576,,,,BAO_0000357,CHEMBL616103,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,14429,,H,1159,8,,,10576,,,,BAO_0000019,CHEMBL616104,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex
B,,,,,1,Expert,,16288,,H,1160,8,,,10576,,,,BAO_0000019,CHEMBL616105,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand"
B,Rattus norvegicus,10116.0,,,1,Expert,,5432,,D,1161,9,,,10576,,,,BAO_0000019,CHEMBL616106,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14429,,H,1162,8,,,10576,,,,BAO_0000019,CHEMBL616107,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex
B,,,,,1,Expert,,13672,,H,1163,8,,,10576,,,,BAO_0000357,CHEMBL616108,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.
B,,,,,1,Expert,,11296,,H,1164,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616109,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
B,,,,,1,Autocuration,,11296,,H,1165,8,,,10576,,,,BAO_0000357,CHEMBL616110,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.
B,,,,CHO,1,Expert,,14749,,H,1166,8,449.0,,10576,,,,BAO_0000219,CHEMBL616111,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.
B,,,,,1,Expert,,15086,,H,1167,8,,,10576,,,,BAO_0000019,CHEMBL616112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,13462,,H,1168,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616113,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.
B,,,,,1,Autocuration,,15363,,H,1169,8,,,10576,,,,BAO_0000019,CHEMBL616114,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15363,,H,1170,8,,,10576,,,,BAO_0000019,CHEMBL616115,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,10796,,H,1171,8,,,10576,,,,BAO_0000357,CHEMBL616116,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,12816,,H,1172,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL615844,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,13542,,H,1173,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615939,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,13308,,H,1174,8,,,10576,,,,BAO_0000019,CHEMBL615940,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.
B,,,,,1,Expert,,13541,,H,1175,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615941,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.
B,,,,,1,Autocuration,,10058,,H,1176,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615942,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12
B,,,,,1,Autocuration,,10058,,H,1177,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615943,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
B,,,,,1,Autocuration,,10058,,H,1178,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615944,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17
B,,,,,1,Autocuration,,10058,,H,1179,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615945,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841
B,,,,,1,Autocuration,,10058,,H,1180,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615946,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.
B,,,,,1,Autocuration,,10058,,H,1181,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615947,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.
B,,,,,1,Autocuration,,10058,,H,1182,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615948,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736
B,,,,,1,Autocuration,,10058,,H,1183,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615949,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84
B,,,,,1,Autocuration,,10058,,H,1184,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615950,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59
B,,,,,1,Autocuration,,10058,,H,1185,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615951,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5
B,,,,,1,Autocuration,,10058,,H,1186,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615952,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31
B,,,,,1,Autocuration,,10058,,H,1187,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615953,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42
B,,,,,1,Autocuration,,10058,,H,1188,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615954,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13
B,Rattus norvegicus,10116.0,,,1,Expert,,10058,,D,1189,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615955,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
B,,,,,1,Autocuration,,10058,,H,1190,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615956,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.
B,,,,,1,Autocuration,,10058,,H,1191,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL615957,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27
B,,,,,1,Expert,,12879,,H,1192,8,,,10576,,,,BAO_0000019,CHEMBL615958,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.
B,,,,,1,Expert,,11964,,H,1193,8,,,10576,,,,BAO_0000019,CHEMBL615959,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate
B,,,,,1,Autocuration,,11964,,H,1194,8,,,10576,,,,BAO_0000019,CHEMBL615960,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1)
B,,,,,1,Autocuration,,11964,,H,1195,8,,,10576,,,,BAO_0000019,CHEMBL615961,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2)
B,,,,,1,Expert,,9548,,H,1196,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL615962,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
B,,,,,1,Expert,,9098,,H,1197,8,,,10576,,,,BAO_0000019,CHEMBL615963,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.
B,,,,,1,Autocuration,,9098,,H,1198,8,,,10576,,,,BAO_0000019,CHEMBL615964,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.
B,,,,,1,Autocuration,,9098,,H,1199,8,,,10576,,,,BAO_0000019,CHEMBL615965,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data
B,,,,CHO,1,Expert,,13248,,H,1200,8,449.0,,10576,,,,BAO_0000219,CHEMBL615966,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells
B,,,,,1,Expert,,3147,,H,1201,8,,,10576,,,,BAO_0000249,CHEMBL615967,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes
B,,,,,1,Expert,,13949,,H,1202,8,,,10576,,,,BAO_0000019,CHEMBL615968,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
B,,,,CHO,1,Autocuration,,11883,,H,1203,8,449.0,,10576,,,,BAO_0000218,CHEMBL615969,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
B,,,,,1,Autocuration,,11883,,H,1204,8,,,10576,,,,BAO_0000218,CHEMBL615970,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc)
B,Rattus norvegicus,10116.0,,,1,Expert,,11883,,D,1205,9,,,10576,,,,BAO_0000357,CHEMBL615971,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT
B,,,,,1,Expert,Membranes,15535,,H,1206,8,,,10576,,,,BAO_0000249,CHEMBL615972,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
B,,,,,1,Autocuration,,15535,,H,1207,8,,,10576,,,,BAO_0000249,CHEMBL615973,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex
B,,,,,1,Autocuration,,15535,,H,1208,8,,,10576,,,,BAO_0000249,CHEMBL615974,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex
B,Homo sapiens,9606.0,,CHO,1,Expert,,16372,,D,1209,9,449.0,,51,,,,BAO_0000219,CHEMBL615975,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
B,,,,,1,Expert,,14608,,H,1210,8,,,10576,,,,BAO_0000249,CHEMBL615976,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.
B,Rattus norvegicus,10116.0,,,1,Expert,,4795,,D,1211,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL872106,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus
B,,,,,1,Autocuration,,13863,,H,1212,8,,,10576,,,,BAO_0000357,CHEMBL615977,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,13863,,H,1213,8,,,10576,,,,BAO_0000357,CHEMBL615978,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230
B,,,,,1,Autocuration,,13863,,H,1214,8,,,10576,,,,BAO_0000357,CHEMBL616166,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14
B,,,,,1,Autocuration,,13863,,H,1215,8,,,10576,,,,BAO_0000357,CHEMBL616167,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20
B,,,,,1,Autocuration,,13863,,H,1216,8,,,10576,,,,BAO_0000357,CHEMBL616168,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430
B,,,,,1,Autocuration,,13863,,H,1217,8,,,10576,,,,BAO_0000357,CHEMBL616169,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224
B,,,,,1,Autocuration,,13863,,H,1218,8,,,10576,,,,BAO_0000357,CHEMBL616170,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503
B,,,,,1,Autocuration,,13863,,H,1219,8,,,10576,,,,BAO_0000357,CHEMBL616171,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23
B,,,,,1,Autocuration,,13863,,H,1220,8,,,10576,,,,BAO_0000357,CHEMBL616172,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2
B,,,,,1,Autocuration,,13863,,H,1221,8,,,10576,,,,BAO_0000357,CHEMBL616173,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6
B,,,,,1,Autocuration,,13863,,H,1222,8,,,10576,,,,BAO_0000357,CHEMBL616174,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23
B,,,,,1,Autocuration,,13863,,H,1223,8,,,10576,,,,BAO_0000357,CHEMBL616175,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28
B,,,,,1,Autocuration,,13863,,H,1224,8,,,10576,,,,BAO_0000357,CHEMBL616176,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760
B,,,,,1,Autocuration,,13863,,H,1225,8,,,10576,,,,BAO_0000357,CHEMBL616177,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87
B,,,,,1,Autocuration,,13863,,H,1226,8,,,10576,,,,BAO_0000357,CHEMBL616178,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2
B,,,,,1,Autocuration,,9742,,H,1227,8,,,10576,,,,BAO_0000019,CHEMBL616179,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat
B,,,,,1,Autocuration,,12073,,H,1228,8,,,10576,,,,BAO_0000357,CHEMBL616180,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,4101,,H,1229,8,,,10576,,,,BAO_0000357,CHEMBL616181,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT
B,,,,,1,Autocuration,,15360,,H,1230,8,,,10576,,,,BAO_0000019,CHEMBL616182,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat
B,,,,,1,Autocuration,,11576,,H,1231,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616183,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,5834,,H,1232,8,,,10576,,,,BAO_0000019,CHEMBL615874,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe
B,Rattus norvegicus,10116.0,,CHO-K1,1,Expert,,2395,,D,1233,9,485.0,,10576,,,,BAO_0000219,CHEMBL615875,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
B,,,,,1,Autocuration,,1375,,H,1234,8,,,10576,,,,BAO_0000019,CHEMBL615876,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand
B,,,,,1,Autocuration,,1375,,H,1235,8,,,10576,,,,BAO_0000019,CHEMBL615877,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested
B,,,,,1,Autocuration,,3967,,H,1236,8,,,10576,,,,BAO_0000357,CHEMBL615878,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats)
B,,,,,1,Expert,,12884,,H,1237,8,,,10576,,,,BAO_0000357,CHEMBL615879,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 
B,,,,,1,Expert,,2343,,H,1238,8,,,10576,,,,BAO_0000357,CHEMBL615880,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay
B,,,,,1,Autocuration,,11511,,H,1239,8,,,10576,,,,BAO_0000019,CHEMBL615881,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
B,Rattus norvegicus,10116.0,,,1,Expert,,11511,,D,1240,9,,,10576,,,,BAO_0000019,CHEMBL615882,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
F,,,,,1,Autocuration,,16394,,H,1241,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615883,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat
F,,,,,1,Autocuration,,16394,,H,1242,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615884,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20)
F,,,,,1,Autocuration,,16394,,H,1243,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615885,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60)
F,,,,,1,Autocuration,,16394,,H,1244,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615886,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80)
F,,,,,1,Autocuration,,16394,,H,1245,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615887,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27)
F,,,,,1,Autocuration,,16394,,H,1246,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615888,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70)
F,,,,,1,Autocuration,,16394,,H,1247,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615889,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4)
F,,,,,1,Autocuration,,16394,,H,1248,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615890,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51)
F,,,,,1,Autocuration,,16394,,H,1249,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615891,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30)
F,,,,,1,Autocuration,,16394,,H,1250,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615892,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60)
F,,,,,1,Autocuration,,16394,,H,1251,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615893,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87)
F,,,,,1,Autocuration,,16394,,H,1252,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615894,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80)
F,,,,,1,Autocuration,,16394,,H,1253,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615895,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5)
F,,,,,1,Autocuration,,16394,,H,1254,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615896,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5)
F,,,,,1,Autocuration,,16394,,H,1255,8,,,10576,,,In vivo,BAO_0000218,CHEMBL615897,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable
F,Rattus norvegicus,10116.0,,,1,Expert,Membranes,16616,,D,1256,9,,,10576,,,,BAO_0000249,CHEMBL615898,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
B,,,,,1,Autocuration,,16796,,H,1257,8,,,10576,,,,BAO_0000019,CHEMBL615899,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes
B,,,,,1,Autocuration,,16796,,H,1258,8,,,10576,,,,BAO_0000019,CHEMBL616291,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
B,,,,,1,Autocuration,,15629,,H,1259,8,,,10576,,,,BAO_0000357,CHEMBL616292,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.
F,,,,,1,Autocuration,,13241,,H,1260,8,,,10576,,,,BAO_0000249,CHEMBL616293,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
B,,,,,1,Expert,,12073,,H,1261,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616294,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Autocuration,,14286,,H,1262,8,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL616295,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane
B,,,,,1,Autocuration,,14542,,H,1263,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616296,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM
F,,,,,1,Autocuration,,13630,,H,1264,8,,,10576,,,,BAO_0000019,CHEMBL616297,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1265,8,,,10576,,,,BAO_0000019,CHEMBL616605,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1266,8,,,10576,,,,BAO_0000019,CHEMBL616606,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1267,8,,,10576,,,,BAO_0000019,CHEMBL616607,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
F,,,,,1,Expert,,13630,,H,1268,8,,,10576,,,,BAO_0000019,CHEMBL616608,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
F,,,,,1,Autocuration,,13630,,H,1269,8,,,10576,,,,BAO_0000019,CHEMBL616609,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.
F,Rattus norvegicus,10116.0,,,1,Expert,,13630,,D,1270,9,,,10576,,,,BAO_0000019,CHEMBL616610,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose
F,,,,,1,Autocuration,,13630,,H,1271,8,,,10576,,,,BAO_0000019,CHEMBL616611,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
F,,,,,1,Expert,,13630,,H,1272,8,,,10576,,,,BAO_0000019,CHEMBL616612,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1273,8,,,10576,,,,BAO_0000019,CHEMBL616613,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.
F,,,,,1,Expert,,13630,,H,1274,8,,,10576,,,,BAO_0000019,CHEMBL616614,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM
F,,,,,1,Autocuration,,13630,,H,1275,8,,,10576,,,,BAO_0000019,CHEMBL616615,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.
F,,,,,1,Expert,,13630,,H,1276,8,,,10576,,,,BAO_0000019,CHEMBL616616,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
F,,,,,1,Autocuration,,13630,,H,1277,8,,,10576,,,,BAO_0000019,CHEMBL616617,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1278,8,,,10576,,,,BAO_0000019,CHEMBL616618,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1279,8,,,10576,,,,BAO_0000019,CHEMBL616619,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.
F,,,,,1,Expert,,13630,,H,1280,8,,,10576,,,,BAO_0000019,CHEMBL616620,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.
F,,,,,1,Expert,,13630,,H,1281,8,,,10576,,,,BAO_0000019,CHEMBL616621,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1282,8,,,10576,,,,BAO_0000019,CHEMBL616622,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM
F,,,,,1,Expert,,13630,,H,1283,8,,,10576,,,,BAO_0000019,CHEMBL616146,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM
F,,,,,1,Autocuration,,13630,,H,1284,8,,,10576,,,,BAO_0000019,CHEMBL832873,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1285,8,,,10576,,,,BAO_0000019,CHEMBL616147,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM
F,,,,,1,Autocuration,,13630,,H,1286,8,,,10576,,,,BAO_0000019,CHEMBL872872,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
F,,,,,1,Autocuration,,13630,,H,1287,8,,,10576,,,,BAO_0000019,CHEMBL616148,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
B,,,,,1,Autocuration,,9783,,H,1288,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616149,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue
B,,,,,1,Expert,,9783,,H,1289,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616150,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,14331,,D,1290,9,,,10576,,,,BAO_0000249,CHEMBL616151,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M
B,,,,,1,Expert,,15260,,H,1291,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL872873,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM
B,,,,,1,Autocuration,,15260,,H,1292,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616670,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration
B,,,,,1,Autocuration,,15260,,H,1293,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616671,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration
F,Rattus norvegicus,10116.0,,,1,Expert,,16616,,D,1294,9,,,10576,,,,BAO_0000249,CHEMBL884861,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
B,,,,,1,Autocuration,,15629,,H,1295,8,,,10576,,,,BAO_0000357,CHEMBL616672,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor
B,,,,,1,Autocuration,,15086,,H,1296,8,,,10576,,,,BAO_0000019,CHEMBL616673,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
F,,,,,1,Expert,,5717,,H,1297,8,,,10576,,,,BAO_0000019,CHEMBL616674,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,12652,,H,1298,8,,,10576,,,,BAO_0000357,CHEMBL616675,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
B,,,,,1,Autocuration,,14608,,H,1299,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616676,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations
B,,,,,1,Autocuration,,12306,,H,1300,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616677,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
B,,,,,1,Autocuration,,12306,,H,1301,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616678,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
B,Rattus norvegicus,10116.0,,,1,Expert,,15247,,D,1302,9,,,10576,,,,BAO_0000357,CHEMBL616679,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,17529,,H,1303,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616680,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand
B,,,,,1,Autocuration,,14826,,H,1304,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616681,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Autocuration,,14826,,H,1305,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616682,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Autocuration,,13241,,H,1306,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616683,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14093,,H,1307,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616684,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14093,,H,1308,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616685,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested
B,,,,,1,Autocuration,,14442,,H,1309,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616686,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined
B,,,,,1,Autocuration,,9919,,H,1310,8,,,10576,,,,BAO_0000357,CHEMBL616687,,Affinity for 5-hydroxytryptamine 1A receptor site
B,,,,,1,Autocuration,,9919,,H,1311,8,,,10576,,,,BAO_0000357,CHEMBL616688,,Affinity for 5-hydroxytryptamine 1A receptor site
B,,,,,1,Autocuration,,11440,,H,1312,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616689,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.
B,,,,,1,Autocuration,,11257,,H,1313,8,,,10576,,,,BAO_0000357,CHEMBL616690,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT
B,,,,,1,Expert,,10330,,H,1314,8,,,10576,,,,BAO_0000357,CHEMBL616691,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,17331,,D,1315,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616692,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes
B,,,,,1,Expert,,16567,,H,1316,8,,,10576,,,,BAO_0000249,CHEMBL616693,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane
B,Rattus norvegicus,10116.0,,,1,Expert,,12058,,D,1317,9,,,10576,,,,BAO_0000019,CHEMBL616694,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
B,,,,,1,Autocuration,,9699,,H,1318,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616695,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue
B,,,,,1,Autocuration,,9547,,H,1319,8,,,10576,,,,BAO_0000357,CHEMBL616696,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay
B,,,,,1,Autocuration,,10330,,H,1320,8,,,10576,,,,BAO_0000357,CHEMBL616697,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand
B,,,,,1,Autocuration,,14331,,H,1321,8,,,10576,,,,BAO_0000357,CHEMBL616698,,Binding affinity against rat 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,14060,,D,1322,9,,,10576,,,,BAO_0000019,CHEMBL616949,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14744,,H,1323,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616950,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates
B,,,,,1,Autocuration,,13506,,H,1324,8,,,10576,,,,BAO_0000357,CHEMBL832875,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
B,,,,,1,Expert,,10862,,H,1325,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616951,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
B,,,,,1,Expert,,10862,,H,1326,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616952,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
B,,,,,1,Expert,,10062,,H,1327,8,,,10576,,,,BAO_0000357,CHEMBL616953,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.
B,,,,,1,Autocuration,,12073,,H,1328,8,,,10576,,,,BAO_0000357,CHEMBL616954,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat
B,,,,,1,Autocuration,,14875,,H,1329,8,,,106,,,,BAO_0000357,CHEMBL616955,,GTPgammaS radioligand binding assay
B,,,,,1,Autocuration,,2391,,H,1330,8,,,106,,,,BAO_0000357,CHEMBL616956,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
F,,,,,1,Autocuration,,2391,,H,1331,8,,,106,,,,BAO_0000019,CHEMBL616957,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist
F,,,,,1,Autocuration,,2391,,H,1332,8,,,106,,,,BAO_0000019,CHEMBL616958,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist
B,,,,,1,Autocuration,,2391,,H,1333,8,,,106,,,,BAO_0000357,CHEMBL616959,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,2391,,H,1334,8,,,106,,,,BAO_0000357,CHEMBL616960,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
F,,,,,1,Autocuration,,2391,,H,1335,8,,,106,,,,BAO_0000019,CHEMBL616961,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist
B,,,,HeLa,1,Expert,,17211,,H,1336,8,308.0,,106,,,,BAO_0000219,CHEMBL616962,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor
B,,,,HeLa,1,Autocuration,,17211,,H,1337,8,308.0,,106,,,,BAO_0000219,CHEMBL616963,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,1338,9,,,106,,,,BAO_0000357,CHEMBL616524,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor
B,,,,CHO,1,Autocuration,,16190,,H,1339,8,449.0,,106,,,,BAO_0000219,CHEMBL616525,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,14165,,H,1340,8,,,106,,,,BAO_0000019,CHEMBL872908,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand
B,,,,,1,Autocuration,,14165,,H,1341,8,,,106,,,,BAO_0000019,CHEMBL616526,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,1342,9,,,106,,,,BAO_0000357,CHEMBL616527,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor
B,,,,,1,Expert,,6328,,H,1343,8,,,106,,,,BAO_0000219,CHEMBL616528,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
B,,,,,1,Autocuration,,14770,,H,1344,8,,,106,,,,BAO_0000357,CHEMBL616529,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,2598,,H,1345,8,,,106,,,,BAO_0000357,CHEMBL616530,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand
B,,,,,1,Expert,,6897,,H,1346,8,,,106,,,,BAO_0000357,CHEMBL616531,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,6897,,H,1347,8,,,106,,,,BAO_0000357,CHEMBL616532,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,6013,,H,1348,8,,,106,,,,BAO_0000357,CHEMBL616533,,Binding affinity towards 5-hydroxytryptamine 1B receptor
B,,,,,1,Expert,,5843,,H,1349,8,,,106,,,,BAO_0000357,CHEMBL616534,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
B,,,,,1,Expert,,14454,,H,1350,8,,,106,,,,BAO_0000357,CHEMBL616535,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand
B,,,,,1,Autocuration,,16209,,H,1351,8,,,106,,,,BAO_0000357,CHEMBL616536,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand
B,,,,,1,Autocuration,,3935,,H,1352,8,,,106,,,,BAO_0000357,CHEMBL616537,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor
F,,,,CHO-K1,1,Expert,,13729,,H,1353,8,485.0,,106,,,,BAO_0000219,CHEMBL616538,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells
F,,,,,1,Expert,,14251,,H,1354,8,,,106,,,,BAO_0000019,CHEMBL616539,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor
B,,,,,1,Expert,,17085,,H,1355,8,,,106,,,,BAO_0000019,CHEMBL616540,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,3025,,H,1356,8,,,106,,,,BAO_0000357,CHEMBL616429,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
B,,,,,1,Expert,,15315,,H,1357,8,,,106,,,,BAO_0000357,CHEMBL616430,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,,1,Expert,,14214,,D,1358,9,,,106,,,,BAO_0000219,CHEMBL616431,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells
B,Homo sapiens,9606.0,,,1,Expert,,3804,,D,1359,9,,,106,,,,BAO_0000357,CHEMBL616432,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,,1,Expert,,2391,,D,1360,9,,,106,,,,BAO_0000357,CHEMBL616433,,Affinity for 5-hydroxytryptamine 1B receptor subtype
B,Homo sapiens,9606.0,,,1,Expert,,4175,,D,1361,9,,,106,,,,BAO_0000357,CHEMBL616434,,Binding affinity for human 5-hydroxytryptamine 1B receptor
B,,,,CHO,1,Autocuration,,17296,,H,1362,8,449.0,,106,,,,BAO_0000219,CHEMBL616435,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined
B,,,,,1,Expert,,17085,,H,1363,8,,,106,,,,BAO_0000019,CHEMBL616436,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined
B,,,,HeLa,1,Autocuration,,17211,,H,1364,8,308.0,,106,,,,BAO_0000219,CHEMBL616437,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
B,,,,HeLa,1,Autocuration,,17211,,H,1365,8,308.0,,106,,,,BAO_0000219,CHEMBL616438,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested
B,,,,HeLa,1,Autocuration,,17211,,H,1366,8,308.0,,106,,,,BAO_0000219,CHEMBL616439,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
B,Homo sapiens,9606.0,,,1,Expert,,15926,,D,1367,9,,,106,,,,BAO_0000357,CHEMBL616440,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested
B,,,,CHO-K1,1,Autocuration,,16312,,H,1368,8,485.0,,106,,,,BAO_0000219,CHEMBL616441,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested
B,,,,,1,Expert,,5843,,H,1369,8,,,106,,,,BAO_0000357,CHEMBL616442,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor
B,,,,,1,Autocuration,,5843,,H,1370,8,,,106,,,,BAO_0000357,CHEMBL616443,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor
B,,,,CHO-K1,1,Expert,,16312,,H,1371,8,485.0,,106,,,,BAO_0000219,CHEMBL616444,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,,1,Expert,,15926,,D,1372,9,,,106,,,,BAO_0000357,CHEMBL616445,,Binding activity against human 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,,1,Expert,,15926,,D,1373,9,,,106,,,,BAO_0000357,CHEMBL616446,,Binding activity against human 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,4540,,D,1374,9,449.0,,106,,,,BAO_0000219,CHEMBL616447,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,6166,,H,1375,8,,,106,,,,BAO_0000357,CHEMBL616448,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined
B,,,,CHO,1,Autocuration,,17296,,H,1376,8,449.0,,106,,,,BAO_0000219,CHEMBL616449,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand
B,,,,CHO,1,Autocuration,,17296,,H,1377,8,449.0,,106,,,,BAO_0000219,CHEMBL616450,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells
B,,,,CHO,1,Autocuration,,17296,,H,1378,8,449.0,,106,,,,BAO_0000219,CHEMBL857974,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand
B,,,,CHO,1,Autocuration,,15779,,H,1379,8,449.0,,106,,,,BAO_0000219,CHEMBL616451,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
B,,,,CHO,1,Autocuration,,15779,,H,1380,8,449.0,,106,,,,BAO_0000219,CHEMBL616452,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
B,,,,CHO,1,Autocuration,,15779,,H,1381,8,449.0,,106,,,,BAO_0000219,CHEMBL616453,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.
B,,,,CHO,1,Autocuration,,4199,,H,1382,8,449.0,,106,,,,BAO_0000219,CHEMBL616454,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand
B,Homo sapiens,9606.0,,,1,Expert,,14875,,D,1383,9,,,106,,,,BAO_0000357,CHEMBL616455,,Binding affinity for human 5-hydroxytryptamine 1B receptor
B,,,,CHO,1,Autocuration,,15146,,H,1384,8,449.0,,106,,,,BAO_0000219,CHEMBL616456,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
B,,,,,1,Autocuration,,5213,,H,1385,8,,,106,,,,BAO_0000357,CHEMBL616457,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand
B,,,,CHO,1,Autocuration,,14818,,H,1386,8,449.0,,106,,,,BAO_0000219,CHEMBL616458,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
B,,,,CHO,1,Autocuration,,4829,,H,1387,8,449.0,,106,,,,BAO_0000219,CHEMBL616459,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand"
F,,,,,1,Expert,,14454,,H,1388,8,,,106,,,,BAO_0000019,CHEMBL616460,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM
F,,,,,1,Expert,,14454,,H,1389,8,,,106,,,,BAO_0000019,CHEMBL616461,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM
F,,,,CHO,1,Autocuration,,14875,,H,1390,8,449.0,,106,,,,BAO_0000219,CHEMBL616462,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor"
F,,,,CHO,1,Autocuration,,14875,,H,1391,8,449.0,,106,,,,BAO_0000219,CHEMBL616463,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor"
F,,,,,1,Autocuration,,15250,,H,1392,8,,,105,,,,BAO_0000019,CHEMBL616464,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT."
B,,,,CHO,1,Autocuration,,15250,,H,1393,8,449.0,,105,,,,BAO_0000219,CHEMBL616465,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.
B,,,,,1,Autocuration,,15086,,H,1394,8,,,17105,,,,BAO_0000357,CHEMBL832874,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3025,,H,1395,8,,,106,,,,BAO_0000019,CHEMBL616184,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14998,,H,1396,8,,,106,,,,BAO_0000019,CHEMBL616185,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).
B,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,14998,,H,1397,8,,,106,,,,BAO_0000019,CHEMBL616186,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)"
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14998,,H,1398,8,,,106,,,,BAO_0000019,CHEMBL616187,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).
B,,,,,1,Expert,,13969,,H,1399,8,,,10577,,,,BAO_0000357,CHEMBL616188,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand
B,,,,,1,Intermediate,,13392,,D,1400,9,,,10577,,,,BAO_0000357,CHEMBL873475,,Binding affinity for 5-hydroxytryptamine 1B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,3651,,D,1401,9,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616189,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active
B,,,,,1,Expert,,10025,,H,1402,8,,,10577,,,,BAO_0000357,CHEMBL616190,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
B,,,,,1,Autocuration,,13863,,H,1403,8,,,10576,,,,BAO_0000357,CHEMBL616191,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77
B,,,,,1,Autocuration,,13863,,H,1404,8,,,10576,,,,BAO_0000357,CHEMBL616192,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95
B,,,,,1,Autocuration,,13863,,H,1405,8,,,10576,,,,BAO_0000357,CHEMBL616193,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980
B,,,,,1,Autocuration,,13863,,H,1406,8,,,10576,,,,BAO_0000357,CHEMBL616194,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140
B,,,,,1,Autocuration,,13863,,H,1407,8,,,10576,,,,BAO_0000357,CHEMBL616195,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130
B,,,,,1,Autocuration,,13863,,H,1408,8,,,10576,,,,BAO_0000357,CHEMBL616196,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280
B,,,,,1,Autocuration,,4622,,H,1409,8,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL616197,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.
B,,,,,1,Intermediate,,14911,,H,1410,8,,,10576,,,,BAO_0000019,CHEMBL616198,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,12678,,H,1411,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616199,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
B,,,,,1,Expert,,12678,,H,1412,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616200,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.
B,,,,,1,Expert,,14235,,H,1413,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616201,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,14949,,H,1414,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616202,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
B,,,,,1,Expert,,14949,,H,1415,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616203,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
B,,,,,1,Expert,,14949,,H,1416,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616204,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined
B,,,,,1,Expert,,14949,,H,1417,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616205,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined
B,,,,,1,Expert,,14949,,H,1418,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616206,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined
B,,,,,1,Expert,,16118,,H,1419,8,,,10576,,,,BAO_0000249,CHEMBL616207,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
B,,,,,1,Autocuration,,3268,,H,1420,8,,,10576,,,,BAO_0000249,CHEMBL616208,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes
B,,,,,1,Autocuration,,3268,,H,1421,8,,,10576,,,,BAO_0000249,CHEMBL616209,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive
B,,,,,1,Expert,,16117,,H,1422,8,,,10576,,,,BAO_0000357,CHEMBL616210,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT
B,,,,,1,Expert,,9783,,H,1423,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616211,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.
B,,,,,1,Autocuration,,9783,,H,1424,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616504,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested
B,Rattus norvegicus,10116.0,,,1,Expert,,14356,,D,1425,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616505,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
F,,,,,1,Autocuration,,15740,,H,1426,8,,,10576,,,,BAO_0000019,CHEMBL616506,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,12306,,H,1427,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL872107,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
B,Rattus norvegicus,10116.0,,,1,Expert,,13348,,D,1428,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616507,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin
B,,,,,1,Autocuration,,10394,,H,1429,8,,,10576,,,,BAO_0000249,CHEMBL616303,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand
B,,,,,1,Autocuration,,15260,,H,1430,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616304,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue
B,,,,,1,Expert,,10046,,H,1431,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616305,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
F,,,,,1,Intermediate,,15260,,H,1432,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616306,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,12851,,H,1433,8,,,10576,,,,BAO_0000357,CHEMBL616307,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,2148,,D,1434,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL881829,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus
B,,,,,1,Expert,,13134,,H,1435,8,,,10576,,,,BAO_0000357,CHEMBL616308,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.
B,,,,,1,Autocuration,,12462,,H,1436,8,,,10576,,,,BAO_0000019,CHEMBL616309,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain
B,,,,,1,Expert,,12462,,H,1437,8,,,10576,,,,BAO_0000019,CHEMBL616310,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue
B,,,,CHO,1,Autocuration,,12462,,H,1438,8,449.0,,10576,,,,BAO_0000219,CHEMBL616311,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells
B,,,,,1,Expert,,11933,,H,1439,8,,,10576,,,,BAO_0000357,CHEMBL616312,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,11933,,H,1440,8,,,10576,,,,BAO_0000357,CHEMBL616313,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined
B,Rattus norvegicus,10116.0,,,1,Expert,,403,,D,1441,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616314,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15538,,H,1442,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616315,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Autocuration,,15538,,H,1443,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616567,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active
B,,,,,1,Autocuration,,15538,,H,1444,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616568,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined
B,,,,,1,Intermediate,,12464,,H,1445,8,,,10576,,,,BAO_0000019,CHEMBL616569,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates
B,,,,,1,Expert,,1455,,H,1446,8,,,10576,,,,BAO_0000357,CHEMBL616570,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.
B,,,,,1,Autocuration,,12652,,H,1447,8,,,10576,,,,BAO_0000357,CHEMBL616571,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
B,,,,,1,Autocuration,,12639,,H,1448,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616572,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal
B,,,,,1,Expert,,13949,,H,1449,8,,,10576,,,,BAO_0000249,CHEMBL616573,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.
B,Rattus norvegicus,10116.0,,,1,Expert,,12463,,D,1450,9,,,10576,,,,BAO_0000357,CHEMBL616574,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT
B,,,,,1,Expert,,14829,,H,1451,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616575,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation
B,,,,,1,Autocuration,,14829,,H,1452,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL872108,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined
B,,,,,1,Autocuration,,12092,,H,1453,8,,,10576,,,,BAO_0000357,CHEMBL616576,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,403,,H,1454,8,,,10576,,,,BAO_0000249,CHEMBL616577,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2
B,,,,,1,Autocuration,,403,,H,1455,8,,,10576,,,,BAO_0000249,CHEMBL616578,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S
B,,,,,1,Expert,,3967,,H,1456,8,,,10576,,,,BAO_0000357,CHEMBL616579,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.
B,Rattus norvegicus,10116.0,,,1,Expert,,12771,,D,1457,9,,,10576,,,,BAO_0000019,CHEMBL616580,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations
B,,,,,1,Autocuration,,15086,,H,1458,8,,,10576,,,,BAO_0000019,CHEMBL616581,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
B,,,,,1,Autocuration,,14909,,H,1459,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616582,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
B,,,,,1,Expert,,14949,,H,1460,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616583,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
B,Rattus norvegicus,10116.0,,,1,Expert,,2309,,D,1461,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616584,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT
B,,,,,1,Expert,,4170,,H,1462,8,,,10576,,,,BAO_0000357,CHEMBL616585,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,11642,,D,1463,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616586,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus
B,,,,,1,Autocuration,,11642,,H,1464,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616587,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus
B,,,,,1,Autocuration,,12953,,H,1465,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616588,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,12953,,H,1466,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616589,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Expert,,12953,,H,1467,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616590,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand
B,,,,CHO,1,Expert,,12903,,H,1468,8,449.0,,10576,,,,BAO_0000219,CHEMBL616591,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand."
B,,,,,1,Expert,,12536,,H,1469,8,,,10576,,,,BAO_0000357,CHEMBL616592,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,10058,,H,1470,8,,,10576,,,,BAO_0000357,CHEMBL616593,,The inhibition activity of 5-HT1A at 1 uM
B,,,,CHO-K1,1,Expert,,12902,,H,1471,8,485.0,,10576,,,,BAO_0000219,CHEMBL616594,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand."
B,,,,,1,Expert,,14057,,H,1472,8,,,10576,,,,BAO_0000249,CHEMBL616595,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane
B,,,,,1,Autocuration,,11296,,H,1473,8,,,10576,,,,BAO_0000357,CHEMBL616596,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.
B,,,,,1,Autocuration,,11296,,H,1474,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616597,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
B,,,,,1,Expert,,11296,,H,1475,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616598,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
F,Rattus norvegicus,10116.0,,,1,Expert,Membranes,16616,,D,1476,9,,,10576,,,,BAO_0000249,CHEMBL616599,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes
F,Rattus norvegicus,10116.0,,,1,Expert,Membranes,16616,,D,1477,9,,,10576,Hippocampus,10000000.0,,BAO_0000249,CHEMBL616600,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
B,,,,,1,Autocuration,,16567,,H,1478,8,,,10576,,,,BAO_0000019,CHEMBL616601,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.
B,,,,,1,Autocuration,,16567,,H,1479,8,,,10576,,,,BAO_0000019,CHEMBL616602,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.
B,,,,,1,Autocuration,,16567,,H,1480,8,,,10576,,,,BAO_0000019,CHEMBL616603,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.
B,,,,,1,Autocuration,,16567,,H,1481,8,,,10576,,,,BAO_0000019,CHEMBL616604,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.
B,,,,,1,Autocuration,,17136,,H,1482,8,,,10576,,,,BAO_0000249,CHEMBL616316,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data
B,,,,,1,Autocuration,,17136,,H,1483,8,,,10576,,,,BAO_0000249,CHEMBL616317,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined
B,Rattus norvegicus,10116.0,,,1,Expert,,16616,,D,1484,9,,,10576,,,,BAO_0000019,CHEMBL616318,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data
B,,,,,1,Autocuration,,17331,,H,1485,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616319,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes
B,,,,,1,Autocuration,,17331,,H,1486,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616320,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested
B,Rattus norvegicus,10116.0,,,1,Expert,,17167,,D,1487,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616321,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested
F,,,,,1,Autocuration,,15740,,H,1488,8,,,10576,,,,BAO_0000019,CHEMBL616322,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
F,,,,,1,Autocuration,,15740,,H,1489,8,,,10576,,,,BAO_0000019,CHEMBL616323,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested
B,,,,,1,Autocuration,,4671,,H,1490,8,,,10576,,,,BAO_0000357,CHEMBL616324,,Ratio of binding affinity to 5-HT 1A and D2 receptor
B,,,,,1,Autocuration,,10058,,H,1491,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616325,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
B,,,,,1,Autocuration,,10058,,H,1492,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616326,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
B,,,,,1,Autocuration,,10058,,H,1493,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616327,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.
B,,,,,1,Autocuration,,12073,,H,1494,8,,,10576,,,,BAO_0000357,CHEMBL616328,,Percentage inhibition against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,2759,,H,1495,8,,,10576,,,,BAO_0000249,CHEMBL858110,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
F,,,,,1,Autocuration,,2759,,H,1496,8,,,10576,,,,BAO_0000249,CHEMBL616329,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
B,,,,,1,Autocuration,,2759,,H,1497,8,,,10576,,,,BAO_0000249,CHEMBL616330,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
F,,,,,1,Autocuration,,2759,,H,1498,8,,,10576,,,,BAO_0000249,CHEMBL616331,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
F,,,,,1,Autocuration,,2759,,H,1499,8,,,10576,,,,BAO_0000249,CHEMBL616332,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
B,,,,,1,Autocuration,,9737,,H,1500,8,,,10576,Brain,955.0,,BAO_0000249,CHEMBL857063,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
B,,,,,1,Autocuration,,9737,,H,1501,8,,,10576,,,,BAO_0000019,CHEMBL616333,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand
F,,,,,1,Expert,,5717,,H,1502,8,,,10576,,,,BAO_0000019,CHEMBL616334,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,12253,,H,1503,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616335,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
B,,,,,1,Autocuration,,14025,,H,1504,8,,,10576,,,,BAO_0000019,CHEMBL616336,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.
B,,,,,1,Expert,,10425,,H,1505,8,,,10576,,,,BAO_0000249,CHEMBL616337,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.
B,,,,,1,Autocuration,,14998,,H,1506,8,,,10576,,,,BAO_0000019,CHEMBL616338,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.
B,,,,,1,Autocuration,,13694,,H,1507,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616339,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay
B,,,,,1,Autocuration,,13694,,H,1508,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616340,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay
B,,,,,1,Autocuration,,4342,,H,1509,8,,,10576,,,,BAO_0000357,CHEMBL616341,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,1510,9,,,10576,,,,BAO_0000357,CHEMBL616342,,Binding affinity against rat 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,13144,,D,1511,9,,,10576,,,,BAO_0000019,CHEMBL616343,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates
B,,,,,1,Expert,,13343,,H,1512,8,,,10576,,,,BAO_0000019,CHEMBL616344,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement
B,,,,,1,Expert,,12132,,H,1513,8,,,10576,,,,BAO_0000357,CHEMBL616345,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Expert,,15419,,H,1514,8,,,10576,,,,BAO_0000019,CHEMBL616346,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand
B,,,,,1,Autocuration,,1479,,H,1515,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616347,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
B,,,,,1,Expert,,14287,,H,1516,8,,,10576,,,,BAO_0000019,CHEMBL616348,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane
B,,,,,1,Expert,,13116,,H,1517,8,,,10576,,,,BAO_0000357,CHEMBL616349,,Binding affinity at 5-hydroxytryptamine 1A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,2759,,D,1518,9,,,10576,,,,BAO_0000249,CHEMBL616152,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes
B,,,,,1,Autocuration,,2759,,H,1519,8,,,10576,,,,BAO_0000249,CHEMBL616153,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
B,,,,,1,Expert,,14748,,H,1520,8,,,10576,,,,BAO_0000019,CHEMBL616154,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand"
B,,,,,1,Autocuration,,12304,,H,1521,8,,,10576,,,,BAO_0000019,CHEMBL616155,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
B,Rattus norvegicus,10116.0,,,1,Expert,,12409,,D,1522,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616156,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT
B,Rattus norvegicus,10116.0,,,1,Expert,,12409,,D,1523,9,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616157,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT
B,,,,,1,Autocuration,,13267,,H,1524,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616158,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand
B,,,,,1,Autocuration,,15194,,H,1525,8,,,10576,,,,BAO_0000357,CHEMBL616159,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
B,,,,,1,Expert,,14256,,H,1526,8,,,10576,,,,BAO_0000357,CHEMBL616160,,pKi value against rat 5-hydroxytryptamine 1A receptor.
B,,,,,1,Autocuration,,16567,,H,1527,8,,,10576,,,,BAO_0000019,CHEMBL616161,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.
F,,,,,1,Autocuration,,15740,,H,1528,8,,,10576,,,,BAO_0000019,CHEMBL616162,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
B,Rattus norvegicus,10116.0,,,1,Expert,,13278,,D,1529,9,,,12687,,,,BAO_0000357,CHEMBL616163,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
B,,,,,1,Expert,Membranes,1970,,H,1530,8,,,10626,,,,BAO_0000249,CHEMBL616164,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
B,,,,,1,Autocuration,,10034,,H,1531,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616165,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated
B,Rattus norvegicus,10116.0,,,1,Autocuration,,13348,,H,1532,8,,,51,,,,BAO_0000019,CHEMBL616355,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker
F,,,,,1,Autocuration,,13630,,H,1533,8,,,10576,,,,BAO_0000019,CHEMBL616356,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
B,,,,,1,Autocuration,,10862,,H,1534,8,,,10576,Brain,955.0,,BAO_0000221,CHEMBL616357,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
B,,,,,1,Autocuration,,12058,,H,1535,8,,,10576,,,,BAO_0000019,CHEMBL616358,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
B,,,,,1,Autocuration,,4639,,H,1536,8,,,51,,,,BAO_0000357,CHEMBL616359,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,15453,,H,1537,8,,,51,,,,BAO_0000357,CHEMBL616360,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT
B,,,,,1,Expert,,4820,,H,1538,8,,,51,,,,BAO_0000357,CHEMBL616361,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,1089,,H,1539,8,,,51,,,,BAO_0000357,CHEMBL616362,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,Brain membranes,386,,H,1540,8,,,51,,,,BAO_0000249,CHEMBL616363,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes
B,,,,,1,Autocuration,,6011,,H,1541,8,,,51,,,,BAO_0000357,CHEMBL616364,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration
B,,,,,1,Autocuration,,5014,,H,1542,8,,,51,,,,BAO_0000357,CHEMBL616365,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor
B,,,,,1,Expert,,4402,,H,1543,8,,,51,,,,BAO_0000357,CHEMBL616366,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Expert,,17066,,H,1544,8,,,51,,,,BAO_0000357,CHEMBL872906,,Binding affinity towards 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,17515,,H,1545,8,,,51,,,,BAO_0000357,CHEMBL616367,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM
B,,,,,1,Autocuration,,2474,,H,1546,8,,,51,,,,BAO_0000357,CHEMBL616368,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,4775,,H,1547,8,,,51,,,,BAO_0000357,CHEMBL616369,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined
B,Homo sapiens,9606.0,,,1,Expert,,14294,,D,1548,9,,,51,,,,BAO_0000357,CHEMBL616370,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.
B,Homo sapiens,9606.0,,,1,Expert,,14294,,D,1549,9,,,51,,,,BAO_0000357,CHEMBL616371,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive
B,,,,CHO,1,Autocuration,,12249,,H,1550,8,449.0,,51,,,,BAO_0000219,CHEMBL616372,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
B,,,,,1,Expert,,11376,,H,1551,8,,,51,,,,BAO_0000219,CHEMBL616373,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes
B,,,,,1,Autocuration,,2474,,H,1552,8,,,51,,,In vivo,BAO_0000218,CHEMBL616374,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,13311,,H,1553,8,,,51,Hippocampus,10000000.0,,BAO_0000221,CHEMBL616375,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
B,,,,,1,Autocuration,,4373,,H,1554,8,,,51,,,,BAO_0000357,CHEMBL616376,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined
B,,,,,1,Expert,,1633,,H,1555,8,,,51,,,,BAO_0000357,CHEMBL857064,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.
B,,,,,1,Autocuration,,11866,,H,1556,8,,,51,,,,BAO_0000357,CHEMBL616377,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
B,,,,,1,Autocuration,,4373,,H,1557,8,,,51,,,,BAO_0000357,CHEMBL616378,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
B,,,,,1,Autocuration,,4687,,H,1558,8,,,51,,,,BAO_0000357,CHEMBL616379,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,16946,,H,1559,8,,,11863,,,,BAO_0000357,CHEMBL616380,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,13291,,H,1560,8,,,11863,,,,BAO_0000357,CHEMBL616381,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand
B,,,,,1,Autocuration,,14159,,H,1561,8,,,11863,,,,BAO_0000357,CHEMBL616382,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,10812,,H,1562,8,,,11863,,,,BAO_0000357,CHEMBL616383,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand
B,Mus musculus,10090.0,,CHO,1,Expert,,3032,,D,1563,9,449.0,,11863,,,,BAO_0000219,CHEMBL616350,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells
B,,,,,1,Autocuration,,16655,,H,1564,8,,,11863,,,,BAO_0000357,CHEMBL616351,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14532,,H,1565,8,,,11863,,,,BAO_0000357,CHEMBL616352,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration
B,,,,,1,Autocuration,,13944,,H,1566,8,,,11863,,,,BAO_0000357,CHEMBL616353,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,13033,,H,1567,8,,,11863,,,,BAO_0000357,CHEMBL616354,,Binding affinity against serotonergic 5-HT1a receptor
B,,,,,1,Autocuration,,10321,,H,1568,8,,,11863,,,,BAO_0000357,CHEMBL616508,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand
B,Mus musculus,10090.0,,,1,Expert,,2968,,D,1569,9,,,11863,,,,BAO_0000357,CHEMBL616559,,Binding affinity for 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,13964,,H,1570,8,,,11863,,,,BAO_0000357,CHEMBL616560,,Binding affinity at 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,15527,,H,1571,8,,,11863,,,,BAO_0000357,CHEMBL616561,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand."
B,,,,CHO,1,Autocuration,,12248,,H,1572,8,449.0,,11863,,,,BAO_0000219,CHEMBL616562,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
B,,,,CHO,1,Autocuration,,12249,,H,1573,8,449.0,,11863,,,,BAO_0000219,CHEMBL616563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
B,,,,,1,Autocuration,,15120,,H,1574,8,,,11863,,,,BAO_0000357,CHEMBL616564,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,13313,,H,1575,8,,,11863,,,,BAO_0000357,CHEMBL616565,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,2613,,H,1576,8,,,11863,,,,BAO_0000218,CHEMBL616566,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,16700,,H,1577,8,,,11863,,,,BAO_0000357,CHEMBL616989,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity
B,,,,,1,Autocuration,,2201,,H,1578,8,,,11863,,,,BAO_0000357,CHEMBL857975,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor
B,Mus musculus,10090.0,,,1,Expert,,1274,,D,1579,9,,,11863,,,,BAO_0000357,CHEMBL616990,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,1317,,H,1580,8,,,11863,,,,BAO_0000357,CHEMBL616991,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay
B,,,,,1,Autocuration,,12146,,H,1581,8,,,11863,,,,BAO_0000357,CHEMBL616992,,Tested against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,14059,,H,1582,8,,,11863,,,,BAO_0000357,CHEMBL616993,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,14025,,H,1583,8,,,106,,,,BAO_0000019,CHEMBL616994,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14025,,H,1584,8,,,106,,,,BAO_0000019,CHEMBL616995,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable
B,Gorilla gorilla,9593.0,,HEK293,1,Intermediate,,14447,,D,1585,9,722.0,,105571,,,,BAO_0000219,CHEMBL616996,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
F,Cavia porcellus,10141.0,,,1,Autocuration,,3025,,H,1586,8,,,106,,,In vivo,BAO_0000218,CHEMBL616997,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
F,Cavia porcellus,10141.0,,,1,Autocuration,,3025,,H,1587,8,,,106,,,In vivo,BAO_0000218,CHEMBL616998,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
F,Cavia porcellus,10141.0,,,1,Autocuration,,15329,,H,1588,8,,,106,,,,BAO_0000019,CHEMBL616999,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery
F,Cavia porcellus,10141.0,,,1,Autocuration,,15329,,H,1589,8,,,106,,,,BAO_0000019,CHEMBL617000,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined
F,Cavia porcellus,10141.0,,,1,Autocuration,,15847,,H,1590,8,,,106,,,,BAO_0000019,CHEMBL617001,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig
F,Cavia porcellus,10141.0,,,1,Autocuration,,15847,,H,1591,8,,,106,,,,BAO_0000019,CHEMBL858111,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done
F,,,,,1,Autocuration,,14165,,H,1592,8,,,106,,,,BAO_0000019,CHEMBL617002,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding
F,,,,,1,Autocuration,,14214,,H,1593,8,,,106,,,,BAO_0000019,CHEMBL617003,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT)
F,,,,,1,Autocuration,,14214,,H,1594,8,,,106,,,,BAO_0000019,CHEMBL617004,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT)
F,Homo sapiens,9606.0,,,1,Expert,,14214,,D,1595,9,,,106,,,,BAO_0000019,CHEMBL617005,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation
F,Homo sapiens,9606.0,,CHO-K1,1,Expert,,13729,,D,1596,9,485.0,,106,,,,BAO_0000219,CHEMBL616623,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells
F,,,,CHO,1,Autocuration,,3025,,H,1597,8,449.0,,106,,,,BAO_0000219,CHEMBL616624,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines
B,,,,,1,Autocuration,,2391,,H,1598,8,,,106,,,,BAO_0000357,CHEMBL883243,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
F,,,,,1,Autocuration,,2391,,H,1599,8,,,106,,,,BAO_0000019,CHEMBL616625,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist
F,,,,CHO,1,Expert,,14956,,H,1600,8,449.0,,106,,,,BAO_0000219,CHEMBL616626,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor"
F,,,,CHO,1,Autocuration,,2598,,H,1601,8,449.0,,106,,,,BAO_0000219,CHEMBL616627,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line
F,,,,CHO,1,Autocuration,,2598,,H,1602,8,449.0,,106,,,,BAO_0000219,CHEMBL616628,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist
F,,,,CHO,1,Autocuration,,2598,,H,1603,8,449.0,,106,,,,BAO_0000219,CHEMBL616629,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist
F,,,,CHO,1,Autocuration,,2598,,H,1604,8,449.0,,106,,,,BAO_0000219,CHEMBL616630,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist
F,,,,,1,Expert,,14956,,H,1605,8,,,106,,,,BAO_0000019,CHEMBL616631,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand"
F,,,,,1,Autocuration,,14956,,H,1606,8,,,106,,,,BAO_0000019,CHEMBL616632,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand"
B,Homo sapiens,9606.0,,,1,Expert,,14214,,D,1607,9,,,106,,,,BAO_0000357,CHEMBL616633,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor
B,,,,CHO,1,Expert,,3463,,H,1608,8,449.0,,106,,,,BAO_0000219,CHEMBL616634,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro
B,,,,,1,Autocuration,,15331,,H,1609,8,,,106,,,,BAO_0000357,CHEMBL616635,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,1610,9,,,106,,,,BAO_0000357,CHEMBL885358,,Binding affinity against 5-hydroxytryptamine 1B receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,14159,,D,1611,9,449.0,,106,,,,BAO_0000219,CHEMBL616636,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells
B,,,,CHO,1,Expert,,14158,,H,1612,8,449.0,,106,,,,BAO_0000219,CHEMBL616637,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.
B,,,,,1,Autocuration,,14159,,H,1613,8,,,106,,,,BAO_0000357,CHEMBL616638,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor
B,,,,CHO,1,Expert,,15250,,H,1614,8,449.0,,106,,,,BAO_0000219,CHEMBL616639,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
B,,,,CHO,1,Expert,,15250,,H,1615,8,449.0,,106,,,,BAO_0000219,CHEMBL616640,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.
B,,,,CHO,1,Expert,,15331,,H,1616,8,449.0,,106,,,,BAO_0000219,CHEMBL616641,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
B,,,,CHO,1,Expert,,15332,,H,1617,8,449.0,,106,,,,BAO_0000219,CHEMBL616642,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.
B,,,,CHO,1,Expert,,14956,,H,1618,8,449.0,,106,,,,BAO_0000219,CHEMBL616643,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells
B,,,,,1,Autocuration,,3805,,H,1619,8,,,106,,,,BAO_0000357,CHEMBL616644,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM)
B,,,,,1,Autocuration,,14875,,H,1620,8,,,106,,,,BAO_0000357,CHEMBL616645,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14454,,H,1621,8,,,105,,,,BAO_0000019,CHEMBL616646,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
F,Oryctolagus cuniculus,9986.0,,,1,Expert,,14454,,H,1622,8,,,105,,,,BAO_0000019,CHEMBL616647,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
B,,,,,1,Autocuration,,16288,,H,1623,8,,,105,,,,BAO_0000357,CHEMBL616509,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9)
B,,,,,1,Autocuration,,16288,,H,1624,8,,,105,,,,BAO_0000357,CHEMBL616510,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9)
B,,,,,1,Autocuration,,16312,,H,1625,8,,,105,,,,BAO_0000357,CHEMBL616511,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor
B,Bos taurus,9913.0,,,1,Expert,,1348,,H,1626,8,,,105,,,,BAO_0000357,CHEMBL616512,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype
B,Bos taurus,9913.0,,,1,Autocuration,,5834,,H,1627,8,,,105,,,,BAO_0000357,CHEMBL616513,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT
B,Bos taurus,9913.0,,,1,Autocuration,,13366,,H,1628,8,,,105,Striatum,2435.0,,BAO_0000019,CHEMBL616514,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
B,Bos taurus,9913.0,,,1,Expert,,1414,,H,1629,8,,,105,,,,BAO_0000357,CHEMBL616515,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra
B,Bos taurus,9913.0,,,1,Autocuration,,14998,,H,1630,8,,,105,,,,BAO_0000019,CHEMBL616516,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.
B,Bos taurus,9913.0,,,1,Autocuration,,11473,,H,1631,8,,,105,,,,BAO_0000357,CHEMBL616517,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,11473,,H,1632,8,,,105,,,,BAO_0000357,CHEMBL616518,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,10639,,H,1633,8,,,105,,,,BAO_0000357,CHEMBL616519,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,10639,,H,1634,8,,,105,,,,BAO_0000357,CHEMBL616520,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,1375,,H,1635,8,,,105,,,,BAO_0000357,CHEMBL616521,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,1375,,H,1636,8,,,105,,,,BAO_0000357,CHEMBL616522,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested
B,Bos taurus,9913.0,,,1,Autocuration,,16532,,H,1637,8,,,105,,,,BAO_0000357,CHEMBL884531,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
B,Bos taurus,9913.0,,,1,Autocuration,,11147,,H,1638,8,,,105,,,,BAO_0000357,CHEMBL616523,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand
B,Bos taurus,9913.0,,,1,Autocuration,,13366,,H,1639,8,,,105,Striatum,2435.0,,BAO_0000019,CHEMBL616731,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
B,Bos taurus,9913.0,,,1,Autocuration,,10444,,H,1640,8,,,105,,,,BAO_0000019,CHEMBL616732,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate
B,Bos taurus,9913.0,,,1,Autocuration,,16532,,H,1641,8,,,105,,,,BAO_0000357,CHEMBL616733,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT
B,Bos taurus,9913.0,,,1,Autocuration,,16532,,H,1642,8,,,105,,,,BAO_0000357,CHEMBL616734,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
B,Bos taurus,9913.0,,,1,Autocuration,,12827,,H,1643,8,,,105,,,,BAO_0000249,CHEMBL616735,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP
B,Bos taurus,9913.0,,,1,Autocuration,,12827,,H,1644,8,,,105,,,,BAO_0000249,CHEMBL616736,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined
F,Bos taurus,9913.0,,,1,Expert,,12919,,H,1645,8,,,105,,,,BAO_0000019,CHEMBL616737,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
B,Bos taurus,9913.0,,,1,Autocuration,,14025,,H,1646,8,,,105,,,,BAO_0000019,CHEMBL616738,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate
F,Bos taurus,9913.0,,,1,Expert,,12919,,H,1647,8,,,105,,,,BAO_0000019,CHEMBL616739,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
F,Bos taurus,9913.0,,,1,Expert,,12919,,H,1648,8,,,105,,,,BAO_0000019,CHEMBL616740,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
F,Bos taurus,9913.0,,,1,Expert,,12919,,H,1649,8,,,105,,,,BAO_0000019,CHEMBL616741,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
B,Gorilla gorilla,9593.0,,HEK293,1,Autocuration,,14447,,H,1650,8,722.0,,105,,,,BAO_0000219,CHEMBL616742,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
B,Cavia porcellus,10141.0,,,1,Intermediate,,1375,,D,1651,9,,,105570,,,,BAO_0000019,CHEMBL616743,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra
B,Cavia porcellus,10141.0,,,1,Intermediate,,1375,,D,1652,9,,,105570,,,,BAO_0000019,CHEMBL616744,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1653,9,,,105570,,,,BAO_0000019,CHEMBL616745,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1654,9,,,105570,,,,BAO_0000019,CHEMBL616746,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1655,9,,,105570,,,,BAO_0000019,CHEMBL616747,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1656,9,,,105570,,,,BAO_0000019,CHEMBL616748,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1657,9,,,105570,,,,BAO_0000019,CHEMBL616648,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2
B,Cavia porcellus,10141.0,,,1,Intermediate,,11574,,D,1658,9,,,105570,,,,BAO_0000357,CHEMBL616649,,Binding affinity against 5-hydroxytryptamine 1D receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,1558,,D,1659,9,,,105570,,,,BAO_0000357,CHEMBL616650,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1660,9,,,105570,,,,BAO_0000218,CHEMBL616651,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1661,9,,,105570,,,,BAO_0000218,CHEMBL616652,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1662,9,,,105570,,,,BAO_0000218,CHEMBL616653,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
F,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1663,9,,,105570,,,,BAO_0000218,CHEMBL616654,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig
B,Cavia porcellus,10141.0,,,1,Intermediate,,12253,,D,1664,9,,,105570,,,,BAO_0000019,CHEMBL616655,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex
B,Cavia porcellus,10141.0,,,1,Intermediate,,12936,,D,1665,9,,,105570,,,,BAO_0000357,CHEMBL616656,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,13181,,H,1666,8,,,105,,,,BAO_0000019,CHEMBL616657,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes
B,Cavia porcellus,10141.0,,,1,Intermediate,,12409,,D,1667,9,,,105570,Striatum,2435.0,,BAO_0000357,CHEMBL616658,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine
B,Cavia porcellus,10141.0,,,1,Intermediate,,10639,,D,1668,9,,,105570,,,,BAO_0000357,CHEMBL616659,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra
B,,,,,1,Autocuration,,5254,,H,1669,8,,,51,,,,BAO_0000357,CHEMBL616660,,Binding affinity against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,13051,,H,1670,8,,,106,,,,BAO_0000357,CHEMBL616661,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta
F,,,,,1,Expert,,3463,,H,1671,8,,,105,,,,BAO_0000019,CHEMBL616662,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor
F,,,,,1,Autocuration,,15315,,H,1672,8,,,105,,,,BAO_0000019,CHEMBL616663,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor
F,,,,,1,Autocuration,,6011,,H,1673,8,,,105,,,,BAO_0000019,CHEMBL616664,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor
F,Homo sapiens,9606.0,,CHO,1,Expert,,14159,,D,1674,9,449.0,,105,,,,BAO_0000219,CHEMBL881820,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor"
F,,,,CHO,1,Autocuration,,14159,,H,1675,8,449.0,,105,,,,BAO_0000219,CHEMBL616665,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor."
B,,,,CHO,1,Expert,,15250,,H,1676,8,449.0,,105,,,,BAO_0000219,CHEMBL616666,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
B,,,,CHO,1,Autocuration,,15250,,H,1677,8,449.0,,105,,,,BAO_0000219,CHEMBL616667,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor
F,,,,CHO,1,Expert,,15331,,H,1678,8,449.0,,105,,,,BAO_0000219,CHEMBL616668,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
F,Homo sapiens,9606.0,,CHO,1,Expert,,15332,,D,1679,9,449.0,,105,,,,BAO_0000219,CHEMBL616669,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
F,,,,CHO,1,Expert,,15332,,H,1680,8,449.0,,105,,,,BAO_0000219,CHEMBL617040,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor."
F,,,,CHO,1,Autocuration,,3294,,H,1681,8,449.0,,105,,,,BAO_0000219,CHEMBL617041,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor"
F,,,,CHO,1,Expert,,14158,,H,1682,8,449.0,,105,,,,BAO_0000219,CHEMBL617042,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor."
F,,,,CHO,1,Expert,,14956,,H,1683,8,449.0,,105,,,,BAO_0000219,CHEMBL617043,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor"
F,,,,,1,Autocuration,,12469,,H,1684,8,,,105,,,,BAO_0000019,CHEMBL617044,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor
F,,,,CHO,1,Expert,,3463,,H,1685,8,449.0,,105,,,,BAO_0000219,CHEMBL617045,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
F,Homo sapiens,9606.0,,CHO,1,Expert,,15250,,D,1686,9,449.0,,105,,,,BAO_0000219,CHEMBL617046,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
F,Homo sapiens,9606.0,,CHO,1,Expert,,15250,,D,1687,9,449.0,,105,,,,BAO_0000219,CHEMBL617047,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
F,,,,,1,Expert,,14956,,H,1688,8,,,105,,,,BAO_0000019,CHEMBL617048,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand"
F,,,,,1,Autocuration,,14159,,H,1689,8,,,105,,,,BAO_0000019,CHEMBL616897,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor."
F,Homo sapiens,9606.0,,,1,Expert,,14159,,D,1690,9,,,105,,,,BAO_0000019,CHEMBL616898,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT"
F,Homo sapiens,9606.0,,CHO,1,Expert,,14499,,D,1691,9,449.0,,105,,,,BAO_0000219,CHEMBL858201,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor
F,,,,,1,Autocuration,,15315,,H,1692,8,,,105,,,,BAO_0000019,CHEMBL616899,,Intrinsic activity for 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,3294,,H,1693,8,,,105,,,In vitro,BAO_0000219,CHEMBL616900,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells)
B,,,,CHO,1,Expert,,3463,,H,1694,8,449.0,,105,,,,BAO_0000219,CHEMBL616901,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro
B,,,,,1,Autocuration,,15331,,H,1695,8,,,105,,,,BAO_0000357,CHEMBL616902,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique
B,Homo sapiens,9606.0,,CHO,1,Expert,,14159,,D,1696,9,449.0,,105,,,,BAO_0000219,CHEMBL616903,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
B,,,,CHO,1,Expert,,14158,,H,1697,8,449.0,,105,,,,BAO_0000219,CHEMBL616904,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.
B,,,,,1,Autocuration,,14159,,H,1698,8,,,105,,,,BAO_0000357,CHEMBL616905,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor
B,,,,CHO,1,Expert,,15250,,H,1699,8,449.0,,105,,,,BAO_0000219,CHEMBL616906,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.
B,,,,CHO,1,Expert,,15250,,H,1700,8,449.0,,105,,,,BAO_0000219,CHEMBL616907,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
B,,,,CHO,1,Expert,,15331,,H,1701,8,449.0,,105,,,,BAO_0000219,CHEMBL616908,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
B,Homo sapiens,9606.0,,CHO,1,Expert,,15332,,D,1702,9,449.0,,105,,,,BAO_0000219,CHEMBL616909,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
B,Homo sapiens,9606.0,,CHO,1,Expert,,14499,,D,1703,9,449.0,,105,,,,BAO_0000219,CHEMBL616910,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
B,,,,CHO,1,Expert,,15332,,H,1704,8,449.0,,105,,,,BAO_0000219,CHEMBL616911,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
B,,,,CHO,1,Expert,,14956,,H,1705,8,449.0,,105,,,,BAO_0000219,CHEMBL616912,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells
B,,,,,1,Autocuration,,3805,,H,1706,8,,,105,,,,BAO_0000357,CHEMBL616913,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM)
B,Homo sapiens,9606.0,,CHO,1,Expert,,6011,,D,1707,9,449.0,,105,,,,BAO_0000219,CHEMBL616914,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM
B,,,,CHO,1,Autocuration,,16190,,H,1708,8,449.0,,105,,,,BAO_0000219,CHEMBL616915,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,14165,,H,1709,8,,,105,,,,BAO_0000019,CHEMBL616916,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,1710,9,,,105,,,,BAO_0000357,CHEMBL616917,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,15527,,H,1711,8,,,105,,,,BAO_0000357,CHEMBL616918,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand."
B,,,,,1,Expert,,6328,,H,1712,8,,,105,,,,BAO_0000219,CHEMBL616919,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
B,,,,,1,Autocuration,,16209,,H,1713,8,,,105,,,,BAO_0000357,CHEMBL616920,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,14770,,H,1714,8,,,105,,,,BAO_0000357,CHEMBL872914,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,2598,,H,1715,8,,,105,,,,BAO_0000357,CHEMBL616921,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand
B,,,,,1,Expert,,6897,,H,1716,8,,,105,,,,BAO_0000357,CHEMBL616922,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,6013,,H,1717,8,,,105,,,,BAO_0000357,CHEMBL616923,,Binding affinity towards 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,5843,,H,1718,8,,,105,,,,BAO_0000357,CHEMBL616924,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,14454,,H,1719,8,,,105,,,,BAO_0000357,CHEMBL875909,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand
B,,,,,1,Autocuration,,14454,,H,1720,8,,,105,,,,BAO_0000357,CHEMBL616925,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined
B,,,,,1,Autocuration,,14454,,H,1721,8,,,105,,,,BAO_0000357,CHEMBL616926,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined
B,,,,,1,Autocuration,,15818,,H,1722,8,,,105,,,,BAO_0000357,CHEMBL616927,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor
F,,,,CHO-K1,1,Expert,,13729,,H,1723,8,485.0,,105,,,,BAO_0000219,CHEMBL616928,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells
B,Homo sapiens,9606.0,,,1,Expert,,6011,,D,1724,9,,,105,,,In vitro,BAO_0000219,CHEMBL616929,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells)
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,1725,9,,,105,,,,BAO_0000357,CHEMBL616930,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,17085,,H,1726,8,,,105,,,,BAO_0000019,CHEMBL616931,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,3025,,H,1727,8,,,105,,,,BAO_0000357,CHEMBL616932,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
B,,,,,1,Expert,,15315,,H,1728,8,,,105,,,,BAO_0000357,CHEMBL616933,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor
B,Homo sapiens,9606.0,,,1,Expert,,14214,,D,1729,9,,,105,,,,BAO_0000219,CHEMBL616934,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells
B,Homo sapiens,9606.0,,,1,Expert,,3804,,D,1730,9,,,105,,,,BAO_0000357,CHEMBL616935,,Binding affinity for human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,16700,,H,1731,8,,,105,,,,BAO_0000357,CHEMBL616936,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity
B,Homo sapiens,9606.0,,,1,Expert,,2391,,D,1732,9,,,105,,,,BAO_0000357,CHEMBL616937,,Affinity for 5-hydroxytryptamine 1D receptor subtype
B,Homo sapiens,9606.0,,,1,Expert,,4175,,D,1733,9,,,105,,,,BAO_0000357,CHEMBL616938,,Binding affinity for human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,17085,,H,1734,8,,,105,,,,BAO_0000019,CHEMBL616939,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,17085,,H,1735,8,,,105,,,,BAO_0000019,CHEMBL616940,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined
B,Homo sapiens,9606.0,,,1,Expert,,15926,,D,1736,9,,,105,,,,BAO_0000357,CHEMBL616941,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested
B,,,,CHO-K1,1,Autocuration,,16312,,H,1737,8,485.0,,105,,,,BAO_0000219,CHEMBL616942,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested
B,,,,CHO-K1,1,Autocuration,,16312,,H,1738,8,485.0,,105,,,,BAO_0000219,CHEMBL616943,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested
B,,,,CHO,1,Autocuration,,14956,,H,1739,4,449.0,,104802,,,,BAO_0000219,CHEMBL616944,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells
F,,,,,1,Autocuration,,3294,,H,1740,8,,,105,,,,BAO_0000019,CHEMBL616945,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT"
B,,,,,1,Autocuration,,12861,,H,1741,8,,,105,,,,BAO_0000357,CHEMBL616946,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,1742,8,,,105,,,,BAO_0000019,CHEMBL616947,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
B,,,,CHO-K1,1,Expert,,16312,,H,1743,8,485.0,,105,,,,BAO_0000219,CHEMBL616948,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,5104,,H,1744,8,,,105,,,,BAO_0000357,CHEMBL616851,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,5105,,H,1745,8,,,105,,,,BAO_0000357,CHEMBL616852,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,14499,,H,1746,8,,,105,,,,BAO_0000357,CHEMBL616853,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor
B,Homo sapiens,9606.0,,,1,Expert,,15926,,D,1747,9,,,105,,,,BAO_0000357,CHEMBL616854,,Binding activity against human 5-hydroxytryptamine 1D receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,4540,,D,1748,9,449.0,,105,,,,BAO_0000219,CHEMBL616855,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
B,,,,CHO,1,Autocuration,,15779,,H,1749,8,449.0,,105,,,,BAO_0000219,CHEMBL616856,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.
B,,,,CHO,1,Autocuration,,15779,,H,1750,8,449.0,,105,,,,BAO_0000219,CHEMBL616857,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,6166,,H,1751,8,,,105,,,,BAO_0000357,CHEMBL616858,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
B,,,,CHO,1,Autocuration,,15779,,H,1752,8,449.0,,105,,,,BAO_0000219,CHEMBL616859,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.
B,,,,CHO,1,Autocuration,,15779,,H,1753,8,449.0,,105,,,,BAO_0000219,CHEMBL616860,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.
B,,,,HEK293,1,Autocuration,,17451,,H,1754,8,722.0,,105,,,,BAO_0000219,CHEMBL616861,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
B,,,,HEK293,1,Autocuration,,17451,,H,1755,8,722.0,,105,,,,BAO_0000219,CHEMBL616541,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
B,,,,HEK293,1,Autocuration,,17451,,H,1756,8,722.0,,105,,,,BAO_0000219,CHEMBL616542,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined
B,,,,CHO,1,Autocuration,,4199,,H,1757,8,449.0,,105,,,,BAO_0000219,CHEMBL616543,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand
B,Homo sapiens,9606.0,,,1,Expert,,14875,,D,1758,9,,,105,,,,BAO_0000357,CHEMBL616544,,Binding affinity for human 5-hydroxytryptamine 1D receptor
B,,,,CHO,1,Autocuration,,15146,,H,1759,8,449.0,,105,,,,BAO_0000219,CHEMBL616545,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT
B,,,,,1,Autocuration,,5213,,H,1760,8,,,105,,,,BAO_0000357,CHEMBL616546,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand
B,,,,CHO,1,Autocuration,,14818,,H,1761,8,449.0,,105,,,,BAO_0000219,CHEMBL616547,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.
B,,,,CHO,1,Autocuration,,4829,,H,1762,8,449.0,,105,,,,BAO_0000219,CHEMBL616548,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand"
F,,,,,1,Expert,,14454,,H,1763,8,,,105,,,,BAO_0000019,CHEMBL616549,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM
F,,,,,1,Expert,,14454,,H,1764,8,,,105,,,,BAO_0000019,CHEMBL616550,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM
B,,,,,1,Autocuration,,5254,,H,1765,8,,,108,,,,BAO_0000357,CHEMBL857066,,Binding affinity against 5-HT2C receptor
B,,,,,1,Autocuration,,5254,,H,1766,8,,,108,,,,BAO_0000357,CHEMBL616551,,Binding affinity against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,10639,,H,1767,8,,,10577,,,,BAO_0000357,CHEMBL616552,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
F,,,,,1,Autocuration,,10639,,H,1768,8,,,10577,,,,BAO_0000019,CHEMBL832876,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
B,,,,,1,Expert,,12352,,H,1769,8,,,10577,,,,BAO_0000019,CHEMBL616553,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus"
B,,,,,1,Autocuration,,9098,,H,1770,8,,,10577,,,,BAO_0000357,CHEMBL616554,,Binding affinity towards 5-HT1B was determined
B,,,,,1,Expert,,14430,,H,1771,8,,,10577,,,,BAO_0000019,CHEMBL616555,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT
B,,,,,1,Expert,,13657,,H,1772,8,,,10577,,,,BAO_0000019,CHEMBL616556,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB"
B,,,,,1,Autocuration,,13657,,H,1773,8,,,10577,,,,BAO_0000019,CHEMBL616557,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB."
B,,,,,1,Expert,,15854,,H,1774,8,,,10577,,,,BAO_0000019,CHEMBL616558,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
B,Rattus norvegicus,10116.0,,,1,Expert,,10639,,D,1775,9,,,10577,,,,BAO_0000019,CHEMBL616749,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT
B,,,,,1,Autocuration,,10025,,H,1776,8,,,10577,,,,BAO_0000357,CHEMBL616750,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
B,,,,,1,Autocuration,,10025,,H,1777,8,,,10577,,,,BAO_0000357,CHEMBL616751,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM"
B,,,,,1,Autocuration,,14286,,H,1778,8,,,10577,,,,BAO_0000249,CHEMBL616752,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
B,,,,,1,Autocuration,,3651,,H,1779,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616753,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,1780,9,,,10577,,,,BAO_0000357,CHEMBL616754,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,10639,,H,1781,8,,,10577,,,,BAO_0000019,CHEMBL616755,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.
B,,,,,1,Autocuration,,13605,,H,1782,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616756,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum
B,,,,,1,Autocuration,,5834,,H,1783,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616757,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT
B,,,,,1,Autocuration,,10922,,H,1784,8,,,10577,Striatum,2435.0,,BAO_0000357,CHEMBL616758,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue
B,,,,,1,Autocuration,,14286,,H,1785,8,,,10577,,,,BAO_0000249,CHEMBL616759,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
B,,,,,1,Autocuration,,11825,,H,1786,8,,,10577,,,,BAO_0000357,CHEMBL616760,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M
B,,,,,1,Autocuration,,14826,,H,1787,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616761,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum
B,,,,,1,Autocuration,,9699,,H,1788,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616762,,Binding affinity against 5-HT1B serotonin receptor in rat striatum
B,,,,,1,Autocuration,,14423,,H,1789,8,,,10577,,,,BAO_0000019,CHEMBL616763,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex
B,,,,,1,Expert,,10062,,H,1790,8,,,10577,,,,BAO_0000357,CHEMBL872909,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.
B,,,,,1,Autocuration,,10062,,H,1791,8,,,10577,,,,BAO_0000357,CHEMBL616764,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12280,,D,1792,9,,,10577,,,,BAO_0000357,CHEMBL616765,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,15412,,H,1793,8,,,10577,Striatum,2435.0,,BAO_0000357,CHEMBL616766,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum
B,,,,,1,Autocuration,,15412,,H,1794,8,,,10577,Striatum,2435.0,,BAO_0000357,CHEMBL616767,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.
B,,,,,1,Autocuration,,10062,,H,1795,8,,,10577,,,,BAO_0000357,CHEMBL616768,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,11147,,H,1796,8,,,10577,,,,BAO_0000357,CHEMBL616769,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,9547,,H,1797,8,,,10577,,,,BAO_0000019,CHEMBL616770,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay
B,,,,,1,Autocuration,,10444,,H,1798,8,,,10577,,,,BAO_0000019,CHEMBL616771,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.
B,,,,,1,Autocuration,,12469,,H,1799,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616772,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT
B,,,,,1,Expert,,9098,,H,1800,8,,,10577,,,,BAO_0000019,CHEMBL616773,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.
B,,,,,1,Autocuration,,9098,,H,1801,8,,,10577,,,,BAO_0000019,CHEMBL616774,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.
B,,,,,1,Autocuration,,9699,,H,1802,8,,,10577,,,,BAO_0000357,CHEMBL616775,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,10394,,H,1803,8,,,10577,,,,BAO_0000249,CHEMBL616776,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand
B,,,,,1,Autocuration,,12092,,H,1804,8,,,10577,,,,BAO_0000357,CHEMBL616777,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.
B,,,,,1,Autocuration,,16700,,H,1805,8,,,10577,,,,BAO_0000357,CHEMBL616778,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity
B,Rattus norvegicus,10116.0,,,1,Expert,,403,,D,1806,9,,,10577,,,,BAO_0000249,CHEMBL616779,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,12771,,D,1807,9,,,10577,,,,BAO_0000357,CHEMBL616780,,Binding affinity towards 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,11642,,H,1808,8,,,10577,,,,BAO_0000019,CHEMBL616781,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex
B,,,,,1,Autocuration,,12953,,H,1809,8,,,10577,,,,BAO_0000357,CHEMBL616782,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,12953,,H,1810,8,,,10577,,,,BAO_0000357,CHEMBL616783,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.
B,,,,,1,Expert,,12953,,H,1811,8,,,10577,Striatum,2435.0,,BAO_0000019,CHEMBL616784,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,12953,,H,1812,8,,,10577,,,,BAO_0000357,CHEMBL616785,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM
B,,,,,1,Autocuration,,9737,,H,1813,8,,,10577,Brain,955.0,,BAO_0000249,CHEMBL857067,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
B,,,,,1,Autocuration,,9737,,H,1814,8,,,10577,,,,BAO_0000019,CHEMBL616786,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand
B,,,,,1,Autocuration,,9737,,H,1815,8,,,10577,Brain,955.0,,BAO_0000249,CHEMBL616787,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
B,,,,,1,Autocuration,,12827,,H,1816,8,,,10577,,,,BAO_0000357,CHEMBL616788,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine
B,,,,,1,Autocuration,,5033,,H,1817,8,,,10577,,,,BAO_0000357,CHEMBL616789,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,9786,,D,1818,9,,,10577,,,,BAO_0000019,CHEMBL616790,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate
B,,,,,1,Expert,,13116,,H,1819,8,,,10577,,,,BAO_0000357,CHEMBL616791,,Binding affinity at 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,16429,,H,1820,8,,,10577,,,,BAO_0000019,CHEMBL616792,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,12409,,D,1821,9,,,10577,,,,BAO_0000249,CHEMBL616793,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol
B,,,,,1,Autocuration,,15194,,H,1822,8,,,10577,,,,BAO_0000357,CHEMBL616794,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,15194,,H,1823,8,,,10577,,,,BAO_0000357,CHEMBL616795,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,5486,,H,1824,4,,,104686,,,,BAO_0000019,CHEMBL616796,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex
B,,,,,1,Autocuration,,4639,,H,1825,8,,,106,,,,BAO_0000357,CHEMBL616797,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,Brain membranes,386,,H,1826,8,,,106,,,,BAO_0000249,CHEMBL616798,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes
B,,,,,1,Autocuration,,2474,,H,1827,8,,,106,,,,BAO_0000357,CHEMBL616799,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand
B,,,,,1,Autocuration,,6011,,H,1828,8,,,106,,,,BAO_0000357,CHEMBL616800,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration
B,,,,,1,Autocuration,,5014,,H,1829,8,,,106,,,,BAO_0000357,CHEMBL616801,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,17515,,H,1830,8,,,106,,,,BAO_0000357,CHEMBL616802,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM
B,,,,,1,Autocuration,,4373,,H,1831,8,,,106,,,,BAO_0000357,CHEMBL616803,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined
B,,,,,1,Expert,,1633,,H,1832,8,,,106,,,,BAO_0000357,CHEMBL857068,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.
B,,,,,1,Autocuration,,1633,,H,1833,8,,,106,,,,BAO_0000357,CHEMBL616804,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.
B,,,,,1,Autocuration,,4373,,H,1834,8,,,106,,,,BAO_0000357,CHEMBL616805,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined
B,,,,,1,Autocuration,,4687,,H,1835,8,,,106,,,,BAO_0000357,CHEMBL616806,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,11574,,H,1836,8,,,106,,,,BAO_0000357,CHEMBL616807,,Binding affinity against 5-hydroxytryptamine 1B receptor
B,,,,,1,Autocuration,,10321,,H,1837,8,,,106,,,,BAO_0000357,CHEMBL616808,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,15527,,H,1838,8,,,106,,,,BAO_0000357,CHEMBL616809,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
B,,,,,1,Autocuration,,17200,,H,1839,8,,,106,,,,BAO_0000357,CHEMBL616810,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand
B,,,,,1,Autocuration,,14423,,H,1840,4,,,104802,,,,BAO_0000224,CHEMBL616811,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.
B,Bos taurus,9913.0,,,1,Autocuration,,5834,,H,1841,8,,,108,,,,BAO_0000357,CHEMBL616812,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine
B,Sus scrofa,9823.0,,,1,Autocuration,,11473,,H,1842,8,,,108,,,,BAO_0000357,CHEMBL616813,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
B,Sus scrofa,9823.0,,,1,Autocuration,,11473,,H,1843,8,,,108,,,,BAO_0000357,CHEMBL616814,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand
B,Sus scrofa,9823.0,,,1,Autocuration,,10639,,H,1844,8,,,108,,,,BAO_0000357,CHEMBL616815,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
B,Sus scrofa,9823.0,,,1,Autocuration,,10639,,H,1845,8,,,108,,,,BAO_0000357,CHEMBL616816,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
B,Sus scrofa,9823.0,,,1,Autocuration,,14331,,H,1846,8,,,108,,,,BAO_0000357,CHEMBL616817,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined
B,Sus scrofa,9823.0,,,1,Autocuration,,10796,,H,1847,8,,,108,,,,BAO_0000357,CHEMBL616818,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor
B,Sus scrofa,9823.0,,,1,Expert,,9098,,H,1848,8,,,108,,,,BAO_0000357,CHEMBL616819,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.
B,Sus scrofa,9823.0,,,1,Expert,,14331,,H,1849,8,,,108,,,,BAO_0000357,CHEMBL616820,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus
B,Sus scrofa,9823.0,,,1,Expert,,11828,,H,1850,8,,,108,,,,BAO_0000019,CHEMBL616821,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,11866,,H,1851,8,,,108,,,,BAO_0000357,CHEMBL616822,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,1852,8,,,108,,,,BAO_0000019,CHEMBL616823,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,188,,D,1853,9,,,12689,,,,BAO_0000357,CHEMBL616824,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11825,,D,1854,9,,,12689,,,,BAO_0000357,CHEMBL616825,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11825,,D,1855,9,,,12689,,,,BAO_0000357,CHEMBL616826,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
B,Rattus norvegicus,10116.0,,,1,Expert,,11624,,D,1856,9,,,12689,,,,BAO_0000019,CHEMBL616827,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11139,,D,1857,9,,,12689,,,,BAO_0000357,CHEMBL616828,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11147,,D,1858,9,,,12689,,,,BAO_0000357,CHEMBL616829,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,10444,,D,1859,9,,,12689,,,,BAO_0000019,CHEMBL616830,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.
B,Rattus norvegicus,10116.0,,,1,Expert,,11624,,D,1860,9,,,12689,,,,BAO_0000357,CHEMBL616831,,Binding affinity against 5-hydroxytryptamine 1C receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11662,,D,1861,9,,,12689,,,,BAO_0000019,CHEMBL616832,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11662,,D,1862,9,,,12689,,,,BAO_0000019,CHEMBL616833,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
B,Rattus norvegicus,10116.0,,,1,Expert,,11662,,D,1863,9,,,12689,,,,BAO_0000019,CHEMBL616834,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11662,,D,1864,9,,,12689,,,,BAO_0000019,CHEMBL829595,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9098,,D,1865,9,,,12689,,,,BAO_0000357,CHEMBL616835,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,10394,,D,1866,9,,,12689,,,,BAO_0000249,CHEMBL872910,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand
B,,,,,1,Expert,,11933,,H,1867,8,,,12689,,,,BAO_0000357,CHEMBL616836,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12092,,D,1868,9,,,12689,,,,BAO_0000357,CHEMBL616837,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12253,,D,1869,9,,,12689,,,,BAO_0000019,CHEMBL616466,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex
B,Rattus norvegicus,10116.0,,HEK293,1,Autocuration,,12253,,D,1870,9,722.0,,12689,,,,BAO_0000219,CHEMBL616467,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells
B,,,,,1,Autocuration,,1558,,H,1871,8,,,108,,,,BAO_0000357,CHEMBL616468,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
B,,,,,1,Autocuration,,2474,,H,1872,8,,,108,,,,BAO_0000357,CHEMBL616469,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,2474,,H,1873,8,,,108,,,,BAO_0000357,CHEMBL616470,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,11574,,H,1874,8,,,12689,,,,BAO_0000357,CHEMBL616471,,Binding affinity against 5-hydroxytryptamine 1C receptor
B,,,,,1,Autocuration,,1558,,H,1875,8,,,12689,,,,BAO_0000357,CHEMBL616472,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
B,,,,,1,Autocuration,,13944,,H,1876,8,,,12689,,,,BAO_0000357,CHEMBL616473,,Binding affinity against 5-hydroxytryptamine 1C receptor
B,,,,,1,Autocuration,,13033,,H,1877,8,,,12689,,,,BAO_0000357,CHEMBL616474,,Binding affinity against serotonergic 5-HT1c receptor
B,,,,,1,Autocuration,,10321,,H,1878,8,,,12689,,,,BAO_0000357,CHEMBL616475,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand
B,,,,,1,Autocuration,,11866,,H,1879,8,,,12689,,,,BAO_0000357,CHEMBL616476,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14454,,H,1880,8,,,105,,,,BAO_0000019,CHEMBL616477,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
B,,,,,1,Autocuration,,11574,,H,1881,4,,,104686,,,,BAO_0000224,CHEMBL616478,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.
B,,,,,1,Autocuration,,11574,,H,1882,4,,,104686,,,,BAO_0000224,CHEMBL616479,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.
B,,,,,1,Autocuration,,13631,,H,1883,4,,,104686,,,,BAO_0000019,CHEMBL616480,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9630,,D,1884,5,,,104686,,,,BAO_0000019,CHEMBL616481,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8822,,D,1885,5,,,104686,,,,BAO_0000249,CHEMBL616482,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9064,,D,1886,5,,,104686,Brain,955.0,,BAO_0000221,CHEMBL884713,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol
B,,,,,1,Autocuration,,8868,,H,1887,4,,,104686,,,,BAO_0000224,CHEMBL616483,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay
B,,,,,1,Autocuration,,9064,,H,1888,4,,,104686,,,,BAO_0000224,CHEMBL616484,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol
B,,,,,1,Autocuration,,9806,,H,1889,4,,,104686,,,,BAO_0000019,CHEMBL616485,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.
B,,,,,1,Autocuration,,9098,,H,1890,4,,,104686,,,,BAO_0000224,CHEMBL616486,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
B,,,,,1,Autocuration,,8868,,H,1891,4,,,104686,,,,BAO_0000224,CHEMBL616487,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay
B,,,,,1,Autocuration,,12765,,H,1892,4,,,104686,,,,BAO_0000224,CHEMBL616488,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
B,,,,,1,Autocuration,,11049,,H,1893,4,,,104686,,,,BAO_0000019,CHEMBL616489,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,11049,,H,1894,4,,,104686,,,,BAO_0000019,CHEMBL616490,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,11049,,H,1895,4,,,104686,,,,BAO_0000019,CHEMBL616491,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined
B,,,,,1,Autocuration,,11049,,H,1896,4,,,104686,,,,BAO_0000019,CHEMBL616492,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined
B,,,,,1,Autocuration,,11049,,H,1897,4,,,104686,,,,BAO_0000019,CHEMBL616493,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,11473,,H,1898,4,,,104686,,,,BAO_0000019,CHEMBL616494,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand
B,,,,,1,Autocuration,,11473,,H,1899,4,,,104686,,,,BAO_0000019,CHEMBL616495,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,3086,,H,1900,4,,,104686,,,,BAO_0000019,CHEMBL616496,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex
B,,,,,1,Autocuration,,11049,,H,1901,4,,,104686,,,,BAO_0000019,CHEMBL616497,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,11049,,H,1902,4,,,104686,,,,BAO_0000019,CHEMBL616498,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,10639,,H,1903,4,,,104686,,,,BAO_0000019,CHEMBL616499,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand
B,,,,,1,Autocuration,,10922,,H,1904,4,,,104686,,,,BAO_0000019,CHEMBL616500,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9064,,D,1905,5,,,104686,Brain,955.0,,BAO_0000221,CHEMBL616501,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
B,,,,,1,Autocuration,,10748,,H,1906,4,,,104686,Brain,955.0,,BAO_0000221,CHEMBL616502,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.
B,,,,,1,Autocuration,Membranes,11614,,H,1907,4,,,104686,,,,BAO_0000249,CHEMBL884529,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.
B,,,,,1,Autocuration,Membranes,11615,,H,1908,4,,,104686,,,,BAO_0000249,CHEMBL616503,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
B,,,,,1,Autocuration,,11615,,H,1909,4,,,104686,,,,BAO_0000224,CHEMBL616964,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,Membranes,11614,,H,1910,4,,,104686,,,,BAO_0000249,CHEMBL616965,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.
B,,,,,1,Autocuration,,11702,,H,1911,4,,,104686,,,,BAO_0000224,CHEMBL616966,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.
B,,,,,1,Autocuration,,11702,,H,1912,4,,,104686,,,,BAO_0000224,CHEMBL616967,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11702,,D,1913,5,,,104686,,,,BAO_0000224,CHEMBL616968,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11702,,H,1914,4,,,104686,,,,BAO_0000224,CHEMBL616969,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested
B,,,,,1,Autocuration,,13346,,H,1915,4,,,104686,,,,BAO_0000019,CHEMBL884530,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.
B,,,,,1,Autocuration,,10025,,H,1916,4,,,104686,,,,BAO_0000224,CHEMBL616970,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,10025,,H,1917,4,,,104686,,,,BAO_0000224,CHEMBL616971,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
B,,,,,1,Autocuration,,10025,,H,1918,4,,,104686,,,,BAO_0000224,CHEMBL616972,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
B,,,,,1,Autocuration,,9036,,H,1919,4,,,104686,,,,BAO_0000224,CHEMBL616973,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone
B,,,,,1,Autocuration,,9036,,H,1920,4,,,104686,,,,BAO_0000224,CHEMBL616974,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive
B,,,,,1,Autocuration,,9161,,H,1921,4,,,104686,,,,BAO_0000019,CHEMBL616975,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.
B,,,,,1,Autocuration,,12304,,H,1922,4,,,104686,,,,BAO_0000019,CHEMBL616976,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex
B,,,,,1,Autocuration,,13276,,H,1923,4,,,104686,,,,BAO_0000224,CHEMBL616977,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,11825,,H,1924,4,,,104686,,,,BAO_0000224,CHEMBL616978,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
B,,,,,1,Autocuration,,12443,,H,1925,4,,,104686,,,,BAO_0000224,CHEMBL616979,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin
B,,,,,1,Autocuration,,13830,,H,1926,4,,,104686,,,,BAO_0000224,CHEMBL616980,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,Membranes,9592,,H,1927,4,,,104686,,,,BAO_0000249,CHEMBL616981,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes
B,,,,,1,Autocuration,Membranes,9592,,H,1928,4,,,104686,,,,BAO_0000249,CHEMBL616982,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested
B,,,,,1,Autocuration,,10881,,H,1929,4,,,104686,,,,BAO_0000224,CHEMBL616983,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.
B,,,,,1,Autocuration,,13605,,H,1930,4,,,104686,,,,BAO_0000019,CHEMBL616984,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11624,,D,1931,5,,,104686,,,,BAO_0000224,CHEMBL616985,,Inhibitory activity against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,4101,,H,1932,4,,,104686,,,,BAO_0000224,CHEMBL616986,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
B,,,,,1,Autocuration,,4101,,H,1933,4,,,104686,,,,BAO_0000224,CHEMBL616987,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
B,,,,,1,Autocuration,,15360,,H,1934,4,,,104686,,,,BAO_0000019,CHEMBL616988,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat
B,,,,,1,Autocuration,,11576,,H,1935,4,,,104686,,,,BAO_0000019,CHEMBL617243,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex
B,,,,,1,Autocuration,,5834,,H,1936,4,,,104686,,,,BAO_0000019,CHEMBL617244,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone
B,Rattus norvegicus,10116.0,,CHO-K1,1,Autocuration,,2395,,D,1937,5,485.0,,104686,,,,BAO_0000219,CHEMBL617245,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
B,,,,,1,Autocuration,Membranes,11965,,H,1938,4,,,104686,,,,BAO_0000249,CHEMBL617246,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
B,,,,,1,Autocuration,,3967,,H,1939,4,,,104686,,,,BAO_0000224,CHEMBL617546,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats)
B,,,,,1,Autocuration,Brain membranes,11130,,H,1940,4,,,104686,,,,BAO_0000249,CHEMBL617547,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro)
B,,,,,1,Autocuration,,13427,,H,1941,4,,,104686,,,In vitro,BAO_0000219,CHEMBL617548,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
B,,,,,1,Autocuration,,9443,,H,1942,4,,,104686,,,,BAO_0000224,CHEMBL617549,,Binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,9443,,H,1943,4,,,104686,,,,BAO_0000224,CHEMBL617550,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
B,,,,,1,Autocuration,,11825,,H,1944,4,,,104686,,,,BAO_0000224,CHEMBL617551,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
B,,,,,1,Autocuration,Membranes,12120,,H,1945,4,,,104686,,,,BAO_0000249,CHEMBL617552,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M
B,,,,,1,Autocuration,Membranes,12120,,H,1946,4,,,104686,,,,BAO_0000249,CHEMBL617553,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.
F,,,,,1,Autocuration,,11963,,H,1947,4,,,104686,Thoracic aorta,1515.0,,BAO_0000019,CHEMBL617554,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta
B,,,,,1,Autocuration,,9069,,H,1948,4,,,104686,,,,BAO_0000019,CHEMBL617555,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,8868,,H,1949,4,,,104686,,,,BAO_0000224,CHEMBL617556,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
B,,,,,1,Autocuration,,17200,,H,1950,8,,,10624,,,,BAO_0000357,CHEMBL617557,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
B,,,,,1,Autocuration,,17200,,H,1951,8,,,10624,,,,BAO_0000357,CHEMBL617558,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
B,,,,,1,Expert,,13969,,H,1952,8,,,17106,,,,BAO_0000357,CHEMBL617559,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand
B,,,,,1,Expert,,13392,,D,1953,9,,,17106,,,,BAO_0000357,CHEMBL617560,,Binding affinity for 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,1742,,H,1954,8,,,17106,,,,BAO_0000249,CHEMBL617561,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
B,,,,,1,Autocuration,,1742,,H,1955,8,,,17106,,,,BAO_0000249,CHEMBL617562,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
B,,,,,1,Autocuration,,14331,,H,1956,8,,,17106,Striatum,2435.0,,BAO_0000357,CHEMBL617563,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex
F,,,,,1,Autocuration,,12861,,H,1957,8,,,17106,,,,BAO_0000019,CHEMBL617564,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,12861,,H,1958,8,,,17106,,,,BAO_0000019,CHEMBL617565,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,12861,,H,1959,8,,,17106,,,,BAO_0000357,CHEMBL856076,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,1960,8,,,17106,,,,BAO_0000019,CHEMBL617566,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
B,,,,,1,Expert,,12861,,H,1961,8,,,17106,,,,BAO_0000019,CHEMBL875911,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
B,,,,,1,Autocuration,,12861,,H,1962,8,,,17106,,,,BAO_0000019,CHEMBL617567,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
B,,,,,1,Autocuration,,675,,H,1963,8,,,17106,,,,BAO_0000249,CHEMBL617568,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
B,,,,,1,Expert,,12490,,H,1964,8,,,17106,,,,BAO_0000019,CHEMBL617569,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane
B,,,,,1,Expert,,11828,,H,1965,8,,,17106,,,,BAO_0000249,CHEMBL617570,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane
B,,,,,1,Autocuration,,11866,,H,1966,8,,,17106,,,,BAO_0000357,CHEMBL617571,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT
B,Sus scrofa,9823.0,,,1,Autocuration,,773,,H,1967,8,,,105,,,,BAO_0000357,CHEMBL617572,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,13047,,H,1968,8,,,105,,,,BAO_0000357,CHEMBL617573,,The compound was tested for intrinsic activity against 5-HT1D receptor
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,1969,8,,,105,,,,BAO_0000019,CHEMBL617574,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,13047,,H,1970,8,,,105,,,,BAO_0000357,CHEMBL617575,,The compound was tested for binding affinity against 5-HT1D receptor
B,,,,,1,Autocuration,,188,,H,1971,8,,,10578,,,,BAO_0000357,CHEMBL617576,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity
F,,,,,1,Autocuration,,10639,,H,1972,8,,,10578,,,,BAO_0000019,CHEMBL617577,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra
F,,,,,1,Autocuration,,12438,,H,1973,8,,,10578,,,,BAO_0000019,CHEMBL617578,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,12438,,H,1974,8,,,10578,,,,BAO_0000357,CHEMBL617579,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor
B,,,,,1,Expert,,15854,,H,1975,8,,,10578,,,,BAO_0000019,CHEMBL617580,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
B,,,,,1,Autocuration,,10394,,H,1976,8,,,10578,,,,BAO_0000249,CHEMBL617581,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand
B,,,,,1,Autocuration,,12092,,H,1977,8,,,10578,,,,BAO_0000357,CHEMBL617582,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.
B,,,,,1,Expert,,3389,,H,1978,8,,,10578,,,,BAO_0000019,CHEMBL617583,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.
B,,,,,1,Autocuration,,6011,,H,1979,8,,,105,,,,BAO_0000357,CHEMBL617584,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration
B,,,,,1,Autocuration,,4639,,H,1980,8,,,105,,,,BAO_0000357,CHEMBL617585,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,2474,,H,1981,8,,,105,,,,BAO_0000357,CHEMBL875912,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,5014,,H,1982,8,,,105,,,,BAO_0000357,CHEMBL617586,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,17515,,H,1983,8,,,105,,,,BAO_0000357,CHEMBL617587,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM
B,,,,,1,Autocuration,,11866,,H,1984,8,,,105,,,,BAO_0000357,CHEMBL617588,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined
B,,,,,1,Autocuration,,4687,,H,1985,8,,,105,,,,BAO_0000357,CHEMBL857980,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,12146,,H,1986,8,,,105,,,,BAO_0000357,CHEMBL617589,,Tested against 5-hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,10321,,H,1987,8,,,105,,,,BAO_0000357,CHEMBL617590,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand
B,,,,HEK293,1,Autocuration,,13267,,H,1988,8,722.0,,105,,,,BAO_0000219,CHEMBL617591,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,1274,,D,1989,9,,,105,,,,BAO_0000357,CHEMBL617592,,Binding affinity against 5-Hydroxytryptamine 1D receptor
B,,,,,1,Autocuration,,15250,,H,1990,8,,,105,,,,BAO_0000357,CHEMBL617593,,
B,,,,CHO-K1,1,Autocuration,,13706,,H,1991,8,485.0,,106,,,,BAO_0000219,CHEMBL617594,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
B,,,,CHO-K1,1,Autocuration,,13706,,H,1992,8,485.0,,105,,,,BAO_0000219,CHEMBL617595,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
B,,,,HEK293,1,Autocuration,,13706,,H,1993,8,722.0,,105,,,,BAO_0000219,CHEMBL617596,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.
B,,,,HEK293,1,Autocuration,,13706,,H,1994,8,722.0,,105,,,,BAO_0000219,CHEMBL617597,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
B,,,,,1,Autocuration,,13047,,H,1995,8,,,105,,,,BAO_0000019,CHEMBL617598,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
B,,,,,1,Autocuration,,13366,,H,1996,8,,,105,,,,BAO_0000357,CHEMBL872916,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human
B,,,,,1,Expert,,13366,,H,1997,8,,,105,,,,BAO_0000357,CHEMBL617599,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.
B,,,,,1,Autocuration,,1558,,H,1998,8,,,105,,,,BAO_0000357,CHEMBL617091,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined
B,,,,CHO-K1,1,Expert,,12902,,H,1999,8,485.0,,105,,,,BAO_0000219,CHEMBL617092,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand."
B,,,,CHO-K1,1,Autocuration,,13706,,H,2000,8,485.0,,105,,,,BAO_0000219,CHEMBL617093,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
F,,,,,1,Autocuration,,13706,,H,2001,8,,,105,,,,BAO_0000019,CHEMBL617094,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.
F,,,,,1,Autocuration,,13706,,H,2002,8,,,105,,,,BAO_0000019,CHEMBL617095,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
F,,,,,1,Autocuration,,14251,,H,2003,8,,,105,,,,BAO_0000019,CHEMBL617096,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
F,,,,,1,Autocuration,,14251,,H,2004,8,,,105,,,,BAO_0000019,CHEMBL617097,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
F,,,,,1,Autocuration,,14251,,H,2005,8,,,105,,,,BAO_0000019,CHEMBL617098,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
B,,,,,1,Autocuration,,13313,,H,2006,8,,,105,,,,BAO_0000357,CHEMBL617301,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,13313,,H,2007,8,,,105,,,,BAO_0000357,CHEMBL617302,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,13366,,H,2008,8,,,105,,,,BAO_0000357,CHEMBL617303,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha
B,,,,,1,Expert,,13051,,H,2009,8,,,105,,,,BAO_0000357,CHEMBL617304,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha
B,,,,CHO,1,Expert,,12903,,H,2010,8,449.0,,105,,,,BAO_0000219,CHEMBL617305,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand"
B,Homo sapiens,9606.0,,,1,Autocuration,,12469,,D,2011,9,,,105,,,,BAO_0000219,CHEMBL617306,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT
B,,,,,1,Autocuration,,5619,,H,2012,8,,,17106,,,,BAO_0000357,CHEMBL617307,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,2013,8,,,105,,,,BAO_0000019,CHEMBL617308,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
B,,,,,1,Autocuration,,16633,,H,2014,8,,,105,,,,BAO_0000357,CHEMBL617309,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha
B,,,,,1,Autocuration,,16633,,H,2015,8,,,105,,,,BAO_0000357,CHEMBL617310,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
B,,,,,1,Autocuration,,16633,,H,2016,8,,,105,,,,BAO_0000357,CHEMBL617311,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
B,,,,,1,Autocuration,,16633,,H,2017,8,,,105,,,,BAO_0000357,CHEMBL617312,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,3269,,H,2018,8,,,105,,,,BAO_0000357,CHEMBL617313,,Affinity against 5-hydroxytryptamine 1D receptor alpha
B,,,,,1,Expert,,12409,,H,2019,8,,,105,,,,BAO_0000357,CHEMBL617314,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha
F,,,,,1,Autocuration,,13706,,H,2020,8,,,106,,,,BAO_0000019,CHEMBL617315,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
B,,,,HEK293,1,Autocuration,,13706,,H,2021,8,722.0,,106,,,,BAO_0000219,CHEMBL617316,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.
B,,,,HEK293,1,Autocuration,,13706,,H,2022,8,722.0,,106,,,,BAO_0000219,CHEMBL617317,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
B,,,,CHO,1,Autocuration,,12903,,H,2023,8,449.0,,106,,,,BAO_0000219,CHEMBL617318,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
B,,,,,1,Autocuration,,13047,,H,2024,8,,,106,,,,BAO_0000019,CHEMBL617319,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
B,,,,,1,Expert,,13366,,D,2025,9,,,106,,,,BAO_0000357,CHEMBL617320,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
B,,,,,1,Expert,,13366,,D,2026,9,,,106,,,,BAO_0000357,CHEMBL617321,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
B,,,,,1,Expert,,13366,,D,2027,9,,,106,,,,BAO_0000357,CHEMBL617322,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
B,,,,,1,Autocuration,,13366,,H,2028,8,,,106,,,,BAO_0000357,CHEMBL616862,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,13366,,H,2029,8,,,106,,,,BAO_0000357,CHEMBL616863,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand
B,,,,CHO,1,Autocuration,,12469,,H,2030,8,449.0,,106,,,,BAO_0000219,CHEMBL616864,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT
B,,,,CHO-K1,1,Autocuration,,13706,,H,2031,8,485.0,,106,,,,BAO_0000219,CHEMBL616865,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.
B,,,,CHO-K1,1,Autocuration,,13706,,H,2032,8,485.0,,106,,,,BAO_0000219,CHEMBL616866,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.
F,,,,,1,Autocuration,,13706,,H,2033,8,,,106,,,,BAO_0000019,CHEMBL616867,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
B,,,,CHO-K1,1,Expert,,12902,,H,2034,8,485.0,,106,,,,BAO_0000219,CHEMBL616868,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand."
B,,,,,1,Expert,,13051,,H,2035,8,,,105,,,,BAO_0000357,CHEMBL616869,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta
B,,,,CHO,1,Expert,,12903,,H,2036,8,449.0,,106,,,,BAO_0000219,CHEMBL616870,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
F,,,,CHO-K1,1,Autocuration,,1558,,H,2037,8,485.0,,105,,,,BAO_0000219,CHEMBL616871,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55
F,,,,CHO-K1,1,Autocuration,,1558,,H,2038,8,485.0,,105,,,,BAO_0000219,CHEMBL616872,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0
F,,,,CHO-K1,1,Autocuration,,1558,,H,2039,8,485.0,,105,,,,BAO_0000219,CHEMBL616873,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5
F,,,,CHO-K1,1,Autocuration,,1558,,H,2040,8,485.0,,105,,,,BAO_0000219,CHEMBL616838,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70
B,,,,,1,Autocuration,,1558,,H,2041,8,,,105,,,,BAO_0000357,CHEMBL616839,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,2042,8,,,106,,,,BAO_0000019,CHEMBL616840,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.
B,,,,,1,Autocuration,,13313,,H,2043,8,,,105,,,,BAO_0000357,CHEMBL616841,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand
B,,,,,1,Autocuration,,13313,,H,2044,8,,,105,,,,BAO_0000357,CHEMBL616842,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand
B,,,,,1,Expert,,12409,,H,2045,8,,,105,,,,BAO_0000357,CHEMBL857976,,Binding affinity against 5-hydroxytryptamine 1D receptor beta
B,,,,CHO,1,Autocuration,,15250,,H,2046,8,449.0,,10618,,,,BAO_0000219,CHEMBL616843,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells
B,Homo sapiens,9606.0,,,1,Expert,,1348,,D,2047,9,,,10618,,,,BAO_0000357,CHEMBL616844,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype
B,,,,,1,Autocuration,,1348,,H,2048,8,,,10618,,,,BAO_0000357,CHEMBL616845,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,2049,9,,,10618,,,,BAO_0000357,CHEMBL616846,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor
B,,,,,1,Autocuration,,16209,,H,2050,8,,,10618,,,,BAO_0000357,CHEMBL616847,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,10444,,H,2051,8,,,10618,,,,BAO_0000019,CHEMBL616848,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate
B,,,,,1,Autocuration,,3935,,H,2052,8,,,10618,,,,BAO_0000357,CHEMBL616849,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor
B,,,,,1,Autocuration,,15818,,H,2053,8,,,10618,,,,BAO_0000357,CHEMBL872911,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor
B,,,,,1,Autocuration,,17085,,H,2054,8,,,10618,,,,BAO_0000019,CHEMBL616850,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor
B,Homo sapiens,9606.0,,CHO,1,Expert,,12936,,D,2055,9,449.0,,10618,,,,BAO_0000219,CHEMBL616699,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells
B,,,,,1,Autocuration,,6166,,H,2056,8,,,10618,,,,BAO_0000357,CHEMBL616700,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined
B,,,,CHO,1,Autocuration,,15779,,H,2057,8,449.0,,10618,,,,BAO_0000219,CHEMBL616701,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
B,,,,CHO,1,Autocuration,,15779,,H,2058,8,449.0,,10618,,,,BAO_0000219,CHEMBL616702,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.
B,,,,CHO,1,Autocuration,,15779,,H,2059,8,449.0,,10618,,,,BAO_0000219,CHEMBL616703,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.
B,,,,,1,Autocuration,,13181,,H,2060,8,,,10618,,,,BAO_0000357,CHEMBL616704,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor
B,,,,CHO,1,Autocuration,,4199,,H,2061,8,449.0,,10618,,,,BAO_0000219,CHEMBL616705,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand
B,,,,,1,Autocuration,,14875,,H,2062,8,,,10618,,,,BAO_0000357,CHEMBL616706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor
B,,,,CHO,1,Autocuration,,15146,,H,2063,8,449.0,,10618,,,,BAO_0000219,CHEMBL616707,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT
B,,,,,1,Autocuration,,5213,,H,2064,8,,,10618,,,,BAO_0000357,CHEMBL616708,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand
B,,,,,1,Autocuration,,12146,,H,2065,8,,,10618,,,,BAO_0000357,CHEMBL616709,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand
B,,,,CHO,1,Autocuration,,13267,,H,2066,8,449.0,,10618,,,,BAO_0000219,CHEMBL616710,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand
B,,,,CHO,1,Autocuration,,14818,,H,2067,8,449.0,,10618,,,,BAO_0000219,CHEMBL616711,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.
B,,,,CHO,1,Autocuration,,4829,,H,2068,8,449.0,,10618,,,,BAO_0000219,CHEMBL616712,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand"
B,,,,,1,Autocuration,,4373,,H,2069,8,,,10618,,,,BAO_0000357,CHEMBL616713,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined
B,,,,,1,Autocuration,,4373,,H,2070,8,,,10618,,,,BAO_0000357,CHEMBL616714,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined
B,,,,,1,Autocuration,,14159,,H,2071,8,,,10618,,,,BAO_0000357,CHEMBL616715,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor
B,,,,,1,Autocuration,,16633,,H,2072,8,,,10618,,,,BAO_0000357,CHEMBL616716,,Binding affinity towards 5-hydroxytryptamine 1E receptor
F,,,,,1,Autocuration,,17085,,H,2073,8,,,279,,,,BAO_0000019,CHEMBL616717,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor"
F,,,,,1,Expert,,17085,,H,2074,8,,,279,,,,BAO_0000019,CHEMBL616718,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor"
F,,,,,1,Autocuration,,16209,,H,2075,8,,,279,,,,BAO_0000019,CHEMBL875905,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor
F,,,,,1,Autocuration,,16209,,H,2076,8,,,279,,,,BAO_0000019,CHEMBL616719,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor
F,,,,,1,Expert,,17085,,H,2077,8,,,279,,,,BAO_0000019,CHEMBL616720,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor"
B,,,,,1,Autocuration,,14159,,H,2078,8,,,279,,,,BAO_0000357,CHEMBL616721,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor
B,,,,CHO,1,Autocuration,,15250,,H,2079,8,449.0,,279,,,,BAO_0000219,CHEMBL616722,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells
B,,,,,1,Autocuration,,3805,,H,2080,8,,,279,,,,BAO_0000357,CHEMBL616723,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM)
B,,,,CHO,1,Autocuration,,16190,,H,2081,8,449.0,,279,,,,BAO_0000219,CHEMBL616724,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand
B,,,,,1,Autocuration,,16190,,H,2082,8,,,279,,,,BAO_0000357,CHEMBL616725,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand
B,,,,,1,Autocuration,,16209,,H,2083,8,,,279,,,,BAO_0000357,CHEMBL616726,,Binding affinity towards human 5-hydroxytryptamine 1F receptor
B,,,,,1,Autocuration,,16209,,H,2084,8,,,279,,,,BAO_0000357,CHEMBL616727,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined
B,,,,,1,Autocuration,,16209,,H,2085,8,,,279,,,,BAO_0000357,CHEMBL616728,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand
B,,,,,1,Autocuration,,6866,,H,2086,8,,,279,,,,BAO_0000357,CHEMBL616729,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor
B,,,,,1,Expert,,17085,,H,2087,8,,,279,,,,BAO_0000019,CHEMBL616730,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor
B,,,,,1,Autocuration,,16312,,H,2088,8,,,279,,,,BAO_0000357,CHEMBL617125,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor
B,,,,,1,Autocuration,,6166,,H,2089,8,,,279,,,,BAO_0000357,CHEMBL857977,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined
B,,,,CHO,1,Autocuration,,15779,,H,2090,8,449.0,,279,,,,BAO_0000219,CHEMBL617126,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
B,,,,CHO,1,Autocuration,,4199,,H,2091,8,449.0,,279,,,,BAO_0000219,CHEMBL617127,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand
B,,,,,1,Autocuration,,14875,,H,2092,8,,,279,,,,BAO_0000357,CHEMBL617128,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor
B,,,,CHO,1,Autocuration,,15146,,H,2093,8,449.0,,279,,,,BAO_0000219,CHEMBL617129,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT
B,,,,,1,Autocuration,,5213,,H,2094,8,,,279,,,,BAO_0000357,CHEMBL617130,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand
B,,,,CHO,1,Autocuration,,14818,,H,2095,8,449.0,,279,,,,BAO_0000219,CHEMBL617131,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.
B,,,,CHO,1,Autocuration,,4829,,H,2096,8,449.0,,279,,,,BAO_0000219,CHEMBL617132,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
B,,,,CHO,1,Autocuration,,4829,,H,2097,8,449.0,,279,,,,BAO_0000219,CHEMBL617133,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
B,,,,,1,Autocuration,,4373,,H,2098,8,,,279,,,,BAO_0000357,CHEMBL617134,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined
B,,,,,1,Autocuration,,4373,,H,2099,8,,,279,,,,BAO_0000357,CHEMBL617135,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined
B,,,,,1,Autocuration,,5014,,H,2100,8,,,279,,,,BAO_0000357,CHEMBL617136,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor
B,,,,,1,Autocuration,,11662,,H,2101,4,,,104686,,,,BAO_0000019,CHEMBL617137,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand"
B,,,,,1,Autocuration,,11662,,H,2102,4,,,104686,,,,BAO_0000019,CHEMBL617138,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
B,,,,,1,Autocuration,,11662,,H,2103,4,,,104686,,,,BAO_0000019,CHEMBL617139,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
B,,,,,1,Autocuration,,14093,,H,2104,8,,,12687,,,,BAO_0000019,CHEMBL617140,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
F,,,,,1,Autocuration,,11200,,H,2105,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617141,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration"
F,,,,,1,Autocuration,,11200,,H,2106,4,,,104686,,,,BAO_0000019,CHEMBL858112,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
B,,,,,1,Intermediate,,12352,,H,2107,8,,,17005,,,,BAO_0000019,CHEMBL617142,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex
B,Bos taurus,9913.0,,,1,Autocuration,,13657,,U,2108,0,,,22226,,,,BAO_0000019,CHEMBL617143,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB"
B,Bos taurus,9913.0,,,1,Autocuration,,14331,,U,2109,0,,,22226,,,,BAO_0000019,CHEMBL617144,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M
B,Bos taurus,9913.0,,,1,Autocuration,,14331,,U,2110,0,,,22226,,,,BAO_0000019,CHEMBL617145,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex
B,,,,,1,Autocuration,,14331,,U,2111,0,,,22226,,,,BAO_0000019,CHEMBL617146,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined
B,Cavia porcellus,10141.0,,,1,Autocuration,,12685,,H,2112,4,,,104784,,,,BAO_0000019,CHEMBL617147,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex
B,Cavia porcellus,10141.0,,,1,Autocuration,,14389,,H,2113,4,,,104784,,,,BAO_0000019,CHEMBL617148,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes
B,Cavia porcellus,10141.0,,,1,Autocuration,,14386,,H,2114,4,,,104784,,,,BAO_0000019,CHEMBL617149,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex
B,,,,,1,Autocuration,,5732,,H,2115,4,,,104784,,,,BAO_0000224,CHEMBL617150,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined
B,,,,,1,Autocuration,,16293,,H,2116,4,,,104784,,,,BAO_0000224,CHEMBL617151,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
B,,,,,1,Autocuration,,2078,,H,2117,4,,,104784,,,,BAO_0000224,CHEMBL617201,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,5486,,H,2118,8,,,10209,,,,BAO_0000357,CHEMBL617202,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
B,,,,,1,Autocuration,,11820,,H,2119,4,,,104826,,,In vivo,BAO_0000218,CHEMBL617203,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
B,,,,,1,Autocuration,,10297,,H,2120,4,,,104826,,,,BAO_0000019,CHEMBL617204,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
B,,,,,1,Autocuration,,13704,,H,2121,4,,,104826,,,,BAO_0000224,CHEMBL617205,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.
B,Mus musculus,10090.0,,,1,Autocuration,,10297,,D,2122,5,,,104826,,,,BAO_0000019,CHEMBL617206,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex
B,,,,,1,Autocuration,,11820,,H,2123,4,,,104826,,,In vivo,BAO_0000218,CHEMBL617207,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
B,Mus musculus,10090.0,,,1,Autocuration,,10297,,D,2124,5,,,104826,,,,BAO_0000019,CHEMBL617208,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex
B,,,,,1,Autocuration,,11555,,H,2125,4,,,104826,,,,BAO_0000224,CHEMBL617209,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11555,,H,2126,4,,,104826,,,,BAO_0000224,CHEMBL617210,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors
B,,,,,1,Autocuration,,11555,,H,2127,4,,,104826,,,,BAO_0000224,CHEMBL617211,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data
B,Mus musculus,10090.0,,,1,Autocuration,,10297,,D,2128,5,,,104826,,,,BAO_0000019,CHEMBL617212,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
B,Sus scrofa,9823.0,,,1,Autocuration,,16688,,H,2129,4,,,104784,,,,BAO_0000224,CHEMBL617213,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin
B,Sus scrofa,9823.0,,,1,Autocuration,,16688,,H,2130,4,,,104784,,,,BAO_0000224,CHEMBL617214,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin
B,,,,,1,Autocuration,,5333,,U,2131,0,,,22226,,,,BAO_0000221,CHEMBL617215,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate
B,,,,,1,Autocuration,,4437,,U,2132,0,,,22226,,,,BAO_0000221,CHEMBL617216,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate
B,Sus scrofa,9823.0,,,1,Autocuration,,5033,,H,2133,8,,,17005,,,,BAO_0000357,CHEMBL617217,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,15267,,H,2134,4,,,104686,,,,BAO_0000019,CHEMBL617218,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,15267,,H,2135,4,,,104686,,,,BAO_0000019,CHEMBL872913,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11820,,H,2136,4,,,104826,,,,BAO_0000019,CHEMBL617219,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.
B,,,,,1,Autocuration,,9069,,H,2137,4,,,104686,,,,BAO_0000224,CHEMBL873482,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9162,,D,2138,5,,,104686,,,,BAO_0000019,CHEMBL617220,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data
B,,,,,1,Autocuration,,9162,,H,2139,4,,,104686,,,,BAO_0000019,CHEMBL617221,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.
B,,,,,1,Autocuration,,9162,,H,2140,4,,,104686,,,,BAO_0000019,CHEMBL617222,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity
F,,,,,1,Autocuration,,10428,,H,2141,4,,,104686,,,,BAO_0000019,CHEMBL875906,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein
B,,,,,1,Autocuration,,9628,,H,2142,4,,,104686,,,,BAO_0000019,CHEMBL617223,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein
B,,,,,1,Autocuration,,12704,,H,2143,4,,,104686,,,,BAO_0000224,CHEMBL617224,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15453,,D,2144,5,,,104686,,,,BAO_0000224,CHEMBL617225,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
B,,,,,1,Autocuration,,188,,H,2145,4,,,104686,,,,BAO_0000224,CHEMBL617226,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity
B,,,,,1,Autocuration,,10349,,H,2146,4,,,104686,,,,BAO_0000224,CHEMBL617227,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.
B,,,,,1,Autocuration,,10349,,H,2147,4,,,104686,,,,BAO_0000224,CHEMBL617228,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.
B,,,,,1,Autocuration,,8868,,H,2148,4,,,104686,,,,BAO_0000224,CHEMBL617229,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
B,,,,,1,Autocuration,,10025,,H,2149,4,,,104686,,,,BAO_0000224,CHEMBL617230,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
B,,,,,1,Autocuration,,10025,,H,2150,4,,,104686,,,,BAO_0000224,CHEMBL617231,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
B,,,,,1,Autocuration,,11702,,H,2151,4,,,104686,,,,BAO_0000224,CHEMBL617232,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor
B,,,,,1,Autocuration,,11702,,H,2152,4,,,104686,,,,BAO_0000224,CHEMBL617233,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11702,,H,2153,4,,,104686,,,,BAO_0000224,CHEMBL617234,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested
F,,,,,1,Autocuration,,11702,,H,2154,4,,,104686,,,,BAO_0000019,CHEMBL617235,,Compound was tested for the inhibition of quipazine induced head twitches in rats
F,,,,,1,Autocuration,,11702,,H,2155,4,,,104686,,,,BAO_0000019,CHEMBL617236,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested
B,,,,,1,Autocuration,,10085,,H,2156,4,,,104686,Hippocampus,10000000.0,,BAO_0000221,CHEMBL617237,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone
B,,,,,1,Autocuration,,10085,,H,2157,4,,,104686,Hippocampus,10000000.0,,BAO_0000221,CHEMBL617238,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9630,,D,2158,5,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617239,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain
B,,,,,1,Autocuration,,11070,,H,2159,4,,,104686,,,,BAO_0000019,CHEMBL617240,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex
B,,,,,1,Autocuration,Membranes,9841,,H,2160,4,,,104686,,,,BAO_0000249,CHEMBL617241,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
B,,,,,1,Autocuration,Membranes,9841,,H,2161,4,,,104686,,,,BAO_0000249,CHEMBL875907,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
B,,,,,1,Autocuration,,13291,,H,2162,4,,,104686,,,,BAO_0000019,CHEMBL617242,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.
F,,,,,1,Autocuration,,10590,,H,2163,4,,,104686,,,,BAO_0000019,CHEMBL617152,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9064,,D,2164,5,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617153,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
B,Rattus norvegicus,10116.0,,,1,Autocuration,Membranes,12268,,D,2165,5,,,104686,,,,BAO_0000249,CHEMBL617154,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes
B,,,,,1,Autocuration,,13508,,H,2166,4,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617155,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand
F,,,,,1,Autocuration,,11279,,H,2167,4,,,104686,,,,BAO_0000019,CHEMBL617156,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
F,,,,,1,Autocuration,,11200,,H,2168,4,,,104686,,,,BAO_0000019,CHEMBL617157,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips
F,,,,,1,Autocuration,,11200,,H,2169,4,,,104686,,,,BAO_0000019,CHEMBL617158,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
F,,,,,1,Autocuration,,11200,,H,2170,4,,,104686,,,,BAO_0000019,CHEMBL617159,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
F,,,,,1,Autocuration,,11200,,H,2171,4,,,104686,,,,BAO_0000019,CHEMBL617160,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
F,,,,,1,Autocuration,,11200,,H,2172,4,,,104686,,,,BAO_0000019,CHEMBL858113,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
B,,,,,1,Autocuration,,9231,,H,2173,4,,,104686,Brain,955.0,,BAO_0000220,CHEMBL617247,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes
B,,,,,1,Autocuration,,9737,,H,2174,4,,,104686,,,,BAO_0000019,CHEMBL617248,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,9737,,H,2175,4,,,104686,Brain,955.0,,BAO_0000249,CHEMBL617249,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
B,,,,,1,Autocuration,,9737,,H,2176,4,,,104686,,,,BAO_0000019,CHEMBL617250,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex
B,,,,,1,Autocuration,,9737,,H,2177,4,,,104686,,,,BAO_0000019,CHEMBL617251,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11828,,D,2178,5,,,104686,,,,BAO_0000019,CHEMBL617252,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,12253,,H,2179,4,,,104686,,,,BAO_0000019,CHEMBL617006,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex
B,,,,,1,Autocuration,,12253,,H,2180,4,,,104686,,,,BAO_0000019,CHEMBL617007,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex
F,,,,,1,Autocuration,,11279,,H,2181,4,,,104686,,,,BAO_0000019,CHEMBL617008,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery."
B,,,,,1,Autocuration,,11866,,H,2182,4,,,104686,,,,BAO_0000019,CHEMBL617009,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin
B,Rattus norvegicus,10116.0,,,1,Autocuration,,14424,,D,2183,5,,,104686,,,,BAO_0000224,CHEMBL617010,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15180,,D,2184,5,,,104686,,,,BAO_0000019,CHEMBL857978,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15180,,D,2185,5,,,104686,,,,BAO_0000019,CHEMBL617011,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9786,,D,2186,5,,,104686,,,,BAO_0000019,CHEMBL617012,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate
B,,,,,1,Autocuration,,12132,,H,2187,4,,,104686,,,,BAO_0000224,CHEMBL617013,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.
B,,,,,1,Autocuration,,5486,,H,2188,4,,,104686,,,,BAO_0000249,CHEMBL617014,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane
B,,,,,1,Autocuration,,15316,,H,2189,4,,,104686,,,,BAO_0000019,CHEMBL617015,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,16429,,H,2190,4,,,104686,,,,BAO_0000019,CHEMBL617016,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand
B,,,,,1,Autocuration,,14617,,H,2191,4,,,104686,,,,BAO_0000224,CHEMBL617017,,pKi value for 5-hydroxytryptamine 2 receptor binding site
B,,,,,1,Autocuration,,11351,,H,2192,4,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617018,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.
F,,,,,1,Autocuration,,11279,,H,2193,4,,,104686,,,,BAO_0000019,CHEMBL617019,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
B,,,,,1,Autocuration,,9523,,H,2194,4,,,105075,,,,BAO_0000019,CHEMBL617020,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2195,4,,,105075,,,,BAO_0000019,CHEMBL617021,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2196,4,,,105075,,,,BAO_0000019,CHEMBL617022,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2197,4,,,105075,,,,BAO_0000019,CHEMBL617023,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2198,4,,,105075,,,,BAO_0000019,CHEMBL617024,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2199,4,,,105075,,,,BAO_0000019,CHEMBL617025,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9523,,H,2200,4,,,105075,,,,BAO_0000224,CHEMBL617026,,Hill coefficient of compound was determined
B,,,,,1,Autocuration,,4771,,U,2201,0,,,22226,,,,BAO_0000019,CHEMBL617027,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,5033,,D,2202,5,,,104686,,,,BAO_0000019,CHEMBL617028,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane
B,,,,,1,Expert,,10845,,H,2203,8,,,12687,,,,BAO_0000019,CHEMBL617029,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand
B,,,,,1,Expert,,10845,,H,2204,8,,,12687,,,,BAO_0000019,CHEMBL875908,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive
B,,,,,1,Autocuration,,16288,,H,2205,8,,,12687,,,,BAO_0000357,CHEMBL617030,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09)
B,,,,,1,Autocuration,,16288,,H,2206,8,,,12687,,,,BAO_0000019,CHEMBL617031,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09)
B,,,,,1,Autocuration,,16190,,H,2207,8,,,12687,,,,BAO_0000019,CHEMBL617032,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12463,,D,2208,5,,,104686,,,,BAO_0000224,CHEMBL617033,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin
B,,,,,1,Autocuration,,9699,,H,2209,4,,,104686,,,,BAO_0000224,CHEMBL617034,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand"
B,,,,,1,Autocuration,,9699,,H,2210,4,,,104686,,,,BAO_0000224,CHEMBL617035,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand
B,,,,,1,Autocuration,,11662,,H,2211,4,,,104686,,,,BAO_0000019,CHEMBL617036,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
B,,,,,1,Autocuration,,1205,,H,2212,4,,,104784,,,,BAO_0000224,CHEMBL617037,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11376,,U,2213,0,,,22226,,,,BAO_0000219,CHEMBL617038,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand
B,,,,,1,Autocuration,,11376,,H,2214,4,,,104784,,,,BAO_0000219,CHEMBL617039,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)"
B,,,,,1,Autocuration,,4639,,H,2215,4,,,104784,,,,BAO_0000224,CHEMBL617161,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,2222,,H,2216,4,,,104784,,,,BAO_0000224,CHEMBL617162,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,1558,,H,2217,4,,,104784,,,,BAO_0000224,CHEMBL617163,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,1089,,H,2218,4,,,104784,,,,BAO_0000224,CHEMBL617164,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,Brain membranes,386,,H,2219,4,,,104784,,,,BAO_0000249,CHEMBL617165,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes
B,,,,,1,Autocuration,,2474,,H,2220,4,,,104784,,,,BAO_0000224,CHEMBL617166,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,17066,,H,2221,4,,,104784,,,,BAO_0000224,CHEMBL617167,,Binding affinity towards 5-HT2 receptor
B,,,,,1,Autocuration,,959,,H,2222,4,,,104784,,,,BAO_0000224,CHEMBL872912,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,6398,,H,2223,4,,,104784,,,,BAO_0000224,CHEMBL617168,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding
B,,,,,1,Autocuration,,11889,,H,2224,4,,,104686,,,,BAO_0000224,CHEMBL617169,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.
B,,,,,1,Autocuration,,4221,,H,2225,4,,,104784,,,,BAO_0000224,CHEMBL617170,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11026,,H,2226,4,,,104784,,,,BAO_0000224,CHEMBL617171,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand
B,,,,,1,Autocuration,,11866,,H,2227,4,,,104784,,,,BAO_0000224,CHEMBL617172,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined
B,,,,,1,Autocuration,,4221,,H,2228,4,,,104784,,,,BAO_0000224,CHEMBL617173,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,13950,,U,2229,0,,,22226,,,,BAO_0000019,CHEMBL617174,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,1263,,H,2230,4,,,104784,,,,BAO_0000224,CHEMBL617175,,5-hydroxytryptamine 2 receptor binding affinity
B,,,,,1,Autocuration,,13291,,H,2231,8,,,17005,,,,BAO_0000357,CHEMBL617176,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand
B,,,,,1,Autocuration,,10812,,H,2232,8,,,17005,,,,BAO_0000357,CHEMBL617177,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,13020,,H,2233,4,,,104784,,,,BAO_0000224,CHEMBL617178,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
B,,,,,1,Autocuration,,13021,,H,2234,4,,,104784,,,,BAO_0000224,CHEMBL617179,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system
B,,,,,1,Autocuration,,13020,,H,2235,4,,,104784,,,,BAO_0000224,CHEMBL617180,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
B,,,,,1,Autocuration,,14532,,H,2236,8,,,17005,,,,BAO_0000357,CHEMBL617181,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration
B,,,,,1,Autocuration,,13944,,H,2237,8,,,17005,,,,BAO_0000357,CHEMBL617182,,Binding affinity against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,14331,,H,2238,8,,,17005,,,,BAO_0000357,CHEMBL617183,,Binding affinity against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,14118,,H,2239,8,,,17005,,,,BAO_0000357,CHEMBL617184,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,13033,,H,2240,8,,,17005,,,,BAO_0000357,CHEMBL617185,,Binding affinity against serotonergic 5-HT2 receptor
B,,,,,1,Autocuration,,10321,,H,2241,8,,,17005,,,,BAO_0000357,CHEMBL617186,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,12918,,H,2242,8,,,17005,,,,BAO_0000357,CHEMBL617187,,Compound was evaluated for the binding affinity at 5- HT2 receptor
B,,,,,1,Autocuration,,15120,,H,2243,8,,,17005,,,,BAO_0000357,CHEMBL617188,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,2613,,H,2244,8,,,17005,,,,BAO_0000218,CHEMBL617189,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor
B,Homo sapiens,9606.0,,,1,Autocuration,,13378,,D,2245,5,,,104784,,,,BAO_0000224,CHEMBL617190,,Inhibitory activity against cloned human 5-HT2 receptor
B,Homo sapiens,9606.0,,CHO,1,Autocuration,,2331,,D,2246,5,449.0,,104784,,,,BAO_0000219,CHEMBL617191,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells"
B,Homo sapiens,9606.0,,CHO,1,Autocuration,,2331,,D,2247,5,449.0,,104784,,,,BAO_0000219,CHEMBL617192,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells."
B,Homo sapiens,9606.0,,CHO,1,Autocuration,,2331,,D,2248,5,449.0,,104784,,,,BAO_0000219,CHEMBL617193,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive"
B,Homo sapiens,9606.0,,CHO,1,Autocuration,,2331,,D,2249,5,449.0,,104784,,,,BAO_0000219,CHEMBL617194,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested"
B,,,,,1,Autocuration,,4170,,H,2250,4,,,104784,,,,BAO_0000224,CHEMBL617195,,Binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,15453,,H,2251,4,,,104784,,,,BAO_0000224,CHEMBL881830,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
B,,,,,1,Autocuration,,1479,,H,2252,8,,,17005,,,,BAO_0000357,CHEMBL617196,,Binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11139,,H,2253,4,,,104686,,,,BAO_0000224,CHEMBL617197,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay
B,,,,,1,Expert,,13969,,H,2254,8,,,17005,,,,BAO_0000357,CHEMBL617198,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand
B,,,,,1,Expert,,13392,,H,2255,8,,,17005,,,,BAO_0000357,CHEMBL873476,,Binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,14430,,H,2256,8,,,17005,,,,BAO_0000019,CHEMBL617199,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin
B,Cavia porcellus,10141.0,,,1,Autocuration,,13181,,H,2257,8,,,107,,,,BAO_0000357,CHEMBL617200,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17200,,H,2258,8,,,51,,,,BAO_0000357,CHEMBL617484,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
B,,,,,1,Autocuration,,17200,,H,2259,8,,,107,,,,BAO_0000357,CHEMBL617485,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
B,,,,,1,Autocuration,,17200,,H,2260,8,,,51,,,,BAO_0000357,CHEMBL617486,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
B,,,,,1,Autocuration,,13463,,H,2261,8,,,107,,,,BAO_0000357,CHEMBL858022,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand
B,,,,CHO,1,Autocuration,,6347,,H,2262,8,449.0,,107,,,,BAO_0000219,CHEMBL617049,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2263,9,449.0,,107,,,,BAO_0000219,CHEMBL617050,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader
F,,,,,1,Autocuration,,4176,,H,2264,8,,,107,,,,BAO_0000219,CHEMBL617051,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
F,,,,,1,Autocuration,,4176,,H,2265,8,,,107,,,,BAO_0000219,CHEMBL617052,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data
F,,,,,1,Autocuration,,4176,,H,2266,8,,,107,,,,BAO_0000219,CHEMBL617053,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
B,,,,CHO,1,Autocuration,,6347,,H,2267,8,449.0,,107,,,,BAO_0000219,CHEMBL617054,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax"
B,,,,CHO,1,Autocuration,,6347,,H,2268,8,449.0,,107,,,,BAO_0000219,CHEMBL617055,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax"
B,,,,,1,Autocuration,,15331,,H,2269,8,,,107,,,,BAO_0000357,CHEMBL882924,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,2270,9,,,107,,,,BAO_0000357,CHEMBL617056,,Inhibition of human 5-hydroxytryptamine 2A receptor
B,,,,CHO,1,Autocuration,,15250,,H,2271,8,449.0,,107,,,,BAO_0000219,CHEMBL617057,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
B,,,,,1,Expert,,13631,,H,2272,8,,,107,,,,BAO_0000219,CHEMBL617058,,Inhibitory concentration against human 5-HT2A receptor in BEK cells
B,,,,,1,Autocuration,,3805,,H,2273,8,,,107,,,,BAO_0000357,CHEMBL617059,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM)
B,,,,CHO,1,Autocuration,,4011,,H,2274,8,449.0,,107,,,,BAO_0000219,CHEMBL617060,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined
B,,,,CHO,1,Expert,,4012,,H,2275,8,449.0,,107,,,,BAO_0000219,CHEMBL617061,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.
B,,,,L929,1,Expert,,6366,,H,2276,8,307.0,,107,,,,BAO_0000219,CHEMBL617062,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells
B,,,,CHO,1,Expert,,15949,,H,2277,8,449.0,,107,,,,BAO_0000219,CHEMBL617063,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
F,,,,,1,Autocuration,,14093,,H,2278,8,,,107,,,,BAO_0000019,CHEMBL617064,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand
F,,,,,1,Autocuration,,13481,,H,2279,8,,,107,,,,BAO_0000019,CHEMBL617065,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
B,,,,CHO,1,Autocuration,,6347,,H,2280,8,449.0,,107,,,,BAO_0000219,CHEMBL617066,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
B,,,,CHO,1,Autocuration,,6347,,H,2281,8,449.0,,107,,,,BAO_0000219,CHEMBL617067,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done
F,,,,,1,Autocuration,,14093,,H,2282,8,,,107,,,,BAO_0000019,CHEMBL617068,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand
F,,,,,1,Autocuration,,14093,,H,2283,8,,,107,,,,BAO_0000019,CHEMBL617069,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested
F,,,,,1,Autocuration,,13481,,H,2284,8,,,107,,,,BAO_0000019,CHEMBL617070,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,14442,,H,2285,8,,,107,,,,BAO_0000357,CHEMBL617071,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand
B,,,,,1,Autocuration,,14442,,H,2286,8,,,107,,,,BAO_0000357,CHEMBL872915,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,14755,,H,2287,8,,,107,,,,BAO_0000357,CHEMBL617072,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.
B,,,,,1,Autocuration,,16441,,H,2288,8,,,107,,,,BAO_0000357,CHEMBL617073,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans
B,,,,,1,Autocuration,,14744,,H,2289,8,,,107,,,,BAO_0000357,CHEMBL617074,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand
B,,,,CHO,1,Expert,,16659,,H,2290,8,449.0,,107,,,,BAO_0000219,CHEMBL617075,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
B,,,,,1,Autocuration,,3307,,H,2291,8,,,107,,,,BAO_0000357,CHEMBL617076,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor
B,Homo sapiens,9606.0,,,1,Expert,,6857,,D,2292,9,,,107,,,,BAO_0000019,CHEMBL617077,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line
B,,,,,1,Expert,,5635,,H,2293,8,,,107,,,,BAO_0000357,CHEMBL617078,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,2294,9,,,107,,,,BAO_0000357,CHEMBL617079,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,15527,,H,2295,8,,,107,,,,BAO_0000357,CHEMBL617080,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
B,,,,CHO,1,Expert,,6588,,H,2296,8,449.0,,107,,,,BAO_0000219,CHEMBL617081,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells
B,,,,,1,Expert,,13631,,H,2297,8,,,107,,,,BAO_0000219,CHEMBL617082,,Binding affinity towards human 5-HT2A receptor in BEK cells
B,,,,,1,Autocuration,,17723,,H,2298,8,,,107,,,,BAO_0000357,CHEMBL617083,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,14770,,H,2299,8,,,107,,,,BAO_0000357,CHEMBL617084,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
B,Homo sapiens,9606.0,,,1,Expert,,16293,,D,2300,9,,,107,,,,BAO_0000357,CHEMBL617085,,Binding affinity for human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,16209,,H,2301,8,,,107,,,,BAO_0000357,CHEMBL617086,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
B,,,,,1,Autocuration,,12469,,H,2302,8,,,107,,,,BAO_0000219,CHEMBL617087,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin
B,,,,,1,Autocuration,,15363,,H,2303,8,,,107,,,,BAO_0000357,CHEMBL617088,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,15363,,H,2304,8,,,107,,,,BAO_0000357,CHEMBL617089,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,16441,,H,2305,8,,,107,,,,BAO_0000019,CHEMBL617090,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand"
B,,,,,1,Autocuration,,8,,H,2306,8,,,107,,,,BAO_0000357,CHEMBL617513,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand
B,,,,HEK293,1,Autocuration,,4176,,H,2307,8,722.0,,107,,,,BAO_0000219,CHEMBL617514,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,17085,,H,2308,8,,,107,,,,BAO_0000019,CHEMBL617515,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17200,,H,2309,8,,,107,,,,BAO_0000357,CHEMBL617516,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
B,Homo sapiens,9606.0,,,1,Expert,,17200,,D,2310,9,,,107,,,,BAO_0000357,CHEMBL617517,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
B,Homo sapiens,9606.0,,CHO,1,Expert,,4013,,D,2311,9,449.0,,107,,,,BAO_0000219,CHEMBL617518,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells
B,,,,,1,Autocuration,,5088,,H,2312,8,,,107,,,,BAO_0000357,CHEMBL617519,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor
B,Homo sapiens,9606.0,,,1,Expert,,5088,,D,2313,9,,,107,,,,BAO_0000357,CHEMBL617520,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,5088,,H,2314,8,,,107,,,,BAO_0000357,CHEMBL617521,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained
B,Homo sapiens,9606.0,,,1,Expert,,5088,,D,2315,9,,,107,,,,BAO_0000357,CHEMBL617522,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,5088,,H,2316,8,,,107,,,,BAO_0000357,CHEMBL617523,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,5088,,H,2317,8,,,107,,,,BAO_0000357,CHEMBL617524,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
B,,,,,1,Autocuration,,9786,,H,2318,4,,,104686,,,,BAO_0000019,CHEMBL617525,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9205,,D,2319,5,,,104686,,,,BAO_0000019,CHEMBL617526,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat
B,,,,,1,Autocuration,,11257,,H,2320,4,,,104686,,,,BAO_0000224,CHEMBL617527,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI
B,,,,,1,Autocuration,,9362,,H,2321,4,,,104686,,,,BAO_0000019,CHEMBL617528,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
B,,,,,1,Autocuration,,9362,,H,2322,4,,,104686,,,,BAO_0000019,CHEMBL617529,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
B,,,,,1,Autocuration,,10590,,H,2323,4,,,104686,,,,BAO_0000224,CHEMBL617530,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.
B,,,,,1,Autocuration,,10468,,H,2324,4,,,104686,,,,BAO_0000019,CHEMBL617531,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
B,,,,,1,Autocuration,,13050,,H,2325,4,,,104686,,,,BAO_0000019,CHEMBL617532,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand
B,,,,,1,Autocuration,,11624,,H,2326,4,,,104686,,,,BAO_0000019,CHEMBL617533,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,10468,,H,2327,4,,,104686,,,,BAO_0000019,CHEMBL617534,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
B,,,,,1,Autocuration,,10330,,H,2328,4,,,104686,,,,BAO_0000224,CHEMBL617535,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,10062,,H,2329,4,,,104686,,,,BAO_0000224,CHEMBL617536,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
B,,,,,1,Autocuration,,11642,,H,2330,4,,,104686,,,,BAO_0000224,CHEMBL617537,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,10062,,H,2331,4,,,104686,,,,BAO_0000224,CHEMBL617538,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,13427,,H,2332,4,,,104686,,,In vitro,BAO_0000219,CHEMBL617539,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12280,,D,2333,5,,,104686,,,,BAO_0000224,CHEMBL617540,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,4101,,D,2334,5,,,104686,,,,BAO_0000224,CHEMBL617541,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin
B,,,,,1,Autocuration,,10062,,H,2335,4,,,104686,,,,BAO_0000224,CHEMBL617542,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11147,,H,2336,4,,,104686,,,,BAO_0000224,CHEMBL617543,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as
B,Rattus norvegicus,10116.0,,CHO-K1,1,Autocuration,,2395,,D,2337,5,485.0,,104686,,,,BAO_0000219,CHEMBL617544,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
B,Rattus norvegicus,10116.0,,CHO-K1,1,Autocuration,,2395,,D,2338,5,485.0,,104686,,,,BAO_0000219,CHEMBL617545,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9098,,D,2339,5,,,104686,,,,BAO_0000019,CHEMBL617413,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand
B,,,,,1,Autocuration,,9098,,H,2340,4,,,104686,,,,BAO_0000019,CHEMBL617414,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9098,,D,2341,5,,,104686,,,,BAO_0000019,CHEMBL617415,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.
B,,,,,1,Autocuration,,9443,,H,2342,4,,,104686,,,,BAO_0000224,CHEMBL617416,,Binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,9443,,H,2343,4,,,104686,,,,BAO_0000224,CHEMBL617417,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
B,,,,,1,Autocuration,,9699,,H,2344,4,,,104686,,,,BAO_0000019,CHEMBL617418,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex"
B,,,,,1,Autocuration,,9699,,H,2345,4,,,104686,,,,BAO_0000019,CHEMBL617419,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex
B,,,,,1,Autocuration,,9098,,H,2346,4,,,104686,,,,BAO_0000224,CHEMBL617420,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
B,Rattus norvegicus,10116.0,,,1,Autocuration,,3070,,D,2347,5,,,104686,,,,BAO_0000224,CHEMBL617421,,Affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,9547,,H,2348,4,,,104686,,,,BAO_0000224,CHEMBL617422,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay
B,,,,,1,Autocuration,,10444,,H,2349,4,,,104686,,,,BAO_0000019,CHEMBL617423,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.
B,,,,,1,Autocuration,,14617,,H,2350,4,,,104686,,,,BAO_0000019,CHEMBL617424,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate
B,,,,,1,Autocuration,,14617,,H,2351,4,,,104686,,,,BAO_0000019,CHEMBL617425,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate
B,,,,,1,Autocuration,,11130,,H,2352,4,,,104686,,,,BAO_0000224,CHEMBL617426,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro)
B,,,,,1,Autocuration,,11130,,H,2353,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617427,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo)
B,,,,,1,Autocuration,,14542,,H,2354,4,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617428,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain
B,,,,,1,Autocuration,,2797,,H,2355,4,,,104686,,,,BAO_0000224,CHEMBL617429,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat
B,,,,,1,Autocuration,,11332,,H,2356,4,,,104686,,,,BAO_0000019,CHEMBL617430,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
B,,,,,1,Autocuration,,11332,,H,2357,4,,,104686,,,,BAO_0000019,CHEMBL617431,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
B,,,,,1,Autocuration,,10752,,H,2358,4,,,104686,Frontal cortex,1870.0,,BAO_0000019,CHEMBL617432,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.
B,,,,,1,Autocuration,,1185,,H,2359,4,,,104686,,,,BAO_0000224,CHEMBL617433,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,1185,,H,2360,4,,,104686,,,,BAO_0000224,CHEMBL617434,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11624,,D,2361,5,,,104686,,,,BAO_0000224,CHEMBL617435,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor
B,,,,,1,Autocuration,,1344,,H,2362,4,,,104686,,,,BAO_0000019,CHEMBL617436,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15453,,D,2363,5,,,104686,Striatum,2435.0,,BAO_0000019,CHEMBL617437,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203
B,,,,,1,Autocuration,,11662,,H,2364,4,,,104686,,,,BAO_0000019,CHEMBL617438,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
B,,,,,1,Autocuration,,11662,,H,2365,4,,,104686,,,,BAO_0000019,CHEMBL617439,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
B,,,,,1,Autocuration,,10796,,H,2366,4,,,104686,,,,BAO_0000224,CHEMBL617440,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,9069,,H,2367,4,,,104686,,,,BAO_0000224,CHEMBL617441,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8814,,D,2368,5,,,104686,,,,BAO_0000019,CHEMBL872918,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates
B,Rattus norvegicus,10116.0,,,1,Autocuration,,8908,,D,2369,5,,,104686,,,,BAO_0000019,CHEMBL617442,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex
B,,,,,1,Autocuration,,9098,,H,2370,4,,,104686,,,,BAO_0000019,CHEMBL617443,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
B,,,,,1,Autocuration,,9098,,H,2371,4,,,104686,,,,BAO_0000019,CHEMBL617444,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
B,,,,,1,Autocuration,,9098,,H,2372,4,,,104686,,,,BAO_0000019,CHEMBL617445,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
B,,,,,1,Autocuration,,9098,,H,2373,4,,,104686,,,,BAO_0000019,CHEMBL617446,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.
B,,,,,1,Autocuration,,9098,,H,2374,4,,,104686,,,,BAO_0000249,CHEMBL617447,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.
B,,,,,1,Autocuration,,9098,,H,2375,4,,,104686,,,,BAO_0000019,CHEMBL617448,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined
B,,,,,1,Autocuration,,9098,,H,2376,4,,,104686,,,,BAO_0000019,CHEMBL617449,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data
B,,,,,1,Autocuration,,9161,,H,2377,4,,,104686,,,,BAO_0000019,CHEMBL617450,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.
B,,,,,1,Autocuration,,9161,,H,2378,4,,,104686,,,,BAO_0000019,CHEMBL617451,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263
B,,,,,1,Autocuration,,9161,,H,2379,4,,,104686,,,,BAO_0000019,CHEMBL617452,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3
B,,,,,1,Autocuration,,9161,,H,2380,4,,,104686,,,,BAO_0000019,CHEMBL617453,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.
B,,,,,1,Autocuration,,9161,,H,2381,4,,,104686,,,,BAO_0000019,CHEMBL617660,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980
B,,,,,1,Autocuration,,9161,,H,2382,4,,,104686,,,,BAO_0000019,CHEMBL617661,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299
B,,,,,1,Autocuration,,9161,,H,2383,4,,,104686,,,,BAO_0000019,CHEMBL617662,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66
B,,,,,1,Autocuration,,9161,,H,2384,4,,,104686,,,,BAO_0000019,CHEMBL872919,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220
B,,,,,1,Autocuration,,9161,,H,2385,4,,,104686,,,,BAO_0000019,CHEMBL617663,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341
B,,,,,1,Autocuration,,9161,,H,2386,4,,,104686,,,,BAO_0000019,CHEMBL617664,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187
B,,,,,1,Autocuration,,9161,,H,2387,4,,,104686,,,,BAO_0000019,CHEMBL617665,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132
B,,,,,1,Autocuration,,9161,,H,2388,4,,,104686,,,,BAO_0000019,CHEMBL617666,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75
B,,,,,1,Autocuration,,12094,,H,2389,4,,,104686,,,,BAO_0000019,CHEMBL617667,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells
B,,,,,1,Autocuration,,12018,,H,2390,4,,,104686,,,,BAO_0000249,CHEMBL617668,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.
B,,,,,1,Autocuration,,10394,,H,2391,4,,,104686,,,,BAO_0000249,CHEMBL617669,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand
B,,,,,1,Autocuration,,15260,,H,2392,4,,,104686,,,,BAO_0000224,CHEMBL617670,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11624,,D,2393,5,,,104686,,,,BAO_0000224,CHEMBL617671,,Inhibitory constant against 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,13654,,H,2394,4,,,104686,,,,BAO_0000224,CHEMBL617672,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,9541,,H,2395,4,,,104686,,,,BAO_0000019,CHEMBL617673,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum
B,,,,,1,Autocuration,,11933,,H,2396,4,,,104686,,,,BAO_0000224,CHEMBL617674,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,15538,,H,2397,4,,,104686,,,,BAO_0000019,CHEMBL617675,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex
B,,,,,1,Autocuration,,15538,,H,2398,4,,,104686,,,,BAO_0000019,CHEMBL617676,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active
B,,,,,1,Autocuration,,15538,,H,2399,4,,,104686,,,,BAO_0000019,CHEMBL617677,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined
B,,,,,1,Autocuration,,8841,,D,2400,5,,,104686,,,,BAO_0000019,CHEMBL617678,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,1455,,H,2401,4,,,104686,,,,BAO_0000224,CHEMBL617679,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.
B,,,,,1,Autocuration,,1455,,H,2402,4,,,104686,,,,BAO_0000224,CHEMBL617680,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay
B,,,,,1,Autocuration,,11752,,H,2403,4,,,104686,,,,BAO_0000019,CHEMBL617681,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain
B,,,,,1,Autocuration,,11642,,H,2404,4,,,104686,Brain,955.0,,BAO_0000221,CHEMBL617682,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue
B,,,,,1,Autocuration,,12092,,H,2405,4,,,104686,,,,BAO_0000224,CHEMBL617683,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.
B,,,,,1,Autocuration,,3967,,H,2406,4,,,104686,,,,BAO_0000224,CHEMBL617684,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12771,,D,2407,5,,,104686,,,,BAO_0000224,CHEMBL617685,,Binding affinity towards 5-hydroxytryptamine 2 receptor
B,,,,,1,Autocuration,,11642,,H,2408,4,,,104686,,,,BAO_0000019,CHEMBL617686,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex
B,,,,,1,Autocuration,,11628,,H,2409,4,,,104686,,,,BAO_0000224,CHEMBL617687,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand
B,,,,,1,Autocuration,,13654,,H,2410,4,,,104686,,,,BAO_0000224,CHEMBL617688,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor
F,,,,,1,Autocuration,,11200,,H,2411,4,,,104686,,,,BAO_0000019,CHEMBL617689,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
F,,,,,1,Autocuration,,11200,,H,2412,4,,,104686,,,,BAO_0000019,CHEMBL617690,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
F,,,,,1,Autocuration,,11200,,H,2413,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617691,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
F,,,,,1,Autocuration,,11200,,H,2414,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617692,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
F,,,,,1,Autocuration,,11200,,H,2415,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617693,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
F,,,,,1,Autocuration,,11200,,H,2416,4,,,104686,,,In vivo,BAO_0000218,CHEMBL617694,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
B,,,,,1,Expert,,15436,,H,2417,8,,,12687,Brain,955.0,,BAO_0000221,CHEMBL857985,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin
B,Rattus norvegicus,10116.0,,,1,Expert,,15436,,D,2418,9,,,12687,,,,BAO_0000019,CHEMBL617695,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
B,,,,,1,Autocuration,,14025,,H,2419,8,,,12687,,,,BAO_0000019,CHEMBL617696,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates
B,,,,,1,Autocuration,,4342,,H,2420,8,,,12687,,,,BAO_0000357,CHEMBL617697,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined
B,Rattus norvegicus,10116.0,,,1,Expert,,13735,,D,2421,9,,,12687,,,,BAO_0000019,CHEMBL617257,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex
B,Rattus norvegicus,10116.0,,,1,Expert,,5816,,D,2422,9,,,12687,,,,BAO_0000357,CHEMBL617258,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
B,,,,,1,Expert,,14287,,H,2423,8,,,12687,,,,BAO_0000019,CHEMBL617259,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane
B,,,,,1,Autocuration,,15738,,H,2424,8,,,12687,,,,BAO_0000357,CHEMBL617260,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,15738,,D,2425,9,,,12687,,,,BAO_0000357,CHEMBL617261,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,15026,,H,2426,8,,,12687,,,,BAO_0000019,CHEMBL617262,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand
B,,,,,1,Expert,,16647,,H,2427,8,,,12687,,,,BAO_0000019,CHEMBL617263,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
B,,,,,1,Autocuration,,16647,,H,2428,8,,,12687,,,,BAO_0000019,CHEMBL617264,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate
B,Rattus norvegicus,10116.0,,,1,Expert,,13345,,D,2429,9,,,12687,,,,BAO_0000019,CHEMBL617265,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,Membranes,1543,,H,2430,8,,,12687,,,,BAO_0000249,CHEMBL617266,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,12444,,H,2431,8,,,12687,,,,BAO_0000019,CHEMBL617267,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane
B,,,,,1,Expert,,16404,,H,2432,8,,,12687,,,,BAO_0000019,CHEMBL617268,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex
B,,,,CHO,1,Autocuration,,16404,,H,2433,8,449.0,,12687,,,,BAO_0000219,CHEMBL617269,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
B,,,,,1,Expert,,15577,,H,2434,8,,,12687,,,,BAO_0000357,CHEMBL617323,,Kinetic inhibition constant evaluated by measuring serotonergic activity
B,,,,,1,Autocuration,,15577,,H,2435,8,,,12687,,,,BAO_0000357,CHEMBL617324,,Serotonergic activity of the compound.
B,,,,,1,Autocuration,,2495,,H,2436,8,,,12687,,,,BAO_0000249,CHEMBL617325,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes
B,Rattus norvegicus,10116.0,,,1,Expert,,15042,,D,2437,9,,,12687,,,,BAO_0000019,CHEMBL617326,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.
B,,,,,1,Expert,,15026,,H,2438,8,,,12687,,,,BAO_0000249,CHEMBL617327,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.
F,Rattus norvegicus,10116.0,,,1,Expert,,12919,,D,2439,9,,,12687,,,,BAO_0000019,CHEMBL617328,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
F,Rattus norvegicus,10116.0,,,1,Expert,,12919,,D,2440,9,,,12687,,,,BAO_0000019,CHEMBL617329,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
F,Rattus norvegicus,10116.0,,,1,Expert,,12919,,D,2441,9,,,12687,,,,BAO_0000019,CHEMBL617330,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
B,,,,,1,Autocuration,,15194,,H,2442,8,,,12687,,,,BAO_0000357,CHEMBL617331,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,15194,,H,2443,8,,,12687,,,,BAO_0000357,CHEMBL617332,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.
B,,,,,1,Expert,,4820,,H,2444,8,,,107,,,,BAO_0000357,CHEMBL617333,,Binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,6736,,H,2445,8,,,107,,,,BAO_0000357,CHEMBL617334,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin
B,,,,,1,Autocuration,,5163,,H,2446,8,,,107,,,,BAO_0000357,CHEMBL617335,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L
B,,,,,1,Autocuration,,5163,,H,2447,8,,,107,,,,BAO_0000357,CHEMBL617336,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L
B,,,,,1,Autocuration,,6011,,H,2448,8,,,107,,,,BAO_0000357,CHEMBL617337,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration
B,Homo sapiens,9606.0,,,1,Expert,,14294,,D,2449,9,,,107,,,,BAO_0000357,CHEMBL617338,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM
B,,,,,1,Autocuration,,5014,,H,2450,8,,,107,,,,BAO_0000357,CHEMBL617339,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,17066,,H,2451,8,,,107,,,,BAO_0000357,CHEMBL617340,,Binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17515,,H,2452,8,,,107,,,,BAO_0000357,CHEMBL617341,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM
B,,,,,1,Expert,,6736,,H,2453,8,,,107,,,,BAO_0000357,CHEMBL617342,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,5163,,H,2454,8,,,107,,,,BAO_0000357,CHEMBL617343,,Affinity for 5-hydroxytryptamine 2A receptor
B,,,,NIH3T3,1,Expert,,16911,,H,2455,8,723.0,,107,,,,BAO_0000219,CHEMBL617344,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).
B,,,,,1,Expert,,6841,,H,2456,8,,,107,,,,BAO_0000357,CHEMBL617345,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
B,,,,,1,Expert,,6119,,H,2457,8,,,107,,,,BAO_0000357,CHEMBL617346,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.
B,,,,,1,Autocuration,,3962,,H,2458,8,,,107,,,,BAO_0000357,CHEMBL617347,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,4373,,H,2459,8,,,107,,,,BAO_0000357,CHEMBL617348,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined
B,,,,,1,Autocuration,,4373,,H,2460,8,,,107,,,,BAO_0000357,CHEMBL617349,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined
F,,,,,1,Autocuration,,3962,,H,2461,8,,,107,,,,BAO_0000019,CHEMBL617350,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,1633,,H,2462,8,,,107,,,,BAO_0000357,CHEMBL872339,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin
B,,,,,1,Autocuration,,4373,,H,2463,8,,,107,,,,BAO_0000357,CHEMBL617351,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined
B,,,,,1,Expert,,6576,,H,2464,8,,,107,,,,BAO_0000357,CHEMBL617352,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,4687,,H,2465,8,,,107,,,,BAO_0000357,CHEMBL617353,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,16946,,H,2466,8,,,107,,,,BAO_0000357,CHEMBL617354,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,14159,,H,2467,8,,,107,,,,BAO_0000357,CHEMBL617355,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor
B,Mus musculus,10090.0,,CHO,1,Expert,,3032,,H,2468,8,449.0,,107,,,,BAO_0000219,CHEMBL617356,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells
B,,,,,1,Autocuration,,16655,,H,2469,8,,,107,,,,BAO_0000357,CHEMBL617357,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,13964,,H,2470,8,,,107,,,,BAO_0000357,CHEMBL617358,,Binding affinity at 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,16989,,H,2471,8,,,107,,,,BAO_0000357,CHEMBL617359,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,16117,,H,2472,8,,,107,,,,BAO_0000357,CHEMBL617360,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined
B,,,,,1,Autocuration,,16700,,H,2473,8,,,107,,,,BAO_0000357,CHEMBL875913,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity
B,,,,,1,Autocuration,,3269,,H,2474,8,,,107,,,,BAO_0000357,CHEMBL617361,,Affinity against 5-hydroxytryptamine 2A receptor
B,Homo sapiens,9606.0,,,1,Expert,,1274,,D,2475,9,,,107,,,,BAO_0000357,CHEMBL617362,,Binding affinity against 5-Hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,1317,,H,2476,8,,,107,,,,BAO_0000357,CHEMBL617363,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay
B,,,,,1,Autocuration,,12146,,H,2477,8,,,107,,,,BAO_0000357,CHEMBL617364,,Tested against 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,12652,,H,2478,4,,,105075,,,,BAO_0000224,CHEMBL617365,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
B,,,,,1,Autocuration,,12652,,H,2479,4,,,105075,,,,BAO_0000224,CHEMBL617366,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin
B,,,,,1,Autocuration,,12652,,H,2480,4,,,105075,,,,BAO_0000224,CHEMBL617367,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI
B,,,,,1,Autocuration,,12652,,H,2481,4,,,105075,,,,BAO_0000224,CHEMBL617368,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
B,,,,,1,Autocuration,,16647,,H,2482,8,,,107,,,,BAO_0000357,CHEMBL617369,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 )
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2483,9,722.0,,227,,,,BAO_0000219,CHEMBL617370,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2484,9,449.0,,227,,,,BAO_0000219,CHEMBL617371,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader
B,,,,,1,Autocuration,,3805,,H,2485,8,,,227,,,,BAO_0000357,CHEMBL617372,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM)
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,2486,9,,,227,,,,BAO_0000357,CHEMBL617373,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor
F,,,,,1,Autocuration,,14093,,H,2487,8,,,227,,,,BAO_0000019,CHEMBL617374,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand
F,,,,,1,Autocuration,,13481,,H,2488,8,,,227,,,,BAO_0000019,CHEMBL617375,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand
F,,,,,1,Autocuration,,14093,,H,2489,8,,,227,,,,BAO_0000019,CHEMBL617376,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand
F,,,,,1,Autocuration,,14093,,H,2490,8,,,227,,,,BAO_0000019,CHEMBL617377,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested
F,,,,,1,Autocuration,,14093,,H,2491,8,,,227,,,,BAO_0000019,CHEMBL617378,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand
F,,,,,1,Autocuration,,13481,,H,2492,8,,,227,,,,BAO_0000019,CHEMBL617379,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
B,,,,,1,Autocuration,,14442,,H,2493,8,,,227,,,,BAO_0000357,CHEMBL617380,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand
B,,,,,1,Autocuration,,14442,,H,2494,8,,,227,,,,BAO_0000357,CHEMBL617381,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand
B,,,,,1,Autocuration,,14442,,H,2495,8,,,227,,,,BAO_0000357,CHEMBL617382,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
B,,,,,1,Autocuration,,12369,,H,2496,8,,,107,,,,BAO_0000357,CHEMBL617383,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,12369,,H,2497,8,,,107,,,,BAO_0000357,CHEMBL617384,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.
B,,,,,1,Expert,,12369,,H,2498,8,,,107,,,,BAO_0000357,CHEMBL617385,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.
B,,,,,1,Autocuration,,14447,,H,2499,8,,,107,,,,BAO_0000019,CHEMBL617386,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes
B,,,,,1,Autocuration,,14447,,H,2500,8,,,107,,,,BAO_0000019,CHEMBL617387,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.
B,,,,NIH3T3,1,Autocuration,,17451,,H,2501,8,723.0,,107,,,,BAO_0000219,CHEMBL617388,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
F,,,,CHO,1,Autocuration,,6857,,H,2502,8,449.0,,107,,,,BAO_0000219,CHEMBL617389,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2503,9,449.0,,107,,,,BAO_0000219,CHEMBL617390,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
B,,,,,1,Autocuration,,5635,,H,2504,4,,,104817,,,,BAO_0000224,CHEMBL617391,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.
B,,,,,1,Autocuration,,12861,,H,2505,8,,,107,,,,BAO_0000357,CHEMBL617392,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,2506,8,,,107,,,,BAO_0000019,CHEMBL617393,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
B,,,,L929,1,Autocuration,,5105,,H,2507,8,307.0,,107,,,,BAO_0000219,CHEMBL617394,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand
B,,,,L929,1,Expert,,5104,,H,2508,8,307.0,,107,,,,BAO_0000219,CHEMBL617395,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand
B,,,,L929,1,Expert,,5105,,H,2509,8,307.0,,107,,,,BAO_0000219,CHEMBL617396,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.
B,,,,L929,1,Autocuration,,5105,,H,2510,8,307.0,,107,,,,BAO_0000219,CHEMBL617397,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested
B,,,,,1,Autocuration,,5254,,H,2511,8,,,107,,,,BAO_0000357,CHEMBL617398,,Binding affinity against 5-HT2A receptor
B,,,,,1,Autocuration,,5254,,H,2512,8,,,107,,,,BAO_0000357,CHEMBL617399,,Binding affinity against 5-hydroxytryptamine 2A receptor
B,,,,HEK293,1,Autocuration,,13267,,H,2513,8,722.0,,107,,,,BAO_0000219,CHEMBL617400,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
B,,,,HEK293,1,Autocuration,,13267,,H,2514,8,722.0,,107,,,,BAO_0000219,CHEMBL617401,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
B,Homo sapiens,9606.0,,HEK293,1,Expert,,14157,,D,2515,9,722.0,,107,,,,BAO_0000219,CHEMBL617402,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2516,9,722.0,,107,,,,BAO_0000219,CHEMBL617403,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
B,,,,,1,Expert,,14068,,H,2517,8,,,107,,,,BAO_0000357,CHEMBL617404,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2518,9,722.0,,107,,,,BAO_0000219,CHEMBL857981,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2519,9,722.0,,107,,,,BAO_0000219,CHEMBL617405,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,2520,9,722.0,,107,,,,BAO_0000219,CHEMBL617253,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand
B,,,,,1,Expert,,6166,,H,2521,8,,,107,,,,BAO_0000357,CHEMBL617254,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.
B,,,,HEK293,1,Autocuration,,17296,,H,2522,8,722.0,,107,,,,BAO_0000219,CHEMBL617255,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
B,,,,HEK293,1,Autocuration,,17296,,H,2523,8,722.0,,107,,,,BAO_0000219,CHEMBL617256,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
B,,,,HEK293,1,Autocuration,,17296,,H,2524,8,722.0,,107,,,,BAO_0000219,CHEMBL616874,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15779,,D,2525,9,722.0,,107,,,,BAO_0000219,CHEMBL616875,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.
B,,,,HEK293,1,Expert,,14391,,H,2526,8,722.0,,107,,,,BAO_0000219,CHEMBL616876,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand
B,,,,HEK293,1,Expert,,15851,,H,2527,8,722.0,,107,,,,BAO_0000219,CHEMBL616877,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand."
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2528,9,722.0,,107,,,,BAO_0000219,CHEMBL616878,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble
B,,,,HEK293,1,Expert,,3832,,H,2529,8,722.0,,107,,,,BAO_0000219,CHEMBL616879,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin
B,,,,HEK293,1,Expert,,3833,,H,2530,8,722.0,,107,,,,BAO_0000219,CHEMBL616880,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2531,9,722.0,,107,,,,BAO_0000219,CHEMBL616881,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
B,,,,NIH3T3,1,Autocuration,,17451,,H,2532,8,723.0,,107,,,,BAO_0000219,CHEMBL616882,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand
B,,,,NIH3T3,1,Autocuration,,17451,,H,2533,8,723.0,,107,,,,BAO_0000219,CHEMBL616883,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
B,,,,NIH3T3,1,Autocuration,,17451,,H,2534,8,723.0,,107,,,,BAO_0000219,CHEMBL616884,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
B,,,,HEK293,1,Autocuration,,4199,,H,2535,8,722.0,,107,,,,BAO_0000219,CHEMBL616885,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand
B,,,,CHO-K1,1,Autocuration,,1883,,H,2536,8,485.0,,107,,,,BAO_0000219,CHEMBL616886,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells
B,,,,CHO-K1,1,Expert,,1883,,H,2537,8,485.0,,107,,,,BAO_0000219,CHEMBL616887,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.
B,Homo sapiens,9606.0,,,1,Expert,,14875,,D,2538,9,,,107,,,,BAO_0000357,CHEMBL616888,,Binding affinity for human 5-hydroxytryptamine 2A receptor
B,,,,HEK293,1,Autocuration,,15146,,H,2539,8,722.0,,107,,,,BAO_0000219,CHEMBL616889,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin
B,,,,HEK293,1,Autocuration,,5213,,H,2540,8,722.0,,107,,,,BAO_0000219,CHEMBL616890,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand
B,Homo sapiens,9606.0,,CHO,1,Expert,,16404,,D,2541,9,449.0,,107,,,,BAO_0000219,CHEMBL616891,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
B,,,,HEK293,1,Autocuration,,14818,,H,2542,8,722.0,,107,,,,BAO_0000219,CHEMBL616892,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.
B,,,,HEK293,1,Autocuration,,4829,,H,2543,8,722.0,,107,,,,BAO_0000219,CHEMBL616893,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand"
F,,,,NIH3T3,1,Autocuration,,12652,,H,2544,8,723.0,,10620,,,,BAO_0000219,CHEMBL616894,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells
B,,,,NIH3T3,1,Expert,,4682,,H,2545,8,723.0,,107,,,,BAO_0000219,CHEMBL616895,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells
F,,,,,1,Autocuration,,12652,,H,2546,8,,,10620,,,,BAO_0000019,CHEMBL616896,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,4921,,H,2547,8,,,10621,,,,BAO_0000357,CHEMBL617099,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,4921,,H,2548,8,,,10621,,,,BAO_0000357,CHEMBL617100,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,16312,,H,2549,8,,,107,,,,BAO_0000357,CHEMBL884532,,Binding affinity against rabbit aorta 5-HT2A receptor
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,14998,,H,2550,8,,,107,,,,BAO_0000357,CHEMBL617101,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,14025,,H,2551,8,,,107,,,,BAO_0000357,CHEMBL617102,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,2552,8,,,107,,,,BAO_0000019,CHEMBL617103,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
B,Oryctolagus cuniculus,9986.0,,,1,Expert,,13047,,H,2553,8,,,107,,,,BAO_0000357,CHEMBL617104,,The compound was tested for binding affinity against 5-HT2A receptor
B,,,,CHO-K1,1,Autocuration,,1883,,H,2554,8,485.0,,10576,,,,BAO_0000219,CHEMBL857979,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.
B,,,,,1,Autocuration,,13463,,H,2555,8,,,12687,,,,BAO_0000019,CHEMBL857502,,Binding affinity analysed towards 5-HT 2A in rat jugular vein
B,,,,,1,Autocuration,,13463,,H,2556,8,,,12687,,,,BAO_0000019,CHEMBL617105,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
B,,,,,1,Autocuration,,13463,,H,2557,8,,,12687,Stomach,945.0,,BAO_0000019,CHEMBL858021,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.
B,Rattus norvegicus,10116.0,,,1,Expert,,13463,,D,2558,9,,,12687,Stomach,945.0,,BAO_0000019,CHEMBL875910,,Binding affinity for 5-HT 2A in rat stomach fundus
B,,,,,1,Autocuration,,13463,,H,2559,8,,,12687,,,,BAO_0000019,CHEMBL617106,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
B,,,,NIH3T3,1,Expert,,16326,,H,2560,8,723.0,,12687,,,,BAO_0000219,CHEMBL617107,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor
F,,,,,1,Autocuration,,14093,,H,2561,8,,,12687,,,,BAO_0000019,CHEMBL617108,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor
F,,,,,1,Autocuration,,14093,,H,2562,8,,,12687,,,,BAO_0000019,CHEMBL617109,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,15740,,H,2563,8,,,12687,,,,BAO_0000357,CHEMBL617110,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,16633,,H,2564,8,,,12687,,,,BAO_0000357,CHEMBL617111,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation
F,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2565,9,,,12687,,,,BAO_0000019,CHEMBL617112,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells
B,,,,,1,Autocuration,,17133,,H,2566,8,,,12687,,,,BAO_0000357,CHEMBL617113,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17133,,H,2567,8,,,12687,,,,BAO_0000357,CHEMBL617114,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17133,,H,2568,8,,,12687,,,,BAO_0000357,CHEMBL617115,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
F,,,,,1,Autocuration,,17200,,H,2569,8,,,12687,,,,BAO_0000219,CHEMBL617116,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
F,,,,,1,Autocuration,,15363,,H,2570,8,,,12687,,,,BAO_0000019,CHEMBL617117,,Efficacy at 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,17200,,H,2571,8,,,12687,,,,BAO_0000357,CHEMBL617118,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
B,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2572,9,,,12687,,,,BAO_0000357,CHEMBL617119,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
B,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2573,9,,,12687,,,,BAO_0000357,CHEMBL617120,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax)
F,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2574,9,,,12687,,,,BAO_0000219,CHEMBL617121,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
F,,,,,1,Autocuration,,17200,,H,2575,8,,,12687,,,,BAO_0000219,CHEMBL617122,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
B,,,,,1,Autocuration,,17211,,H,2576,8,,,12687,,,,BAO_0000019,CHEMBL617123,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,17331,,H,2577,8,,,12687,,,,BAO_0000019,CHEMBL617124,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes
B,,,,,1,Expert,,13565,,H,2578,8,,,12687,,,,BAO_0000249,CHEMBL617600,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes
B,,,,,1,Expert,,13730,,H,2579,8,,,12687,,,,BAO_0000357,CHEMBL617601,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand
B,,,,,1,Expert,,12416,,H,2580,8,,,12687,,,,BAO_0000019,CHEMBL882923,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex
B,,,,,1,Autocuration,,15295,,H,2581,8,,,12687,,,,BAO_0000357,CHEMBL617602,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,1742,,H,2582,8,,,12687,,,,BAO_0000019,CHEMBL617603,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates
B,,,,,1,Autocuration,,15295,,H,2583,8,,,12687,,,,BAO_0000357,CHEMBL617604,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,14970,,H,2584,8,,,12687,,,,BAO_0000019,CHEMBL617605,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand
B,,,,,1,Expert,,16693,,H,2585,8,,,12687,,,,BAO_0000019,CHEMBL617606,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,14776,,D,2586,9,,,12687,,,,BAO_0000019,CHEMBL617607,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,14286,,H,2587,8,,,12687,,,,BAO_0000249,CHEMBL617455,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2588,9,,,12687,,,,BAO_0000019,CHEMBL617456,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
B,,,,,1,Expert,,15306,,H,2589,8,,,12687,,,,BAO_0000357,CHEMBL617457,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration)
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,2590,9,,,12687,,,,BAO_0000357,CHEMBL617458,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,14229,,D,2591,9,,,12687,,,,BAO_0000019,CHEMBL617459,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain
B,,,,,1,Expert,,12884,,H,2592,8,,,12687,,,,BAO_0000357,CHEMBL617460,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 
B,,,,,1,Expert,,13149,,H,2593,8,,,12687,,,,BAO_0000357,CHEMBL617461,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values."
B,Rattus norvegicus,10116.0,,,1,Expert,,15295,,D,2594,9,,,12687,,,,BAO_0000019,CHEMBL617462,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M
B,,,,,1,Autocuration,,15740,,H,2595,8,,,12687,,,,BAO_0000357,CHEMBL617463,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.
B,,,,,1,Autocuration,,15185,,H,2596,8,,,12687,,,,BAO_0000019,CHEMBL617464,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI)."
B,,,,,1,Autocuration,,15185,,H,2597,8,,,12687,,,,BAO_0000019,CHEMBL617465,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate."
B,,,,,1,Expert,,17529,,H,2598,8,,,12687,,,,BAO_0000019,CHEMBL617466,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand
B,,,,,1,Autocuration,,14826,,H,2599,8,,,12687,,,,BAO_0000019,CHEMBL617467,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
B,,,,,1,Expert,,17211,,H,2600,8,,,12687,,,,BAO_0000019,CHEMBL617468,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors
B,,,,,1,Autocuration,,14826,,H,2601,8,,,12687,,,,BAO_0000019,CHEMBL617469,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
B,,,,,1,Autocuration,,14093,,H,2602,8,,,12687,,,,BAO_0000019,CHEMBL617470,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,14093,,H,2603,8,,,12687,,,,BAO_0000019,CHEMBL617471,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested
B,,,,NIH3T3,1,Expert,,13246,,H,2604,8,723.0,,12687,,,,BAO_0000219,CHEMBL617472,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes
B,,,,,1,Expert,,13246,,H,2605,8,,,12687,,,,BAO_0000357,CHEMBL617473,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.
B,Rattus norvegicus,10116.0,,,1,Expert,,15436,,D,2606,9,,,12687,,,,BAO_0000019,CHEMBL617474,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
B,Rattus norvegicus,10116.0,,,1,Expert,,15436,,D,2607,9,,,12687,,,,BAO_0000019,CHEMBL617475,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
B,,,,,1,Autocuration,,14442,,H,2608,8,,,12687,Brain,955.0,,BAO_0000221,CHEMBL617476,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined
B,,,,,1,Expert,,12457,,H,2609,8,,,12687,,,,BAO_0000357,CHEMBL617477,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor
B,,,,NIH3T3,1,Expert,,12457,,H,2610,8,723.0,,12687,,,,BAO_0000219,CHEMBL617478,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor
F,,,,,1,Autocuration,,14755,,H,2611,8,,,12687,,,,BAO_0000221,CHEMBL617479,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates."
B,,,,,1,Autocuration,,4707,,H,2612,8,,,12687,,,,BAO_0000357,CHEMBL617480,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand
B,,,,,1,Expert,,13297,,H,2613,8,,,12687,,,,BAO_0000357,CHEMBL617481,,Binding affinity against 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,17331,,H,2614,8,,,12687,,,,BAO_0000019,CHEMBL617482,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes
B,,,,,1,Autocuration,,4664,,H,2615,8,,,12687,,,,BAO_0000019,CHEMBL617483,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,16633,,H,2616,8,,,12687,,,,BAO_0000357,CHEMBL621528,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
B,Rattus norvegicus,10116.0,,NIH3T3,1,Expert,,4664,,D,2617,9,723.0,,12687,,,,BAO_0000219,CHEMBL621529,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin
B,,,,,1,Expert,,16133,,H,2618,8,,,12687,,,,BAO_0000357,CHEMBL621530,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
B,,,,,1,Expert,,16133,,H,2619,8,,,12687,,,,BAO_0000357,CHEMBL621531,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,14060,,D,2620,9,,,12687,,,,BAO_0000019,CHEMBL621532,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,16326,,H,2621,8,,,12687,,,,BAO_0000357,CHEMBL621533,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
B,,,,CHO,1,Expert,,16659,,H,2622,8,449.0,,12687,,,,BAO_0000219,CHEMBL621534,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
B,,,,,1,Autocuration,,14776,,H,2623,8,,,12687,,,,BAO_0000019,CHEMBL621535,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.
B,,,,,1,Autocuration,,13481,,H,2624,8,,,12687,,,,BAO_0000357,CHEMBL621536,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay
B,,,,,1,Autocuration,,17386,,H,2625,8,,,12687,,,,BAO_0000357,CHEMBL621537,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,6611,,D,2626,9,,,12687,,,,BAO_0000357,CHEMBL621538,,Binding affinity for 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,14423,,H,2627,8,,,12687,,,,BAO_0000019,CHEMBL621539,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.
B,,,,,1,Autocuration,,15412,,H,2628,8,,,12687,,,,BAO_0000019,CHEMBL621540,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex
B,,,,,1,Autocuration,,15412,,H,2629,8,,,12687,,,,BAO_0000019,CHEMBL621541,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.
B,,,,,1,Autocuration,,6238,,H,2630,8,,,12687,,,,BAO_0000019,CHEMBL621542,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand
B,,,,,1,Expert,,6648,,H,2631,8,,,12687,,,,BAO_0000357,CHEMBL621543,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.
B,,,,,1,Expert,,5667,,H,2632,8,,,12687,,,,BAO_0000357,CHEMBL621544,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,6611,,D,2633,9,,,12687,,,,BAO_0000357,CHEMBL621545,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor
B,,,,,1,Autocuration,,13481,,H,2634,8,,,12687,,,,BAO_0000357,CHEMBL621546,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,13481,,H,2635,8,,,12687,,,,BAO_0000357,CHEMBL621547,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested
B,,,,NIH3T3,1,Expert,,15558,,H,2636,8,723.0,,12687,,,,BAO_0000219,CHEMBL618692,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,6013,,H,2637,8,,,12687,,,,BAO_0000357,CHEMBL618693,,Binding affinity towards 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,16633,,H,2638,8,,,12687,,,,BAO_0000357,CHEMBL872922,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
B,,,,,1,Autocuration,,6013,,H,2639,8,,,12687,,,,BAO_0000357,CHEMBL618694,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,6013,,D,2640,9,,,12687,,,,BAO_0000357,CHEMBL618695,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB
B,,,,,1,Autocuration,,6013,,H,2641,8,,,12687,,,,BAO_0000357,CHEMBL618696,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data
B,,,,,1,Expert,,6013,,H,2642,8,,,12687,,,,BAO_0000357,CHEMBL618697,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.
B,,,,,1,Autocuration,,6013,,H,2643,8,,,12687,,,,BAO_0000357,CHEMBL618892,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand
B,,,,,1,Autocuration,,6013,,H,2644,8,,,12687,,,,BAO_0000357,CHEMBL618893,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,16293,,H,2645,8,,,12687,,,,BAO_0000357,CHEMBL618894,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor
B,,,,NIH3T3,1,Expert,,17175,,H,2646,8,723.0,,12687,,,,BAO_0000219,CHEMBL618895,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,13278,,D,2647,9,,,12687,,,,BAO_0000357,CHEMBL618896,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
B,,,,,1,Autocuration,,3682,,H,2648,8,,,12687,Caudate-putamen,5383.0,,BAO_0000019,CHEMBL618897,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain
B,,,,,1,Autocuration,,2014,,H,2649,8,,,12687,,,,BAO_0000357,CHEMBL618898,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand
B,,,,,1,Autocuration,,2014,,H,2650,8,,,12687,,,,BAO_0000357,CHEMBL618899,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined
B,,,,,1,Autocuration,,4932,,H,2651,8,,,12687,,,,BAO_0000357,CHEMBL618900,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture
B,,,,,1,Autocuration,,4932,,H,2652,8,,,12687,,,,BAO_0000019,CHEMBL618901,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate
B,,,,,1,Autocuration,,3935,,H,2653,8,,,12687,,,,BAO_0000357,CHEMBL618902,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,5432,,D,2654,9,,,12687,Hippocampus,10000000.0,,BAO_0000221,CHEMBL618903,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,15818,,H,2655,8,,,12687,,,,BAO_0000357,CHEMBL618904,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,13672,,H,2656,8,,,12687,,,,BAO_0000357,CHEMBL618905,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.
B,,,,,1,Autocuration,,13672,,H,2657,8,,,12687,,,,BAO_0000357,CHEMBL618906,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.
B,,,,NIH3T3,1,Expert,,14749,,H,2658,8,723.0,,12687,,,,BAO_0000219,CHEMBL618907,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.
B,,,,,1,Autocuration,,13462,,H,2659,8,,,12687,,,,BAO_0000019,CHEMBL618908,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.
B,,,,,1,Autocuration,,15740,,H,2660,8,,,12687,,,,BAO_0000357,CHEMBL617909,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,16647,,H,2661,8,,,12687,,,,BAO_0000019,CHEMBL617910,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
B,,,,,1,Autocuration,,13345,,H,2662,8,,,12687,Brain,955.0,,BAO_0000221,CHEMBL617911,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.
B,,,,,1,Autocuration,,16740,,H,2663,8,,,12687,,,,BAO_0000249,CHEMBL872923,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,,,,,1,Autocuration,,16740,,H,2664,8,,,12687,,,,BAO_0000249,CHEMBL617912,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,Rattus norvegicus,10116.0,,,1,Expert,,15535,,D,2665,9,,,12687,,,,BAO_0000019,CHEMBL617913,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex
B,,,,,1,Expert,,16740,,H,2666,8,,,12687,,,,BAO_0000249,CHEMBL617914,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,,,,,1,Autocuration,,16740,,H,2667,8,,,12687,,,,BAO_0000249,CHEMBL617915,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,,,,,1,Autocuration,,16740,,H,2668,8,,,12687,,,,BAO_0000249,CHEMBL617916,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane
B,Rattus norvegicus,10116.0,,,1,Expert,,4795,,D,2669,9,,,12687,,,,BAO_0000019,CHEMBL617917,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor
B,,,,,1,Expert,,8,,H,2670,8,,,12687,,,,BAO_0000019,CHEMBL617918,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,8,,H,2671,8,,,12687,,,,BAO_0000019,CHEMBL617919,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M
B,Rattus norvegicus,10116.0,,,1,Expert,,17200,,D,2672,9,,,12687,,,,BAO_0000019,CHEMBL617920,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
B,Rattus norvegicus,10116.0,,,1,Expert,,2148,,D,2673,9,,,12687,,,,BAO_0000019,CHEMBL617921,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex
B,Rattus norvegicus,10116.0,,,1,Expert,,13345,,D,2674,5,,,105102,,,,BAO_0000224,CHEMBL617922,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki"
B,,,,,1,Autocuration,,5088,,H,2675,8,,,12687,,,,BAO_0000357,CHEMBL617923,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
B,,,,,1,Autocuration,,5088,,H,2676,8,,,12687,,,,BAO_0000357,CHEMBL617924,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
B,,,,,1,Autocuration,,17133,,H,2677,8,,,12687,,,,BAO_0000357,CHEMBL617925,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,17133,,D,2678,9,,,12687,,,,BAO_0000357,CHEMBL617926,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI
B,,,,,1,Autocuration,,16532,,H,2679,8,,,12687,,,,BAO_0000357,CHEMBL617927,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin
B,,,,,1,Autocuration,,15086,,H,2680,8,,,12687,,,,BAO_0000357,CHEMBL617928,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,2309,,D,2681,9,,,12687,,,,BAO_0000019,CHEMBL617929,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
B,,,,,1,Expert,,12953,,H,2682,8,,,12687,,,,BAO_0000019,CHEMBL617930,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.
B,,,,,1,Autocuration,,12953,,H,2683,8,,,12687,,,,BAO_0000019,CHEMBL617931,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM
B,,,,,1,Autocuration,,12953,,H,2684,8,,,12687,,,,BAO_0000019,CHEMBL617932,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM
B,,,,CHO,1,Autocuration,,16659,,H,2685,8,449.0,,12687,,,,BAO_0000219,CHEMBL617933,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data
B,,,,,1,Autocuration,,16740,,H,2686,8,,,12687,,,,BAO_0000019,CHEMBL617934,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
B,,,,,1,Autocuration,,16740,,H,2687,8,,,12687,,,,BAO_0000019,CHEMBL617935,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
B,,,,,1,Autocuration,,17133,,H,2688,8,,,12687,,,,BAO_0000357,CHEMBL617936,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined
B,,,,,1,Autocuration,,17211,,H,2689,8,,,12687,,,,BAO_0000019,CHEMBL617937,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested
B,,,,,1,Autocuration,,17331,,H,2690,8,,,12687,,,,BAO_0000019,CHEMBL617938,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested
B,,,,,1,Autocuration,,16633,,H,2691,8,,,12687,,,,BAO_0000218,CHEMBL617939,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63
B,,,,,1,Autocuration,,16633,,H,2692,8,,,12687,,,,BAO_0000218,CHEMBL617940,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg
B,,,,,1,Autocuration,,16633,,H,2693,8,,,12687,,,,BAO_0000218,CHEMBL617941,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg
B,,,,,1,Expert,,15026,,H,2694,8,,,12687,,,,BAO_0000357,CHEMBL617942,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor
B,,,,,1,Expert,,15026,,H,2695,8,,,12687,,,,BAO_0000357,CHEMBL617943,,Ratio of pKi of 5-HT2A to that of D2 receptor
B,,,,,1,Expert,,16404,,H,2696,4,,,105093,,,,BAO_0000224,CHEMBL617944,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
B,,,,,1,Expert,,16404,,H,2697,4,,,105093,,,,BAO_0000224,CHEMBL617945,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
B,,,,,1,Expert,,16404,,H,2698,4,,,105075,,,,BAO_0000224,CHEMBL617946,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16404,,H,2699,8,,,12687,,,,BAO_0000357,CHEMBL617947,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data
B,,,,,1,Expert,,16326,,H,2700,8,,,12687,,,,BAO_0000357,CHEMBL617948,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM
F,,,,,1,Autocuration,,15847,,H,2701,8,,,12687,,,,BAO_0000019,CHEMBL858116,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat
F,,,,,1,Autocuration,,15847,,H,2702,8,,,12687,,,,BAO_0000019,CHEMBL617949,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done
F,,,,,1,Autocuration,,15329,,H,2703,8,,,12687,,,,BAO_0000019,CHEMBL617950,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery
F,,,,,1,Expert,,16404,,H,2704,8,,,12687,Thoracic aorta,1515.0,,BAO_0000019,CHEMBL617951,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta
F,,,,,1,Expert,,16404,,H,2705,8,,,12687,Thoracic aorta,1515.0,,BAO_0000019,CHEMBL617952,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta
F,,,,,1,Autocuration,,16404,,H,2706,8,,,12687,Thoracic aorta,1515.0,,BAO_0000019,CHEMBL617953,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.
B,,,,,1,Autocuration,,12861,,H,2707,8,,,12687,,,,BAO_0000357,CHEMBL617954,,Binding activity radioligand.
B,,,,,1,Expert,,12861,,H,2708,8,,,12687,,,,BAO_0000019,CHEMBL617955,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
B,,,,,1,Autocuration,,12861,,H,2709,8,,,12687,,,,BAO_0000019,CHEMBL857071,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
B,,,,,1,Expert,,12490,,H,2710,8,,,12687,,,,BAO_0000019,CHEMBL617270,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate
B,,,,N1E-115,1,Autocuration,,12827,,H,2711,8,339.0,,12687,,,,BAO_0000219,CHEMBL617271,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930
B,,,,N1E-115,1,Autocuration,,12827,,H,2712,8,339.0,,12687,,,,BAO_0000219,CHEMBL617272,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined
B,,,,,1,Autocuration,,12918,,H,2713,8,,,12687,,,,BAO_0000019,CHEMBL617273,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin
F,Rattus norvegicus,10116.0,,,1,Expert,,12919,,D,2714,9,,,12687,,,,BAO_0000019,CHEMBL617274,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin
B,,,,,1,Autocuration,,17723,,H,2715,8,,,108,,,,BAO_0000357,CHEMBL617275,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,6013,,H,2716,8,,,108,,,,BAO_0000357,CHEMBL617276,,Binding affinity towards 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16293,,H,2717,8,,,108,,,,BAO_0000357,CHEMBL617277,,Binding affinity towards human 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,3857,,H,2718,8,,,108,,,,BAO_0000019,CHEMBL617278,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,3857,,H,2719,8,,,108,,,,BAO_0000019,CHEMBL617279,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined
B,,,,,1,Expert,,3857,,H,2720,8,,,108,,,,BAO_0000019,CHEMBL617280,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,15363,,H,2721,8,,,108,,,,BAO_0000357,CHEMBL617281,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,15363,,H,2722,8,,,108,,,,BAO_0000357,CHEMBL617282,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,16441,,H,2723,8,,,108,,,,BAO_0000019,CHEMBL617283,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine
B,,,,,1,Expert,,16441,,H,2724,8,,,108,,,,BAO_0000019,CHEMBL617284,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.
B,,,,HEK293,1,Autocuration,,4176,,H,2725,8,722.0,,108,,,,BAO_0000219,CHEMBL617285,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,17085,,H,2726,8,,,108,,,,BAO_0000019,CHEMBL617286,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor
B,Homo sapiens,9606.0,,,1,Expert,,17200,,D,2727,9,,,108,,,,BAO_0000357,CHEMBL617287,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand
B,,,,,1,Expert,,5088,,H,2728,8,,,108,,,,BAO_0000357,CHEMBL617288,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.
B,,,,,1,Autocuration,,5088,,H,2729,8,,,108,,,,BAO_0000357,CHEMBL617289,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand
B,,,,,1,Autocuration,,5088,,H,2730,8,,,108,,,,BAO_0000357,CHEMBL872917,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,5088,,H,2731,8,,,108,,,,BAO_0000357,CHEMBL617290,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
B,,,,CHO,1,Autocuration,,16659,,H,2732,8,449.0,,108,,,,BAO_0000219,CHEMBL617291,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
B,,,,CHO,1,Autocuration,,16659,,H,2733,8,449.0,,108,,,,BAO_0000219,CHEMBL617292,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data
B,,,,NIH3T3,1,Autocuration,,17451,,H,2734,8,723.0,,108,,,,BAO_0000219,CHEMBL617293,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2735,9,449.0,,108,,,,BAO_0000219,CHEMBL617294,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
B,,,,,1,Expert,,3857,,H,2736,8,,,108,,,,BAO_0000019,CHEMBL617295,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
B,,,,,1,Autocuration,,12861,,H,2737,8,,,108,,,,BAO_0000357,CHEMBL617296,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,2738,8,,,108,,,,BAO_0000019,CHEMBL617297,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
B,,,,CHO,1,Expert,,5104,,H,2739,8,449.0,,108,,,,BAO_0000219,CHEMBL617298,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand
B,,,,CHO,1,Expert,,5105,,H,2740,8,449.0,,108,,,,BAO_0000219,CHEMBL617299,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.
B,,,,CHO,1,Autocuration,,5105,,H,2741,8,449.0,,108,,,,BAO_0000219,CHEMBL617300,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested
B,,,,,1,Autocuration,,5254,,H,2742,8,,,108,,,,BAO_0000357,CHEMBL617454,,Binding affinity against 5-HT2C receptor
B,,,,HEK293,1,Autocuration,,13267,,H,2743,8,722.0,,108,,,,BAO_0000219,CHEMBL617505,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
B,Homo sapiens,9606.0,,HEK293,1,Expert,,14157,,D,2744,9,722.0,,108,,,,BAO_0000219,CHEMBL617506,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2745,9,722.0,,108,,,,BAO_0000219,CHEMBL617507,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
B,,,,,1,Expert,,14068,,H,2746,8,,,108,,,,BAO_0000357,CHEMBL617508,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB
B,Homo sapiens,9606.0,,HEK293,1,Expert,,12936,,D,2747,9,722.0,,108,,,,BAO_0000219,CHEMBL857982,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,2748,9,722.0,,108,,,,BAO_0000219,CHEMBL617509,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,2749,9,722.0,,108,,,,BAO_0000219,CHEMBL617510,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined
B,,,,,1,Autocuration,,6166,,H,2750,8,,,108,,,,BAO_0000357,CHEMBL617511,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined
B,,,,HEK293,1,Autocuration,,17296,,H,2751,8,722.0,,108,,,,BAO_0000219,CHEMBL617512,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand
B,,,,HEK293,1,Autocuration,,17296,,H,2752,8,722.0,,108,,,,BAO_0000219,CHEMBL617749,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,2753,8,722.0,,108,,,,BAO_0000219,CHEMBL617750,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,2754,8,722.0,,108,,,,BAO_0000219,CHEMBL617751,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
B,,,,HEK293,1,Expert,,14391,,H,2755,8,722.0,,108,,,,BAO_0000219,CHEMBL617752,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,2756,8,722.0,,108,,,,BAO_0000219,CHEMBL617753,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand"
B,,,,HEK293,1,Expert,,15851,,H,2757,8,722.0,,108,,,,BAO_0000219,CHEMBL617754,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand."
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2758,9,722.0,,108,,,,BAO_0000219,CHEMBL617755,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble
B,,,,HEK293,1,Autocuration,,15779,,H,2759,8,722.0,,108,,,,BAO_0000219,CHEMBL617756,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data"
B,,,,HEK293,1,Expert,,3832,,H,2760,8,722.0,,108,,,,BAO_0000219,CHEMBL617757,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine
B,,,,HEK293,1,Expert,,3833,,H,2761,8,722.0,,108,,,,BAO_0000219,CHEMBL617758,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.
B,,,,NIH3T3,1,Autocuration,,17451,,H,2762,8,723.0,,108,,,,BAO_0000219,CHEMBL617759,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand
B,,,,HEK293,1,Autocuration,,4199,,H,2763,8,722.0,,108,,,,BAO_0000219,CHEMBL617760,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand
B,,,,CHO-K1,1,Expert,,1883,,H,2764,8,485.0,,108,,,,BAO_0000219,CHEMBL617761,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells
B,Homo sapiens,9606.0,,,1,Expert,,4321,,D,2765,9,,,108,,,,BAO_0000357,CHEMBL617762,,Binding affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,14875,,H,2766,8,,,108,,,,BAO_0000357,CHEMBL617763,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor
B,,,,HEK293,1,Autocuration,,15146,,H,2767,8,722.0,,108,,,,BAO_0000219,CHEMBL857983,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine
B,,,,HEK293,1,Autocuration,,5213,,H,2768,8,722.0,,108,,,,BAO_0000219,CHEMBL617764,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand
B,,,,HeLa,1,Autocuration,,16404,,H,2769,8,308.0,,108,,,,BAO_0000219,CHEMBL617765,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells
F,,,,,1,Autocuration,,13267,,H,2770,8,,,108,,,,BAO_0000019,CHEMBL617766,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor
F,,,,,1,Autocuration,,13267,,H,2771,8,,,108,Hippocampus,10000000.0,,BAO_0000221,CHEMBL617767,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand
B,,,,HEK293,1,Autocuration,,14818,,H,2772,8,722.0,,108,,,,BAO_0000219,CHEMBL617768,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.
B,,,,HEK293,1,Autocuration,,4829,,H,2773,8,722.0,,108,,,,BAO_0000219,CHEMBL617769,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand"
B,,,,,1,Autocuration,,13463,,H,2774,8,,,11864,,,,BAO_0000357,CHEMBL858023,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,13463,,H,2775,8,,,11864,Stomach,945.0,,BAO_0000019,CHEMBL617770,,Binding affinity analysed on 5-HT 2C in rat stomach fundus
B,,,,,1,Autocuration,,13463,,H,2776,8,,,11864,Stomach,945.0,,BAO_0000019,CHEMBL617771,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus
F,,,,A9,1,Autocuration,,12652,,H,2777,8,625.0,,11864,,,,BAO_0000219,CHEMBL617772,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells
B,,,,NIH3T3,1,Autocuration,,4682,,H,2778,8,723.0,,11864,,,,BAO_0000219,CHEMBL617773,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
B,,,,NIH3T3,1,Autocuration,,4682,,H,2779,8,723.0,,11864,,,,BAO_0000219,CHEMBL617850,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells
B,,,,NIH3T3,1,Autocuration,,4682,,H,2780,8,723.0,,11864,,,,BAO_0000219,CHEMBL617851,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
F,,,,,1,Autocuration,,12652,,H,2781,8,,,11864,,,,BAO_0000019,CHEMBL617852,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor
B,Mus musculus,10090.0,,,1,Autocuration,,13463,,H,2782,8,,,12689,Stomach,945.0,,BAO_0000019,CHEMBL858024,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.
B,Rattus norvegicus,10116.0,,,1,Expert,,13463,,D,2783,9,,,12689,Stomach,945.0,,BAO_0000019,CHEMBL617853,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus
B,,,,,1,Expert,,13969,,H,2784,8,,,108,,,,BAO_0000357,CHEMBL617854,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand
B,Sus scrofa,9823.0,,,1,Expert,,13392,,H,2785,8,,,108,,,,BAO_0000357,CHEMBL873477,,Binding affinity for 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,13392,,H,2786,8,,,108,,,,BAO_0000357,CHEMBL617855,,Binding affinity towards 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,14430,,H,2787,8,,,108,,,,BAO_0000019,CHEMBL617856,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine
B,,,,,1,Autocuration,,1742,,H,2788,8,,,108,,,,BAO_0000019,CHEMBL617857,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex
B,,,,,1,Autocuration,,14286,,H,2789,8,,,108,,,,BAO_0000249,CHEMBL617858,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane
B,,,,,1,Autocuration,,5619,,H,2790,8,,,108,,,,BAO_0000357,CHEMBL617859,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,15086,,H,2791,8,,,108,,,,BAO_0000357,CHEMBL617860,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,12861,,H,2792,8,,,108,,,,BAO_0000357,CHEMBL617861,,Binding activity radioligand.
B,,,,,1,Expert,,12861,,H,2793,8,,,108,,,,BAO_0000019,CHEMBL617862,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
B,,,,,1,Autocuration,,12861,,H,2794,8,,,108,,,,BAO_0000019,CHEMBL617863,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
B,,,,,1,Autocuration,,12827,,H,2795,8,,,108,,,,BAO_0000249,CHEMBL617864,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT
B,,,,,1,Autocuration,,12827,,H,2796,8,,,108,,,,BAO_0000249,CHEMBL617649,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined
F,Sus scrofa,9823.0,,,1,Expert,,12919,,H,2797,8,,,108,,,,BAO_0000019,CHEMBL617650,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
F,Sus scrofa,9823.0,,,1,Expert,,12919,,H,2798,8,,,108,,,,BAO_0000019,CHEMBL617651,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
B,Sus scrofa,9823.0,,,1,Autocuration,,16429,,H,2799,8,,,108,,,,BAO_0000357,CHEMBL617652,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand
B,Sus scrofa,9823.0,,,1,Autocuration,,773,,H,2800,8,,,108,,,,BAO_0000019,CHEMBL857072,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex
B,Sus scrofa,9823.0,,,1,Autocuration,,5033,,H,2801,8,,,108,,,,BAO_0000357,CHEMBL617653,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,12861,,H,2802,8,,,12687,,,,BAO_0000019,CHEMBL617654,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
F,,,,,1,Autocuration,,14093,,H,2803,8,,,12689,,,,BAO_0000019,CHEMBL617655,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,14970,,H,2804,8,,,12689,,,,BAO_0000357,CHEMBL617656,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,14970,,H,2805,8,,,12689,,,,BAO_0000357,CHEMBL617657,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,14970,,H,2806,8,,,12689,,,,BAO_0000357,CHEMBL617658,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,2807,9,,,12689,,,,BAO_0000357,CHEMBL617659,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,2808,9,,,12689,,,,BAO_0000357,CHEMBL617838,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor
B,Rattus norvegicus,10116.0,,,1,Expert,Brain membranes,14229,,D,2809,9,,,12689,,,,BAO_0000249,CHEMBL617839,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes
B,,,,,1,Autocuration,,16532,,H,2810,8,,,12689,,,,BAO_0000357,CHEMBL617840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested
B,,,,,1,Autocuration,,14826,,H,2811,8,,,12689,,,,BAO_0000019,CHEMBL617841,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex
B,,,,,1,Autocuration,,17211,,H,2812,8,,,12689,,,,BAO_0000019,CHEMBL875915,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor
B,,,,,1,Expert,,17211,,H,2813,8,,,12689,,,In vitro,BAO_0000219,CHEMBL617842,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells
B,,,,NIH3T3,1,Expert,,13246,,H,2814,8,723.0,,12689,,,,BAO_0000219,CHEMBL617843,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes
B,,,,,1,Expert,,13246,,H,2815,8,,,12689,,,,BAO_0000357,CHEMBL617844,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.
B,,,,,1,Expert,,12457,,H,2816,8,,,12689,,,,BAO_0000357,CHEMBL617845,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor
B,,,,NIH3T3,1,Expert,,12457,,H,2817,8,723.0,,12689,,,,BAO_0000219,CHEMBL617846,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,4707,,H,2818,8,,,12689,,,,BAO_0000357,CHEMBL617847,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand
B,,,,,1,Expert,,13297,,H,2819,8,,,12689,,,,BAO_0000357,CHEMBL617848,,Binding affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16633,,H,2820,8,,,12689,,,,BAO_0000357,CHEMBL617849,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
B,,,,,1,Expert,,16133,,H,2821,8,,,12689,,,,BAO_0000357,CHEMBL621507,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
B,,,,,1,Expert,,16326,,H,2822,8,,,12689,,,,BAO_0000357,CHEMBL621508,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand
B,,,,,1,Autocuration,,14423,,H,2823,8,,,12689,,,,BAO_0000019,CHEMBL621509,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.
B,,,,,1,Autocuration,,15412,,H,2824,8,,,12689,,,,BAO_0000019,CHEMBL621510,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex
B,,,,,1,Autocuration,,15412,,H,2825,8,,,12689,,,,BAO_0000019,CHEMBL621511,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.
B,,,,A9,1,Expert,,15558,,H,2826,8,625.0,,12689,,,,BAO_0000219,CHEMBL621512,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16633,,H,2827,8,,,12689,,,,BAO_0000357,CHEMBL621513,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
B,,,,,1,Expert,,6013,,H,2828,8,,,12689,,,,BAO_0000357,CHEMBL621514,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.
B,,,,,1,Expert,,17175,,H,2829,8,,,12689,,,In vitro,BAO_0000219,CHEMBL621515,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,12469,,H,2830,8,,,12689,,,,BAO_0000219,CHEMBL621516,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine
B,,,,,1,Autocuration,,3682,,H,2831,8,,,12689,Caudate-putamen,5383.0,,BAO_0000019,CHEMBL621517,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain
B,,,,,1,Autocuration,,4932,,H,2832,8,,,12689,,,,BAO_0000357,CHEMBL621518,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture
B,,,,,1,Autocuration,,4932,,H,2833,8,,,12689,,,,BAO_0000019,CHEMBL621519,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data
B,,,,,1,Autocuration,,3935,,H,2834,8,,,12689,,,,BAO_0000357,CHEMBL621520,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,15818,,H,2835,8,,,12689,,,,BAO_0000357,CHEMBL621521,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,15818,,H,2836,8,,,12689,,,,BAO_0000357,CHEMBL621522,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,14749,,H,2837,8,,,12689,,,,BAO_0000219,CHEMBL621523,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.
B,,,,,1,Autocuration,,15740,,H,2838,8,,,12689,,,,BAO_0000357,CHEMBL621524,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,17133,,D,2839,9,,,12689,,,,BAO_0000357,CHEMBL621525,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI
B,,,,,1,Autocuration,,16532,,H,2840,8,,,12689,,,,BAO_0000357,CHEMBL872921,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine
B,,,,,1,Autocuration,,12369,,H,2841,8,,,12689,,,,BAO_0000357,CHEMBL621526,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,12369,,H,2842,8,,,12689,,,,BAO_0000219,CHEMBL621527,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.
B,Rattus norvegicus,10116.0,,,1,Expert,,2309,,D,2843,9,,,12689,,,,BAO_0000019,CHEMBL617865,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine
B,,,,,1,Autocuration,,12953,,H,2844,8,,,12689,,,,BAO_0000357,CHEMBL617866,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,12953,,H,2845,8,,,12689,,,,BAO_0000019,CHEMBL617867,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM
B,,,,,1,Autocuration,,12953,,H,2846,8,,,12689,,,,BAO_0000357,CHEMBL617487,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM
B,,,,,1,Expert,,12953,,H,2847,8,,,12689,,,,BAO_0000357,CHEMBL617488,,Binding affinity for 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,17133,,H,2848,8,,,12689,,,,BAO_0000357,CHEMBL617489,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined
B,,,,,1,Autocuration,,17211,,H,2849,8,,,12689,,,,BAO_0000019,CHEMBL617490,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested
B,,,,,1,Autocuration,,17211,,H,2850,8,,,12689,,,,BAO_0000019,CHEMBL617491,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested
B,,,,,1,Autocuration,,14025,,H,2851,8,,,12689,,,,BAO_0000019,CHEMBL617492,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.
B,,,,,1,Autocuration,,14998,,H,2852,8,,,12689,,,,BAO_0000019,CHEMBL617493,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.
B,,,,,1,Autocuration,,4342,,H,2853,8,,,12689,,,,BAO_0000357,CHEMBL617494,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined
B,Rattus norvegicus,10116.0,,,1,Expert,,13735,,D,2854,9,,,12689,,,,BAO_0000019,CHEMBL617495,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293
B,,,,,1,Autocuration,,13181,,H,2855,8,,,12689,,,,BAO_0000357,CHEMBL617496,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
B,,,,CHO-K1,1,Autocuration,,1883,,H,2856,8,485.0,,12689,,,,BAO_0000219,CHEMBL617497,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.
B,,,,,1,Autocuration,,15194,,H,2857,8,,,12689,,,,BAO_0000357,CHEMBL617498,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,15194,,H,2858,8,,,12689,,,,BAO_0000357,CHEMBL617499,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.
F,,,,,1,Autocuration,,14579,,H,2859,8,,,12689,,,,BAO_0000019,CHEMBL617500,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,4639,,H,2860,8,,,108,,,,BAO_0000357,CHEMBL617501,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,4820,,H,2861,8,,,108,,,,BAO_0000357,CHEMBL617502,,Binding affinity towards 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,14442,,H,2862,8,,,227,,,,BAO_0000357,CHEMBL617503,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested
B,,,,,1,Autocuration,,14755,,H,2863,8,,,227,,,,BAO_0000357,CHEMBL617504,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.
B,,,,,1,Autocuration,,14744,,H,2864,8,,,227,,,,BAO_0000357,CHEMBL617406,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand
B,Homo sapiens,9606.0,,,1,Expert,,6857,,D,2865,9,,,227,,,,BAO_0000019,CHEMBL617407,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line
B,,,,,1,Autocuration,,16209,,H,2866,8,,,227,,,,BAO_0000357,CHEMBL617408,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,15363,,H,2867,8,,,227,,,,BAO_0000357,CHEMBL617409,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,15363,,H,2868,8,,,227,,,,BAO_0000357,CHEMBL617410,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,15363,,H,2869,8,,,227,,,,BAO_0000357,CHEMBL617411,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,17085,,H,2870,8,,,227,,,,BAO_0000019,CHEMBL617412,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor
B,Homo sapiens,9606.0,,,1,Expert,,17200,,D,2871,9,,,227,,,,BAO_0000357,CHEMBL617774,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2872,9,722.0,,227,,,,BAO_0000219,CHEMBL617775,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2873,9,722.0,,227,,,,BAO_0000219,CHEMBL617776,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2874,9,449.0,,227,,,,BAO_0000219,CHEMBL617777,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2875,9,449.0,,227,,,,BAO_0000219,CHEMBL617778,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
B,,,,HEK293,1,Autocuration,,15779,,H,2876,8,722.0,,227,,,,BAO_0000219,CHEMBL617779,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
B,,,,HEK293,1,Expert,,15851,,H,2877,8,722.0,,227,,,,BAO_0000219,CHEMBL617780,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,2878,8,722.0,,227,,,,BAO_0000219,CHEMBL617781,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data"
B,Homo sapiens,9606.0,,HEK293,1,Expert,,14157,,D,2879,9,722.0,,227,,,,BAO_0000219,CHEMBL617782,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,2880,9,722.0,,227,,,,BAO_0000219,CHEMBL617783,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand
B,,,,,1,Autocuration,,6166,,H,2881,8,,,227,,,,BAO_0000357,CHEMBL617784,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined
B,,,,HEK293,1,Autocuration,,15779,,H,2882,8,722.0,,227,,,,BAO_0000219,CHEMBL617785,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.
B,,,,HEK293,1,Expert,,14391,,H,2883,8,722.0,,227,,,,BAO_0000219,CHEMBL857984,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand
B,,,,HEK293,1,Expert,,3832,,H,2884,8,722.0,,227,,,,BAO_0000219,CHEMBL617786,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT
B,,,,HEK293,1,Expert,,3833,,H,2885,8,722.0,,227,,,,BAO_0000219,CHEMBL617787,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2886,9,722.0,,227,,,,BAO_0000219,CHEMBL617788,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells
B,Homo sapiens,9606.0,,HEK293,1,Expert,,15851,,D,2887,9,722.0,,227,,,,BAO_0000219,CHEMBL617789,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble
B,,,,HEK293,1,Autocuration,,4199,,H,2888,8,722.0,,227,,,,BAO_0000219,CHEMBL617790,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand
B,,,,CHO-K1,1,Expert,,1883,,H,2889,8,485.0,,227,,,,BAO_0000219,CHEMBL617791,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells
B,,,,,1,Expert,,4321,,H,2890,8,,,227,,,,BAO_0000357,CHEMBL617608,,Binding affinity against 5-hydroxytryptamine 2B receptor
B,,,,HEK293,1,Autocuration,,15146,,H,2891,8,722.0,,227,,,,BAO_0000219,CHEMBL617609,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT
B,,,,HEK293,1,Autocuration,,5213,,H,2892,8,722.0,,227,,,,BAO_0000219,CHEMBL617610,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand
B,,,,HEK293,1,Autocuration,,14818,,H,2893,8,722.0,,227,,,,BAO_0000219,CHEMBL617611,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.
B,,,,HEK293,1,Autocuration,,4829,,H,2894,8,722.0,,227,,,,BAO_0000219,CHEMBL617612,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
B,,,,HEK293,1,Autocuration,,4829,,H,2895,8,722.0,,227,,,,BAO_0000219,CHEMBL617613,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14025,,H,2896,8,,,227,,,,BAO_0000019,CHEMBL617614,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.
B,,,,,1,Expert,,13463,,H,2897,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617615,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus
B,,,,,1,Expert,,7259,,H,2898,8,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL858114,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus
B,,,,,1,Autocuration,,7259,,H,2899,8,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617616,,Affinity against serotonergic receptor in the isolated rat stomach fundus
F,Rattus norvegicus,10116.0,,,1,Expert,,7185,,D,2900,9,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617617,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation
F,Rattus norvegicus,10116.0,,,1,Expert,,7185,,D,2901,9,,,12688,,,,BAO_0000019,CHEMBL875914,,Antagonistic against 5-hydroxytryptamine 2B receptor
F,,,,,1,Autocuration,,13267,,H,2902,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617618,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus
B,Rattus norvegicus,10116.0,,,1,Expert,,13735,,D,2903,9,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617619,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus
F,,,,,1,Autocuration,,15738,,H,2904,8,,,12688,,,,BAO_0000019,CHEMBL617620,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor
F,,,,,1,Autocuration,,15738,,H,2905,8,,,12688,,,,BAO_0000019,CHEMBL617621,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data
F,,,,,1,Autocuration,,15738,,H,2906,8,,,12688,,,,BAO_0000019,CHEMBL617622,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,2907,9,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617623,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,2908,9,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617624,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,2909,9,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617625,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,2910,9,,,12688,Stomach,945.0,,BAO_0000357,CHEMBL617626,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
F,,,,,1,Autocuration,,16404,,H,2911,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617627,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
F,,,,,1,Expert,,16404,,H,2912,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617628,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
F,,,,,1,Autocuration,,16404,,H,2913,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617629,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.
F,,,,,1,Autocuration,,16404,,H,2914,8,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL858115,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.
F,Rattus norvegicus,10116.0,,,1,Expert,,16404,,D,2915,9,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617630,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined
F,,,,,1,Autocuration,,16404,,H,2916,8,,,12688,Thoracic aorta,1515.0,,BAO_0000019,CHEMBL617631,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined
B,,,,,1,Autocuration,,7483,,H,2917,8,,,12688,,,,BAO_0000357,CHEMBL617632,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
B,,,,,1,Expert,,7483,,H,2918,8,,,12688,,,,BAO_0000357,CHEMBL617633,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus
B,,,,,1,Autocuration,,7483,,H,2919,8,,,12688,,,,BAO_0000357,CHEMBL617634,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
B,,,,,1,Autocuration,,7483,,H,2920,8,,,12688,,,,BAO_0000357,CHEMBL617635,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot
F,Rattus norvegicus,10116.0,,,1,Autocuration,,16404,,D,2922,9,,,12688,Stomach,945.0,,BAO_0000019,CHEMBL617637,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
B,,,,,1,Autocuration,,6347,,H,2923,8,,,227,,,,BAO_0000357,CHEMBL617638,,Binding affinity against 5-hydroxytryptamine 1A receptor
B,,,,,1,Autocuration,,4373,,H,2924,8,,,227,,,,BAO_0000357,CHEMBL617639,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined
B,,,,,1,Autocuration,,4373,,H,2925,8,,,227,,,,BAO_0000357,CHEMBL617640,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined
B,,,,,1,Autocuration,,4687,,H,2926,8,,,227,,,,BAO_0000357,CHEMBL617641,,Evaluated for the binding affinity to 5-HT 2B receptor
B,,,,,1,Autocuration,,16946,,H,2927,8,,,227,,,,BAO_0000357,CHEMBL617642,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,16633,,H,2928,8,,,227,,,,BAO_0000357,CHEMBL617643,,Binding affinities against 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,16633,,H,2929,8,,,227,,,,BAO_0000357,CHEMBL617644,,Binding affinities towards 5-hydroxytryptamine 2B receptor
B,,,,,1,Autocuration,,16633,,H,2930,8,,,227,,,,BAO_0000357,CHEMBL617645,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand
B,,,,,1,Expert,,15026,,H,2931,8,,,108,,,,BAO_0000357,CHEMBL617646,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
B,Bos taurus,9913.0,,,1,Autocuration,,15738,,H,2932,8,,,108,,,,BAO_0000357,CHEMBL617647,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
B,Bos taurus,9913.0,,,1,Autocuration,,15738,,H,2933,8,,,108,,,,BAO_0000357,CHEMBL617648,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M
B,Bos taurus,9913.0,,,1,Autocuration,,15738,,H,2934,8,,,108,,,,BAO_0000357,CHEMBL617875,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M
B,Bos taurus,9913.0,,,1,Autocuration,,15738,,H,2935,8,,,108,,,,BAO_0000357,CHEMBL617876,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M
B,Bos taurus,9913.0,,,1,Expert,,16404,,H,2936,8,,,108,,,,BAO_0000357,CHEMBL617877,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus
B,Bos taurus,9913.0,,,1,Expert,,15026,,H,2937,8,,,108,,,,BAO_0000357,CHEMBL617878,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
B,Bos taurus,9913.0,,,1,Autocuration,,15738,,H,2938,8,,,108,,,,BAO_0000357,CHEMBL617879,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,16312,,H,2939,8,,,108,,,,BAO_0000019,CHEMBL617880,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine
B,Cavia porcellus,10141.0,,,1,Intermediate,,5486,,D,2940,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL617881,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum
B,,,,,1,Autocuration,,5254,,H,2941,8,,,51,,,,BAO_0000357,CHEMBL857073,,Binding affinity against 5-HT1A receptor
F,,,,CHO,1,Expert,,3857,,H,2942,8,449.0,,108,,,,BAO_0000219,CHEMBL617882,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed
F,Homo sapiens,9606.0,,CHO,1,Expert,,6857,,D,2943,9,449.0,,108,,,,BAO_0000219,CHEMBL617883,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader
F,,,,,1,Autocuration,,4176,,H,2944,8,,,108,,,,BAO_0000219,CHEMBL617884,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line
B,,,,CHO,1,Autocuration,,6347,,H,2945,8,449.0,,108,,,,BAO_0000219,CHEMBL617885,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand
B,,,,CHO,1,Autocuration,,6347,,H,2946,8,449.0,,108,,,,BAO_0000219,CHEMBL617886,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax"
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,2947,9,,,108,,,,BAO_0000357,CHEMBL617887,,Inhibition of human 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,3805,,H,2948,8,,,108,,,,BAO_0000357,CHEMBL617888,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM)
B,,,,,1,Autocuration,,3857,,H,2949,8,,,108,,,,BAO_0000019,CHEMBL617889,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
B,,,,,1,Autocuration,,5635,,H,2950,8,,,108,,,,BAO_0000357,CHEMBL617890,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,5635,,H,2951,8,,,108,,,,BAO_0000357,CHEMBL617891,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
B,,,,,1,Autocuration,,5635,,H,2952,8,,,108,,,,BAO_0000357,CHEMBL617892,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
B,,,,CHO,1,Expert,,4012,,H,2953,8,449.0,,108,,,,BAO_0000219,CHEMBL617893,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.
B,,,,CHO,1,Expert,,6366,,H,2954,8,449.0,,108,,,,BAO_0000219,CHEMBL617894,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells
B,,,,CHO,1,Expert,,15949,,H,2955,8,449.0,,108,,,,BAO_0000219,CHEMBL617895,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
B,,,,CHO,1,Autocuration,,17211,,H,2956,8,449.0,,108,,,,BAO_0000219,CHEMBL617896,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,2957,9,,,108,,,,BAO_0000357,CHEMBL617897,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor
F,,,,,1,Autocuration,,14093,,H,2958,8,,,108,,,,BAO_0000019,CHEMBL617898,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand
F,,,,,1,Autocuration,,13481,,H,2959,8,,,108,,,,BAO_0000019,CHEMBL617899,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
B,Rattus norvegicus,10116.0,,CHO,1,Expert,,6347,,H,2960,8,449.0,,108,,,,BAO_0000219,CHEMBL617900,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI 
F,,,,,1,Autocuration,,14093,,H,2961,8,,,108,,,,BAO_0000019,CHEMBL617901,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand
F,,,,,1,Autocuration,,14093,,H,2962,8,,,108,,,,BAO_0000019,CHEMBL617902,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested
F,,,,,1,Autocuration,,13481,,H,2963,8,,,108,,,,BAO_0000019,CHEMBL617903,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
B,,,,,1,Autocuration,,14442,,H,2964,8,,,108,,,,BAO_0000357,CHEMBL617904,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand
B,,,,,1,Autocuration,,14442,,H,2965,8,,,108,,,,BAO_0000357,CHEMBL617905,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand
B,,,,,1,Autocuration,,14442,,H,2966,8,,,108,,,,BAO_0000357,CHEMBL617906,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested
B,,,,,1,Autocuration,,14755,,H,2967,8,,,108,,,,BAO_0000357,CHEMBL617907,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.
B,,,,,1,Autocuration,,14744,,H,2968,8,,,108,,,,BAO_0000357,CHEMBL617908,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand
B,,,,CHO,1,Expert,,16659,,H,2969,8,449.0,,108,,,,BAO_0000219,CHEMBL620617,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
B,Homo sapiens,9606.0,,,1,Expert,,6857,,D,2970,9,,,108,,,,BAO_0000019,CHEMBL620618,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line
B,,,,,1,Expert,,5635,,H,2971,8,,,108,,,,BAO_0000357,CHEMBL620619,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,2972,9,,,108,,,,BAO_0000357,CHEMBL620620,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16209,,H,2973,8,,,108,,,,BAO_0000357,CHEMBL620621,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,Membranes,5778,,D,2974,7,,,104698,,,,BAO_0000249,CHEMBL872920,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes
B,,,,,1,Autocuration,,5094,,H,2975,6,,,104698,,,,BAO_0000223,CHEMBL620622,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated
B,Rattus norvegicus,10116.0,,,1,Autocuration,,809,,D,2976,7,,,104698,,,,BAO_0000019,CHEMBL620623,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex
B,,,,,1,Autocuration,,1578,,H,2977,6,,,104698,,,,BAO_0000019,CHEMBL620624,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex
B,,,,,1,Autocuration,,809,,H,2978,6,,,104698,,,,BAO_0000019,CHEMBL620625,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested
B,,,,,1,Autocuration,,12469,,H,2979,6,,,104698,,,,BAO_0000219,CHEMBL620626,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630
B,,,,,1,Autocuration,,14290,,H,2980,6,,,104698,,,,BAO_0000019,CHEMBL621307,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex
B,,,,,1,Autocuration,,14290,,H,2981,6,,,104698,,,,BAO_0000019,CHEMBL621308,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.
B,,,,,1,Autocuration,,10609,,H,2982,6,,,104698,,,,BAO_0000223,CHEMBL621309,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT
B,,,,,1,Autocuration,,10609,,H,2983,6,,,104698,,,,BAO_0000223,CHEMBL621310,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630
B,,,,,1,Autocuration,,10609,,H,2984,6,,,104698,,,,BAO_0000223,CHEMBL621311,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin
B,,,,,1,Autocuration,,15253,,H,2985,6,,,104698,,,,BAO_0000249,CHEMBL621502,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
B,,,,,1,Autocuration,,15253,,H,2986,6,,,104698,,,,BAO_0000249,CHEMBL621503,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
B,,,,,1,Autocuration,Membranes,11683,,H,2987,6,,,104698,,,,BAO_0000249,CHEMBL621504,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.
B,,,,,1,Autocuration,,12092,,H,2988,6,,,104698,,,,BAO_0000223,CHEMBL621505,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1946,,H,2989,6,,,104698,,,,BAO_0000019,CHEMBL621506,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
B,,,,,1,Autocuration,,11623,,H,2990,6,,,104698,,,,BAO_0000223,CHEMBL619781,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.
B,,,,,1,Autocuration,,11623,,H,2991,6,,,104698,,,,BAO_0000223,CHEMBL619782,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. 
B,,,,,1,Autocuration,,14788,,H,2992,6,,,104698,,,,BAO_0000019,CHEMBL619783,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex
B,Rattus norvegicus,10116.0,,,1,Autocuration,,5432,,D,2993,7,,,104698,,,,BAO_0000019,CHEMBL619784,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor
B,,,,,1,Autocuration,,14826,,H,2994,6,,,104698,,,,BAO_0000249,CHEMBL619785,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane
B,,,,,1,Autocuration,,2222,,H,2995,6,,,104698,,,,BAO_0000223,CHEMBL619786,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,11963,,H,2996,6,,,104698,,,,BAO_0000019,CHEMBL619787,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex
B,,,,,1,Autocuration,,14145,,H,2997,6,,,104698,,,,BAO_0000019,CHEMBL872925,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex
B,,,,,1,Autocuration,,17819,,H,2998,6,,,104698,,,,BAO_0000019,CHEMBL619788,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.
B,,,,,1,Autocuration,,10394,,H,2999,6,,,104698,,,,BAO_0000249,CHEMBL619789,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
B,,,,,1,Autocuration,,10394,,H,3000,6,,,104698,,,,BAO_0000249,CHEMBL619790,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
B,,,,,1,Autocuration,,15034,,H,3001,6,,,104698,,,,BAO_0000019,CHEMBL619791,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
B,,,,,1,Autocuration,,691,,H,3002,6,,,104698,,,,BAO_0000019,CHEMBL619792,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
B,,,,,1,Autocuration,Membranes,12092,,H,3003,6,,,104698,,,,BAO_0000249,CHEMBL619793,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11752,,D,3004,7,,,104698,,,,BAO_0000223,CHEMBL619794,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,11752,,H,3005,6,,,104698,Brain,955.0,,BAO_0000221,CHEMBL619795,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices
B,,,,,1,Autocuration,,301,,H,3006,6,,,104698,,,,BAO_0000019,CHEMBL619796,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.
B,,,,,1,Autocuration,,16532,,H,3007,6,,,104698,,,,BAO_0000223,CHEMBL620448,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584
B,,,,,1,Autocuration,,16532,,H,3008,6,,,104698,,,,BAO_0000223,CHEMBL620449,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
B,,,,,1,Autocuration,,12092,,H,3009,6,,,104698,,,,BAO_0000223,CHEMBL620450,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.
B,,,,,1,Autocuration,,11684,,H,3010,6,,,104698,,,,BAO_0000223,CHEMBL620451,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630
B,,,,,1,Autocuration,,11684,,H,3011,6,,,104698,,,,BAO_0000223,CHEMBL620631,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.
B,,,,,1,Autocuration,,12953,,H,3012,6,,,104698,,,,BAO_0000019,CHEMBL620632,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand
B,,,,,1,Autocuration,,12953,,H,3013,6,,,104698,,,,BAO_0000019,CHEMBL620633,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active
B,,,,,1,Autocuration,,12953,,H,3014,6,,,104698,,,,BAO_0000223,CHEMBL620634,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM
B,,,,,1,Autocuration,,12861,,H,3015,6,,,104698,,,,BAO_0000019,CHEMBL620635,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
F,,,,,1,Autocuration,,11454,,H,3016,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620636,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3017,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620637,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3018,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620638,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3019,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620639,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3020,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620640,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3021,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620641,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3022,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620642,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3023,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620643,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3024,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620644,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3025,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620645,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3026,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620646,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3027,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620647,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3028,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620648,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3029,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620649,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3030,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620650,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3031,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620651,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3032,6,,,104698,,,In vivo,BAO_0000218,CHEMBL872875,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3033,6,,,104698,,,In vivo,BAO_0000218,CHEMBL620652,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats
F,,,,,1,Autocuration,,10609,,H,3034,6,,,104698,,,,BAO_0000019,CHEMBL620653,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart
B,,,,,1,Autocuration,,12861,,H,3035,6,,,104698,,,,BAO_0000019,CHEMBL857076,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12861,,D,3036,7,,,104698,,,,BAO_0000019,CHEMBL620654,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,12861,,H,3037,6,,,104698,,,,BAO_0000223,CHEMBL620655,,Binding activity radioligand.
B,,,,,1,Autocuration,Brain membranes,10728,,H,3038,6,,,104698,,,,BAO_0000249,CHEMBL620656,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes
B,,,,,1,Autocuration,Brain membranes,10728,,H,3039,6,,,104698,,,,BAO_0000249,CHEMBL620657,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.
B,,,,,1,Autocuration,,5163,,H,3040,8,,,108,,,,BAO_0000357,CHEMBL620658,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L
B,,,,,1,Autocuration,,5163,,H,3041,8,,,108,,,,BAO_0000357,CHEMBL620659,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L
B,,,,,1,Autocuration,,6011,,H,3042,8,,,108,,,,BAO_0000357,CHEMBL620660,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration
B,,,,,1,Autocuration,,5014,,H,3043,8,,,108,,,,BAO_0000357,CHEMBL620661,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,5635,,H,3044,8,,,108,,,,BAO_0000357,CHEMBL620662,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor
B,,,,,1,Expert,,5163,,H,3045,8,,,108,,,,BAO_0000357,CHEMBL620663,,Affinity for 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,6841,,H,3046,8,,,108,,,,BAO_0000357,CHEMBL620664,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
B,,,,,1,Expert,,6119,,H,3047,8,,,108,,,,BAO_0000357,CHEMBL620665,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.
B,,,,,1,Autocuration,,4373,,H,3048,8,,,108,,,,BAO_0000357,CHEMBL620666,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined
B,,,,,1,Autocuration,,1633,,H,3049,8,,,108,,,,BAO_0000357,CHEMBL620667,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin
B,,,,,1,Expert,,1633,,H,3050,8,,,108,,,,BAO_0000357,CHEMBL620668,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine
B,,,,,1,Autocuration,,4373,,H,3051,8,,,108,,,,BAO_0000357,CHEMBL620669,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined
B,,,,,1,Expert,,6576,,H,3052,8,,,108,,,,BAO_0000357,CHEMBL620670,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,4687,,H,3053,8,,,108,,,,BAO_0000357,CHEMBL620671,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,12146,,H,3054,8,,,108,,,,BAO_0000357,CHEMBL620672,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1
B,,,,,1,Autocuration,,12146,,H,3055,8,,,108,,,,BAO_0000357,CHEMBL620673,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2
B,,,,,1,Autocuration,,16946,,H,3056,8,,,108,,,,BAO_0000357,CHEMBL620674,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,14159,,H,3057,8,,,108,,,,BAO_0000357,CHEMBL620675,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,16700,,H,3058,8,,,108,,,,BAO_0000357,CHEMBL620676,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity
B,,,,,1,Autocuration,,3269,,H,3059,8,,,108,,,,BAO_0000357,CHEMBL621382,,Affinity against 5-hydroxytryptamine 2C receptor
B,Homo sapiens,9606.0,,,1,Expert,,1274,,D,3060,9,,,108,,,,BAO_0000357,CHEMBL621383,,Binding affinity against 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,1317,,H,3061,8,,,108,,,,BAO_0000357,CHEMBL621384,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay
B,Bos taurus,9913.0,,,1,Autocuration,,5834,,H,3062,8,,,144,,,,BAO_0000357,CHEMBL621385,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630
B,Bos taurus,9913.0,,,1,Autocuration,,11147,,H,3063,8,,,144,,,,BAO_0000357,CHEMBL617989,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand
F,Cavia porcellus,10141.0,,,1,Expert,,14145,,H,3064,4,,,104714,,,,BAO_0000019,CHEMBL617990,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay
B,Cavia porcellus,10141.0,,,1,Autocuration,,10561,,H,3065,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL875085,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Autocuration,,15847,,H,3066,4,,,104714,,,,BAO_0000019,CHEMBL617991,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig
F,Cavia porcellus,10141.0,,,1,Autocuration,,15847,,H,3067,4,,,104714,,,,BAO_0000019,CHEMBL617992,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done
B,Cavia porcellus,10141.0,,,1,Autocuration,,10561,,H,3068,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617993,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
B,Cavia porcellus,10141.0,,,1,Autocuration,,11454,,H,3069,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617994,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3070,4,,,104714,,,,BAO_0000019,CHEMBL617995,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3071,4,,,104714,,,,BAO_0000019,CHEMBL617996,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3072,4,,,104714,,,,BAO_0000019,CHEMBL617997,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3073,4,,,104714,,,,BAO_0000019,CHEMBL617998,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3074,4,,,104714,,,,BAO_0000019,CHEMBL617999,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3075,4,,,104714,,,,BAO_0000019,CHEMBL618000,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,15253,,H,3076,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617815,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum"
F,Cavia porcellus,10141.0,,,1,Autocuration,,15253,,H,3077,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617816,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum."
F,Cavia porcellus,10141.0,,,1,Autocuration,,11963,,H,3078,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617817,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum
B,Cavia porcellus,10141.0,,,1,Autocuration,,1946,,H,3079,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617818,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum
B,Cavia porcellus,10141.0,,,1,Autocuration,,1946,,H,3080,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617819,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested
B,Cavia porcellus,10141.0,,,1,Autocuration,,12045,,H,3081,4,,,104714,,,,BAO_0000223,CHEMBL617820,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15
B,Cavia porcellus,10141.0,,,1,Autocuration,,1559,,H,3082,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617821,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Autocuration,,273,,H,3083,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617822,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
F,Cavia porcellus,10141.0,,,1,Autocuration,,273,,H,3084,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617823,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI)
F,Cavia porcellus,10141.0,,,1,Autocuration,,188,,H,3085,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617824,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum
F,Cavia porcellus,10141.0,,,1,Autocuration,,12919,,H,3086,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617825,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay
F,Cavia porcellus,10141.0,,,1,Autocuration,,12918,,H,3087,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617826,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay
B,Cavia porcellus,10141.0,,,1,Autocuration,,1559,,H,3088,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617827,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Autocuration,,273,,H,3089,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617828,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
B,Cavia porcellus,10141.0,,,1,Autocuration,,1559,,H,3090,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617829,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
B,Cavia porcellus,10141.0,,,1,Autocuration,,1559,,H,3091,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617830,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined
B,Cavia porcellus,10141.0,,,1,Autocuration,,1559,,H,3092,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617831,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined
B,Cavia porcellus,10141.0,,,1,Autocuration,,14424,,H,3093,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617832,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.
B,Cavia porcellus,10141.0,,,1,Autocuration,,13181,,U,3094,0,,,22226,,,,BAO_0000019,CHEMBL617833,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
B,,,,,1,Autocuration,,5486,,H,3095,8,,,51,,,,BAO_0000357,CHEMBL617834,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,3096,5,,,104714,,,,BAO_0000223,CHEMBL617835,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor
B,,,,,1,Autocuration,,6013,,H,3097,4,,,104714,,,,BAO_0000223,CHEMBL617836,,Binding affinity towards 5-HT3 receptor
B,,,,,1,Autocuration,,12861,,H,3098,4,,,104714,,,,BAO_0000223,CHEMBL617837,,Binding activity radioligand.
B,,,,,1,Autocuration,,12861,,H,3099,4,,,104714,,,,BAO_0000019,CHEMBL620392,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.
B,,,,,1,Autocuration,,5104,,H,3100,4,,,104714,,,,BAO_0000223,CHEMBL620393,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,5105,,H,3101,4,,,104714,,,,BAO_0000223,CHEMBL620394,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,5104,,H,3102,4,,,104714,,,,BAO_0000223,CHEMBL620395,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested
B,,,,,1,Autocuration,,3935,,U,3103,0,,,22226,,,,BAO_0000019,CHEMBL620396,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor
B,,,,NG108-15,1,Expert,,13657,,H,3104,4,433.0,,105030,,,,BAO_0000219,CHEMBL620582,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells
B,,,,,1,Autocuration,,10369,,H,3105,4,,,105030,,,In vivo,BAO_0000218,CHEMBL620583,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)"
B,,,,,1,Autocuration,,10369,,H,3106,4,,,105030,,,,BAO_0000019,CHEMBL620584,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
B,,,,,1,Autocuration,,12918,,H,3107,4,,,105030,,,,BAO_0000224,CHEMBL620585,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype
B,,,,,1,Autocuration,,12918,,H,3108,4,,,105030,,,,BAO_0000224,CHEMBL620586,,Compound was evaluated for the binding affinity at 5- HT3 receptor
B,,,,,1,Autocuration,,10369,,H,3109,4,,,105030,,,,BAO_0000019,CHEMBL620587,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
B,,,,,1,Autocuration,,773,,H,3110,4,,,105030,,,,BAO_0000019,CHEMBL620588,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
F,,,,,1,Autocuration,,12918,,H,3111,4,,,105030,,,,BAO_0000218,CHEMBL620589,,5-hydroxytryptamine 3 receptor agonism in mouse
B,,,,,1,Autocuration,,10561,,H,3112,4,,,105030,,,,BAO_0000219,CHEMBL620590,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells
B,,,,,1,Autocuration,,12827,,H,3113,4,,,105030,,,,BAO_0000019,CHEMBL617956,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
B,,,,,1,Autocuration,,12827,,H,3114,4,,,105030,,,,BAO_0000019,CHEMBL617957,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
B,,,,,1,Autocuration,,12918,,H,3115,4,,,105030,,,,BAO_0000224,CHEMBL617958,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron
B,,,,,1,Autocuration,,273,,H,3116,4,,,105030,,,,BAO_0000219,CHEMBL617959,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
B,,,,,1,Autocuration,,273,,H,3117,4,,,105030,,,,BAO_0000219,CHEMBL617960,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
B,,,,,1,Autocuration,,10561,,H,3118,4,,,105030,,,,BAO_0000224,CHEMBL617961,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
B,,,,,1,Autocuration,,5033,,H,3119,4,,,105030,,,In vitro,BAO_0000219,CHEMBL617962,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells
B,,,,N1E-115,1,Autocuration,,16429,,H,3120,4,339.0,,105030,,,,BAO_0000219,CHEMBL617963,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand
B,,,,,1,Autocuration,,10322,,H,3121,8,,,11765,,,,BAO_0000019,CHEMBL617964,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
B,,,,,1,Autocuration,,14331,,H,3122,8,,,11765,,,,BAO_0000219,CHEMBL617965,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15
B,Mus musculus,10090.0,,,1,Autocuration,,13462,,D,3123,9,,,10630,,,,BAO_0000357,CHEMBL617966,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.
B,,,,,1,Autocuration,,12861,,H,3124,8,,,17106,,,,BAO_0000019,CHEMBL857074,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
B,Sus scrofa,9823.0,,,1,Autocuration,,15086,,H,3125,8,,,144,,,,BAO_0000357,CHEMBL617967,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,12861,,H,3126,8,,,144,,,,BAO_0000357,CHEMBL617968,,Binding activity radioligand.
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,10561,,H,3127,4,,,104714,,,,BAO_0000223,CHEMBL617969,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,10561,,H,3128,4,,,104714,,,,BAO_0000223,CHEMBL617970,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,10561,,H,3129,4,,,104714,,,,BAO_0000223,CHEMBL617971,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,10561,,H,3130,4,,,104714,,,,BAO_0000019,CHEMBL617972,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3131,4,,,104714,,,,BAO_0000019,CHEMBL617973,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3132,4,,,104714,,,,BAO_0000019,CHEMBL617974,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3133,4,,,104714,Ileum,2116.0,,BAO_0000221,CHEMBL617975,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3134,4,,,104714,,,,BAO_0000019,CHEMBL617976,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3135,4,,,104714,,,,BAO_0000019,CHEMBL617977,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3136,4,,,104714,,,,BAO_0000019,CHEMBL617978,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,273,,H,3137,4,,,104714,,,,BAO_0000019,CHEMBL617979,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
B,Oryctolagus cuniculus,9986.0,,CHO,1,Autocuration,,13047,,H,3138,4,449.0,,104714,,,,BAO_0000219,CHEMBL617980,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand
B,Rattus norvegicus,10116.0,,,1,Autocuration,,1650,,D,3139,7,,,104698,,,,BAO_0000019,CHEMBL617981,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,16288,,H,3140,8,,,12020,,,,BAO_0000019,CHEMBL617982,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01)
B,,,,,1,Autocuration,,16288,,H,3141,8,,,12020,,,,BAO_0000357,CHEMBL617983,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01)
B,Rattus norvegicus,10116.0,,,1,Autocuration,,10254,,D,3142,7,,,104698,,,,BAO_0000019,CHEMBL617984,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells
B,,,,,1,Autocuration,,14532,,H,3143,6,,,104698,,,,BAO_0000019,CHEMBL617985,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630"
F,,,,,1,Autocuration,,13392,,H,3144,6,,,104698,Heart,948.0,In vivo,BAO_0000218,CHEMBL617986,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
F,,,,,1,Autocuration,,13392,,H,3145,6,,,104698,Heart,948.0,,BAO_0000019,CHEMBL617987,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
F,,,,,1,Autocuration,,13392,,H,3146,6,,,104698,Heart,948.0,,BAO_0000019,CHEMBL617988,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
F,,,,,1,Autocuration,,13392,,H,3147,6,,,104698,Heart,948.0,,BAO_0000019,CHEMBL617792,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate"
F,,,,,1,Autocuration,,13392,,H,3148,6,,,104698,Heart,948.0,,BAO_0000019,CHEMBL617793,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
F,,,,,1,Autocuration,,13392,,H,3149,6,,,104698,,,,BAO_0000019,CHEMBL617794,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia"
F,,,,,1,Autocuration,,13392,,H,3150,6,,,104698,,,,BAO_0000019,CHEMBL617795,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
F,,,,,1,Autocuration,,13392,,H,3151,6,,,104698,,,,BAO_0000019,CHEMBL617796,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
F,,,,,1,Autocuration,,13392,,H,3152,6,,,104698,,,,BAO_0000019,CHEMBL617797,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia"
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1089,,D,3153,7,,,104698,,,In vivo,BAO_0000218,CHEMBL617798,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism)
F,,,,,1,Autocuration,,1089,,H,3154,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617799,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor)
F,Rattus norvegicus,10116.0,,,1,Autocuration,,11454,,D,3155,7,,,104698,,,In vivo,BAO_0000218,CHEMBL617800,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
F,Rattus norvegicus,10116.0,,,1,Autocuration,,11454,,D,3156,7,,,104698,,,,BAO_0000019,CHEMBL617801,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+
F,Rattus norvegicus,10116.0,,,1,Autocuration,,12205,,D,3157,7,,,104698,,,In vivo,BAO_0000218,CHEMBL617802,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1089,,D,3158,7,,,104698,,,,BAO_0000019,CHEMBL617803,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism)
B,,,,,1,Autocuration,,5094,,H,3159,6,,,104698,,,,BAO_0000019,CHEMBL617804,,Binding affinity towards 5-HT3 receptor in rat was evaluated
B,Rattus norvegicus,10116.0,,,1,Autocuration,,2622,,D,3160,7,,,104698,,,,BAO_0000019,CHEMBL617805,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,245,,H,3161,6,,,104698,,,,BAO_0000223,CHEMBL617806,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,14788,,H,3162,6,,,104698,,,,BAO_0000019,CHEMBL617807,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.
B,,,,,1,Autocuration,,14788,,H,3163,6,,,104698,,,,BAO_0000019,CHEMBL617808,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex
B,,,,,1,Autocuration,,3020,,H,3164,6,,,104698,,,,BAO_0000249,CHEMBL617809,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand
B,,,,,1,Autocuration,,1742,,H,3165,6,,,104698,,,,BAO_0000019,CHEMBL617810,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates
B,,,,,1,Autocuration,,17394,,H,3166,6,,,104698,Brain,955.0,,BAO_0000249,CHEMBL617811,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane
B,,,,,1,Autocuration,,17394,,H,3167,6,,,104698,Brain,955.0,,BAO_0000221,CHEMBL617812,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane
B,,,,,1,Autocuration,,17394,,H,3168,6,,,104698,,,,BAO_0000249,CHEMBL617813,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane
B,,,,,1,Autocuration,,14286,,H,3169,6,,,104698,,,,BAO_0000249,CHEMBL617814,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane
B,,,,,1,Autocuration,,14178,,H,3170,6,,,104698,,,,BAO_0000019,CHEMBL617698,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,14178,,D,3171,7,,,104698,,,,BAO_0000019,CHEMBL617699,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm
B,Rattus norvegicus,10116.0,,,1,Autocuration,,14178,,D,3172,7,,,104698,,,,BAO_0000019,CHEMBL617700,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM
B,Rattus norvegicus,10116.0,,,1,Autocuration,,14178,,D,3173,7,,,104698,,,,BAO_0000223,CHEMBL617701,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,15034,,H,3174,6,,,104698,,,,BAO_0000019,CHEMBL617702,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
B,,,,,1,Autocuration,Membranes,1089,,H,3175,6,,,104698,,,,BAO_0000249,CHEMBL617703,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50"
B,Rattus norvegicus,10116.0,,,1,Autocuration,,1089,,D,3176,7,,,104698,,,,BAO_0000019,CHEMBL617704,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor
B,,,,,1,Autocuration,,16532,,H,3177,6,,,104698,,,,BAO_0000223,CHEMBL617705,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12801,,D,3178,7,,,104698,,,,BAO_0000223,CHEMBL617706,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor
B,,,,NG108-15,1,Autocuration,,15194,,H,3179,6,433.0,,104698,,,,BAO_0000219,CHEMBL617707,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand)
B,,,,NG108-15,1,Autocuration,,15194,,H,3180,6,433.0,,104698,,,,BAO_0000219,CHEMBL617708,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand
B,,,,,1,Autocuration,,15194,,H,3181,6,,,104698,,,,BAO_0000019,CHEMBL617709,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand
B,,,,,1,Autocuration,,15194,,H,3182,6,,,104698,,,,BAO_0000019,CHEMBL617710,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active
B,,,,,1,Autocuration,,15194,,H,3183,6,,,104698,,,,BAO_0000019,CHEMBL882925,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active
B,,,,,1,Autocuration,,15194,,H,3184,6,,,104698,,,,BAO_0000019,CHEMBL617711,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active
F,,,,,1,Autocuration,,10610,,H,3185,6,,,104698,,,,BAO_0000019,CHEMBL617712,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats
F,Rattus norvegicus,10116.0,,,1,Autocuration,,10355,,D,3186,7,,,104698,,,,BAO_0000019,CHEMBL617713,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat
F,,,,,1,Autocuration,,691,,H,3187,6,,,104698,,,,BAO_0000019,CHEMBL617714,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously"
F,,,,,1,Autocuration,,10611,,H,3188,6,,,104698,,,,BAO_0000218,CHEMBL617715,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats
F,,,,,1,Autocuration,,12801,,H,3189,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617716,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats
F,,,,,1,Autocuration,,10609,,H,3190,6,,,104698,,,,BAO_0000218,CHEMBL617717,,Inhibition of 5-HT evoked reflex bradycardia in rat.
F,,,,,1,Autocuration,,11454,,H,3191,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617718,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3192,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617719,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3193,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617720,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)
F,Rattus norvegicus,10116.0,,,1,Autocuration,,11454,,D,3194,7,,,104698,,,In vivo,BAO_0000218,CHEMBL617721,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3195,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617722,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3196,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617723,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats
F,,,,,1,Autocuration,,11454,,H,3197,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617724,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3198,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617725,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3199,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617726,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3200,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617727,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3201,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617728,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3202,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617729,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3203,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617730,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3204,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617731,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3205,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617732,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3206,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617733,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3207,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617734,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3208,6,,,104698,,,In vivo,BAO_0000218,CHEMBL872874,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour
F,,,,,1,Autocuration,,11454,,H,3209,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617735,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour
F,,,,,1,Autocuration,,11454,,H,3210,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617736,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour
F,,,,,1,Autocuration,,11454,,H,3211,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617737,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour
F,,,,,1,Autocuration,,11454,,H,3212,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617738,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour
F,,,,,1,Autocuration,,11454,,H,3213,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617739,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3214,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617740,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3215,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617741,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3216,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617742,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3217,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617743,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3218,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617744,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,11454,,H,3219,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617745,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats
F,,,,,1,Autocuration,,670,,H,3220,6,,,104698,,,,BAO_0000218,CHEMBL617746,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)"
F,,,,,1,Autocuration,,670,,H,3221,6,,,104698,,,,BAO_0000218,CHEMBL617747,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested"
F,,,,,1,Autocuration,,10321,,H,3222,6,,,104698,,,In vivo,BAO_0000218,CHEMBL617748,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg
F,,,,,1,Autocuration,,10321,,H,3223,6,,,104698,,,In vivo,BAO_0000218,CHEMBL618909,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg
F,,,,,1,Autocuration,,10321,,H,3224,6,,,104698,,,In vivo,BAO_0000218,CHEMBL618910,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg
F,,,,,1,Autocuration,,10321,,H,3225,6,,,104698,,,In vivo,BAO_0000218,CHEMBL618911,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg
F,,,,,1,Autocuration,,10321,,H,3226,6,,,104698,,,In vivo,BAO_0000218,CHEMBL618912,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg
F,,,,,1,Autocuration,,10322,,H,3227,6,,,104698,,,In vivo,BAO_0000218,CHEMBL618913,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg)
F,,,,,1,Autocuration,,15412,,H,3228,6,,,104698,,,,BAO_0000019,CHEMBL618914,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
F,,,,,1,Autocuration,,15412,,H,3229,6,,,104698,,,,BAO_0000019,CHEMBL618915,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15412,,D,3230,7,,,104698,,,,BAO_0000223,CHEMBL618916,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor
F,,,,,1,Autocuration,,15412,,H,3231,6,,,104698,,,,BAO_0000019,CHEMBL618917,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist
B,,,,,1,Intermediate,,15412,,D,3232,7,,,104698,Hippocampus,10000000.0,,BAO_0000221,CHEMBL618918,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15412,,D,3233,7,,,104698,,,,BAO_0000019,CHEMBL618919,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane
B,Rattus norvegicus,10116.0,,,1,Autocuration,,17394,,D,3234,7,,,104698,,,,BAO_0000019,CHEMBL618920,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,12457,,H,3235,6,,,104698,,,,BAO_0000223,CHEMBL618921,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,12457,,H,3236,6,,,104698,,,,BAO_0000019,CHEMBL618922,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,12205,,H,3237,6,,,104698,,,,BAO_0000019,CHEMBL618923,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.
B,,,,,1,Autocuration,,14532,,H,3238,6,,,104698,,,,BAO_0000019,CHEMBL618924,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices
B,,,,,1,Autocuration,,1122,,H,3239,6,,,104698,,,,BAO_0000019,CHEMBL618925,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand
B,,,,,1,Autocuration,,5094,,H,3240,6,,,104698,,,,BAO_0000019,CHEMBL618926,,Binding affinity towards 5-HT3 receptor in rat was evaluated
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3241,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL618927,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3242,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL618928,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3243,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL618929,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3244,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL618930,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3245,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL618931,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3246,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619594,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3247,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619595,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation"
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3248,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619596,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3249,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619755,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3250,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619756,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3251,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619757,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3252,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619758,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3253,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619759,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3254,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619760,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3255,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619761,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3256,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619762,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3257,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619763,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3258,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL617868,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
B,Cavia porcellus,10141.0,,,1,Intermediate,,15034,,D,3259,9,,,20033,,,,BAO_0000357,CHEMBL617869,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum
B,Cavia porcellus,10141.0,,,1,Intermediate,,5094,,D,3260,9,,,20033,Striatum,2435.0,,BAO_0000249,CHEMBL882926,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
B,Cavia porcellus,10141.0,,,1,Intermediate,,5094,,D,3261,9,,,20033,Striatum,2435.0,,BAO_0000249,CHEMBL617870,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
B,Cavia porcellus,10141.0,,,1,Intermediate,,5399,,D,3262,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL617871,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand
B,Cavia porcellus,10141.0,,,1,Intermediate,,17394,,D,3263,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL617872,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum
B,Cavia porcellus,10141.0,,,1,Intermediate,,17394,,D,3264,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL617873,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum
B,Cavia porcellus,10141.0,,,1,Intermediate,,17394,,D,3265,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL617874,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3266,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619067,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3267,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619068,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3268,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619069,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
B,Cavia porcellus,10141.0,,,1,Intermediate,,16946,,D,3269,9,,,20033,,,,BAO_0000357,CHEMBL619070,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig
B,Cavia porcellus,10141.0,,,1,Intermediate,,16946,,D,3270,9,,,20033,,,,BAO_0000357,CHEMBL619071,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig
F,Cavia porcellus,10141.0,,,1,Intermediate,,15034,,D,3271,9,,,20033,,,,BAO_0000019,CHEMBL619072,,Agonistic activity against 5-hydroxytryptamine 4 receptor
F,Cavia porcellus,10141.0,,,1,Intermediate,,15034,,D,3272,9,,,20033,,,,BAO_0000019,CHEMBL619073,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested
F,Cavia porcellus,10141.0,,,1,Intermediate,,12918,,D,3273,9,,,20033,,,,BAO_0000019,CHEMBL619074,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,16946,,D,3274,9,,,20033,,,,BAO_0000357,CHEMBL619075,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,17394,,D,3275,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL619076,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,15034,,D,3276,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL619077,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand
B,Cavia porcellus,10141.0,,,1,Intermediate,,5094,,D,3277,9,,,20033,Striatum,2435.0,,BAO_0000249,CHEMBL619078,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
B,Cavia porcellus,10141.0,,,1,Intermediate,,5094,,D,3278,9,,,20033,Striatum,2435.0,,BAO_0000249,CHEMBL619079,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
B,Cavia porcellus,10141.0,,,1,Intermediate,,17358,,D,3279,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619080,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.
B,Cavia porcellus,10141.0,,,1,Expert,,12953,,D,3280,9,,,20033,,,,BAO_0000357,CHEMBL619081,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum
B,Cavia porcellus,10141.0,,,1,Intermediate,,12953,,D,3281,9,,,20033,,,,BAO_0000357,CHEMBL619082,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
B,Cavia porcellus,10141.0,,,1,Intermediate,,12953,,D,3282,9,,,20033,,,,BAO_0000357,CHEMBL619083,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.
B,Cavia porcellus,10141.0,,,1,Intermediate,,12953,,D,3283,9,,,20033,,,,BAO_0000357,CHEMBL619084,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,3284,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL859397,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
F,Cavia porcellus,10141.0,,,1,Intermediate,,12918,,D,3285,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619085,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay
F,Cavia porcellus,10141.0,,,1,Intermediate,,12919,,D,3286,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619086,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,3287,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619087,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).
F,Cavia porcellus,10141.0,,,1,Intermediate,,273,,D,3288,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619088,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
B,Cavia porcellus,10141.0,,,1,Intermediate,,13181,,D,3289,9,,,20033,,,,BAO_0000357,CHEMBL619089,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP
B,Cavia porcellus,10141.0,,,1,Autocuration,,13181,,H,3290,8,,,168,,,,BAO_0000357,CHEMBL619090,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor
F,Cavia porcellus,10141.0,,,1,Intermediate,,15034,,D,3291,9,,,20033,,,,BAO_0000019,CHEMBL619091,,Antagonistic activity against 5-hydroxytryptamine 4 receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,5033,,D,3292,9,,,20033,,,,BAO_0000357,CHEMBL619092,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor
B,Cavia porcellus,10141.0,,,1,Intermediate,,1980,,D,3293,9,,,20033,,,,BAO_0000019,CHEMBL619093,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.
B,Cavia porcellus,10141.0,,HEK293,1,Autocuration,,13181,,H,3294,8,722.0,,168,,,,BAO_0000219,CHEMBL619094,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine
B,Cavia porcellus,10141.0,,,1,Intermediate,,14287,,D,3295,9,,,20033,,,,BAO_0000019,CHEMBL619095,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane
B,Cavia porcellus,10141.0,,,1,Intermediate,,1317,,D,3296,9,,,20033,,,,BAO_0000357,CHEMBL857988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand
B,Cavia porcellus,10141.0,,,1,Intermediate,,15316,,D,3297,9,,,20033,,,,BAO_0000357,CHEMBL619096,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.
B,Cavia porcellus,10141.0,,,1,Intermediate,,16429,,D,3298,9,,,20033,Striatum,2435.0,,BAO_0000357,CHEMBL619097,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand
B,Cavia porcellus,10141.0,,,1,Intermediate,,14818,,D,3299,9,,,20033,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619098,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.
B,Cavia porcellus,10141.0,,,1,Intermediate,,15194,,D,3300,9,,,20033,,,,BAO_0000357,CHEMBL619751,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand
B,Cavia porcellus,10141.0,,,1,Intermediate,,15194,,D,3301,9,,,20033,,,,BAO_0000357,CHEMBL619752,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.
F,Cavia porcellus,10141.0,,,1,Intermediate,,13961,,D,3302,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL875096,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
B,,,,,1,Autocuration,,5486,,H,3303,8,,,108,,,,BAO_0000357,CHEMBL619004,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell
B,,,,,1,Autocuration,,16209,,H,3304,8,,,168,,,,BAO_0000357,CHEMBL619005,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,17085,,H,3305,8,,,168,,,,BAO_0000019,CHEMBL619006,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor
B,,,,HeLa,1,Autocuration,,4199,,H,3306,8,308.0,,168,,,,BAO_0000219,CHEMBL619007,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand
B,,,,,1,Autocuration,,15146,,H,3307,8,,,168,,,,BAO_0000357,CHEMBL619008,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,5213,,H,3308,8,,,168,,,,BAO_0000357,CHEMBL619009,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor
B,,,,HeLa,1,Autocuration,,4829,,H,3309,8,308.0,,168,,,,BAO_0000219,CHEMBL619010,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand"
B,,,,,1,Autocuration,,17358,,H,3310,8,,,10622,,,,BAO_0000357,CHEMBL619011,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons
B,,,,,1,Autocuration,,17358,,H,3311,8,,,10622,,,,BAO_0000357,CHEMBL619012,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive
B,,,,,1,Autocuration,,16946,,H,3312,8,,,10622,,,,BAO_0000219,CHEMBL619013,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells
B,,,,,1,Autocuration,,17358,,H,3313,8,,,10622,,,,BAO_0000357,CHEMBL619014,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons
F,,,,,1,Autocuration,,268,,H,3314,8,,,11249,Cardiac atrium,2081.0,,BAO_0000019,CHEMBL857503,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model
F,,,,,1,Autocuration,,268,,H,3315,8,,,11249,Cardiac atrium,2081.0,,BAO_0000019,CHEMBL619015,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM
B,,,,,1,Autocuration,,15086,,H,3316,8,,,11249,,,,BAO_0000357,CHEMBL619016,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,14875,,H,3317,8,,,11249,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619017,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor
B,Sus scrofa,9823.0,,,1,Autocuration,,13267,,H,3318,8,,,168,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619018,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,13047,,H,3319,8,,,168,,,,BAO_0000019,CHEMBL619019,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.
B,Rattus norvegicus,10116.0,,,1,Expert,,1650,,D,3320,9,,,10623,,,,BAO_0000357,CHEMBL619020,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor
F,,,,,1,Autocuration,,567,,H,3321,8,,,10623,,,,BAO_0000019,CHEMBL619021,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
B,,,,,1,Autocuration,,17358,,H,3322,8,,,10623,,,,BAO_0000357,CHEMBL619022,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus
B,,,,,1,Autocuration,,188,,H,3323,8,,,10623,,,,BAO_0000357,CHEMBL619023,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity
F,,,,,1,Autocuration,,670,,H,3324,8,,,10623,,,,BAO_0000019,CHEMBL619024,,lntrinsic activity relative to 5-HT receptor
F,,,,,1,Autocuration,,204,,H,3325,8,,,10623,,,,BAO_0000019,CHEMBL619025,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay
F,,,,,1,Expert,,1946,,H,3326,8,,,10623,,,,BAO_0000019,CHEMBL619026,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.
F,,,,,1,Autocuration,,6398,,H,3327,8,,,10623,,,,BAO_0000019,CHEMBL619027,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay
F,,,,,1,Autocuration,,6398,,H,3328,8,,,10623,,,,BAO_0000019,CHEMBL619028,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive
F,,,,,1,Autocuration,,17358,,H,3329,8,,,10623,,,,BAO_0000019,CHEMBL619029,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae
F,,,,,1,Autocuration,,6398,,H,3330,8,,,10623,,,,BAO_0000019,CHEMBL619030,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture
B,,,,,1,Expert,,11752,,H,3331,8,,,10623,,,,BAO_0000357,CHEMBL619031,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae
F,,,,,1,Autocuration,,809,,H,3332,8,,,10623,,,,BAO_0000019,CHEMBL619032,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae
B,Rattus norvegicus,10116.0,,,1,Expert,,14178,,D,3333,9,,,10623,,,,BAO_0000357,CHEMBL619033,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,567,,H,3334,8,,,10623,,,,BAO_0000357,CHEMBL619034,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
B,,,,,1,Autocuration,,1946,,H,3335,8,,,10623,,,,BAO_0000357,CHEMBL619035,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.
B,,,,,1,Autocuration,,1946,,H,3336,8,,,10623,,,,BAO_0000357,CHEMBL619036,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration
B,Rattus norvegicus,10116.0,,,1,Expert,,13961,,D,3337,9,,,10623,,,,BAO_0000019,CHEMBL619037,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum
B,,,,,1,Autocuration,,6238,,H,3338,8,,,10623,Striatum,2435.0,,BAO_0000249,CHEMBL619038,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand
B,,,,,1,Autocuration,,14290,,H,3339,8,,,10623,,,,BAO_0000249,CHEMBL619039,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested
B,,,,,1,Expert,,14290,,H,3340,8,,,10623,,,,BAO_0000249,CHEMBL619040,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand
B,Rattus norvegicus,10116.0,,,1,Expert,,809,,D,3341,9,,,10623,Striatum,2435.0,,BAO_0000019,CHEMBL619041,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
B,,,,,1,Autocuration,,1578,,H,3342,8,,,10623,Striatum,2435.0,,BAO_0000019,CHEMBL619042,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
B,,,,,1,Expert,,16709,,H,3343,8,,,10623,Striatum,2435.0,,BAO_0000249,CHEMBL619043,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane
B,,,,,1,Expert,,1946,,H,3344,8,,,10623,Striatum,2435.0,,BAO_0000019,CHEMBL619044,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.
B,,,,,1,Expert,,15253,,H,3345,8,,,10623,Striatum,2435.0,,BAO_0000249,CHEMBL619045,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.
B,,,,,1,Expert,,4535,,H,3346,8,,,10623,Striatum,2435.0,,BAO_0000249,CHEMBL619046,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane
B,,,,,1,Expert,,13961,,H,3347,8,,,10623,,,,BAO_0000249,CHEMBL619047,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.
F,,,,,1,Autocuration,,17358,,H,3348,8,,,10623,Brain,955.0,,BAO_0000221,CHEMBL619048,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain
F,,,,,1,Autocuration,,15847,,H,3349,8,,,10623,,,,BAO_0000019,CHEMBL859398,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat
F,,,,,1,Autocuration,,15847,,H,3350,8,,,10623,,,,BAO_0000019,CHEMBL619049,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done
F,,,,,1,Autocuration,,670,,H,3351,8,,,10623,,,,BAO_0000019,CHEMBL857886,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae
F,,,,,1,Autocuration,,670,,H,3352,8,,,10623,,,,BAO_0000019,CHEMBL619050,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested
F,,,,,1,Autocuration,,1317,,H,3353,8,,,10623,,,,BAO_0000019,CHEMBL620591,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
B,Rattus norvegicus,10116.0,,,1,Expert,,12936,,D,3354,9,,,10623,,,,BAO_0000357,CHEMBL620592,,Binding affinity against rat 5-hydroxytryptamine 4 receptor
B,,,,,1,Expert,,4535,,H,3355,8,,,10623,Striatum,2435.0,,BAO_0000249,CHEMBL620593,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane
F,Rattus norvegicus,10116.0,,,1,Expert,,14424,,D,3356,9,,,10623,,,,BAO_0000019,CHEMBL620594,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.
F,,,,,1,Expert,,14424,,H,3357,8,,,10623,,,,BAO_0000019,CHEMBL875079,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.
F,,,,,1,Expert,,14424,,H,3358,8,,,10623,,,,BAO_0000019,CHEMBL620595,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
F,Rattus norvegicus,10116.0,,,1,Expert,,14424,,D,3359,9,,,10623,,,,BAO_0000019,CHEMBL620596,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.
F,,,,,1,Autocuration,,14424,,H,3360,8,,,10623,,,,BAO_0000019,CHEMBL620597,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.
F,,,,,1,Expert,,14424,,H,3361,8,,,10623,,,,BAO_0000019,CHEMBL620598,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.
F,,,,,1,Expert,,14424,,H,3362,8,,,10623,,,,BAO_0000218,CHEMBL620599,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.)
F,,,,,1,Autocuration,,14424,,H,3363,8,,,10623,,,,BAO_0000019,CHEMBL620600,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1980,,H,3364,8,,,168,,,,BAO_0000019,CHEMBL620601,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae
F,,,,,1,Autocuration,,4639,,H,3365,8,,,168,,,,BAO_0000019,CHEMBL620602,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM
B,,,,,1,Autocuration,,17358,,H,3366,8,,,168,,,,BAO_0000357,CHEMBL620603,,Tested for affinity towards 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,17358,,H,3367,8,,,168,,,,BAO_0000357,CHEMBL620604,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.
B,,,,,1,Autocuration,,17358,,H,3368,8,,,168,,,,BAO_0000357,CHEMBL620605,,Compound was tested for 5-hydroxytryptamine 4 binding affinity
B,,,,,1,Autocuration,,1558,,H,3369,8,,,168,,,,BAO_0000357,CHEMBL620606,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor
F,,,,,1,Autocuration,,17358,,H,3370,8,,,168,,,,BAO_0000019,CHEMBL620607,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
B,,,,,1,Autocuration,,16117,,H,3371,8,,,168,,,,BAO_0000357,CHEMBL620608,,In vitro binding affinity towards 5-HT4 receptor was determined
F,,,,,1,Autocuration,,17358,,H,3372,8,,,168,,,,BAO_0000019,CHEMBL620609,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
F,,,,,1,Autocuration,,17358,,H,3373,8,,,168,,,,BAO_0000019,CHEMBL620610,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,17358,,H,3374,8,,,168,,,,BAO_0000357,CHEMBL620611,,Tested for selectivity for 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,17358,,H,3375,8,,,168,,,,BAO_0000357,CHEMBL620612,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride
B,,,,,1,Autocuration,,17358,,H,3376,8,,,168,,,,BAO_0000357,CHEMBL620613,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride
B,,,,,1,Autocuration,,17358,,H,3377,8,,,168,,,,BAO_0000357,CHEMBL620614,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride
B,,,,,1,Expert,,1274,,H,3378,8,,,168,,,,BAO_0000357,CHEMBL620615,,Binding affinity against 5-Hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,Brain membranes,10728,,H,3379,6,,,104698,,,,BAO_0000249,CHEMBL857075,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes
B,,,,,1,Autocuration,Brain membranes,11695,,H,3380,6,,,104698,,,,BAO_0000249,CHEMBL620616,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes
B,,,,,1,Autocuration,Brain membranes,11695,,H,3381,6,,,104698,,,,BAO_0000249,CHEMBL619411,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes
B,,,,,1,Autocuration,,12490,,H,3382,6,,,104698,,,,BAO_0000019,CHEMBL619412,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11828,,D,3383,7,,,104698,,,,BAO_0000019,CHEMBL619413,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,12253,,H,3384,6,,,104698,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619414,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex
B,,,,,1,Autocuration,,10561,,H,3385,6,,,104698,,,,BAO_0000019,CHEMBL619415,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
B,,,,,1,Autocuration,,10561,,H,3386,6,,,104698,,,,BAO_0000019,CHEMBL619416,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex
F,,,,,1,Autocuration,,14432,,H,3387,6,,,104698,,,,BAO_0000019,CHEMBL619417,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12936,,D,3388,7,,,104698,,,,BAO_0000223,CHEMBL619418,,Binding affinity against rat 5-hydroxytryptamine 3 receptor
B,Rattus norvegicus,10116.0,,,1,Autocuration,,1274,,D,3389,7,,,104698,,,,BAO_0000223,CHEMBL619419,,Binding affinity against 5-Hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1980,,H,3390,6,,,104698,,,,BAO_0000019,CHEMBL619420,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex
B,,,,,1,Autocuration,,670,,H,3391,6,,,104698,,,,BAO_0000249,CHEMBL619421,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,968,,D,3392,7,,,104698,,,,BAO_0000019,CHEMBL619422,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex
B,,,,,1,Autocuration,,14287,,H,3393,6,,,104698,,,,BAO_0000019,CHEMBL619423,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex
B,,,,,1,Autocuration,,567,,H,3394,6,,,104698,,,,BAO_0000019,CHEMBL875080,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex
B,,,,,1,Autocuration,,13267,,H,3395,6,,,104698,,,,BAO_0000019,CHEMBL619424,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand
B,,,,,1,Autocuration,,14826,,H,3396,6,,,104698,,,,BAO_0000249,CHEMBL619425,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.
B,,,,,1,Autocuration,,15194,,H,3397,6,,,104698,,,,BAO_0000223,CHEMBL619426,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand
B,,,,,1,Autocuration,,15194,,H,3398,6,,,104698,,,,BAO_0000223,CHEMBL619427,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,10394,,D,3399,7,,,104698,,,,BAO_0000223,CHEMBL619645,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor
B,,,,,1,Expert,,13657,,D,3400,9,,,10576,,,,BAO_0000249,CHEMBL619646,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding"
F,,,,,1,Autocuration,,1879,,H,3401,8,,,12020,Brain,955.0,,BAO_0000221,CHEMBL619647,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.
F,,,,,1,Autocuration,,1879,,H,3402,8,,,12020,,,,BAO_0000019,CHEMBL619648,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor
F,,,,,1,Autocuration,,1879,,H,3403,8,,,12020,,,,BAO_0000019,CHEMBL619165,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.
F,,,,,1,Autocuration,,204,,H,3404,8,,,12020,,,In vivo,BAO_0000218,CHEMBL620719,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1879,,H,3405,8,,,12020,,,,BAO_0000019,CHEMBL872924,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
B,,,,,1,Autocuration,,1879,,H,3406,8,,,12020,,,,BAO_0000357,CHEMBL620720,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1879,,H,3407,8,,,12020,,,,BAO_0000019,CHEMBL620721,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
B,,,,,1,Autocuration,,1879,,H,3408,8,,,12020,,,,BAO_0000019,CHEMBL620722,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.
B,,,,,1,Autocuration,,10641,,H,3409,6,,,104698,,,,BAO_0000019,CHEMBL620723,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex"
B,,,,,1,Autocuration,,773,,H,3410,8,,,12020,,,,BAO_0000019,CHEMBL620724,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
B,,,,,1,Autocuration,,11952,,H,3411,6,,,104698,,,,BAO_0000249,CHEMBL620725,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine
F,Rattus norvegicus,10116.0,,,1,Autocuration,,14145,,D,3412,9,,,12020,,,,BAO_0000019,CHEMBL620726,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.
B,,,,,1,Expert,,17066,,H,3413,8,,,144,,,,BAO_0000357,CHEMBL620727,,Binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,6398,,H,3414,4,,,104714,,,,BAO_0000223,CHEMBL620728,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding
B,,,,,1,Autocuration,,10321,,U,3415,0,,,22226,,,,BAO_0000019,CHEMBL620729,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
F,,,,,1,Autocuration,,511,,H,3416,4,,,104714,,,,BAO_0000019,CHEMBL858288,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex
B,,,,,1,Autocuration,,4639,,H,3417,4,,,104714,,,,BAO_0000223,CHEMBL620730,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,4639,,H,3418,4,,,104714,,,,BAO_0000223,CHEMBL620731,,Binding affinity towards 5-hydroxytryptamine 3 receptor
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3419,4,,,104714,,,,BAO_0000019,CHEMBL620732,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3420,4,,,104714,,,,BAO_0000019,CHEMBL618042,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3421,4,,,104714,,,,BAO_0000019,CHEMBL618043,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM
B,,,,,1,Autocuration,,1558,,H,3422,4,,,104714,,,,BAO_0000223,CHEMBL618044,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
F,,,,,1,Autocuration,,268,,H,3423,4,,,104714,,,,BAO_0000019,CHEMBL618045,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection
B,,,,,1,Autocuration,,2474,,H,3424,4,,,104714,,,,BAO_0000223,CHEMBL618046,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand
F,,,,,1,Autocuration,,5067,,H,3425,4,,,104714,,,,BAO_0000019,CHEMBL618047,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist
F,,,,,1,Autocuration,,5067,,H,3426,4,,,104714,,,,BAO_0000019,CHEMBL875084,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist
F,,,,,1,Autocuration,,5067,,H,3427,4,,,104714,,,,BAO_0000019,CHEMBL618048,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist
B,,,,,1,Autocuration,,5067,,H,3428,4,,,104714,,,,BAO_0000223,CHEMBL618049,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available
F,,,,,1,Autocuration,,5067,,H,3429,4,,,104714,,,,BAO_0000019,CHEMBL619764,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist
F,,,,,1,Autocuration,,5067,,H,3430,4,,,104714,,,,BAO_0000019,CHEMBL619765,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist
F,,,,,1,Autocuration,,5067,,H,3431,4,,,104714,,,,BAO_0000019,CHEMBL619766,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist
B,,,,,1,Autocuration,,5067,,H,3432,4,,,104714,,,,BAO_0000223,CHEMBL619767,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active
B,,,,,1,Autocuration,,5067,,H,3433,4,,,104714,,,,BAO_0000223,CHEMBL619768,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available
F,,,,,1,Autocuration,,5067,,H,3434,4,,,104714,,,,BAO_0000019,CHEMBL619769,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist
B,,,,,1,Autocuration,,5067,,H,3435,4,,,104714,,,,BAO_0000223,CHEMBL619770,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available
B,,,,,1,Autocuration,,5067,,H,3436,4,,,104714,,,,BAO_0000223,CHEMBL619771,,Binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,14331,,H,3437,4,,,104714,,,,BAO_0000219,CHEMBL619772,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined
B,,,,,1,Autocuration,,5067,,H,3438,4,,,104714,,,,BAO_0000223,CHEMBL619773,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active
B,,,,NG108-15,1,Autocuration,,6179,,H,3439,4,433.0,,104714,,,,BAO_0000219,CHEMBL619774,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630
B,,,,,1,Autocuration,,4265,,H,3440,4,,,104714,,,,BAO_0000019,CHEMBL875083,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.
B,,,,NG108-15,1,Autocuration,,4265,,H,3441,4,433.0,,104714,,,,BAO_0000219,CHEMBL620718,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand
B,,,,,1,Autocuration,,17358,,H,3442,4,,,104714,,,,BAO_0000223,CHEMBL618127,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
B,,,,,1,Autocuration,,17358,,H,3443,4,,,104714,,,,BAO_0000223,CHEMBL618128,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity
B,,,,,1,Autocuration,,13628,,H,3444,4,,,104714,,,In vitro,BAO_0000219,CHEMBL618129,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells
B,,,,,1,Autocuration,,4612,,H,3445,4,,,104714,,,,BAO_0000223,CHEMBL618130,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined
F,,,,,1,Autocuration,,17358,,H,3446,4,,,104714,,,,BAO_0000019,CHEMBL618131,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3447,4,,,104714,,,,BAO_0000019,CHEMBL618132,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3448,4,,,104714,,,,BAO_0000019,CHEMBL618133,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3449,4,,,104714,,,,BAO_0000019,CHEMBL618134,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3450,4,,,104714,,,,BAO_0000019,CHEMBL618135,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
B,,,,,1,Autocuration,,511,,H,3451,4,,,104714,,,,BAO_0000223,CHEMBL618136,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.
B,,,,,1,Autocuration,,1479,,H,3452,4,,,104714,,,,BAO_0000223,CHEMBL618137,,Binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1317,,H,3453,4,,,104714,,,,BAO_0000223,CHEMBL618138,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay
B,,,,,1,Autocuration,,12146,,H,3454,4,,,104714,,,,BAO_0000223,CHEMBL618139,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1
B,,,,,1,Autocuration,,12146,,H,3455,4,,,104714,,,,BAO_0000223,CHEMBL618140,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2
B,,,,,1,Autocuration,,13969,,H,3456,4,,,104714,,,,BAO_0000223,CHEMBL618141,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand
B,,,,,1,Expert,,13392,,H,3457,8,,,108,,,,BAO_0000357,CHEMBL873478,,Binding affinity for 5-hydroxytryptamine 2C receptor
B,,,,,1,Autocuration,,13392,,H,3458,6,,,104698,,,,BAO_0000223,CHEMBL618142,,Binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,14159,,H,3459,8,,,144,,,,BAO_0000357,CHEMBL618143,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,1558,,H,3460,8,,,144,,,,BAO_0000357,CHEMBL618144,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,16655,,H,3461,8,,,144,,,,BAO_0000357,CHEMBL618145,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,13020,,H,3462,4,,,104714,,,,BAO_0000223,CHEMBL618146,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
B,,,,,1,Autocuration,,13021,,H,3463,4,,,104714,,,,BAO_0000223,CHEMBL618147,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system
B,,,,,1,Autocuration,,13020,,H,3464,4,,,104714,,,,BAO_0000223,CHEMBL618148,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
B,,,,,1,Autocuration,,10321,,H,3465,8,,,144,,,,BAO_0000019,CHEMBL618149,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
B,,,,,1,Autocuration,,15818,,H,3466,8,,,144,,,,BAO_0000357,CHEMBL872927,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,15818,,H,3467,8,,,144,,,,BAO_0000357,CHEMBL618150,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,17358,,H,3468,8,,,144,,,,BAO_0000357,CHEMBL618151,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
B,,,,,1,Autocuration,,2222,,H,3469,8,,,144,,,,BAO_0000357,CHEMBL875094,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,10322,,H,3470,8,,,144,,,,BAO_0000019,CHEMBL618152,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
B,,,,,1,Autocuration,,16117,,H,3471,8,,,144,,,,BAO_0000357,CHEMBL618153,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined
B,,,,,1,Autocuration,,17200,,H,3472,8,,,144,,,,BAO_0000357,CHEMBL618888,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand
F,,,,,1,Autocuration,,17358,,H,3473,8,,,144,,,,BAO_0000019,CHEMBL618889,,Tested for 5-hydroxytryptamine 3 receptor agonist activity
B,,,,,1,Autocuration,,16700,,H,3474,8,,,144,,,,BAO_0000357,CHEMBL618890,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity
B,,,,,1,Autocuration,,1980,,H,3475,8,,,144,,,,BAO_0000019,CHEMBL618891,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes
B,,,,,1,Autocuration,,1980,,H,3476,8,,,144,,,,BAO_0000019,CHEMBL619054,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes
B,,,,,1,Autocuration,,12409,,H,3477,4,,,104714,,,,BAO_0000223,CHEMBL619055,,Binding affinity against the 5-hydroxytryptamine 3 receptor
B,,,,,1,Autocuration,,4365,,H,3478,8,,,144,,,,BAO_0000357,CHEMBL619056,,Binding affinity against human 5-hydroxytryptamine 3A receptor
F,,,,,1,Autocuration,,4365,,H,3479,8,,,144,,,,BAO_0000019,CHEMBL619057,,Percent efficacy against 5-hydroxytryptamine 3A receptor
B,,,,,1,Autocuration,,4365,,H,3480,8,,,144,,,,BAO_0000357,CHEMBL619058,,Binding affinity against human 5-hydroxytryptamine 3A receptor
F,Rattus norvegicus,10116.0,,Oocytes,1,Expert,,6769,,D,3481,9,,,12020,,,,BAO_0000219,CHEMBL619059,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes
F,Rattus norvegicus,10116.0,,Oocytes,1,Expert,,6769,,D,3482,9,,,12020,,,,BAO_0000219,CHEMBL619060,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes
F,Rattus norvegicus,10116.0,,Oocytes,1,Expert,,6769,,D,3483,9,,,12020,,,,BAO_0000219,CHEMBL875095,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3484,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619061,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Intermediate,,809,,D,3485,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619062,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum
F,Cavia porcellus,10141.0,,,1,Intermediate,,14290,,D,3486,9,,,20033,,,,BAO_0000019,CHEMBL619063,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response
B,Cavia porcellus,10141.0,,,1,Intermediate,,17358,,D,3487,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619064,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum
B,Cavia porcellus,10141.0,,,1,Intermediate,,17358,,D,3488,9,,,20033,,,,BAO_0000357,CHEMBL619065,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation
B,Cavia porcellus,10141.0,,,1,Intermediate,,17358,,D,3489,9,,,20033,Ileum,2116.0,,BAO_0000221,CHEMBL619066,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation
B,,,,,1,Autocuration,,17386,,H,3490,8,,,10209,Ileum,2116.0,,BAO_0000221,CHEMBL619775,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
B,,,,,1,Autocuration,,3269,,H,3491,8,,,10209,,,,BAO_0000357,CHEMBL619776,,Affinity against 5-hydroxytryptamine 7 receptor
B,Cavia porcellus,10141.0,,,1,Autocuration,,7721,,H,3492,4,,,104841,,,,BAO_0000224,CHEMBL619777,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
B,Cavia porcellus,10141.0,,,1,Autocuration,,7721,,H,3493,4,,,104841,,,,BAO_0000224,CHEMBL619778,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
B,Cavia porcellus,10141.0,,,1,Autocuration,,9117,,H,3494,4,,,104841,Ileum,2116.0,,BAO_0000221,CHEMBL619779,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect
B,Cavia porcellus,10141.0,,,1,Autocuration,,7721,,H,3495,4,,,104841,,,,BAO_0000224,CHEMBL619780,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd."
B,Cavia porcellus,10141.0,,,1,Autocuration,,7721,,H,3496,4,,,104841,,,,BAO_0000224,CHEMBL619166,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd."
F,Cavia porcellus,10141.0,,,1,Autocuration,,15796,,H,3497,4,,,104841,,,,BAO_0000019,CHEMBL619167,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
F,Cavia porcellus,10141.0,,,1,Autocuration,,15796,,H,3498,4,,,104841,,,,BAO_0000019,CHEMBL619168,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
B,Homo sapiens,9606.0,,,1,Expert,,15650,,D,3499,9,,,168,Cardiac atrium,2081.0,,BAO_0000219,CHEMBL619169,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes
B,Homo sapiens,9606.0,,,1,Expert,,15650,,D,3500,9,,,168,Cardiac atrium,2081.0,,BAO_0000219,CHEMBL619170,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes
F,Homo sapiens,9606.0,,,1,Autocuration,,6866,,D,3501,5,,,104841,,,,BAO_0000019,CHEMBL619171,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine"
F,Homo sapiens,9606.0,,,1,Expert,,15650,,D,3502,9,,,168,Cardiac atrium,2081.0,,BAO_0000219,CHEMBL619172,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes"
B,Mus musculus,10090.0,,,1,Autocuration,,10063,,U,3503,0,,,22226,,,,BAO_0000019,CHEMBL619173,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice
B,Mus musculus,10090.0,,,1,Autocuration,,12665,,U,3504,0,,,22226,,,,BAO_0000019,CHEMBL619174,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration
B,,,,,1,Autocuration,,7504,,H,3505,4,,,104705,,,,BAO_0000019,CHEMBL619175,,5-hydroxytryptamine receptor binding affinity was determined in rats
B,,,,,1,Autocuration,,7504,,H,3506,4,,,104705,,,,BAO_0000224,CHEMBL619176,,Binding affinity at rat 5-hydroxytryptamine receptor.
B,,,,,1,Autocuration,,7038,,H,3507,4,,,104705,,,,BAO_0000019,CHEMBL619177,,Affinity against 5-hydroxytryptamine receptors in rat fundus model
B,,,,,1,Autocuration,,7626,,H,3508,4,,,104705,,,,BAO_0000224,CHEMBL619178,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation
B,,,,,1,Autocuration,,7626,,H,3509,4,,,104705,,,,BAO_0000224,CHEMBL619179,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined
F,,,,,1,Autocuration,,7185,,H,3510,4,,,104705,Stomach,945.0,,BAO_0000019,CHEMBL619180,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation
F,,,,,1,Autocuration,,7185,,H,3511,4,,,104705,Stomach,945.0,,BAO_0000019,CHEMBL619181,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).
F,,,,,1,Autocuration,,7185,,H,3512,4,,,104705,,,,BAO_0000019,CHEMBL619182,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
B,,,,,1,Autocuration,,6960,,H,3513,4,,,104705,,,,BAO_0000224,CHEMBL619183,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2
B,,,,,1,Autocuration,,6960,,H,3514,4,,,104705,,,,BAO_0000224,CHEMBL619184,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot."
B,,,,,1,Autocuration,,12416,,H,3515,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619185,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
B,,,,,1,Expert,,15753,,H,3516,8,,,12198,,,,BAO_0000357,CHEMBL619186,,Binding affinity for rat 5-hydroxytryptamine transporter.
B,,,,,1,Autocuration,,8062,,H,3517,4,,,104705,,,,BAO_0000019,CHEMBL619187,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,9036,,D,3518,5,,,104705,,,,BAO_0000019,CHEMBL619188,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15067,,D,3519,5,,,104705,,,,BAO_0000224,CHEMBL619189,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor
F,Rattus norvegicus,10116.0,,,1,Expert,,15753,,D,3520,9,,,12198,Brain,955.0,,BAO_0000019,CHEMBL619190,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum
F,Rattus norvegicus,10116.0,,,1,Expert,,15753,,D,3521,9,,,12198,Cerebellum,2037.0,,BAO_0000221,CHEMBL619191,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,15295,,D,3522,5,,,104705,,,,BAO_0000019,CHEMBL619192,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M
B,Rattus norvegicus,10116.0,,,1,Autocuration,,6347,,D,3523,5,,,104705,,,,BAO_0000224,CHEMBL619193,,Percent binding affinity against 5-hydroxytryptamine receptor
B,,,,,1,Autocuration,,6763,,U,3524,0,,,22226,,,,BAO_0000019,CHEMBL619194,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex
B,Rattus norvegicus,10116.0,,,1,Autocuration,,12092,,D,3525,5,,,104705,,,,BAO_0000224,CHEMBL619195,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.
B,Rattus norvegicus,10116.0,,,1,Autocuration,,1579,,D,3526,5,,,104705,,,,BAO_0000224,CHEMBL619196,,Affinity against 5-hydroxytryptamine receptor was determined
B,Rattus norvegicus,10116.0,,,1,Autocuration,,1579,,D,3527,5,,,104705,Stomach,945.0,,BAO_0000019,CHEMBL619197,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip
B,Homo sapiens,9606.0,,,1,Expert,,5963,,D,3528,9,,,121,,,In vitro,BAO_0000219,CHEMBL619198,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
B,Homo sapiens,9606.0,,,1,Expert,,5963,,D,3529,9,,,121,,,In vitro,BAO_0000219,CHEMBL875081,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
B,,,,,1,Autocuration,,5030,,H,3530,8,,,18065,,,,BAO_0000357,CHEMBL884712,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete
B,,,,,1,Expert,,15796,,H,3531,8,,,121,,,,BAO_0000357,CHEMBL884710,,Inhibition of 5-hydroxytryptamine reuptake
F,,,,,1,Autocuration,,15413,,H,3532,8,,,18065,,,,BAO_0000019,CHEMBL619199,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding"
F,,,,,1,Autocuration,,15413,,H,3533,8,,,18065,,,,BAO_0000019,CHEMBL619200,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)"
F,,,,,1,Autocuration,,15413,,H,3534,8,,,18065,,,,BAO_0000019,CHEMBL619201,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)"
F,,,,,1,Autocuration,,12409,,H,3535,8,,,18065,,,,BAO_0000019,CHEMBL619202,,Tested for 5-hydroxytryptamine receptor uptake
B,Homo sapiens,9606.0,,CHO,1,Expert,,16909,,D,3536,9,449.0,,51,,,,BAO_0000219,CHEMBL619203,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
F,Homo sapiens,9606.0,,,1,Expert,,16909,,D,3537,9,,,51,,,,BAO_0000019,CHEMBL619204,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype
B,Homo sapiens,9606.0,,,1,Autocuration,,15629,,H,3538,8,,,10576,,,,BAO_0000249,CHEMBL619205,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.
B,,,,,1,Autocuration,,15629,,H,3539,8,,,10576,,,,BAO_0000357,CHEMBL619206,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A
B,,,,,1,Expert,,15629,,H,3540,8,,,10576,,,,BAO_0000249,CHEMBL619207,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.
F,,,,,1,Autocuration,,10034,,H,3541,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL619208,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3542,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL619209,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3543,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL619210,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg
F,,,,,1,Autocuration,,10034,,H,3544,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL619211,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg
F,,,,,1,Autocuration,,10034,,H,3545,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL619212,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg
F,,,,,1,Autocuration,,10034,,H,3546,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620681,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg
F,,,,,1,Autocuration,,10034,,H,3547,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620682,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg
F,,,,,1,Autocuration,,10034,,H,3548,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620683,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3549,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620684,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg
F,,,,,1,Autocuration,,10034,,H,3550,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620685,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg
F,,,,,1,Autocuration,,10034,,H,3551,8,,,10825,Striatum,2435.0,,BAO_0000019,CHEMBL620686,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg
F,,,,,1,Autocuration,,10034,,H,3552,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620687,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg
F,,,,,1,Autocuration,,10034,,H,3553,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620688,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3554,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620689,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg
F,,,,,1,Autocuration,,10034,,H,3555,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620690,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg
F,,,,,1,Autocuration,,10034,,H,3556,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620691,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3557,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620692,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg
F,,,,,1,Autocuration,,10034,,H,3558,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL620693,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg
B,,,,,1,Expert,,1274,,H,3559,8,,,168,,,,BAO_0000357,CHEMBL620694,,Binding affinity against 5-hydroxytryptamine 4 receptor
F,,,,,1,Autocuration,,17358,,H,3560,8,,,168,,,,BAO_0000019,CHEMBL857986,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
B,,,,,1,Autocuration,,14532,,H,3561,8,,,168,,,,BAO_0000357,CHEMBL620695,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration
B,,,,,1,Expert,,16989,,H,3562,8,,,168,,,,BAO_0000357,CHEMBL620696,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,17200,,H,3563,8,,,168,,,,BAO_0000357,CHEMBL620697,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand
B,,,,,1,Autocuration,,15779,,H,3564,8,,,168,,,,BAO_0000357,CHEMBL620698,,Binding affinity towards 5-hydroxytryptamine 4 receptor
B,,,,,1,Autocuration,,15779,,H,3565,8,,,168,,,,BAO_0000357,CHEMBL620699,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
B,,,,,1,Autocuration,,15779,,H,3566,8,,,168,,,,BAO_0000357,CHEMBL620700,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
B,,,,COS-7,1,Autocuration,,15650,,H,3567,8,643.0,,168,,,,BAO_0000219,CHEMBL620701,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells
B,,,,COS-7,1,Autocuration,,15650,,H,3568,8,643.0,,168,,,,BAO_0000219,CHEMBL875082,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells
B,,,,COS-7,1,Autocuration,,15650,,H,3569,8,643.0,,168,,,,BAO_0000219,CHEMBL620702,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells
B,,,,COS-7,1,Autocuration,,15650,,H,3570,8,643.0,,168,,,,BAO_0000219,CHEMBL620703,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells
B,,,,C6,1,Autocuration,,17046,,H,3571,8,673.0,,168,,,,BAO_0000219,CHEMBL620704,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
B,,,,C6,1,Expert,,17046,,H,3572,8,673.0,,168,,,,BAO_0000219,CHEMBL620705,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
B,,,,C6,1,Expert,,15650,,H,3573,8,673.0,,168,,,,BAO_0000219,CHEMBL620706,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808
B,,,,C6,1,Expert,,17046,,H,3574,8,673.0,,168,,,,BAO_0000219,CHEMBL620707,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined
B,,,,,1,Expert,,17066,,H,3575,8,,,10624,,,,BAO_0000357,CHEMBL620708,,Binding affinity towards 5-hydroxytryptamine 5 receptor
B,,,,,1,Autocuration,,17200,,H,3576,8,,,105,,,,BAO_0000357,CHEMBL620709,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,3577,9,,,10624,,,,BAO_0000357,CHEMBL620710,,Binding affinity against 5-hydroxytryptamine 5A receptor
B,,,,CHO,1,Autocuration,,15250,,H,3578,8,449.0,,10624,,,,BAO_0000219,CHEMBL620711,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,3579,9,,,10624,,,,BAO_0000357,CHEMBL620712,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3580,9,,,10624,,,,BAO_0000357,CHEMBL620713,,Binding affinity towards human 5-hydroxytryptamine 5A receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3581,9,,,10624,,,,BAO_0000357,CHEMBL620714,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,3582,9,,,10624,,,,BAO_0000357,CHEMBL620715,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor
B,,,,,1,Autocuration,,6013,,H,3583,8,,,10624,,,,BAO_0000357,CHEMBL620716,,Binding affinity towards 5-HT5A receptor
B,,,,,1,Expert,,17175,,H,3584,8,,,10624,,,,BAO_0000357,CHEMBL620717,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand
B,,,,,1,Autocuration,,15818,,H,3585,8,,,10624,,,,BAO_0000357,CHEMBL618072,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor
B,,,,,1,Autocuration,,6166,,H,3586,8,,,10624,,,,BAO_0000357,CHEMBL857987,,Binding affinity towards cloned human 5-HT5A receptor was determined
B,,,,HEK293,1,Autocuration,,15779,,H,3587,8,722.0,,10624,,,,BAO_0000219,CHEMBL618073,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3588,8,722.0,,10624,,,,BAO_0000219,CHEMBL618074,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
B,,,,HEK293,1,Autocuration,,5213,,H,3589,8,722.0,,10624,,,,BAO_0000219,CHEMBL618075,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand )
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3590,9,,,10625,,,,BAO_0000357,CHEMBL618076,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3591,9,,,10625,,,,BAO_0000357,CHEMBL618077,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3592,9,,,10625,,,,BAO_0000357,CHEMBL618078,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3593,9,,,10625,,,,BAO_0000357,CHEMBL881821,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3594,9,,,10625,,,,BAO_0000357,CHEMBL618079,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor
B,,,,,1,Expert,,17175,,H,3595,8,,,10625,,,,BAO_0000357,CHEMBL618080,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand
B,,,,HEK293,1,Autocuration,,16190,,H,3596,8,722.0,,10576,,,,BAO_0000219,CHEMBL618081,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
B,,,,HEK293,1,Autocuration,,16190,,H,3597,8,722.0,,10626,,,,BAO_0000219,CHEMBL618082,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
B,,,,,1,Expert,,4820,,H,3598,8,,,10624,,,,BAO_0000357,CHEMBL618083,,Binding affinity towards 5-HT5a receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3599,9,,,10624,,,,BAO_0000357,CHEMBL618084,,Binding affinity towards 5-hydroxytryptamine 5A receptor
B,,,,,1,Expert,,17066,,H,3600,8,,,10624,,,,BAO_0000357,CHEMBL618085,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor
B,,,,,1,Expert,,17175,,H,3601,8,,,10624,,,,BAO_0000357,CHEMBL618086,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand
B,,,,,1,Autocuration,,16633,,H,3602,8,,,10624,,,,BAO_0000357,CHEMBL875092,,Binding affinities against 5-hydroxytryptamine 5A receptor
B,,,,,1,Autocuration,,16633,,H,3603,8,,,10624,,,,BAO_0000357,CHEMBL618087,,Binding affinities towards 5-hydroxytryptamine 5A receptor
B,,,,,1,Autocuration,,16700,,H,3604,8,,,10624,,,,BAO_0000357,CHEMBL872926,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity
F,Cavia porcellus,10141.0,,,1,Autocuration,,4639,,H,3605,4,,,104714,,,,BAO_0000019,CHEMBL618088,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM
B,,,,,1,Autocuration,,5486,,H,3606,4,,,104714,,,,BAO_0000223,CHEMBL618089,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,3607,9,,,10627,,,,BAO_0000357,CHEMBL618090,,Inhibition of human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,,1,Expert,,17273,,D,3608,9,,,10627,,,,BAO_0000357,CHEMBL618091,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand
B,,,,,1,Autocuration,,17687,,H,3609,8,,,10627,,,,BAO_0000357,CHEMBL618092,,Inhibition against human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,3610,9,,,10627,,,,BAO_0000357,CHEMBL618093,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor
B,,,,HeLa,1,Expert,,16190,,H,3611,8,308.0,,10627,,,,BAO_0000219,CHEMBL618094,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3612,9,,,10627,,,,BAO_0000357,CHEMBL618095,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3613,9,,,10627,,,,BAO_0000357,CHEMBL875093,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3614,9,,,10627,,,,BAO_0000357,CHEMBL618096,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3615,9,,,10627,,,,BAO_0000357,CHEMBL618118,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand
B,Homo sapiens,9606.0,,,1,Expert,,3555,,D,3616,9,,,10627,,,,BAO_0000357,CHEMBL618119,,Binding affinity against 5-hydroxytryptamine 6 receptor
B,,,,,1,Expert,,5808,,H,3617,8,,,10627,,,,BAO_0000357,CHEMBL618120,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,6013,,H,3618,8,,,10627,,,,BAO_0000357,CHEMBL618121,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,,,,HEK293,1,Expert,,15818,,H,3619,8,722.0,,10627,,,,BAO_0000219,CHEMBL618122,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand"
B,,,,,1,Autocuration,,16209,,H,3620,8,,,10627,,,,BAO_0000357,CHEMBL618123,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand
B,,,,HEK293,1,Expert,,3935,,H,3621,8,722.0,,10627,,,,BAO_0000219,CHEMBL618124,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand
B,,,,,1,Autocuration,,15818,,H,3622,8,,,10627,,,,BAO_0000357,CHEMBL618125,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,HEK293,1,Expert,,3805,,D,3623,9,722.0,,10627,,,,BAO_0000219,CHEMBL618126,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
B,,,,,1,Expert,,16441,,H,3624,8,,,10627,,,,BAO_0000019,CHEMBL618236,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD
B,,,,,1,Expert,,16441,,H,3625,8,,,10627,,,,BAO_0000019,CHEMBL618237,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.
B,,,,COS-7,1,Expert,,6786,,H,3626,8,643.0,,10627,,,,BAO_0000219,CHEMBL618238,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,3627,9,,,10627,,,,BAO_0000357,CHEMBL618239,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,17085,,H,3628,8,,,10627,,,,BAO_0000019,CHEMBL618240,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,17200,,H,3629,8,,,10627,,,,BAO_0000357,CHEMBL618241,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand
B,,,,HEK293,1,Autocuration,,17451,,H,3630,8,722.0,,10627,,,,BAO_0000219,CHEMBL859399,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
F,,,,,1,Autocuration,,3935,,H,3631,8,,,10627,,,,BAO_0000019,CHEMBL618242,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase
B,,,,,1,Autocuration,,5033,,H,3632,8,,,10627,,,,BAO_0000357,CHEMBL857991,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor
B,,,,,1,Expert,,4540,,H,3633,8,,,10627,,,,BAO_0000357,CHEMBL619951,,Binding affinity against human 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,HeLa,1,Expert,,4540,,D,3634,9,308.0,,10627,,,,BAO_0000219,CHEMBL619952,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand
B,Homo sapiens,9606.0,,HeLa,1,Expert,,4540,,D,3635,9,308.0,,10627,,,,BAO_0000219,CHEMBL619953,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand
B,,,,HeLa,1,Autocuration,,17296,,H,3636,8,308.0,,10627,,,,BAO_0000219,CHEMBL619954,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells
B,,,,HeLa,1,Autocuration,,17296,,H,3637,8,308.0,,10627,,,,BAO_0000219,CHEMBL619955,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
B,,,,HeLa,1,Autocuration,,17296,,H,3638,8,308.0,,10627,,,,BAO_0000219,CHEMBL619956,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
B,,,,CHO,1,Autocuration,,15779,,H,3639,8,449.0,,10627,,,,BAO_0000219,CHEMBL619957,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,3640,8,722.0,,10627,,,,BAO_0000219,CHEMBL619958,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3641,8,722.0,,10627,,,,BAO_0000219,CHEMBL620627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.
B,,,,HEK293,1,Autocuration,,15779,,H,3642,8,722.0,,10627,,,,BAO_0000219,CHEMBL620628,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
B,,,,HeLa,1,Autocuration,,15779,,H,3643,8,308.0,,10627,,,,BAO_0000219,CHEMBL620629,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.
B,,,,,1,Autocuration,,6166,,H,3644,8,,,10627,,,,BAO_0000357,CHEMBL620630,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,,,,HeLa,1,Autocuration,,17451,,H,3645,8,308.0,,10627,,,,BAO_0000219,CHEMBL620782,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand
B,,,,,1,Autocuration,,15316,,H,3646,8,,,10627,,,,BAO_0000357,CHEMBL620783,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor
B,,,,,1,Expert,,4199,,H,3647,8,,,10627,,,,BAO_0000357,CHEMBL620784,,Binding affinity against human 5-hydroxytryptamine 6 receptor
B,,,,HeLa,1,Expert,,15146,,H,3648,8,308.0,,10627,,,,BAO_0000219,CHEMBL620785,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD
B,,,,,1,Autocuration,,5213,,H,3649,8,,,10627,,,,BAO_0000357,CHEMBL857992,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand )
B,,,,,1,Autocuration,,16429,,H,3650,8,,,10627,,,,BAO_0000219,CHEMBL620786,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand
B,,,,HeLa,1,Autocuration,,14818,,H,3651,8,308.0,,10627,,,,BAO_0000219,CHEMBL620787,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.
B,,,,HeLa,1,Autocuration,,4829,,H,3652,8,308.0,,10627,,,,BAO_0000219,CHEMBL620788,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3"
B,,,,HeLa,1,Autocuration,,4829,,H,3653,8,308.0,,10627,,,,BAO_0000219,CHEMBL620789,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9"
B,,,,HeLa,1,Autocuration,,4829,,H,3654,8,308.0,,10627,,,,BAO_0000219,CHEMBL620790,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3"
B,,,,CHO,1,Autocuration,,15250,,H,3655,8,449.0,,10628,,,,BAO_0000219,CHEMBL620791,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells
B,,,,,1,Autocuration,,14423,,H,3656,8,,,10628,,,,BAO_0000019,CHEMBL620792,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.
B,,,,,1,Autocuration,,15086,,H,3657,8,,,10628,,,,BAO_0000357,CHEMBL620793,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,4342,,H,3658,8,,,10628,,,,BAO_0000357,CHEMBL620794,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined
B,Homo sapiens,9606.0,,HeLa,1,Autocuration,,16190,,D,3659,9,308.0,,10627,,,,BAO_0000219,CHEMBL620795,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells
B,,,,,1,Expert,,4820,,H,3660,8,,,10627,,,,BAO_0000357,CHEMBL620796,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,4639,,H,3661,8,,,10627,,,,BAO_0000357,CHEMBL620797,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M
F,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3662,9,,,10627,,,,BAO_0000019,CHEMBL620798,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
B,,,,,1,Autocuration,,6011,,H,3663,8,,,10627,,,,BAO_0000357,CHEMBL620799,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration
B,,,,,1,Expert,,17066,,H,3664,8,,,10627,,,,BAO_0000357,CHEMBL620800,,Binding affinity towards human 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,17515,,H,3665,8,,,10627,,,,BAO_0000357,CHEMBL620801,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM
B,,,,,1,Autocuration,,5014,,H,3666,8,,,10627,,,,BAO_0000357,CHEMBL875100,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,4373,,H,3667,8,,,10627,,,,BAO_0000357,CHEMBL620802,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined
F,,,,,1,Expert,,17066,,H,3668,8,,,10627,,,,BAO_0000019,CHEMBL620803,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor
F,,,,,1,Expert,,17066,,H,3669,8,,,10627,,,,BAO_0000019,CHEMBL620804,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
B,,,,,1,Autocuration,,4373,,H,3670,8,,,10627,,,,BAO_0000357,CHEMBL620805,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined
B,,,,,1,Autocuration,,4687,,H,3671,8,,,10627,,,,BAO_0000357,CHEMBL620806,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,16946,,H,3672,8,,,10627,,,,BAO_0000357,CHEMBL620807,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M
B,,,,,1,Autocuration,,16946,,H,3673,8,,,10627,,,,BAO_0000357,CHEMBL620808,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M
B,,,,,1,Autocuration,,16633,,H,3674,8,,,10627,,,,BAO_0000357,CHEMBL620809,,Binding affinities against 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,16633,,H,3675,8,,,10627,,,,BAO_0000357,CHEMBL620810,,Binding affinities towards 5-hydroxytryptamine 6 receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3676,9,,,10627,,,,BAO_0000357,CHEMBL620811,,Binding affinity towards 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,16700,,H,3677,8,,,10627,,,,BAO_0000357,CHEMBL620812,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity
B,,,,,1,Autocuration,,3269,,H,3678,8,,,10627,,,,BAO_0000357,CHEMBL620813,,Affinity against 5-hydroxytryptamine 6 receptor
B,,,,,1,Autocuration,,5486,,H,3679,8,,,10627,,,,BAO_0000357,CHEMBL620814,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT]
B,Homo sapiens,9606.0,,,1,Expert,,16146,,D,3680,9,,,10209,,,,BAO_0000357,CHEMBL620815,,Inhibition of human 5-hydroxytryptamine 7 receptor
B,,,,HEK293,1,Autocuration,,5014,,H,3681,8,722.0,,10209,,,,BAO_0000219,CHEMBL620816,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD
B,,,,,1,Autocuration,,15463,,H,3682,8,,,10209,,,,BAO_0000357,CHEMBL620817,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,3805,,H,3683,8,,,10209,,,,BAO_0000357,CHEMBL620818,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM)
B,,,,HEK293,1,Expert,,5014,,H,3684,8,722.0,,10209,,,,BAO_0000219,CHEMBL620819,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells
B,Homo sapiens,9606.0,,,1,Expert,,6491,,D,3685,9,,,10209,,,,BAO_0000357,CHEMBL620820,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor
B,,,,CHO,1,Autocuration,,16190,,H,3686,8,449.0,,10209,,,,BAO_0000219,CHEMBL620821,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3687,9,,,10209,,,,BAO_0000357,CHEMBL620822,,Binding affinity towards human 5-hydroxytryptamine 7 receptor
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3688,9,,,10209,,,,BAO_0000357,CHEMBL620823,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor
B,Homo sapiens,9606.0,,,1,Expert,,3555,,D,3689,9,,,10209,,,,BAO_0000357,CHEMBL620824,,Binding affinity against 5-hydroxytryptamine 7 receptor
B,,,,CHO,1,Expert,,6588,,H,3690,8,449.0,,10209,,,,BAO_0000219,CHEMBL620825,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells
B,,,,,1,Autocuration,,15463,,H,3691,8,,,10209,,,,BAO_0000357,CHEMBL872930,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand
B,,,,,1,Autocuration,,6013,,H,3692,8,,,10209,,,,BAO_0000357,CHEMBL620826,,Binding affinity towards 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,16209,,H,3693,8,,,10209,,,,BAO_0000357,CHEMBL620827,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,3935,,H,3694,8,,,10209,,,,BAO_0000357,CHEMBL620828,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,15818,,H,3695,8,,,10209,,,,BAO_0000357,CHEMBL620829,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor
B,,,,HEK293,1,Expert,,5014,,H,3696,8,722.0,,10209,,,,BAO_0000219,CHEMBL620830,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD
B,,,,,1,Expert,,16441,,H,3697,8,,,10209,,,,BAO_0000019,CHEMBL620831,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD
B,,,,,1,Expert,,16441,,H,3698,8,,,10209,,,,BAO_0000019,CHEMBL620832,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.
B,Homo sapiens,9606.0,,,1,Expert,,4234,,D,3699,9,,,10209,,,,BAO_0000357,CHEMBL621548,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,17085,,H,3700,8,,,10209,,,,BAO_0000019,CHEMBL621549,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,17200,,H,3701,8,,,10209,,,,BAO_0000357,CHEMBL621550,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand
B,,,,CHO,1,Autocuration,,17451,,H,3702,8,449.0,,10209,,,,BAO_0000219,CHEMBL621551,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined
B,,,,,1,Autocuration,,17085,,H,3703,8,,,10209,,,,BAO_0000019,CHEMBL621552,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined
B,,,,,1,Autocuration,,5104,,H,3704,8,,,10209,,,,BAO_0000357,CHEMBL857077,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,5104,,H,3705,8,,,10209,,,,BAO_0000357,CHEMBL618158,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested
B,Homo sapiens,9606.0,,COS-7,1,Expert,,5033,,D,3706,9,643.0,,10209,,,,BAO_0000219,CHEMBL618159,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
B,,,,COS-7,1,Autocuration,,5486,,H,3707,8,643.0,,10209,,,,BAO_0000219,CHEMBL875101,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
B,Homo sapiens,9606.0,,HEK293,1,Expert,,4540,,D,3708,9,722.0,,10209,,,,BAO_0000219,CHEMBL618160,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand
B,,,,,1,Expert,,6166,,H,3709,8,,,10209,,,,BAO_0000357,CHEMBL618161,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.
B,,,,HEK293,1,Expert,,17342,,H,3710,8,722.0,,10209,,,,BAO_0000219,CHEMBL618162,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand
B,,,,,1,Expert,,17342,,H,3711,8,,,10209,,,,BAO_0000357,CHEMBL618163,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand
B,,,,,1,Autocuration,,17296,,H,3712,8,,,10209,,,,BAO_0000357,CHEMBL618164,,Binding affinity against 5-hydroxytryptamine 7 human receptors
B,,,,,1,Expert,,16429,,H,3713,8,,,10209,,,,BAO_0000219,CHEMBL618165,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand
B,,,,HEK293,1,Autocuration,,15779,,H,3714,8,722.0,,10209,,,,BAO_0000219,CHEMBL618166,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3715,8,722.0,,10209,,,,BAO_0000219,CHEMBL857989,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3716,8,722.0,,10209,,,,BAO_0000219,CHEMBL619888,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3717,8,722.0,,10209,,,,BAO_0000219,CHEMBL619889,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
B,,,,HEK293,1,Autocuration,,15779,,H,3718,8,722.0,,10209,,,,BAO_0000219,CHEMBL619890,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.
B,,,,CHO,1,Autocuration,,17451,,H,3719,8,449.0,,10209,,,,BAO_0000219,CHEMBL619891,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand
B,,,,HEK293,1,Autocuration,,4199,,H,3720,8,722.0,,10209,,,,BAO_0000219,CHEMBL619892,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3)
B,,,,HEK293,1,Expert,,4199,,D,3721,9,722.0,,10209,,,,BAO_0000219,CHEMBL619893,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells
B,,,,HEK293,1,Autocuration,,4199,,H,3722,8,722.0,,10209,,,,BAO_0000219,CHEMBL619894,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6)
B,,,,HEK293,1,Intermediate,,3680,,D,3723,9,722.0,,10209,,,,BAO_0000219,CHEMBL619895,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells
B,,,,,1,Intermediate,,3680,,D,3724,9,,,10209,,,,BAO_0000357,CHEMBL619896,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand
B,,,,COS-7,1,Autocuration,,15316,,H,3725,8,643.0,,10209,,,,BAO_0000219,CHEMBL619897,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.
B,,,,HEK293,1,Autocuration,,15146,,H,3726,8,722.0,,10209,,,,BAO_0000219,CHEMBL619898,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT
B,,,,HEK293,1,Expert,,5213,,H,3727,8,722.0,,10209,,,,BAO_0000219,CHEMBL619899,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand
B,,,,HEK293,1,Autocuration,,5213,,H,3728,8,722.0,,10209,,,,BAO_0000219,CHEMBL619900,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand )
B,Homo sapiens,9606.0,,HEK293,1,Expert,,14818,,D,3729,9,722.0,,10209,,,,BAO_0000219,CHEMBL619901,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT
B,,,,HEK293,1,Autocuration,,14818,,H,3730,8,722.0,,10209,,,,BAO_0000219,CHEMBL620580,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. 
B,,,,HEK293,1,Autocuration,,14818,,H,3731,8,722.0,,10209,,,,BAO_0000219,CHEMBL620581,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.
B,,,,HEK293,1,Autocuration,,4829,,H,3732,8,722.0,,10209,,,,BAO_0000219,CHEMBL620733,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand"
B,Homo sapiens,9606.0,,,1,Autocuration,,17200,,D,3733,9,,,10209,,,,BAO_0000357,CHEMBL620734,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined
B,Mus musculus,10090.0,,,1,Expert,,17066,,D,3734,9,,,10022,,,,BAO_0000357,CHEMBL620735,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14025,,H,3735,8,,,10209,,,,BAO_0000019,CHEMBL620736,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.
B,,,,CHO,1,Autocuration,,15250,,H,3736,8,449.0,,11923,,,,BAO_0000219,CHEMBL620737,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells
B,,,,CHO,1,Autocuration,,16372,,H,3737,8,449.0,,11923,,,,BAO_0000219,CHEMBL620738,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM
B,,,,CHO,1,Autocuration,,16372,,H,3738,8,449.0,,11923,,,,BAO_0000219,CHEMBL620739,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM
B,,,,CHO,1,Autocuration,,16372,,H,3739,8,449.0,,11923,,,,BAO_0000219,CHEMBL620740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM
B,,,,CHO,1,Autocuration,,16372,,H,3740,8,449.0,,11923,,,,BAO_0000219,CHEMBL620741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.
B,,,,CHO,1,Autocuration,,16372,,H,3741,8,449.0,,11923,,,,BAO_0000219,CHEMBL620742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.
B,,,,CHO,1,Autocuration,,16372,,H,3742,8,449.0,,11923,,,,BAO_0000219,CHEMBL620743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT
B,,,,CHO,1,Autocuration,,16372,,H,3743,8,449.0,,11923,,,,BAO_0000219,CHEMBL620744,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM
B,,,,CHO,1,Autocuration,,16372,,H,3744,8,449.0,,11923,,,,BAO_0000219,CHEMBL620745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM
B,,,,CHO,1,Autocuration,,16372,,H,3745,8,449.0,,11923,,,,BAO_0000219,CHEMBL620746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM
B,,,,CHO,1,Autocuration,,16372,,H,3746,8,449.0,,11923,,,,BAO_0000219,CHEMBL620747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.
B,,,,CHO,1,Autocuration,,16372,,H,3747,8,449.0,,11923,,,,BAO_0000219,CHEMBL620748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.
B,,,,CHO,1,Autocuration,,16372,,H,3748,8,449.0,,11923,,,,BAO_0000219,CHEMBL620749,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.
B,,,,,1,Expert,,17066,,H,3749,8,,,11923,,,,BAO_0000357,CHEMBL620750,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor
B,Rattus norvegicus,10116.0,,,1,Expert,,17066,,D,3750,9,,,11923,,,,BAO_0000357,CHEMBL620751,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
B,,,,,1,Expert,,17386,,H,3751,8,,,11923,,,,BAO_0000357,CHEMBL620752,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,14423,,H,3752,8,,,11923,,,,BAO_0000019,CHEMBL872929,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.
B,Rattus norvegicus,10116.0,,,1,Expert,,15874,,D,3753,9,,,11923,,,,BAO_0000357,CHEMBL620753,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT
B,Rattus norvegicus,10116.0,,,1,Expert,,15874,,D,3754,9,,,11923,,,,BAO_0000357,CHEMBL620754,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor
B,Rattus norvegicus,10116.0,,CHO,1,Expert,,16372,,D,3755,9,449.0,,11923,,,,BAO_0000219,CHEMBL620755,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells
B,,,,,1,Autocuration,,4622,,H,3756,8,,,11923,,,,BAO_0000357,CHEMBL620756,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
B,,,,,1,Autocuration,,15086,,H,3757,8,,,11923,,,,BAO_0000357,CHEMBL620757,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor
B,,,,CHO,1,Autocuration,,16372,,H,3758,8,449.0,,11923,,,,BAO_0000219,CHEMBL620758,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested"
B,,,,CHO,1,Autocuration,,16372,,H,3759,8,449.0,,11923,,,,BAO_0000219,CHEMBL620759,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested"
B,,,,CHO,1,Autocuration,,16372,,H,3760,8,449.0,,11923,,,,BAO_0000219,CHEMBL620760,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested
B,,,,CHO,1,Autocuration,,16372,,H,3761,8,449.0,,11923,,,,BAO_0000219,CHEMBL620761,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested
F,,,,,1,Autocuration,,17386,,H,3762,8,,,11923,Ileum,2116.0,,BAO_0000221,CHEMBL620762,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
F,,,,,1,Autocuration,,17386,,H,3763,8,,,11923,Ileum,2116.0,,BAO_0000221,CHEMBL620763,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
F,,,,,1,Autocuration,,17386,,H,3764,8,,,11923,Ileum,2116.0,,BAO_0000221,CHEMBL620764,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization
B,Rattus norvegicus,10116.0,,,1,Expert,Membranes,5831,,D,3765,9,,,11923,,,,BAO_0000249,CHEMBL857990,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes
B,,,,,1,Autocuration,,4342,,H,3766,8,,,11923,,,,BAO_0000357,CHEMBL620765,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined
B,,,,,1,Expert,,17319,,H,3767,8,,,11923,,,,BAO_0000357,CHEMBL620766,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.
B,,,,,1,Expert,,17342,,H,3768,8,,,11923,Hypothalamus,1898.0,,BAO_0000019,CHEMBL620767,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.
B,,,,,1,Autocuration,,17342,,H,3769,8,,,11923,,,,BAO_0000357,CHEMBL620768,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand
B,,,,,1,Expert,,3680,,H,3770,8,,,11923,Hypothalamus,1898.0,,BAO_0000249,CHEMBL619051,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes
B,,,,,1,Expert,,3680,,H,3771,8,,,11923,,,,BAO_0000357,CHEMBL619052,,Binding affinity towards 5-hydroxytryptamine 7 receptor
F,Rattus norvegicus,10116.0,,HEK293,1,Expert,,17319,,D,3772,9,722.0,,11923,,,,BAO_0000219,CHEMBL619053,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells
F,Rattus norvegicus,10116.0,,HEK293,1,Expert,,17319,,D,3773,9,722.0,,11923,,,,BAO_0000219,CHEMBL619703,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active
F,Rattus norvegicus,10116.0,,HEK293,1,Autocuration,,17319,,D,3774,9,722.0,,11923,,,,BAO_0000219,CHEMBL619704,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active
B,,,,,1,Expert,,4820,,H,3775,8,,,10209,,,,BAO_0000357,CHEMBL619851,,Binding affinity towards 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,4639,,H,3776,8,,,10209,,,,BAO_0000357,CHEMBL619852,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M
B,,,,,1,Autocuration,,6011,,H,3777,8,,,10209,,,,BAO_0000357,CHEMBL619853,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration
B,Homo sapiens,9606.0,,,1,Expert,,17066,,D,3778,9,,,10209,,,,BAO_0000357,CHEMBL619854,,Binding affinity towards human 5-hydroxytryptamine 7 receptor
B,,,,,1,Expert,,17066,,H,3779,8,,,10209,,,,BAO_0000357,CHEMBL619855,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,17515,,H,3780,8,,,10209,,,,BAO_0000357,CHEMBL619856,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM
B,,,,,1,Autocuration,,4373,,H,3781,8,,,10209,,,,BAO_0000357,CHEMBL619857,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
F,,,,,1,Expert,,17066,,H,3782,8,,,10209,,,,BAO_0000019,CHEMBL619858,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay
B,,,,,1,Autocuration,,4373,,H,3783,8,,,10209,,,,BAO_0000357,CHEMBL619859,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined
B,,,,,1,Autocuration,,4373,,H,3784,8,,,10209,,,,BAO_0000357,CHEMBL619860,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
B,,,,,1,Autocuration,,4687,,H,3785,8,,,10209,,,,BAO_0000357,CHEMBL619861,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor
B,,,,,1,Expert,,17342,,H,3786,8,,,10209,,,,BAO_0000357,CHEMBL619862,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,16946,,H,3787,8,,,10209,,,,BAO_0000357,CHEMBL619863,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M
B,,,,,1,Autocuration,,16946,,H,3788,8,,,10209,,,,BAO_0000357,CHEMBL619864,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M
B,,,,,1,Autocuration,,16633,,H,3789,8,,,10209,,,,BAO_0000357,CHEMBL872928,,Binding affinities against 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,16633,,H,3790,8,,,10209,,,,BAO_0000357,CHEMBL619865,,Binding affinities towards 5-hydroxytryptamine 7 receptor
B,,,,,1,Expert,,17066,,H,3791,8,,,10209,,,,BAO_0000357,CHEMBL619866,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor
B,,,,,1,Autocuration,,16700,,H,3792,8,,,10209,,,,BAO_0000357,CHEMBL619867,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity
B,,,,,1,Autocuration,,17386,,H,3793,8,,,10209,Ileum,2116.0,,BAO_0000221,CHEMBL619868,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
F,,,,,1,Autocuration,,14080,,H,3794,8,,,55,,,,BAO_0000019,CHEMBL619869,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay
F,Homo sapiens,9606.0,,,1,Expert,,14080,,D,3795,9,,,55,,,,BAO_0000019,CHEMBL619870,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay
B,,,,,1,Autocuration,,409,,H,3796,8,,,55,,,,BAO_0000357,CHEMBL619871,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme
B,,,,,1,Autocuration,,409,,H,3797,8,,,55,,,,BAO_0000357,CHEMBL619872,,In vitro inhibition of human recombinant lipoxygenase enzyme
B,,,,,1,Autocuration,,409,,H,3798,8,,,55,,,,BAO_0000357,CHEMBL619873,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition
B,,,,,1,Expert,,11090,,H,3799,8,,,55,Blood,178.0,,BAO_0000357,CHEMBL619874,,Inhibition of 5-lipoxygenase in human whole blood.
B,,,,,1,Expert,,11090,,H,3800,8,,,55,Blood,178.0,,BAO_0000357,CHEMBL619875,,Inhibition of 5-lipoxygenase in human whole blood.
B,,,,,1,Autocuration,,948,,H,3801,8,,,55,,,,BAO_0000357,CHEMBL619876,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE
B,,,,,1,Autocuration,,948,,H,3802,8,,,55,,,,BAO_0000357,CHEMBL619877,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4)
F,,,,,1,Expert,,13622,,H,3803,8,,,55,,,,BAO_0000219,CHEMBL619878,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.
F,,,,,1,Autocuration,,13622,,H,3804,8,,,55,Blood,178.0,,BAO_0000019,CHEMBL619879,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood
B,,,,,1,Autocuration,,9637,,H,3805,8,,,55,,,,BAO_0000357,CHEMBL619880,,In vitro inhibition of 5-lipoxygenase from human polymorphs
B,,,,,1,Autocuration,,11320,,H,3806,8,,,55,,,,BAO_0000357,CHEMBL619881,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase)
B,,,,,1,Expert,,11320,,H,3807,8,,,55,,,,BAO_0000357,CHEMBL619882,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase
B,,,,,1,Autocuration,,6838,,H,3808,8,,,55,,,,BAO_0000357,CHEMBL619883,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay
B,Homo sapiens,9606.0,,,1,Expert,,17667,,D,3809,9,,,55,Blood,178.0,,BAO_0000357,CHEMBL619884,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB)
B,,,,,1,Autocuration,,12703,,H,3810,8,,,55,,,,BAO_0000357,CHEMBL619885,,In vitro potency against human 5-Lipoxygenase
F,Homo sapiens,9606.0,,,1,Expert,,14312,,D,3811,9,,,55,,,,BAO_0000019,CHEMBL619886,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay
F,,,,,1,Autocuration,,14312,,H,3812,8,,,55,Blood,178.0,,BAO_0000019,CHEMBL619887,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data
F,,,,,1,Autocuration,,5364,,H,3813,8,,,55,,,,BAO_0000019,CHEMBL875097,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
B,,,,,1,Autocuration,,951,,H,3814,8,,,55,,,,BAO_0000219,CHEMBL618001,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE
B,,,,,1,Autocuration,,951,,H,3815,8,,,55,,,,BAO_0000219,CHEMBL618002,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active
B,,,,,1,Autocuration,,951,,H,3816,8,,,55,,,,BAO_0000219,CHEMBL618003,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4
B,,,,,1,Autocuration,,951,,H,3817,8,,,55,,,,BAO_0000219,CHEMBL618004,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active
B,,,,,1,Autocuration,,12365,,H,3818,8,,,55,,,,BAO_0000219,CHEMBL618005,,Inhibition of human 5-lipoxygenase in human cells
B,,,,,1,Expert,,10603,,H,3819,8,,,55,,,,BAO_0000357,CHEMBL618006,,Inhibition of human neutrophil 5-lipoxygenase
B,,,,,1,Autocuration,,10501,,H,3820,8,,,55,,,,BAO_0000019,CHEMBL875086,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells
B,,,,,1,Expert,,12281,,H,3821,8,,,55,Blood,178.0,,BAO_0000357,CHEMBL618007,,Inhibition of 5-lipoxygenase from human whole blood
B,,,,,1,Autocuration,,2567,,H,3822,8,,,55,,,,BAO_0000357,CHEMBL618008,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
B,,,,,1,Autocuration,,2567,,H,3823,8,,,55,,,,BAO_0000219,CHEMBL618009,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils
B,,,,,1,Expert,,10193,,H,3824,8,,,55,,,,BAO_0000357,CHEMBL618010,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase
B,,,,,1,Autocuration,,10193,,H,3825,8,,,55,,,,BAO_0000357,CHEMBL618011,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
B,,,,,1,Expert,,13623,,H,3826,8,,,55,,,,BAO_0000357,CHEMBL618012,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase
B,,,,,1,Autocuration,,12780,,H,3827,8,,,55,,,,BAO_0000357,CHEMBL882927,,Tested against 5-lipoxygenase
B,,,,,1,Autocuration,,12780,,H,3828,8,,,55,,,,BAO_0000357,CHEMBL618013,,Tested for activity against 5-Lipoxygenase (5-LO)
B,,,,,1,Autocuration,,12780,,H,3829,8,,,55,,,,BAO_0000357,CHEMBL618014,,Tested for activity against 5-lipoxygenase
B,,,,,1,Autocuration,,11966,,H,3830,8,,,55,,,,BAO_0000357,CHEMBL618015,,Tested for inhibition of 5-HPETE production by human 5-LO
F,,,,,1,Autocuration,,5364,,H,3831,8,,,55,,,,BAO_0000019,CHEMBL618016,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
B,,,,,1,Expert,,13165,,H,3832,8,,,55,,,,BAO_0000357,CHEMBL618017,,Inhibition of Human 5-lipoxygenase
B,,,,,1,Autocuration,,5364,,H,3833,8,,,55,,,,BAO_0000019,CHEMBL618018,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells
B,,,,,1,Autocuration,,11311,,H,3834,8,,,55,,,,BAO_0000219,CHEMBL875087,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS]
B,,,,,1,Autocuration,,11311,,H,3835,8,,,55,,,,BAO_0000219,CHEMBL618019,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS]
B,,,,,1,Autocuration,,14863,,H,3836,8,,,55,,,,BAO_0000019,CHEMBL618020,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.
B,,,,,1,Autocuration,,14863,,H,3837,8,,,55,,,,BAO_0000019,CHEMBL618021,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested
B,,,,,1,Autocuration,,11087,,H,3838,8,,,55,Blood,178.0,,BAO_0000357,CHEMBL618022,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL)
B,,,,,1,Autocuration,,455,,H,3839,8,,,55,,,,BAO_0000357,CHEMBL618023,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils
B,,,,,1,Autocuration,,13183,,H,3840,8,,,55,,,,BAO_0000357,CHEMBL618024,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
B,,,,,1,Expert,,10319,,H,3841,8,,,55,,,,BAO_0000019,CHEMBL873950,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells
B,,,,,1,Autocuration,,10193,,H,3842,8,,,55,,,,BAO_0000357,CHEMBL618025,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
B,,,,,1,Autocuration,,951,,H,3843,8,,,55,,,,BAO_0000219,CHEMBL618026,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM
B,,,,,1,Autocuration,,951,,H,3844,8,,,55,,,,BAO_0000219,CHEMBL618027,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive
B,,,,,1,Autocuration,,951,,H,3845,8,,,55,,,,BAO_0000219,CHEMBL618028,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM
B,,,,,1,Autocuration,,951,,H,3846,8,,,55,,,,BAO_0000219,CHEMBL618029,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive
B,,,,,1,Expert,,9859,,H,3847,8,,,55,,,,BAO_0000357,CHEMBL618030,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration
B,,,,,1,Expert,,9859,,H,3848,8,,,55,,,,BAO_0000357,CHEMBL618031,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration
B,,,,,1,Autocuration,,9859,,H,3849,8,,,55,,,,BAO_0000357,CHEMBL618032,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration
B,,,,,1,Autocuration,,2567,,H,3850,8,,,55,,,,BAO_0000357,CHEMBL618033,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
B,,,,,1,Autocuration,,10193,,H,3851,8,,,55,,,,BAO_0000357,CHEMBL618034,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM
B,,,,,1,Autocuration,,10193,,H,3852,8,,,55,,,,BAO_0000357,CHEMBL875088,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
B,,,,,1,Autocuration,,949,,H,3853,8,,,55,,,,BAO_0000019,CHEMBL618035,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive
B,,,,,1,Autocuration,,949,,H,3854,8,,,55,,,,BAO_0000019,CHEMBL618036,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90
B,,,,,1,Expert,,10603,,H,3855,8,,,55,,,,BAO_0000357,CHEMBL618037,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM
B,,,,,1,Expert,,10603,,H,3856,8,,,55,,,,BAO_0000357,CHEMBL618038,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
F,,,,,1,Autocuration,,10603,,H,3857,8,,,55,,,,BAO_0000019,CHEMBL618761,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
B,,,,,1,Expert,,10603,,H,3858,8,,,55,,,,BAO_0000357,CHEMBL618762,,Inhibition of lipoxygenase at the concentration of 0.1 uM
B,,,,,1,Expert,,10603,,H,3859,8,,,55,,,,BAO_0000357,CHEMBL618763,,Inhibition of lipoxygenase at the concentration of 1 uM
B,,,,,1,Autocuration,,10193,,H,3860,8,,,55,,,,BAO_0000357,CHEMBL618764,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell
B,Homo sapiens,9606.0,,,1,Expert,,14580,,D,3861,9,,,55,,,,BAO_0000357,CHEMBL618765,,Inhibition of 5-Lipoxygenase (5-LOX)
B,,,,,1,Expert,,11090,,H,3862,8,,,17087,,,,BAO_0000357,CHEMBL618766,,Inhibition of 5-lipoxygenase in mouse macrophages.
B,,,,,1,Expert,,11090,,H,3863,8,,,17087,,,,BAO_0000357,CHEMBL618767,,Inhibition of 5-lipoxygenase in mouse macrophages.
B,,,,,1,Autocuration,,6339,,H,3864,8,,,17087,,,,BAO_0000357,CHEMBL619380,,Inhibitory activity against lipoxygenase-2 in mice
B,,,,,1,Expert,,6339,,H,3865,8,,,17087,,,,BAO_0000357,CHEMBL619381,,Inhibitory activity against murine lipoxygenase-2.
B,Mus musculus,10090.0,,,1,Expert,,12281,,D,3866,9,,,17087,,,,BAO_0000357,CHEMBL619382,,Inhibition of 5-lipoxygenase from mouse macrophage
B,,,,,1,Autocuration,,11311,,H,3867,8,,,17087,,,,BAO_0000357,CHEMBL619383,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages
B,Sus scrofa,9823.0,,,1,Autocuration,,11089,,H,3868,8,,,55,,,,BAO_0000019,CHEMBL619384,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.
B,Sus scrofa,9823.0,,,1,Autocuration,,10091,,H,3869,8,,,55,,,,BAO_0000019,CHEMBL619385,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes
B,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,14352,,H,3870,8,,,55,,,,BAO_0000019,CHEMBL882928,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes
B,Rattus norvegicus,10116.0,,,1,Expert,,13329,,D,3871,9,,,12166,,,,BAO_0000019,CHEMBL619386,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE
B,,,,,1,Autocuration,,13329,,H,3872,8,,,12166,,,,BAO_0000019,CHEMBL619387,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. "
B,,,,,1,Autocuration,,13329,,H,3873,8,,,12166,,,,BAO_0000019,CHEMBL619388,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
B,,,,,1,Autocuration,,13329,,H,3874,8,,,12166,,,,BAO_0000019,CHEMBL619389,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4."
B,,,,,1,Expert,,13329,,H,3875,8,,,12166,,,,BAO_0000019,CHEMBL619390,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation)
B,,,,,1,Expert,,13329,,H,3876,8,,,12166,,,,BAO_0000019,CHEMBL619391,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM"
B,,,,,1,Autocuration,,13329,,H,3877,8,,,12166,,,,BAO_0000019,CHEMBL619392,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE
B,,,,,1,Autocuration,,11311,,H,3878,8,,,12166,,,,BAO_0000019,CHEMBL619393,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo)
B,,,,,1,Autocuration,,11311,,H,3879,8,,,12166,,,,BAO_0000019,CHEMBL619394,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration
B,,,,RBL-1,1,Autocuration,,105,,H,3880,8,702.0,,12166,,,,BAO_0000219,CHEMBL619395,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
B,,,,RBL-1,1,Autocuration,,105,,H,3881,8,702.0,,12166,,,,BAO_0000219,CHEMBL619396,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
B,,,,,1,Autocuration,,9138,,H,3882,8,,,12166,,,,BAO_0000357,CHEMBL619397,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO)
B,,,,,1,Autocuration,,9138,,H,3883,8,,,12166,,,,BAO_0000357,CHEMBL619398,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),"
B,,,,,1,Autocuration,,9138,,H,3884,8,,,12166,,,,BAO_0000357,CHEMBL619399,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),"
B,,,,,1,Autocuration,,14427,,H,3885,8,,,12166,,,,BAO_0000357,CHEMBL619400,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
B,,,,,1,Autocuration,,13329,,H,3886,8,,,12166,,,,BAO_0000019,CHEMBL619401,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
B,,,,,1,Autocuration,,13329,,H,3887,8,,,12166,,,,BAO_0000019,CHEMBL619402,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. "
B,Rattus norvegicus,10116.0,,RBL-2H3,1,Expert,,14427,,D,3888,9,663.0,,12166,,,,BAO_0000219,CHEMBL619403,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells
B,,,,,1,Autocuration,,14427,,H,3889,8,,,12166,,,,BAO_0000357,CHEMBL619404,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
B,,,,,1,Autocuration,,14427,,H,3890,8,,,12166,,,,BAO_0000357,CHEMBL619405,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.
B,,,,RBL-1,1,Expert,,10293,,H,3891,8,702.0,,12166,,,,BAO_0000219,CHEMBL619406,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,338,,D,3892,9,702.0,,12166,,,,BAO_0000219,CHEMBL619407,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells
B,,,,,1,Autocuration,,303,,H,3893,8,,,12166,,,,BAO_0000357,CHEMBL619408,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase)
B,,,,RBL-1,1,Autocuration,,303,,H,3894,8,702.0,,12166,,,,BAO_0000219,CHEMBL619409,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
B,,,,RBL-1,1,Expert,,9247,,H,3895,8,702.0,,12166,,,,BAO_0000219,CHEMBL619410,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase
B,,,,RBL-1,1,Autocuration,,9247,,H,3896,8,702.0,,12166,,,,BAO_0000219,CHEMBL619753,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
B,,,,RBL-1,1,Autocuration,,137,,H,3897,8,702.0,,12166,,,,BAO_0000219,CHEMBL619754,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
B,,,,,1,Expert,,11481,,H,3898,8,,,12166,,,,BAO_0000357,CHEMBL619903,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase
B,,,,,1,Expert,,11481,,H,3899,8,,,12166,,,,BAO_0000357,CHEMBL619904,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration"
B,,,,,1,Expert,,9029,,H,3900,8,,,12166,,,,BAO_0000357,CHEMBL619905,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro
B,,,,,1,Autocuration,,1701,,H,3901,8,,,12166,,,,BAO_0000019,CHEMBL619906,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells
B,,,,,1,Autocuration,,1701,,H,3902,8,,,12166,,,,BAO_0000019,CHEMBL619907,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active
B,,,,,1,Autocuration,,1701,,H,3903,8,,,12166,,,,BAO_0000019,CHEMBL619908,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active
B,,,,,1,Autocuration,,1701,,H,3904,8,,,12166,,,,BAO_0000019,CHEMBL619909,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data
F,,,,RBL-1,1,Expert,,13358,,H,3905,8,702.0,,12166,,,,BAO_0000219,CHEMBL619910,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant
B,,,,RBL-1,1,Expert,,1175,,H,3906,8,702.0,,12166,,,,BAO_0000219,CHEMBL882929,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
B,,,,RBL-1,1,Expert,,8797,,H,3907,8,702.0,,12166,,,,BAO_0000219,CHEMBL619911,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.
B,,,,,1,Autocuration,,8797,,H,3908,8,,,12166,,,,BAO_0000019,CHEMBL619912,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data
B,Rattus norvegicus,10116.0,,,1,Expert,,577,,D,3909,9,,,12166,,,,BAO_0000357,CHEMBL619913,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase
B,,,,RBL-1,1,Expert,,9295,,H,3910,8,702.0,,12166,,,,BAO_0000219,CHEMBL619914,,In vitro inhibitory activity against RBL-1 5-LO
B,,,,RBL-1,1,Autocuration,,9295,,H,3911,8,702.0,,12166,,,,BAO_0000219,CHEMBL619915,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM)
B,,,,RBL-1,1,Autocuration,,9295,,H,3912,8,702.0,,12166,,,,BAO_0000219,CHEMBL619916,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent)
B,,,,,1,Autocuration,,9295,,H,3913,8,,,12166,,,,BAO_0000218,CHEMBL619917,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.
B,,,,,1,Autocuration,,9295,,H,3914,8,,,12166,,,,BAO_0000357,CHEMBL619918,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme
B,,,,,1,Autocuration,,216,,H,3915,8,,,12166,,,,BAO_0000218,CHEMBL619919,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.
B,,,,RBL-1,1,Autocuration,,11090,,H,3916,8,702.0,,12166,,,,BAO_0000219,CHEMBL883710,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.
B,,,,,1,Autocuration,,11090,,H,3917,8,,,12166,Blood,178.0,,BAO_0000019,CHEMBL619920,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.
B,,,,,1,Expert,,10091,,H,3918,8,,,12166,,,,BAO_0000357,CHEMBL619921,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase
F,,,,,1,Autocuration,,10274,,H,3919,8,,,12166,,,,BAO_0000019,CHEMBL619922,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.
F,,,,,1,Autocuration,,13622,,H,3920,8,,,12166,,,,BAO_0000219,CHEMBL619923,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes
B,,,,RBL-1,1,Expert,,12118,,H,3921,8,702.0,,12166,,,,BAO_0000219,CHEMBL619924,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
B,,,,,1,Expert,,12576,,H,3922,8,,,12166,,,,BAO_0000357,CHEMBL619925,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay
B,,,,RBL-1,1,Expert,,9546,,H,3923,8,702.0,,12166,,,,BAO_0000219,CHEMBL619926,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells
B,,,,RBL-1,1,Autocuration,,9521,,H,3924,8,702.0,,12166,,,,BAO_0000219,CHEMBL619927,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells
B,,,,RBL-1,1,Expert,,10626,,H,3925,8,702.0,,12166,,,,BAO_0000219,CHEMBL619928,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
B,,,,RBL-1,1,Autocuration,,9225,,H,3926,8,702.0,,12166,,,,BAO_0000219,CHEMBL619929,,In vitro inhibition of RBL-1 5-lipoxygenase
B,,,,RBL-1,1,Autocuration,,9225,,H,3927,8,702.0,,12166,,,,BAO_0000219,CHEMBL875089,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31
B,,,,RBL-1,1,Autocuration,,9225,,H,3928,8,702.0,,12166,,,,BAO_0000219,CHEMBL619930,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6
B,,,,RBL-1,1,Autocuration,,9225,,H,3929,8,702.0,,12166,,,,BAO_0000219,CHEMBL619931,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2
B,,,,RBL-1,1,Autocuration,,9225,,H,3930,8,702.0,,12166,,,,BAO_0000219,CHEMBL619932,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07
B,,,,RBL-1,1,Autocuration,,9225,,H,3931,8,702.0,,12166,,,,BAO_0000219,CHEMBL619933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0
B,,,,RBL-1,1,Autocuration,,9225,,H,3932,8,702.0,,12166,,,,BAO_0000219,CHEMBL619934,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5
B,,,,RBL-1,1,Autocuration,,9225,,H,3933,8,702.0,,12166,,,,BAO_0000219,CHEMBL619935,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7
B,,,,RBL-1,1,Autocuration,,9225,,H,3934,8,702.0,,12166,,,,BAO_0000219,CHEMBL619936,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4
B,,,,RBL-1,1,Autocuration,,9225,,H,3935,8,702.0,,12166,,,,BAO_0000219,CHEMBL619937,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54
B,,,,RBL-1,1,Autocuration,,9225,,H,3936,8,702.0,,12166,,,,BAO_0000219,CHEMBL619938,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6
B,,,,RBL-1,1,Autocuration,,9225,,H,3937,8,702.0,,12166,,,,BAO_0000219,CHEMBL619939,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8
B,,,,RBL-1,1,Autocuration,,9225,,H,3938,8,702.0,,12166,,,,BAO_0000219,CHEMBL619940,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2
B,,,,RBL-1,1,Autocuration,,9225,,H,3939,8,702.0,,12166,,,,BAO_0000219,CHEMBL875090,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6
B,,,,RBL-1,1,Autocuration,,9225,,H,3940,8,702.0,,12166,,,,BAO_0000219,CHEMBL619941,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8
B,,,,RBL-1,1,Autocuration,,9225,,H,3941,8,702.0,,12166,,,,BAO_0000219,CHEMBL619942,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7
B,,,,RBL-1,1,Autocuration,,9225,,H,3942,8,702.0,,12166,,,,BAO_0000219,CHEMBL883711,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4
B,,,,RBL-1,1,Autocuration,,9225,,H,3943,8,702.0,,12166,,,,BAO_0000219,CHEMBL619943,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8
B,,,,RBL-1,1,Autocuration,,9225,,H,3944,8,702.0,,12166,,,,BAO_0000219,CHEMBL619944,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63
B,,,,RBL-1,1,Autocuration,,9225,,H,3945,8,702.0,,12166,,,,BAO_0000219,CHEMBL619945,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5
B,,,,RBL-1,1,Autocuration,,9225,,H,3946,8,702.0,,12166,,,,BAO_0000219,CHEMBL619946,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1
B,,,,RBL-1,1,Autocuration,,9225,,H,3947,8,702.0,,12166,,,,BAO_0000219,CHEMBL619947,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4
B,,,,RBL-1,1,Autocuration,,9225,,H,3948,8,702.0,,12166,,,,BAO_0000219,CHEMBL619948,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6
B,,,,RBL-1,1,Autocuration,,9225,,H,3949,8,702.0,,12166,,,,BAO_0000219,CHEMBL619949,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8
B,,,,,1,Expert,,9401,,H,3950,8,,,12166,,,,BAO_0000019,CHEMBL619950,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.
B,,,,,1,Autocuration,,10325,,H,3951,8,,,12166,,,,BAO_0000019,CHEMBL618050,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay
F,,,,RBL-2H3,1,Expert,,1556,,H,3952,8,663.0,,12166,,,,BAO_0000219,CHEMBL875091,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.
F,,,,RBL-2H3,1,Expert,,1556,,H,3953,8,663.0,,12166,,,,BAO_0000219,CHEMBL618051,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,961,,D,3954,9,702.0,,12166,,,,BAO_0000219,CHEMBL618052,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells
B,,,,,1,Autocuration,,6838,,H,3955,8,,,12166,,,,BAO_0000019,CHEMBL618053,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate
B,,,,,1,Expert,,10325,,H,3956,8,,,12166,,,,BAO_0000019,CHEMBL618054,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay)
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,9209,,D,3957,9,702.0,,12166,,,,BAO_0000219,CHEMBL618055,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
B,,,,RBL-1,1,Expert,,11520,,H,3958,8,702.0,,12166,,,,BAO_0000219,CHEMBL618056,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.
B,,,,,1,Autocuration,,137,,H,3959,8,,,12166,,,,BAO_0000357,CHEMBL618057,,In vitro inhibitory activity against 5-lipoxygenase was determined
B,,,,RBL-1,1,Autocuration,,4717,,H,3960,8,702.0,,12166,,,,BAO_0000219,CHEMBL618058,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells
B,,,,RBL-1,1,Expert,,10636,,H,3961,8,702.0,,12166,,,,BAO_0000219,CHEMBL618059,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line
F,Rattus norvegicus,10116.0,,,1,Expert,,14312,,D,3962,9,,,12166,,,,BAO_0000019,CHEMBL618060,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate
B,,,,RBL-1,1,Autocuration,,1203,,H,3963,8,702.0,,12166,,,,BAO_0000219,CHEMBL618061,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells
B,,,,,1,Autocuration,,1203,,H,3964,8,,,12166,,,,BAO_0000019,CHEMBL618062,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells
B,,,,RBL-1,1,Expert,,13622,,H,3965,8,702.0,,12166,,,,BAO_0000219,CHEMBL618063,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation
B,,,,,1,Autocuration,,9793,,H,3966,8,,,12166,,,,BAO_0000357,CHEMBL618064,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,1143,,D,3967,9,702.0,,12166,,,,BAO_0000219,CHEMBL618065,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,11854,,D,3968,9,702.0,,12166,,,,BAO_0000219,CHEMBL618066,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
B,,,,RBL-1,1,Autocuration,,3595,,H,3969,8,702.0,,12166,,,,BAO_0000219,CHEMBL618067,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
B,,,,RBL-1,1,Autocuration,,3595,,H,3970,8,702.0,,12166,,,,BAO_0000219,CHEMBL618068,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,10501,,D,3971,9,702.0,,12166,,,,BAO_0000219,CHEMBL618069,,Inhibition of 5-lipoxygenase in rat RBL-1 cells
B,,,,RBL-1,1,Expert,,12526,,H,3972,8,702.0,,12166,,,,BAO_0000219,CHEMBL618070,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
F,,,,,1,Autocuration,,10034,,H,3973,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL618071,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg
F,,,,,1,Autocuration,,10034,,H,3974,8,,,10825,Limbic system,349.0,,BAO_0000019,CHEMBL619247,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
F,,,,,1,Autocuration,,10034,,H,3975,8,,,10825,,,,BAO_0000019,CHEMBL619248,,Approximate dose levels for a half maximal reduction of 5-HTP levels
B,,,,,1,Autocuration,,10046,,H,3976,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619249,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
B,,,,,1,Autocuration,,10046,,H,3977,8,,,10576,Hippocampus,10000000.0,,BAO_0000221,CHEMBL619250,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
B,,,,,1,Autocuration,,10046,,H,3978,8,,,10577,,,,BAO_0000019,CHEMBL619251,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12079,,H,3979,8,,,55,Blood,178.0,,BAO_0000019,CHEMBL619252,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood
F,,,,,1,Autocuration,,12079,,H,3980,8,,,55,Blood,178.0,,BAO_0000019,CHEMBL619253,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood
B,,,,,1,Autocuration,,11311,,H,3981,8,,,12166,,,,BAO_0000219,CHEMBL619254,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
B,,,,,1,Expert,,12338,,H,3982,8,,,17140,,,,BAO_0000219,CHEMBL619255,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes
B,,,,,1,Expert,,12143,,H,3983,8,,,17140,,,,BAO_0000219,CHEMBL619256,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).
B,,,,,1,Autocuration,,12143,,H,3984,8,,,17140,,,,BAO_0000219,CHEMBL875418,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL)
B,,,,,1,Expert,,12143,,H,3985,8,,,17140,,,,BAO_0000219,CHEMBL619257,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
B,,,,,1,Autocuration,,12143,,H,3986,8,,,17140,,,,BAO_0000219,CHEMBL619258,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
B,,,,,1,Expert,,12365,,H,3987,8,,,17140,,,,BAO_0000357,CHEMBL619259,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.
B,,,,,1,Expert,,13500,,H,3988,8,,,17140,,,,BAO_0000357,CHEMBL619260,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3989,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619261,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3990,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619263,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3991,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619264,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3992,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619265,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3993,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619266,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3994,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619902,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3995,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620058,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3996,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620059,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3997,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620060,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3998,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620061,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,3999,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620062,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4000,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620063,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4001,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620064,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4002,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620065,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4003,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620066,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4004,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620067,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4005,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620068,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4006,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620069,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4007,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620070,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4008,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620071,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4009,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620072,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4010,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620036,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4011,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL857702,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4012,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620037,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4013,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620038,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4014,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620039,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4015,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620040,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4016,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620041,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4017,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620042,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4018,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620043,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4019,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620044,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4020,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620045,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4021,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620046,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4022,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620047,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4023,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620048,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4024,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL857703,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4025,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620049,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4026,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620050,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4027,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL620051,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4028,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619213,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4029,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619214,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4030,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619804,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4031,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619805,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4032,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619806,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4033,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619807,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,12832,,H,4034,8,,,55,Blood,178.0,In vivo,BAO_0000218,CHEMBL619808,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4035,8,,,55,,,,BAO_0000218,CHEMBL619809,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4036,8,,,55,,,,BAO_0000218,CHEMBL619810,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4037,8,,,55,,,,BAO_0000218,CHEMBL619811,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4038,8,,,55,,,,BAO_0000218,CHEMBL620769,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4039,8,,,55,,,,BAO_0000218,CHEMBL620770,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4040,8,,,55,,,,BAO_0000218,CHEMBL620771,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4041,8,,,55,,,,BAO_0000218,CHEMBL620772,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,3595,,H,4042,8,,,55,,,,BAO_0000218,CHEMBL620773,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine
B,Cavia porcellus,10141.0,,,1,Autocuration,,9203,,H,4043,8,,,55,,,,BAO_0000357,CHEMBL620774,,Ability to inhibit 5-lipoxygenase in guinea pig
B,Cavia porcellus,10141.0,,,1,Expert,,82,,H,4044,8,,,55,,,,BAO_0000357,CHEMBL620775,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN)
B,Cavia porcellus,10141.0,,,1,Autocuration,,11090,,H,4045,8,,,55,,,,BAO_0000357,CHEMBL620776,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.
B,Cavia porcellus,10141.0,,,1,Autocuration,,12832,,H,4046,8,,,55,Blood,178.0,,BAO_0000218,CHEMBL620777,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg"
B,Cavia porcellus,10141.0,,,1,Autocuration,,1065,,H,4047,8,,,55,,,,BAO_0000357,CHEMBL620778,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production
B,Cavia porcellus,10141.0,,,1,Autocuration,,1065,,H,4048,8,,,55,,,,BAO_0000357,CHEMBL620779,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production
B,Cavia porcellus,10141.0,,,1,Expert,,12832,,H,4049,8,,,55,,,,BAO_0000019,CHEMBL621500,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes
B,Cavia porcellus,10141.0,,,1,Expert,,12832,,H,4050,8,,,55,,,,BAO_0000019,CHEMBL621501,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
B,Cavia porcellus,10141.0,,,1,Autocuration,,12832,,H,4051,8,,,55,,,,BAO_0000019,CHEMBL618098,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
B,Cavia porcellus,10141.0,,,1,Autocuration,,10504,,H,4052,8,,,55,,,,BAO_0000019,CHEMBL618099,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
B,Cavia porcellus,10141.0,,,1,Autocuration,,7788,,H,4053,8,,,55,,,,BAO_0000357,CHEMBL618100,,Inhibitory activity against 5-lipoxygenase
B,Cavia porcellus,10141.0,,,1,Autocuration,,10001,,H,4054,8,,,55,,,,BAO_0000357,CHEMBL618101,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte
B,Cavia porcellus,10141.0,,,1,Autocuration,,10193,,H,4055,8,,,55,,,,BAO_0000357,CHEMBL618102,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant
B,Cavia porcellus,10141.0,,,1,Autocuration,,13243,,H,4056,8,,,55,,,,BAO_0000357,CHEMBL618103,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase
B,Cavia porcellus,10141.0,,,1,Autocuration,,13243,,H,4057,8,,,55,,,,BAO_0000357,CHEMBL618104,,Inhibitory activity uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,969,,H,4058,8,,,55,,,,BAO_0000219,CHEMBL883712,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined
B,Cavia porcellus,10141.0,,,1,Autocuration,,10001,,H,4059,8,,,55,,,,BAO_0000357,CHEMBL618105,,Inhibitory activity against 5-lipoxygenase at 10 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,7788,,H,4060,8,,,55,,,,BAO_0000357,CHEMBL618106,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
B,Cavia porcellus,10141.0,,,1,Autocuration,,10001,,H,4061,8,,,55,,,,BAO_0000357,CHEMBL618107,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,10193,,H,4062,8,,,55,,,,BAO_0000357,CHEMBL618108,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,13243,,H,4063,8,,,55,,,,BAO_0000357,CHEMBL618109,,Inhibitory activity uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,13243,,H,4064,8,,,55,,,,BAO_0000357,CHEMBL618110,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM
B,Cavia porcellus,10141.0,,,1,Expert,,13243,,H,4065,8,,,55,,,,BAO_0000357,CHEMBL618111,,Inhibitory activity uM
F,Cavia porcellus,10141.0,,,1,Autocuration,,13243,,H,4066,8,,,55,,,,BAO_0000019,CHEMBL618112,,Inhibitory activity uM
B,Cavia porcellus,10141.0,,,1,Autocuration,,10504,,H,4067,8,,,55,,,,BAO_0000019,CHEMBL618113,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
B,Cavia porcellus,10141.0,,,1,Autocuration,,7788,,H,4068,8,,,55,,,,BAO_0000357,CHEMBL618114,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
F,Cavia porcellus,10141.0,,,1,Expert,,10546,,H,4069,8,,,55,Ileum,2116.0,,BAO_0000221,CHEMBL620871,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum
B,,,,,1,Autocuration,,13183,,H,4070,8,,,55,,,,BAO_0000357,CHEMBL620872,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
B,,,,,1,Autocuration,,13183,,H,4071,8,,,55,,,,BAO_0000357,CHEMBL620873,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
B,,,,,1,Autocuration,,2578,,H,4072,8,,,55,,,,BAO_0000357,CHEMBL620874,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO)
B,,,,,1,Expert,,12780,,H,4073,8,,,55,,,,BAO_0000357,CHEMBL620875,,In vitro inhibition of human 5-Lipoxygenase.
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4074,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620876,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4075,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620877,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4076,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL857854,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4077,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620878,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4078,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620879,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4079,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620880,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4080,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620881,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4081,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620882,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4082,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620883,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4083,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620884,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4084,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620885,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4085,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620886,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4086,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620887,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4087,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618039,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4088,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618040,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4089,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618041,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4090,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618216,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4091,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618217,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4092,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618218,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4093,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618219,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4094,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618220,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4095,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618221,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4096,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618222,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4097,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618223,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4098,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618224,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4099,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618225,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4100,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618226,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4101,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618227,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4102,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618228,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4103,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618229,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4104,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618230,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4105,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618231,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4106,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618232,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4107,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618233,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4108,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618234,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4109,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618235,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4110,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618115,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4111,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618116,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4112,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL618117,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4113,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619968,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4114,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619969,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4115,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619970,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4116,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619971,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4117,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619972,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4118,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619973,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4119,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619974,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4120,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619975,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4121,0,,,22226,,,,BAO_0000251,CHEMBL619976,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4122,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619977,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4123,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619978,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4124,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619979,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4125,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619980,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4126,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619981,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,10797,,N,4127,1,741.0,,80433,,,,BAO_0000219,CHEMBL619982,,In vitro inhibition of 7226/S myeloma cancer cell line
F,Homo sapiens,9606.0,,BEL-7404 tumor cell line,1,Intermediate,,6881,,N,4128,1,993.0,,80698,,,,BAO_0000219,CHEMBL619983,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells)
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,3838,,N,4129,1,391.0,,80640,,,,BAO_0000219,CHEMBL620031,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,3838,,N,4130,1,391.0,,80640,,,,BAO_0000219,CHEMBL620032,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
F,Cricetulus griseus,10029.0,,V79,1,Expert,,12981,,N,4131,1,505.0,,81264,,,,BAO_0000219,CHEMBL620033,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.
F,Cricetulus griseus,10029.0,,V79,1,Expert,,12981,,N,4132,1,505.0,,81264,,,,BAO_0000219,CHEMBL620034,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4133,1,1119.0,,80635,,,,BAO_0000219,CHEMBL620035,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4134,1,1119.0,,80635,,,,BAO_0000219,CHEMBL618318,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4135,1,1119.0,,80635,,,,BAO_0000219,CHEMBL618319,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4136,1,1119.0,,80635,,,,BAO_0000219,CHEMBL618320,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4137,1,1119.0,,80635,,,,BAO_0000219,CHEMBL618321,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose
F,Rattus norvegicus,10116.0,,7800C1 cell line,1,Intermediate,,7653,,N,4138,1,1119.0,,80635,,,,BAO_0000219,CHEMBL883118,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,17229,,N,4139,1,391.0,,80640,,,,BAO_0000219,CHEMBL883795,,In vitro antitumor activity against renal 786-0 tumor cell lines
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,12858,,N,4140,1,391.0,,80640,,,,BAO_0000219,CHEMBL618322,,Cytotoxic activity against 786-0 Renal cancer cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16325,,N,4141,1,391.0,,80640,,,,BAO_0000219,CHEMBL618323,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16325,,N,4142,1,391.0,,80640,,,,BAO_0000219,CHEMBL618324,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,5858,,N,4143,1,391.0,,80640,,,,BAO_0000219,CHEMBL618325,,In vitro antitumor activity against human renal 786-0 cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16325,,N,4144,1,391.0,,80640,,,,BAO_0000219,CHEMBL875416,,Inhibition of Renal cancer in 786-0 cancer cell lines
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14696,,N,4145,1,391.0,,80640,,,,BAO_0000219,CHEMBL618326,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,3786,,N,4146,1,391.0,,80640,,,,BAO_0000219,CHEMBL618327,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14696,,N,4147,1,391.0,,80640,,,,BAO_0000219,CHEMBL619215,,inhibition of the growth of renal cancer(786-0) cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14769,,N,4148,1,391.0,,80640,,,,BAO_0000219,CHEMBL619216,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,15354,,N,4149,1,391.0,,80640,,,,BAO_0000219,CHEMBL619217,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14255,,N,4150,1,391.0,,80640,,,,BAO_0000219,CHEMBL619218,,The IC50 value was measured on 786-0 cell line in ovarian tumor
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14255,,N,4151,1,391.0,,80640,,,,BAO_0000219,CHEMBL619219,,The IC50 value was measured on 786-0 cell line in ovarian tumor t
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14255,,N,4152,1,391.0,,80640,,,,BAO_0000219,CHEMBL619220,,The IC50 value was measured on 786-0 cell line in renal tumor type.
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14696,,N,4153,1,391.0,,80640,,,,BAO_0000219,CHEMBL619221,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,12016,,N,4154,1,391.0,,80640,,,,BAO_0000219,CHEMBL619222,,Tested for cytotoxic activity against renal cancer 786-0 cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,2597,,N,4155,1,391.0,,80640,,,,BAO_0000219,CHEMBL857454,,Compound was tested for growth inhibitory activity against 786-0 cell line
B,,,,RBL-1,1,Autocuration,,12526,,H,4156,8,702.0,,12166,,,,BAO_0000219,CHEMBL619223,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM
B,,,,RBL-1,1,Autocuration,,12526,,H,4157,8,702.0,,12166,,,,BAO_0000219,CHEMBL619224,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive
B,,,,,1,Autocuration,,14799,,H,4158,8,,,12166,,,,BAO_0000019,CHEMBL619225,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
B,,,,RBL-1,1,Expert,,3595,,H,4159,8,702.0,,12166,,,,BAO_0000219,CHEMBL619226,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
B,,,,RBL-1,1,Expert,,3595,,H,4160,8,702.0,,12166,,,,BAO_0000219,CHEMBL619227,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
B,,,,,1,Autocuration,,12767,,H,4161,8,,,12166,,,,BAO_0000357,CHEMBL619228,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase
B,,,,,1,Autocuration,,10997,,H,4162,8,,,12166,,,,BAO_0000219,CHEMBL619229,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes
B,,,,RBL-1,1,Autocuration,,11388,,H,4163,8,702.0,,12166,,,,BAO_0000219,CHEMBL619230,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
B,,,,,1,Autocuration,,167,,H,4164,8,,,12166,,,,BAO_0000357,CHEMBL619231,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated
B,,,,,1,Autocuration,,167,,H,4165,8,,,12166,,,,BAO_0000357,CHEMBL619232,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated"
B,,,,,1,Expert,,13744,,H,4166,8,,,12166,,,,BAO_0000357,CHEMBL619233,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.
B,,,,,1,Autocuration,,1630,,H,4167,8,,,12166,,,,BAO_0000357,CHEMBL619234,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase
B,,,,,1,Autocuration,,1630,,H,4168,8,,,12166,,,,BAO_0000357,CHEMBL619235,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO)
B,Rattus norvegicus,10116.0,,,1,Expert,,969,,D,4169,9,,,12166,,,,BAO_0000019,CHEMBL619236,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production"
B,,,,RBL-1,1,Autocuration,,13621,,H,4170,8,702.0,,12166,,,,BAO_0000219,CHEMBL619237,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells
B,,,,,1,Autocuration,,10089,,H,4171,8,,,12166,,,,BAO_0000357,CHEMBL619238,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat
B,,,,,1,Expert,,10193,,H,4172,8,,,12166,,,,BAO_0000357,CHEMBL619239,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase
B,,,,,1,Autocuration,,11966,,H,4173,8,,,12166,,,,BAO_0000357,CHEMBL619240,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM
B,,,,,1,Autocuration,,12251,,H,4174,8,,,12166,,,,BAO_0000019,CHEMBL875417,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
B,,,,RBL-1,1,Autocuration,,211,,H,4175,8,702.0,,12166,,,,BAO_0000219,CHEMBL619241,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
F,,,,,1,Expert,,12251,,H,4176,8,,,12166,,,,BAO_0000019,CHEMBL619242,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
B,,,,RBL-1,1,Autocuration,,12495,,H,4177,8,702.0,,12166,,,,BAO_0000219,CHEMBL883796,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells
B,,,,,1,Autocuration,,414,,H,4178,8,,,12166,,,,BAO_0000357,CHEMBL619243,,Tested for its inhibitory activity against 5-lipoxygenase
B,,,,,1,Autocuration,,414,,H,4179,8,,,12166,,,,BAO_0000357,CHEMBL619244,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined
B,,,,,1,Expert,,10325,,H,4180,8,,,12166,,,,BAO_0000019,CHEMBL619245,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)"
B,,,,,1,Expert,,11966,,H,4181,8,,,12166,,,,BAO_0000019,CHEMBL619246,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
B,,,,RBL-1,1,Expert,,165,,H,4182,8,702.0,,12166,,,,BAO_0000219,CHEMBL619984,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.
B,,,,RBL-1,1,Autocuration,,165,,H,4183,8,702.0,,12166,,,,BAO_0000219,CHEMBL619985,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM
B,,,,RBL-1,1,Autocuration,,165,,H,4184,8,702.0,,12166,,,,BAO_0000219,CHEMBL619986,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
B,,,,RBL-1,1,Expert,,165,,H,4185,8,702.0,,12166,,,,BAO_0000219,CHEMBL619987,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
B,,,,,1,Autocuration,,11311,,H,4186,8,,,12166,,,,BAO_0000218,CHEMBL619988,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse
B,,,,RBL-1,1,Autocuration,,11311,,H,4187,8,702.0,,12166,,,,BAO_0000219,CHEMBL619989,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1
B,,,,RBL-1,1,Autocuration,,11311,,H,4188,8,702.0,,12166,,,,BAO_0000219,CHEMBL619990,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
B,,,,,1,Autocuration,,11311,,H,4189,8,,,12166,,,,BAO_0000219,CHEMBL619991,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
B,,,,,1,Autocuration,,11311,,H,4190,8,,,12166,,,,BAO_0000219,CHEMBL619992,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro)
B,,,,,1,Autocuration,,11311,,H,4191,8,,,12166,,,In vivo,BAO_0000218,CHEMBL619993,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo)
F,,,,RBL-2H3,1,Autocuration,,11311,,H,4192,8,663.0,,12166,,,,BAO_0000219,CHEMBL619994,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells
F,,,,RBL-2H3,1,Autocuration,,11311,,H,4193,8,663.0,,12166,,,,BAO_0000219,CHEMBL619995,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells
B,,,,,1,Autocuration,,11311,,H,4194,8,,,12166,,,,BAO_0000019,CHEMBL619996,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS]
B,,,,,1,Autocuration,,11732,,H,4195,8,,,12166,,,,BAO_0000019,CHEMBL619997,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase
B,,,,,1,Expert,,11732,,H,4196,8,,,12166,,,,BAO_0000019,CHEMBL619998,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.
B,,,,,1,Expert,,11087,,H,4197,8,,,12166,,,,BAO_0000019,CHEMBL619999,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells
B,,,,,1,Autocuration,,11087,,H,4198,8,,,12166,,,,BAO_0000019,CHEMBL620000,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells
B,,,,RBL-1,1,Autocuration,,11087,,H,4199,8,702.0,,12166,,,,BAO_0000219,CHEMBL620001,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells
B,Rattus norvegicus,10116.0,,,1,Expert,,11087,,D,4200,9,,,12166,,,,BAO_0000357,CHEMBL620002,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL
B,,,,RBL-1,1,Autocuration,,496,,H,4201,8,702.0,,12166,,,,BAO_0000219,CHEMBL620003,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells
F,,,,RBL-1,1,Expert,,13986,,H,4202,8,702.0,,12166,,,,BAO_0000219,CHEMBL620004,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production
B,,,,,1,Autocuration,,11520,,H,4203,8,,,12166,,,,BAO_0000357,CHEMBL874063,,Compound was evaluated for the inhibition of 5-lipoxygenase
B,,,,RBL-1,1,Autocuration,,10293,,H,4204,8,702.0,,12166,,,,BAO_0000219,CHEMBL620005,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM
B,,,,RBL-1,1,Autocuration,,303,,H,4205,8,702.0,,12166,,,,BAO_0000219,CHEMBL620006,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay
B,,,,RBL-1,1,Autocuration,,303,,H,4206,8,702.0,,12166,,,,BAO_0000219,CHEMBL620007,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active
B,,,,RBL-1,1,Autocuration,,9247,,H,4207,8,702.0,,12166,,,,BAO_0000219,CHEMBL620008,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,9247,,D,4208,9,702.0,,12166,,,,BAO_0000219,CHEMBL620009,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM
B,,,,RBL-1,1,Autocuration,,9247,,H,4209,8,702.0,,12166,,,,BAO_0000219,CHEMBL620010,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
B,,,,RBL-1,1,Autocuration,,9247,,H,4210,8,702.0,,12166,,,,BAO_0000219,CHEMBL620011,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM
B,,,,RBL-1,1,Autocuration,,9247,,H,4211,8,702.0,,12166,,,,BAO_0000219,CHEMBL620677,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM
B,,,,RBL-1,1,Autocuration,,9247,,H,4212,8,702.0,,12166,,,,BAO_0000219,CHEMBL620678,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM
B,,,,RBL-1,1,Autocuration,,9247,,H,4213,8,702.0,,12166,,,,BAO_0000219,CHEMBL620679,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM
B,,,,RBL-1,1,Autocuration,,9247,,H,4214,8,702.0,,12166,,,,BAO_0000219,CHEMBL620680,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM
B,Rattus norvegicus,10116.0,,,1,Expert,,11481,,D,4215,9,,,12166,,,,BAO_0000357,CHEMBL620838,,Inhibitory activity against 5-lipoxygenase at 10 uM
B,,,,,1,Autocuration,,105,,H,4216,8,,,12166,,,,BAO_0000357,CHEMBL620839,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition
B,,,,,1,Expert,,9029,,H,4217,8,,,12166,,,,BAO_0000357,CHEMBL620840,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM
B,,,,RBL-1,1,Expert,,1175,,H,4218,8,702.0,,12166,,,,BAO_0000219,CHEMBL620841,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM
B,,,,RBL-1,1,Autocuration,,12118,,H,4219,8,702.0,,12166,,,,BAO_0000219,CHEMBL620842,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM
B,,,,RBL-1,1,Autocuration,,12118,,H,4220,8,702.0,,12166,,,,BAO_0000219,CHEMBL620843,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M
B,,,,RBL-1,1,Autocuration,,12118,,H,4221,8,702.0,,12166,,,,BAO_0000219,CHEMBL620844,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM
B,,,,RBL-1,1,Autocuration,,9225,,H,4222,8,702.0,,12166,,,,BAO_0000219,CHEMBL620845,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM
B,,,,,1,Autocuration,,9401,,H,4223,8,,,12166,,,,BAO_0000019,CHEMBL620846,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration
B,,,,,1,Autocuration,,137,,H,4224,8,,,12166,,,,BAO_0000357,CHEMBL873951,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
B,,,,,1,Autocuration,,137,,H,4225,8,,,12166,,,,BAO_0000357,CHEMBL620847,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
B,,,,RBL-1,1,Autocuration,,4717,,H,4226,8,702.0,,12166,,,,BAO_0000219,CHEMBL620848,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
B,,,,RBL-1,1,Autocuration,,3595,,H,4227,8,702.0,,12166,,,,BAO_0000219,CHEMBL620849,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
B,,,,RBL-1,1,Autocuration,,10501,,H,4228,8,702.0,,12166,,,,BAO_0000219,CHEMBL620850,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration
B,,,,RBL-1,1,Autocuration,,10501,,H,4229,8,702.0,,12166,,,,BAO_0000219,CHEMBL620851,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM
B,,,,RBL-1,1,Autocuration,,10501,,H,4230,8,702.0,,12166,,,,BAO_0000219,CHEMBL620852,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.
B,,,,RBL-1,1,Autocuration,,12526,,H,4231,8,702.0,,12166,,,,BAO_0000219,CHEMBL875098,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,14799,,D,4232,9,702.0,,12166,,,,BAO_0000219,CHEMBL620853,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM
B,,,,,1,Autocuration,,14799,,H,4233,8,,,12166,,,,BAO_0000019,CHEMBL620854,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested
B,,,,RBL-1,1,Autocuration,,3595,,H,4234,8,702.0,,12166,,,,BAO_0000219,CHEMBL620855,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
B,,,,RBL-1,1,Expert,,3595,,H,4235,8,702.0,,12166,,,,BAO_0000219,CHEMBL839884,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
B,,,,RBL-1,1,Autocuration,,12526,,H,4236,8,702.0,,12166,,,,BAO_0000219,CHEMBL620856,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
B,,,,RBL-1,1,Autocuration,,12526,,H,4237,8,702.0,,12166,,,,BAO_0000219,CHEMBL620857,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
B,,,,,1,Autocuration,,10193,,H,4238,8,,,12166,,,,BAO_0000019,CHEMBL620858,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
B,,,,,1,Autocuration,,10193,,H,4239,8,,,12166,,,,BAO_0000019,CHEMBL620859,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
B,,,,,1,Autocuration,,10193,,H,4240,8,,,12166,,,,BAO_0000019,CHEMBL620860,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
B,,,,,1,Autocuration,,10193,,H,4241,8,,,12166,,,,BAO_0000019,CHEMBL620861,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM
B,,,,,1,Expert,,9138,,H,4242,8,,,12166,,,,BAO_0000357,CHEMBL620862,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO)
B,,,,,1,Autocuration,,9138,,H,4243,8,,,12166,,,,BAO_0000357,CHEMBL620863,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM
B,,,,,1,Autocuration,,11966,,H,4244,8,,,12166,,,,BAO_0000019,CHEMBL620864,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
B,,,,RBL-1,1,Autocuration,,165,,H,4245,8,702.0,,12166,,,,BAO_0000219,CHEMBL620865,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM
B,,,,RBL-1,1,Autocuration,,165,,H,4246,8,702.0,,12166,,,,BAO_0000219,CHEMBL620866,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM
B,,,,RBL-2H3,1,Autocuration,,11311,,H,4247,8,663.0,,12166,,,,BAO_0000219,CHEMBL620867,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells
B,,,,RBL-2H3,1,Autocuration,,11311,,H,4248,8,663.0,,12166,,,,BAO_0000219,CHEMBL620868,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
F,,,,RBL-2H3,1,Autocuration,,11311,,H,4249,8,663.0,,12166,,,,BAO_0000219,CHEMBL620869,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
F,,,,,1,Autocuration,,11311,,H,4250,8,,,12166,,,,BAO_0000019,CHEMBL873952,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase
B,,,,,1,Autocuration,,11311,,H,4251,8,,,12166,,,,BAO_0000357,CHEMBL875099,,The compound was tested for inhibition of isolated 5-lipoxygenase
F,,,,RBL-2H3,1,Autocuration,,11311,,H,4252,8,663.0,,12166,,,,BAO_0000219,CHEMBL620870,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells
B,,,,,1,Autocuration,,11087,,H,4253,8,,,12166,,,,BAO_0000019,CHEMBL618261,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM
B,,,,,1,Autocuration,,11087,,H,4254,8,,,12166,,,,BAO_0000019,CHEMBL618262,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM
B,,,,,1,Autocuration,,11087,,H,4255,8,,,12166,,,,BAO_0000019,CHEMBL619428,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM
B,,,,,1,Autocuration,,11087,,H,4256,8,,,12166,,,,BAO_0000019,CHEMBL619429,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
B,,,,,1,Autocuration,,11087,,H,4257,8,,,12166,,,,BAO_0000019,CHEMBL619430,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
B,,,,RBL-1,1,Autocuration,,496,,H,4258,8,702.0,,12166,,,,BAO_0000219,CHEMBL620017,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM
B,,,,RBL-1,1,Autocuration,,496,,H,4259,8,702.0,,12166,,,,BAO_0000219,CHEMBL620018,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4260,8,702.0,,12166,,,,BAO_0000219,CHEMBL620019,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4261,8,702.0,,12166,,,,BAO_0000219,CHEMBL620020,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4262,8,702.0,,12166,,,,BAO_0000219,CHEMBL620021,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4263,8,702.0,,12166,,,,BAO_0000219,CHEMBL620022,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4264,8,702.0,,12166,,,,BAO_0000219,CHEMBL620023,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39
F,,,,RBL-1,1,Autocuration,,13986,,H,4265,8,702.0,,12166,,,,BAO_0000219,CHEMBL620024,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4266,8,702.0,,12166,,,,BAO_0000219,CHEMBL620025,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4267,8,702.0,,12166,,,,BAO_0000219,CHEMBL620026,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM
F,,,,RBL-1,1,Autocuration,,13986,,H,4268,8,702.0,,12166,,,,BAO_0000219,CHEMBL620027,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM
F,Rattus norvegicus,10116.0,,,1,Expert,,13986,,D,4269,9,,,12166,,,,BAO_0000019,CHEMBL620028,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM
B,,,,,1,Autocuration,,10193,,H,4270,8,,,12166,,,,BAO_0000357,CHEMBL620029,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase
B,,,,,1,Autocuration,,9295,,H,4271,8,,,12166,,,,BAO_0000357,CHEMBL620030,,Compound was tested for the percent of inhibition against 5-LO at 10 uM
B,,,,RBL-1,1,Autocuration,,4717,,H,4272,8,702.0,,12166,,,,BAO_0000219,CHEMBL875415,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration
B,,,,RBL-1,1,Autocuration,,4717,,H,4273,8,702.0,,12166,,,,BAO_0000219,CHEMBL618256,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
B,,,,RBL-1,1,Autocuration,,11854,,H,4274,8,702.0,,12166,,,,BAO_0000219,CHEMBL618257,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line
B,,,,RBL-1,1,Autocuration,,11854,,H,4275,8,702.0,,12166,,,,BAO_0000219,CHEMBL618258,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM
B,,,,RBL-1,1,Autocuration,,11854,,H,4276,8,702.0,,12166,,,,BAO_0000219,CHEMBL618259,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM
B,,,,,1,Autocuration,,10193,,H,4277,8,,,12166,,,,BAO_0000019,CHEMBL618260,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
B,,,,RBL-1,1,Autocuration,,9295,,H,4278,8,702.0,,12166,,,,BAO_0000219,CHEMBL618215,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM
B,,,,RBL-1,1,Autocuration,,9295,,H,4279,8,702.0,,12166,,,,BAO_0000219,CHEMBL618390,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM
B,,,,RBL-1,1,Autocuration,,9295,,H,4280,8,702.0,,12166,,,,BAO_0000219,CHEMBL618391,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM
B,,,,RBL-1,1,Autocuration,,9295,,H,4281,8,702.0,,12166,,,,BAO_0000219,CHEMBL618392,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM
B,,,,RBL-1,1,Autocuration,,165,,H,4282,8,702.0,,12166,,,,BAO_0000219,CHEMBL618393,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM
B,,,,,1,Autocuration,,11311,,H,4283,8,,,12166,,,,BAO_0000219,CHEMBL618394,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration
B,Homo sapiens,9606.0,,RBL-1,1,Expert,,10489,,H,4284,8,702.0,,12166,,,,BAO_0000219,CHEMBL618395,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,10489,,D,4285,9,702.0,,12166,,,,BAO_0000219,CHEMBL618396,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
B,Rattus norvegicus,10116.0,,RBL-1,1,Expert,,10489,,D,4286,9,702.0,,12166,,,,BAO_0000219,CHEMBL858253,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)
B,Rattus norvegicus,10116.0,,,1,Autocuration,,14799,,D,4287,9,,,12166,,,,BAO_0000019,CHEMBL618397,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
B,Glycine max,3847.0,,,1,Autocuration,,9295,,H,4288,8,,,12054,,,,BAO_0000357,CHEMBL618398,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM)
B,,,,,1,Autocuration,,16811,,U,4289,0,,,22226,,,,BAO_0000019,CHEMBL618399,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay"
B,,,,,1,Expert,,168,,H,4290,8,,,55,,,,BAO_0000357,CHEMBL618400,,In vitro inhibition of 5-Lipoxygenase; Inactive.
B,,,,,1,Autocuration,,6309,,H,4291,8,,,55,,,,BAO_0000357,CHEMBL618401,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition
B,,,,,1,Autocuration,,6309,,H,4292,8,,,55,,,,BAO_0000357,CHEMBL618402,,Inhibitory concentration against 5-lipoxygenase; No inhibition
B,,,,RBL-1,1,Autocuration,,3092,,H,4293,8,702.0,,55,,,,BAO_0000219,CHEMBL876400,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig
B,,,,,1,Expert,,168,,H,4294,8,,,55,,,,BAO_0000357,CHEMBL618403,,Inhibitory activity against 5-lipoxygenase.
B,,,,,1,Autocuration,,168,,H,4295,8,,,55,,,,BAO_0000357,CHEMBL618404,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive
B,,,,,1,Autocuration,,168,,H,4296,8,,,55,,,,BAO_0000357,CHEMBL618405,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM
B,,,,,1,Autocuration,,168,,H,4297,8,,,55,,,,BAO_0000357,CHEMBL618406,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM
F,,,,,1,Expert,,12338,,H,4298,8,,,55,,,,BAO_0000019,CHEMBL618407,,Inhibitory concentration against arachidonic acid 5-lipoxygenation
B,,,,,1,Autocuration,,4501,,H,4299,8,,,55,,,,BAO_0000357,CHEMBL618408,,Tested for the inhibitory activity against 5-lipoxygenase
B,,,,,1,Autocuration,,1132,,H,4300,8,,,55,,,,BAO_0000357,CHEMBL618409,,Compound was tested for its inhibitory activity against 5-lipoxygenase
B,,,,,1,Autocuration,,2117,,H,4301,8,,,55,,,,BAO_0000357,CHEMBL618410,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed
B,,,,,1,Autocuration,,168,,H,4302,8,,,55,,,,BAO_0000357,CHEMBL618411,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active
B,,,,,1,Autocuration,,168,,H,4303,8,,,55,,,,BAO_0000357,CHEMBL618412,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined
B,,,,RBL-1,1,Autocuration,,13575,,H,4304,8,702.0,,12166,,,,BAO_0000219,CHEMBL618413,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase
B,,,,,1,Autocuration,,11089,,H,4305,8,,,12166,,,,BAO_0000357,CHEMBL618414,,
B,,,,,1,Autocuration,,216,,H,4306,8,,,10102,,,,BAO_0000357,CHEMBL618415,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP)
B,,,,,1,Autocuration,,13165,,H,4307,8,,,10102,,,,BAO_0000019,CHEMBL618416,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations
B,,,,,1,Autocuration,,3278,,H,4308,8,,,10102,,,,BAO_0000357,CHEMBL876401,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.
B,,,,,1,Expert,,3278,,H,4309,8,,,10102,,,,BAO_0000357,CHEMBL618417,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.
B,,,,,1,Autocuration,,11966,,H,4310,8,,,10102,,,,BAO_0000357,CHEMBL618418,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein
B,,,,,1,Autocuration,,175,,H,4311,8,,,10102,,,,BAO_0000357,CHEMBL618419,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein"
B,,,,,1,Autocuration,,175,,H,4312,8,,,10102,,,,BAO_0000357,CHEMBL618420,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)"
B,,,,,1,Autocuration,,13449,,H,4313,8,,,10102,,,,BAO_0000357,CHEMBL618421,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay
B,,,,,1,Autocuration,,12014,,H,4314,8,,,11238,,,,BAO_0000019,CHEMBL618422,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane
B,,,,,1,Autocuration,,12014,,H,4315,8,,,11238,,,,BAO_0000019,CHEMBL618423,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant)
B,,,,,1,Autocuration,,12014,,H,4316,8,,,11238,,,,BAO_0000019,CHEMBL618424,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate)
B,,,,,1,Intermediate,,99,,S,4317,2,,,100284,,,,BAO_0000220,CHEMBL618425,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit
F,Homo sapiens,9606.0,,,1,Autocuration,,4349,,U,4318,0,,,22226,,,,BAO_0000019,CHEMBL618426,,The dark toxicity against 543 human galactophore carcinoma cells
F,Homo sapiens,9606.0,,Panel (56 tumour cell lines),1,Expert,,4071,,N,4319,1,390.0,,80623,,,,BAO_0000219,CHEMBL618427,,Tested in vitro for cytotoxicity against 56 human tumor cell lines
F,Homo sapiens,9606.0,,5637,1,Expert,,17589,,N,4320,1,345.0,,80008,,,,BAO_0000219,CHEMBL618428,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value
F,Homo sapiens,9606.0,,5637,1,Intermediate,,15002,,N,4321,1,345.0,,80008,,,,BAO_0000219,CHEMBL618429,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
F,Homo sapiens,9606.0,,5637,1,Intermediate,,13958,,N,4322,1,345.0,,80008,,,,BAO_0000219,CHEMBL618430,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line"
F,Homo sapiens,9606.0,,5637,1,Expert,,17589,,N,4323,1,345.0,,80008,,,,BAO_0000219,CHEMBL618431,,Growth inhibition against human 5637 cell lines
F,Homo sapiens,9606.0,,5637,1,Expert,,16748,,N,4324,1,345.0,,80008,,,,BAO_0000219,CHEMBL883799,,Antitumor activity against human bladder carcinoma 5637 cells.
F,Homo sapiens,9606.0,,5637,1,Intermediate,,16747,,N,4325,1,345.0,,80008,,,,BAO_0000219,CHEMBL618432,,Antitumor activity against human bladder carcinoma 5637 cells
F,Homo sapiens,9606.0,,5637,1,Intermediate,,16747,,N,4326,1,345.0,,80008,,,,BAO_0000219,CHEMBL618433,,Antitumor activity against human bladder carcinoma 5637 cells
B,Bos taurus,9913.0,,,1,Expert,,15285,,D,4327,9,,,10443,,,,BAO_0000357,CHEMBL618434,,In vitro inhibition of bovine trypsin(Trp).
B,Cercopithecidae,9527.0,,CV-1,1,Expert,,3726,,H,4328,8,407.0,,240,,,,BAO_0000219,CHEMBL618435,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor
B,,,,,1,Autocuration,,5033,,H,4329,8,,,10577,,,,BAO_0000357,CHEMBL876402,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor
F,,,,,1,Autocuration,,11756,,H,4330,6,,,104698,,,,BAO_0000019,CHEMBL618436,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.
F,,,,,1,Autocuration,,11953,,U,4331,0,,,22226,,,In vivo,BAO_0000218,CHEMBL618437,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat
B,Cavia porcellus,10141.0,,,1,Intermediate,,5033,,D,4332,9,,,20033,,,,BAO_0000357,CHEMBL618438,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor
A,Rattus norvegicus,10116.0,,,1,Expert,Microsomes,11347,,H,4333,8,,,17045,,,,BAO_0000251,CHEMBL883800,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
A,Rattus norvegicus,10116.0,,,1,Expert,Microsomes,11347,,H,4334,8,,,17045,,,,BAO_0000251,CHEMBL618439,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
F,,,,,1,Intermediate,,1229,,U,4335,0,,,22226,,,,BAO_0000019,CHEMBL618440,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
F,,,,,1,Intermediate,,1229,,U,4336,0,,,22226,,,,BAO_0000019,CHEMBL618441,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
B,Trypanosoma brucei,5691.0,,,1,Expert,,17588,,H,4337,8,,,11938,,,,BAO_0000019,CHEMBL618442,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli
B,Trypanosoma brucei,5691.0,,,1,Autocuration,,17588,,H,4338,8,,,11938,,,,BAO_0000019,CHEMBL618443,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition
B,Ovis aries,9940.0,,,1,Expert,,17588,,H,4339,8,,,11938,,,,BAO_0000019,CHEMBL619158,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver
B,Ovis aries,9940.0,,,1,Autocuration,,17588,,H,4340,8,,,11938,,,,BAO_0000019,CHEMBL620974,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition
B,,,,,1,Autocuration,,16485,,H,4341,8,,,11938,,,,BAO_0000357,CHEMBL620975,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase
F,Homo sapiens,9606.0,,,1,Intermediate,,4337,,U,4342,0,,,22226,,,,BAO_0000019,CHEMBL620976,,Average inhibitory concentration against 60 human cell lines was reported
F,Homo sapiens,9606.0,,,1,Expert,,4112,,U,4343,0,,,22226,,,,BAO_0000019,CHEMBL620977,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines
F,Homo sapiens,9606.0,,Panel NCI-60 (60 carcinoma cell lines),1,Intermediate,,16160,,N,4344,1,542.0,,80315,,,,BAO_0000219,CHEMBL620978,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line
F,Homo sapiens,9606.0,,Panel NCI-60 (60 carcinoma cell lines),1,Intermediate,,16160,,N,4345,1,542.0,,80315,,,,BAO_0000219,CHEMBL620979,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. 
F,,,,Panel NCI-60 (60 carcinoma cell lines),1,Expert,,17376,,N,4346,1,542.0,,80315,,,,BAO_0000219,CHEMBL620980,,In vitro mean growth inhibitory activity against 60-cell panel
F,,,,Panel NCI-60 (60 carcinoma cell lines),1,Expert,,17376,,N,4347,1,542.0,,80315,,,,BAO_0000219,CHEMBL620981,,In vitro mean growth lethal concentration against 60-cell panel
F,,,,Panel NCI-60 (60 carcinoma cell lines),1,Expert,,17376,,N,4348,1,542.0,,80315,,,,BAO_0000219,CHEMBL620982,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel
F,,,,Panel NCI-60 (60 carcinoma cell lines),1,Expert,,17376,,N,4349,1,542.0,,80315,,,,BAO_0000219,CHEMBL620983,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel
F,,,,,1,Autocuration,,3241,,H,4350,4,,,104775,,,,BAO_0000019,CHEMBL620984,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
F,,,,,1,Autocuration,,3241,,H,4351,4,,,104775,,,,BAO_0000019,CHEMBL620985,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
B,,,,,1,Expert,,3725,,H,4352,8,,,275,,,,BAO_0000357,CHEMBL620986,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha
F,Plasmodium falciparum,5833.0,,,1,Expert,,10805,,N,4353,1,,,50425,,,,BAO_0000218,CHEMBL620987,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase
F,Plasmodium falciparum,5833.0,,,1,Expert,,10805,,N,4354,1,,,50425,,,,BAO_0000218,CHEMBL620988,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells
F,Plasmodium falciparum,5833.0,,,1,Expert,,10805,,N,4355,1,,,50425,,,,BAO_0000218,CHEMBL620989,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.
F,Plasmodium falciparum,5833.0,,,1,Expert,,10805,,N,4356,1,,,50425,,,,BAO_0000218,CHEMBL620990,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.
F,Plasmodium falciparum,5833.0,,,1,Intermediate,,10805,,N,4357,1,,,50425,,,,BAO_0000218,CHEMBL620991,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4358,1,850.0,,80628,,,,BAO_0000218,CHEMBL620992,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4359,1,850.0,,80628,,,,BAO_0000218,CHEMBL620993,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4360,1,850.0,,80628,,,,BAO_0000218,CHEMBL620994,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4361,1,850.0,,80628,,,,BAO_0000218,CHEMBL620995,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4362,1,850.0,,80628,,,,BAO_0000218,CHEMBL620996,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10144,,N,4363,1,850.0,,80628,,,,BAO_0000218,CHEMBL875581,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4364,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620997,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4365,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620998,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4366,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620999,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days)
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4367,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621000,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4368,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621001,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4369,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621002,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4370,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621003,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4371,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621004,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg"
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4372,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621005,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days)
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4373,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621006,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days)
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4374,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621007,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg
F,Mus musculus,10090.0,,,1,Autocuration,,10144,,U,4375,0,,,22224,,,,BAO_0000218,CHEMBL621008,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
F,Mus musculus,10090.0,,,1,Autocuration,,10144,,U,4376,0,,,22224,,,,BAO_0000218,CHEMBL621009,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
F,Mus musculus,10090.0,,,1,Autocuration,,10144,,U,4377,0,,,22224,,,,BAO_0000218,CHEMBL857705,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
F,Mus musculus,10090.0,,,1,Autocuration,,10144,,U,4378,0,,,22224,,,,BAO_0000218,CHEMBL619828,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4379,0,,,22224,,,,BAO_0000218,CHEMBL619829,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4380,0,,,22224,,,,BAO_0000218,CHEMBL619830,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4381,0,,,22224,,,,BAO_0000218,CHEMBL619831,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally
F,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4382,0,,,22224,,,,BAO_0000218,CHEMBL619832,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally
A,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4383,0,,,22224,,,,BAO_0000218,CHEMBL619833,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10
A,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4384,0,,,22224,,,,BAO_0000218,CHEMBL619834,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10
A,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4385,0,,,22224,,,,BAO_0000218,CHEMBL619835,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10
A,Mus musculus,10090.0,,,1,Autocuration,,10685,,U,4386,0,,,22224,,,,BAO_0000218,CHEMBL619836,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,8831,,N,4387,1,850.0,,80628,,,,BAO_0000218,CHEMBL619837,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg"
F,,,,,1,Autocuration,,11704,,U,4388,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619838,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,11704,,N,4389,1,,,50594,,,,BAO_0000218,CHEMBL619839,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10685,,N,4390,1,850.0,,80628,,,In vivo,BAO_0000218,CHEMBL619840,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,10685,,N,4391,1,850.0,,80628,,,In vivo,BAO_0000218,CHEMBL619841,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition
F,Mus musculus,10090.0,,6C3HED,1,Expert,,11368,,N,4392,1,850.0,,80628,,,,BAO_0000218,CHEMBL857704,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8)
F,Mus musculus,10090.0,,6C3HED,1,Intermediate,,11368,,N,4393,1,850.0,,80628,,,,BAO_0000218,CHEMBL619842,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8)
F,Mus musculus,10090.0,,6C3HED,1,Expert,,11368,,N,4394,1,850.0,,80628,,,,BAO_0000218,CHEMBL619843,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8)
B,Staphylococcus aureus,1280.0,,,1,Autocuration,,17763,,U,4395,0,,,22226,,,,BAO_0000019,CHEMBL619844,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase"
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4396,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL857855,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4397,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619845,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4398,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619846,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4399,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619847,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4400,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL619848,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4401,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620893,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4402,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620894,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4403,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620895,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4404,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620896,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4405,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620897,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4406,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620898,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
B,Rattus norvegicus,10116.0,,,1,Autocuration,Microsomes,7411,,U,4407,0,,,22226,Liver,2107.0,,BAO_0000251,CHEMBL620899,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
A,Cercopithecidae,9527.0,,,1,Autocuration,,347,,U,4408,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620900,,The apparent total plasma clearance in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,3341,,U,4409,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620901,,Compound was evaluated for Hepatic clearance in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,17853,,U,4410,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620902,,Lower clearance in monkey (i.v.) at 0.5 mpk
A,Cercopithecidae,9527.0,,,1,Autocuration,,4514,,U,4411,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620903,,Plasma clearance in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6062,,U,4412,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620904,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,6821,,U,4413,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620905,,Plasma clearance of compound was determined in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6057,,U,4414,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620906,,Plasma clearance was calculated in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5145,,U,4415,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875420,,Plasma clearance in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6641,,U,4416,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620907,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5472,,U,4417,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620908,,Plasma clearance was evaluated in rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,4257,,U,4418,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620909,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose
A,Cercopithecidae,9527.0,,,1,Autocuration,,5546,,U,4419,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620910,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,4420,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620911,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,4421,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620912,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17509,,U,4422,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620913,,Cmax 24 hr after 2 mg/kg oral administration in monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,6535,,U,4423,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620914,,Cmax in monkey after administration of 1 mg/kg iv
A,Cercopithecidae,9527.0,,,1,Autocuration,,5668,,U,4424,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620915,,Cmax was determine after peroral administration at 10 mpk in Rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,5922,,U,4425,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620916,,Cmax in cynomolgus monkey by iv administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,5922,,U,4426,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620917,,Cmax in cynomolgus monkey by po administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,6078,,U,4427,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620918,,Cmax value evaluated in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,4428,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620919,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,3249,,U,4429,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620920,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,3249,,U,4430,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620921,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,5553,,U,4431,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620922,,Maximal plasma concentration in squirrel monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,1916,,U,4432,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620923,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,6227,,U,4433,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620924,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4434,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620925,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4435,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620926,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4436,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620927,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4437,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620928,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4438,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620929,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,6221,,U,4439,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620930,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,167,,U,4440,0,,,22224,,,,BAO_0000218,CHEMBL620931,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours
A,Cercopithecidae,9527.0,,,1,Autocuration,,167,,U,4441,0,,,22224,,,,BAO_0000218,CHEMBL620932,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours
A,monkey,9443.0,,,1,Autocuration,,4257,,U,4442,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620933,,Absolute bioavailability was evaluated in monkey
A,monkey,9443.0,,,1,Autocuration,,6221,,U,4443,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620934,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined
A,monkey,9443.0,,,1,Autocuration,,17667,,U,4444,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620935,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration
A,Macaca mulatta,9544.0,,,1,Autocuration,,17267,,U,4445,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620936,,Bioavailability of compound was determined in rhesus monkey
A,marmosets,38020.0,,,1,Autocuration,,4256,,U,4446,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620937,,Bioavailability determined after oral administration in marmoset
A,Macaca fascicularis,9541.0,,,1,Autocuration,,4256,,U,4447,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620938,,Oral bioavailability in cynomolgus monkey
A,monkey,9443.0,,,1,Autocuration,,17853,,U,4448,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620939,,Bioavailability in monkey (p.o.) at 2.0 mpk
A,monkey,9443.0,,,1,Autocuration,,16365,,U,4449,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620940,,Bioavailability was evaluated after oral administration in monkey
A,Macaca fascicularis,9541.0,,,1,Autocuration,,1916,,U,4450,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620941,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
A,Macaca mulatta,9544.0,,,1,Autocuration,,5334,,U,4451,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620942,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
A,Macaca mulatta,9544.0,,,1,Autocuration,,5334,,U,4452,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620943,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
A,monkey,9443.0,,,1,Autocuration,,17592,,U,4453,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620944,,Bioavailability of the compound was determined in monkey
A,Saimiri sciureus,9521.0,,,1,Autocuration,,1399,,U,4454,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620945,,Bioavailability in squirrel monkey (dose 5 mg/kg)
A,monkey,9443.0,,,1,Autocuration,,4809,,U,4455,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620946,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg)
A,monkey,9443.0,,,1,Autocuration,,3341,,U,4456,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620947,,Oral bioavailability in monkey
A,Saimiri sciureus,9521.0,,,1,Autocuration,,64,,U,4457,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620948,,Compound was tested for bioavailability in squirrel monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,4458,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620949,,Oral bioavailability in Rhesus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,4459,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620950,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.)
A,Macaca fascicularis,9541.0,,,1,Autocuration,,5237,,U,4460,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620951,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable
A,Macaca fascicularis,9541.0,,,1,Autocuration,,5237,,U,4461,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620952,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable
A,monkey,9443.0,,,1,Autocuration,,5302,,U,4462,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875421,,Oral bioavailability in monkey (dose 5 mg/kg)
A,monkey,9443.0,,,1,Autocuration,,17667,,U,4463,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620953,,Oral bioavailability of compound at 5 mg/kg in monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6161,,N,4464,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873491,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6161,,N,4465,1,,,50588,,,In vivo,BAO_0000218,CHEMBL620954,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3854,,N,4466,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL620955,,Plasma half life determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,993,,N,4467,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL618097,,Plasma half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4514,,N,4468,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL618268,,Plasma half-life in Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,4469,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618269,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,4470,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618270,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,4471,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618271,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,4472,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873493,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,4473,1,,,50588,,,,BAO_0000218,CHEMBL621031,,Tested for the half life period in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,4474,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621032,,Tested for the half life period in dog at dosage of 10 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3880,,N,4475,1,,,50588,,,,BAO_0000218,CHEMBL621033,,The compound was tested for half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,4476,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621034,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma."
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3880,,N,4477,1,,,50588,,,,BAO_0000218,CHEMBL621035,,The half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3918,,N,4478,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621036,,The plasma half-life in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,4479,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621037,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17796,,N,4480,1,,,50588,,,,BAO_0000218,CHEMBL619812,,Half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,4481,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619813,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,4482,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873335,,tmax upon peroral administration of 10.0 mg/Kg dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16456,,N,4483,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619814,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg
A,Mustela putorius furo,9669.0,,,1,Expert,,6113,,N,4484,1,,,50506,,,In vivo,BAO_0000218,CHEMBL619815,,Cmax in ferrets after 30 mg/kg oral dose
F,Mustela putorius furo,9669.0,,,1,Expert,,6113,,N,4485,1,,,50506,,,In vivo,BAO_0000218,CHEMBL619816,,Emesis in ferrets at 30 mg/kg oral dose
A,Macaca fascicularis,9541.0,,,1,Autocuration,,17796,,U,4486,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619817,,Bioavailability in cynomolgus monkey
A,Macaca fascicularis,9541.0,,,1,Intermediate,,17796,,N,4487,1,,,100710,,,In vivo,BAO_0000218,CHEMBL619818,,Volume of distribution in cynomolgus
A,Cavia porcellus,10141.0,,,1,Autocuration,,5308,,U,4488,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL619819,,AUC tested in guinea pig when 3 mg/kg dose was given perorally
A,Cavia porcellus,10141.0,,,1,Autocuration,,4877,,U,4489,0,,,22224,,,,BAO_0000218,CHEMBL619820,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
A,Cavia porcellus,10141.0,,,1,Autocuration,,4876,,U,4490,0,,,22224,,,,BAO_0000218,CHEMBL875419,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg"
A,Cavia porcellus,10141.0,,,1,Autocuration,,4878,,U,4491,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL619821,,AUC in guinea pig after 3mg/kg oral dose
A,Cavia porcellus,10141.0,,,1,Autocuration,,5308,,U,4492,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619822,,Bioavailability in guinea pig was tested
A,Cavia porcellus,10141.0,,,1,Autocuration,,4877,,U,4493,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619823,,Tested for oral bioavailability in guinea pig at 5 mg/kg
A,Cavia porcellus,10141.0,,,1,Autocuration,,4876,,U,4494,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619824,,Tested for the oral bioavailability of the compound
A,Cavia porcellus,10141.0,,,1,Autocuration,,4876,,U,4495,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619825,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported
A,Cavia porcellus,10141.0,,,1,Autocuration,,5308,,U,4496,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619826,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally
A,Cavia porcellus,10141.0,,,1,Autocuration,,4877,,U,4497,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL619827,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
A,Cavia porcellus,10141.0,,,1,Autocuration,,4878,,U,4498,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618167,,Cmax in guinea pig after 3mg/kg oral dose
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4499,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL618168,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4500,0,,,22224,Brain,955.0,,BAO_0000019,CHEMBL618169,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4501,0,,,22224,,,,BAO_0000019,CHEMBL618170,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4502,0,,,22224,Intestine,160.0,,BAO_0000019,CHEMBL618171,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4503,0,,,22224,Kidney,2113.0,,BAO_0000019,CHEMBL618172,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4504,0,,,22224,Liver,2107.0,,BAO_0000019,CHEMBL618173,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4505,0,,,22224,,,,BAO_0000019,CHEMBL618174,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4506,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL875408,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram
A,Cavia porcellus,10141.0,,,1,Autocuration,,14465,,U,4507,0,,,22224,,,In vivo,BAO_0000218,CHEMBL839827,,Elimination T1/2 in Guinea pig (PO dose)
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4508,0,,,22224,,,,BAO_0000019,CHEMBL618175,,Partition coefficient was measured as -log (counts per min )
A,Cavia porcellus,10141.0,,,1,Autocuration,,611,,U,4509,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618176,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism
A,Cavia porcellus,10141.0,,,1,Autocuration,,611,,U,4510,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618177,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism
A,Cavia porcellus,10141.0,,,1,Autocuration,,14465,,U,4511,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618178,,Elimination T1/2 in Guinea pig (PO dose)
A,Cavia porcellus,10141.0,,,1,Autocuration,,4876,,U,4512,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618179,,"Tested for the half life period of the compound, intravenously"
A,Cavia porcellus,10141.0,,,1,Autocuration,,5689,,U,4513,0,,,22224,,,,BAO_0000019,CHEMBL873489,,Half-life was measured
A,Cavia porcellus,10141.0,,,1,Autocuration,,7515,,U,4514,0,,,22224,,,,BAO_0000019,CHEMBL618180,,The time required for onset of inotropy after addition of a single dose of delta F75
A,Cavia porcellus,10141.0,,,1,Autocuration,,17667,,U,4515,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618181,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration
A,Cavia porcellus,10141.0,,,1,Autocuration,,17667,,U,4516,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618182,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4517,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618183,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4518,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618184,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4519,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618185,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4520,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618186,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4521,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618187,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4522,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618188,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4523,1,,,50594,,,In vivo,BAO_0000218,CHEMBL875409,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,4524,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618189,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4525,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL618190,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4526,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL618191,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4527,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL618192,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4528,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618193,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4529,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618194,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4530,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618195,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4531,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL618196,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4532,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL618197,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4533,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL618198,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4534,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL618199,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4535,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL618200,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4536,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL618201,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4537,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL618202,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4538,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL618203,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4539,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL618204,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4540,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618205,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4541,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618206,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4542,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618207,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4543,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618208,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4544,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618932,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4545,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618933,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4546,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618934,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4547,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618935,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4548,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618936,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4549,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL618937,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4550,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL618938,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4551,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619104,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4552,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL619105,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4553,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL619106,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4554,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL619107,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4555,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL875410,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4556,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL619108,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,3655,,N,4557,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL619109,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4558,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619110,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
F,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4559,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619111,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4560,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619112,,MRT value at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4561,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619113,,MRT value at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4562,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619114,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4563,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619115,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3830,,N,4564,1,478.0,,81034,,,,BAO_0000219,CHEMBL619116,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3829,,N,4565,1,478.0,,81034,,,,BAO_0000219,CHEMBL619117,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2040,,N,4566,1,478.0,,81034,,,,BAO_0000219,CHEMBL619118,,Compound was evaluated for cytotoxicity against A2780 cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4567,1,478.0,,81034,,,,BAO_0000219,CHEMBL619119,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4568,1,478.0,,81034,,,,BAO_0000219,CHEMBL619120,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4569,1,478.0,,81034,,,,BAO_0000219,CHEMBL619121,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4570,1,478.0,,81034,,,,BAO_0000219,CHEMBL619122,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4571,1,478.0,,81034,,,,BAO_0000219,CHEMBL619123,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4572,1,478.0,,81034,,,,BAO_0000219,CHEMBL619124,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2859,,N,4573,1,478.0,,81034,,,,BAO_0000219,CHEMBL619125,,Compound was evaluated for cytotoxicity against A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5618,,N,4574,1,478.0,,81034,,,,BAO_0000219,CHEMBL875411,,In vitro inhibitory activity against human tumor cell line A2780
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4575,1,478.0,,81034,,,,BAO_0000219,CHEMBL619126,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4576,1,478.0,,81034,,,,BAO_0000219,CHEMBL619127,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4577,1,478.0,,81034,,,,BAO_0000219,CHEMBL619128,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4578,1,478.0,,81034,,,,BAO_0000219,CHEMBL619129,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2113,,N,4579,1,478.0,,81034,,,,BAO_0000219,CHEMBL619130,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2113,,N,4580,1,478.0,,81034,,,,BAO_0000219,CHEMBL619131,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16745,,N,4581,1,478.0,,81034,,,,BAO_0000219,CHEMBL619132,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,4582,1,478.0,,81034,,,,BAO_0000218,CHEMBL619133,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4583,1,478.0,,81034,,,,BAO_0000219,CHEMBL619134,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15684,,N,4584,1,478.0,,81034,,,,BAO_0000219,CHEMBL619135,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2040,,N,4585,1,478.0,,81034,,,,BAO_0000219,CHEMBL619136,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2040,,N,4586,1,478.0,,81034,,,,BAO_0000219,CHEMBL619137,,Relative resistance factor in A2780 cisplatin-resistant line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16165,,N,4587,1,478.0,,81034,,,,BAO_0000219,CHEMBL883713,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16165,,N,4588,1,478.0,,81034,,,,BAO_0000219,CHEMBL875412,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,4589,1,478.0,,81034,,,,BAO_0000218,CHEMBL619138,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,4590,1,478.0,,81034,,,,BAO_0000218,CHEMBL619262,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3992,,N,4591,1,478.0,,81034,,,,BAO_0000219,CHEMBL619139,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,10553,,N,4592,1,478.0,,81034,,,,BAO_0000219,CHEMBL619140,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4593,1,478.0,,81034,,,,BAO_0000219,CHEMBL619141,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4594,1,478.0,,81034,,,,BAO_0000219,CHEMBL619142,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4595,1,478.0,,81034,,,,BAO_0000219,CHEMBL619143,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4596,1,478.0,,81034,,,,BAO_0000219,CHEMBL619144,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4597,1,478.0,,81034,,,,BAO_0000219,CHEMBL619145,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,4598,1,478.0,,81034,,,,BAO_0000219,CHEMBL619146,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15569,,N,4599,1,478.0,,81034,,,,BAO_0000219,CHEMBL619147,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17420,,N,4600,1,478.0,,81034,,,,BAO_0000219,CHEMBL619148,,Antiproliferative effect of compound on A2780/DX cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17420,,N,4601,1,478.0,,81034,,,,BAO_0000219,CHEMBL619149,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15099,,N,4602,1,478.0,,81034,,,,BAO_0000219,CHEMBL619150,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15099,,N,4603,1,478.0,,81034,,,,BAO_0000219,CHEMBL619151,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17672,,N,4604,1,478.0,,81034,,,,BAO_0000219,CHEMBL883794,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17672,,N,4605,1,478.0,,81034,,,,BAO_0000219,CHEMBL619152,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17270,,N,4606,1,478.0,,81034,,,,BAO_0000219,CHEMBL619153,,In vitro cytotoxicity against A2780ADR cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17270,,N,4607,1,478.0,,81034,,,,BAO_0000219,CHEMBL619154,,In vitro cytotoxicity against A2780CIS cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5574,,N,4608,1,478.0,,81034,,,,BAO_0000219,CHEMBL619155,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2113,,N,4609,1,478.0,,81034,,,,BAO_0000219,CHEMBL619156,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4610,1,478.0,,81034,,,,BAO_0000219,CHEMBL619157,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4611,1,478.0,,81034,,,,BAO_0000219,CHEMBL619797,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines"
A,Macaca mulatta,9544.0,,,1,Autocuration,,17839,,U,4612,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619798,,Oral bioavailability of compound in rhesus macaques
A,monkey,9443.0,,,1,Autocuration,,6821,,U,4613,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619799,,Oral bioavailability in monkey
A,monkey,9443.0,,,1,Autocuration,,6078,,U,4614,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619800,,Oral bioavailability evaluated in monkey
A,monkey,9443.0,,,1,Autocuration,,6535,,U,4615,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619801,,Oral bioavailability in monkey (dose 1 mg/kg p.o.)
A,Macaca mulatta,9544.0,,,1,Autocuration,,4449,,U,4616,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619802,,Oral bioavailability in Rhesus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,6057,,U,4617,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619803,,Oral bioavailability was calculated in rhesus monkey
A,Macaca fascicularis,9541.0,,,1,Autocuration,,5922,,U,4618,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619965,,Oral bioavailability in cynomolgus monkey
A,monkey,9443.0,,,1,Autocuration,,5940,,U,4619,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619966,,Oral bioavailability in monkey
A,monkey,9443.0,,,1,Autocuration,,6265,,U,4620,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619967,,Oral bioavailability in monkey
A,monkey,9443.0,,,1,Autocuration,,6265,,U,4621,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620073,,Oral bioavailability in monkey (dose 1 mg/kg)
A,monkey,9443.0,,,1,Autocuration,,6265,,U,4622,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620074,,Oral bioavailability in monkey (dose 5 mg/kg)
A,monkey,9443.0,,,1,Autocuration,,5940,,U,4623,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620075,,Oral bioavailability in monkey
A,monkey,9443.0,,,1,Autocuration,,5940,,U,4624,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620076,,Oral bioavailability in monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,4514,,U,4625,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620077,,Oral bioavailability in rhesus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5546,,U,4626,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620078,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration
A,Saimiri sciureus,9521.0,,,1,Autocuration,,5553,,U,4627,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620079,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg
A,monkey,9443.0,,,1,Autocuration,,6641,,U,4628,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620080,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Macaca mulatta,9544.0,,,1,Autocuration,,5472,,U,4629,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620081,,Oral bioavailability in Rhesus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5668,,U,4630,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620082,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.)
A,monkey,9443.0,,,1,Autocuration,,5711,,U,4631,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620083,,Oral bioavailability in monkey at 10 mg/kg of the compound
A,Macaca mulatta,9544.0,,,1,Autocuration,,5145,,U,4632,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620084,,Bioavailability in Rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4633,0,,,22224,,,,BAO_0000218,CHEMBL620085,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4634,0,,,22224,,,,BAO_0000218,CHEMBL874595,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3249,,U,4635,0,,,22224,,,In vivo,BAO_0000218,CHEMBL873352,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,3249,,U,4636,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620086,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4637,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620087,,Mean residence time was determined after intravenous administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4638,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620088,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4639,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620089,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4640,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620090,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4641,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620091,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,Microsomes,14294,,U,4642,0,,,22224,,,,BAO_0000251,CHEMBL620092,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak)
A,Cercopithecidae,9527.0,,,1,Autocuration,Microsomes,14294,,U,4643,0,,,22224,,,,BAO_0000251,CHEMBL620093,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak)
A,Cercopithecidae,9527.0,,,1,Autocuration,Microsomes,14294,,U,4644,0,,,22224,,,,BAO_0000251,CHEMBL620094,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak)
A,Cercopithecidae,9527.0,,,1,Autocuration,Microsomes,14294,,U,4645,0,,,22224,,,,BAO_0000251,CHEMBL620095,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak)
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4646,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620096,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4647,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620097,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,4648,0,,,22224,,,,BAO_0000019,CHEMBL620098,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4649,0,,,22224,,,,BAO_0000218,CHEMBL620099,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4650,0,,,22224,,,,BAO_0000218,CHEMBL620100,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,6821,,U,4651,0,,,22224,,,,BAO_0000019,CHEMBL620101,,Elimination Half-life of compound was determined in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,17267,,U,4652,0,,,22224,,,,BAO_0000019,CHEMBL620102,,Half life of compound was determined in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5819,,U,4653,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL620103,,Half life in monkey plasma
A,Cercopithecidae,9527.0,,,1,Autocuration,,5819,,U,4654,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL620104,,Half life in monkey plasma; Not detected
A,Cercopithecidae,9527.0,,,1,Autocuration,,1916,,U,4655,0,,,22224,,,In vivo,BAO_0000218,CHEMBL874596,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,17509,,U,4656,0,,,22224,,,In vivo,BAO_0000218,CHEMBL873490,,Half-life 24 hr after 2 mg/kg iv administration in monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,1399,,U,4657,0,,,22224,,,,BAO_0000019,CHEMBL620105,,Terminal half life of the compound.
A,Cercopithecidae,9527.0,,,1,Autocuration,,1916,,U,4658,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620780,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4659,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620781,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5546,,U,4660,0,,,22224,,,,BAO_0000218,CHEMBL620956,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4661,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL620957,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4662,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL620958,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,4257,,U,4663,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620959,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose
A,Cercopithecidae,9527.0,,,1,Autocuration,,6221,,U,4664,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620960,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,5472,,U,4665,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620961,,Volume of distribution was evaluated in rhesus
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4666,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620962,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4667,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620963,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4668,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620964,,Bioavailability in hamster was determined
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4669,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620965,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4670,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620966,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration
A,Cricetulus griseus,10029.0,,,1,Autocuration,,4727,,U,4671,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL620967,,Half life of compound was determined in hamster blood
A,Sus scrofa,9823.0,,,1,Autocuration,,1452,,U,4672,0,,,22224,,,,BAO_0000019,CHEMBL620968,,Michaelis-Menten constant of the compound.
A,Sus scrofa,9823.0,,,1,Autocuration,,1452,,U,4673,0,,,22224,,,,BAO_0000019,CHEMBL874597,,Vmax value was measured at 0 uM concentration of silyl ether.
A,Sus scrofa,9823.0,,,1,Autocuration,,1452,,U,4674,0,,,22224,,,,BAO_0000019,CHEMBL620969,,Vmax value was measured at 10 uM concentration of silyl ether.
A,Sus scrofa,9823.0,,,1,Autocuration,,1452,,U,4675,0,,,22224,,,,BAO_0000019,CHEMBL620970,,Vmax value was measured at 5 uM concentration of silyl ether.
B,Homo sapiens,9606.0,,,1,Expert,,11706,,D,4676,9,,,235,,,,BAO_0000357,CHEMBL620971,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant
A,Homo sapiens,9606.0,,,1,Autocuration,,1916,,U,4677,0,,,22224,,,,BAO_0000218,CHEMBL620972,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration
A,Homo sapiens,9606.0,,,1,Autocuration,,17791,,U,4678,0,,,22224,,,,BAO_0000019,CHEMBL620973,,Compound was evaluated for area under the curve expressed as (h*ug/ml)
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4679,0,,,22224,,,,BAO_0000019,CHEMBL618243,,Active metabolite of ifosfamide determined in humans; A-Active
A,Homo sapiens,9606.0,,,1,Autocuration,,6567,,U,4680,0,,,22224,,,,BAO_0000019,CHEMBL618244,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis
A,Homo sapiens,9606.0,,,1,Autocuration,,6567,,U,4681,0,,,22224,,,,BAO_0000019,CHEMBL618245,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1
A,Homo sapiens,9606.0,,,1,Autocuration,,6567,,U,4682,0,,,22224,,,,BAO_0000019,CHEMBL618246,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2
A,Homo sapiens,9606.0,,,1,Autocuration,,6567,,U,4683,0,,,22224,,,,BAO_0000019,CHEMBL618247,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace
A,Homo sapiens,9606.0,,,1,Autocuration,,17791,,U,4684,0,,,22224,,,,BAO_0000218,CHEMBL618248,,Compound was evaluated for oral bioavailability in human
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4685,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618249,,Metabolite of ifosfamide determined in urine; NF-Not found
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4686,0,,,22224,,,,BAO_0000019,CHEMBL618250,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4687,0,,,22224,,,,BAO_0000019,CHEMBL874598,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4688,0,,,22224,,,,BAO_0000019,CHEMBL618251,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4689,0,,,22224,,,,BAO_0000019,CHEMBL618252,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4690,0,,,22224,,,,BAO_0000019,CHEMBL618253,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4691,0,,,22224,,,,BAO_0000019,CHEMBL618254,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C)
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,4692,0,,,22224,,,,BAO_0000019,CHEMBL618255,,Percent of compound in healthy individuals (Group D)
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,4397,,U,4693,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL618983,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,17409,,U,4694,0,,,22224,,,,BAO_0000019,CHEMBL618984,,Binding towards human plasma protein at 10 uM
A,Homo sapiens,9606.0,,,1,Autocuration,,17409,,U,4695,0,,,22224,,,,BAO_0000019,CHEMBL618985,,Binding towards human plasma protein at 100 uM
A,Homo sapiens,9606.0,,,1,Autocuration,,17176,,U,4696,0,,,22224,,,,BAO_0000019,CHEMBL618986,,Human plasma protein binding activity was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,15444,,U,4697,0,,,22224,,,,BAO_0000019,CHEMBL618987,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)
A,Homo sapiens,9606.0,,,1,Autocuration,,17267,,U,4698,0,,,22224,,,,BAO_0000019,CHEMBL618988,,Percent binding of compound towards human plasma protein was determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5944,,U,4699,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618989,,Plasma clearance in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5668,,U,4700,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618990,,In vitro intrinsic clearance in human liver microsome
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5669,,U,4701,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618991,,In vitro intrinsic clearance in human liver microsome
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5041,,U,4702,0,,,22224,,,In vitro,BAO_0000251,CHEMBL876725,,In vitro microsome metabolism clearance in human was determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5041,,U,4703,0,,,22224,,,In vitro,BAO_0000251,CHEMBL618992,,In vitro microsome metabolism clearance in human was determined; High
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5041,,U,4704,0,,,22224,,,In vitro,BAO_0000251,CHEMBL618993,,In vitro microsome metabolism clearance in human was determined; ND denotes no data
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5676,,U,4705,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618994,,Pharmacokinetic property (clearance) in human liver microsome
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5944,,U,4706,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618995,,Plasma clearance in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,17538,,U,4707,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618996,,In vitro clearance in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6331,,U,4708,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618997,,Intrinsic clearance in human liver microsomes was determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5948,,U,4709,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618998,,Intrinsic clearance in human liver microsomes was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,5965,,U,4710,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618999,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human
A,Homo sapiens,9606.0,,,1,Autocuration,,1916,,U,4711,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620223,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration
A,Homo sapiens,9606.0,,,1,Autocuration,,5965,,U,4712,0,,,22224,,,,BAO_0000218,CHEMBL620224,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human
A,Homo sapiens,9606.0,,,1,Autocuration,,1299,,U,4713,0,,,22224,,,,BAO_0000019,CHEMBL620225,,Stability in human plasma 2 hr after incubation expressed as percent concentration
A,Homo sapiens,9606.0,,,1,Autocuration,,1299,,U,4714,0,,,22224,,,,BAO_0000019,CHEMBL620226,,Stability in human plasma 4 hr after incubation expressed as percent concentration
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4715,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL620227,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4716,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL876726,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4717,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL620228,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4718,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL620229,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4719,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620230,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4720,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620231,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4721,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620232,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4722,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620233,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,14294,,N,4723,1,,,50594,,,,BAO_0000218,CHEMBL620234,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak)
A,Mus musculus,10090.0,,,1,Intermediate,,14294,,N,4724,1,,,50594,,,,BAO_0000218,CHEMBL620235,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak)
A,Mus musculus,10090.0,,,1,Intermediate,,14294,,N,4725,1,,,50594,,,,BAO_0000218,CHEMBL620236,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak)
A,Mus musculus,10090.0,,,1,Intermediate,,6251,,N,4726,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL620237,,In vitro metabolic potential in mouse liver microsomes
A,Mus musculus,10090.0,,,1,Intermediate,,17582,,N,4727,1,,,50594,,,,BAO_0000218,CHEMBL620238,,Ability of compound to bind to plasma protein was evaluated in HSA cells
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4728,1,,,50594,Adrenal gland,2369.0,,BAO_0000218,CHEMBL620239,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled)
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4729,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL620240,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4730,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL620241,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4731,1,,,50594,,,,BAO_0000218,CHEMBL876727,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled)
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4732,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL620242,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled)
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,4733,1,,,50594,,,,BAO_0000218,CHEMBL620243,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled)
A,Mus musculus,10090.0,,,1,Intermediate,,5288,,N,4734,1,,,50594,,,,BAO_0000218,CHEMBL620244,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,2717,,N,4735,1,,,50594,Serum,1977.0,,BAO_0000218,CHEMBL620245,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined
A,Mus musculus,10090.0,,,1,Intermediate,,2717,,N,4736,1,,,50594,Serum,1977.0,,BAO_0000218,CHEMBL620246,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined
A,Mus musculus,10090.0,,,1,Intermediate,,2717,,N,4737,1,,,50594,Serum,1977.0,,BAO_0000218,CHEMBL620247,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4738,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620248,,Half life of compound was determined in plasma of mice at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4739,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873497,,Half life of compound was determined in plasma of mice at 40 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4740,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620249,,Half life of compound was determined in plasma of mice at 5 mg/Kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4741,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620250,,Half life after intraperitoneal administration in mice at 18 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4742,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620251,,Half life after intraperitoneal administration in mice at 23 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4743,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620252,,Half life after intraperitoneal administration in mice at 25 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4744,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620253,,Half life after intraperitoneal administration in mice at 26 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4745,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620254,,Half life after intravenous administration in mice at 23 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4746,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620255,,Half life after intravenous administration in mice at 24 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4747,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620256,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,4748,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876728,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,4749,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620257,,Maximum time required to reach Cp max was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4750,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620258,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
A,Mus musculus,10090.0,,,1,Intermediate,,4890,,N,4751,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620259,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period"
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,4752,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620260,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,4753,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL620261,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4754,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620262,,Half life at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4755,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620263,,Half life at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,6619,,N,4756,1,,,50594,,,,BAO_0000218,CHEMBL620264,,Half life in ob/ob mice
A,Mus musculus,10090.0,,,1,Intermediate,,4066,,N,4757,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620265,,Half-life at a single subcutaneous administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,4239,,N,4758,1,,,50594,,,,BAO_0000218,CHEMBL620266,,Half-life was measured in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4759,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620267,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,8999,,N,4760,1,,,50594,,,,BAO_0000218,CHEMBL619364,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation
A,Mus musculus,10090.0,,,1,Intermediate,,8999,,N,4761,1,,,50594,,,,BAO_0000218,CHEMBL619365,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4762,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL619366,,T2 in brain of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4763,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL619367,,T2 in kidney of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4764,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL619368,,T2 in liver of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4765,1,,,50594,Lung,2048.0,,BAO_0000218,CHEMBL619369,,T2 in lungs of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4766,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL876729,,T2 in spleen of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4767,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619370,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
A,Mus musculus,10090.0,,,1,Intermediate,,4890,,N,4768,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619371,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant"
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,4769,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619372,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,4770,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620012,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4771,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620013,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4772,1,478.0,,81034,,,,BAO_0000219,CHEMBL620014,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4773,1,478.0,,81034,,,,BAO_0000219,CHEMBL620015,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4774,1,478.0,,81034,,,,BAO_0000219,CHEMBL621010,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4775,1,478.0,,81034,,,,BAO_0000219,CHEMBL621011,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4776,1,478.0,,81034,,,,BAO_0000219,CHEMBL621012,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16913,,N,4777,1,478.0,,81034,,,,BAO_0000219,CHEMBL621013,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17270,,N,4778,1,478.0,,81034,,,,BAO_0000219,CHEMBL621014,,In vitro cytotoxicity against A2780TAX cell line
F,Homo sapiens,9606.0,,A2780cisR,1,Intermediate,,5618,,N,4779,1,481.0,,80017,,,,BAO_0000219,CHEMBL618154,,In vitro inhibitory activity against human tumor cell line A2780cis
F,Homo sapiens,9606.0,,A2780,1,Expert,,17777,,N,4780,1,478.0,,81034,,,,BAO_0000219,CHEMBL618155,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines
F,Homo sapiens,9606.0,,A2780cisR,1,Intermediate,,16112,,N,4781,1,481.0,,80017,,,,BAO_0000219,CHEMBL618156,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line
F,Homo sapiens,9606.0,,A2780cisR,1,Intermediate,,15748,,N,4782,1,481.0,,80017,,,,BAO_0000219,CHEMBL618157,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,6633,,N,4783,1,478.0,,81034,,,,BAO_0000219,CHEMBL618328,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16930,,N,4784,1,478.0,,81034,,,,BAO_0000219,CHEMBL618329,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17496,,N,4785,1,478.0,,81034,,,,BAO_0000219,CHEMBL618330,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,12989,,N,4786,1,478.0,,81034,,,,BAO_0000219,CHEMBL618331,,In vitro antitumor activity against A2780cisR cell line.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4840,,N,4787,1,478.0,,81034,,,,BAO_0000219,CHEMBL618332,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin)
F,Homo sapiens,9606.0,,A2780,1,Expert,,12989,,N,4788,1,478.0,,81034,,,,BAO_0000219,CHEMBL618333,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line
F,Homo sapiens,9606.0,,A2780cisR,1,Intermediate,,16745,,N,4789,1,481.0,,80017,,,,BAO_0000219,CHEMBL618334,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,4790,1,478.0,,81034,,,,BAO_0000219,CHEMBL618335,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation
B,Rattus norvegicus,10116.0,,,1,Expert,,16547,,D,4791,9,,,11736,,,,BAO_0000019,CHEMBL618336,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes
F,,,,,1,Expert,,16547,,H,4792,8,,,11736,,,,BAO_0000019,CHEMBL618337,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
F,Rattus norvegicus,10116.0,,,1,Expert,,16547,,D,4793,9,,,11736,,,,BAO_0000019,CHEMBL618338,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
F,Homo sapiens,9606.0,,HEK293,1,Expert,,15856,,D,4794,9,722.0,,278,,,,BAO_0000219,CHEMBL618339,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX
F,Homo sapiens,9606.0,,HEK293,1,Expert,,15856,,D,4795,9,722.0,,278,,,,BAO_0000219,CHEMBL618340,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M
B,Mus musculus,10090.0,,,1,Expert,,16547,,D,4796,9,,,11831,,,,BAO_0000019,CHEMBL618341,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes
F,,,,,1,Expert,,16547,,H,4797,8,,,11831,,,,BAO_0000019,CHEMBL618342,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
F,Mus musculus,10090.0,,,1,Expert,,16547,,D,4798,9,,,11831,,,,BAO_0000019,CHEMBL618343,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
B,,,,,1,Expert,,17402,,H,4799,8,,,280,,,,BAO_0000357,CHEMBL621038,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM
F,Homo sapiens,9606.0,,T-cells,1,Autocuration,,11746,,U,4800,0,574.0,,22226,,,,BAO_0000219,CHEMBL621039,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
F,Homo sapiens,9606.0,,T-cells,1,Autocuration,,11746,,U,4801,0,574.0,,22226,,,,BAO_0000219,CHEMBL621040,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,5455,,N,4802,1,455.0,,80018,,,,BAO_0000219,CHEMBL621041,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,2068,,N,4803,1,455.0,,80018,,,,BAO_0000219,CHEMBL621042,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,2683,,N,4804,1,455.0,,80018,,,,BAO_0000219,CHEMBL621043,,In vitro antitumor activity against A375cell line extracted form melanoma
F,Homo sapiens,9606.0,,A-375,1,Expert,,15313,,N,4805,1,455.0,,80018,,,,BAO_0000219,CHEMBL621044,,Inhibition of cell growth in (A375) melan cell line
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,13739,,N,4806,1,455.0,,80018,,,,BAO_0000219,CHEMBL621045,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,13739,,N,4807,1,455.0,,80018,,,,BAO_0000219,CHEMBL621046,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,14750,,N,4808,1,455.0,,80018,,,,BAO_0000219,CHEMBL621047,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,14777,,N,4809,1,797.0,,80019,,,,BAO_0000219,CHEMBL621048,,Antiproliferative activity measured against A427 human lung carcinoma
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,14777,,N,4810,1,797.0,,80019,,,,BAO_0000219,CHEMBL883798,,Antiproliferative activity measured against A427 human lung carcinoma
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,17672,,N,4811,1,797.0,,80019,,,,BAO_0000219,CHEMBL621049,,Cytotoxicity against lung carcinoma A427 tumor cell lines
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,14368,,N,4812,1,797.0,,80019,,,,BAO_0000219,CHEMBL621050,,Inhibition of large cell lung carcinoma (A427)
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,14368,,N,4813,1,797.0,,80019,,,,BAO_0000219,CHEMBL621051,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,13866,,N,4814,1,797.0,,80019,,,,BAO_0000219,CHEMBL621052,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,2545,,N,4815,1,797.0,,80019,,,,BAO_0000219,CHEMBL621053,,Inhibitory concentration in human lung carcinoma A427 cell line
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,2545,,N,4816,1,797.0,,80019,,,,BAO_0000219,CHEMBL621054,,Inhibitory concentration in human lung carcinoma A427/VCR cell line
A,Cercopithecidae,9527.0,,,1,Autocuration,,6062,,U,4817,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621055,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,4578,,U,4818,0,,,22224,,,In vivo,BAO_0000218,CHEMBL876398,,Tested for volume of distribution upon iv administration to african green monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,17592,,U,4819,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621056,,Volume of distribution in monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,4820,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621057,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,4821,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621058,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
A,Cercopithecidae,9527.0,,,1,Autocuration,,5922,,U,4822,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621059,,Pharmacokinetic property(Vdss) in cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4823,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621060,,The distribution volume after intravenous administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4824,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621061,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4825,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621062,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,6057,,U,4826,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621063,,Volume displacement was calculated in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5145,,U,4827,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621064,,Volume of distribution in steady state was determined in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6821,,U,4828,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621065,,Volume of distribution of compound was determined in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,4829,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621066,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,4830,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621067,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,6641,,U,4831,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621068,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,4832,0,,,22224,,,In vivo,BAO_0000218,CHEMBL876399,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6535,,U,4833,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621069,,Volume distribution in monkey after administration of 1 mg/kg iv
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4834,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621070,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,6062,,U,4835,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621071,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,4836,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621072,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,4578,,U,4837,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618209,,Oral systemic bioavailability upon iv administration to african green monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4838,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618210,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,4839,0,,,22224,,,,BAO_0000019,CHEMBL618211,,Baboon plasma free fraction. 
A,Cercopithecidae,9527.0,,,1,Autocuration,,6057,,U,4840,0,,,22224,,,,BAO_0000218,CHEMBL618212,,Area under the curve was calculated in rhesus monkey after iv administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,6057,,U,4841,0,,,22224,,,,BAO_0000019,CHEMBL618213,,Area under the curve was calculated in rhesus monkey after peroral administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,17853,,U,4842,0,,,22224,,,,BAO_0000019,CHEMBL618214,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk
A,Cercopithecidae,9527.0,,,1,Autocuration,,5302,,U,4843,0,,,22224,,,In vivo,BAO_0000218,CHEMBL873492,,Half life period in monkey after 5 mg/kg dose
A,Cercopithecidae,9527.0,,,1,Autocuration,,4257,,U,4844,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618272,,Half-life was determined in monkey after 3 mg/kg of i.v. dose
A,Cercopithecidae,9527.0,,,1,Autocuration,,4257,,U,4845,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618273,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,13501,,U,4846,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618274,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5394,,U,4847,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618275,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,4848,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618276,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,3341,,U,4849,0,,,22224,,,,BAO_0000019,CHEMBL618277,,Compound was evaluated for terminal half life in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,3045,,U,4850,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618278,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,4851,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618279,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
A,Cercopithecidae,9527.0,,,1,Autocuration,,4847,,U,4852,0,,,22224,,,,BAO_0000019,CHEMBL618280,,Half life of compound was determined in squirrel monkey
A,Macaca fascicularis,9541.0,,,1,Autocuration,,4256,,U,4853,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618281,,Half life after iv administration in cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6535,,U,4854,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618282,,Half life in monkey plasma after administration of 1 mg/kg iv
A,Cercopithecidae,9527.0,,,1,Autocuration,,6057,,U,4855,0,,,22224,,,,BAO_0000019,CHEMBL618283,,Half life was calculated in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,17592,,U,4856,0,,,22224,,,,BAO_0000019,CHEMBL618284,,Half life in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6641,,U,4857,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618285,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5472,,U,4858,0,,,22224,,,,BAO_0000019,CHEMBL618286,,Half life was evaluated in rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,6221,,U,4859,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618287,,Half life period after oral administration (2.5 mg/kg) in monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,5668,,U,4860,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618288,,Half life period was determine after peroral administration at 10 mpk in Rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,4809,,U,4861,0,,,22224,,,In vivo,BAO_0000218,CHEMBL876393,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5546,,U,4862,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618289,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,5553,,U,4863,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618290,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,6078,,U,4864,0,,,22224,,,,BAO_0000019,CHEMBL618291,,Half-life was calculated in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5147,,U,4865,0,,,22224,,,,BAO_0000019,CHEMBL618292,,Half-life in Squirrel monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5145,,U,4866,0,,,22224,,,,BAO_0000019,CHEMBL618293,,Half-life in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6062,,U,4867,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618294,,Half-life was measured in monkey after an iv dose of 1 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4868,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618295,,Half-life period after intravenous administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4869,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618296,,Half-life period after oral administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,4870,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618297,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4871,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618298,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4872,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618299,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4873,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618300,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4874,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618301,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4875,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618302,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4876,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL876394,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4877,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618303,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4878,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618304,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,1916,,U,4879,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618305,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined
A,Homo sapiens,9606.0,,,1,Autocuration,,16643,,U,4880,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618306,,Oral bioavailability in human
A,Homo sapiens,9606.0,,,1,Autocuration,,17248,,U,4881,0,,,22224,,,,BAO_0000019,CHEMBL618307,,Compound was tested for human plasma protein binding
A,Homo sapiens,9606.0,,,1,Autocuration,,17248,,U,4882,0,,,22224,,,,BAO_0000019,CHEMBL618308,,Compound was tested for human plasma protein binding; Not determined
A,Homo sapiens,9606.0,,,1,Autocuration,,6241,,U,4883,0,,,22224,,,,BAO_0000019,CHEMBL618309,,Protein binding activity of compound in human plasma; % Free
A,Homo sapiens,9606.0,,,1,Autocuration,,17716,,U,4884,0,,,22224,,,,BAO_0000019,CHEMBL618310,,Unbound fraction (plasma)
A,Homo sapiens,9606.0,,,1,Autocuration,,17605,,U,4885,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL873353,,Half life for the hydrolysis of compound in human blood serum
A,Homo sapiens,9606.0,,,1,Autocuration,,17625,,U,4886,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618311,,Half life period in human plasma using phosphate buffer (0.08 M)
A,Homo sapiens,9606.0,,,1,Autocuration,,17625,,U,4887,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618312,,Half life period in human plasma using phosphate buffer (0.1 M)
A,Homo sapiens,9606.0,,,1,Autocuration,,17747,,U,4888,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618313,,Half-life in human plasma was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,15613,,U,4889,0,,,22224,,,,BAO_0000019,CHEMBL618314,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.
A,Homo sapiens,9606.0,,,1,Autocuration,,354,,U,4890,0,,,22224,,,,BAO_0000019,CHEMBL618315,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT)
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,4891,0,,,22224,,,,BAO_0000019,CHEMBL618316,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,4892,0,,,22224,,,,BAO_0000019,CHEMBL618317,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,4893,0,,,22224,,,,BAO_0000019,CHEMBL620138,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
A,Homo sapiens,9606.0,,,1,Autocuration,,17599,,U,4894,0,,,22224,,,,BAO_0000019,CHEMBL858280,,Partition coefficient (logP)
A,Homo sapiens,9606.0,,,1,Autocuration,,5486,,U,4895,0,,,22224,,,,BAO_0000019,CHEMBL620139,,In vitro metabolic stability in human was measured as pmol/min/mg/protein
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5600,,U,4896,0,,,22224,,,,BAO_0000251,CHEMBL620140,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,14294,,U,4897,0,,,22224,,,,BAO_0000019,CHEMBL620141,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak)
A,Homo sapiens,9606.0,,,1,Autocuration,,14294,,U,4898,0,,,22224,,,,BAO_0000019,CHEMBL620142,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak)
A,Homo sapiens,9606.0,,,1,Autocuration,,14294,,U,4899,0,,,22224,,,,BAO_0000019,CHEMBL620143,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak)
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,14294,,U,4900,0,,,22224,,,,BAO_0000251,CHEMBL620144,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak)
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,14294,,U,4901,0,,,22224,,,,BAO_0000251,CHEMBL620145,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak)
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,14294,,U,4902,0,,,22224,,,,BAO_0000251,CHEMBL620146,,Metabolism of compound in human microsomes; Trace
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6260,,U,4903,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL620147,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6187,,U,4904,0,,,22224,,,,BAO_0000251,CHEMBL620148,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6251,,U,4905,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL620149,,In vitro metabolic potential in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,3246,,U,4906,0,,,22224,,,,BAO_0000019,CHEMBL876412,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated
A,Homo sapiens,9606.0,,,1,Autocuration,,17313,,U,4907,0,,,22224,,,,BAO_0000019,CHEMBL619352,,Tested for human plasma protein binding of the compound; Not tested
A,Homo sapiens,9606.0,,,1,Autocuration,,6227,,U,4908,0,,,22224,,,,BAO_0000019,CHEMBL619353,,Compound was tested for percent protein binding (PB) in human
A,Homo sapiens,9606.0,,,1,Autocuration,,5530,,U,4909,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL619354,,Protein binding in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4910,0,,,22224,,,,BAO_0000019,CHEMBL619355,,Permeability coefficient (B to A) in Caco-2 cell
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4911,0,,,22224,,,,BAO_0000019,CHEMBL619356,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell
A,Homo sapiens,9606.0,,,1,Autocuration,,2774,,U,4912,0,,,22224,,,,BAO_0000019,CHEMBL619357,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3)
A,Homo sapiens,9606.0,,,1,Autocuration,,16643,,U,4913,0,,,22224,,,,BAO_0000019,CHEMBL619358,,In vitro rate of absorption observed as Caco-2 permeability in humans
A,Homo sapiens,9606.0,,Caco-2,1,Autocuration,,17582,,U,4914,0,495.0,,22224,,,,BAO_0000219,CHEMBL619359,,Cellular permeability of compound was determined in Caco-2 cells; High
A,Homo sapiens,9606.0,,Caco-2,1,Autocuration,,6838,,U,4915,0,495.0,,22224,,,,BAO_0000219,CHEMBL619360,,Permeability in Caco-2 cells of compound
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4916,0,,,22224,,,,BAO_0000019,CHEMBL619361,,Permeability coefficient (A to B) in Caco-2 cell
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4917,0,,,22224,,,,BAO_0000019,CHEMBL619362,,Permeability coefficient (B to A) in Caco-2 cell
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4918,0,,,22224,,,,BAO_0000019,CHEMBL619363,,Permeability coefficient (Papp) (Caco-2 cell monolayer)
A,Homo sapiens,9606.0,,,1,Autocuration,,2146,,U,4919,0,,,22224,,,,BAO_0000019,CHEMBL618942,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL
A,Homo sapiens,9606.0,,,1,Autocuration,,4514,,U,4920,0,,,22224,,,,BAO_0000019,CHEMBL618943,,Compound was tested for protein binding in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,6108,,U,4921,0,,,22224,,,,BAO_0000019,CHEMBL618944,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,4922,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL618945,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4923,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618946,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,3277,,N,4924,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876413,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
A,Mus musculus,10090.0,,,1,Intermediate,,3802,,N,4925,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618947,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,4926,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618948,,Time taken to reach maximum concentration in plasma upon oral administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,4927,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618949,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4928,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618950,,Tmax after intraperitoneal administration in mice at 23 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5781,,N,4929,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618951,,Tmax after oral administration at 30 mg/kg in ICR mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4930,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618952,,Tmax after peroral administration in mice at 2.4 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,4066,,N,4931,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618953,,Tmax at a single subcutaneous administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4932,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL618954,,Tmax in brain of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4933,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618955,,Tmax in kidney of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4934,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618956,,Tmax in liver of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4935,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618957,,Tmax in lungs of mice at the oral dose of 50 mg/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4936,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618958,,Tmax in mice at 18 uM/kg i.p. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4937,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618959,,Tmax in mice at 23 uM/kg i.v. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4938,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618960,,Tmax in mice at 25 uM/kg i.p. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4939,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876723,,Tmax in mice at 26 uM/kg i.p. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,4940,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618961,,Tmax in spleen of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4941,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618962,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4942,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618963,,Tmax value at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,5951,,N,4943,1,,,50594,,,,BAO_0000218,CHEMBL618964,,Tmax value in IRC mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,4944,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618965,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,4945,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618966,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,4946,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL618967,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr )
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,4947,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL618968,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr)
A,Mus musculus,10090.0,,,1,Intermediate,,4066,,N,4948,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL618969,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h)
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,4949,1,,,50594,,,,BAO_0000218,CHEMBL618970,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,4950,1,,,50594,,,,BAO_0000218,CHEMBL618971,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6062,,N,4951,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618972,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4952,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618973,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4953,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618974,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,4954,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618975,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
A,Mus musculus,10090.0,,,1,Intermediate,,5980,,N,4955,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618976,,Vd in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17592,,N,4956,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618977,,Volume of distribution in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,4957,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876724,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4958,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618978,,Volume of distribution of compound in plasma was determined at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4959,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618979,,Volume of distribution of compound in plasma was determined at 40 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,4960,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618980,,Volume of distribution of compound in plasma was determined at 5 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,4239,,N,4961,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618981,,Pharmacokinetic property (vdss) was measured in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,4962,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618982,,Value distribution upon iv administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,4963,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620150,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,4964,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620151,,Volume of distribution was evaluated in mice after intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,4965,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620152,,Volume of distribution was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,4966,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620153,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5727,,N,4967,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876395,,Steady state volume of distribution was determined in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17852,,N,4968,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620154,,Volume distribution (steady state) of compound was determined in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,4969,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620155,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,4970,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620156,,Vss value at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,6062,,N,4971,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620157,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,4972,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL620158,,Biodistribution of compound (oxidized form) in in kidney tissue
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,4973,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL620159,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,4974,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL620160,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,4975,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL620161,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,10708,,N,4976,1,797.0,,80019,,,,BAO_0000219,CHEMBL620162,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
F,Homo sapiens,9606.0,,A-431,1,Expert,,16597,,N,4977,1,500.0,,80852,,,,BAO_0000219,CHEMBL620163,,Inhibition of A431 human squamous cell carcinoma cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,16062,,N,4978,1,500.0,,80852,,,,BAO_0000219,CHEMBL620833,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay
F,Homo sapiens,9606.0,,A-431,1,Expert,,16062,,N,4979,1,500.0,,80852,,,,BAO_0000219,CHEMBL876396,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth
F,Homo sapiens,9606.0,,A-431,1,Expert,,16958,,N,4980,1,500.0,,80852,,,,BAO_0000219,CHEMBL620834,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line
F,Homo sapiens,9606.0,,A-431,1,Expert,,6700,,N,4981,1,500.0,,80852,,,,BAO_0000219,CHEMBL620835,,Inhibition of A431 human carcinoma cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,17226,,N,4982,1,500.0,,80852,,,,BAO_0000219,CHEMBL620836,,In vitro inhibition of A431 (human carcinoma) cell basal growth.
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,6828,,N,4983,1,500.0,,80852,,,,BAO_0000219,CHEMBL620837,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,12314,,N,4984,1,500.0,,80852,,,,BAO_0000219,CHEMBL621017,,In vitro cytotoxicity against epidermoid carcinoma cell line
F,Homo sapiens,9606.0,,A-431,1,Expert,,13412,,D,4985,9,500.0,,9,,,,BAO_0000218,CHEMBL621018,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R"
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,13299,,N,4986,1,500.0,,80852,,,,BAO_0000219,CHEMBL621019,,Antiproliferative activity of compound was measured on human tumor cell line A431.
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,17420,,N,4987,1,500.0,,80852,,,,BAO_0000219,CHEMBL621020,,Antiproliferative effect of compound on A431 cell line expressing mutant p53
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,13678,,N,4988,1,500.0,,80852,,,,BAO_0000219,CHEMBL621021,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
F,,,,A-431,1,Expert,,14171,,H,4989,8,500.0,,9,,,,BAO_0000219,CHEMBL621022,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.
F,Homo sapiens,9606.0,,A-431,1,Expert,,6333,,N,4990,1,500.0,,80852,,,,BAO_0000219,CHEMBL621023,,Tested for antiproliferative activity against human A431 cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,2356,,D,4991,9,500.0,,9,,,,BAO_0000219,CHEMBL621024,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,15578,,N,4992,1,500.0,,80852,,,,BAO_0000219,CHEMBL621025,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines
F,Homo sapiens,9606.0,,A-431,1,Expert,,5126,,N,4993,1,500.0,,80852,,,,BAO_0000219,CHEMBL621026,,Inhibition of A431 cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,6844,,N,4994,1,500.0,,80852,,,,BAO_0000219,CHEMBL621027,,Cytotoxic effect on A431 human epidermoid carcinoma cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,6844,,N,4995,1,500.0,,80852,,,,BAO_0000219,CHEMBL876397,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM)
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,4925,,N,4996,1,500.0,,80852,,,,BAO_0000219,CHEMBL883797,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,4925,,N,4997,1,500.0,,80852,,,,BAO_0000219,CHEMBL621028,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,13978,,N,4998,1,500.0,,80852,,,,BAO_0000219,CHEMBL621029,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,16786,,N,4999,1,500.0,,80852,,,,BAO_0000219,CHEMBL621030,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure
F,,,,A-431,1,Expert,,13412,,H,5000,8,500.0,,9,,,,BAO_0000219,CHEMBL621147,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,17824,,N,5001,1,500.0,,80852,,,,BAO_0000218,CHEMBL621148,,In vivo antiproliferative activity against A431 cell line
F,Homo sapiens,9606.0,,A-431,1,Expert,,12751,,D,5002,9,500.0,,9,,,,BAO_0000219,CHEMBL621149,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,12380,,N,5003,1,500.0,,80852,,,,BAO_0000219,CHEMBL621150,,Inhibition of A431 human epidermoid carcinoma cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,4959,,D,5004,9,500.0,,9,,,,BAO_0000219,CHEMBL621151,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,6333,,N,5005,1,500.0,,80852,,,,BAO_0000219,CHEMBL621152,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,6333,,N,5006,1,500.0,,80852,,,,BAO_0000219,CHEMBL621153,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,6333,,N,5007,1,500.0,,80852,,,,BAO_0000219,CHEMBL884000,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
F,Homo sapiens,9606.0,,,1,Expert,,5296,,D,5008,9,,,9,,,,BAO_0000019,CHEMBL621154,,Inhibition of EGFR overexpressing A431 cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,12624,,N,5009,1,500.0,,80852,,,,BAO_0000219,CHEMBL621155,,Inhibition of A431 cell proliferation
F,Homo sapiens,9606.0,,A-431,1,Expert,,14926,,D,5010,9,500.0,,9,,,,BAO_0000219,CHEMBL621156,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor
F,Homo sapiens,9606.0,,A-431,1,Expert,,14926,,D,5011,9,500.0,,9,,,,BAO_0000219,CHEMBL621157,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor"
F,,,,A-431,1,Expert,,14926,,H,5012,8,500.0,,9,,,,BAO_0000219,CHEMBL621158,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor)
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,15144,,N,5013,1,500.0,,80852,,,,BAO_0000219,CHEMBL621159,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,15144,,N,5014,1,500.0,,80852,,,,BAO_0000219,CHEMBL621160,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5015,1,500.0,,80852,,,,BAO_0000219,CHEMBL621161,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5016,1,500.0,,80852,,,,BAO_0000219,CHEMBL621162,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5017,1,500.0,,80852,,,,BAO_0000219,CHEMBL621163,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5018,1,500.0,,80852,,,,BAO_0000219,CHEMBL621164,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5019,1,500.0,,80852,,,,BAO_0000219,CHEMBL621165,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death
A,Cercopithecidae,9527.0,,,1,Autocuration,,5922,,U,5020,0,,,22224,,,,BAO_0000019,CHEMBL619159,,Half-life period in cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,1116,,U,5021,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL619160,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma"
A,Cercopithecidae,9527.0,,,1,Autocuration,,17853,,U,5022,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619161,,Longer half-life in monkey (i.v.) at 0.5 mpk
A,Cercopithecidae,9527.0,,,1,Autocuration,,993,,U,5023,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL619162,,Plasma half life in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,4514,,U,5024,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL619163,,Plasma half-life in rhesus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,5025,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL619164,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5334,,U,5026,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL619320,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
A,Cercopithecidae,9527.0,,,1,Autocuration,,4578,,U,5027,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619321,,Tested for half life upon iv administration to african green monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,5028,0,,,22224,,,In vivo,BAO_0000218,CHEMBL873336,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,5029,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619322,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,5030,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619323,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,5031,0,,,22224,,,In vivo,BAO_0000218,CHEMBL619324,,The time for peak concentration value after oral administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5032,0,,,22224,,,,BAO_0000019,CHEMBL619325,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5033,0,,,22224,,,,BAO_0000019,CHEMBL876411,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5034,0,,,22224,,,,BAO_0000019,CHEMBL619326,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5035,0,,,22224,,,,BAO_0000019,CHEMBL619327,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5036,0,,,22224,,,,BAO_0000019,CHEMBL619328,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5037,0,,,22224,,,,BAO_0000019,CHEMBL619329,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5038,0,,,22224,,,,BAO_0000019,CHEMBL619330,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5039,0,,,22224,,,,BAO_0000019,CHEMBL619331,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5040,0,,,22224,,,,BAO_0000019,CHEMBL619332,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5041,0,,,22224,,,,BAO_0000019,CHEMBL619333,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5042,0,,,22224,,,,BAO_0000019,CHEMBL619334,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5043,0,,,22224,,,,BAO_0000019,CHEMBL619335,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5044,0,,,22224,,,,BAO_0000019,CHEMBL619336,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5045,0,,,22224,,,,BAO_0000019,CHEMBL619337,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5046,0,,,22224,,,,BAO_0000019,CHEMBL619338,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound
A,Cercopithecidae,9527.0,,,1,Autocuration,,11271,,U,5047,0,,,22224,,,,BAO_0000019,CHEMBL619339,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5809,,N,5048,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619340,,Bioavailability in rat (cannulated) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,5049,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873496,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5050,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL619341,,AUC value in rat after IV administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5051,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL619342,,AUC value in rat after oral administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5052,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619343,,Cmax value in rat after oral administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5053,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619344,,Bioavailability in rat after oral administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5054,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619345,,Tmax value in rat after oral administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5055,1,,,50597,,,,BAO_0000218,CHEMBL619346,,Vc value in rat after IV administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3546,,N,5056,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619347,,Half life period in rat after IV administration at a dose of 10 mg/kg
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5057,0,,,22224,,,,BAO_0000019,CHEMBL619348,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5058,0,,,22224,,,,BAO_0000019,CHEMBL619349,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11)
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5059,0,,,22224,,,,BAO_0000019,CHEMBL619350,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11)
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5060,0,,,22224,,,,BAO_0000019,CHEMBL619351,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5061,0,,,22224,,,,BAO_0000019,CHEMBL875953,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5062,0,,,22224,,,,BAO_0000019,CHEMBL621716,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5063,0,,,22224,,,,BAO_0000019,CHEMBL621717,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound
A,Papio hamadryas,9557.0,,,1,Autocuration,,10625,,U,5064,0,,,22224,,,,BAO_0000019,CHEMBL621718,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
A,beagle,9615.0,,,1,Autocuration,,3510,,U,5065,0,,,22224,,,,BAO_0000019,CHEMBL621719,,Area under curve after 1 mpk peroral administration to beagles
A,beagle,9615.0,,,1,Autocuration,,3510,,U,5066,0,,,22224,,,,BAO_0000019,CHEMBL621720,,Area under curve after 2 mpk peroral administration to beagles
A,beagle,9615.0,,,1,Autocuration,,3510,,U,5067,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621721,,Cmax value after 1 mpk peroral administration to beagles
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5068,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL621722,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5069,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL621723,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5070,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL621724,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5071,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623443,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5072,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623444,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5073,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623445,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5
A,Homo sapiens,9606.0,,,1,Autocuration,,7766,,U,5074,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623446,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,16643,,U,5075,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL623447,,Metabolic stability observed at 30 min after administration in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,5076,0,,,22224,,,,BAO_0000019,CHEMBL623448,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,5077,0,,,22224,,,,BAO_0000019,CHEMBL623449,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients
A,Homo sapiens,9606.0,,,1,Autocuration,,6852,,U,5078,0,,,22224,,,,BAO_0000019,CHEMBL623450,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6567,,U,5079,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL623451,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer"
A,Homo sapiens,9606.0,,,1,Autocuration,,6570,,U,5080,0,,,22224,,,,BAO_0000019,CHEMBL623452,,Metabolic stability (% remaining at 30 mins) in human S9.
A,Homo sapiens,9606.0,,,1,Autocuration,,6570,,U,5081,0,,,22224,,,,BAO_0000019,CHEMBL623453,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5237,,U,5082,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL623454,,Percent parent compound remaining after 20 min incubation with human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5237,,U,5083,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL623455,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5237,,U,5084,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL624371,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data
A,Homo sapiens,9606.0,,,1,Autocuration,,5202,,U,5085,0,,,22224,,,,BAO_0000218,CHEMBL624372,,First pass metabolism and metabolic bioavailability using human hepatic microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,5481,,U,5086,0,,,22224,,,,BAO_0000019,CHEMBL624373,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.
A,Homo sapiens,9606.0,,,1,Autocuration,,5481,,U,5087,0,,,22224,,,,BAO_0000019,CHEMBL624374,,Percent remaining in human plasma after incubation for 60 min at 37 C.
A,Homo sapiens,9606.0,,,1,Autocuration,,3956,,U,5088,0,,,22224,,,,BAO_0000019,CHEMBL624556,,The percent remaining in human plasma after 30 min was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,5074,,U,5089,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL624557,,Conversion rate of the prodrug in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,5074,,U,5090,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL624558,,Conversion rate of the prodrug in human plasma; ND means no data
A,Homo sapiens,9606.0,,,1,Autocuration,,4727,,U,5091,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL624559,,Half life of compound was determined in human blood
A,Homo sapiens,9606.0,,,1,Autocuration,,5965,,U,5092,0,,,22224,,,,BAO_0000019,CHEMBL624560,,Half life of compound was determined in man with once daily dosing
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5732,,U,5093,0,,,22224,,,In vitro,BAO_0000251,CHEMBL624561,,Half life in human microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,5819,,U,5094,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL624562,,Half life in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,5819,,U,5095,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL624563,,Half life in human plasma; Not detected
A,Homo sapiens,9606.0,,,1,Autocuration,,1916,,U,5096,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624564,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6597,,U,5097,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL624565,,Half-life for oxidative metabolic stability was determined using rat liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,5229,,U,5098,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL875152,,Half-life in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,5229,,U,5099,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL624566,,Half-life of the parent prodrug in plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,2192,,U,5100,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL873805,,In vitro half life in human plasma was determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,3032,,U,5101,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL624567,,The compound was tested In Vitro for half life in human liver microsomes.
A,Homo sapiens,9606.0,,,1,Autocuration,,1916,,U,5102,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624568,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration
A,Homo sapiens,9606.0,,,1,Autocuration,,17716,,U,5103,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624569,,Observed volume of distribution
A,Homo sapiens,9606.0,,,1,Autocuration,,15778,,U,5104,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624570,,Oral bioavailability in human
A,Homo sapiens,9606.0,,,1,Autocuration,,17313,,U,5105,0,,,22224,,,,BAO_0000019,CHEMBL624571,,Tested for human plasma protein binding of the compound
A,Homo sapiens,9606.0,,,1,Autocuration,,4231,,U,5106,0,,,22224,,,,BAO_0000019,CHEMBL624572,,"First order rate constant, k was determined in human plasma"
A,Homo sapiens,9606.0,,,1,Autocuration,,4755,,U,5107,0,,,22224,,,,BAO_0000019,CHEMBL624573,,Observed rate constant in 80% human plasma at 37 degree Centigrade
A,Homo sapiens,9606.0,,,1,Autocuration,,4755,,U,5108,0,,,22224,,,,BAO_0000019,CHEMBL875153,,Observed rate constant in 80% human plasma at 37 degree Centigrade
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,16907,,U,5109,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL624574,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,10839,,U,5110,0,,,22224,,,,BAO_0000019,CHEMBL624575,,The compound was tested for the plasma binding in human
A,Homo sapiens,9606.0,,,1,Autocuration,,10839,,U,5111,0,,,22224,,,,BAO_0000019,CHEMBL624576,,Plasma protein binding (human)
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,3199,,U,5112,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL624577,,Compound was evaluated for half-life in human liver microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,1345,,U,5113,0,,,22224,Blood,178.0,In vitro,BAO_0000221,CHEMBL624578,,Half life measured in vitro for its stability in human blood
A,Homo sapiens,9606.0,,,1,Autocuration,,4297,,U,5114,0,,,22224,Serum,1977.0,,BAO_0000019,CHEMBL622796,,Half life in human serum
A,Homo sapiens,9606.0,,,1,Autocuration,,4297,,U,5115,0,,,22224,Serum,1977.0,,BAO_0000019,CHEMBL622797,,Half life in human serum; ND=not determined
A,Homo sapiens,9606.0,,,1,Autocuration,,4297,,U,5116,0,,,22224,,,,BAO_0000019,CHEMBL622798,,Half life were determined in CEM-SS cell extract in decomposition step 1
A,Homo sapiens,9606.0,,,1,Autocuration,,4297,,U,5117,0,,,22224,,,,BAO_0000019,CHEMBL622799,,Half life were determined in CEM-SS cell extract in decomposition step 2
A,Homo sapiens,9606.0,,,1,Autocuration,,4231,,U,5118,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL622800,,Half life of the in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,S9,5633,,U,5119,0,,,22224,,,In vitro,BAO_0000220,CHEMBL622801,,Half life period in human hepatic S9 fraction was determined
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5633,,U,5120,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL622802,,Half life period in human liver microsome was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,17791,,U,5121,0,,,22224,,,,BAO_0000019,CHEMBL622803,,Half life period was determined; 6-7
A,Homo sapiens,9606.0,,,1,Autocuration,,17791,,U,5122,0,,,22224,,,,BAO_0000019,CHEMBL875154,,Half life period was evaluated in human
A,Homo sapiens,9606.0,,,1,Autocuration,,3160,,U,5123,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL622804,,Half life time in human plasma
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5124,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622805,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5125,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622611,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5126,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622612,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5127,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL875160,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5128,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622613,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5129,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622614,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5130,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622615,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5131,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622616,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5132,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622617,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5133,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622618,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5134,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622619,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5135,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622620,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5136,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622621,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5137,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622622,,Biodistribution of compound (oxidized form) in blood tissue
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5138,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622623,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5139,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622624,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5140,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622625,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5141,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622626,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5142,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622627,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5143,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622628,,Biodistribution of compound (oxidized form) in brain tissue of mice
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5144,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622629,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5145,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622630,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5146,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622631,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5147,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622632,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5148,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622633,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5149,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622634,,Biodistribution of compound (oxidized form) in heart tissue of mice
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5150,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622635,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5151,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL875161,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5152,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622636,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5153,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL623335,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5154,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL623336,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5155,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623337,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5156,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623338,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5157,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623339,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5158,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623524,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5159,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623525,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5160,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623526,,Biodistribution of compound (oxidized form) in liver tissue
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5161,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623527,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,5162,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623528,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5163,1,500.0,,80852,,,,BAO_0000219,CHEMBL624615,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,5245,,N,5164,1,500.0,,80852,,,,BAO_0000219,CHEMBL621672,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
F,,,,A-431,1,Expert,,16289,,N,5165,1,500.0,,80852,,,,BAO_0000218,CHEMBL621673,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)"
F,,,,A-431,1,Expert,,16289,,N,5166,1,500.0,,80852,,,,BAO_0000218,CHEMBL621674,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)"
F,Homo sapiens,9606.0,,A-431,1,Expert,,16093,,D,5167,9,500.0,,9,,,,BAO_0000219,CHEMBL884002,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,16825,,N,5168,1,500.0,,80852,,,,BAO_0000219,CHEMBL621850,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. "
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,4848,,N,5169,1,500.0,,80852,,,,BAO_0000219,CHEMBL621851,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,14827,,D,5170,9,500.0,,9,,,,BAO_0000219,CHEMBL621852,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells
F,Homo sapiens,9606.0,,A-431,1,Expert,,14827,,D,5171,9,500.0,,9,,,,BAO_0000219,CHEMBL621853,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture
F,,,,A-431,1,Expert,,16289,,N,5172,1,500.0,,80852,,,,BAO_0000218,CHEMBL621854,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)"
F,,,,A-431,1,Expert,,16289,,N,5173,1,500.0,,80852,,,,BAO_0000218,CHEMBL621855,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
F,,,,A-431,1,Expert,,16289,,N,5174,1,500.0,,80852,,,,BAO_0000218,CHEMBL623724,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
F,,,,A-431,1,Expert,,16289,,N,5175,1,500.0,,80852,,,,BAO_0000218,CHEMBL623725,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24"
F,,,,A-431,1,Expert,,16289,,N,5176,1,500.0,,80852,,,,BAO_0000218,CHEMBL623726,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26"
F,Homo sapiens,9606.0,,A-431,1,Expert,,16289,,D,5177,9,500.0,,9,,,,BAO_0000219,CHEMBL623727,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound"
F,,,,A-431,1,Expert,,16289,,H,5178,8,500.0,,9,,,,BAO_0000219,CHEMBL623728,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound
F,,,,A-431,1,Expert,,16289,,N,5179,1,500.0,,80852,,,,BAO_0000218,CHEMBL623729,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24"
F,,,,A-431,1,Expert,,16289,,N,5180,1,500.0,,80852,,,,BAO_0000218,CHEMBL623730,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
F,,,,A-431,1,Expert,,16289,,N,5181,1,500.0,,80852,,,,BAO_0000218,CHEMBL623731,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
F,Mus musculus,10090.0,,A-431,1,Expert,,14555,,N,5182,1,500.0,,80852,,,,BAO_0000218,CHEMBL623732,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration"
F,Mus musculus,10090.0,,A-431,1,Expert,,14555,,N,5183,1,500.0,,80852,,,,BAO_0000218,CHEMBL623733,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration"
F,Mus musculus,10090.0,,A-431,1,Expert,,14555,,N,5184,1,500.0,,80852,,,,BAO_0000218,CHEMBL623734,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
F,Mus musculus,10090.0,,A-431,1,Expert,,14555,,N,5185,1,500.0,,80852,,,,BAO_0000218,CHEMBL623735,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
F,Homo sapiens,9606.0,,A-431,1,Expert,,1937,,N,5186,1,500.0,,80852,,,,BAO_0000219,CHEMBL623736,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,13739,,N,5187,1,500.0,,80852,,,,BAO_0000219,CHEMBL623737,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,3558,,N,5188,1,500.0,,80852,,,,BAO_0000219,CHEMBL623738,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye
F,Homo sapiens,9606.0,,A-431,1,Intermediate,,3558,,N,5189,1,500.0,,80852,,,,BAO_0000219,CHEMBL875168,,Dose giving a 50% decrease in the living cell number (A437 cells)
F,Homo sapiens,9606.0,,A549,1,Expert,,17686,,N,5190,1,646.0,,80682,,,,BAO_0000219,CHEMBL623739,,In vitro inhibitory concentration against proliferation of A459 cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5305,,N,5191,1,646.0,,80682,,,,BAO_0000219,CHEMBL623740,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3614,,N,5192,1,646.0,,80682,,,,BAO_0000219,CHEMBL624424,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure
F,Homo sapiens,9606.0,,A498,1,Intermediate,,17229,,N,5193,1,624.0,,80021,,,,BAO_0000219,CHEMBL624425,,In vitro antitumor activity against renal A498 tumor cell lines
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15935,,N,5194,1,624.0,,80021,,,,BAO_0000219,CHEMBL624426,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors"
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15935,,N,5195,1,624.0,,80021,,,,BAO_0000219,CHEMBL624427,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium"
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15560,,N,5196,1,624.0,,80021,,,,BAO_0000219,CHEMBL624428,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
F,Homo sapiens,9606.0,,A498,1,Intermediate,,13891,,N,5197,1,624.0,,80021,,,,BAO_0000219,CHEMBL624429,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,13891,,N,5198,1,624.0,,80021,,,,BAO_0000219,CHEMBL624620,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested
F,Homo sapiens,9606.0,,A498,1,Intermediate,,13788,,N,5199,1,624.0,,80021,,,,BAO_0000219,CHEMBL624621,,Cytotoxicity on kidney carcinoma (A-498) cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15403,,N,5200,1,624.0,,80021,,,,BAO_0000219,CHEMBL624622,,Compound was evaluated against Human cell line renal A498
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1009,,N,5201,1,624.0,,80021,,,,BAO_0000219,CHEMBL624623,,Compound was tested for inhibition of A498 human renal cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1043,,N,5202,1,624.0,,80021,,,,BAO_0000219,CHEMBL874365,,Growth inhibitory activity against A498 human cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,5858,,N,5203,1,624.0,,80021,,,,BAO_0000219,CHEMBL624624,,In vitro antitumor activity against human renal A498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,5958,,N,5204,1,624.0,,80021,,,,BAO_0000219,CHEMBL624625,,In vitro cytotoxic activity against renal (A498) cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,5506,,N,5205,1,624.0,,80021,,,,BAO_0000219,CHEMBL624626,,In vitro cytotoxic activity against human renal cancer (A498) cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,12781,,N,5206,1,624.0,,80021,,,,BAO_0000219,CHEMBL624627,,Tested for cytostatic activity against renal A498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,14399,,N,5207,1,624.0,,80021,,,,BAO_0000219,CHEMBL883157,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
F,Homo sapiens,9606.0,,A498,1,Expert,,5958,,N,5208,1,624.0,,80021,,,,BAO_0000219,CHEMBL624628,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M
A,beagle,9615.0,,,1,Autocuration,,3510,,U,5209,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624629,,Cmax value after 2 mpk peroral administration to beagles
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,3510,beagle,U,5210,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623551,,Bioavailability
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,3510,beagle,U,5211,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623552,,Bioavailability after 1 mpk peroral administration to beagles
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,3510,beagle,U,5212,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623553,,Bioavailability after 2 mpk peroral administration to beagles
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5213,0,,,22224,,,,BAO_0000019,CHEMBL623554,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5214,0,,,22224,,,,BAO_0000019,CHEMBL623555,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5215,0,,,22224,,,,BAO_0000019,CHEMBL623556,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound
A,Bos taurus,9913.0,,,1,Autocuration,,9372,,U,5216,0,,,22224,,,,BAO_0000019,CHEMBL623557,,Solubility against bovine alpha-chymotrypsin
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5217,0,,,22224,,,,BAO_0000019,CHEMBL623558,,Rate constant of the bovine serum albumin catalyzed reaction of the compound
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5218,0,,,22224,,,,BAO_0000019,CHEMBL623559,,Rate constant of the bovine serum albumin catalyzed reaction of the compound
A,Bos taurus,9913.0,,,1,Autocuration,,1469,,U,5219,0,,,22224,Spleen,2106.0,,BAO_0000221,CHEMBL623560,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg
A,Bos taurus,9913.0,,,1,Autocuration,,4297,,U,5220,0,,,22224,,,,BAO_0000019,CHEMBL623561,,Half life in culture medium containing 10% of heat inactivated foetal calf serum
A,Bos taurus,9913.0,,,1,Autocuration,,4297,,U,5221,0,,,22224,,,,BAO_0000019,CHEMBL623562,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined
A,Bos taurus,9913.0,,,1,Autocuration,,17585,,U,5222,0,,,22224,,,,BAO_0000019,CHEMBL623563,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2
A,Bos taurus,9913.0,,,1,Autocuration,,1336,,U,5223,0,,,22224,Spleen,2106.0,,BAO_0000221,CHEMBL623564,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase
A,Bos taurus,9913.0,,,1,Autocuration,,3085,,U,5224,0,,,22224,,,,BAO_0000019,CHEMBL873806,,Half life in presence of 2 mg/mL BSA at pH 8.8
A,Bos taurus,9913.0,,,1,Autocuration,,2857,,U,5225,0,,,22224,,,,BAO_0000019,CHEMBL623565,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1
A,Bos taurus,9913.0,,,1,Autocuration,,2857,,U,5226,0,,,22224,,,,BAO_0000019,CHEMBL623566,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2
A,Bos taurus,9913.0,,,1,Autocuration,,2857,,U,5227,0,,,22224,,,,BAO_0000019,CHEMBL623567,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined
A,Bos taurus,9913.0,,,1,Autocuration,,1540,,U,5228,0,,,22224,,,,BAO_0000019,CHEMBL623568,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6316,,N,5229,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623569,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,5230,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623570,,AUC after administration at 100 mg/kg/day in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4953,,N,5231,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624254,,AUC in dog at 0-24 hr by peroral administration at 3 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5232,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624255,,AUC value after 15 mg/kg iv dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5233,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624256,,AUC value after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,5234,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624257,,AUC value after administration of 4 mg/Kg oral dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,5235,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624258,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5356,,N,5236,1,,,50588,,,,BAO_0000218,CHEMBL875277,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16807,,N,5237,1,,,50588,,,,BAO_0000218,CHEMBL622667,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,5238,1,,,50588,,,,BAO_0000218,CHEMBL622668,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,5239,1,,,50588,,,,BAO_0000218,CHEMBL622669,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,5240,1,,,50588,,,,BAO_0000218,CHEMBL622670,,Area under curve determined in dogs after intravenous administration of 3 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,5241,1,,,50588,,,,BAO_0000218,CHEMBL622671,,Area under curve determined in dogs after oral administration of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5802,,N,5242,1,,,50588,,,,BAO_0000218,CHEMBL622672,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,5243,1,,,50588,,,,BAO_0000218,CHEMBL622673,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,5244,1,,,50588,,,,BAO_0000218,CHEMBL622674,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5245,1,,,50588,,,,BAO_0000218,CHEMBL622675,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5246,1,,,50588,,,,BAO_0000218,CHEMBL622676,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5247,1,,,50588,,,,BAO_0000218,CHEMBL622677,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5248,1,,,50588,,,,BAO_0000218,CHEMBL622678,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4186,,N,5249,1,,,50588,,,,BAO_0000218,CHEMBL622679,,Area under curve in dog after administration of 20 mg/kg dose through peroral route
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5007,,N,5250,1,,,50588,,,,BAO_0000218,CHEMBL622680,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5251,1,,,50588,,,,BAO_0000218,CHEMBL622681,,Area under curve was determine after peroral administration at 10 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5252,1,,,50588,,,,BAO_0000218,CHEMBL875278,,Area under curve was determine after peroral administration at 5 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,5253,1,,,50588,,,,BAO_0000218,CHEMBL622682,,Area under curve was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,5254,1,,,50588,,,,BAO_0000218,CHEMBL622683,,Area under curve in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3771,,N,5255,1,,,50588,,,,BAO_0000218,CHEMBL622684,,Area under curve in dogs at 10 mg/kg dose fo oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3771,,N,5256,1,,,50588,,,,BAO_0000218,CHEMBL622685,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3771,,N,5257,1,,,50588,,,,BAO_0000218,CHEMBL622686,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1916,,N,5258,1,,,50588,,,,BAO_0000218,CHEMBL618344,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5302,,N,5259,1,,,50588,,,,BAO_0000218,CHEMBL875582,,Area under curve value in dog at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,5260,1,,,50588,,,,BAO_0000218,CHEMBL618345,,Area under curve was determined after 0.1 mg/kg iv administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,5261,1,,,50588,,,,BAO_0000218,CHEMBL618346,,Area under curve was determined after 0.3 mg/kg po administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,5262,1,,,50588,,,,BAO_0000218,CHEMBL618347,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4368,,N,5263,1,,,50588,,,,BAO_0000218,CHEMBL618348,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog
A,Homo sapiens,9606.0,,,1,Autocuration,,5318,,U,5264,0,,,22224,,,,BAO_0000019,CHEMBL618349,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase
A,Homo sapiens,9606.0,,,1,Autocuration,,5318,,U,5265,0,,,22224,,,,BAO_0000019,CHEMBL618350,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
A,Homo sapiens,9606.0,,,1,Autocuration,,5318,,U,5266,0,,,22224,,,,BAO_0000019,CHEMBL618351,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase
A,Homo sapiens,9606.0,,,1,Autocuration,,5318,,U,5267,0,,,22224,,,,BAO_0000019,CHEMBL618352,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase
A,Homo sapiens,9606.0,,,1,Autocuration,,14518,,U,5268,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL873494,,Time taken to reduce 50% of the concentration of compound in blood plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,2209,,U,5269,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618353,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
A,Homo sapiens,9606.0,,,1,Autocuration,,6787,,U,5270,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618354,,Half life in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,4898,,U,5271,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL875583,,Half life in human plasma was reported
A,Homo sapiens,9606.0,,,1,Autocuration,,6072,,U,5272,0,,,22224,Serum,1977.0,,BAO_0000019,CHEMBL618355,,Half life in human serum
A,Homo sapiens,9606.0,,,1,Autocuration,,16907,,U,5273,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618356,,Half life upon exposure to human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,5656,,U,5274,0,,,22224,,,In vitro,BAO_0000251,CHEMBL618357,,t1/2 in human microsomes
A,Homo sapiens,9606.0,,,1,Autocuration,,4755,,U,5275,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618358,,Half life period in 80% human plasma at 37 degree Centigrade
A,Homo sapiens,9606.0,,,1,Autocuration,,17503,,U,5276,0,,,22224,Zone of skin,14.0,,BAO_0000221,CHEMBL618359,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4)
A,Homo sapiens,9606.0,,,1,Autocuration,,12357,,U,5277,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL618360,,Half-life measured in in vitro Cathepsin B assay in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,3076,,U,5278,0,,,22224,,,,BAO_0000019,CHEMBL618361,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,6410,,U,5279,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618362,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,5280,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618363,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,5281,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618364,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
A,Homo sapiens,9606.0,,,1,Autocuration,,3741,,U,5282,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL875584,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
A,Homo sapiens,9606.0,,,1,Autocuration,,1540,,U,5283,0,,,22224,,,,BAO_0000019,CHEMBL618365,,Half-life in the CEM cell extracts
A,Homo sapiens,9606.0,,,1,Autocuration,,2905,,U,5284,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL873495,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade
A,Homo sapiens,9606.0,,,1,Autocuration,,2905,,U,5285,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618366,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed
A,Homo sapiens,9606.0,,,1,Autocuration,,5523,,U,5286,0,,,22224,,,,BAO_0000019,CHEMBL618367,,Half-life was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,1499,,U,5287,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL618368,,Half-life (human blood stability)
A,Homo sapiens,9606.0,,,1,Autocuration,,1499,,U,5288,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL618369,,Half-life (human blood stability); no data
A,Homo sapiens,9606.0,,,1,Autocuration,,17065,,U,5289,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618370,,Half-life in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,6861,,U,5290,0,,,22224,,,,BAO_0000019,CHEMBL618371,,CYP3A4 metabolism half-life (t1/2)
A,Homo sapiens,9606.0,,,1,Autocuration,,1499,,U,5291,0,,,22224,Blood,178.0,,BAO_0000221,CHEMBL618372,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability)
A,Homo sapiens,9606.0,,,1,Autocuration,,530,,U,5292,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL618373,,In vitro half life in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,1116,,U,5293,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL618374,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma"
A,Homo sapiens,9606.0,,,1,Autocuration,,6695,,U,5294,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL618375,,In vitro hydrolysis in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,6695,,U,5295,0,,,22224,Plasma,1969.0,In vitro,BAO_0000366,CHEMBL618376,,In vitro hydrolysis in human plasma; no data
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,10,,U,5296,0,,,22224,Liver,2107.0,In vitro,BAO_0000251,CHEMBL618377,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C
A,Homo sapiens,9606.0,,,1,Autocuration,,993,,U,5297,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618378,,Plasma half life in human
A,Homo sapiens,9606.0,,,1,Autocuration,,15429,,U,5298,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618379,,Stability after incubation with human plasma (at 37 degree C)
A,Homo sapiens,9606.0,,,1,Autocuration,,1675,,U,5299,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618380,,T1/2 was evaluated in human plasma
A,Homo sapiens,9606.0,,,1,Autocuration,,2209,,U,5300,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618381,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
A,Homo sapiens,9606.0,,,1,Autocuration,,2209,,U,5301,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL618382,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined"
A,Homo sapiens,9606.0,,,1,Autocuration,,5318,,U,5302,0,,,22224,,,,BAO_0000019,CHEMBL618383,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
A,Homo sapiens,9606.0,,,1,Autocuration,,2412,,U,5303,0,,,22224,,,In vitro,BAO_0000019,CHEMBL618384,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase
A,Homo sapiens,9606.0,,,1,Autocuration,,2412,,U,5304,0,,,22224,,,In vitro,BAO_0000019,CHEMBL618385,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined
A,Homo sapiens,9606.0,,,1,Autocuration,,2906,,U,5305,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL619099,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay
A,Homo sapiens,9606.0,,,1,Autocuration,,2906,,U,5306,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL619100,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed
A,Homo sapiens,9606.0,,,1,Autocuration,,5495,,U,5307,0,,,22224,,,,BAO_0000019,CHEMBL619101,,Time taken for 50% to be consumed by serum PON1 was determined
A,Homo sapiens,9606.0,,,1,Autocuration,,5495,,U,5308,0,,,22224,,,,BAO_0000019,CHEMBL619102,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed
A,Homo sapiens,9606.0,,,1,Autocuration,Microsomes,4397,,U,5309,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL619103,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5310,0,,,22224,,,,BAO_0000218,CHEMBL619268,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5311,0,,,22224,,,,BAO_0000218,CHEMBL619269,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5312,0,,,22224,,,,BAO_0000218,CHEMBL619270,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5313,0,,,22224,,,,BAO_0000218,CHEMBL619271,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5314,0,,,22224,,,,BAO_0000218,CHEMBL875585,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5315,0,,,22224,,,,BAO_0000218,CHEMBL619272,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,6058,,N,5316,1,391.0,,80640,,,,BAO_0000219,CHEMBL619273,,Compound tested for growth inhibition of renal cancer cell line 786-0
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,17708,,N,5317,1,391.0,,80640,,,,BAO_0000219,CHEMBL619274,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line
F,Homo sapiens,9606.0,,786-0,1,Expert,,14017,,N,5318,1,391.0,,80640,,,,BAO_0000219,CHEMBL619275,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16818,,N,5319,1,391.0,,80640,,,,BAO_0000219,CHEMBL619276,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration"
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16818,,N,5320,1,391.0,,80640,,,,BAO_0000219,CHEMBL619277,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration"
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,16818,,N,5321,1,391.0,,80640,,,,BAO_0000219,CHEMBL619278,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration"
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,11970,,N,5322,1,391.0,,80640,,,,BAO_0000219,CHEMBL619279,,Tested for cytotoxicity against 786-0 cell lines in renal cancer
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,12400,,N,5323,1,391.0,,80640,,,,BAO_0000219,CHEMBL858458,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer
F,Homo sapiens,9606.0,,786-0,1,Expert,,12888,,N,5324,1,391.0,,80640,,,,BAO_0000219,CHEMBL619280,,Cytotoxic effect on renal cancer line 786-0
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,15300,,N,5325,1,391.0,,80640,,,,BAO_0000219,CHEMBL619281,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14769,,N,5326,1,391.0,,80640,,,,BAO_0000219,CHEMBL619282,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,15895,,N,5327,1,391.0,,80640,,,,BAO_0000219,CHEMBL619283,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line"
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,17376,,N,5328,1,391.0,,80640,,,,BAO_0000219,CHEMBL619284,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14882,,N,5329,1,391.0,,80640,,,,BAO_0000219,CHEMBL619285,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,14882,,N,5330,1,391.0,,80640,,,,BAO_0000219,CHEMBL619286,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death)
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,15176,,N,5331,1,391.0,,80640,,,,BAO_0000219,CHEMBL619287,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,12696,,N,5332,1,391.0,,80640,,,,BAO_0000219,CHEMBL857455,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,2496,,N,5333,1,391.0,,80640,,,,BAO_0000219,CHEMBL883801,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5334,1,972.0,,80641,,,,BAO_0000219,CHEMBL619288,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5335,1,972.0,,80641,,,,BAO_0000219,CHEMBL619289,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5336,1,972.0,,80641,,,,BAO_0000219,CHEMBL619290,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5337,1,972.0,,80641,,,,BAO_0000219,CHEMBL619291,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5338,1,972.0,,80641,,,,BAO_0000219,CHEMBL619292,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5339,1,972.0,,80641,,,,BAO_0000219,CHEMBL619293,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5340,1,972.0,,80641,,,,BAO_0000219,CHEMBL619294,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5341,1,972.0,,80641,,,,BAO_0000219,CHEMBL619295,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5342,1,972.0,,80641,,,,BAO_0000219,CHEMBL619296,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved)
F,Homo sapiens,9606.0,,791T cell line,1,Intermediate,,11831,,N,5343,1,972.0,,80641,,,,BAO_0000219,CHEMBL619297,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved
F,Homo sapiens,9606.0,,786-0,1,Intermediate,,12782,,N,5344,1,391.0,,80640,,,,BAO_0000219,CHEMBL619298,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line
F,,,,,1,Intermediate,,1229,,U,5345,0,,,22226,,,,BAO_0000019,CHEMBL619299,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive
F,Homo sapiens,9606.0,,RPMI-8226,1,Expert,,15313,,N,5346,1,741.0,,80433,,,,BAO_0000219,CHEMBL619300,,Inhibition of cell growth in drug resistant 8226 myeloma cell line
F,Homo sapiens,9606.0,,RPMI-8226,1,Expert,,15313,,N,5347,1,741.0,,80433,,,,BAO_0000219,CHEMBL619301,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,11544,,N,5348,1,741.0,,80433,,,,BAO_0000219,CHEMBL619302,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5349,1,741.0,,80433,,,,BAO_0000219,CHEMBL619303,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5350,1,741.0,,80433,,,,BAO_0000219,CHEMBL619304,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5351,1,741.0,,80433,,,,BAO_0000219,CHEMBL857706,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5352,1,741.0,,80433,,,,BAO_0000219,CHEMBL619305,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5353,1,741.0,,80433,,,,BAO_0000219,CHEMBL619306,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5354,1,741.0,,80433,,,,BAO_0000219,CHEMBL619307,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5355,1,741.0,,80433,,,,BAO_0000219,CHEMBL619308,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5356,1,741.0,,80433,,,,BAO_0000219,CHEMBL619309,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5357,1,741.0,,80433,,,,BAO_0000219,CHEMBL619310,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,A498,1,Intermediate,,14769,,N,5358,1,624.0,,80021,,,,BAO_0000219,CHEMBL619311,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15354,,N,5359,1,624.0,,80021,,,,BAO_0000219,CHEMBL619312,,Compound was tested for the growth inhibition of A498 renal tumor cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,17445,,N,5360,1,624.0,,80021,,,,BAO_0000219,CHEMBL619313,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer)
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4337,,N,5361,1,624.0,,80021,,,,BAO_0000219,CHEMBL619314,,In vitro inhibitory concentration against renal cancer cell line A498
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15277,,N,5362,1,624.0,,80021,,,,BAO_0000219,CHEMBL619959,,Cytotoxicity against A 498 tumor cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4812,,N,5363,1,624.0,,80021,,,,BAO_0000219,CHEMBL619960,,In vitro antitumor activity against A498 human cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4812,,N,5364,1,624.0,,80021,,,,BAO_0000219,CHEMBL619961,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening)
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4995,,N,5365,1,624.0,,80021,,,,BAO_0000219,CHEMBL619962,,Inhibitory dose required against A498 human tumor cell lines
F,Homo sapiens,9606.0,,A498,1,Intermediate,,5847,,N,5366,1,624.0,,80021,,,,BAO_0000219,CHEMBL875586,,Anticancer activity against one renal cancer (A498 cell line)
F,Homo sapiens,9606.0,,A498,1,Intermediate,,6557,,N,5367,1,624.0,,80021,,,,BAO_0000219,CHEMBL619963,,In vitro cytotoxicity against melanoma A498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,2597,,N,5368,1,624.0,,80021,,,,BAO_0000219,CHEMBL619964,,Compound was tested for growth inhibitory activity against A498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,6058,,N,5369,1,624.0,,80021,,,,BAO_0000219,CHEMBL620108,,Compound tested for growth inhibition of renal cancer cell line A498
F,Homo sapiens,9606.0,,A498,1,Intermediate,,17708,,N,5370,1,624.0,,80021,,,,BAO_0000219,CHEMBL620109,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15176,,N,5371,1,624.0,,80021,,,,BAO_0000219,CHEMBL620110,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15300,,N,5372,1,624.0,,80021,,,,BAO_0000219,CHEMBL620111,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay
F,Homo sapiens,9606.0,,A498,1,Intermediate,,11970,,N,5373,1,624.0,,80021,,,,BAO_0000219,CHEMBL620112,,Tested for cytotoxicity against A498 cell lines in renal cancer
F,Homo sapiens,9606.0,,A498,1,Intermediate,,12400,,N,5374,1,624.0,,80021,,,,BAO_0000219,CHEMBL620113,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer
F,Homo sapiens,9606.0,,A498,1,Expert,,12888,,N,5375,1,624.0,,80021,,,,BAO_0000219,CHEMBL620114,,Cytotoxic effect on renal cancer lines A498
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3030,,N,5376,1,624.0,,80021,,,,BAO_0000219,CHEMBL620115,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM
F,Homo sapiens,9606.0,,A498,1,Intermediate,,14769,,N,5377,1,624.0,,80021,,,,BAO_0000219,CHEMBL620116,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,A498,1,Intermediate,,17376,,N,5378,1,624.0,,80021,,,,BAO_0000219,CHEMBL620117,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,16558,,N,5379,1,624.0,,80021,,,,BAO_0000219,CHEMBL620118,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay
F,Homo sapiens,9606.0,,A498,1,Intermediate,,5194,,N,5380,1,624.0,,80021,,,,BAO_0000219,CHEMBL620119,,Cytotoxicity against human kidney carcinoma cell lines A4982LM
F,Homo sapiens,9606.0,,A498,1,Intermediate,,10708,,N,5381,1,624.0,,80021,,,,BAO_0000219,CHEMBL620120,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
F,Homo sapiens,9606.0,,A549,1,Expert,,16880,,N,5382,1,646.0,,80682,,,,BAO_0000219,CHEMBL620121,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10196,,N,5383,1,646.0,,80682,,,,BAO_0000219,CHEMBL620122,,Antitumor activity against A549 human lung carcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10196,,N,5384,1,646.0,,80682,,,,BAO_0000219,CHEMBL620123,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10196,,N,5385,1,646.0,,80682,,,,BAO_0000219,CHEMBL620124,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12083,,N,5386,1,646.0,,80682,,,,BAO_0000219,CHEMBL620125,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line"
F,Homo sapiens,9606.0,,A549,1,Expert,,16464,,N,5387,1,646.0,,80682,,,,BAO_0000219,CHEMBL620126,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16464,,N,5388,1,646.0,,80682,,,,BAO_0000219,CHEMBL883027,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A549,1,Expert,,16470,,N,5389,1,646.0,,80682,,,,BAO_0000219,CHEMBL620127,,In vitro cytotoxic activity against human lung A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16470,,N,5390,1,646.0,,80682,,,,BAO_0000219,CHEMBL620128,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16470,,N,5391,1,646.0,,80682,,,,BAO_0000219,CHEMBL620129,,In vitro cytotoxic activity against human lung A549 cell line)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16470,,N,5392,1,646.0,,80682,,,,BAO_0000219,CHEMBL620130,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested
F,Homo sapiens,9606.0,,A549,1,Expert,,16582,,N,5393,1,646.0,,80682,,,,BAO_0000219,CHEMBL620131,,In vitro cytotoxicity against human non small-cell-lung cell line A549.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15935,,N,5394,1,646.0,,80682,,,,BAO_0000219,CHEMBL620132,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15935,,N,5395,1,646.0,,80682,,,,BAO_0000219,CHEMBL620133,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium"
F,Homo sapiens,9606.0,,A549,1,Expert,,16597,,N,5396,1,646.0,,80682,,,,BAO_0000219,CHEMBL620134,,Inhibition of A549 human lung carcinoma cell proliferation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17376,,N,5397,1,646.0,,80682,,,,BAO_0000219,CHEMBL620135,,Inhibitory activity against A549 lung adenocarcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16496,,N,5398,1,646.0,,80682,,,,BAO_0000219,CHEMBL620136,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16152,,N,5399,1,646.0,,80682,,,,BAO_0000219,CHEMBL620137,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16152,,N,5400,1,646.0,,80682,,,,BAO_0000219,CHEMBL620268,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16464,,N,5401,1,646.0,,80682,,,,BAO_0000219,CHEMBL620269,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2288,,N,5402,1,646.0,,80682,,,,BAO_0000219,CHEMBL620270,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17350,,N,5403,1,646.0,,80682,,,,BAO_0000219,CHEMBL620271,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
F,Homo sapiens,9606.0,,A549,1,Expert,,4090,,N,5404,1,646.0,,80682,,,,BAO_0000219,CHEMBL620272,,Inhibition of A549 cancer cell proliferation
F,Homo sapiens,9606.0,,A549,1,Expert,,4090,,N,5405,1,646.0,,80682,,,,BAO_0000219,CHEMBL620273,,Inhibition of A549 cancer cell proliferation (Not tested)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17350,,N,5406,1,646.0,,80682,,,,BAO_0000219,CHEMBL620274,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4197,,N,5407,1,646.0,,80682,,,,BAO_0000219,CHEMBL620275,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17072,,N,5408,1,646.0,,80682,,,,BAO_0000219,CHEMBL620276,,Antiproliferative potency determined as inhibitory concentration against A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17072,,N,5409,1,646.0,,80682,,,,BAO_0000219,CHEMBL620277,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5194,,N,5410,1,646.0,,80682,,,,BAO_0000219,CHEMBL620278,,Cytotoxicity against Renal cell lines A549 was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4257,,N,5411,1,,,50588,,,,BAO_0000218,CHEMBL620279,,Area under curve was determined in dog after a 3 mg/kg of oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6123,,N,5412,1,,,50588,,,,BAO_0000218,CHEMBL620280,,Area under curve was determined in dog after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,5413,1,,,50588,,,,BAO_0000218,CHEMBL620281,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,5414,1,,,50588,,,,BAO_0000218,CHEMBL620282,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8833,,N,5415,1,,,50588,,,,BAO_0000218,CHEMBL621134,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8833,,N,5416,1,,,50588,,,,BAO_0000218,CHEMBL621135,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8833,,N,5417,1,,,50588,,,,BAO_0000218,CHEMBL621136,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8833,,N,5418,1,,,50588,,,,BAO_0000218,CHEMBL621137,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,5419,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621138,,Area under plasma concentration time curve in dog upon oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17650,,N,5420,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL875587,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1977,,N,5421,1,,,50588,,,,BAO_0000218,CHEMBL621139,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1977,,N,5422,1,,,50588,,,,BAO_0000218,CHEMBL621140,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3132,,N,5423,1,,,50588,,,,BAO_0000218,CHEMBL621141,,Area under the curve for the compound was obtained when tested in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5473,,N,5424,1,,,50588,,,,BAO_0000218,CHEMBL621142,,Area under the curve at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,5425,1,,,50588,,,,BAO_0000218,CHEMBL621143,,Area under the curve at a dose of 1 mg/kg (oral)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,5426,1,,,50588,,,,BAO_0000218,CHEMBL621144,,Area under the curve at i.v. dose of 0.2 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6062,,N,5427,1,,,50588,,,,BAO_0000218,CHEMBL621145,,Area under the curve was measured in dog after an iv dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,5428,1,,,50588,,,,BAO_0000218,CHEMBL621146,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,5429,1,,,50588,,,,BAO_0000218,CHEMBL622567,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,5430,1,,,50588,,,,BAO_0000218,CHEMBL622568,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2877,,N,5431,1,,,50588,,,,BAO_0000218,CHEMBL622569,,Compound was evaluated for area under the curve in dog blood.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,5432,1,,,50588,,,,BAO_0000218,CHEMBL622570,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5130,,N,5433,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL622571,,AUC in dog after oral dose (1 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6265,,N,5434,1,,,50588,,,,BAO_0000218,CHEMBL622572,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4657,,N,5435,1,,,50588,,,,BAO_0000218,CHEMBL622573,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported."
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,5436,1,,,50588,,,,BAO_0000218,CHEMBL622574,,Pharmacokinetic parameter AUC after intravenous administration to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,5437,1,,,50588,,,,BAO_0000218,CHEMBL622575,,Pharmacokinetic parameter AUC after oral administration to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,5438,1,,,50588,,,,BAO_0000218,CHEMBL622576,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,5439,1,,,50588,,,,BAO_0000218,CHEMBL622577,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,5440,1,,,50588,,,,BAO_0000218,CHEMBL622578,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6241,,N,5441,1,,,50588,,,,BAO_0000218,CHEMBL622579,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,5442,1,,,50588,,,,BAO_0000218,CHEMBL622580,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,5443,1,,,50588,,,,BAO_0000218,CHEMBL622581,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,5444,1,,,50588,,,,BAO_0000218,CHEMBL622582,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,5445,1,,,50588,,,,BAO_0000218,CHEMBL622583,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6641,,N,5446,1,,,50588,,,,BAO_0000218,CHEMBL622584,,Oral AUCN in dog (dosed at 0.5 mpk iv )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,5447,1,,,50588,,,,BAO_0000218,CHEMBL622585,,Oral AUCN in dog (dosed at 0.5 mpk iv )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17791,,N,5448,1,,,50588,,,,BAO_0000218,CHEMBL622586,,Compound was evaluated for oral bioavailability in dog; 90-100
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17655,,N,5449,1,,,50588,,,,BAO_0000218,CHEMBL623281,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17655,,N,5450,1,,,50588,,,,BAO_0000218,CHEMBL623282,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6596,,N,5451,1,,,50588,,,,BAO_0000218,CHEMBL623283,,PAPP (membrane permeability) in dog kidney cell monolayer assay
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3880,,N,5452,1,,,50588,,,,BAO_0000218,CHEMBL623284,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,5453,1,,,50588,,,,BAO_0000218,CHEMBL623285,,Bioavailability administered orally at a dose of 10 mg/kg to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17409,,N,5454,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623463,,Plasma protein binding towards dog plasma at 10 uM
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17409,,N,5455,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL875952,,Plasma protein binding towards dog plasma at 100 uM
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,5456,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621705,,Bioavailability in dog (dose 4 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13501,,N,5457,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621706,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,5458,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621707,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15145,,N,5459,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621708,,Bioavailability in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4219,,N,5460,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621709,,Bioavailability
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17538,,N,5461,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621710,,Oral bioavailability in dog (dose 10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17538,,N,5462,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621711,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,5463,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621712,,Bioavailability in dog (dose 10.0 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17650,,N,5464,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621713,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3132,,N,5465,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621714,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5466,0,,,22224,,,,BAO_0000218,CHEMBL621715,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5467,0,,,22224,Liver,2107.0,,BAO_0000218,CHEMBL623717,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5468,0,,,22224,Liver,2107.0,,BAO_0000218,CHEMBL623718,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5469,0,,,22224,Liver,2107.0,,BAO_0000218,CHEMBL623719,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5470,0,,,22224,,,,BAO_0000218,CHEMBL623720,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5471,0,,,22224,,,,BAO_0000218,CHEMBL623721,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5472,0,,,22224,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623722,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5473,0,,,22224,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623723,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5474,0,,,22224,Muscle tissue,2385.0,,BAO_0000218,CHEMBL618543,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5475,0,,,22224,Spleen,2106.0,,BAO_0000218,CHEMBL618544,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5476,0,,,22224,Spleen,2106.0,,BAO_0000218,CHEMBL875155,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5477,0,,,22224,,,,BAO_0000218,CHEMBL618545,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5478,0,,,22224,,,,BAO_0000218,CHEMBL618546,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5479,0,,,22224,,,,BAO_0000218,CHEMBL623529,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5480,0,,,22224,,,,BAO_0000218,CHEMBL623530,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour
A,Mus sp.,10095.0,,,1,Autocuration,,2413,,U,5481,0,,,22224,,,,BAO_0000218,CHEMBL621764,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5482,0,,,22224,,,,BAO_0000019,CHEMBL621765,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5483,0,,,22224,Cerebellum,2037.0,,BAO_0000019,CHEMBL621766,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5484,0,,,22224,Frontal cortex,1870.0,,BAO_0000019,CHEMBL621767,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5485,0,,,22224,,,,BAO_0000019,CHEMBL621768,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5486,0,,,22224,Striatum,2435.0,,BAO_0000019,CHEMBL621769,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5487,0,,,22224,,,,BAO_0000019,CHEMBL621770,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5488,0,,,22224,Cerebellum,2037.0,,BAO_0000019,CHEMBL621771,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5489,0,,,22224,Frontal cortex,1870.0,,BAO_0000019,CHEMBL621772,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5490,0,,,22224,,,,BAO_0000019,CHEMBL621773,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17827,,U,5491,0,,,22224,Striatum,2435.0,,BAO_0000019,CHEMBL621774,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound)
A,Cercopithecidae,9527.0,,,1,Autocuration,,17791,,U,5492,0,,,22224,,,,BAO_0000218,CHEMBL621775,,Compound was evaluated for oral bioavailability in rats
A,Cercopithecidae,9527.0,,,1,Autocuration,,17667,,U,5493,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621776,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,17791,,U,5494,0,,,22224,,,,BAO_0000019,CHEMBL621777,,Half life period was evaluated in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,110,,U,5495,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875162,,Half-life in rhesus monkeys by intravenous administration of dose
A,Mus musculus,10090.0,,,1,Intermediate,,5781,,N,5496,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL621778,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,5497,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL621779,,AUC after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17718,,N,5498,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622479,,AUC value was determined after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,4573,,N,5499,1,,,50594,,,,BAO_0000218,CHEMBL622480,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice
A,Mus musculus,10090.0,,,1,Intermediate,,3277,,N,5500,1,,,50594,,,,BAO_0000218,CHEMBL622481,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,5501,1,,,50594,,,,BAO_0000218,CHEMBL622482,,Area under curve by ioral administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,5502,1,,,50594,,,,BAO_0000218,CHEMBL622483,,Area under curve by iv administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,5951,,N,5503,1,,,50594,,,,BAO_0000218,CHEMBL622484,,Area under curve at 0-8 hr in IRC mice after peroral administration
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,5504,1,,,50594,,,,BAO_0000218,CHEMBL622641,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,5505,1,,,50594,,,,BAO_0000218,CHEMBL622642,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,5506,1,,,50594,,,,BAO_0000218,CHEMBL622643,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,5507,1,,,50594,,,,BAO_0000218,CHEMBL622644,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5508,1,741.0,,80433,,,,BAO_0000219,CHEMBL622645,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5509,1,741.0,,80433,,,,BAO_0000219,CHEMBL622646,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5510,1,741.0,,80433,,,,BAO_0000219,CHEMBL621238,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5511,1,741.0,,80433,,,,BAO_0000219,CHEMBL621239,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5512,1,741.0,,80433,,,,BAO_0000219,CHEMBL621240,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5513,1,741.0,,80433,,,,BAO_0000219,CHEMBL621241,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5514,1,741.0,,80433,,,,BAO_0000219,CHEMBL621242,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5515,1,741.0,,80433,,,,BAO_0000219,CHEMBL620350,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5516,1,741.0,,80433,,,,BAO_0000219,CHEMBL620351,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5517,1,741.0,,80433,,,,BAO_0000219,CHEMBL620352,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5518,1,741.0,,80433,,,,BAO_0000219,CHEMBL620353,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5519,1,741.0,,80433,,,,BAO_0000219,CHEMBL620354,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5520,1,741.0,,80433,,,,BAO_0000219,CHEMBL620355,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5521,1,741.0,,80433,,,,BAO_0000219,CHEMBL620356,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5522,1,741.0,,80433,,,,BAO_0000219,CHEMBL620357,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,9424,,N,5523,1,741.0,,80433,,,,BAO_0000219,CHEMBL620358,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
F,Homo sapiens,9606.0,,RPMI-8226,1,Expert,,9424,,N,5524,1,741.0,,80433,,,,BAO_0000219,CHEMBL620359,,In vitro inhibition of human 8226 myeloma tumor cell line growth.
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,11544,,N,5525,1,741.0,,80433,,,,BAO_0000219,CHEMBL620360,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,17378,,N,5526,1,741.0,,80433,,,,BAO_0000219,CHEMBL620361,,Cytotoxicity of compound against 8226/DOX1V cells
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,17378,,N,5527,1,741.0,,80433,,,,BAO_0000219,CHEMBL620362,,Cytotoxicity of compound against 8226/S cells
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,17079,,N,5528,1,741.0,,80433,,,,BAO_0000219,CHEMBL620363,,Inhibitory concentration against 8226 myeloma cancer cell line
F,Homo sapiens,9606.0,,RPMI-8226,1,Intermediate,,17079,,N,5529,1,741.0,,80433,,,,BAO_0000219,CHEMBL620364,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line
F,Homo sapiens,9606.0,,833K,1,Intermediate,,13466,,N,5530,1,854.0,,80647,,,,BAO_0000219,CHEMBL620365,,Inhibition of cell growth was studied in human teratocarcinoma (833K).
F,Homo sapiens,9606.0,,833K,1,Intermediate,,13466,,N,5531,1,854.0,,80647,,,,BAO_0000219,CHEMBL620366,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined'
F,Homo sapiens,9606.0,,833K,1,Expert,,2392,,N,5532,1,854.0,,80647,,,,BAO_0000219,CHEMBL620367,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
F,Homo sapiens,9606.0,,833K,1,Intermediate,,2392,,N,5533,1,854.0,,80647,,,,BAO_0000219,CHEMBL620368,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data
B,,,,,1,Autocuration,,6608,,U,5534,0,,,22226,,,,BAO_0000019,CHEMBL620369,,Inhibitory activity against caspase-1
B,Enterococcus faecalis,1351.0,,,1,Autocuration,,10199,,H,5535,8,,,45,,,,BAO_0000357,CHEMBL620370,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound
F,Homo sapiens,9606.0,,8701-BC,1,Intermediate,,17749,,N,5536,1,705.0,,80648,,,,BAO_0000219,CHEMBL620371,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
F,Homo sapiens,9606.0,,8701-BC,1,Intermediate,,17749,,N,5537,1,705.0,,80648,,,,BAO_0000219,CHEMBL620372,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM
F,,,,,1,Intermediate,,1229,,U,5538,0,,,22226,,,,BAO_0000019,CHEMBL876492,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive
F,,,,,1,Intermediate,,1229,,U,5539,0,,,22226,,,,BAO_0000019,CHEMBL620373,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive
F,,,,,1,Intermediate,,1229,,U,5540,0,,,22226,,,,BAO_0000019,CHEMBL620374,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive
B,,,,,1,Autocuration,,6390,,U,5541,0,,,22226,,,,BAO_0000019,CHEMBL620375,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin
F,Streptococcus pyogenes,1314.0,,,1,Autocuration,,16219,,U,5542,0,,,22226,,,,BAO_0000019,CHEMBL857902,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
F,Streptococcus pyogenes,1314.0,,,1,Autocuration,,16219,,U,5543,0,,,22226,,,,BAO_0000019,CHEMBL620376,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
B,,,,,1,Autocuration,,17043,,H,5544,8,,,11922,,,,BAO_0000357,CHEMBL620377,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound
F,Homo sapiens,9606.0,,KB ,1,Intermediate,,6929,,N,5545,1,324.0,,81115,,,,BAO_0000219,CHEMBL620378,,Tested for in vitro cytotoxic potency of compound in 9KB assay
A,Homo sapiens,9606.0,,KB ,1,Intermediate,,6929,,N,5546,1,324.0,,81115,,,,BAO_0000219,CHEMBL620379,,Tested for in vitro cytotoxic potency of compound in 9KB assay
F,Homo sapiens,9606.0,,,1,Autocuration,,7083,,U,5547,0,,,22226,,,,BAO_0000219,CHEMBL620380,,In vitro cytotoxicity of compound was tested against 9KB cells.
F,Rattus norvegicus,10116.0,,9L,1,Intermediate,,12446,,N,5548,1,392.0,,80653,,,,BAO_0000219,CHEMBL884006,,Cytotoxic concentration against 9L cells was determined on day 3
F,Rattus norvegicus,10116.0,,9L,1,Expert,,15345,,N,5549,1,392.0,,80653,,,,BAO_0000219,CHEMBL620381,,Tested in vitro for anticancer activity against 9L cells
F,Rattus norvegicus,10116.0,,9L,1,Expert,,15345,,N,5550,1,392.0,,80653,,,,BAO_0000219,CHEMBL620382,,Tested in vitro for anticancer activity against 9L cells; Not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6301,,N,5551,1,646.0,,80682,,,,BAO_0000219,CHEMBL620383,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4833,,N,5552,1,646.0,,80682,,,,BAO_0000219,CHEMBL876493,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4833,,N,5553,1,646.0,,80682,,,,BAO_0000219,CHEMBL620384,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4833,,N,5554,1,646.0,,80682,,,,BAO_0000219,CHEMBL620385,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition
F,Homo sapiens,9606.0,,A549,1,Expert,,13330,,N,5555,1,646.0,,80682,,,,BAO_0000219,CHEMBL620386,,Cytotoxicity against human lung carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,17517,,D,5556,9,646.0,,25,,,,BAO_0000219,CHEMBL620387,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.
F,Homo sapiens,9606.0,,A549,1,Expert,,17517,,D,5557,9,646.0,,25,,,,BAO_0000219,CHEMBL621404,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%."
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5558,1,646.0,,80682,,,,BAO_0000219,CHEMBL621405,,"In vitro growth inhibition of A549, lung carcinoma"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5559,1,646.0,,80682,,,,BAO_0000219,CHEMBL621406,,"In vitro growth inhibition of A549, lung carcinoma."
F,Homo sapiens,9606.0,,A549,1,Expert,,5228,,N,5560,1,646.0,,80682,,,,BAO_0000219,CHEMBL621407,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5351,,N,5561,1,646.0,,80682,,,,BAO_0000219,CHEMBL621408,,Cytotoxic activity against human lung cancer A549 cell line was determined
F,Homo sapiens,9606.0,,A549,1,Expert,,12198,,N,5562,1,646.0,,80682,,,,BAO_0000219,CHEMBL885345,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13891,,N,5563,1,646.0,,80682,,,,BAO_0000219,CHEMBL621409,,Cytotoxicity concentration against human lung carcinoma A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,5677,,N,5564,1,646.0,,80682,,,,BAO_0000219,CHEMBL876034,,Cytotoxicity in A549 (human carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13788,,N,5565,1,646.0,,80682,,,,BAO_0000219,CHEMBL621410,,Cytotoxicity on lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,13384,,N,5566,1,646.0,,80682,,,,BAO_0000219,CHEMBL621411,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6726,,N,5567,1,646.0,,80682,,,,BAO_0000219,CHEMBL621412,,Effective dose of compound against replication of A549 cell line was evaluated
F,Homo sapiens,9606.0,,A549,1,Expert,,3455,,N,5568,1,646.0,,80682,,,,BAO_0000219,CHEMBL621413,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5726,,N,5569,1,646.0,,80682,,,,BAO_0000219,CHEMBL621414,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5726,,N,5570,1,646.0,,80682,,,,BAO_0000219,CHEMBL621415,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3936,,N,5571,1,646.0,,80682,,,,BAO_0000219,CHEMBL621416,,The compound was evaluated for antiproliferative activity against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14991,,N,5572,1,646.0,,80682,,,,BAO_0000219,CHEMBL621417,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5243,,N,5573,1,646.0,,80682,,,,BAO_0000219,CHEMBL621418,,Concentration required for growth inhibition of human lung carcinoma cell line A549
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12858,,N,5574,1,646.0,,80682,,,,BAO_0000219,CHEMBL621419,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6776,,N,5575,1,646.0,,80682,,,,BAO_0000219,CHEMBL621420,,Growth inhibition against A549 cell line was evaluated
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16558,,N,5576,1,646.0,,80682,,,,BAO_0000219,CHEMBL875823,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay
F,Homo sapiens,9606.0,,A549,1,Expert,,4583,,N,5577,1,646.0,,80682,,,,BAO_0000219,CHEMBL621421,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13514,,N,5578,1,646.0,,80682,,,,BAO_0000219,CHEMBL621422,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs
F,Homo sapiens,9606.0,,A549,1,Expert,,15166,,N,5579,1,646.0,,80682,,,,BAO_0000219,CHEMBL884014,,Chemosensitivity against DT-diaphorase rich A549 cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13873,,N,5580,1,646.0,,80682,,,,BAO_0000219,CHEMBL621423,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.
F,Homo sapiens,9606.0,,A549,1,Expert,,6447,,N,5581,1,646.0,,80682,,,,BAO_0000219,CHEMBL621424,,In vitro cytotoxicity against human A549 (lung cancer) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2068,,N,5582,1,646.0,,80682,,,,BAO_0000219,CHEMBL621425,,In vitro antitumor activity against A549 (lung) human tumor cell lines.
F,Homo sapiens,9606.0,,A549,1,Expert,,1863,,N,5583,1,646.0,,80682,,,,BAO_0000219,CHEMBL621426,,In vitro cytotoxic activity against human lung carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13873,,N,5584,1,646.0,,80682,,,,BAO_0000219,CHEMBL621427,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13873,,N,5585,1,646.0,,80682,,,,BAO_0000219,CHEMBL621428,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
F,Homo sapiens,9606.0,,A549,1,Expert,,13873,,N,5586,1,646.0,,80682,,,,BAO_0000219,CHEMBL621429,,Tested against A549 lung carcinoma in the sulforhodamine B assay.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,579,,N,5587,1,646.0,,80682,,,,BAO_0000219,CHEMBL621430,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,579,,N,5588,1,646.0,,80682,,,,BAO_0000219,CHEMBL621431,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4584,,N,5589,1,646.0,,80682,,,,BAO_0000219,CHEMBL621432,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition
F,Homo sapiens,9606.0,,A549,1,Expert,,5421,,N,5590,1,646.0,,80682,,,,BAO_0000219,CHEMBL621433,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5591,1,646.0,,80682,,,,BAO_0000219,CHEMBL875824,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5592,1,646.0,,80682,,,,BAO_0000219,CHEMBL621434,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5593,1,646.0,,80682,,,,BAO_0000219,CHEMBL621435,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14188,,N,5594,1,646.0,,80682,,,,BAO_0000219,CHEMBL621436,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14188,,N,5595,1,646.0,,80682,,,,BAO_0000219,CHEMBL621437,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15354,,N,5596,1,646.0,,80682,,,,BAO_0000219,CHEMBL621438,,Compound was tested for the growth inhibition of A549 lung tumor cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,14253,,N,5597,1,646.0,,80682,,,,BAO_0000219,CHEMBL621439,,Growth inhibition of human non-small-lung carcinoma (A549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13873,,N,5598,1,646.0,,80682,,,,BAO_0000219,CHEMBL621440,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3043,,N,5599,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621441,,Oral bioavailability in dog (conscious)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3045,,N,5600,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621442,,Compound was evaluated for the oral bioavailability after oral administration in dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3022,,N,5601,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621443,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4453,,N,5602,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621444,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1696,,N,5603,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625133,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5045,,N,5604,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625134,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5356,,N,5605,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625135,,Oral bioavailability in dog (fasted)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,5606,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625136,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,5607,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625137,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1475,,N,5608,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625138,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3788,,N,5609,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625139,,Percent bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,5610,1,,,50588,,,In vivo,BAO_0000218,CHEMBL872264,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13397,,N,5611,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625140,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2137,,N,5612,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624436,,The compound was evaluated for bioavailability in dogs; 34-44
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,5613,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624437,,Bioavailability in dog (dose 4 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,5614,1,,,50588,,,In vivo,BAO_0000218,CHEMBL872261,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,5615,1,,,50588,,,,BAO_0000218,CHEMBL624438,,8 hour trough Blood level in dog was measured after administration of compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,5616,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624439,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6316,,N,5617,1,,,50588,,,,BAO_0000218,CHEMBL624440,,C24 after oral administration at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5238,,N,5618,1,,,50588,,,,BAO_0000218,CHEMBL624441,,Clearance after oral and iv dosing in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17796,,N,5619,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624442,,Clearance of the drug was measured in the plasma of dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,5620,1,,,50588,,,,BAO_0000218,CHEMBL624443,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5654,,N,5621,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624444,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6621,,N,5622,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624445,,Clearance of compound was determined in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6505,,N,5623,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624446,,Clearance on i.v. administration of 2 mg/kg was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5802,,N,5624,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624447,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17267,,N,5625,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624448,,Plasma clearance in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,5626,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624449,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,5627,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624450,,Plasma clearance in dog after administration of 0.25 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,5628,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875942,,Plasma clearance in dog after administration of 1 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,5629,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624451,,Plasma clearance in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,5630,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624452,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,5631,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624453,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5632,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624454,,Plasma clearance after 15 mg/kg iv dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5633,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624455,,Plasma clearance after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,5634,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624456,,Plasma administration to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5505,,N,5635,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624457,,Plasma clearance was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6215,,N,5636,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624458,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,5637,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624459,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog
A,Homo sapiens,9606.0,,,1,Intermediate,Microsomes,5007,,S,5638,2,,,102164,Liver,2107.0,In vitro,BAO_0000251,CHEMBL624460,,Intrinsic clearance in human liver microsomes
A,Homo sapiens,9606.0,,,1,Intermediate,Microsomes,5007,,S,5639,2,,,102164,Liver,2107.0,In vitro,BAO_0000251,CHEMBL624461,,Intrinsic clearance in human liver microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,5640,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875943,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,5641,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624462,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,5642,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624463,,Clearance in dog (dose 1 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6221,,N,5643,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624464,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5007,,N,5644,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624465,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5645,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624466,,Plasma clearance after peroral administration at 10 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5646,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624467,,Plasma clearance after peroral administration at 5 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5647,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624468,,Plasma clearance after peroral administration at 5 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,5648,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624469,,Plasma clearance was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,5649,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624470,,Plasma clearance was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,5650,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624471,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,5651,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624472,,Total clearance was determined after 0.1 mg/kg iv administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,5652,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622775,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,5653,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622776,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,5654,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622777,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,5655,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622778,,Clearance after peroral administration of 0.2 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4368,,N,5656,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622779,,Clearance by intravenous administration of 1.2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4305,,N,5657,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622780,,Clearance by iv administration in dogs at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1918,,N,5658,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622781,,Clearance value was evaluated in dog plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6005,,N,5659,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622782,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4839,,N,5660,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622783,,Compound was tested for plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4239,,N,5661,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622784,,Pharmacokinetic property (Plasma clearance) was measured in dog
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,5662,1,,,50594,,,,BAO_0000218,CHEMBL622785,,Area under curve when injected perorally in mice at a dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,5663,1,,,50594,,,,BAO_0000218,CHEMBL622786,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5302,,N,5664,1,,,50594,,,,BAO_0000218,CHEMBL622787,,Area under curve value in mouse at a dose of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,5665,1,,,50594,,,,BAO_0000218,CHEMBL875949,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,5666,1,,,50594,,,,BAO_0000218,CHEMBL622788,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,5667,1,,,50594,,,,BAO_0000218,CHEMBL622789,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,5668,1,,,50594,,,,BAO_0000218,CHEMBL622790,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,5669,1,,,50594,,,,BAO_0000218,CHEMBL622791,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,5670,1,,,50594,,,,BAO_0000218,CHEMBL622792,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,5671,1,,,50594,,,,BAO_0000218,CHEMBL622793,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,5672,1,,,50594,,,,BAO_0000218,CHEMBL622794,,Area under curve was determined for the compound at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,5673,1,,,50594,,,,BAO_0000218,CHEMBL622795,,Area under curve was determined for the compound at 40 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,5674,1,,,50594,,,,BAO_0000218,CHEMBL621803,,Area under curve was determined for the compound at 5 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,5675,1,,,50594,,,,BAO_0000218,CHEMBL621804,,Area under the curve for the compound is obtained at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,5676,1,,,50594,,,,BAO_0000218,CHEMBL621805,,Area under the curve for the compound was obtained when tested in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,5677,1,,,50594,,,,BAO_0000218,CHEMBL621806,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,5678,1,,,50594,,,,BAO_0000218,CHEMBL621807,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,6062,,N,5679,1,,,50594,,,,BAO_0000218,CHEMBL621808,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,4066,,N,5680,1,,,50594,,,,BAO_0000218,CHEMBL621809,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,5681,1,,,50594,,,,BAO_0000218,CHEMBL621810,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,5682,1,,,50594,,,,BAO_0000218,CHEMBL875164,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,5683,1,,,50594,,,,BAO_0000218,CHEMBL621811,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,4890,,N,5684,1,,,50594,,,,BAO_0000218,CHEMBL621812,,"Compound was evaluated for the pharmacokinetic parameter, area under curve"
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,5685,1,,,50594,,,,BAO_0000218,CHEMBL621813,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr )
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,5686,1,,,50594,,,,BAO_0000218,CHEMBL621814,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr)
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,5687,1,,,50594,,,,BAO_0000218,CHEMBL621815,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,5688,1,,,50594,,,,BAO_0000218,CHEMBL621816,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,5689,1,,,50594,,,,BAO_0000218,CHEMBL621817,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,5690,1,,,50594,,,,BAO_0000218,CHEMBL621818,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,5691,1,,,50594,,,,BAO_0000218,CHEMBL621819,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,5692,1,,,50594,,,,BAO_0000218,CHEMBL621820,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,5693,1,,,50594,,,,BAO_0000218,CHEMBL621821,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,6178,,N,5694,1,,,50594,,,,BAO_0000218,CHEMBL621822,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6178,,N,5695,1,,,50594,,,,BAO_0000218,CHEMBL619474,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6619,,N,5696,1,,,50594,,,,BAO_0000218,CHEMBL619475,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
A,Mus musculus,10090.0,,,1,Intermediate,,6619,,N,5697,1,,,50594,,,,BAO_0000218,CHEMBL619476,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,5698,1,,,50594,,,,BAO_0000218,CHEMBL619477,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,5699,1,,,50594,,,,BAO_0000218,CHEMBL619478,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,5700,1,,,50594,,,,BAO_0000218,CHEMBL619479,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,5701,1,,,50594,,,,BAO_0000218,CHEMBL619480,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,3192,,N,5702,1,,,50594,,,,BAO_0000218,CHEMBL619481,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1
A,Mus musculus,10090.0,,,1,Intermediate,,3192,,N,5703,1,,,50594,,,,BAO_0000218,CHEMBL619482,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,5704,1,,,50594,,,,BAO_0000218,CHEMBL619483,,Area under the curve was evaluated in mice after intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,5705,1,,,50594,,,,BAO_0000218,CHEMBL619484,,Area under the curve was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,5706,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL619485,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,5707,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL619486,,AUC total value at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,5708,1,,,50594,,,,BAO_0000218,CHEMBL619487,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,5709,1,,,50594,,,,BAO_0000218,CHEMBL619488,,AUMC after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5710,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL620106,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram
F,,,,9L,1,Intermediate,,15345,,N,5711,1,392.0,,80653,,,,BAO_0000219,CHEMBL620107,,The compound was tested in vitro for anticancer activity against 9L cells
F,Rattus norvegicus,10116.0,,,1,Autocuration,,2181,,U,5712,0,,,22226,,,,BAO_0000019,CHEMBL620283,,Anti proliferation activity determined; Weak effect
F,Rattus norvegicus,10116.0,,,1,Autocuration,,2181,,U,5713,0,,,22226,,,,BAO_0000219,CHEMBL875176,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process
F,Rattus norvegicus,10116.0,,,1,Autocuration,,2181,,U,5714,0,,,22226,,,,BAO_0000219,CHEMBL620284,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells
F,Rattus norvegicus,10116.0,,,1,Autocuration,,2181,,U,5715,0,,,22226,,,,BAO_0000219,CHEMBL623515,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process
F,Mus musculus,10090.0,,,1,Autocuration,,10486,,U,5716,0,,,22226,,,,BAO_0000019,CHEMBL623516,,The cytotoxic activity was in vitro tested by 9PS assay method
F,Mus musculus,10090.0,,,1,Autocuration,,10486,,U,5717,0,,,22226,,,,BAO_0000019,CHEMBL623517,,The cytotoxic activity was in vitro tested by 9PS assay method.
A,,,,,1,Autocuration,,15508,,U,5718,0,,,22224,,,,BAO_0000019,CHEMBL857878,,Partition coefficient (logD6.5)
F,Homo sapiens,9606.0,,A2780,1,Expert,,5242,,N,5719,1,478.0,,81034,,,,BAO_0000219,CHEMBL623518,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,16167,,N,5720,1,455.0,,80018,,,,BAO_0000219,CHEMBL624195,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM)
F,Homo sapiens,9606.0,,A-431,1,Expert,,4782,,N,5721,1,500.0,,80852,,,,BAO_0000219,CHEMBL624196,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
F,Homo sapiens,9606.0,,A-431,1,Expert,,16093,,D,5722,9,500.0,,9,,,,BAO_0000219,CHEMBL624197,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
F,Homo sapiens,9606.0,,A498,1,Intermediate,,2596,,N,5723,1,624.0,,80021,,,,BAO_0000219,CHEMBL624198,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,2596,,N,5724,1,624.0,,80021,,,,BAO_0000219,CHEMBL621287,,in vitro cytotoxicity against A 498 cancer cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3239,,N,5725,1,624.0,,80021,,,,BAO_0000219,CHEMBL621288,,In vitro cytotoxic activity against renal (A 498) cancer cell line.
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1847,,N,5726,1,624.0,,80021,,,,BAO_0000219,CHEMBL876496,,Cytotoxic activity against A 498 renal cancer cell lines.
F,Homo sapiens,9606.0,,A498,1,Intermediate,,10553,,N,5727,1,624.0,,80021,,,,BAO_0000219,CHEMBL621289,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen
F,Staphylococcus aureus,1280.0,,,1,Autocuration,,16219,,U,5728,0,,,22226,,,,BAO_0000019,CHEMBL621290,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
F,Staphylococcus aureus,1280.0,,,1,Autocuration,,16219,,U,5729,0,,,22226,,,,BAO_0000019,CHEMBL621291,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
F,Staphylococcus aureus,1280.0,,,1,Autocuration,,16219,,U,5730,0,,,22226,,,,BAO_0000019,CHEMBL621292,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
F,Staphylococcus aureus,1280.0,,,1,Autocuration,,16219,,U,5731,0,,,22226,,,,BAO_0000019,CHEMBL621293,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4782,,N,5732,1,646.0,,80682,,,,BAO_0000219,CHEMBL621294,,Inhibitory concentration required against A 549 lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11805,,N,5733,1,646.0,,80682,,,,BAO_0000219,CHEMBL621295,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11805,,N,5734,1,646.0,,80682,,,,BAO_0000219,CHEMBL884007,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2007,,N,5735,1,646.0,,80682,,,,BAO_0000219,CHEMBL621296,,In vitro cytotoxicity against lung cancer A 549 cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4594,,N,5736,1,646.0,,80682,,,,BAO_0000219,CHEMBL621297,,Compound was tested for its cytotoxicity against A 549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,6018,,N,5737,1,646.0,,80682,,,,BAO_0000219,CHEMBL839828,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay."
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6018,,N,5738,1,646.0,,80682,,,,BAO_0000219,CHEMBL620397,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data"
F,Homo sapiens,9606.0,,A549,1,Expert,,3599,,N,5739,1,646.0,,80682,,,,BAO_0000219,CHEMBL620398,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2551,,N,5740,1,646.0,,80682,,,,BAO_0000219,CHEMBL620399,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
F,Homo sapiens,9606.0,,A549,1,Expert,,16132,,N,5741,1,646.0,,80682,,,,BAO_0000219,CHEMBL620400,,In vitro inhibition of A549 (human lung cancer) cell growth.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16132,,N,5742,1,646.0,,80682,,,,BAO_0000219,CHEMBL620401,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available
F,Homo sapiens,9606.0,,A549,1,Expert,,2551,,N,5743,1,646.0,,80682,,,,BAO_0000219,CHEMBL620402,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
F,Homo sapiens,9606.0,,A549,1,Expert,,2551,,N,5744,1,646.0,,80682,,,,BAO_0000219,CHEMBL620403,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM)
F,,,,,1,Autocuration,,11913,,U,5745,0,,,22226,,,,BAO_0000218,CHEMBL620404,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h
F,,,,,1,Autocuration,,12621,,H,5746,4,,,104694,,,In vivo,BAO_0000218,CHEMBL620405,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.
F,,,,,1,Autocuration,,12621,,H,5747,4,,,104694,,,In vivo,BAO_0000218,CHEMBL620406,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.
F,,,,,1,Autocuration,,12621,,H,5748,4,,,104694,,,In vivo,BAO_0000218,CHEMBL620407,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.
F,,,,,1,Autocuration,,12621,,H,5749,4,,,104694,,,In vivo,BAO_0000218,CHEMBL620408,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.
F,,,,,1,Autocuration,,12621,,H,5750,4,,,104694,,,In vivo,BAO_0000218,CHEMBL620409,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.
F,Homo sapiens,9606.0,,A498,1,Expert,,3600,,N,5751,1,624.0,,80021,,,,BAO_0000219,CHEMBL620410,,Inhibition of A-498 human Renal cell proliferation
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1796,,U,5752,0,,,22226,,,,BAO_0000019,CHEMBL620411,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM"
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1796,,U,5753,0,,,22226,,,,BAO_0000019,CHEMBL620412,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM"
F,Rattus norvegicus,10116.0,,,1,Autocuration,,1796,,U,5754,0,,,22226,,,,BAO_0000019,CHEMBL876596,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM"
F,Homo sapiens,9606.0,,A 172,1,Expert,,16464,,N,5755,1,622.0,,80012,,,,BAO_0000219,CHEMBL620413,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,16464,,N,5756,1,622.0,,80012,,,,BAO_0000219,CHEMBL620414,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,16464,,N,5757,1,622.0,,80012,,,,BAO_0000219,CHEMBL620415,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A549,1,Expert,,13617,,N,5758,1,646.0,,80682,,,,BAO_0000219,CHEMBL620416,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4584,,N,5759,1,646.0,,80682,,,,BAO_0000219,CHEMBL620417,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549
F,Homo sapiens,9606.0,,A549,1,Expert,,13799,,N,5760,1,646.0,,80682,,,,BAO_0000219,CHEMBL620418,,Cytotoxic activity evaluated against A549 tumor cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16726,,N,5761,1,646.0,,80682,,,,BAO_0000219,CHEMBL620419,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16109,,N,5762,1,646.0,,80682,,,,BAO_0000219,CHEMBL620420,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16109,,N,5763,1,646.0,,80682,,,,BAO_0000219,CHEMBL620421,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15474,,N,5764,1,646.0,,80682,,,,BAO_0000219,CHEMBL620422,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6851,,N,5765,1,646.0,,80682,,,,BAO_0000219,CHEMBL620423,,Cytotoxicity of compound against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,17534,,N,5766,1,646.0,,80682,,,,BAO_0000219,CHEMBL620424,,Cytotoxicity against human lung cell carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2621,,N,5767,1,646.0,,80682,,,,BAO_0000219,CHEMBL620425,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,830,,N,5768,1,646.0,,80682,,,,BAO_0000219,CHEMBL620426,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14255,,N,5769,1,646.0,,80682,,,,BAO_0000219,CHEMBL620427,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14255,,N,5770,1,646.0,,80682,,,,BAO_0000219,CHEMBL620428,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1590,,N,5771,1,646.0,,80682,,,,BAO_0000219,CHEMBL620429,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells
F,Homo sapiens,9606.0,,A549,1,Expert,,6146,,N,5772,1,646.0,,80682,,,,BAO_0000219,CHEMBL620430,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,17427,,N,5773,1,646.0,,80682,,,,BAO_0000219,CHEMBL839887,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5280,,N,5774,1,646.0,,80682,,,,BAO_0000219,CHEMBL620431,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16786,,N,5775,1,646.0,,80682,,,,BAO_0000219,CHEMBL884010,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5895,,N,5776,1,646.0,,80682,,,,BAO_0000219,CHEMBL620538,,In vitro cytotoxicity against A549 (human lung cancer)
F,Homo sapiens,9606.0,,A549,1,Expert,,14297,,N,5777,1,646.0,,80682,,,,BAO_0000219,CHEMBL620539,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5778,1,646.0,,80682,,,,BAO_0000218,CHEMBL623373,,In vivo antiproliferative activity against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14368,,N,5779,1,646.0,,80682,,,,BAO_0000219,CHEMBL623374,,Inhibition of non-small-cell lung adenocarcinoma (A549)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14368,,N,5780,1,646.0,,80682,,,,BAO_0000219,CHEMBL623375,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14254,,N,5781,1,646.0,,80682,,,,BAO_0000219,CHEMBL623376,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15897,,N,5782,1,646.0,,80682,,,,BAO_0000219,CHEMBL623377,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13866,,N,5783,1,646.0,,80682,,,,BAO_0000219,CHEMBL623378,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
F,Homo sapiens,9606.0,,A549,1,Intermediate,,13370,,N,5784,1,646.0,,80682,,,,BAO_0000219,CHEMBL623379,,Inhibitory activity of compound against human A549 lung carcinoma cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4862,,N,5785,1,646.0,,80682,,,,BAO_0000219,CHEMBL623380,,Inhibitory activity against A549 lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4862,,N,5786,1,646.0,,80682,,,,BAO_0000219,CHEMBL623381,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4862,,N,5787,1,646.0,,80682,,,,BAO_0000219,CHEMBL623382,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15970,,N,5788,1,646.0,,80682,,,,BAO_0000219,CHEMBL623383,,Inhibitory concentration against A549 (lung cancer) cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,17713,,N,5789,1,646.0,,80682,,,,BAO_0000219,CHEMBL623384,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4833,,N,5790,1,646.0,,80682,,,,BAO_0000219,CHEMBL623385,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,13736,,N,5791,1,646.0,,80682,,,,BAO_0000219,CHEMBL623386,,Activity against A549 cancer cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4312,,N,5792,1,646.0,,80682,,,,BAO_0000219,CHEMBL884105,,The compound was evaluated for cytotoxicity against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5793,1,646.0,,80682,,,,BAO_0000219,CHEMBL623387,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5794,1,646.0,,80682,,,,BAO_0000219,CHEMBL621568,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14717,,N,5795,1,646.0,,80682,,,,BAO_0000219,CHEMBL621569,,Growth inhibitory activity was measured for human A549 tumor cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4634,,N,5796,1,646.0,,80682,,,,BAO_0000219,CHEMBL621570,,Inhibitory activity against A549 lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1149,,N,5797,1,646.0,,80682,,,,BAO_0000219,CHEMBL621571,,Inhibitory activity against A549 cell line; inactive
F,Homo sapiens,9606.0,,A549,1,Expert,,5421,,N,5798,1,646.0,,80682,,,,BAO_0000219,CHEMBL621572,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
F,Homo sapiens,9606.0,,A549,1,Expert,,5421,,N,5799,1,646.0,,80682,,,,BAO_0000219,CHEMBL621573,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5421,,N,5800,1,646.0,,80682,,,,BAO_0000219,CHEMBL621574,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3320,,N,5801,1,646.0,,80682,,,,BAO_0000219,CHEMBL621575,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3320,,N,5802,1,646.0,,80682,,,,BAO_0000219,CHEMBL621576,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3320,,N,5803,1,646.0,,80682,,,,BAO_0000219,CHEMBL621577,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3320,,N,5804,1,646.0,,80682,,,,BAO_0000219,CHEMBL621578,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3320,,N,5805,1,646.0,,80682,,,,BAO_0000219,CHEMBL621579,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5726,,N,5806,1,646.0,,80682,,,,BAO_0000219,CHEMBL621580,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17800,,N,5807,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621581,,Plasma clearance (in vivo) in mongrel dogs was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5985,,N,5808,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621582,,Plasma clearance was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,5809,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621583,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,5810,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621584,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4839,,N,5811,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621585,,Tested for plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,5812,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621586,,The compound was tested for clearance in dog plasma.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4838,,N,5813,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875835,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4137,,N,5814,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621587,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5017,,N,5815,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621588,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,Microsomes,17538,,N,5816,1,,,50588,Liver,2107.0,In vitro,BAO_0000218,CHEMBL621589,,In vitro clearance in dog liver microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6161,,N,5817,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621590,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6161,,N,5818,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621591,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1696,,N,5819,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621592,,Plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6762,,N,5820,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621593,,Clearance rate in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5932,,N,5821,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621594,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6305,,N,5822,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621595,,Clearance in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4942,,N,5823,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621596,,Plasma clearance in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4219,,N,5824,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621597,,Plasma clearance was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17853,,N,5825,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621598,,Lower clearance in dog (i.v.) at 0.5 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4514,,N,5826,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621599,,Plasma clearance in Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,5827,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875836,,Plasma clearance (Clp) in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,5828,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621600,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,5829,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621601,,Plasma clearance (pharmacokinetic parameter) in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6062,,N,5830,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618474,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6821,,N,5831,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618475,,Plasma clearance of compound was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,5832,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624524,,Plasma clearance after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,5833,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624525,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5374,,N,5834,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624526,,Plasma clearance in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,5835,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624527,,Plasma clearance was calculated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4727,,N,5836,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624528,,Plasma clearance at the dose of 2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5145,,N,5837,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624529,,Plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,5838,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624530,,Plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,5839,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624531,,Plasma clearance in dog; Unable to calculate
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5145,,N,5840,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624532,,Plasma clearance in rhesus monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,5841,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624533,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6641,,N,5842,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624534,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,5843,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624535,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,5844,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624536,,Plasma clearance was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,5845,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624537,,Plasma clearance was evaluated in dog; Not tested
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,5846,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624538,,Plasma clearance was evaluated in rhesus
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,5847,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624539,,Plasma clearance was evaluated in rhesus; Not tested
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4257,,N,5848,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624540,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6679,,N,5849,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624541,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5546,,N,5850,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624542,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,5851,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624543,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,5852,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624544,,Clearance value at a dose of 0.2 mg/kg i.v.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6316,,N,5853,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624545,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,5854,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624546,,Cmax after oral dose of compound at 3 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,5855,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875957,,Cmax after single intravenous bolus of 1 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5802,,N,5856,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624547,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,5857,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624548,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,5858,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624549,,Cmax in dog after administration of 1 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,5859,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624550,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6505,,N,5860,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621613,,Cmax on p.o. administration of 10 mg/kg was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5861,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621614,,Cmax was determine after peroral administration at 10 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5862,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623431,,Cmax was determine after peroral administration at 5 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,5863,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623432,,Cmax was determine after peroral administration at 5 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,5864,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623433,,Cmax after 0.3 mg/kg po administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,5865,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623434,,Cmax after peroral administration in dogs at 2.4 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6123,,N,5866,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623435,,Cmax in dog after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6123,,N,5867,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623436,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6757,,N,5868,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875958,,Cmax upon oral administration in male Beagle dog at 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5869,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623437,,Cmax value after 15 mg/kg iv dose in Dogs
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5870,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL623438,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5871,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL623439,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5872,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL623440,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5873,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL623441,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5874,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL623442,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5875,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623469,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5876,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623470,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5877,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623471,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5878,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL623472,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5879,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL623473,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5880,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL623474,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5881,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623475,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5882,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623476,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5883,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623477,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5884,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621896,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5885,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621897,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5886,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621898,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5887,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621899,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5888,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621900,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5889,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621901,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5890,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL621902,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5891,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL621903,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5892,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622587,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5893,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL620285,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5894,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL875285,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5895,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL620286,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5896,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620287,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5897,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620288,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5898,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620289,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5899,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL620290,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5900,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL620291,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5901,1,,,50594,Intestine,160.0,In vivo,BAO_0000218,CHEMBL620292,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5902,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620293,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5903,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620294,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5904,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618614,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5905,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL618615,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,5906,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL618616,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
F,Homo sapiens,9606.0,,A 172,1,Expert,,2036,,N,5907,1,622.0,,80012,,,,BAO_0000219,CHEMBL618617,,Cytotoxicity against A-172 human tumor cell lines
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,2357,,N,5908,1,622.0,,80012,,,,BAO_0000219,CHEMBL618618,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line
F,Homo sapiens,9606.0,,A204,1,Intermediate,,1457,,N,5909,1,623.0,,80014,,,,BAO_0000219,CHEMBL618619,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4379,,N,5910,1,478.0,,81034,,,,BAO_0000219,CHEMBL618620,,Tested for antiproliferative activity against A-2780 tumoral cell line
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,1093,,N,5911,1,455.0,,80018,,,,BAO_0000219,CHEMBL618621,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,12152,,N,5912,1,455.0,,80018,,,,BAO_0000219,CHEMBL618622,,Tested in vitro against A-375 cell line human melanoma
F,Homo sapiens,9606.0,,A-427,1,Expert,,16464,,N,5913,1,797.0,,80019,,,,BAO_0000219,CHEMBL618623,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,16464,,N,5914,1,797.0,,80019,,,,BAO_0000219,CHEMBL618624,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A-427,1,Expert,,16582,,N,5915,1,797.0,,80019,,,,BAO_0000219,CHEMBL618625,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,16464,,N,5916,1,797.0,,80019,,,,BAO_0000219,CHEMBL618626,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,10413,,N,5917,1,797.0,,80019,,,,BAO_0000219,CHEMBL618627,,Antitumor activity on A-427 lung carcinoma cell lines
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,6418,,N,5918,1,797.0,,80019,,,,BAO_0000219,CHEMBL618628,,Cytotoxic activity against human A-427 lung tumor cell line
F,Homo sapiens,9606.0,,A-427,1,Expert,,17134,,N,5919,1,797.0,,80019,,,,BAO_0000219,CHEMBL618629,,In vitro antitumor effects against human A-427 cell lines.
F,Homo sapiens,9606.0,,A-427,1,Expert,,16132,,N,5920,1,797.0,,80019,,,,BAO_0000219,CHEMBL618630,,In vitro inhibition of A-427 (human lung cancer) cell growth.
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,16132,,N,5921,1,797.0,,80019,,,,BAO_0000219,CHEMBL618631,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available
F,Homo sapiens,9606.0,,A-427,1,Intermediate,,16780,,N,5922,1,797.0,,80019,,,,BAO_0000219,CHEMBL618632,,Cytotoxic activity of compound against A-427 lung human tumor cell line
F,Homo sapiens,9606.0,,A-431,1,Expert,,4085,,N,5923,1,500.0,,80852,,,,BAO_0000219,CHEMBL618633,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1276,,N,5924,1,624.0,,80021,,,,BAO_0000219,CHEMBL619315,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
F,Homo sapiens,9606.0,,A498,1,Expert,,3498,,N,5925,1,624.0,,80021,,,,BAO_0000219,CHEMBL619316,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1169,,N,5926,1,624.0,,80021,,,,BAO_0000219,CHEMBL619317,,Cytotoxicity against human kidney carcinoma A-498cell lines
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4450,,N,5927,1,624.0,,80021,,,,BAO_0000219,CHEMBL619318,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3311,,N,5928,1,624.0,,80021,,,,BAO_0000219,CHEMBL619319,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
F,Homo sapiens,9606.0,,A498,1,Intermediate,,4461,,N,5929,1,624.0,,80021,,,,BAO_0000219,CHEMBL619739,,Antitumor cytotoxic activity against A-498 cell line was determined
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3311,,N,5930,1,624.0,,80021,,,,BAO_0000219,CHEMBL619740,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3311,,N,5931,1,624.0,,80021,,,,BAO_0000219,CHEMBL883158,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data
F,Homo sapiens,9606.0,,A498,1,Intermediate,,1457,,N,5932,1,624.0,,80021,,,,BAO_0000219,CHEMBL884012,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
F,Homo sapiens,9606.0,,A498,1,Intermediate,,3664,,N,5933,1,624.0,,80021,,,,BAO_0000219,CHEMBL619741,,In vitro inhibitory activity against A-498 ovarian cancer cell lines
F,Homo sapiens,9606.0,,A498,1,Intermediate,,15895,,N,5934,1,624.0,,80021,,,,BAO_0000219,CHEMBL619742,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11843,,N,5935,1,646.0,,80682,,,,BAO_0000219,CHEMBL876610,,Inhibition of growth lung non-small cell carcinoma A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11843,,N,5936,1,646.0,,80682,,,,BAO_0000219,CHEMBL619743,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17705,,N,5937,1,646.0,,80682,,,,BAO_0000219,CHEMBL619744,,In vitro antiproliferative activity against human A-549 NSCL cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17705,,N,5938,1,646.0,,80682,,,,BAO_0000219,CHEMBL619745,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5939,1,646.0,,80682,,,,BAO_0000219,CHEMBL619746,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5940,1,646.0,,80682,,,,BAO_0000219,CHEMBL619747,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5941,1,646.0,,80682,,,,BAO_0000219,CHEMBL619748,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5942,1,646.0,,80682,,,,BAO_0000219,CHEMBL619749,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5943,1,646.0,,80682,,,,BAO_0000219,CHEMBL619750,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5944,1,646.0,,80682,,,,BAO_0000219,CHEMBL624014,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4369,,N,5945,1,646.0,,80682,,,,BAO_0000219,CHEMBL624015,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data
F,Homo sapiens,9606.0,,A549,1,Expert,,4787,,N,5946,1,646.0,,80682,,,,BAO_0000219,CHEMBL885344,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4787,,N,5947,1,646.0,,80682,,,,BAO_0000219,CHEMBL623224,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6513,,N,5948,1,646.0,,80682,,,,BAO_0000219,CHEMBL623225,,Cytotoxic activity against A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6690,,N,5949,1,646.0,,80682,,,,BAO_0000219,CHEMBL622698,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6690,,N,5950,1,646.0,,80682,,,,BAO_0000219,CHEMBL622699,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1
F,Homo sapiens,9606.0,,A549,1,Expert,,12263,,N,5951,1,646.0,,80682,,,,BAO_0000219,CHEMBL622700,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1054,,N,5952,1,646.0,,80682,,,,BAO_0000219,CHEMBL622701,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1359,,N,5953,1,646.0,,80682,,,,BAO_0000219,CHEMBL622702,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3547,,N,5954,1,646.0,,80682,,,,BAO_0000219,CHEMBL622703,,Cytotoxic activity against human lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,5771,,N,5955,1,646.0,,80682,,,,BAO_0000219,CHEMBL622704,,Cytotoxic activity towards A-549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5956,1,646.0,,80682,,,,BAO_0000219,CHEMBL622705,,"In vitro percent inhibition of A549, lung carcinoma."
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5957,1,646.0,,80682,,,,BAO_0000219,CHEMBL622706,,"In vitro percent inhibition of A549, lung carcinoma"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5958,1,646.0,,80682,,,,BAO_0000219,CHEMBL622707,,"In vitro percent inhibition of A549, lung carcinoma."
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14425,,N,5959,1,646.0,,80682,,,,BAO_0000219,CHEMBL622708,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5280,,N,5960,1,646.0,,80682,,,,BAO_0000219,CHEMBL622709,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15176,,N,5961,1,646.0,,80682,,,,BAO_0000219,CHEMBL622710,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15300,,N,5962,1,646.0,,80682,,,,BAO_0000219,CHEMBL622711,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5963,1,646.0,,80682,,,,BAO_0000218,CHEMBL622712,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5964,1,646.0,,80682,,,,BAO_0000218,CHEMBL622713,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5965,1,646.0,,80682,,,,BAO_0000218,CHEMBL622714,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5966,1,646.0,,80682,,,,BAO_0000218,CHEMBL622715,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5967,1,646.0,,80682,,,,BAO_0000218,CHEMBL622716,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17824,,N,5968,1,646.0,,80682,,,,BAO_0000219,CHEMBL622717,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17528,,N,5969,1,646.0,,80682,,,,BAO_0000218,CHEMBL622718,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3)
F,Homo sapiens,9606.0,,A549,1,Expert,,6870,,N,5970,1,646.0,,80682,,,,BAO_0000219,CHEMBL622719,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6870,,N,5971,1,646.0,,80682,,,,BAO_0000219,CHEMBL622720,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6870,,N,5972,1,646.0,,80682,,,,BAO_0000219,CHEMBL622721,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6870,,N,5973,1,646.0,,80682,,,,BAO_0000219,CHEMBL622722,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16726,,N,5974,1,646.0,,80682,,,,BAO_0000219,CHEMBL876030,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6170,,N,5975,1,646.0,,80682,,,,BAO_0000219,CHEMBL620206,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation"
F,Homo sapiens,9606.0,,A549,1,Expert,,6583,,N,5976,1,646.0,,80682,,,,BAO_0000219,CHEMBL620207,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6583,,N,5977,1,646.0,,80682,,,,BAO_0000219,CHEMBL620208,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6583,,N,5978,1,646.0,,80682,,,,BAO_0000219,CHEMBL620209,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6583,,N,5979,1,646.0,,80682,,,,BAO_0000219,CHEMBL620210,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6583,,N,5980,1,646.0,,80682,,,,BAO_0000219,CHEMBL621639,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17321,,N,5981,1,646.0,,80682,,,,BAO_0000219,CHEMBL621640,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,17528,,N,5982,1,646.0,,80682,,,,BAO_0000219,CHEMBL621641,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
F,Homo sapiens,9606.0,,A549,1,Expert,,12888,,N,5983,1,646.0,,80682,,,,BAO_0000219,CHEMBL621642,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4312,,N,5984,1,646.0,,80682,,,,BAO_0000219,CHEMBL621643,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4312,,N,5985,1,646.0,,80682,,,,BAO_0000219,CHEMBL621644,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4312,,N,5986,1,646.0,,80682,,,,BAO_0000219,CHEMBL621645,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data
F,Mus musculus,10090.0,,A549,1,Intermediate,,17737,,N,5987,1,646.0,,80682,,,,BAO_0000219,CHEMBL621646,,In vitro antiproliferative activity against A549 cell line
F,,,,A549,1,Intermediate,,6630,,N,5988,1,646.0,,80682,,,,BAO_0000219,CHEMBL621647,,Synergism with indomethacin in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5989,1,646.0,,80682,,,,BAO_0000219,CHEMBL621648,,Synergism with tolmetin in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5990,1,646.0,,80682,,,,BAO_0000219,CHEMBL621649,,Synergism with sulindac in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5991,1,646.0,,80682,,,,BAO_0000219,CHEMBL621650,,Antagonism of indomethacin in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5992,1,646.0,,80682,,,,BAO_0000219,CHEMBL621651,,Antagonism of sulindac in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5993,1,646.0,,80682,,,,BAO_0000219,CHEMBL621652,,Antagonism of tolmetin in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5994,1,646.0,,80682,,,,BAO_0000219,CHEMBL621653,,Synergism with indomethacin in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5995,1,646.0,,80682,,,,BAO_0000219,CHEMBL621654,,Synergism with sulindac in A549 cells
F,,,,A549,1,Intermediate,,6630,,N,5996,1,646.0,,80682,,,,BAO_0000219,CHEMBL621655,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,5997,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621656,,Cmax value after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5998,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621657,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,5999,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621658,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,6000,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621659,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5944,,N,6001,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621660,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,6002,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621661,,Cmax value after administration of 4 mg/Kg oral dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6241,,N,6003,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621662,,Cmax value in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6241,,N,6004,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621663,,Cmax value in dogs after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,6005,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621664,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1806,,N,6006,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621665,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1806,,N,6007,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621666,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1021,,N,6008,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621667,,Concentration maxima after oral dosing in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1021,,N,6009,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876738,,Concentration maxima after oral dosing in dogs; not available
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1021,,N,6010,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621668,,Concentration maxima after oral dosing in dogs; not available
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,6011,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621669,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,6012,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621670,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,6013,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621671,,In vivo maximal concentration was calculated at 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,6014,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622360,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,6015,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622361,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5130,,N,6016,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622362,,Cmax in dog plasma after oral dose (1 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3249,,N,6017,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622363,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5473,,N,6018,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622364,,Maximal plasma concentration at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,6019,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622365,,Maximal plasma concentration at a dose of 1 mg/kg (oral)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4657,,N,6020,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622533,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3031,,N,6021,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622534,,Maximum concentration of compound in dog was evaluated.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,6022,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622535,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4186,,N,6023,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876739,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5007,,N,6024,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622536,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3132,,N,6025,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622537,,Maximum concentration obtained in dog plasma was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,6026,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622538,,Maximum concentration was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4727,,N,6027,1,,,50588,,,In vivo,BAO_0000218,CHEMBL627867,,Maximum concentration at the dose of 2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1916,,N,6028,1,,,50588,,,In vivo,BAO_0000218,CHEMBL627868,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1918,,N,6029,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627869,,Maximum concentration was evaluated in dog plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3045,,N,6030,1,,,50588,,,In vivo,BAO_0000218,CHEMBL627870,,Maximum concentration was evaluated after 75 min after administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6031,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627871,,Maximum plasma concentration determined in dog after oral administration of 17b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6032,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627872,,Maximum plasma concentration determined in dog after oral administration of 2b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,933,,N,6033,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627873,,Maximum plasma concentration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6034,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627874,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6035,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627875,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6036,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627876,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6037,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627877,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,6038,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627878,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,6039,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627879,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,6040,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875355,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,6041,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627880,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,6042,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627881,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17650,,N,6043,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627882,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6679,,N,6044,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627883,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5356,,N,6045,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628526,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5356,,N,6046,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628527,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6047,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628528,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6048,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628529,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6049,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628530,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6050,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625243,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,6051,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625244,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4368,,N,6052,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625245,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6265,,N,6053,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625246,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,6054,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL625247,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,6055,1,,,50594,Urine,1088.0,In vivo,BAO_0000218,CHEMBL625248,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,6056,1,,,50594,Urine,1088.0,In vivo,BAO_0000218,CHEMBL625249,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data
A,Mus musculus,10090.0,,,1,Intermediate,,7767,,N,6057,1,,,50594,Urine,1088.0,In vivo,BAO_0000218,CHEMBL625250,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,6058,1,,,50594,,,,BAO_0000218,CHEMBL625251,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase
A,Mus musculus,10090.0,,,1,Intermediate,,17811,,N,6059,1,,,50594,,,,BAO_0000218,CHEMBL875356,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6060,1,,,50594,,,,BAO_0000218,CHEMBL625252,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6061,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL625253,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6062,1,,,50594,,,,BAO_0000218,CHEMBL625254,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6063,1,,,50594,,,,BAO_0000218,CHEMBL625255,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6064,1,,,50594,,,,BAO_0000218,CHEMBL625256,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6065,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL625257,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6066,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL625258,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6067,1,,,50594,,,,BAO_0000218,CHEMBL625259,,Compound was evaluated for washout rate in mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6068,1,,,50594,,,,BAO_0000218,CHEMBL625260,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6069,1,,,50594,,,,BAO_0000218,CHEMBL625261,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6070,1,,,50594,,,,BAO_0000218,CHEMBL625262,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6071,1,,,50594,,,,BAO_0000218,CHEMBL622639,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
A,Mus musculus,10090.0,,,1,Intermediate,,17257,,N,6072,1,,,50594,,,,BAO_0000218,CHEMBL622640,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17257,,N,6073,1,,,50594,,,,BAO_0000218,CHEMBL622812,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.
A,Mus musculus,10090.0,,,1,Intermediate,,17257,,N,6074,1,,,50594,,,,BAO_0000218,CHEMBL622813,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17257,,N,6075,1,,,50594,,,,BAO_0000218,CHEMBL622814,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,17827,,N,6076,1,,,50594,,,,BAO_0000218,CHEMBL622815,,Time at maximum activity in mice (Radiolabeled compound)
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6077,1,,,50594,,,,BAO_0000218,CHEMBL625342,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6078,1,,,50594,,,,BAO_0000218,CHEMBL625343,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17409,,N,6079,1,,,50594,,,,BAO_0000218,CHEMBL877591,,Binding towards mouse plasma protein at 10 uM
A,Mus musculus,10090.0,,,1,Intermediate,,17409,,N,6080,1,,,50594,,,,BAO_0000218,CHEMBL625344,,Binding towards mouse plasma protein at 100 uM
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6081,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625345,,Bioavailability was evaluated in mice after intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6082,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625346,,Bioavailability was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,6083,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625347,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,6084,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625348,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,6085,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625349,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,6086,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625350,,Oral bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6087,1,,,50594,,,In vivo,BAO_0000218,CHEMBL882952,,Oral bioavailability after intravenous administration in mice at 24 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6088,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL625351,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6089,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL625352,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6090,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL877592,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6091,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL625353,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6092,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL625354,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6093,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL626019,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6094,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL626020,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6095,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL626021,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6096,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL626022,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6097,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL626192,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1276,,N,6098,1,646.0,,80682,,,,BAO_0000219,CHEMBL626193,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
F,Homo sapiens,9606.0,,A549,1,Expert,,3498,,N,6099,1,646.0,,80682,,,,BAO_0000219,CHEMBL626194,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1169,,N,6100,1,646.0,,80682,,,,BAO_0000219,CHEMBL626195,,Cytotoxicity against human lung carcinoma A-549 cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4450,,N,6101,1,646.0,,80682,,,,BAO_0000219,CHEMBL626196,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6102,1,646.0,,80682,,,,BAO_0000219,CHEMBL626197,,In vitro cytotoxicity against human lung carcinoma cell line A-549
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6103,1,646.0,,80682,,,,BAO_0000219,CHEMBL626198,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6104,1,646.0,,80682,,,,BAO_0000219,CHEMBL626199,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6105,1,646.0,,80682,,,,BAO_0000219,CHEMBL626200,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6106,1,646.0,,80682,,,,BAO_0000219,CHEMBL626201,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6107,1,646.0,,80682,,,,BAO_0000219,CHEMBL626202,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,358,,N,6108,1,646.0,,80682,,,,BAO_0000219,CHEMBL626203,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15167,,N,6109,1,646.0,,80682,,,,BAO_0000219,CHEMBL626204,,In vitro cytotoxicity against A-549 human lung cancer cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4139,,N,6110,1,646.0,,80682,,,,BAO_0000219,CHEMBL624701,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,833,,N,6111,1,646.0,,80682,,,,BAO_0000219,CHEMBL624702,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines
F,Homo sapiens,9606.0,,A549,1,Expert,,15718,,N,6112,1,646.0,,80682,,,,BAO_0000219,CHEMBL624703,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12373,,N,6113,1,646.0,,80682,,,,BAO_0000219,CHEMBL624704,,Tested in vitro for cytotoxicity against A-549 lung cancer cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,637,,N,6114,1,646.0,,80682,,,,BAO_0000219,CHEMBL624705,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma
F,Homo sapiens,9606.0,,A549,1,Expert,,14867,,N,6115,1,646.0,,80682,,,,BAO_0000219,CHEMBL624706,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4461,,N,6116,1,646.0,,80682,,,,BAO_0000219,CHEMBL624707,,Antitumor cytotoxic activity against A-549 cell line was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5406,,N,6117,1,646.0,,80682,,,,BAO_0000219,CHEMBL624708,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4457,,N,6118,1,646.0,,80682,,,,BAO_0000219,CHEMBL624709,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,1386,,N,6119,1,646.0,,80682,,,,BAO_0000219,CHEMBL884107,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3265,,N,6120,1,646.0,,80682,,,,BAO_0000219,CHEMBL624710,,Antitumoral activity was assayed against A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2359,,N,6121,1,646.0,,80682,,,,BAO_0000219,CHEMBL624711,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4457,,N,6122,1,646.0,,80682,,,,BAO_0000219,CHEMBL624712,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,12454,,N,6123,1,646.0,,80682,,,,BAO_0000219,CHEMBL624713,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1481,,N,6124,1,646.0,,80682,,,,BAO_0000219,CHEMBL624714,,Compound was tested for inhibition of cell growth of A-549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1750,,N,6125,1,646.0,,80682,,,,BAO_0000219,CHEMBL624715,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5065,,N,6126,1,646.0,,80682,,,,BAO_0000219,CHEMBL624716,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
F,Homo sapiens,9606.0,,A549,1,Expert,,808,,N,6127,1,646.0,,80682,,,,BAO_0000219,CHEMBL619505,,In vitro cytotoxicity against A549-human lung carcinoma cells.
F,Homo sapiens,9606.0,,A549,1,Expert,,16364,,N,6128,1,646.0,,80682,,,,BAO_0000219,CHEMBL619506,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1847,,N,6129,1,646.0,,80682,,,,BAO_0000219,CHEMBL619507,,Cytotoxic activity against A-549 cell lines.
F,Homo sapiens,9606.0,,A549,1,Expert,,1747,,N,6130,1,646.0,,80682,,,,BAO_0000219,CHEMBL619508,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1003,,N,6131,1,646.0,,80682,,,,BAO_0000219,CHEMBL619509,,Cytotoxicity against human A549 non small cell lung cell lines
F,Homo sapiens,9606.0,,A549,1,Expert,,15313,,N,6132,1,646.0,,80682,,,,BAO_0000219,CHEMBL619510,,Inhibition of cell growth in (A-549) lung cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3122,,N,6133,1,646.0,,80682,,,,BAO_0000219,CHEMBL619511,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16049,,N,6134,1,646.0,,80682,,,,BAO_0000219,CHEMBL619512,,In vitro antitumor activity against A-549 tumor cells.
F,Homo sapiens,9606.0,,A549,1,Expert,,17134,,N,6135,1,646.0,,80682,,,,BAO_0000219,CHEMBL619513,,In vitro antitumor effects against human A-549 cell lines.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6406,,N,6136,1,646.0,,80682,,,,BAO_0000219,CHEMBL619514,,In vitro cytotoxic activity of compound against A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,627,,N,6137,1,646.0,,80682,,,,BAO_0000219,CHEMBL619515,,In vitro cytotoxicity against human lung carcinoma A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12307,,N,6138,1,646.0,,80682,,,,BAO_0000219,CHEMBL619516,,In vitro cytotoxicity against human non-small cell lung carcinoma A549
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17861,,N,6139,1,646.0,,80682,,,,BAO_0000219,CHEMBL884005,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated
F,Homo sapiens,9606.0,,A549,1,Expert,,6682,,N,6140,1,646.0,,80682,,,,BAO_0000219,CHEMBL619517,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6141,1,646.0,,80682,,,,BAO_0000219,CHEMBL619518,,Inhibitory concentration of compound against A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2454,,N,6142,1,646.0,,80682,,,,BAO_0000219,CHEMBL619519,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14709,,N,6143,1,646.0,,80682,,,,BAO_0000219,CHEMBL876489,,cytotoxic activity against leukemia (A-549) cancer cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,15718,,N,6144,1,646.0,,80682,,,,BAO_0000219,CHEMBL619520,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15718,,N,6145,1,646.0,,80682,,,,BAO_0000219,CHEMBL619521,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6146,1,646.0,,80682,,,,BAO_0000219,CHEMBL619522,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6147,1,646.0,,80682,,,,BAO_0000219,CHEMBL619523,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6148,1,646.0,,80682,,,,BAO_0000219,CHEMBL619524,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6149,1,646.0,,80682,,,,BAO_0000219,CHEMBL619525,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)
F,,,,A549,1,Intermediate,,6630,,N,6150,1,646.0,,80682,,,,BAO_0000219,CHEMBL619526,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16726,,N,6151,1,646.0,,80682,,,,BAO_0000219,CHEMBL619527,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17846,,N,6152,1,646.0,,80682,,,,BAO_0000219,CHEMBL619528,,Cytotoxicity against A549 cells; No cytotoxicity
F,Homo sapiens,9606.0,,A549,1,Expert,,3415,,N,6153,1,646.0,,80682,,,,BAO_0000219,CHEMBL619529,,Cytotoxicity against human lung carcinoma (A549) cell lines
F,Homo sapiens,9606.0,,A549,1,Expert,,3415,,N,6154,1,646.0,,80682,,,,BAO_0000219,CHEMBL619530,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5609,,N,6155,1,646.0,,80682,,,,BAO_0000219,CHEMBL876490,,In vitro anticancer activity against human lung (A549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6156,1,646.0,,80682,,,,BAO_0000219,CHEMBL619531,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6157,1,646.0,,80682,,,,BAO_0000219,CHEMBL619532,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6158,1,646.0,,80682,,,,BAO_0000219,CHEMBL619533,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6159,1,646.0,,80682,,,,BAO_0000219,CHEMBL619534,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6160,1,646.0,,80682,,,,BAO_0000219,CHEMBL620164,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6161,1,646.0,,80682,,,,BAO_0000219,CHEMBL620165,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Expert,,16295,,N,6162,1,646.0,,80682,,,,BAO_0000219,CHEMBL620166,,Inhibition of A549 human lung tumor cell proliferation
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16825,,N,6163,1,646.0,,80682,,,,BAO_0000219,CHEMBL620167,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. "
F,Homo sapiens,9606.0,,A549,1,Expert,,3439,,N,6164,1,646.0,,80682,,,,BAO_0000219,CHEMBL620168,,In vitro cytotoxicity against human tumor cell line A549
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10870,,N,6165,1,646.0,,80682,,,,BAO_0000219,CHEMBL620338,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. 
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4845,,N,6166,1,646.0,,80682,,,,BAO_0000219,CHEMBL620339,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5822,,N,6167,1,646.0,,80682,,,,BAO_0000219,CHEMBL620340,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5822,,N,6168,1,646.0,,80682,,,,BAO_0000219,CHEMBL620341,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5822,,N,6169,1,646.0,,80682,,,,BAO_0000219,CHEMBL876491,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6170,1,646.0,,80682,,,,BAO_0000219,CHEMBL620342,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6171,1,646.0,,80682,,,,BAO_0000219,CHEMBL620343,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6172,1,646.0,,80682,,,,BAO_0000219,CHEMBL620344,,% inhibition against A549 cells (lung cancer) at 4 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5609,,N,6173,1,646.0,,80682,,,,BAO_0000219,CHEMBL620345,,In vitro anticancer activity against human lung (A549) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4644,,N,6174,1,646.0,,80682,,,,BAO_0000219,CHEMBL620346,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4644,,N,6175,1,646.0,,80682,,,,BAO_0000219,CHEMBL620347,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4644,,N,6176,1,646.0,,80682,,,,BAO_0000219,CHEMBL620348,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4644,,N,6177,1,646.0,,80682,,,,BAO_0000219,CHEMBL620349,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5822,,N,6178,1,646.0,,80682,,,,BAO_0000219,CHEMBL618667,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM
F,Homo sapiens,9606.0,,A549,1,Expert,,3415,,N,6179,1,646.0,,80682,,,,BAO_0000219,CHEMBL618668,,Percentage inhibition of human lung carcinoma (A549) cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16726,,N,6180,1,646.0,,80682,,,,BAO_0000219,CHEMBL876031,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6181,1,646.0,,80682,,,,BAO_0000219,CHEMBL618759,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6182,1,646.0,,80682,,,,BAO_0000219,CHEMBL618760,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6183,1,646.0,,80682,,,,BAO_0000219,CHEMBL619000,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6184,1,646.0,,80682,,,,BAO_0000219,CHEMBL619001,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6185,1,646.0,,80682,,,,BAO_0000219,CHEMBL619002,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6186,1,646.0,,80682,,,,BAO_0000219,CHEMBL619003,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6187,1,646.0,,80682,,,,BAO_0000219,CHEMBL619597,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6188,1,646.0,,80682,,,,BAO_0000219,CHEMBL619598,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM"
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6189,1,646.0,,80682,,,,BAO_0000219,CHEMBL619599,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6190,1,646.0,,80682,,,,BAO_0000219,CHEMBL619600,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16726,,N,6191,1,646.0,,80682,,,,BAO_0000219,CHEMBL619601,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6192,1,646.0,,80682,,,,BAO_0000219,CHEMBL619602,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6193,1,646.0,,80682,,,,BAO_0000219,CHEMBL619603,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6194,1,646.0,,80682,,,,BAO_0000219,CHEMBL619604,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6195,1,646.0,,80682,,,,BAO_0000219,CHEMBL619605,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6196,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619606,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6197,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876032,,Pharmacokinetic activity (Cmax) in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,6198,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619607,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,6199,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619608,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6251,,N,6200,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619609,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5932,,N,6201,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL619610,,Cmax in dog plasma after 30mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4273,,N,6202,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL619611,,Tested for the peak blood level in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,6203,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619612,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,6204,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619613,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6221,,N,6205,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL619614,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,6206,1,,,50588,,,,BAO_0000218,CHEMBL619615,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,167,,N,6207,1,,,50588,,,,BAO_0000218,CHEMBL619616,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6241,,N,6208,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL619617,,Final plasma concentration in dogs after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,344,,N,6209,1,,,50588,,,,BAO_0000218,CHEMBL619618,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,344,,N,6210,1,,,50588,,,,BAO_0000218,CHEMBL876033,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,344,,N,6211,1,,,50588,,,,BAO_0000218,CHEMBL619619,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2189,,N,6212,1,,,50588,,,,BAO_0000218,CHEMBL619620,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2189,,N,6213,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL619621,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2189,,N,6214,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL619622,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2189,,N,6215,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL618874,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4257,,N,6216,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618875,,Absolute bioavailability was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6221,,N,6217,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618876,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6215,,N,6218,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618877,,Bioavailability after peroral administration (1 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17267,,N,6219,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618878,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6621,,N,6220,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618879,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3854,,N,6221,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618880,,Bioavailability after intravenous administration in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3854,,N,6222,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618881,,Bioavailability after peroral administration in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5007,,N,6223,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618882,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4333,,N,6224,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624226,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4333,,N,6225,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624227,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,6226,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624228,,Bioavailability
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,6227,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624229,,Bioavailability
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4368,,N,6228,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624230,,Bioavailability by intravenous administration of 1.2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3771,,N,6229,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624231,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4953,,N,6230,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624232,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5064,,N,6231,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625127,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,6232,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625128,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17796,,N,6233,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621675,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17853,,N,6234,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621676,,Bioavailability in dog (p.o.) at 2.0 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,6235,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621677,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,6236,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621678,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,6237,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621679,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16365,,N,6238,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621680,,Bioavailability was evaluated after oral administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1916,,N,6239,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621681,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1918,,N,6240,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876740,,Bioavailability was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4239,,N,6241,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621682,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6505,,N,6242,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621683,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,6243,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621684,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,6244,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621685,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,6245,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621686,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,6246,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621687,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6005,,N,6247,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621688,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17804,,N,6248,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621689,,Bioavailability of compound in dog was determined after peroral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3184,,N,6249,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621690,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1806,,N,6250,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621691,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1806,,N,6251,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875941,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1806,,N,6252,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621692,,Compound was evaluated for oral bioavailability in dogs; 37-38 %
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4839,,N,6253,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621693,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5017,,N,6254,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621694,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.)
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6255,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621695,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6256,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621696,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6257,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621697,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6258,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621698,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6259,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623420,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6260,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623421,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6261,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623422,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6262,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623423,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6263,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623424,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6264,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623425,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6265,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623426,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6266,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623427,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6267,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623428,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6268,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL875947,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6269,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623429,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6270,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623430,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6271,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622588,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6272,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622589,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6273,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622751,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,,1,Intermediate,,846,,N,6274,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622752,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6275,1,42.0,,50594,,,,BAO_0000218,CHEMBL622753,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6276,1,42.0,,50594,,,,BAO_0000218,CHEMBL622647,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6277,1,42.0,,50594,,,,BAO_0000218,CHEMBL875163,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6278,1,42.0,,50594,,,,BAO_0000218,CHEMBL622648,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6279,1,42.0,,50594,,,,BAO_0000218,CHEMBL622649,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6280,1,42.0,,50594,Brain,955.0,,BAO_0000218,CHEMBL622650,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6281,1,42.0,,50594,Brain,955.0,,BAO_0000218,CHEMBL622651,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6282,1,42.0,,50594,Brain,955.0,,BAO_0000218,CHEMBL622652,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6283,1,42.0,,50594,Brain,955.0,,BAO_0000218,CHEMBL622653,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6284,1,42.0,,50594,Brain,955.0,,BAO_0000218,CHEMBL622654,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6285,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL622655,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6286,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL622656,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6287,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL622657,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6288,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL622658,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6289,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL622659,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6290,1,42.0,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL624630,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6291,1,42.0,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL624631,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6292,1,42.0,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL624632,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6293,1,646.0,,80682,,,,BAO_0000219,CHEMBL624633,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6294,1,646.0,,80682,,,,BAO_0000219,CHEMBL624634,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6295,1,646.0,,80682,,,,BAO_0000219,CHEMBL624635,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17130,,N,6296,1,646.0,,80682,,,,BAO_0000219,CHEMBL624636,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml))
F,Homo sapiens,9606.0,,A549,1,Expert,,3263,,N,6297,1,646.0,,80682,,,,BAO_0000219,CHEMBL857055,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Expert,,6663,,N,6298,1,646.0,,80682,,,,BAO_0000219,CHEMBL624637,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6663,,N,6299,1,646.0,,80682,,,,BAO_0000219,CHEMBL624638,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6663,,N,6300,1,646.0,,80682,,,,BAO_0000219,CHEMBL874366,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6663,,N,6301,1,646.0,,80682,,,,BAO_0000219,CHEMBL624639,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L
F,Homo sapiens,9606.0,,A549,1,Expert,,6663,,N,6302,1,646.0,,80682,,,,BAO_0000219,CHEMBL624640,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6303,1,646.0,,80682,,,,BAO_0000219,CHEMBL624641,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6304,1,646.0,,80682,,,,BAO_0000219,CHEMBL624642,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6305,1,646.0,,80682,,,,BAO_0000219,CHEMBL624643,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6306,1,646.0,,80682,,,,BAO_0000219,CHEMBL624644,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6663,,N,6307,1,646.0,,80682,,,,BAO_0000219,CHEMBL624645,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3983,,N,6308,1,646.0,,80682,,,,BAO_0000219,CHEMBL619445,,The compound was evaluated for its cytotoxic potency against A-549 cell line
F,Homo sapiens,9606.0,,A549,1,Expert,,11141,,N,6309,1,646.0,,80682,,,,BAO_0000219,CHEMBL839886,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5076,,N,6310,1,646.0,,80682,,,,BAO_0000219,CHEMBL619446,,Cytotoxic activity of compound against A-549 tumor cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3311,,N,6311,1,646.0,,80682,,,,BAO_0000219,CHEMBL619447,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3311,,N,6312,1,646.0,,80682,,,,BAO_0000219,CHEMBL619448,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3311,,N,6313,1,646.0,,80682,,,,BAO_0000219,CHEMBL619449,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5076,,N,6314,1,646.0,,80682,,,,BAO_0000219,CHEMBL619450,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4150,,N,6315,1,646.0,,80682,,,,BAO_0000219,CHEMBL619451,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185)
F,Homo sapiens,9606.0,,A549,1,Expert,,2150,,N,6316,1,646.0,,80682,,,,BAO_0000219,CHEMBL619452,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4644,,N,6317,1,646.0,,80682,,,,BAO_0000219,CHEMBL619453,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,263,,N,6318,1,646.0,,80682,,,,BAO_0000219,CHEMBL874367,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11333,,N,6319,1,646.0,,80682,,,,BAO_0000219,CHEMBL619454,,Cytotoxic concentration against A-549 tumor cells.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11333,,N,6320,1,646.0,,80682,,,,BAO_0000219,CHEMBL619455,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,15895,,N,6321,1,646.0,,80682,,,,BAO_0000219,CHEMBL619456,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line"
F,Acinetobacter baumannii,470.0,,,1,Expert,,16677,,N,6322,1,,,50191,,,,BAO_0000218,CHEMBL619457,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A
F,Acinetobacter calcoaceticus,471.0,,,1,Intermediate,,10624,,N,6323,1,,,50192,,,,BAO_0000218,CHEMBL619458,,Activity against Acinetobacter calcoaceticus (AC54)
F,Aspergillus flavus,5059.0,,,1,Expert,,16717,,N,6324,1,,,50274,,,,BAO_0000218,CHEMBL619459,,In vitro antifungal activity against Aspergillus flavus CM74
F,Aspergillus flavus,5059.0,,,1,Expert,,16717,,N,6325,1,,,50274,,,,BAO_0000218,CHEMBL619460,,In vitro antifungal activity against Aspergillus flavus CM74
F,Aspergillus fumigatus,746128.0,,,1,Intermediate,,5513,,N,6326,1,,,50416,,,,BAO_0000218,CHEMBL619461,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration
F,Aspergillus fumigatus,746128.0,,,1,Intermediate,,15962,,N,6327,1,,,50416,,,,BAO_0000218,CHEMBL619462,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC)
F,Aspergillus fumigatus,746128.0,,,1,Intermediate,,15962,,N,6328,1,,,50416,,,,BAO_0000218,CHEMBL620388,,Antimicrobial activity against Aspergillus fumigatus (MIC)
F,Aspergillus fumigatus,746128.0,,,1,Intermediate,,15962,,N,6329,1,,,50416,,,,BAO_0000218,CHEMBL620389,,Antimicrobial activity against Aspergillus fumigatus (MIC)
F,Aspergillus fumigatus,746128.0,,,1,Intermediate,,15962,,N,6330,1,,,50416,,,,BAO_0000218,CHEMBL620390,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC)
F,Aspergillus fumigatus,746128.0,,,1,Expert,,16717,,N,6331,1,,,50416,,,,BAO_0000218,CHEMBL620391,,In vitro antifungal activity against Aspergillus fumigatus 48238E
F,Aspergillus fumigatus,746128.0,,,1,Expert,,16717,,N,6332,1,,,50416,,,,BAO_0000218,CHEMBL621073,,In vitro antifungal activity against Aspergillus fumigatus 48238E
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,8117,,N,6333,1,,,50296,,,,BAO_0000218,CHEMBL621074,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,8117,,N,6334,1,,,50366,,,,BAO_0000218,CHEMBL621075,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,15472,,N,6335,1,,,50535,,,,BAO_0000218,CHEMBL619554,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,15472,,N,6336,1,,,50535,,,,BAO_0000218,CHEMBL619555,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
F,Aggregatibacter actinomycetemcomitans,714.0,,,1,Intermediate,,16443,,N,6337,1,,,50169,,,,BAO_0000218,CHEMBL619556,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527
F,Aggregatibacter actinomycetemcomitans,714.0,,,1,Intermediate,,16443,,N,6338,1,,,50169,,,,BAO_0000218,CHEMBL619557,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2
F,Aggregatibacter actinomycetemcomitans,714.0,,,1,Intermediate,,16443,,N,6339,1,,,50169,,,,BAO_0000218,CHEMBL619558,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6340,1,646.0,,80682,,,,BAO_0000219,CHEMBL619559,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6341,1,646.0,,80682,,,,BAO_0000219,CHEMBL619560,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6342,1,646.0,,80682,,,,BAO_0000219,CHEMBL619561,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6343,1,646.0,,80682,,,,BAO_0000219,CHEMBL619562,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6344,1,646.0,,80682,,,,BAO_0000219,CHEMBL619563,,% inhibition against A549 cells (lung cancer) at 4 ug/mL
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16381,,N,6345,1,646.0,,80682,,,,BAO_0000219,CHEMBL857457,,GI values against A549 cells (lung cancer)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17206,,N,6346,1,646.0,,80682,,,,BAO_0000219,CHEMBL619564,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16325,,N,6347,1,646.0,,80682,,,,BAO_0000219,CHEMBL619565,,Inhibitory activity against A549 human adenocarcinoma
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10708,,N,6348,1,646.0,,80682,,,,BAO_0000218,CHEMBL619566,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10708,,N,6349,1,646.0,,80682,,,,BAO_0000218,CHEMBL619567,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17376,,N,6350,1,646.0,,80682,,,,BAO_0000219,CHEMBL619568,,Inhibitory activity against A549 lung adenocarcinoma cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17376,,N,6351,1,646.0,,80682,,,,BAO_0000219,CHEMBL619569,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17488,,N,6352,1,646.0,,80682,,,,BAO_0000219,CHEMBL619570,,Cytotoxicity against human A549 lung cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17404,,N,6353,1,646.0,,80682,,,,BAO_0000218,CHEMBL619571,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor
F,Homo sapiens,9606.0,,A549,1,Expert,,10958,,N,6354,1,646.0,,80682,,,,BAO_0000219,CHEMBL619572,,Growth inhibition of A549 (human lung carcinoma) cell line.
F,Homo sapiens,9606.0,,A549,1,Expert,,17099,,N,6355,1,646.0,,80682,,,,BAO_0000219,CHEMBL619573,,Effective dose required for inhibitory activity against A549 human tumor cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17099,,N,6356,1,646.0,,80682,,,,BAO_0000219,CHEMBL619574,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4096,,N,6357,1,646.0,,80682,,,,BAO_0000219,CHEMBL619575,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive
F,Homo sapiens,9606.0,,A549,1,Expert,,4096,,N,6358,1,646.0,,80682,,,,BAO_0000219,CHEMBL619576,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity
F,Homo sapiens,9606.0,,A549,1,Intermediate,,4096,,N,6359,1,646.0,,80682,,,,BAO_0000219,CHEMBL619577,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2525,,N,6360,1,646.0,,80682,,,,BAO_0000219,CHEMBL619578,,In vitro inhibitory activity against A549 tumor cell culture
F,Homo sapiens,9606.0,,A549,1,Intermediate,,2525,,N,6361,1,646.0,,80682,,,,BAO_0000219,CHEMBL884009,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive
F,Homo sapiens,9606.0,,A549,1,Intermediate,,5302,,N,6362,1,646.0,,80682,,,,BAO_0000219,CHEMBL619579,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415)
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16325,,N,6363,1,646.0,,80682,,,,BAO_0000219,CHEMBL619580,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer
F,Homo sapiens,9606.0,,A549,1,Intermediate,,16939,,N,6364,1,646.0,,80682,,,,BAO_0000219,CHEMBL619581,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17229,,N,6365,1,646.0,,80682,,,,BAO_0000219,CHEMBL619582,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17380,,N,6366,1,646.0,,80682,,,,BAO_0000219,CHEMBL619583,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17380,,N,6367,1,646.0,,80682,,,,BAO_0000219,CHEMBL876502,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1903,,N,6368,1,646.0,,80682,,,,BAO_0000219,CHEMBL619584,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3838,,N,6369,1,646.0,,80682,,,,BAO_0000219,CHEMBL619585,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14696,,N,6370,1,646.0,,80682,,,,BAO_0000219,CHEMBL619586,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3838,,N,6371,1,646.0,,80682,,,,BAO_0000219,CHEMBL619587,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1522,,N,6372,1,646.0,,80682,,,,BAO_0000219,CHEMBL619588,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12400,,N,6373,1,646.0,,80682,,,,BAO_0000219,CHEMBL619589,,Tested in vitro for cytotoxicity in A549/ATCC cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14696,,N,6374,1,646.0,,80682,,,,BAO_0000219,CHEMBL619590,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14769,,N,6375,1,646.0,,80682,,,,BAO_0000219,CHEMBL619591,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,A549,1,Intermediate,,14696,,N,6376,1,646.0,,80682,,,,BAO_0000219,CHEMBL619592,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM
F,Homo sapiens,9606.0,,A549,1,Intermediate,,1888,,N,6377,1,646.0,,80682,,,,BAO_0000219,CHEMBL619593,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12016,,N,6378,1,646.0,,80682,,,,BAO_0000219,CHEMBL620217,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,6058,,N,6379,1,646.0,,80682,,,,BAO_0000219,CHEMBL620218,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17708,,N,6380,1,646.0,,80682,,,,BAO_0000219,CHEMBL620219,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12301,,N,6381,1,646.0,,80682,,,,BAO_0000219,CHEMBL620220,,Antitumor activity against A549/ATCC cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,11970,,N,6382,1,646.0,,80682,,,,BAO_0000219,CHEMBL625141,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer
F,Homo sapiens,9606.0,,A549,1,Expert,,11818,,N,6383,1,646.0,,80682,,,,BAO_0000219,CHEMBL625142,,In vitro cytotoxicity against A549/ATCC cell line.
F,Homo sapiens,9606.0,,A549,1,Intermediate,,12400,,N,6384,1,646.0,,80682,,,,BAO_0000219,CHEMBL625143,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer
F,Homo sapiens,9606.0,,A549,1,Intermediate,,3381,,N,6385,1,646.0,,80682,,,,BAO_0000219,CHEMBL625144,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines
F,Homo sapiens,9606.0,,A549,1,Intermediate,,17376,,N,6386,1,646.0,,80682,,,,BAO_0000219,CHEMBL622474,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line
F,Homo sapiens,9606.0,,A549,1,Intermediate,,10708,,N,6387,1,646.0,,80682,,,,BAO_0000219,CHEMBL884104,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
F,Homo sapiens,9606.0,,,1,Autocuration,,2964,,U,6388,0,,,22226,,,,BAO_0000219,CHEMBL622475,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5005,,U,6389,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622476,,Compound was tested for oral bioavailability in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6229,,N,6390,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875831,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6229,,N,6391,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622477,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5374,,N,6392,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622478,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5374,,N,6393,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623172,,Compound was tested for the oral bioavailability in dog; No availability
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6265,,N,6394,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623173,,Oral bioavailability in dog (dose 5 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5654,,N,6395,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623174,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5654,,N,6396,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623175,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16456,,N,6397,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623340,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5302,,N,6398,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623341,,Oral bioavailability in dog (dose 5 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3624,,N,6399,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623342,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,6400,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623343,,Oral bioavailability of active FTIs in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5802,,N,6401,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623344,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,6402,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623345,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6403,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875832,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6762,,N,6404,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623346,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6821,,N,6405,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623347,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6821,,N,6406,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623348,,Oral bioavailability of compound was determined in dog; Not tested
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5210,,N,6407,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623349,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6408,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623350,,Oral bioavailability (10 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,761,,N,6409,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623351,,Oral bioavailability
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,761,,N,6410,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623352,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,761,,N,6411,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623353,,Oral bioavailability administered in solution in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6412,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875833,,Oral bioavailability after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,6413,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623354,,Oral bioavailability at a dose of 1 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,6414,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623355,,Oral bioavailability in dog (dose 1 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,6415,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623356,,Oral bioavailability in Dog; ND = not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3352,,N,6416,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623357,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6168,,N,6417,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623358,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5988,,N,6418,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623359,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4942,,N,6419,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623360,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4942,,N,6420,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623361,,Oral bioavailability in dogs; No data
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14541,,N,6421,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623362,,Oral bioavailability measured in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4449,,N,6422,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623363,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,6423,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623364,,Oral bioavailability was calculated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,6424,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875834,,Oral bioavailability after 0.3 mg/kg po administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,6425,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623365,,Oral bioavailability in dog (i.v. dosing)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,6426,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623366,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5546,,N,6427,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623367,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4514,,N,6428,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623368,,Oral bioavailability in Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3624,,N,6429,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623369,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3854,,N,6430,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623370,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5836,,N,6431,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623371,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5940,,N,6432,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623372,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6168,,N,6433,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621351,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6434,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621352,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6251,,N,6435,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621353,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,6436,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621354,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6647,,N,6437,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621355,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5940,,N,6438,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621356,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,933,,N,6439,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621357,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5210,,N,6440,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621358,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,6441,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621359,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6641,,N,6442,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621360,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,6443,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621361,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,6444,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621362,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5985,,N,6445,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621363,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,6446,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621364,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,6447,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621166,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,6448,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621167,,Oral bioavailability in dog (dose 1 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6305,,N,6449,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621168,,Oral bioavailability (F) in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5210,,N,6450,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621169,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5238,,N,6451,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875950,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,6452,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621170,,Oral bioavailability in dog (dose 10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,6453,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621171,,Oral bioavailability after peroral administration at 5 mpk in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,6454,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621172,,Oral bioavailability in dog (dose 5 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6455,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621173,,Oral bioavailability in dog (dose 10 mg/kg)
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6456,1,42.0,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL621174,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6457,1,42.0,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL621175,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6458,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621176,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6459,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621177,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6460,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621178,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6461,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621179,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6462,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6463,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL875951,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6464,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL621181,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6465,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL621182,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6466,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL621183,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6467,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL621184,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6468,1,42.0,,50594,,,,BAO_0000218,CHEMBL621185,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6469,1,42.0,,50594,,,,BAO_0000218,CHEMBL621186,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6470,1,42.0,,50594,,,,BAO_0000218,CHEMBL621187,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6471,1,42.0,,50594,,,,BAO_0000218,CHEMBL621188,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6472,1,42.0,,50594,,,,BAO_0000218,CHEMBL621189,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6473,1,42.0,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL621190,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6474,1,42.0,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL618520,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6475,1,42.0,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL621739,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6476,1,42.0,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL621740,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6477,1,42.0,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL621741,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6478,1,42.0,,50594,,,,BAO_0000218,CHEMBL621742,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6479,1,42.0,,50594,,,,BAO_0000218,CHEMBL621743,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6480,1,42.0,,50594,,,,BAO_0000218,CHEMBL621744,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6481,1,42.0,,50594,,,,BAO_0000218,CHEMBL621745,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6482,1,42.0,,50594,,,,BAO_0000218,CHEMBL621746,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6483,1,42.0,,50594,,,,BAO_0000218,CHEMBL621747,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6484,1,42.0,,50594,,,,BAO_0000218,CHEMBL621748,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6485,1,42.0,,50594,,,,BAO_0000218,CHEMBL621749,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6486,1,42.0,,50594,,,,BAO_0000218,CHEMBL621750,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6487,1,42.0,,50594,,,,BAO_0000218,CHEMBL621751,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6488,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL621752,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6489,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL621753,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6490,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL875955,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6491,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL621754,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6492,1,42.0,,50594,Heart,948.0,,BAO_0000218,CHEMBL621755,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6493,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL621756,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6494,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL624199,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6495,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL624200,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6496,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL624375,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6497,1,42.0,,50594,Liver,2107.0,,BAO_0000218,CHEMBL624376,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6498,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL624377,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6499,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL624378,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours
F,aeinetobacter anitrotap,107673.0,,,1,Intermediate,,12269,,N,6500,1,,,50067,,,,BAO_0000218,CHEMBL857901,,Compound tested for the antimicrobial activity against Acinetobacter anitratus
F,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,1,Intermediate,,12269,,N,6501,1,,,50067,,,,BAO_0000218,CHEMBL875274,,Compound tested for the antimicrobial activity against Acinetobacter anitratus
F,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,1,Intermediate,,12269,,N,6502,1,,,50067,,,,BAO_0000218,CHEMBL624379,,Compound tested for the antimicrobial activity against Acinetobacter anitratus
F,aeinetobacter anitrotap,107673.0,,,1,Intermediate,,12269,,N,6503,1,,,50067,,,,BAO_0000218,CHEMBL624380,,Compound tested for the antimicrobial activity against Acinetobacter anitratus
F,Acinetobacter calcoaceticus,471.0,,,1,Intermediate,,10624,,N,6504,1,,,50192,,,,BAO_0000218,CHEMBL624381,,Activity against Acinetobacter calcoaceticus (AC54)
F,Anolis carolinensis,28377.0,,,1,Intermediate,,17216,,N,6505,1,,,50714,,,,BAO_0000218,CHEMBL624382,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity
F,Anolis carolinensis,28377.0,,,1,Intermediate,,17216,,N,6506,1,,,50714,,,,BAO_0000218,CHEMBL624383,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6507,1,,,50296,,,,BAO_0000218,CHEMBL624384,,Chlorohexidine coefficient for Actinomyces naeslundii 631
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6508,1,,,50296,,,,BAO_0000218,CHEMBL624385,,Chlorohexidine coefficient for Actinomyces naeslundii B74
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6509,1,,,50296,,,,BAO_0000218,CHEMBL624386,,Chlorohexidine coefficient for Actinomyces naeslundii N/3
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6510,1,,,50296,,,,BAO_0000218,CHEMBL624387,,Chlorohexidine coefficient for Actinomyces naeslundii N/9
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6511,1,,,50296,,,,BAO_0000218,CHEMBL624388,,Plaque bactericidal index against Actinomyces naeslundii 631
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6512,1,,,50296,,,,BAO_0000218,CHEMBL624389,,Plaque bactericidal index against Actinomyces naeslundii N/9
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6513,1,,,50296,,,,BAO_0000218,CHEMBL624390,,Plaque bactericidal index against Actinomyces naeslundii B74
F,Actinomyces naeslundii,1655.0,,,1,Intermediate,,9560,,N,6514,1,,,50296,,,,BAO_0000218,CHEMBL875275,,Plaque bactericidal index against Actinomyces naeslundii N/3
F,Artemia salina,85549.0,,,1,Intermediate,,114,,N,6515,1,,,50056,,,,BAO_0000218,CHEMBL624391,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay
F,Artemia salina,85549.0,,,1,Intermediate,,114,,N,6516,1,,,50056,,,,BAO_0000218,CHEMBL623636,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity"
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6517,1,,,50532,,,,BAO_0000218,CHEMBL623637,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6518,1,,,50532,,,,BAO_0000218,CHEMBL623638,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6519,1,,,50532,,,,BAO_0000218,CHEMBL623639,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6520,1,,,50532,,,,BAO_0000218,CHEMBL623640,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6521,1,,,50532,,,,BAO_0000218,CHEMBL623641,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6522,1,,,50532,,,,BAO_0000218,CHEMBL623642,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6523,1,,,50532,,,,BAO_0000218,CHEMBL623643,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6524,1,,,50532,,,,BAO_0000218,CHEMBL623644,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6525,1,,,50532,,,,BAO_0000218,CHEMBL623645,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6526,1,,,50532,,,,BAO_0000218,CHEMBL623646,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6527,1,,,50532,,,,BAO_0000218,CHEMBL623647,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM
F,Ascaris suum,6253.0,,,1,Intermediate,,10841,,N,6528,1,,,50532,,,,BAO_0000218,CHEMBL623648,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,8117,,N,6529,1,,,50366,,,,BAO_0000218,CHEMBL623649,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,8117,,N,6530,1,,,50366,,,,BAO_0000218,CHEMBL623650,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6531,1,,,50366,,,,BAO_0000218,CHEMBL623651,,Chlorohexidine coefficient for Actinomyces viscosus 8A06
F,Actinomyces viscosus,1656.0,,,1,Expert,,9560,,N,6532,1,,,50366,,,,BAO_0000218,CHEMBL623652,,Chlorohexidine coefficient for Actinomyces viscosus M-100
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6533,1,,,50366,,,,BAO_0000218,CHEMBL623653,,Chlorohexidine coefficient for Actinomyces viscosus M-626
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6534,1,,,50366,,,,BAO_0000218,CHEMBL623654,,Chlorohexidine coefficient for Actinomyces viscosus T14V
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6535,1,,,50366,,,,BAO_0000218,CHEMBL623655,,Plaque bactericidal index against Actinomyces viscosus 8A06
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6536,1,,,50366,,,,BAO_0000218,CHEMBL623656,,Plaque bactericidal index against Actinomyces viscosus M-100
F,Actinomyces viscosus,1656.0,,,1,Expert,,9560,,N,6537,1,,,50366,,,,BAO_0000218,CHEMBL623657,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6538,1,,,50366,,,,BAO_0000218,CHEMBL623658,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6539,1,,,50366,,,,BAO_0000218,CHEMBL623659,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6540,1,,,50366,,,,BAO_0000218,CHEMBL623660,,Plaque bactericidal index against Actinomyces viscosus 626
F,Actinomyces viscosus,1656.0,,,1,Intermediate,,9560,,N,6541,1,,,50366,,,,BAO_0000218,CHEMBL623661,,Plaque bactericidal index against Actinomyces viscosus T14V
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6542,1,,,50535,,,,BAO_0000218,CHEMBL875281,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6543,1,,,50535,,,,BAO_0000218,CHEMBL623662,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6544,1,,,50535,,,,BAO_0000218,CHEMBL623663,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6545,1,,,50535,,,,BAO_0000218,CHEMBL623664,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6546,1,,,50535,,,,BAO_0000218,CHEMBL623665,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose
F,Homo sapiens,9606.0,,A673,1,Intermediate,,10708,,N,6547,1,165.0,,80023,,,,BAO_0000219,CHEMBL621856,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay
F,Homo sapiens,9606.0,,A704,1,Intermediate,,10708,,N,6548,1,645.0,,80661,,,,BAO_0000219,CHEMBL620432,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay
F,Rattus norvegicus,10116.0,,,1,Autocuration,,416,,U,6549,0,,,22226,,,,BAO_0000219,CHEMBL620433,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells
F,Mus musculus,10090.0,,A9,1,Intermediate,,14354,,N,6550,1,625.0,,80024,,,,BAO_0000219,CHEMBL620434,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
F,Mus musculus,10090.0,,A9,1,Intermediate,,14354,,N,6551,1,625.0,,80024,,,,BAO_0000219,CHEMBL620435,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
F,Homo sapiens,9606.0,,A9,1,Intermediate,,5116,,N,6552,1,625.0,,80024,,,,BAO_0000219,CHEMBL620436,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested
F,Homo sapiens,9606.0,,A9,1,Intermediate,,5116,,N,6553,1,625.0,,80024,,,,BAO_0000219,CHEMBL876597,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line
F,Homo sapiens,9606.0,,Human ovarian carcinoma cell line,1,Expert,,15694,,N,6554,1,874.0,,81037,,,,BAO_0000219,CHEMBL620437,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation
F,Mus musculus,10090.0,,A9,1,Expert,,13038,,N,6555,1,625.0,,80024,,,,BAO_0000219,CHEMBL620438,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM."
F,Mus musculus,10090.0,,A9,1,Expert,,13038,,N,6556,1,625.0,,80024,,,,BAO_0000219,CHEMBL620439,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.
F,Mus musculus,10090.0,,A9,1,Expert,,10923,,N,6557,1,625.0,,80024,,,,BAO_0000219,CHEMBL619657,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.
F,Mus musculus,10090.0,,A9,1,Intermediate,,10923,,N,6558,1,625.0,,80024,,,,BAO_0000219,CHEMBL619658,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined
F,Mus musculus,10090.0,,A9,1,Intermediate,,10923,,N,6559,1,625.0,,80024,,,,BAO_0000219,CHEMBL619659,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive
F,,,,,1,Expert,,10923,,H,6560,8,,,10649,,,,BAO_0000019,CHEMBL619660,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar"
F,Mus musculus,10090.0,,A9,1,Intermediate,,10923,,N,6561,1,625.0,,80024,,,,BAO_0000219,CHEMBL619661,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined
F,Mus musculus,10090.0,,A9,1,Intermediate,,10923,,N,6562,1,625.0,,80024,,,,BAO_0000219,CHEMBL619662,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive
F,Cricetulus griseus,10029.0,,AA6,1,Intermediate,,8158,,N,6563,1,975.0,,80663,,,,BAO_0000219,CHEMBL619663,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined
F,Homo sapiens,9606.0,,,1,Autocuration,,15494,,U,6564,0,,,22226,,,,BAO_0000219,CHEMBL619664,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.
F,Homo sapiens,9606.0,,,1,Autocuration,,15494,,U,6565,0,,,22226,,,,BAO_0000219,CHEMBL619665,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation."
F,Homo sapiens,9606.0,,AA5,1,Intermediate,,12348,,N,6566,1,974.0,,80662,,,,BAO_0000219,CHEMBL883244,,Anti -HIV activity was measured against AA5/HIV-1(IIIB)
F,Homo sapiens,9606.0,,AA5,1,Intermediate,,12348,,N,6567,1,974.0,,80662,,,,BAO_0000219,CHEMBL884011,,Cytotoxicity was measured against AA5/HIV-1(IIIB)
F,Homo sapiens,9606.0,,AA5,1,Intermediate,,2726,,N,6568,1,974.0,,80662,,,,BAO_0000219,CHEMBL619666,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell
F,Homo sapiens,9606.0,,U-937,1,Intermediate,,2726,,N,6569,1,379.0,,80566,,,,BAO_0000219,CHEMBL619667,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell
F,Cricetulus griseus,10029.0,,UV4,1,Intermediate,,10747,,N,6570,1,274.0,,80578,,,,BAO_0000219,CHEMBL619668,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,11005,,N,6571,1,185.0,,80089,,,,BAO_0000219,CHEMBL619669,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6572,1,185.0,,80089,,,,BAO_0000219,CHEMBL876608,,Average intracellular compound concentration when the hypoxic SER=1.6
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6573,1,185.0,,80089,,,,BAO_0000219,CHEMBL619670,,Average intracellular compound concentration when the hypoxic SER=1.6.
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6574,1,185.0,,80089,,,,BAO_0000219,CHEMBL619671,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6575,1,185.0,,80089,,,,BAO_0000219,CHEMBL619672,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6576,1,185.0,,80089,,,,BAO_0000219,CHEMBL619673,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13436,,N,6577,1,185.0,,80089,,,,BAO_0000219,CHEMBL619674,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay."
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13435,,N,6578,1,185.0,,80089,,,,BAO_0000219,CHEMBL619675,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml"
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13302,,N,6579,1,185.0,,80089,,,,BAO_0000219,CHEMBL619676,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6580,1,185.0,,80089,,,,BAO_0000219,CHEMBL619677,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6581,1,185.0,,80089,,,,BAO_0000219,CHEMBL619678,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6582,1,185.0,,80089,,,,BAO_0000219,CHEMBL619679,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,12878,,N,6583,1,185.0,,80089,,,,BAO_0000219,CHEMBL619680,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12878,,N,6584,1,185.0,,80089,,,,BAO_0000219,CHEMBL621457,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,14367,,N,6585,1,185.0,,80089,,,,BAO_0000219,CHEMBL876609,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,14367,,N,6586,1,185.0,,80089,,,,BAO_0000219,CHEMBL621458,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay
F,hampster,36483.0,,CHO-AA8,1,Expert,,12398,,N,6587,1,185.0,,80089,,,,BAO_0000219,CHEMBL621459,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,12878,,N,6588,1,185.0,,80089,,,,BAO_0000219,CHEMBL621460,,Aerobic growth inhibition in Chinese hamster cell line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,13820,,N,6589,1,185.0,,80089,,,,BAO_0000219,CHEMBL621461,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,13436,,N,6590,1,185.0,,80089,,,,BAO_0000219,CHEMBL621462,,Inhibition of growth under aerobic conditions in AA8 cells
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6591,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621463,,Oral bioavailability in dog (dose 10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5711,,N,6592,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621464,,Oral bioavailability in dog at 10 mg/kg of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,6593,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621465,,Oral bioavailability in dog (dose 5 uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,6594,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621466,,Oral bioavailability in dog (dose 5 uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17800,,N,6595,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621467,,Oral bioavailability in dog (mongrel)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3994,,N,6596,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621468,,Oral bioavailability in dog (dose 10 mg/kg)
F,Canis lupus familiaris,9615.0,,,1,Intermediate,,3994,,N,6597,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876734,,Oral bioavailability in dog (dose 10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5145,,N,6598,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618476,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,6599,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618477,,Bioavailability in dog (dose 1 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,6600,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618478,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,6601,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618479,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4273,,N,6602,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618480,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,6603,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618481,,Bioavailability in dog (dose 3-10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,6604,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618482,,The compound was tested for bioavailability of compound in plasma of dog; Complete
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,6605,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618483,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3880,,N,6606,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618484,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4838,,N,6607,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618485,,Bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15600,,N,6608,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618486,,oral bioavailability was measured in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,6609,1,,,50588,,,,BAO_0000218,CHEMBL618487,,Compound was tested for plasma protein binding in dog; Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,6610,1,,,50588,,,,BAO_0000218,CHEMBL618488,,Compound was tested for plasma protein binding of dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,6611,1,,,50588,,,,BAO_0000218,CHEMBL876735,,Compound was tested for plasma protein binding of dog; Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17443,,N,6612,1,,,50588,,,,BAO_0000218,CHEMBL618489,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4186,,N,6613,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618490,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3749,,N,6614,1,,,50588,,,,BAO_0000218,CHEMBL618491,,Half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3249,,N,6615,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618492,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3022,,N,6616,1,,,50588,,,,BAO_0000218,CHEMBL873354,,Half life was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3749,,N,6617,1,,,50588,,,,BAO_0000218,CHEMBL618493,,Half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6618,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618494,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6619,1,,,50588,Heart,948.0,In vivo,BAO_0000218,CHEMBL618495,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6620,1,,,50588,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618496,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6621,1,,,50588,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618497,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6622,1,,,50588,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618498,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2517,,N,6623,1,,,50588,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618499,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,6624,1,,,50588,,,,BAO_0000218,CHEMBL876736,,LogP in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6625,1,,,50588,,,,BAO_0000218,CHEMBL618500,,Partition coefficient (logP)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6626,1,,,50588,,,,BAO_0000218,CHEMBL857831,,Partition coefficient in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,6627,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618501,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,6628,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618502,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,6629,1,,,50588,,,,BAO_0000218,CHEMBL618503,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14294,,N,6630,1,,,50588,,,,BAO_0000218,CHEMBL618504,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14294,,N,6631,1,,,50588,,,,BAO_0000218,CHEMBL618505,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14294,,N,6632,1,,,50588,,,,BAO_0000218,CHEMBL618506,,Metabolism of compound in dog S9 microsomes; Trace
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6251,,N,6633,1,,,50588,Liver,2107.0,,BAO_0000218,CHEMBL618507,,In vitro metabolic potential in dog liver microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3748,,N,6634,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876737,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2713,,N,6635,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618508,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6512,,N,6636,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618509,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6679,,N,6637,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618510,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3749,,N,6638,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618511,,The compound was tested for bioavailability in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3749,,N,6639,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618512,,The compound was tested for oral bioavailability in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6742,,N,6640,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618513,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,6641,1,,,50588,,,,BAO_0000218,CHEMBL618514,,Compound was tested for percent protein binding (PB) in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6874,,N,6642,1,,,50588,,,,BAO_0000218,CHEMBL620052,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2877,,N,6643,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620053,,Compound was evaluated for plasma clearance.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,6644,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620054,,The compound was tested for plasma clearance in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,6645,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620055,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,6646,1,,,50588,,,,BAO_0000218,CHEMBL620056,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,6647,1,,,50588,Liver,2107.0,,BAO_0000218,CHEMBL620057,,In vitro relative rate of metabolism was determined in dog liver microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,6648,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618939,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,6649,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618940,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,6650,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618941,,Half life after intravenous administration in dogs at 1.2 uM/kg
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6651,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL624473,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6652,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL624474,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6653,1,42.0,,50594,Lung,2048.0,,BAO_0000218,CHEMBL624475,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6654,1,42.0,,50594,,,,BAO_0000218,CHEMBL624476,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6655,1,42.0,,50594,,,,BAO_0000218,CHEMBL623478,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6656,1,42.0,,50594,,,,BAO_0000218,CHEMBL623479,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6657,1,42.0,,50594,,,,BAO_0000218,CHEMBL623480,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours
A,Mus musculus,10090.0,,CCRF S-180,1,Intermediate,,6599,,N,6658,1,42.0,,50594,,,,BAO_0000218,CHEMBL623481,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6659,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL623482,,C2 in brain of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6660,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL623483,,C2 in kidney of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6661,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL623484,,C2 in liver of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6662,1,,,50594,Lung,2048.0,,BAO_0000218,CHEMBL623485,,C2 in lungs of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6663,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL623486,,C2 in spleen of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17852,,N,6664,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623487,,Plasma clearance in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6665,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623488,,Clearance of compound after intravenous administration in mice at 24 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,6666,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623489,,Clearance from mouse blood following i.v. administration of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6667,1,,,50594,,,In vivo,BAO_0000218,CHEMBL875157,,Clearance was evaluated in mice after intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6668,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623490,,Clearance was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,4239,,N,6669,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623491,,Pharmacokinetic property (Plasma clearance) was measured in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,6670,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623492,,Plasma clearance of compound was determined at 40 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,6671,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623493,,Plasma clearance of at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,6672,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623494,,Plasma clearance at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,6673,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623495,,Plasma clearance at 5 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,5727,,N,6674,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623496,,Plasma clearance in mice
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,6675,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623497,,Plasma clearance value upon iv administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,5980,,N,6676,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623498,,Total plasma clearance in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17592,,N,6677,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623499,,Clearance in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17718,,N,6678,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623500,,Clearance value was determined
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,6679,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623501,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.
P,,,,,1,Intermediate,,17384,,U,6680,0,,,22229,,,,BAO_0000100,CHEMBL875158,,Calculated partition coefficient (clogP)
A,Mus musculus,10090.0,,,1,Intermediate,,6062,,N,6681,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623502,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,6682,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623503,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,6683,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623504,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,6684,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623505,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,6685,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623506,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,6686,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623507,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,6687,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623508,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax
A,Mus musculus,10090.0,,,1,Intermediate,,5781,,N,6688,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623509,,Cmax after oral administration at 30 mg/kg in ICR mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6689,1,,,50594,,,In vivo,BAO_0000218,CHEMBL875159,,Cmax after peroral administration in mice at 2.4 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6690,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL623510,,Cmax in brain of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6691,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623511,,Cmax in kidney of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6692,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623512,,Cmax in liver of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6693,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623513,,Cmax in lungs of mice at the oral dose of 50 mg/kg
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6694,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623514,,Cmax in mice at 18 uM/kg i.p. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6695,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622609,,Cmax in mice at 23 uM/kg i.v. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6696,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622610,,Cmax in mice at 24 uM/kg i.p. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6697,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621823,,Cmax in mice at 25 uM/kg i.p. administration
F,Mus musculus,10090.0,,,1,Intermediate,,17764,,N,6698,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621824,,Cmax in mice at 26 uM/kg i.p. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17641,,N,6699,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621825,,Cmax in spleen of mice at the oral dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,6700,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621826,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,6701,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621827,,Cmax value at a dose of 10 mg/kg peroral administration in mice.
A,Mus musculus,10090.0,,,1,Intermediate,,5727,,N,6702,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621828,,Cmax value was determined
A,Mus musculus,10090.0,,,1,Intermediate,,5951,,N,6703,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621829,,Cmax value in IRC mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,6704,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621830,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,6705,1,,,50594,,,In vivo,BAO_0000218,CHEMBL621831,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,6706,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621832,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,4890,,N,6707,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624579,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration"
A,Mus musculus,10090.0,,,1,Intermediate,,429,,N,6708,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624580,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6709,1,,,50535,,,,BAO_0000218,CHEMBL624581,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6710,1,,,50535,,,,BAO_0000218,CHEMBL624582,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose
F,Acanthocheilonema viteae,6277.0,,,1,Intermediate,,10986,,N,6711,1,,,50535,,,,BAO_0000218,CHEMBL624583,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose
F,Homo sapiens,9606.0,,A-375,1,Intermediate,,13227,,N,6712,1,455.0,,80018,,,,BAO_0000219,CHEMBL624584,,Inhibitory activity against human tumor cell line A0375 melanoma.
B,Rattus norvegicus,10116.0,,,1,Expert,Brain membranes,4481,,D,6713,9,,,12512,,,,BAO_0000249,CHEMBL624585,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes
F,Homo sapiens,9606.0,,,1,Expert,,16931,,D,6714,9,,,114,,,,BAO_0000019,CHEMBL875165,,Forskolin-induced cAMP production at human A1 adenosine receptor
F,,,,CHO,1,Autocuration,,3850,,H,6715,8,449.0,,114,,,,BAO_0000219,CHEMBL619490,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.
F,,,,CHO,1,Autocuration,,3850,,H,6716,8,449.0,,114,,,,BAO_0000219,CHEMBL619491,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
F,,,,CHO,1,Expert,,3850,,H,6717,8,449.0,,114,,,,BAO_0000219,CHEMBL619492,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM
F,,,,CHO,1,Expert,,3850,,H,6718,8,449.0,,114,,,,BAO_0000219,CHEMBL619493,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration
F,,,,CHO,1,Autocuration,,3850,,H,6719,8,449.0,,114,,,,BAO_0000219,CHEMBL619494,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells
F,,,,CHO,1,Autocuration,,3850,,H,6720,8,449.0,,114,,,,BAO_0000219,CHEMBL619495,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement
F,,,,CHO,1,Autocuration,,3850,,H,6721,8,449.0,,114,,,,BAO_0000219,CHEMBL619496,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.
F,Homo sapiens,9606.0,,CHO,1,Expert,,3850,,D,6722,9,449.0,,114,,,,BAO_0000219,CHEMBL619497,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
F,,,,CHO,1,Autocuration,,3850,,H,6723,8,449.0,,114,,,,BAO_0000219,CHEMBL619498,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM
F,,,,CHO,1,Autocuration,,3850,,H,6724,8,449.0,,114,,,,BAO_0000219,CHEMBL619499,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.
F,,,,CHO,1,Expert,,3850,,H,6725,8,449.0,,114,,,,BAO_0000219,CHEMBL619500,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration
F,,,,CHO,1,Autocuration,,3850,,H,6726,8,449.0,,114,,,,BAO_0000219,CHEMBL619501,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.
F,,,,CHO,1,Expert,,3850,,H,6727,8,449.0,,114,,,,BAO_0000219,CHEMBL619502,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells
F,,,,CHO,1,Autocuration,,3850,,H,6728,8,449.0,,114,,,,BAO_0000219,CHEMBL619503,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM
F,,,,CHO,1,Autocuration,,3850,,H,6729,8,449.0,,114,,,,BAO_0000219,CHEMBL619504,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
F,,,,CHO,1,Autocuration,,3850,,H,6730,8,449.0,,114,,,,BAO_0000219,CHEMBL621298,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.
F,,,,CHO,1,Expert,,3850,,H,6731,8,449.0,,114,,,,BAO_0000219,CHEMBL621299,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration
F,,,,CHO,1,Autocuration,,3850,,H,6732,8,449.0,,114,,,,BAO_0000219,CHEMBL621300,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells
F,,,,CHO,1,Autocuration,,3850,,H,6733,8,449.0,,114,,,,BAO_0000219,CHEMBL621301,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.
F,,,,CHO,1,Expert,,3850,,H,6734,8,449.0,,114,,,,BAO_0000219,CHEMBL621302,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
F,Oryctolagus cuniculus,9986.0,,A10,1,Intermediate,,12680,,N,6735,1,164.0,,80013,,,,BAO_0000219,CHEMBL621303,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells
F,Rattus norvegicus,10116.0,,A10,1,Autocuration,,1313,,U,6736,0,164.0,,22226,,,,BAO_0000219,CHEMBL621304,,In vitro potassium channel opening activity in A10 (smooth muscle) cells
F,Rattus norvegicus,10116.0,,A10,1,Autocuration,,1313,,U,6737,0,164.0,,22226,,,,BAO_0000219,CHEMBL621305,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive
F,Rattus norvegicus,10116.0,,A10,1,Intermediate,,17567,,N,6738,1,164.0,,80013,,,,BAO_0000219,CHEMBL621306,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats
F,Rattus norvegicus,10116.0,,A10,1,Intermediate,,17567,,N,6739,1,164.0,,80013,,,,BAO_0000219,CHEMBL618444,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats
F,Rattus norvegicus,10116.0,,A10,1,Intermediate,,11819,,N,6740,1,164.0,,80013,,,,BAO_0000219,CHEMBL618445,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13436,,N,6741,1,185.0,,80089,,,,BAO_0000219,CHEMBL618446,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6742,1,185.0,,80089,,,,BAO_0000219,CHEMBL618447,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12651,,N,6743,1,185.0,,80089,,,,BAO_0000219,CHEMBL618448,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13300,,N,6744,1,185.0,,80089,,,,BAO_0000219,CHEMBL618449,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,15296,,N,6745,1,185.0,,80089,,,,BAO_0000219,CHEMBL618637,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,15328,,N,6746,1,185.0,,80089,,,,BAO_0000219,CHEMBL618638,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay."
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13302,,N,6747,1,185.0,,80089,,,,BAO_0000219,CHEMBL618639,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure)
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,14367,,N,6748,1,185.0,,80089,,,,BAO_0000219,CHEMBL618640,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure"
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,17002,,N,6749,1,185.0,,80089,,,,BAO_0000219,CHEMBL618641,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13436,,N,6750,1,185.0,,80089,,,,BAO_0000219,CHEMBL618642,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,13435,,N,6751,1,185.0,,80089,,,,BAO_0000219,CHEMBL618643,,Inhibitory activity against aerobic growth of AA8 cells.
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,10503,,N,6752,1,185.0,,80089,,,,BAO_0000219,CHEMBL884013,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,10503,,N,6753,1,185.0,,80089,,,,BAO_0000219,CHEMBL622723,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,10503,,N,6754,1,185.0,,80089,,,,BAO_0000219,CHEMBL622724,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,15090,,N,6755,1,185.0,,80089,,,,BAO_0000219,CHEMBL622725,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,10368,,N,6756,1,185.0,,80089,,,,BAO_0000219,CHEMBL622726,,Cytotoxicity against AA8 cell line
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12651,,N,6757,1,185.0,,80089,,,,BAO_0000219,CHEMBL622727,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4)
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6758,1,185.0,,80089,,,,BAO_0000219,CHEMBL622728,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6759,1,185.0,,80089,,,,BAO_0000219,CHEMBL622729,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,12687,,N,6760,1,185.0,,80089,,,,BAO_0000219,CHEMBL622730,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,1890,,N,6761,1,185.0,,80089,,,,BAO_0000219,CHEMBL622731,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,10747,,N,6762,1,185.0,,80089,,,,BAO_0000219,CHEMBL622732,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Intermediate,,10747,,N,6763,1,185.0,,80089,,,,BAO_0000219,CHEMBL622733,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
F,Cricetulus griseus,10029.0,,,1,Autocuration,,11616,,U,6764,0,,,22224,,,,BAO_0000218,CHEMBL622734,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose)
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,11616,,N,6765,1,185.0,,80089,,,,BAO_0000219,CHEMBL622735,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6766,0,185.0,,22224,,,,BAO_0000219,CHEMBL618746,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6767,0,185.0,,22224,,,,BAO_0000219,CHEMBL618747,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6768,0,185.0,,22224,,,,BAO_0000219,CHEMBL620540,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6769,0,185.0,,22224,,,,BAO_0000219,CHEMBL620541,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6770,0,185.0,,22224,,,,BAO_0000219,CHEMBL620542,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6771,0,185.0,,22224,,,,BAO_0000219,CHEMBL620543,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,3471,,U,6772,0,185.0,,22224,,,,BAO_0000219,CHEMBL618832,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,11616,,N,6773,1,185.0,,80089,,,,BAO_0000219,CHEMBL618833,,Concentration required to reduce AA8 cell survival by 10%
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,2656,,U,6774,0,185.0,,22224,,,,BAO_0000219,CHEMBL618834,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells"
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6775,0,185.0,,22224,,,,BAO_0000219,CHEMBL618835,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6776,0,185.0,,22224,,,,BAO_0000219,CHEMBL618836,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6777,0,185.0,,22224,,,,BAO_0000219,CHEMBL618837,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6778,0,185.0,,22224,,,,BAO_0000219,CHEMBL618838,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,16156,,U,6779,0,185.0,,22224,,,,BAO_0000219,CHEMBL618839,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,2656,,U,6780,0,185.0,,22224,,,,BAO_0000219,CHEMBL618840,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells
F,Cricetulus griseus,10029.0,,,1,Autocuration,,11005,,U,6781,0,,,22224,,,,BAO_0000019,CHEMBL618841,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,11942,,U,6782,0,185.0,,22224,,,,BAO_0000219,CHEMBL618842,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,2128,,U,6783,0,185.0,,22224,,,,BAO_0000219,CHEMBL618843,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6784,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618844,,Half life period after 15 mg/kg iv dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6785,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618845,,Half life period after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6786,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618846,,Half life was measured after oral 2b administration (tested in 6 dogs)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6787,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618847,,Half life was measured in dog after oral 17b administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6788,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618848,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9579,,N,6789,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618849,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6790,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618850,,Tmax value after 15 mg/kg iv dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6791,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618851,,Tmax value after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3184,,N,6792,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873815,,Compound was evaluated for its half life when administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5017,,N,6793,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618852,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6821,,N,6794,1,,,50588,,,,BAO_0000218,CHEMBL618853,,Elimination Half-life of compound was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,6795,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618854,,Half life of compound in dog following oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17267,,N,6796,1,,,50588,,,,BAO_0000218,CHEMBL618855,,Half life of compound was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4727,,N,6797,1,,,50588,Blood,178.0,,BAO_0000218,CHEMBL618856,,Half life of compound was determined in dog blood
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5238,,N,6798,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875827,,Half life after oral and iv dosing in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4942,,N,6799,1,,,50588,,,,BAO_0000218,CHEMBL618857,,Half life in dogs in hours
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6505,,N,6800,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618858,,Half life on i.v. administration of 2 mg/kg was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5130,,N,6801,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618859,,t1/2 in dog after oral dose (1 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1475,,N,6802,1,,,50588,,,,BAO_0000218,CHEMBL618860,,Half life was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17804,,N,6803,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618861,,Half life period of compound was determined after intravenous administration at 2 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17804,,N,6804,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622539,,Half life period of compound was determined after peroral administration at 2 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6805,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622540,,Half life period (10 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6806,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873803,,Half life period (10 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,6807,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873804,,Half life period by iv administration in dog at a dose of 0.3 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,6808,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624311,,Half life period by po administration in dog at a dose of 0.3 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6084,,N,6809,1,,,50588,,,,BAO_0000218,CHEMBL624312,,Half life period in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6241,,N,6810,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624313,,Half life period in dogs after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1916,,N,6811,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624314,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6621,,N,6812,1,,,50588,,,,BAO_0000218,CHEMBL624315,,Half-life of compound was determined in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1696,,N,6813,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624316,,Half-life in dog plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17800,,N,6814,1,,,50588,,,,BAO_0000218,CHEMBL624317,,Half-life in mongrel dogs was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,6815,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624318,,Half-life in dog upon oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17657,,N,6816,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624319,,Half-life in dog upon oral administration; Unable to calculate
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4239,,N,6817,1,,,50588,,,,BAO_0000218,CHEMBL624496,,Half-life was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5985,,N,6818,1,,,50588,,,,BAO_0000218,CHEMBL624497,,Half-life was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9932,,N,6819,1,,,50588,,,,BAO_0000218,CHEMBL624498,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,6820,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624499,,Oral half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,6821,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624500,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1475,,N,6822,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL624501,,Plasma half life was evaluated
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1475,,N,6823,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623666,,Plasma half life was evaluated in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1475,,N,6824,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623667,,Plasma half life was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6316,,N,6825,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623668,,T1/2 (Half-life) was after oral administration at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4883,,N,6826,1,,,50588,,,,BAO_0000218,CHEMBL623669,,Tested for the half life value in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4727,,N,6827,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623670,,Maximum time at the dose of 2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1916,,N,6828,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623671,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,6829,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL875945,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,6830,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL623672,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6265,,N,6831,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623673,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,6832,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623674,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5983,,N,6833,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623675,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,6834,1,,,50588,,,,BAO_0000218,CHEMBL872526,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5313,,N,6835,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623676,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17650,,N,6836,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623677,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,6837,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623678,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,933,,N,6838,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL623679,,Time taken for maximum plasma concentration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,6839,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623680,,Time to reach Cmax after oral administration to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,6840,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623681,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6316,,N,6841,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623682,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6215,,N,6842,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623683,,Tmax after peroral administration (1 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,6843,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623684,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,6844,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622745,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,6845,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622746,,Tmax after peroral administration in dogs at 2.4 uM/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,6846,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622747,,In vivo Cmax in mice at dose of 100 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5969,,N,6847,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622748,,In vivo Cmax in mice at dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,4573,,N,6848,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622749,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice
A,Mus musculus,10090.0,,,1,Intermediate,,3277,,N,6849,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622750,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,6850,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623411,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,6851,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875946,,Maximum concentration obtained in mouse plasma was determined
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,6852,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623412,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,6853,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623413,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,6854,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623414,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,6855,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623415,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,6856,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623416,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,6857,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623417,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,6858,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623418,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,6859,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623419,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,4066,,N,6860,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622816,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6178,,N,6861,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623313,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6178,,N,6862,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623314,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6863,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876788,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6864,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623315,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6865,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623316,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,6866,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623317,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice
A,Mus musculus,10090.0,,,1,Intermediate,,5961,,N,6868,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623319,,Cmax in male mice after 2 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,6137,,N,6869,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623320,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine
A,Mus musculus,10090.0,,,1,Intermediate,,3802,,N,6870,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623321,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6871,1,,,50594,,,,BAO_0000218,CHEMBL623322,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6872,1,,,50594,,,,BAO_0000218,CHEMBL623323,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6873,1,,,50594,,,,BAO_0000218,CHEMBL623324,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6874,1,,,50594,,,,BAO_0000218,CHEMBL623325,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6875,1,,,50594,,,,BAO_0000218,CHEMBL623326,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,3535,,N,6876,1,,,50594,,,,BAO_0000218,CHEMBL623327,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,6877,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL623328,,Maximum concentration in plasma upon oral administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6878,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL623329,,Maximum plasma concentration was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,6879,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623330,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,5399,,N,6880,1,,,50594,,,,BAO_0000218,CHEMBL876789,,Dose at which the compound induced fecal excretion in mice
F,Rattus norvegicus,10116.0,,A10,1,Expert,,11819,,N,6893,1,164.0,,80013,,,,BAO_0000219,CHEMBL623333,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM
F,Rattus norvegicus,10116.0,,A10,1,Expert,,11819,,N,6894,1,164.0,,80013,,,,BAO_0000219,CHEMBL623334,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM
F,Rattus norvegicus,10116.0,,A10,1,Expert,,11819,,N,6895,1,164.0,,80013,,,,BAO_0000219,CHEMBL627536,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM
F,Rattus norvegicus,10116.0,,A10,1,Expert,,11819,,N,6896,1,164.0,,80013,,,,BAO_0000219,CHEMBL627537,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM
F,Rattus norvegicus,10116.0,,A10,1,Intermediate,,16361,,N,6897,1,164.0,,80013,,,,BAO_0000219,CHEMBL627538,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM)
F,Homo sapiens,9606.0,,A121,1,Intermediate,,2288,,N,6898,1,393.0,,80655,,,,BAO_0000219,CHEMBL884106,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
F,Homo sapiens,9606.0,,A121,1,Intermediate,,10404,,N,6899,1,393.0,,80655,,,,BAO_0000219,CHEMBL625294,,Anticancer activity against human ovarian carcinoma A121 cells
F,Homo sapiens,9606.0,,A121,1,Intermediate,,14790,,N,6900,1,393.0,,80655,,,,BAO_0000219,CHEMBL625295,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM
F,Homo sapiens,9606.0,,A121,1,Intermediate,,14790,,N,6901,1,393.0,,80655,,,,BAO_0000219,CHEMBL625296,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM
F,Homo sapiens,9606.0,,A121,1,Expert,,14253,,N,6902,1,393.0,,80655,,,,BAO_0000219,CHEMBL625297,,Growth inhibition of human ovarian carcinoma (A121) cell line
F,Homo sapiens,9606.0,,A121,1,Expert,,13617,,N,6903,1,393.0,,80655,,,,BAO_0000219,CHEMBL625298,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
F,Homo sapiens,9606.0,,A121,1,Intermediate,,1003,,N,6904,1,393.0,,80655,,,,BAO_0000219,CHEMBL625960,,Cytotoxicity against human A121 ovarian cells
F,Homo sapiens,9606.0,,A121,1,Intermediate,,830,,N,6905,1,393.0,,80655,,,,BAO_0000219,CHEMBL625961,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
F,Homo sapiens,9606.0,,A121,1,Intermediate,,12307,,N,6906,1,393.0,,80655,,,,BAO_0000219,CHEMBL625962,,In vitro cytotoxicity against human ovarian carcinoma A21
F,Homo sapiens,9606.0,,A121,1,Intermediate,,14254,,N,6907,1,393.0,,80655,,,,BAO_0000219,CHEMBL624717,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
F,Homo sapiens,9606.0,,A121,1,Intermediate,,13370,,N,6908,1,393.0,,80655,,,,BAO_0000219,CHEMBL624718,,Inhibitory activity of compound against human A121 ovarian cell line.
F,Homo sapiens,9606.0,,A121,1,Intermediate,,14790,,N,6909,1,393.0,,80655,,,,BAO_0000219,CHEMBL624719,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.
F,Homo sapiens,9606.0,,A121,1,Intermediate,,3614,,N,6910,1,393.0,,80655,,,,BAO_0000219,CHEMBL624720,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,2664,,N,6911,1,622.0,,80012,,,,BAO_0000219,CHEMBL624721,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line
F,Homo sapiens,9606.0,,A 172,1,Expert,,2037,,N,6912,1,622.0,,80012,,,,BAO_0000219,CHEMBL624722,,In vitro cytotoxicity against A172 human tumor cell lines.
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,14539,,N,6913,1,622.0,,80012,,,,BAO_0000219,CHEMBL877597,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,2836,,N,6914,1,622.0,,80012,,,,BAO_0000219,CHEMBL624723,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line
F,Homo sapiens,9606.0,,A 172,1,Intermediate,,10708,,N,6915,1,622.0,,80012,,,,BAO_0000219,CHEMBL624724,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
B,Canis lupus familiaris,9615.0,,,1,Autocuration,,8975,,H,6916,4,,,104729,,,,BAO_0000224,CHEMBL624725,,Association constant against A2 adenosine receptor
F,fish,,,A2,1,Intermediate,,7645,,N,6917,1,1085.0,,80656,,,,BAO_0000219,CHEMBL624726,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma
B,Rattus norvegicus,10116.0,,,1,Autocuration,,11377,,D,6918,5,,,104713,,,,BAO_0000224,CHEMBL857535,,Ratio of Ki for adenosine A2 and A1 receptor binding
F,Homo sapiens,9606.0,,A204,1,Expert,,13528,,N,6919,1,623.0,,80014,,,,BAO_0000219,CHEMBL624727,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line
F,Homo sapiens,9606.0,,A204,1,Expert,,10160,,N,6920,1,623.0,,80014,,,,BAO_0000219,CHEMBL624728,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined
F,Homo sapiens,9606.0,,A2058,1,Intermediate,,15144,,N,6921,1,404.0,,80015,,,,BAO_0000219,CHEMBL624729,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,13160,,N,6922,1,973.0,,80657,,,,BAO_0000219,CHEMBL624730,,Growth inhibition against Human squamous cell line(A 253)
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,12898,,N,6923,1,973.0,,80657,,,,BAO_0000219,CHEMBL624731,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,13069,,N,6924,1,973.0,,80657,,,,BAO_0000219,CHEMBL624732,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,15984,,N,6925,1,973.0,,80657,,,,BAO_0000219,CHEMBL883245,,Growth inhibition of A253 cell lines.
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,15564,,N,6926,1,973.0,,80657,,,,BAO_0000219,CHEMBL624733,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h)
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,15564,,N,6927,1,973.0,,80657,,,,BAO_0000219,CHEMBL624734,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
F,Homo sapiens,9606.0,,A253 cell line,1,Intermediate,,15564,,N,6928,1,973.0,,80657,,,,BAO_0000219,CHEMBL624735,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4720,,N,6929,1,478.0,,81034,,,,BAO_0000219,CHEMBL621780,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16112,,N,6930,1,478.0,,81034,,,,BAO_0000219,CHEMBL877598,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,6931,1,478.0,,81034,,,,BAO_0000219,CHEMBL621781,,Cytotoxic activity against A2780 human ovarian carcinoma cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16378,,N,6932,1,478.0,,81034,,,,BAO_0000219,CHEMBL621782,,Cytotoxicity against human cancer cell lines A2780 (ovarian)
F,Homo sapiens,9606.0,,A2780,1,Expert,,16085,,N,6933,1,478.0,,81034,,,,BAO_0000219,CHEMBL621783,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16317,,N,6934,1,478.0,,81034,,,,BAO_0000219,CHEMBL621784,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15748,,N,6935,1,478.0,,81034,,,,BAO_0000219,CHEMBL621785,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,6936,1,478.0,,81034,,,,BAO_0000219,CHEMBL621968,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,6937,1,478.0,,81034,,,,BAO_0000219,CHEMBL621969,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation
F,Homo sapiens,9606.0,,A2780,1,Expert,,16597,,N,6938,1,478.0,,81034,,,,BAO_0000219,CHEMBL621970,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,6939,1,478.0,,81034,,,,BAO_0000219,CHEMBL621971,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,6940,1,478.0,,81034,,,,BAO_0000219,CHEMBL621972,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,6941,1,478.0,,81034,,,,BAO_0000219,CHEMBL884108,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5
F,Cricetulus griseus,10029.0,,,1,Autocuration,,15296,,U,6942,0,,,22224,,,,BAO_0000019,CHEMBL623826,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
A,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10251,,U,6943,0,185.0,,22224,,,,BAO_0000219,CHEMBL623827,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10251,,U,6944,0,185.0,,22224,,,,BAO_0000219,CHEMBL623828,,Evaluated for growth inhibition of AA8 cells under aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10251,,U,6945,0,185.0,,22224,,,,BAO_0000219,CHEMBL623829,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10251,,U,6946,0,185.0,,22224,,,,BAO_0000219,CHEMBL623830,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2)
F,Cricetulus griseus,10029.0,,,1,Autocuration,,11858,,U,6947,0,,,22224,,,,BAO_0000019,CHEMBL623831,,Growth inhibition against CHO-derived cell line AA8
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,11858,,U,6948,0,185.0,,22224,,,,BAO_0000219,CHEMBL623832,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control]
F,hampster,36483.0,,CHO-AA8,1,Expert,,11616,,N,6949,1,185.0,,80089,,,,BAO_0000219,CHEMBL623833,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,11616,,N,6950,1,185.0,,80089,,,,BAO_0000219,CHEMBL623834,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6951,0,185.0,,22224,,,,BAO_0000219,CHEMBL623835,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,11396,,U,6952,0,185.0,,22224,,,,BAO_0000219,CHEMBL623836,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Autocuration,,10518,,U,6953,0,185.0,,22224,,,,BAO_0000219,CHEMBL623837,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay
F,Cricetulus griseus,10029.0,,CHO-AA8,1,Expert,,11616,,N,6954,1,185.0,,80089,,,,BAO_0000219,CHEMBL623838,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.
F,,,,,1,Autocuration,,14837,,H,6955,8,,,12675,,,,BAO_0000019,CHEMBL623839,,compound was evaluated for association constant (Ka) of isolated serum protein AAG
F,,,,,1,Autocuration,,14837,,H,6956,8,,,12675,,,,BAO_0000019,CHEMBL623840,,Number of binding sites (n) of isolated serum protein AAG
B,,,,,1,Intermediate,,16037,,M,6957,3,,,22222,,,,BAO_0000225,CHEMBL623841,,Association constant for binding to AATT duplex
F,Homo sapiens,9606.0,,ABAE,1,Expert,,16597,,N,6958,1,416.0,,100090,,,,BAO_0000219,CHEMBL623842,,Inhibition of ABAE human fibroblast cell proliferation
F,Mus musculus,10090.0,,AC755,1,Intermediate,,8831,,N,6959,1,1064.0,,80668,,,,BAO_0000218,CHEMBL623843,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg"
F,Oryctolagus cuniculus,9986.0,,,1,Expert,,13419,,D,6960,9,,,102444,,,,BAO_0000218,CHEMBL618669,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model
F,Oryctolagus cuniculus,9986.0,,,1,Expert,,13419,,D,6961,9,,,102444,,,In vivo,BAO_0000218,CHEMBL618670,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay
B,,,,,1,Autocuration,,15778,,H,6962,8,,,69,,,,BAO_0000357,CHEMBL618671,,Inhibitory activity against angiotensin-converting enzyme (ACE).
B,,,,,1,Autocuration,,15778,,H,6963,8,,,69,,,,BAO_0000357,CHEMBL618672,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.
F,Homo sapiens,9606.0,,ACH-2 cell line,1,Intermediate,,12988,,N,6964,1,978.0,,80669,,,,BAO_0000219,CHEMBL618673,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells
F,Homo sapiens,9606.0,,ACH-2 cell line,1,Intermediate,,12988,,N,6965,1,978.0,,80669,,,,BAO_0000219,CHEMBL618674,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate)
F,Human immunodeficiency virus 1,11676.0,,T cell line,1,Autocuration,,12988,,U,6966,0,998.0,,22224,,,,BAO_0000219,CHEMBL618675,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2
F,Human immunodeficiency virus 1,11676.0,,T cell line,1,Autocuration,,12988,,U,6967,0,998.0,,22224,,,,BAO_0000219,CHEMBL618676,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate)
F,Human immunodeficiency virus 1,11676.0,,T cell line,1,Autocuration,,12988,,U,6968,0,998.0,,22224,,,,BAO_0000219,CHEMBL618677,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate)
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,11843,,N,6969,1,626.0,,80025,,,,BAO_0000219,CHEMBL618678,,Inhibition of growth of renal cancer ACHN cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,16939,,N,6970,1,626.0,,80025,,,,BAO_0000219,CHEMBL618679,,Inhibition of growth of ACHN renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,4782,,N,6971,1,626.0,,80025,,,,BAO_0000219,CHEMBL618680,,Inhibitory concentration required against ACHN renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Expert,,6310,,N,6972,1,626.0,,80025,,,,BAO_0000219,CHEMBL618681,,Concentration required to inhibit growth of human renal (ACHN) cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,6310,,N,6973,1,626.0,,80025,,,,BAO_0000219,CHEMBL618682,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12858,,N,6974,1,626.0,,80025,,,,BAO_0000219,CHEMBL618683,,Cytotoxic activity against ACHN Renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,17380,,N,6975,1,626.0,,80025,,,,BAO_0000219,CHEMBL618684,,Cytotoxicity evaluation against ACHN renal cancer cells
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,5858,,N,6976,1,626.0,,80025,,,,BAO_0000219,CHEMBL618685,,In vitro antitumor activity against human renal ACHN cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,3838,,N,6977,1,626.0,,80025,,,,BAO_0000219,CHEMBL876499,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,3838,,N,6978,1,626.0,,80025,,,,BAO_0000219,CHEMBL618686,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,5406,,N,6979,1,626.0,,80025,,,,BAO_0000219,CHEMBL618687,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported"
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,4071,,N,6980,1,626.0,,80025,,,,BAO_0000219,CHEMBL618688,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
F,Homo sapiens,9606.0,,ACHN,1,Expert,,4071,,N,6981,1,626.0,,80025,,,,BAO_0000219,CHEMBL618689,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,4071,,N,6982,1,626.0,,80025,,,,BAO_0000219,CHEMBL618690,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15002,,N,6983,1,626.0,,80025,,,,BAO_0000219,CHEMBL618691,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,14769,,N,6984,1,626.0,,80025,,,,BAO_0000219,CHEMBL619373,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,13958,,N,6985,1,626.0,,80025,,,,BAO_0000219,CHEMBL884008,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma"
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,1665,,N,6986,1,626.0,,80025,,,,BAO_0000219,CHEMBL619374,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15354,,N,6987,1,626.0,,80025,,,,BAO_0000219,CHEMBL619375,,Compound was tested for the growth inhibition of ACHN renal tumor cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15354,,N,6988,1,626.0,,80025,,,,BAO_0000219,CHEMBL619376,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,13978,,N,6989,1,626.0,,80025,,,,BAO_0000219,CHEMBL619377,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,6798,,N,6990,1,626.0,,80025,,,,BAO_0000219,CHEMBL619378,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,6991,1,,,50588,,,In vivo,BAO_0000218,CHEMBL872527,,Tmax value after administration of 4 mg/Kg oral dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9932,,N,6992,1,,,50588,,,,BAO_0000218,CHEMBL876500,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5546,,N,6993,1,,,50588,,,,BAO_0000218,CHEMBL619379,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6994,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619538,,Volume distribution after 15 mg/kg iv dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,6995,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619539,,Volume distribution after 30 mg/kg po dose in Dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4257,,N,6996,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619540,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4305,,N,6997,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619541,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,6998,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619542,,Volume of distribution was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6062,,N,6999,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619543,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Expert,,3598,,N,7000,1,,,50588,,,,BAO_0000218,CHEMBL619544,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,7001,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619545,,The compound was tested for volume of distribution in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,7002,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619546,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,7003,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619547,,Vd (1 mg/kg) was determined in dog (in vivo)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,7004,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619548,,Vd in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4219,,N,7005,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619549,,Volume distribution was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1696,,N,7006,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619550,,Volume of distribution in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5542,,N,7007,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876501,,Volume of distribution by as 4 fold increase by iv administration in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5199,,N,7008,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619551,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,7009,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619552,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4727,,N,7010,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619553,,Volume distribution at the dose of 2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,7011,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618722,,Steady state volume of distribution was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,7012,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618723,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7013,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618724,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7014,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618725,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7015,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618726,,Bioavailability in dog (dose 1 mg/kg i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,7016,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618727,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4239,,N,7017,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624233,,Pharmacokinetic property (vdss) was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,7018,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624234,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,7019,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624235,,Vdss was determined after iv 0.1 mg/kg administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,7020,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624236,,Volume displacement was calculated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5654,,N,7021,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624237,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5505,,N,7022,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624238,,Volume distribution constant was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,7023,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624239,,Volume distribution at a dose of 1 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,7024,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875829,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,7025,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624240,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,7026,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624241,,Volume distribution (Vdss) was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,7027,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624242,,Volume distribution (Vdss) was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6679,,N,7028,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624243,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5145,,N,7029,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624244,,Volume of distribution in steady state was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6821,,N,7030,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624245,,Volume of distribution of compound was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4137,,N,7031,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624246,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5334,,N,7032,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624247,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,7033,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624248,,Volume of distribution (Vdss) was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,7034,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624249,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6641,,N,7035,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624250,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,7036,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624251,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11659,,N,7037,1,,,50588,,,,BAO_0000218,CHEMBL624252,,Maximum rate of depolarization of the upstroke of the action potential
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,7038,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624253,,Steady state volume distribution in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,7039,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624950,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1466,,N,7040,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624951,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,7041,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875830,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,7042,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624952,,Volume distribution in dog after administration of 1 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17764,,N,7043,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624953,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6215,,N,7044,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624954,,Vss after intravenous administration (0.5 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6505,,N,7045,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624955,,Vss on i.v. administration of 2 mg/kg was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,7046,1,,,50588,,,,BAO_0000218,CHEMBL624956,,Vss was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,7047,1,,,50588,,,,BAO_0000218,CHEMBL625129,,Vss in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6062,,N,7048,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625130,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4942,,N,7049,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625131,,Volume distribution in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17796,,N,7050,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625132,,Volume of distribution in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4883,,N,7051,1,,,50588,,,In vivo,BAO_0000218,CHEMBL872263,,Tested for the oral bioavailability in dog
A,Mus musculus,10090.0,,,1,Intermediate,,17837,,N,7060,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624336,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,7061,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624337,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,7062,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624338,,Bioavailability after peroral administration of 50 mg/kg of dose in mice
A,Mus musculus,10090.0,,,1,Intermediate,,4239,,N,7063,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624339,,Bioavailability was measured in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,17592,,N,7064,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624340,,Bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,7065,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624341,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
A,Mus musculus,10090.0,,,1,Intermediate,,2801,,N,7066,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624342,,Bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2801,,N,7067,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624343,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17718,,N,7068,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624344,,Oral bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,5727,,N,7069,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624345,,Oral availability at 50 mg/kg po in male mice
A,Mus musculus,10090.0,,,1,Intermediate,,5302,,N,7070,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624346,,Oral bioavailability in mouse (dose 10 mg/kg)
A,Mus musculus,10090.0,,,1,Expert,,3598,,N,7071,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624347,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,5961,,N,7072,1,,,50594,,,In vivo,BAO_0000218,CHEMBL624348,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose"
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,7074,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622754,,Oral bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6091,,N,7075,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622755,,Oral bioavailability in vivo in mice;ND=Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,5711,,N,7076,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622756,,Oral bioavailability in mouse at 10 mg/kg of the compound
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,7077,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622757,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.)
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,7078,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622758,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.)
A,Mus musculus,10090.0,,,1,Intermediate,,3802,,N,7079,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622759,,Tested for bioavailability of the compound
A,Mus musculus,10090.0,,,1,Intermediate,,3802,,N,7080,1,,,50594,,,In vivo,BAO_0000218,CHEMBL622760,,Tested for half life at the dose of 10 mg/kg when administered intravenously
A,Mus musculus,10090.0,,,1,Intermediate,,14029,,N,7081,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622761,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. 
A,Mus musculus,10090.0,,,1,Intermediate,,14029,,N,7082,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622762,,The plasma half life of compound was determined on heparin prepared by human plasma. 
A,Mus musculus,10090.0,,,1,Intermediate,,14029,,N,7083,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622763,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded
A,Mus musculus,10090.0,,,1,Intermediate,,14029,,N,7084,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622764,,The plasma half life of compound was determined on heparin prepared by mouse plasma. 
A,Mus musculus,10090.0,,,1,Intermediate,,14029,,N,7085,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622765,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded
F,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,7086,1,,,50594,,,,BAO_0000218,CHEMBL622766,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,7087,1,,,50594,,,,BAO_0000218,CHEMBL622767,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,17753,,N,7088,1,,,50594,,,,BAO_0000218,CHEMBL622768,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7089,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL875948,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7090,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622769,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7091,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622770,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7092,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622771,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7093,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622772,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7094,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622773,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7095,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622774,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7096,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL621725,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7097,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL621726,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15608,,N,7098,1,478.0,,81034,,,,BAO_0000219,CHEMBL621727,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8
F,Homo sapiens,9606.0,,A2780,1,Expert,,3290,,N,7099,1,478.0,,81034,,,,BAO_0000219,CHEMBL622413,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2859,,N,7100,1,478.0,,81034,,,,BAO_0000219,CHEMBL622414,,Compound was evaluated for cytotoxicity against A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,15688,,N,7101,1,478.0,,81034,,,,BAO_0000219,CHEMBL622415,,Inhibition of A2780 cell clonogenic assay
F,Homo sapiens,9606.0,,A2780,1,Expert,,5642,,N,7102,1,478.0,,81034,,,,BAO_0000219,CHEMBL884001,,Cytotoxic effect on ovarian cancer cell line (A2780)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,6633,,N,7103,1,478.0,,81034,,,,BAO_0000219,CHEMBL622416,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3906,,N,7104,1,478.0,,81034,,,,BAO_0000219,CHEMBL622417,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL"
F,Homo sapiens,9606.0,,A2780,1,Expert,,6788,,N,7105,1,478.0,,81034,,,,BAO_0000219,CHEMBL622590,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells
F,Homo sapiens,9606.0,,A2780,1,Expert,,17582,,N,7106,1,478.0,,81034,,,,BAO_0000219,CHEMBL622591,,Antiproliferative activity against human A2780 cells
F,Homo sapiens,9606.0,,A2780,1,Expert,,17764,,N,7107,1,478.0,,81034,,,,BAO_0000219,CHEMBL622592,,Inhibition of human A2780 cell proliferation
F,Homo sapiens,9606.0,,A2780,1,Expert,,17764,,N,7108,1,478.0,,81034,,,,BAO_0000219,CHEMBL622593,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay
F,Homo sapiens,9606.0,,A2780,1,Expert,,17764,,N,7109,1,478.0,,81034,,,,BAO_0000219,CHEMBL622594,,Inhibition of human A2780 cell proliferation (No data)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,2815,,N,7110,1,478.0,,81034,,,,BAO_0000219,CHEMBL622595,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16930,,N,7111,1,478.0,,81034,,,,BAO_0000219,CHEMBL622596,,Compound was evaluated against human Ovarian carcinoma cell line A2780
F,Homo sapiens,9606.0,,A2780,1,Expert,,17777,,N,7112,1,478.0,,81034,,,,BAO_0000219,CHEMBL622597,,Growth inhibition against A2780 wild-type ovarian cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17777,,N,7113,1,478.0,,81034,,,,BAO_0000219,CHEMBL622598,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data
F,Homo sapiens,9606.0,,,1,Autocuration,,16936,,D,7114,5,,,104766,,,,BAO_0000019,CHEMBL622599,,Inhibition of tubulin polymerization in human ovarian cancer cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13759,,N,7115,1,478.0,,81034,,,,BAO_0000219,CHEMBL622600,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13759,,N,7116,1,478.0,,81034,,,,BAO_0000219,CHEMBL622601,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13759,,N,7117,1,478.0,,81034,,,,BAO_0000219,CHEMBL622602,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13759,,N,7118,1,478.0,,81034,,,,BAO_0000219,CHEMBL622603,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15292,,N,7119,1,478.0,,81034,,,,BAO_0000219,CHEMBL622604,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15292,,N,7120,1,478.0,,81034,,,,BAO_0000219,CHEMBL622605,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values
F,Homo sapiens,9606.0,,A2780,1,Expert,,15069,,N,7121,1,478.0,,81034,,,,BAO_0000219,CHEMBL622606,,In vitro inhibition of human ovarian cell line A2780
F,Homo sapiens,9606.0,,A2780,1,Expert,,15069,,N,7122,1,478.0,,81034,,,,BAO_0000219,CHEMBL619463,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR)."
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,14073,,N,7123,1,478.0,,81034,,,,BAO_0000219,CHEMBL619464,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
F,Homo sapiens,9606.0,,A2780,1,Expert,,14553,,N,7124,1,478.0,,81034,,,,BAO_0000219,CHEMBL619465,,Concentration required to inhibit A2780-cell growth by 50%
F,Homo sapiens,9606.0,,A2780,1,Expert,,13040,,N,7125,1,478.0,,81034,,,,BAO_0000219,CHEMBL619466,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.
F,Homo sapiens,9606.0,,A2780,1,Expert,,6891,,N,7126,1,478.0,,81034,,,,BAO_0000219,CHEMBL619467,,Cytotoxic effect on human ovarian (A2780) cancer cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15569,,N,7127,1,478.0,,81034,,,,BAO_0000219,CHEMBL619468,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure
F,Homo sapiens,9606.0,,A2780,1,Expert,,14190,,N,7128,1,478.0,,81034,,,,BAO_0000219,CHEMBL619469,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs
F,Homo sapiens,9606.0,,A2780,1,Expert,,15014,,N,7129,1,478.0,,81034,,,,BAO_0000219,CHEMBL619470,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15014,,N,7130,1,478.0,,81034,,,,BAO_0000219,CHEMBL619471,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17496,,N,7131,1,478.0,,81034,,,,BAO_0000219,CHEMBL619472,,Cytotoxicity against human ovarian carcinoma A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13617,,N,7132,1,478.0,,81034,,,,BAO_0000219,CHEMBL619473,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13617,,N,7133,1,478.0,,81034,,,,BAO_0000219,CHEMBL874368,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13617,,N,7134,1,478.0,,81034,,,,BAO_0000219,CHEMBL884003,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13617,,N,7135,1,478.0,,81034,,,,BAO_0000219,CHEMBL622690,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17672,,N,7136,1,478.0,,81034,,,,BAO_0000219,CHEMBL622691,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4544,,N,7137,1,478.0,,81034,,,,BAO_0000219,CHEMBL622692,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4544,,N,7138,1,478.0,,81034,,,,BAO_0000219,CHEMBL623406,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16317,,N,7139,1,478.0,,81034,,,,BAO_0000219,CHEMBL884004,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15099,,N,7140,1,478.0,,81034,,,,BAO_0000219,CHEMBL623407,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,13978,,N,7141,1,478.0,,81034,,,,BAO_0000219,CHEMBL623408,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,12989,,N,7142,1,478.0,,81034,,,,BAO_0000219,CHEMBL623409,,In vitro antitumor activity against A2780 cell line.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5574,,N,7143,1,478.0,,81034,,,,BAO_0000219,CHEMBL623410,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours
F,Homo sapiens,9606.0,,A2780,1,Expert,,13528,,N,7144,1,478.0,,81034,,,,BAO_0000219,CHEMBL623576,,In vitro cytotoxicity against A2780 human ovarian cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12782,,N,7145,1,626.0,,80025,,,,BAO_0000219,CHEMBL623577,,Inhibitory activity against kidney A-CHN tumor cell growth in culture
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,14255,,N,7146,1,626.0,,80025,,,,BAO_0000219,CHEMBL623578,,The IC50 value was measured on ACHN cell line in renal tumor type.
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,16364,,N,7147,1,626.0,,80025,,,,BAO_0000219,CHEMBL623579,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro
F,Homo sapiens,9606.0,,ACHN,1,Expert,,17376,,N,7148,1,626.0,,80025,,,,BAO_0000219,CHEMBL623580,,In vitro lethal concentration against most sensitive ACHN cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12016,,N,7149,1,626.0,,80025,,,,BAO_0000219,CHEMBL623581,,Tested for cytotoxic activity against renal cancer ACHN cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,6058,,N,7150,1,626.0,,80025,,,,BAO_0000219,CHEMBL857456,,Compound tested for growth inhibition of renal cancer cell line ACHN
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,17708,,N,7151,1,626.0,,80025,,,,BAO_0000219,CHEMBL623582,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15176,,N,7152,1,626.0,,80025,,,,BAO_0000219,CHEMBL623583,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,2806,,N,7153,1,626.0,,80025,,,,BAO_0000219,CHEMBL623584,,In vitro anticancer activity against ACHN renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15300,,N,7154,1,626.0,,80025,,,,BAO_0000219,CHEMBL623585,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,16364,,N,7155,1,626.0,,80025,,,,BAO_0000219,CHEMBL623586,,Percent selectivity was evaluated in renal ACHN cell lines
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,13859,,N,7156,1,626.0,,80025,,,,BAO_0000219,CHEMBL623587,,In vitro inhibitory activity against renal ACHN cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,11970,,N,7157,1,626.0,,80025,,,,BAO_0000219,CHEMBL875279,,Tested for cytotoxicity against ACHN cell lines in renal cancer
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,2450,,N,7158,1,626.0,,80025,,,,BAO_0000219,CHEMBL623588,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12696,,N,7159,1,626.0,,80025,,,,BAO_0000219,CHEMBL623589,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12400,,N,7160,1,626.0,,80025,,,,BAO_0000219,CHEMBL623590,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer
F,Homo sapiens,9606.0,,ACHN,1,Expert,,12888,,N,7161,1,626.0,,80025,,,,BAO_0000219,CHEMBL623591,,Cytotoxic effect on renal cancer line ACHN
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,3156,,N,7162,1,626.0,,80025,,,,BAO_0000219,CHEMBL623592,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,3381,,N,7163,1,626.0,,80025,,,,BAO_0000219,CHEMBL623593,,In vitro inhibition of Renal Cancer ACHN cell lines
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,16747,,N,7164,1,626.0,,80025,,,,BAO_0000219,CHEMBL623594,,Antitumor activity against human renal adenocarcinoma ACHN cells
F,Homo sapiens,9606.0,,ACHN,1,Expert,,16748,,N,7165,1,626.0,,80025,,,,BAO_0000219,CHEMBL621833,,Antitumor activity against human renal adenocarcinoma ACHN cells.
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,12062,,N,7166,1,626.0,,80025,,,,BAO_0000219,CHEMBL621834,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,14769,,N,7167,1,626.0,,80025,,,,BAO_0000219,CHEMBL621835,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15895,,N,7168,1,626.0,,80025,,,,BAO_0000219,CHEMBL621836,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line"
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,17376,,N,7169,1,626.0,,80025,,,,BAO_0000219,CHEMBL621837,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,14882,,N,7170,1,626.0,,80025,,,,BAO_0000219,CHEMBL875280,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,14882,,N,7171,1,626.0,,80025,,,,BAO_0000219,CHEMBL621838,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).
F,Homo sapiens,9606.0,,ACHN,1,Intermediate,,15661,,N,7172,1,626.0,,80025,,,,BAO_0000219,CHEMBL621839,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.
A,,,,,1,Autocuration,,9680,,U,7173,0,,,22224,,,,BAO_0000019,CHEMBL621840,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade
F,,,,,1,Autocuration,,14579,,H,7174,8,,,10647,,,,BAO_0000019,CHEMBL621841,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.
F,Cytomegalovirus,10358.0,,HEL,1,Expert,,17290,,N,7175,1,468.0,,50529,,,,BAO_0000218,CHEMBL622979,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.
F,Cytomegalovirus,10358.0,,,1,Intermediate,,17290,,N,7176,1,,,50529,,,,BAO_0000218,CHEMBL876595,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data
B,,,,,1,Autocuration,,15891,,H,7177,8,,,12159,,,,BAO_0000357,CHEMBL620221,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA)
B,,,,,1,Autocuration,,15890,,H,7178,8,,,12159,,,,BAO_0000357,CHEMBL620222,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA)
F,Bos taurus,9913.0,,ADDP cell line,1,Intermediate,,3801,,N,7179,1,979.0,,80670,,,,BAO_0000219,CHEMBL620506,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound
F,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,9222,,N,7180,1,980.0,,80671,,,,BAO_0000219,CHEMBL620507,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells
F,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,9222,,N,7181,1,980.0,,80671,,,,BAO_0000219,CHEMBL620508,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells
F,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,7257,,N,7182,1,980.0,,80671,,,,BAO_0000219,CHEMBL620509,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor"
F,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,7257,,N,7183,1,980.0,,80671,,,,BAO_0000219,CHEMBL620510,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg
A,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,7257,,N,7184,1,980.0,,80671,,,,BAO_0000219,CHEMBL620511,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group
F,Mus musculus,10090.0,,ADJ/PC6,1,Intermediate,,8084,,N,7185,1,980.0,,80671,,,,BAO_0000219,CHEMBL620512,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells
F,Mus musculus,10090.0,,,1,Autocuration,,14943,,U,7186,0,,,22224,,,,BAO_0000019,CHEMBL620513,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma
F,Mus musculus,10090.0,,,1,Autocuration,,14943,,U,7187,0,,,22224,,,,BAO_0000019,CHEMBL620514,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined
F,Mus musculus,10090.0,,,1,Autocuration,,14943,,U,7188,0,,,22224,,,,BAO_0000019,CHEMBL620515,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma
A,Bacillus subtilis,1423.0,,,1,Autocuration,,10524,,U,7189,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620516,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7190,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL620517,,AUC value in dog after IV administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7191,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL620518,,AUC value in dog after oral administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7192,1,,,50588,,,In vivo,BAO_0000218,CHEMBL620519,,Cmax value in dog after oral administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7193,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621386,,Bioavailability in dog after oral administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7194,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621387,,Tmax value in dog after oral administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3184,,N,7195,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621388,,Compound was evaluated for its clearance when administered intravenously in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16456,,N,7196,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621389,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,7197,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621390,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
P,,,,,1,Intermediate,,4219,,U,7198,0,,,22229,,,,BAO_0000100,CHEMBL621391,,Calculated partition coefficient (clogP)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3748,,N,7199,1,,,50588,,,,BAO_0000218,CHEMBL621392,,Half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3132,,N,7200,1,,,50588,,,,BAO_0000218,CHEMBL621393,,Time taken for EC90 was determined when tested in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4219,,N,7201,1,,,50588,,,,BAO_0000218,CHEMBL621394,,Half life (iv) was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,7202,1,,,50588,Liver,2107.0,,BAO_0000218,CHEMBL621395,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,7203,1,,,50588,,,,BAO_0000218,CHEMBL621396,,Area under the curve was calculated in dog after iv administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,7204,1,,,50588,,,,BAO_0000218,CHEMBL621397,,Area under the curve was calculated in dog after peroral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17853,,N,7205,1,,,50588,,,,BAO_0000218,CHEMBL621398,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3639,,N,7206,1,,,50588,,,,BAO_0000218,CHEMBL618818,,pKa was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14541,,N,7207,1,,,50588,,,,BAO_0000218,CHEMBL618819,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16456,,N,7208,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618820,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16456,,N,7209,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873810,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2652,,N,7210,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876606,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3624,,N,7211,1,,,50588,,,,BAO_0000218,CHEMBL618821,,Compound was evaluated for the half-life (t 1/2) in hours
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,7212,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL618822,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1337,,N,7213,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL618823,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4709,,N,7214,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618824,,Half life after intravenous administration of 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15660,,N,7215,1,,,50588,,,,BAO_0000218,CHEMBL618825,,Half life was measured in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5302,,N,7216,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618826,,Half life period in dog after 5 mg/kg dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17791,,N,7217,1,,,50588,,,,BAO_0000218,CHEMBL618827,,Half life period was evaluated in dog; 4-4.8
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6348,,N,7218,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618828,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4257,,N,7219,1,,,50588,,,In vivo,BAO_0000218,CHEMBL618829,,Half-life was determined in dog after a3 mg/kg of iv dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3771,,N,7220,1,,,50588,,,,BAO_0000218,CHEMBL618830,,Half-life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6305,,N,7221,1,,,50588,,,,BAO_0000218,CHEMBL618831,,Half life in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13501,,N,7222,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL619489,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,7223,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619649,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3045,,N,7224,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876607,,Compound was evaluated for the half life period after iv administration in Beagle dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3043,,N,7225,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619650,,Compound was evaluated for the half life period after oral administration in conscious dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4839,,N,7226,1,,,50588,,,,BAO_0000218,CHEMBL619651,,Compound was tested for half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4839,,N,7227,1,,,50588,,,,BAO_0000218,CHEMBL619652,,Compound was tested for its half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5802,,N,7228,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619653,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,7229,1,,,50588,,,,BAO_0000218,CHEMBL619654,,Half life of compound in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4219,,N,7230,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619655,,Half life (iv) was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13966,,N,7231,1,,,50588,Blood,178.0,,BAO_0000218,CHEMBL619656,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3994,,N,7232,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873812,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
F,Canis lupus familiaris,9615.0,,,1,Intermediate,,3994,,N,7233,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621365,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4453,,N,7234,1,,,50588,,,,BAO_0000218,CHEMBL621366,,Half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,7235,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621367,,Half life in dog plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,7236,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621368,,Half life in dog plasma after administration of 0.25 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6535,,N,7237,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621369,,Half life in dog plasma after administration of 1 mg/kg iv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3132,,N,7238,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621370,,Half life in dog plasma was determined at dose 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5374,,N,7239,1,,,50588,,,,BAO_0000218,CHEMBL621371,,Half life in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5007,,N,7240,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621372,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16907,,N,7241,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621373,,Half life upon exposure to human plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6057,,N,7242,1,,,50588,,,,BAO_0000218,CHEMBL621374,,Half life was calculated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,7243,1,,,50588,,,,BAO_0000218,CHEMBL621375,,Half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5473,,N,7244,1,,,50588,,,,BAO_0000218,CHEMBL621376,,Half life was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4368,,N,7245,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619624,,Half life by intravenous administration of 1.2 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6448,,N,7246,1,,,50588,,,,BAO_0000218,CHEMBL875840,,Half life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,7247,1,,,50588,,,,BAO_0000218,CHEMBL619625,,Half life in dog after intra venous administration of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,7248,1,,,50588,,,,BAO_0000218,CHEMBL619626,,Half life in dog after intra venous administration of the compound; ND means Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,7249,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619627,,Half life in dog after po administration of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,7250,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873817,,Half life in dog after po administration of the compound; ND means Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6265,,N,7251,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619628,,Half life in dog at the single oral dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5006,,N,7252,1,,,50588,,,,BAO_0000218,CHEMBL619629,,Half life in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5356,,N,7253,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619630,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,405,,N,7254,1,,,50588,,,,BAO_0000218,CHEMBL619631,,Half life in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,7255,1,,,50588,,,In vivo,BAO_0000218,CHEMBL619632,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7256,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL619633,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7257,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL875841,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7258,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL619634,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7259,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL619635,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7260,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL619636,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7261,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619637,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7262,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619638,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7263,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619639,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7264,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619640,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7265,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619641,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7266,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619642,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7267,1,,,50594,Gut,10000004.0,In vivo,BAO_0000218,CHEMBL619643,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7268,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL619644,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7269,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621112,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7270,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621113,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7271,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621114,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7272,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621115,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7273,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621116,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7274,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL621117,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7275,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621118,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7276,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621119,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7277,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621120,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7278,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621757,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7279,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621758,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7280,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621759,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7281,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621760,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7282,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621761,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7283,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621762,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7284,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621763,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7285,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624502,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7286,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624503,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7287,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624504,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7288,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624505,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7289,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624506,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5895,,N,7290,1,478.0,,81034,,,,BAO_0000219,CHEMBL624507,,In vitro cytotoxicity against A2780 (human ovarian cancer)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,6338,,N,7291,1,478.0,,81034,,,,BAO_0000219,CHEMBL624508,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15163,,N,7292,1,478.0,,81034,,,,BAO_0000219,CHEMBL624509,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15163,,N,7293,1,478.0,,81034,,,,BAO_0000219,CHEMBL624510,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).
F,Homo sapiens,9606.0,,A2780,1,Expert,,15000,,N,7294,1,478.0,,81034,,,,BAO_0000219,CHEMBL875956,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,15000,,N,7295,1,478.0,,81034,,,,BAO_0000219,CHEMBL839885,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,14729,,N,7296,1,478.0,,81034,,,,BAO_0000219,CHEMBL624511,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17270,,N,7297,1,478.0,,81034,,,,BAO_0000219,CHEMBL624512,,In vitro cytotoxicity against A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5685,,N,7298,1,478.0,,81034,,,,BAO_0000219,CHEMBL624513,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3563,,N,7299,1,478.0,,81034,,,,BAO_0000219,CHEMBL624514,,In vitro inhibitory activity against human ovarian cancer A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17753,,N,7300,1,478.0,,81034,,,,BAO_0000218,CHEMBL618547,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16317,,N,7301,1,478.0,,81034,,,,BAO_0000219,CHEMBL618548,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7302,1,478.0,,81034,,,,BAO_0000219,CHEMBL618549,,Inhibition of tubulin polymerization in analogy of ca.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3801,,N,7303,1,478.0,,81034,,,,BAO_0000219,CHEMBL618550,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound
F,Homo sapiens,9606.0,,A2780,1,Expert,,6181,,N,7304,1,478.0,,81034,,,,BAO_0000219,CHEMBL618551,,Cytotoxic effect in ovarian cancer cell line (A2780)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,5318,,N,7305,1,478.0,,81034,,,,BAO_0000219,CHEMBL618552,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,4840,,N,7306,1,478.0,,81034,,,,BAO_0000219,CHEMBL618553,,Tested for the cytotoxicity in A2780 ovarian cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15748,,N,7307,1,478.0,,81034,,,,BAO_0000219,CHEMBL618554,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,15748,,N,7308,1,478.0,,81034,,,,BAO_0000219,CHEMBL618555,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma
F,,,,A2780cisR,1,Intermediate,,15748,,N,7309,1,481.0,,80017,,,,BAO_0000219,CHEMBL618556,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma
F,,,,A2780cisR,1,Intermediate,,15748,,N,7310,1,481.0,,80017,,,,BAO_0000219,CHEMBL618557,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
F,,,,A2780cisR,1,Intermediate,,15748,,N,7311,1,481.0,,80017,,,,BAO_0000219,CHEMBL618558,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data
F,,,,A2780cisR,1,Intermediate,,15748,,N,7312,1,481.0,,80017,,,,BAO_0000219,CHEMBL618559,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17753,,N,7313,1,478.0,,81034,,,,BAO_0000218,CHEMBL618560,,In vivo log of cells killed after administration of compound in A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17753,,N,7314,1,478.0,,81034,,,In vivo,BAO_0000218,CHEMBL618561,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7315,1,478.0,,81034,,,,BAO_0000219,CHEMBL618562,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7316,1,478.0,,81034,,,,BAO_0000219,CHEMBL618563,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7317,1,478.0,,81034,,,,BAO_0000219,CHEMBL618564,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7318,1,478.0,,81034,,,,BAO_0000219,CHEMBL618565,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,17528,,N,7319,1,478.0,,81034,,,,BAO_0000218,CHEMBL618566,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2)
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,6633,,N,7320,1,478.0,,81034,,,,BAO_0000219,CHEMBL618567,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,15000,,N,7321,1,478.0,,81034,,,,BAO_0000219,CHEMBL618568,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line
F,Homo sapiens,9606.0,,A2780,1,Expert,,17528,,N,7322,1,478.0,,81034,,,,BAO_0000219,CHEMBL618569,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7323,1,478.0,,81034,,,,BAO_0000219,CHEMBL621857,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7324,1,478.0,,81034,,,,BAO_0000219,CHEMBL621858,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7325,1,478.0,,81034,,,,BAO_0000219,CHEMBL621859,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7326,1,478.0,,81034,,,,BAO_0000219,CHEMBL621860,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7327,1,478.0,,81034,,,,BAO_0000219,CHEMBL621861,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM )
F,Homo sapiens,9606.0,,A2780,1,Expert,,16936,,N,7328,1,478.0,,81034,,,,BAO_0000219,CHEMBL621862,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )"
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7329,1,478.0,,81034,,,,BAO_0000219,CHEMBL621863,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7330,1,478.0,,81034,,,,BAO_0000219,CHEMBL621864,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,16936,,N,7331,1,478.0,,81034,,,,BAO_0000219,CHEMBL621865,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM )
F,Mus musculus,10090.0,,A2780,1,Intermediate,,17737,,N,7332,1,478.0,,81034,,,,BAO_0000219,CHEMBL621866,,In vitro antiproliferative activity against A2780 cell line
F,Mus musculus,10090.0,,A2780,1,Expert,,17764,,N,7333,1,478.0,,81034,,,,BAO_0000219,CHEMBL621867,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3830,,N,7334,1,478.0,,81034,,,,BAO_0000219,CHEMBL621868,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr
F,Homo sapiens,9606.0,,A2780,1,Intermediate,,3829,,N,7335,1,478.0,,81034,,,,BAO_0000219,CHEMBL875282,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7336,1,,,50588,,,,BAO_0000218,CHEMBL621869,,Vc value in dog after IV administration at a dose of 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3546,,N,7337,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621870,,Half life period in dog after IV administration at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,5668,,U,7338,0,,,22224,,,,BAO_0000019,CHEMBL621871,,Area under curve was determine after peroral administration at 10 mpk in Rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,7339,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL621243,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,7340,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL621244,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Macaca fascicularis,9541.0,,,1,Autocuration,,4256,,U,7341,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621245,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
A,Macaca fascicularis,9541.0,,,1,Autocuration,,4256,,U,7342,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621246,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey
A,Macaca fascicularis,9541.0,,,1,Autocuration,,4256,,U,7343,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621247,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey
A,Rattus norvegicus,10116.0,,,1,Autocuration,,4256,,U,7344,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618386,,Oral Bioavailability in rat
A,Cercopithecidae,9527.0,,,1,Autocuration,,1916,,U,7345,0,,,22224,,,,BAO_0000218,CHEMBL618387,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
A,Cercopithecidae,9527.0,,,1,Autocuration,,5302,,U,7346,0,,,22224,,,,BAO_0000218,CHEMBL618388,,Area under curve value in monkey at a dose of 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,4257,,U,7347,0,,,22224,,,,BAO_0000218,CHEMBL618389,,Area under curve was determined in monkey after a 3 mg/kg of oral dose
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7348,0,,,22224,,,,BAO_0000019,CHEMBL618574,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7349,0,,,22224,,,,BAO_0000019,CHEMBL618575,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7350,0,,,22224,,,,BAO_0000019,CHEMBL618576,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,6078,,U,7351,0,,,22224,,,,BAO_0000218,CHEMBL618577,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6078,,U,7352,0,,,22224,,,,BAO_0000218,CHEMBL876487,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6062,,U,7353,0,,,22224,,,,BAO_0000218,CHEMBL618578,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,7354,0,,,22224,,,,BAO_0000218,CHEMBL618579,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,7355,0,,,22224,,,,BAO_0000019,CHEMBL618580,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,5394,,U,7356,0,,,22224,,,,BAO_0000218,CHEMBL618581,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,4397,,U,7357,0,,,22224,,,,BAO_0000218,CHEMBL618582,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.
A,Cercopithecidae,9527.0,,,1,Autocuration,,17509,,U,7358,0,,,22224,,,,BAO_0000218,CHEMBL618583,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,17509,,U,7359,0,,,22224,,,,BAO_0000218,CHEMBL618584,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,6641,,U,7360,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618585,,Oral AUCN in monkey (dosed at 0.5 mpk iv )
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7361,0,,,22224,,,,BAO_0000218,CHEMBL618586,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration)
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,7362,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618587,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,3443,,U,7363,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618588,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
A,Cercopithecidae,9527.0,,,1,Autocuration,,17409,,U,7364,0,,,22224,,,,BAO_0000019,CHEMBL618589,,Binding towards monkey plasma protein at 10 uM
A,Cercopithecidae,9527.0,,,1,Autocuration,,17409,,U,7365,0,,,22224,,,,BAO_0000019,CHEMBL618590,,Binding towards monkey plasma protein at 100 uM
A,Cercopithecidae,9527.0,,,1,Autocuration,,1052,,U,7366,0,,,22224,,,In vivo,BAO_0000218,CHEMBL872262,,Apparent bioavailability in squirrel monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,13501,,U,7367,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618591,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
A,monkey,9443.0,,,1,Autocuration,,17509,,U,7368,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618592,,Bioavailability in monkey (dose 2 mg/kg)
A,Cercopithecidae,9527.0,,,1,Autocuration,,5394,,U,7369,0,,,22224,,,In vivo,BAO_0000218,CHEMBL876488,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,7370,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618593,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey
A,monkey,9443.0,,,1,Autocuration,,11219,,U,7371,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618594,,Bioavailability in monkey (i.d. dosing)
A,Cercopithecidae,9527.0,,,1,Autocuration,,3045,,U,7372,0,,,22224,,,In vivo,BAO_0000218,CHEMBL618595,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,17796,,U,7373,0,,,22224,,,,BAO_0000019,CHEMBL621469,,Clearance of the drug was measured in cynomolgus
A,Cercopithecidae,9527.0,,,1,Autocuration,,1399,,U,7374,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621470,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg
A,Cercopithecidae,9527.0,,,1,Autocuration,,2661,,U,7375,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621471,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey
A,Macaca mulatta,9544.0,,,1,Autocuration,,5005,,U,7376,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621472,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
A,Cercopithecidae,9527.0,,,1,Autocuration,,17267,,U,7377,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621473,,Plasma clearance in rhesus monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,6535,,U,7378,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621474,,Plasma clearance in monkey after administration of 1 mg/kg iv
A,Cercopithecidae,9527.0,,,1,Autocuration,,5922,,U,7379,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621475,,Plasma clearance in cynomolgus monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,6221,,U,7380,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621476,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined
A,Cercopithecidae,9527.0,,,1,Autocuration,,5668,,U,7381,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624290,,Plasma clearance after peroral administration at 10 mpk in Rhesus
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7382,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624291,,The total clearance was determined after intravenous administration in cynomolgus monkeys
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7383,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624292,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,5355,,U,7384,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624293,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable
A,Cercopithecidae,9527.0,,,1,Autocuration,,4578,,U,7385,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624294,,Tested for Clearance upon iv administration to african green monkey
A,Cercopithecidae,9527.0,,,1,Autocuration,,17592,,U,7386,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624295,,Clearance in monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6641,,N,7387,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624296,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6642,,N,7388,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624297,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16367,,N,7389,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624298,,Half life was evaluated after intravenous administration to dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5472,,N,7390,1,,,50588,,,,BAO_0000218,CHEMBL624299,,Half life was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5474,,N,7391,1,,,50588,,,,BAO_0000218,CHEMBL624300,,Half life was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5654,,N,7392,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624301,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,7393,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624302,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,7394,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876026,,Half life period after intravenous administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6221,,N,7395,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624303,,Half life period after oral administration (2.5 mg/kg) in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,7396,1,,,50588,,,,BAO_0000218,CHEMBL624304,,Half life period at a dose of 1 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,7397,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624305,,Half life period was determine after peroral administration at 10 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5668,,N,7398,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624306,,Half life period was determine after peroral administration at 5 mpk in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3854,,N,7399,1,,,50588,,,,BAO_0000218,CHEMBL624307,,Half life period was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5505,,N,7400,1,,,50588,,,,BAO_0000218,CHEMBL624308,,Half life period was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6251,,N,7401,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624309,,Half life period by iv administration in dog at a dose of 6 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1918,,N,7402,1,,,50588,,,,BAO_0000218,CHEMBL624310,,Half life period was evaluated in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5546,,N,7403,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625003,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4809,,N,7404,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625004,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6215,,N,7405,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625005,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4527,,N,7406,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873813,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17594,,N,7407,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625006,,Half-life after oral dose of compound at 3 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,7408,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625007,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,7409,1,,,50588,,,In vivo,BAO_0000218,CHEMBL876027,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,7410,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625008,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17839,,N,7411,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625009,,Half-life of compound in dog following p.o. administration of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5210,,N,7412,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL625010,,Half-life of compound in plasma of dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5210,,N,7413,1,,,50588,,,,BAO_0000218,CHEMBL625011,,Half-life of compound was determined in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2959,,N,7414,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621553,,Half-life after administration of 4 mg/Kg oral dose in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4137,,N,7415,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621554,,Half-life after intravenous administration of 1 mg/kg/h in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5064,,N,7416,1,,,50588,,,,BAO_0000218,CHEMBL621555,,Half-life in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5147,,N,7417,1,,,50588,,,,BAO_0000218,CHEMBL621556,,Half-life in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5145,,N,7418,1,,,50588,,,,BAO_0000218,CHEMBL621557,,Half-life in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6123,,N,7419,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621558,,Half-life in dog after oral administration at 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6123,,N,7420,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621559,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4333,,N,7421,1,,,50588,,,,BAO_0000218,CHEMBL621560,,Half-life in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4333,,N,7422,1,,,50588,,,,BAO_0000218,CHEMBL876028,,Half-life in dogs; ND indicates not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,7423,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621561,,Half-life in plasma of dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12500,,N,7424,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL621562,,Half-life in plasma of dog at dose of 3-10 mgkg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6005,,N,7425,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621563,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6062,,N,7426,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621564,,Half-life was measured in dog after an iv dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17650,,N,7427,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621565,,Half-life was measured in dogs after an oral dose of 10 uM/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,7428,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621566,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5530,,N,7429,1,,,50588,,,In vivo,BAO_0000218,CHEMBL621567,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5600,,N,7430,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622978,,Half-life of the compound after 0.3 mg/kg po administration in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,7431,1,,,50588,,,In vivo,BAO_0000218,CHEMBL873814,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,7432,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623219,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6039,,N,7433,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624477,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6227,,N,7434,1,,,50588,,,,BAO_0000218,CHEMBL624478,,t1/2 in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14541,,N,7435,1,,,50588,,,,BAO_0000218,CHEMBL624479,,Half-life period measured in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,7436,1,,,50588,,,In vivo,BAO_0000218,CHEMBL624480,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4521,,N,7437,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623595,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6679,,N,7438,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623596,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,1116,,N,7439,1,,,50588,Plasma,1969.0,In vitro,BAO_0000218,CHEMBL623597,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,7440,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623598,,In vivo half life period was calculated at 1 mg/kg in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5444,,N,7441,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623599,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17853,,N,7442,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623600,,Longer half-life in dog (i.v.) at 0.5 mpk
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4353,,N,7443,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623601,,Oral bioavailability in dog (dose 5 uM/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7444,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623602,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7445,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623603,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,7446,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623604,,Bioavailability in dog (dose 1 mg/kg i.v.)
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7447,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623605,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7448,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623606,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7449,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623607,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7450,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623608,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7451,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623609,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7452,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623610,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7453,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623611,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7454,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623612,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7455,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623613,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7456,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623614,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7457,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623615,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7458,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623616,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7459,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL623617,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7460,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL875944,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7461,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623618,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7462,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623619,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7463,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623620,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7464,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623621,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7465,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623622,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7466,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL623623,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7467,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL623624,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7468,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618521,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7469,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618522,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7470,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618523,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7471,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618524,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7472,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL618525,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7473,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL624586,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7474,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624587,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7475,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624588,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7476,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624589,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7477,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624590,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7478,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624591,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7479,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624592,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
A,Mus musculus,10090.0,,,1,Intermediate,,10107,,N,7480,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL624593,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,7481,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624594,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4950,,N,7482,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624595,,Tested for the bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5328,,N,7483,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624596,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,406,,N,7484,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624597,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,7485,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624598,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,7486,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624599,,Bioavailability in rat (dose 3-10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5247,,N,7487,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875166,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,7488,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624600,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,7489,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624601,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,7490,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624602,,Half life after oral administration was determined in rats at 6 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6484,,N,7491,1,,,50597,,,,BAO_0000218,CHEMBL624603,,Half life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3249,,N,7492,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624604,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6281,,N,7493,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624605,,Plasma half life in rat at oral dose 2.8 mg/mk body weight
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3307,,N,7494,1,,,50597,,,,BAO_0000218,CHEMBL624606,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12058,,N,7495,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624607,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8833,,N,7496,1,,,50597,,,,BAO_0000218,CHEMBL624608,,Hill coefficient of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7497,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624609,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7498,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624610,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7499,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624611,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7500,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624612,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7501,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL875167,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7502,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624613,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3193,,N,7503,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624614,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,7504,1,,,50597,,,,BAO_0000218,CHEMBL624392,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7505,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624393,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7506,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624394,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7507,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624395,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7508,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624396,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7509,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624397,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7510,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL624398,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7511,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL624399,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7512,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL624400,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7513,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL624401,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,7514,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL624402,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7515,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624403,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7516,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624404,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7517,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624405,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7518,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL624406,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7519,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL624407,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7520,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL624408,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7521,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL618644,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7522,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL618645,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7523,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL618646,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7524,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618647,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7525,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618648,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7526,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL618649,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7527,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618650,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7528,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618651,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7529,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL876497,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7530,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618652,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7531,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618653,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7532,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618654,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6351,,N,7533,1,,,50597,,,,BAO_0000218,CHEMBL618655,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1465,,N,7534,1,,,50597,,,,BAO_0000218,CHEMBL618656,,Compound was tested for solubility in water
P,,,,,1,Intermediate,,5182,,U,7535,0,,,22229,,,,BAO_0000100,CHEMBL618657,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17847,,N,7536,1,,,50597,,,,BAO_0000218,CHEMBL618658,,Solubility was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15339,,N,7537,1,,,50597,,,,BAO_0000218,CHEMBL618659,,solubility in water (ug/mL) at 37 degree C.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5202,,N,7538,1,,,50597,,,,BAO_0000218,CHEMBL618660,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1088,,N,7539,1,,,50597,,,,BAO_0000218,CHEMBL618661,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,7540,1,,,50597,,,,BAO_0000218,CHEMBL873807,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5353,,N,7541,1,,,50597,,,,BAO_0000218,CHEMBL618662,,Half life in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2864,,N,7542,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618663,,Half life period after 3 mg/kg iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2864,,N,7543,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618664,,Half life period after 3 mg/kg iv administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2864,,N,7544,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618665,,Half life period after 3 mg/kg iv administration in the rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6362,,N,7545,1,,,50597,,,,BAO_0000218,CHEMBL876498,,Half life period in female Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6249,,N,7546,1,,,50597,,,,BAO_0000218,CHEMBL618666,,Half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,7547,1,,,50597,,,,BAO_0000218,CHEMBL620440,,Half-life in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,7548,1,,,50597,,,,BAO_0000218,CHEMBL620441,,Half-life in rats with metabolic oxidation
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,7549,1,,,50597,,,,BAO_0000218,CHEMBL620442,,Half-life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7550,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620443,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7551,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620444,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7552,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620445,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7553,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620446,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,7554,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL620447,,Biological half-life measured in plasma of rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,7555,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621129,,Biological half-life measured in plasma of rat; 22-25
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,7556,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621130,,Biological half-life measured in plasma of rat; 9-16
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3184,,N,7557,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873808,,Compound was evaluated for its half life when administered intravenously in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,7558,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876598,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,7559,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621131,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,7560,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621132,,Half life (T1/2) after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4413,,N,7561,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621133,,Half life of compound after iv administration of 20 mg/kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,7562,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621312,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17267,,N,7563,1,,,50597,,,,BAO_0000218,CHEMBL621313,,Half life of compound was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,7564,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621314,,Half life of compound was determined in rat blood
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,7565,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621315,,Half life at 1 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,7566,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621316,,Half life at 10 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,401,,N,7567,1,,,50597,,,,BAO_0000218,CHEMBL621317,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4942,,N,7568,1,,,50597,,,,BAO_0000218,CHEMBL621318,,Half life in rats in hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17735,,N,7569,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621319,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6056,,N,7570,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621377,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5213,,N,7571,1,,,50597,,,,BAO_0000218,CHEMBL621378,,Half life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6616,,N,7572,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876599,,Half life after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5937,,N,7573,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621379,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5819,,N,7574,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621380,,Half life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5819,,N,7575,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621381,,Half life in rat plasma; Not detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6803,,N,7576,1,,,50597,,,,BAO_0000218,CHEMBL618515,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,7577,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618516,,Half life period of compound was determined after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,7578,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618517,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5948,,N,7579,1,,,50597,,,,BAO_0000218,CHEMBL618518,,Half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,7580,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618519,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,7581,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618698,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,7582,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618862,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,7583,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618863,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,7584,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618864,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,7585,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618865,,Half life time in rat the dose of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,7586,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618866,,Half-life 24 hr after 10 mg/kg iv administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,7587,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618867,,Half-life 24 hr after 2 mg/kg iv administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,7588,1,,,50597,,,,BAO_0000218,CHEMBL875828,,Half-life consistent with the observed metabolic steady state in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17735,,N,7589,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618868,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,7590,1,,,50597,,,,BAO_0000218,CHEMBL618869,,Half-life for oxidative metabolic stability was determined using male human
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17670,,N,7591,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618870,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1696,,N,7592,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL618871,,Half-life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1742,,N,7593,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL618872,,Half-life in rat plasma was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17800,,N,7594,1,,,50597,,,,BAO_0000218,CHEMBL873816,,Half-life in rats was determined
A,,,,,1,Autocuration,,12923,,U,7595,0,,,22224,,,,BAO_0000218,CHEMBL618873,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog
A,,,,,1,Autocuration,,11954,,U,7596,0,,,22224,,,,BAO_0000019,CHEMBL621602,,Area under curve after oral dose of 0.1 mg//kg
A,,,,,1,Autocuration,,11954,,U,7597,0,,,22224,,,,BAO_0000218,CHEMBL621603,,Area under curve after oral dose of 0.3 mg/kg
A,,,,,1,Autocuration,,11954,,U,7598,0,,,22224,,,,BAO_0000218,CHEMBL621604,,Area under curve after oral dose of 1 mg/kg
A,,,,,1,Autocuration,,11954,,U,7599,0,,,22224,,,,BAO_0000218,CHEMBL621605,,Area under curve after oral dose of 10 mg/kg
A,,,,,1,Autocuration,,11954,,U,7600,0,,,22224,,,,BAO_0000218,CHEMBL621606,,Area under curve after oral dose of 23.4 mg/kg
A,,,,,1,Autocuration,,11954,,U,7601,0,,,22224,,,,BAO_0000218,CHEMBL621607,,Area under curve after oral dose of 3 mg/kg
A,,,,,1,Autocuration,,11954,,U,7602,0,,,22224,,,,BAO_0000218,CHEMBL621608,,Area under curve after oral dose of 3.87 mg/kg
A,,,,,1,Autocuration,,5237,,U,7603,0,,,22224,,,,BAO_0000019,CHEMBL621609,,Area under curve was determined
A,,,,,1,Autocuration,,4026,,U,7604,0,,,22224,,,,BAO_0000218,CHEMBL621610,,Area under curve at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5237,,N,7605,1,,,50597,,,,BAO_0000218,CHEMBL621611,,Area under curve was determined; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7606,1,,,50597,,,,BAO_0000218,CHEMBL621612,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7607,1,,,50597,,,,BAO_0000218,CHEMBL622308,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7608,1,,,50597,,,,BAO_0000218,CHEMBL622309,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7609,1,,,50597,,,,BAO_0000218,CHEMBL622310,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7610,1,,,50597,,,,BAO_0000218,CHEMBL622311,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7611,1,,,50597,,,,BAO_0000218,CHEMBL622312,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7612,1,,,50597,,,,BAO_0000218,CHEMBL622931,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7613,1,,,50597,,,,BAO_0000218,CHEMBL622932,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7614,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622736,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7615,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622737,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7616,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622738,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7617,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622739,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7618,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622740,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7619,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622741,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7620,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622742,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,7621,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622743,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours
A,Mus musculus,10090.0,,,1,Intermediate,,11637,,N,7622,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL622744,,AUC in mice
A,,,,,1,Autocuration,,11149,,U,7623,0,,,22224,,,,BAO_0000019,CHEMBL624134,,Area under curve was measured from the graph obtained from concentration Vs time
A,,,,,1,Autocuration,,10016,,U,7624,0,,,22224,,,,BAO_0000019,CHEMBL624135,,Area under curve value of compound per hour after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,7625,1,,,50597,,,,BAO_0000218,CHEMBL624136,,Area under curve was determined after oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,7626,1,,,50597,,,,BAO_0000218,CHEMBL624137,,Area under curve was determined after oral administration in rats; No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,7627,1,,,50597,,,,BAO_0000218,CHEMBL624320,,Area under curve was determined after oral administration in rats;No data
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12923,,N,7628,1,,,50588,,,,BAO_0000218,CHEMBL624321,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7629,1,,,50597,,,,BAO_0000218,CHEMBL624322,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7630,1,,,50597,,,,BAO_0000218,CHEMBL624323,,Area under curve was determined for the compound after iv dose of 5.06 in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7631,1,,,50597,,,,BAO_0000218,CHEMBL624324,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7632,1,,,50597,,,,BAO_0000218,CHEMBL624325,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7633,1,,,50597,,,,BAO_0000218,CHEMBL624326,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7634,1,,,50597,,,,BAO_0000218,CHEMBL624327,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,7635,1,,,50597,,,,BAO_0000218,CHEMBL624328,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14169,,N,7636,1,,,50588,,,,BAO_0000218,CHEMBL627848,,Area under curve was determined in Dogs after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14169,,N,7637,1,,,50597,,,,BAO_0000218,CHEMBL627849,,Area under curve was determined in Rats after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14258,,N,7638,1,,,50597,,,,BAO_0000218,CHEMBL627850,,Area under curve was determined in carotid blood of rat when administered intradermally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14258,,N,7639,1,,,50597,,,,BAO_0000218,CHEMBL627851,,Area under curve was determined in portal blood of rat when administered intradermally
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7640,1,,,50594,,,,BAO_0000218,CHEMBL627852,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7641,1,,,50594,,,,BAO_0000218,CHEMBL627853,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7642,1,,,50594,,,,BAO_0000218,CHEMBL627854,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample)
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7643,1,,,50594,,,,BAO_0000218,CHEMBL627855,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7644,1,,,50594,,,,BAO_0000218,CHEMBL627856,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr)
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7645,1,,,50594,,,,BAO_0000218,CHEMBL875339,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7646,1,,,50594,,,,BAO_0000218,CHEMBL627857,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,7647,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627858,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7648,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627859,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7649,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL627860,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7650,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL627019,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7651,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL627020,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7652,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627021,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7653,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL627022,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7654,1,,,50597,,,,BAO_0000218,CHEMBL627023,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7655,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL627024,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7656,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL627025,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7657,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL627026,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7658,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627027,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7659,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL627028,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7660,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL627029,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7661,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL627030,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7662,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL627031,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7663,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627032,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7664,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL627033,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7665,1,,,50597,,,,BAO_0000218,CHEMBL627034,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7666,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL627035,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7667,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL627036,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7668,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL875340,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7669,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL627037,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7670,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL627038,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7671,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL627039,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7672,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL627040,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7673,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL624663,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7674,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL625963,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7675,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL876799,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7676,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626133,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,7677,1,,,50597,,,,BAO_0000218,CHEMBL626134,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6295,,N,7678,1,,,50597,,,,BAO_0000218,CHEMBL626135,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6296,,N,7679,1,,,50597,,,,BAO_0000218,CHEMBL626136,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6296,,N,7680,1,,,50597,,,,BAO_0000218,CHEMBL626137,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6295,,N,7681,1,,,50597,,,,BAO_0000218,CHEMBL626138,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6296,,N,7682,1,,,50597,,,,BAO_0000218,CHEMBL626139,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7683,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626140,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7684,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626141,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,7685,1,,,50597,,,,BAO_0000218,CHEMBL626142,,C24h in rat p.o. at 20 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7686,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627930,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7687,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627931,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7688,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627932,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7689,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627933,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7690,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627934,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7691,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627935,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7692,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627936,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7693,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627937,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7694,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627938,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7695,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627939,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7696,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627940,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7697,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627941,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7698,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL876800,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7699,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627942,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7700,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627943,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7701,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627944,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7702,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627945,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7703,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628584,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7704,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628585,,Biodistribution in rat blood in the presence of GdDTPA at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7705,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628586,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7706,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628587,,Biodistribution in rat blood in the presence of GdDTPA at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7707,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628588,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7708,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628589,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7709,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625304,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7710,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625305,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7711,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625306,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7712,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625307,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7713,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625308,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7714,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627740,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7715,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627741,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7716,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627742,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7717,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627743,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7718,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627744,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7719,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627745,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7720,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627746,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7721,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627747,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7722,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL876810,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7723,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627748,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7724,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627749,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7725,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627750,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7726,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618728,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7727,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618729,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7728,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618730,,Biodistribution in rat bone in the presence of GdDTPA at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7729,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618731,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7730,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618732,,Biodistribution in rat bone in the presence of GdDTPA at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7731,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618733,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7732,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618734,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7733,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618735,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7734,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL876602,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7735,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618736,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7736,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618737,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7737,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618738,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7738,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618739,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7739,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618740,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7740,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618741,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7741,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618742,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7742,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL618743,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,7743,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618744,,Half-life from rat plasma at a single oral dose of 25 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5610,,N,7744,1,,,50597,,,,BAO_0000218,CHEMBL618745,,Half-life in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,7745,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620479,,Half-life in rat after peroral administration at 10 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,7746,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620480,,Half-life in rat after peroral administration at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17771,,N,7747,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620481,,Half-life in rat at a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1974,,N,7748,1,,,50597,,,,BAO_0000218,CHEMBL620482,,Half-life was evaluated in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4239,,N,7749,1,,,50597,,,,BAO_0000218,CHEMBL876603,,Half-life was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6681,,N,7750,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620483,,Half-life period for the compound was determined in rats at 50 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,7751,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620484,,Half-life period in rats after intravenous administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6046,,N,7752,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620485,,Half-life period in rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7753,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620486,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7754,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620487,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7755,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620488,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,7756,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620489,,Half-life time in rat the dose of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1088,,N,7757,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620490,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5610,,N,7758,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620491,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3032,,N,7759,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL876604,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,7760,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620492,,Oral half life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,7761,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620493,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4408,,N,7762,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620494,,Pharmacokinetic property (t1/2) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2552,,N,7763,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL620495,,Plasma elimination half-life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,7764,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620496,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,7765,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620497,,Plasma half life was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1465,,N,7766,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL620498,,Plasma half-life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,7767,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL620499,,Plasma half-life following oral administration in Fisher rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6824,,N,7768,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL620500,,Plasma half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17533,,N,7769,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873809,,Plasmatic Half-life after intravenous administration to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,7770,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620501,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,7771,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620502,,Terminal half life after intravenous administration (1 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,7772,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620503,,Terminal half life in Rat at a oral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2463,,N,7773,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620504,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,7774,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876605,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,7775,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620505,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,7776,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873811,,plasma half life was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,7777,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624016,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,7778,1,,,50597,,,,BAO_0000218,CHEMBL624017,,Half life of compound determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,7779,1,,,50597,,,,BAO_0000218,CHEMBL624018,,Mean residence time determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,7780,1,,,50597,,,,BAO_0000218,CHEMBL624019,,Plasma half life determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,7781,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624020,,Compound was evaluated for Tmax in brain after intravenous administration in male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,7782,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624201,,Compound was evaluated for pharmacokinetic parameter maximum time period
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,7783,1,,,50597,,,In vivo,BAO_0000218,CHEMBL872528,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,7784,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624202,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,7785,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624203,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,7786,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624350,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,7787,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621320,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,7788,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621321,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,7789,1,,,50597,,,,BAO_0000218,CHEMBL621322,,Maximum time (Tmax) required to reach Cmax in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,7790,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621323,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,7791,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621324,,Maximum time of clearance of compound in rats after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,7792,1,,,50597,,,,BAO_0000218,CHEMBL621325,,Maximum time at the dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,7793,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875837,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,7794,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621326,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14465,,N,7795,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621327,,Tmax in Guinea pig (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,7796,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621328,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,7797,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621329,,Pharmacokinetic parameter (Tmax) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5022,,N,7798,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621330,,Pharmacokinetic parameter (Tmax) was estimated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4408,,N,7799,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621331,,Pharmacokinetic property (Tmax) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,7800,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621332,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,7801,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621333,,T max in Rat at a oral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,7802,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621334,,T max was determined at 10 mg/kg po dose in rats
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,7803,1,,,50594,,,,BAO_0000218,CHEMBL621335,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14180,,N,7804,1,,,50588,,,,BAO_0000218,CHEMBL621336,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14180,,N,7805,1,,,50597,,,,BAO_0000218,CHEMBL621337,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,7806,1,,,50588,,,,BAO_0000218,CHEMBL621338,,Area under curve was measured after i.v. administration into Beagle dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,7807,1,,,50588,,,,BAO_0000218,CHEMBL875838,,Area under curve was measured after iv administration into Beagle dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,7808,1,,,50588,,,,BAO_0000218,CHEMBL621339,,Area under curve was measured after po administration into Beagle dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,7809,1,,,50588,,,,BAO_0000218,CHEMBL621340,,Area under curve was measured after po administration into Beagle dog.
A,,,,,1,Autocuration,,15675,,U,7810,0,,,22224,,,,BAO_0000218,CHEMBL621341,,Area under curve was measured at peroral dose of 3 mg/kg
A,,,,,1,Autocuration,,12706,,U,7811,0,,,22224,,,,BAO_0000019,CHEMBL621342,,Area under curve was measured by using concentration Vs time
A,,,,,1,Autocuration,,12706,,U,7812,0,,,22224,,,,BAO_0000019,CHEMBL621343,,Area under curve was measured by using concentration Vs time; not tested
A,Mus musculus,10090.0,,,1,Intermediate,,9750,,N,7813,1,,,50594,,,,BAO_0000218,CHEMBL621344,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg)
A,Mus musculus,10090.0,,,1,Intermediate,,9750,,N,7814,1,,,50594,,,,BAO_0000218,CHEMBL621345,,Area under curve(AUC) was measured in mice after oral administration.
A,,,,,1,Autocuration,,14691,,U,7815,0,,,22224,,,,BAO_0000019,CHEMBL621346,,Area under curve(AUC) value of the compound
A,,,,,1,Autocuration,,14691,,U,7816,0,,,22224,,,,BAO_0000218,CHEMBL621347,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14691,,N,7817,1,,,50588,,,,BAO_0000218,CHEMBL621348,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration
A,,,,,1,Autocuration,,2939,,U,7818,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL621349,,Area under curve(carotid artery) was determined by the availability in blood
A,,,,,1,Autocuration,,2939,,U,7819,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL621350,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data
A,,,,,1,Autocuration,,2939,,U,7820,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL875839,,Area under curve(carotid artery) was determined by the availability in blood; No data
A,,,,,1,Autocuration,,2939,,U,7821,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL620211,,Area under curve(portal vein) was determined by the availability in blood
A,,,,,1,Autocuration,,2939,,U,7822,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL620212,,Area under curve(portal vein) was determined by the availability in blood; ND means no data
A,,,,,1,Autocuration,,2939,,U,7823,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL620213,,Area under curve(portal vein) was determined by the availability in blood; No data
A,Macaca mulatta,9544.0,,,1,Intermediate,,9552,,N,7824,1,,,50797,Plasma,1969.0,,BAO_0000218,CHEMBL620214,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose"
A,Macaca mulatta,9544.0,,,1,Intermediate,,9552,,N,7825,1,,,50797,Plasma,1969.0,,BAO_0000218,CHEMBL620215,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose"
A,Macaca mulatta,9544.0,,,1,Intermediate,,9552,,N,7826,1,,,50797,Plasma,1969.0,,BAO_0000218,CHEMBL620216,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9552,,N,7827,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL620888,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9552,,N,7828,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL620889,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose"
A,,,,,1,Autocuration,,9552,,U,7829,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL620890,,Area under plasma concentration vs time curve observed in rats for 0-3 h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11911,,N,7830,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL620891,,Area under plasma time curve determined in male rat
A,,,,,1,Autocuration,,16618,,U,7831,0,,,22224,,,,BAO_0000019,CHEMBL620892,,Area under the MAP curve measured over 5 min.
A,Mus musculus,10090.0,,,1,Intermediate,,14387,,N,7832,1,,,50594,,,,BAO_0000218,CHEMBL621079,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice
A,Mus musculus,10090.0,,,1,Intermediate,,14387,,N,7833,1,,,50594,,,,BAO_0000218,CHEMBL621080,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12836,,N,7834,1,,,50588,,,,BAO_0000218,CHEMBL621081,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose
A,Cricetinae,10026.0,,,1,Intermediate,,12836,,N,7835,1,,,100712,,,,BAO_0000218,CHEMBL621082,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12836,,N,7836,1,,,50597,,,,BAO_0000218,CHEMBL621083,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14339,,N,7837,1,,,50588,,,,BAO_0000218,CHEMBL621084,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14339,,N,7838,1,,,50588,,,,BAO_0000218,CHEMBL621085,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14339,,N,7839,1,,,50588,,,,BAO_0000218,CHEMBL621086,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,10524,,N,7840,1,,,50588,,,,BAO_0000218,CHEMBL621087,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9994,,N,7841,1,,,50588,,,,BAO_0000218,CHEMBL622607,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11325,,N,7842,1,,,50588,,,,BAO_0000218,CHEMBL622608,,Serum AUC in marmosets (IV dose)
A,,,,,1,Autocuration,,12536,,U,7843,0,,,22224,,,,BAO_0000019,CHEMBL624481,,Area under the curve after intravenous administration at a dose of 10 umol/kg
A,,,,,1,Autocuration,,12536,,U,7844,0,,,22224,,,,BAO_0000019,CHEMBL624482,,Area under the curve after intravenous administration at a dose of 2 umol/kg
A,,,,,1,Autocuration,,12536,,U,7845,0,,,22224,,,,BAO_0000019,CHEMBL624483,,Area under the curve after intravenous administration at a dose of 4 umol/kg
A,,,,,1,Autocuration,,12536,,U,7846,0,,,22224,,,,BAO_0000019,CHEMBL624484,,Area under the curve after intravenous administration at a dose of 40 umol/kg
A,,,,,1,Autocuration,,12536,,U,7847,0,,,22224,,,,BAO_0000019,CHEMBL624485,,Area under the curve after intravenous administration at a dose of 5 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15556,,N,7848,1,,,50597,,,,BAO_0000218,CHEMBL624486,,Area under the curve for fumarate salt was evaluated in F344 Rats.
A,,,,,1,Autocuration,,2809,,U,7849,0,,,22224,,,,BAO_0000019,CHEMBL624487,,Area under the curve for the compound was calculated.
A,,,,,1,Autocuration,,9511,,U,7850,0,,,22224,,,,BAO_0000019,CHEMBL624488,,Area under the curve in concentration/ time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12818,,N,7851,1,,,50597,,,,BAO_0000218,CHEMBL624489,,Area under the curve administered intraintestinal in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12818,,N,7852,1,,,50597,,,,BAO_0000218,CHEMBL625184,,Area under the curve administered intravenously in rats.
A,,,,,1,Autocuration,,15118,,U,7853,0,,,22224,,,,BAO_0000019,CHEMBL625185,,Area under the curve during intravenous administration
A,,,,,1,Autocuration,,15118,,U,7854,0,,,22224,,,,BAO_0000019,CHEMBL875954,,Area under the curve during intravenous administration; Not determined
A,,,,,1,Autocuration,,15118,,U,7855,0,,,22224,,,,BAO_0000019,CHEMBL625186,,Area under the curve during systemic administration
A,,,,,1,Autocuration,,15118,,U,7856,0,,,22224,,,,BAO_0000019,CHEMBL625187,,Area under the curve during systemic administration; Not determined
A,,,,,1,Autocuration,,2632,,U,7857,0,,,22224,,,,BAO_0000019,CHEMBL625188,,Area under the curve was calculated for the compound.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,7858,1,,,50588,,,,BAO_0000218,CHEMBL625189,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,7859,1,,,50588,,,,BAO_0000218,CHEMBL625190,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,7860,1,,,50597,,,,BAO_0000218,CHEMBL621733,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,7861,1,,,50597,,,,BAO_0000218,CHEMBL621734,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,7862,1,,,50597,,,,BAO_0000218,CHEMBL621735,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,7863,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621736,,Clearance of the drug was measured in the plasma of rat; No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5247,,N,7864,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL621737,,The pharmacokinetic parameter plasma clearance in vivo in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,7865,1,,,50597,,,,BAO_0000218,CHEMBL621738,,Plasma clearance at the dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,7866,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622806,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,7867,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623519,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,7868,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623520,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,7869,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623521,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,7870,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623522,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6672,,N,7871,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623523,,Clearance rate in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6673,,N,7872,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623690,,Clearance rate in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,7873,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623691,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,7874,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623692,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,7875,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623693,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,7876,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623694,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4413,,N,7877,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623695,,Clearance of compound after iv administration of 20 mg/kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,7878,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623696,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,7879,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623697,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats
A,Macaca mulatta,9544.0,,,1,Intermediate,,5005,,U,7880,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623698,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,7881,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623699,,Compound was tested for its plasma clearance rate in Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,7882,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623700,,Mean (%CV) PK parameters for CL(mL/min/kg).
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3747,,N,7883,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623701,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,7884,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623702,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,7885,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623703,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17267,,N,7886,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623704,,Plasma clearance in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,7887,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623705,,Plasma clearance in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,7888,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623706,,Plasma clearance in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,7889,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623707,,Plasma clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,7890,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623708,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5937,,N,7891,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623709,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5871,,N,7892,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623710,,Plasma clearance in rat by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,7893,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623711,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6504,,N,7894,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623712,,Plasma clearance in rat p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6803,,N,7895,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623713,,Plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,7896,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623714,,Plasma clearance was determined; ND denotes no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,7897,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623715,,Plasma clearance was determined; ND denotes not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,7898,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623716,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,7899,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622980,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,7900,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622981,,Plasma administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6362,,N,7901,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622982,,Plasma clearance of the compound in female Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,7902,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622983,,Plasma clearance was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6215,,N,7903,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622984,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,7904,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622985,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,7905,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623631,,plasma clearance was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,7906,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623632,,In vivo CL/F determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,7907,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623633,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,7908,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623634,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5213,,N,7909,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623635,,Compound was tested for the lower blood clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4687,,N,7910,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621195,,Evaluated for the low clearance in rat (in vivo)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3371,,N,7911,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621196,,Pharmacokinetic property (CLb)of the compound was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4690,,N,7912,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875287,,Rapid clearance after intravenous administration in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5702,,N,7913,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621197,,Clearance measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,740,,N,7914,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621198,,Compound was evaluated for plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,7915,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621199,,Low plasma clearance was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5789,,N,7916,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621200,,Pharmacokinetic property (Clp) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,7917,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621201,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,7918,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621202,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,7919,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621203,,Plasma clearance after IV dosing at 0.5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,7920,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621204,,Plasma clearance after IV dosing at 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7921,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621205,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7922,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621206,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7923,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621207,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7924,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621208,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7925,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621209,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7926,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL876484,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7927,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621210,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7928,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621211,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7929,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621212,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7930,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621213,,Biodistribution in rat heart in the presence of GdDTPA at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7931,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621214,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7932,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621215,,Biodistribution in rat heart in the presence of GdDTPA at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7933,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621216,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7934,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621217,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7935,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621218,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7936,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621219,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7937,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621220,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7938,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621221,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7939,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621222,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7940,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621223,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7941,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL876485,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7942,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621224,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7943,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621225,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7944,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621226,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7945,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621227,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7946,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621228,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7947,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621229,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7948,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621230,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7949,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621231,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7950,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621232,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7951,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621233,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7952,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621234,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7953,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621235,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7954,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621236,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7955,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621237,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7956,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL876486,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7957,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622436,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7958,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622437,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7959,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622438,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7960,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622439,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7961,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622440,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7962,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622441,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7963,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622442,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7964,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622443,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7965,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622444,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7966,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622445,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7967,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622446,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7968,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622447,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7969,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622448,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7970,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622449,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7971,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622450,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7972,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622451,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7973,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622452,,Biodistribution in rat liver in the presence of GdDTPA at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7974,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622453,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7975,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622454,,Biodistribution in rat liver in the presence of GdDTPA at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7976,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622455,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,7977,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL876024,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,7978,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622456,,T max was determined at 3 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,7979,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622457,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,7980,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622458,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,7981,1,,,50597,,,,BAO_0000218,CHEMBL622459,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,7982,1,,,50597,,,,BAO_0000218,CHEMBL873343,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,7983,1,,,50597,,,,BAO_0000218,CHEMBL622460,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,7984,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622461,,Time for maximum plasma concentration determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6681,,N,7985,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622462,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,7986,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622463,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,7987,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622464,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,7988,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622465,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,7989,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622466,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,7990,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622467,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6824,,N,7991,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622468,,Time of maximum plasma concentration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7992,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL876025,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7993,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622469,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,7994,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622470,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,7995,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622471,,Time required to reach maximum concentration (Cmax) after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1742,,N,7996,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622472,,Time required to reach maximum concentration in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2774,,N,7997,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622473,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,7998,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624282,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,7999,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624283,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,8000,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624284,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,8001,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624285,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,8002,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624286,,Time to reach Cmax after oral administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,8003,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624287,,Time to reach Cmax when a dose of 1 mg/kg is administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,216,,N,8004,1,,,50597,,,,BAO_0000218,CHEMBL624288,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,8005,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624289,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,8006,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873344,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6215,,N,8007,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619623,,Tmax after peroral administration (10 mg/kg) was determined in rat
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,8008,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621399,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,8009,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621400,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17670,,N,8010,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621401,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1465,,N,8011,1,,,50597,,,,BAO_0000218,CHEMBL621402,,Tmax was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2552,,N,8012,1,,,50597,,,,BAO_0000218,CHEMBL621403,,Tmax was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,8013,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621121,,Tmax after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,8014,1,,,50597,,,In vivo,BAO_0000218,CHEMBL872525,,Tmax after peroral administration in rats at 2.4 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5610,,N,8015,1,,,50597,,,,BAO_0000218,CHEMBL621122,,Tmax in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6046,,N,8016,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621123,,Tmax in rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,8017,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621124,,Tmax in rat by po administration at a dose of 40 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,8018,1,,,50597,,,,BAO_0000218,CHEMBL621125,,Tmax in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,8019,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621126,,Tmax was measured in rats after peroral administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,8020,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621127,,Tmax value after oral dose at a dose of 10 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,8021,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621128,,Tmax value after administration of 20 mg/Kg oral dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8022,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618263,,Tmax value at a dose of 10 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8023,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618264,,Tmax value at a dose of 100 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8024,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618265,,Tmax value at a dose of 50 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,8025,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618266,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,8026,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618267,,time required to reach maximum concentration (Cmax) after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,8027,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL618450,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,8028,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL618451,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5546,,N,8029,1,,,50597,,,,BAO_0000218,CHEMBL618452,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3173,,N,8030,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL618453,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3173,,N,8031,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL618454,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3173,,N,8032,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL618455,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4257,,N,8033,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618456,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,8034,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618457,,Compound distribution in rat tissues was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,8035,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618458,,Volume of distribution was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8036,1,,,50597,,,,BAO_0000218,CHEMBL618459,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8037,1,,,50597,,,,BAO_0000218,CHEMBL876733,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,8038,1,,,50588,,,,BAO_0000218,CHEMBL618460,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8039,1,,,50597,,,,BAO_0000218,CHEMBL618461,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats
A,,,,,1,Autocuration,,15469,,U,8040,0,,,22224,,,,BAO_0000019,CHEMBL618462,,Area under the curve was determined after oral administration (300 uM/Kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8041,1,,,50597,,,,BAO_0000218,CHEMBL618463,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8042,1,,,50597,,,,BAO_0000218,CHEMBL618464,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8043,1,,,50597,,,,BAO_0000218,CHEMBL618465,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8044,1,,,50597,,,,BAO_0000218,CHEMBL618466,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,8045,1,,,50597,,,,BAO_0000218,CHEMBL618467,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,8046,1,,,50597,,,,BAO_0000218,CHEMBL618468,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12935,,N,8047,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL618469,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12935,,N,8048,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL618470,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg
A,,,,,1,Autocuration,,14813,,U,8049,0,,,22224,,,,BAO_0000218,CHEMBL618471,,Plasma drug AUC in rat (PO dose)
A,Mus musculus,10090.0,,,1,Intermediate,,15792,,N,8050,1,,,50594,,,,BAO_0000218,CHEMBL618472,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.
A,,,,,1,Autocuration,,3579,,U,8051,0,,,22224,,,,BAO_0000218,CHEMBL618473,,Area under was determined at a dose of 30 mg/kg
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12487,,N,8052,1,,,50506,,,,BAO_0000218,CHEMBL621699,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12487,,N,8053,1,,,50597,,,,BAO_0000218,CHEMBL621700,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12487,,N,8054,1,,,50597,,,,BAO_0000218,CHEMBL621701,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12487,,N,8055,1,,,50506,,,,BAO_0000218,CHEMBL621702,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12487,,N,8056,1,,,50588,,,,BAO_0000218,CHEMBL621703,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12487,,N,8057,1,,,50588,,,,BAO_0000218,CHEMBL621704,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8058,1,,,50597,,,,BAO_0000218,CHEMBL624259,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8059,1,,,50597,,,,BAO_0000218,CHEMBL624260,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8060,1,,,50597,,,,BAO_0000218,CHEMBL624430,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8061,1,,,50597,,,,BAO_0000218,CHEMBL624431,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8062,1,,,50597,,,,BAO_0000218,CHEMBL624432,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8063,1,,,50597,,,,BAO_0000218,CHEMBL624433,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8064,1,,,50597,,,,BAO_0000218,CHEMBL624434,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,8065,1,,,50597,,,,BAO_0000218,CHEMBL624435,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)"
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8066,1,,,50594,,,,BAO_0000218,CHEMBL618570,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8067,1,,,50594,,,,BAO_0000218,CHEMBL618571,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8068,1,,,50594,,,,BAO_0000218,CHEMBL618572,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8069,1,,,50594,,,,BAO_0000218,CHEMBL618573,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8070,1,,,50594,,,,BAO_0000218,CHEMBL619267,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8071,1,,,50594,,,,BAO_0000218,CHEMBL619431,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8072,1,,,50594,,,,BAO_0000218,CHEMBL619432,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,8073,1,,,50594,,,,BAO_0000218,CHEMBL619433,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
A,,,,,1,Autocuration,,13298,,U,8074,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL619434,,AUC in mice after oral dose (50 mg/kg)
A,Mus musculus,10090.0,,,1,Intermediate,,12226,,N,8075,1,,,50594,Serum,1977.0,,BAO_0000218,CHEMBL619435,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum
A,,,,,1,Autocuration,,12634,,U,8076,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL619436,,AUC (0-4 hr) ug/ml/h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14810,,N,8077,1,,,50597,,,,BAO_0000218,CHEMBL619437,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported
A,,,,,1,Autocuration,,13889,,U,8078,0,,,22224,,,,BAO_0000218,CHEMBL619438,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration
A,Mus musculus,10090.0,,,1,Intermediate,,10018,,N,8079,1,,,50594,,,,BAO_0000218,CHEMBL619439,,Compound was evaluated for Area under curve in mice
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8758,,N,8080,1,,,50597,,,,BAO_0000218,CHEMBL619440,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
F,,,,,1,Autocuration,,8758,,U,8081,0,,,22224,,,,BAO_0000218,CHEMBL619441,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8758,,N,8082,1,,,50597,,,,BAO_0000218,CHEMBL619442,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po
A,,,,,1,Autocuration,,2249,,U,8083,0,,,22224,,,,BAO_0000019,CHEMBL875156,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1
A,,,,,1,Autocuration,,2249,,U,8084,0,,,22224,,,,BAO_0000019,CHEMBL619443,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4
A,,,,,1,Autocuration,,2249,,U,8085,0,,,22224,,,,BAO_0000019,CHEMBL619444,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1
A,,,,,1,Autocuration,,2249,,U,8086,0,,,22224,,,,BAO_0000019,CHEMBL623464,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4
A,Mus musculus,10090.0,,,1,Intermediate,,15115,,N,8087,1,,,50594,,,,BAO_0000218,CHEMBL623465,,Compound was evaluated for area under curve when administered through oral route in mouse
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8088,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623466,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8089,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623467,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6249,,N,8090,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623468,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2463,,N,8091,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622660,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4969,,N,8092,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622661,,Plasma clearance rate in Sprague-Dawley rats
F,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,8093,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622662,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3457,,N,8094,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622663,,Pharmacokinetic property (total body clearance) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,8095,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622664,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6295,,N,8096,1,,,50597,,,,BAO_0000218,CHEMBL622665,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6296,,N,8097,1,,,50597,,,,BAO_0000218,CHEMBL622666,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,8098,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621615,,Cl in rat i.v. at 2 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,8099,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621616,,Clearance of compound after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5503,,N,8100,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621617,,Clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4368,,N,8101,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621618,,Clearance by intravenous administration of 3.4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6005,,N,8102,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621619,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5031,,N,8103,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621620,,Clearance rate after i.v. administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,8104,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621786,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,8105,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621787,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,8106,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621788,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,8107,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621789,,Clearance (Cl) after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,8108,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621790,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4839,,N,8109,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621791,,Compound was tested for plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,5041,,N,8110,1,,,50597,,,In vitro,BAO_0000218,CHEMBL621792,,In vitro microsome metabolism clearance in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,5041,,N,8111,1,,,50597,,,In vitro,BAO_0000218,CHEMBL621793,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8112,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621794,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5496,,N,8113,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621795,,In vivo plasma clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5739,,N,8114,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621796,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats
A,Rattus norvegicus,10116.0,,Hepatocyte,1,Intermediate,,5676,,N,8115,1,401.0,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621797,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4239,,N,8116,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621798,,Pharmacokinetic property (Plasma clearance) was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5676,,N,8117,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621799,,Pharmacokinetic property (clearance) in rat i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1918,,N,8118,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621800,,"Plasma Clearance was evaluated in rats, iv"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17800,,N,8119,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621801,,Plasma clearance (in vivo) in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6056,,N,8120,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621802,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5496,,N,8121,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618596,,Plasma clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,8122,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618597,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,8123,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618598,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,8124,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618599,,Plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,8125,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618600,,Plasma clearance rate determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,8126,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618601,,Plasma clearance was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,8127,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618602,,Plasma clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5948,,N,8128,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618603,,Plasma clearance value in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6125,,N,8129,1,,,50597,Liver,2107.0,Ex vivo,BAO_0000218,CHEMBL618604,,Clearance rate constant using isolated perfused rat liver (IPRL) assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4839,,N,8130,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618605,,Clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,8131,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618606,,Total body clearance in rat i.v. at 2 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,8132,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618607,,Clearance of compound in rats after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3364,,N,8133,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618608,,Clearance after iv administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8134,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618609,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8135,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618610,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8136,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618611,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8137,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618612,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8138,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618613,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8139,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621076,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8140,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621077,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17670,,N,8141,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621078,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5970,,N,8142,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621251,,Clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,8143,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621252,,Clearance in rat after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4590,,N,8144,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621253,,Clearance in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6193,,N,8145,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621254,,Clearance rate following an oral dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2832,,N,8146,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621255,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1052,,N,8147,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621256,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8148,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621257,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8149,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621258,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8150,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621259,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8151,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621260,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8152,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL876494,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8153,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621261,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8154,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621262,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8155,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621263,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8156,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621264,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8157,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621265,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8158,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621266,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8159,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621267,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8160,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621268,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8161,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621269,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8162,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621270,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8163,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621271,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8164,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621272,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8165,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621273,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8166,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621274,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8167,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL876495,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8168,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621275,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8169,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621276,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8170,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621277,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8171,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621278,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8172,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621279,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8173,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621280,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8174,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621281,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8175,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621282,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8176,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621283,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8177,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621284,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8178,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621285,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8179,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621286,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8180,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL623220,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8181,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL623221,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8182,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL876029,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8183,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL623222,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8184,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL623223,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9866,,N,8185,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL621445,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8186,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL621446,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8187,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL621447,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8188,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL619681,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8189,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL619682,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8190,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL619683,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8191,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL619684,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8192,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL619685,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8193,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL619686,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8194,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL619687,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8195,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL619688,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8196,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL619689,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8197,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL619690,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8198,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL619691,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6062,,N,8199,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619692,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,8200,1,,,50597,,,,BAO_0000218,CHEMBL619693,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,8201,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619694,,Vc value after IV dose at a dose of 5 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,8202,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619695,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,8203,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619696,,Compound was evaluated for pharmacokinetic parameter volume of distribution
A,Rattus norvegicus,10116.0,,,1,Intermediate,,740,,N,8204,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619697,,Compound was evaluated for volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,8205,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619698,,Steady state volume distribution was determined; steady state(ss)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3364,,N,8206,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619699,,Steady state volume of distribution after iv administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2552,,N,8207,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619700,,Steady state volume of distribution dosing at 3 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,406,,N,8208,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619701,,The compound was evaluated for volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,8209,1,,,50597,,,In vivo,BAO_0000218,CHEMBL619702,,The compound was tested for volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,8210,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620335,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,8211,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620336,,Volume distribution (VD) after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,8212,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620337,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1094,,N,8213,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620520,,Volume distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5833,,N,8214,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620521,,Volume distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,8215,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875825,,Volume distribution in rat after peroral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,8216,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620522,,Volume distribution in rat after peroral administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6005,,N,8217,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620523,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1696,,N,8218,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620524,,Volume of distribution in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6672,,N,8219,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620525,,Volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6673,,N,8220,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620526,,Volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5871,,N,8221,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620527,,Volume of distribution in rat by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6803,,N,8222,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620528,,Volume of distribution in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,8223,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620529,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,8224,1,,,50597,,,,BAO_0000218,CHEMBL620530,,Volume distribution at the dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,8225,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620531,,Steady state volume of distribution was determined
A,Macaca mulatta,9544.0,,,1,Intermediate,,5005,,U,8226,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620532,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,8227,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620533,,Compound was tested for its plasma volume distribution in Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,8228,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620534,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,8229,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620535,,Mean (%CV) PK parameters for Vdss(mL/kg).
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,8230,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875826,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,8231,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620536,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8232,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620537,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8233,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618526,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5739,,N,8234,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618527,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5789,,N,8235,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618528,,Pharmacokinetic property (Vdss) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4239,,N,8236,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618529,,Pharmacokinetic property (vdss) was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,8237,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618530,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6642,,N,8238,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618531,,Volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5247,,N,8239,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618532,,The pharmacokinetic parameter volume of distribution in vivo in rats
F,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,8240,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618533,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,8241,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618534,,Vdss in rat i.v. at 2 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,8242,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618535,,Volume distribution after intravenous administration (1 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,8243,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618536,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,8244,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618537,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,8245,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618538,,Volume distribution at a dose of 10 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4521,,N,8246,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618539,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,8247,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618540,,Volume distribution was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,8248,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618541,,Volume distribution was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2938,,N,8249,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618542,,Volume of distribution after intravenous administration was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6679,,N,8250,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622544,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8251,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622545,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8252,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622546,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8253,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622547,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5145,,N,8254,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622548,,Volume of distribution in steady state was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,8255,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622549,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,8256,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622550,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined
A,Mus musculus,10090.0,,,1,Intermediate,,15115,,N,8257,1,,,50594,,,,BAO_0000218,CHEMBL622551,,Compound was evaluated for area under curve when administered through oral route to mouse
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8758,,N,8258,1,,,50597,,,,BAO_0000218,CHEMBL622552,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8758,,N,8259,1,,,50597,,,,BAO_0000218,CHEMBL622553,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po
F,,,,,1,Autocuration,,8267,,U,8260,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622554,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8267,,N,8261,1,,,50588,,,,BAO_0000218,CHEMBL622555,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,8262,1,,,50594,,,,BAO_0000218,CHEMBL622556,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,8263,1,,,50594,,,,BAO_0000218,CHEMBL622557,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,8264,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL622558,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,8265,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL622559,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,10754,,N,8266,1,,,50588,,,,BAO_0000218,CHEMBL622560,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14681,,N,8267,1,,,50597,,,,BAO_0000218,CHEMBL622561,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14681,,N,8268,1,,,50597,,,,BAO_0000218,CHEMBL622562,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. 
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14681,,N,8269,1,,,50597,,,,BAO_0000218,CHEMBL622563,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose
A,,,,,1,Autocuration,,13118,,U,8270,0,,,22224,,,,BAO_0000019,CHEMBL622564,,Concentration of compound in Central nervous system
A,,,,,1,Autocuration,,13118,,U,8271,0,,,22224,,,,BAO_0000019,CHEMBL622565,,Concentration of compound in Central nervous system; Not detectable
A,Mus musculus,10090.0,,,1,Intermediate,,13318,,N,8272,1,,,50594,,,,BAO_0000218,CHEMBL622566,,"Concentration of diester in the blood, following oral administration in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,13318,,N,8273,1,,,50594,,,,BAO_0000218,CHEMBL624515,,"Concentration of monoester in the blood, following oral administration in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,13318,,N,8274,1,,,50594,,,,BAO_0000218,CHEMBL624516,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice
A,,,,,1,Autocuration,,15692,,U,8275,0,,,22224,,,,BAO_0000019,CHEMBL624517,,Evaluated for Pharmacokinetic property: Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8276,1,,,50594,,,,BAO_0000218,CHEMBL624518,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8277,1,,,100710,,,,BAO_0000218,CHEMBL624519,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8278,1,,,100710,,,,BAO_0000218,CHEMBL624520,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8279,1,,,100710,,,,BAO_0000218,CHEMBL624521,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8280,1,,,100710,,,,BAO_0000218,CHEMBL624522,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8281,1,,,100710,,,,BAO_0000218,CHEMBL624523,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8282,1,,,100710,,,,BAO_0000218,CHEMBL624409,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8283,1,,,100710,,,,BAO_0000218,CHEMBL624410,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8284,1,,,100710,,,,BAO_0000218,CHEMBL624411,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8285,1,,,100710,,,,BAO_0000218,CHEMBL623531,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8286,1,,,100710,,,,BAO_0000218,CHEMBL623532,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8287,1,,,100710,,,,BAO_0000218,CHEMBL623533,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,8288,1,,,100710,,,,BAO_0000218,CHEMBL623534,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8289,1,,,50594,,,,BAO_0000218,CHEMBL623535,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8290,1,,,50594,,,,BAO_0000218,CHEMBL623536,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8291,1,,,50594,,,,BAO_0000218,CHEMBL623537,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8292,1,,,50594,,,,BAO_0000218,CHEMBL623538,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8293,1,,,50594,,,,BAO_0000218,CHEMBL623539,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8294,1,,,50594,,,,BAO_0000218,CHEMBL623540,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8295,1,,,50594,,,,BAO_0000218,CHEMBL623541,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined."
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8296,1,,,50594,,,,BAO_0000218,CHEMBL623542,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8297,1,,,50594,,,,BAO_0000218,CHEMBL623543,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8298,1,,,50594,,,,BAO_0000218,CHEMBL623544,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8299,1,,,50594,,,,BAO_0000218,CHEMBL623545,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,8300,1,,,50594,,,,BAO_0000218,CHEMBL623546,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,8301,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623547,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6827,,N,8302,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623548,,High i.v. clearance in Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,17538,,N,8303,1,,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL623549,,In vitro clearance in rat liver microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,6331,,N,8304,1,,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL623550,,Intrinsic clearance in rat liver microsomes was determined
A,Rattus norvegicus,10116.0,,Hepatocyte,1,Intermediate,,5948,,N,8305,1,401.0,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL875276,,Intrinsic clearance in rat hepatocytes was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,8306,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621872,,Plasma Clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,8307,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621873,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1696,,N,8308,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621874,,Plasma clearance in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,8309,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621875,,Plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,347,,N,8310,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621876,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,8311,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621877,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,8312,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621878,,Plasma clearance was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,8313,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621879,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5328,,N,8314,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621880,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5160,,N,8315,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621881,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,8316,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621882,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,8317,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875283,,Total clearance at 1 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,8318,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621883,,Total clearance at 10 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6596,,N,8319,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621884,,Clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4796,,N,8320,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621885,,Plasma clearance rate determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6850,,N,8321,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621886,,Clearance of compound in rat was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,8322,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621887,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3371,,N,8323,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621888,,Pharmacokinetic property (blood clearance) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2083,,N,8324,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621889,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4942,,N,8325,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621890,,Plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,6838,,N,8326,1,,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL621891,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5353,,N,8327,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621892,,Clearance in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8328,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621893,,Clearance rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8329,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621894,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8330,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621895,,Clearance rat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8331,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875284,,Clearance rate was determined in rat at a dose of 1 mpk i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8332,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618699,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8333,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618700,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6211,,N,8334,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618701,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,8335,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL876600,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,8336,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618702,,Clearance of compound in rat after 1 mg/kg i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3341,,N,8337,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618703,,Compound was evaluated for Hepatic clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,8338,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618704,,In vivo clearance after 5 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1094,,N,8339,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618705,,Compound was tested for plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2938,,N,8340,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618706,,Hepatic clearance after intravenous administration was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,8341,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618707,,Lower clearance in rat (i.v.) at 0.5 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6049,,N,8342,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618708,,Pharmacokinetic parameter expressed as plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5789,,N,8343,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618709,,Pharmacokinetic property (Clp) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,8344,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618710,,Plasma clearance in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,8345,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618711,,Plasma clearance (Clp) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6062,,N,8346,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618712,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,8347,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618713,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,8348,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618714,,Plasma clearance after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4521,,N,8349,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618715,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1742,,N,8350,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618716,,Plasma clearance in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,8351,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876601,,Plasma clearance measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,8352,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618717,,Plasma clearance was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5145,,N,8353,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618718,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5833,,N,8354,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618719,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6453,,N,8355,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618720,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,8356,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618721,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6305,,N,8357,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621477,,Plasma clearance in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6642,,N,8358,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621478,,Plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,8359,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621479,,Plasma clearance was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,8360,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621480,,Plasma clearance was evaluated in rat; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5144,,N,8361,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621481,,Plasma clearance rate was determined for the compound in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8362,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621482,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8363,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621483,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8364,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621484,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8365,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621485,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8366,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL621486,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8367,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621487,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8368,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621488,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8369,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621489,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8370,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621490,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8371,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL621491,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8372,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621492,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8373,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621493,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8374,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621494,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8375,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621495,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8376,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621496,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8377,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621497,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8378,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621498,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8379,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621499,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8380,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618634,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8381,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618635,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8382,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL618636,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8383,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL619737,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8384,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL619738,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8385,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624329,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8386,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624330,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8387,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624331,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8388,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624332,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8389,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624333,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8390,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624334,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8391,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624335,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8392,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620016,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8393,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620169,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8394,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620170,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8395,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620171,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8396,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL620172,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8397,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL620173,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8398,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL620174,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8399,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL620175,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8400,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL620176,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8401,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL620177,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8402,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL620178,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8403,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL620179,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8404,1,,,50597,,,,BAO_0000218,CHEMBL620180,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,8405,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620181,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,8406,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620182,,Volume of distribution of compound in rats after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6453,,N,8407,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620183,,Volume of distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8408,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620184,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8409,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620185,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,8410,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620186,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5353,,N,8411,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620187,,Volume of distribution was determined in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8412,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620188,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8413,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620189,,Volume of distribution was reported in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8414,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620190,,Volumes of distribution in rat after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8415,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620191,,Volumes of distribution in rat after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,8416,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620192,,Volumes of distribution in rat after po administration; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5676,,N,8417,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620193,,Pharmacokinetic property (Volume) in rat i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,8418,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620194,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17670,,N,8419,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876730,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,8420,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620195,,Volume distribution in rat after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,8421,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620196,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,8422,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620197,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,8423,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620198,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,8424,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620199,,Volume of distribution in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,8425,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620200,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,8426,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620201,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8427,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620202,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8428,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620203,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8429,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620204,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8430,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620205,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,8431,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624664,,Pharmacokinetic parameter (Vss) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5676,,N,8432,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624665,,Pharmacokinetic property (Volume) in rat i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5948,,N,8433,1,,,50597,,,,BAO_0000218,CHEMBL624666,,Pharmacokinetic property (Vss) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,8434,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624667,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8435,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624668,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8436,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624669,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8437,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624670,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8438,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624671,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,8439,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624672,,Steady state volume distribution in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,8440,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624673,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,8441,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624674,,Steady state volume of distribution determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,8442,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624675,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,8443,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621728,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,8444,1,,,50597,,,,BAO_0000218,CHEMBL621729,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,8445,1,,,50597,,,,BAO_0000218,CHEMBL621730,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,8446,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621731,,Volume distribution in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,8447,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621732,,Volume distribution in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,8448,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621908,,Volume in steady state distribution value was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,8449,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875347,,Volume in steady state distribution value was determined; ND denotes no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,8450,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621909,,Volume in steady state distribution value was determined; ND denotes not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,8451,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621910,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,8452,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621911,,Volume of distribution at steady state was evaluated in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,8453,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621912,,Volume of distribution at steady state was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6485,,N,8454,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621913,,Volume of distribution in steady state was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,8455,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621914,,Volume of distribution in steady state was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6616,,N,8456,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621915,,Volume of distribution after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,8457,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621916,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8458,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621917,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8459,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621918,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8460,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621919,,Biodistribution of compound (oxidized form) in spleen tissue
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8461,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621920,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8462,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL621921,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8463,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622401,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8464,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL875348,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8465,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622402,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8466,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622403,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8467,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL622404,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8468,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622405,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8469,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622406,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8470,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL622407,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8471,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622408,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8472,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622409,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8473,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL622410,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8474,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622411,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8475,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627864,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8476,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627865,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8477,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627866,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8478,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627751,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8479,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627752,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8480,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627753,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,16438,,N,8481,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627754,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
A,Mus musculus,10090.0,,,1,Intermediate,,12467,,N,8482,1,,,50594,,,,BAO_0000218,CHEMBL627755,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8483,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627756,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8484,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627757,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8485,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627758,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8486,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627759,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8487,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627760,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8488,1,,,50594,Brain,955.0,In vivo,BAO_0000218,CHEMBL627761,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8489,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL876811,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8490,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL627762,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8491,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL627763,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8492,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL627764,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8493,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL627765,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8494,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL627766,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8495,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627767,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8496,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627768,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8497,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628422,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8498,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628423,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,8499,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628424,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,8500,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628425,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4257,,N,8501,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628426,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6679,,N,8502,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628427,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5546,,N,8503,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626938,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6141,,N,8504,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626939,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8505,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626940,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8506,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626941,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,8507,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626942,,Plasma clearance was reported in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,8508,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876812,,Plasma clearance after intravenous administration (1 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6848,,N,8509,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626943,,Plasma clearance of compound in rats was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6848,,N,8510,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626944,,Plasma clearance of compound in rats was evaluated; ND indicates not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,8511,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626945,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,8512,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626946,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4956,,N,8513,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626856,,Plasma clearance rate in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5529,,N,8514,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626857,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,406,,N,8515,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626858,,The compound was evaluated for plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,8516,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627018,,Total plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3293,,N,8517,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625331,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4075,,N,8518,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625332,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,8519,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877590,,C max was determined at 10 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,8520,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625333,,C max was determined at 3 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,8521,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625334,,Cmax after repeated oral dose of compound at 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,8522,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625335,,Cmax after single intravenous bolus of 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4762,,N,8523,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625336,,Cmax of compound at 5 mg/kg after po administration was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,8524,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625337,,Cmax 24 hr after 10 mg/kg oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,8525,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625338,,Cmax 24 hr after 2 mg/kg oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,8526,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625339,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,8527,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625340,,Cmax in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,8528,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625341,,Cmax in rat after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,8529,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622687,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6515,,N,8530,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622688,,Cmax wa determined in rat plasma at 30 mg/kg after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,8531,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622689,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,8532,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL620295,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17858,,N,8533,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620296,,Cmax after 10 mg/kg oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8534,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620297,,Cmax after IV dosing at 0.5 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8535,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620298,,Cmax after IV dosing at 1 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,8536,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620299,,Cmax after oral administration at 20 mpk in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,8537,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620300,,Cmax after oral administration at 20 mpk in rats; Not performed.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,8538,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620301,,Cmax after oral administration at 20 mpk in rats d; Not performed.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,8539,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620302,,Cmax after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8540,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620303,,Cmax after oral administration at a dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,8541,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620304,,Cmax after oral administration at a dose of 4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6113,,N,8542,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620305,,Cmax in rats after 20 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,8543,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620306,,Cmax after peroral administration in rats at 2.4 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,8544,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620307,,Cmax at the dose of 2 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,8545,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620308,,Cmax at the dose of 5 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6402,,N,8546,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620309,,Cmax by administering at 20 mg/kg p.o. in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5610,,N,8547,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620310,,Cmax in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5207,,N,8548,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620311,,Cmax in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,8549,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620312,,Cmax in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6504,,N,8550,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620313,,Cmax in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6046,,N,8551,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620314,,Cmax in rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6504,,N,8552,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620315,,Cmax in rat at the dose of 1 mg/kg i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,8553,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620316,,Cmax in rat by po administration at a dose of 40 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,8554,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620317,,Cmax in rat p.o. at 20 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5836,,N,8555,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620318,,Cmax in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,8556,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620319,,Cmax in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,8557,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620320,,Cmax was evaluated after 20 uM/kg of peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,8558,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620321,,Cmax was measured in rats after peroral administration at 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,8559,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620322,,Cmax value after oral dose at a dose of 10 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8560,1,,,50597,,,,BAO_0000218,CHEMBL620323,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8561,1,,,50597,Frontal cortex,1870.0,,BAO_0000218,CHEMBL620324,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8562,1,,,50597,Frontal cortex,1870.0,,BAO_0000218,CHEMBL620325,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8563,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL620326,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8564,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL620327,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8565,1,,,50597,,,,BAO_0000218,CHEMBL620328,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8566,1,,,50597,,,,BAO_0000218,CHEMBL620329,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8567,1,,,50597,Midbrain,1891.0,,BAO_0000218,CHEMBL620330,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8568,1,,,50597,Midbrain,1891.0,,BAO_0000218,CHEMBL875286,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8569,1,,,50597,,,,BAO_0000218,CHEMBL620331,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8570,1,,,50597,,,,BAO_0000218,CHEMBL620332,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8571,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL620333,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13950,,N,8572,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL620334,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8573,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621015,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8574,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621016,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8575,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621191,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8576,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621192,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8577,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621193,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8578,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621194,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8579,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624204,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8580,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624205,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8581,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624206,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8582,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624207,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8583,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624208,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8584,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624209,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8585,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624210,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8586,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624211,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8587,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624212,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8588,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624213,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8589,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL876611,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8590,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624214,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8591,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624215,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8592,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624216,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8593,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624217,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8594,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624218,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8595,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624219,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8596,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624220,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8597,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624221,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8598,1,,,50597,,,,BAO_0000218,CHEMBL624222,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8599,1,,,50597,,,,BAO_0000218,CHEMBL624223,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8600,1,,,50597,,,,BAO_0000218,CHEMBL624224,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8601,1,,,50597,,,,BAO_0000218,CHEMBL624225,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,8602,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622420,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5031,,N,8603,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622421,,Volume of steady state distribution after i.v. administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6215,,N,8604,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622422,,Vss after intravenous administration (5.0 mg/kg) was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,8605,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622423,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,8606,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622424,,Vss was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6596,,N,8607,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622425,,Vss in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,8608,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876612,,Vss was evaluated after 10 uM/kg of intra arterial administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,8609,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622426,,volume of distribution at steady state was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6062,,N,8610,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622427,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,8611,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622428,,Pharmacokinetic (PK) parameter Vz in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4942,,N,8612,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622429,,Volume distribution in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,8613,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622430,,Volume of distribution in rat; No data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,8614,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622431,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,8615,1,,,50597,Ileum,2116.0,,BAO_0000218,CHEMBL622432,,% absorption predicted from in vitro rat ileum transport studies
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8616,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622433,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8617,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622434,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8618,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622435,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8619,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618748,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8620,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618749,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8621,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618750,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8622,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618751,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13569,,N,8623,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618752,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,8624,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618753,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,750,,N,8625,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL618754,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations
A,Rattus norvegicus,10116.0,,,1,Intermediate,,750,,N,8626,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618755,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4590,,N,8627,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618756,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1716,,N,8628,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618757,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1974,,N,8629,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618758,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4502,,N,8630,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621088,,Oral bioavailability in rat (dose 30 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3371,,N,8631,1,,,50597,,,,BAO_0000218,CHEMBL621089,,Pharmacokinetic property (cLogP) in rat
F,Rattus norvegicus,10116.0,,,1,Intermediate,,9099,,N,8632,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621090,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally
F,Rattus norvegicus,10116.0,,,1,Intermediate,,9099,,N,8633,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL621091,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4590,,N,8634,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876731,,Clearance in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3184,,N,8635,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621092,,Compound was evaluated for its clearance when administered intravenously in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16456,,N,8636,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621093,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,8637,1,,,50597,,,,BAO_0000218,CHEMBL621094,,Blood: Brain distribution ratio is determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,8638,1,,,50597,,,,BAO_0000218,CHEMBL621095,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,8639,1,,,50597,,,,BAO_0000218,CHEMBL621096,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,8640,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621097,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,8641,1,,,50597,,,,BAO_0000218,CHEMBL621098,,Percent dose excreted in 0-48 hours administered ip to male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8642,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL621099,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8643,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL621100,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8644,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL621101,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8645,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL621102,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8646,1,,,50597,Cerebellum,2037.0,,BAO_0000218,CHEMBL876732,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8647,1,,,50597,,,,BAO_0000218,CHEMBL621103,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8648,1,,,50597,,,,BAO_0000218,CHEMBL621104,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8649,1,,,50597,,,,BAO_0000218,CHEMBL621105,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8650,1,,,50597,,,,BAO_0000218,CHEMBL621106,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8651,1,,,50597,,,,BAO_0000218,CHEMBL621107,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8652,1,,,50597,,,,BAO_0000218,CHEMBL621108,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8653,1,,,50597,,,,BAO_0000218,CHEMBL621109,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8654,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621110,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8655,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL621111,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8656,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622541,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8657,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622542,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8658,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622543,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8659,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624412,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8660,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624413,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8661,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624414,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8662,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624415,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8663,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624416,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8664,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624417,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8665,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624418,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8666,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624419,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8667,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624420,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8668,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624421,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8669,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624422,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8670,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624423,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8671,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625123,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8672,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625124,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8673,1,,,50594,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625125,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8674,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL625126,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8675,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL626947,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8676,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL626948,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8677,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL626949,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8678,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL626950,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8679,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL626951,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8680,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626952,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8681,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626953,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8682,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626954,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8683,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626955,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8684,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626956,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8685,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626957,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8686,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626958,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8687,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626959,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8688,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626960,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8689,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626961,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8690,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL627589,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,17208,,N,8691,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL627590,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY)
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,8692,1,,,50594,,,,BAO_0000218,CHEMBL627591,,Time taken for EC90 was determined when tested in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,8693,1,,,50594,,,,BAO_0000218,CHEMBL627592,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,16597,,N,8694,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627593,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
A,Mus musculus,10090.0,,,1,Intermediate,,5727,,N,8695,1,,,50594,,,,BAO_0000218,CHEMBL627594,,Half life in mice
A,Mus musculus,10090.0,,,1,Intermediate,,5302,,N,8696,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876813,,Half life period in mouse after 10 mg/Kg dose
A,Mus musculus,10090.0,,,1,Intermediate,,5302,,N,8697,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627595,,Half life period in mouse after 10 mg/kg dose
A,Mus musculus,10090.0,,,1,Intermediate,,6348,,N,8698,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627596,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,8699,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627597,,Cmax value at 5 mg/kg po was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,8700,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627598,,Cmax value evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5206,,N,8701,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL627599,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,8702,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627600,,Cmax value after administration of 20 mg/Kg oral dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,8703,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627601,,Cmax value at 1 mg/kg po in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,8704,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627776,,Cmax value at 5 mg/kg po in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8705,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627777,,Cmax value at a dose of 10 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8706,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627778,,Cmax value at a dose of 100 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,8707,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627779,,Cmax value at a dose of 50 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17617,,N,8708,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876814,,Cmax value in rats at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1445,,N,8709,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627780,,Cmax value was evaluated in rats at a dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6082,,N,8710,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627781,,Cmax value was determined after peroral administration of 20 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,8711,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627782,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5407,,N,8712,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627783,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2690,,N,8713,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627784,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,8714,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627785,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,8715,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627786,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,8716,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627787,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2807,,N,8717,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627788,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2807,,N,8718,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626579,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2807,,N,8719,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626580,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3634,,N,8720,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876815,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1881,,N,8721,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626581,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1881,,N,8722,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626582,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,8723,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626583,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8724,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626205,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8725,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626206,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8726,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626207,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,8727,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623882,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,8728,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623883,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,8729,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623884,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3032,,N,8730,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623885,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6295,,N,8731,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623886,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6619,,N,8732,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623887,,Maximal concentration in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6616,,N,8733,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623888,,Maximal concentration after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3249,,N,8734,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623889,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,8735,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623890,,Maximal plasma concentration in rat after oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,8736,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623891,,Cmax in rat plasma after oral dose (50 mg/Kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1360,,N,8737,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623892,,Maximal plasma concentration was determined.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2552,,N,8738,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623893,,Maximal plasma drug concentration was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,8739,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877616,,Maximal concentration in rats after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,8740,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623894,,Maximum concentration in rat after 2 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6567,,N,8741,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623895,,Maximum concentration in rat plasma after 5 mg/kg oral gavage
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3031,,N,8742,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623896,,Maximum concentration of compound in rat was evaluated.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3436,,N,8743,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623897,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3436,,N,8744,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623898,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2083,,N,8745,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623899,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3436,,N,8746,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623900,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,8747,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623901,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1974,,N,8748,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623902,,Maximum concentration was evaluated in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3307,,N,8749,1,,,50597,Cerebrospinal fluid,1359.0,In vivo,BAO_0000218,CHEMBL623903,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3307,,N,8750,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623904,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,8751,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL877617,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,8752,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623905,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,8753,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623906,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,8754,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623907,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8755,1,,,50597,,,,BAO_0000218,CHEMBL623908,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8756,1,,,50597,,,,BAO_0000218,CHEMBL623909,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8757,1,,,50597,,,,BAO_0000218,CHEMBL623910,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8758,1,,,50597,,,,BAO_0000218,CHEMBL623911,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8759,1,,,50597,,,,BAO_0000218,CHEMBL623912,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8760,1,,,50597,,,,BAO_0000218,CHEMBL624616,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8761,1,,,50597,,,,BAO_0000218,CHEMBL624617,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8762,1,,,50597,,,,BAO_0000218,CHEMBL624618,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8763,1,,,50597,,,,BAO_0000218,CHEMBL624619,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8764,1,,,50597,,,,BAO_0000218,CHEMBL624794,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8765,1,,,50597,,,,BAO_0000218,CHEMBL624795,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8766,1,,,50597,,,,BAO_0000218,CHEMBL623921,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8767,1,,,50597,,,,BAO_0000218,CHEMBL623922,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8768,1,,,50597,,,,BAO_0000218,CHEMBL623923,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8769,1,,,50597,,,,BAO_0000218,CHEMBL623924,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8770,1,,,50597,,,,BAO_0000218,CHEMBL623925,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8771,1,,,50597,,,,BAO_0000218,CHEMBL623926,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8772,1,,,50597,,,,BAO_0000218,CHEMBL623927,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8773,1,,,50597,,,,BAO_0000218,CHEMBL623928,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8774,1,,,50597,,,,BAO_0000218,CHEMBL623929,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8775,1,,,50597,,,,BAO_0000218,CHEMBL623930,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8776,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL623931,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8777,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622165,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8778,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621249,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8779,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621250,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8780,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621448,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8781,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621449,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8782,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621450,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8783,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621451,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8784,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621452,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8785,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621453,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8786,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621454,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8787,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621455,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8788,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL621456,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8789,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625145,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8790,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL875847,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8791,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625146,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8792,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625147,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8793,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625148,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8794,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625149,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8795,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625150,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8796,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625151,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8797,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625152,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8798,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625153,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8799,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625154,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8800,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL625155,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8801,1,,,50597,,,,BAO_0000218,CHEMBL625156,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8802,1,,,50597,,,,BAO_0000218,CHEMBL624354,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8803,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL624355,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8804,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL624356,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8805,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL624357,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8806,1,,,50597,Hippocampus,10000000.0,,BAO_0000218,CHEMBL624358,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8807,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL624359,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8808,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL624360,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8809,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL624361,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8810,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL624362,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8811,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL624363,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8812,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624364,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8813,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624365,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8814,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624366,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8815,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624367,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8816,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624368,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8817,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624369,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8818,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624370,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8819,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625069,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8820,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625070,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8821,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626051,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8822,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626052,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8823,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626053,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8824,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626054,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8825,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626055,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8826,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626056,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8827,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626057,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8828,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625193,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8829,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625194,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8830,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625195,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8831,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625196,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8832,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625197,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8833,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625198,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8834,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627929,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8835,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627074,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8836,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627075,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8837,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627076,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8838,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627077,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8839,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627078,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8840,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627079,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats)
A,Mus musculus,10090.0,,,1,Intermediate,,4573,,N,8841,1,,,50594,,,In vivo,BAO_0000218,CHEMBL873824,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,8842,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627080,,Half life in mouse plasma was determined at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17718,,N,8843,1,,,50594,,,,BAO_0000218,CHEMBL627081,,Half life was determined
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8844,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627082,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration
A,Mus musculus,10090.0,,,1,Intermediate,,5961,,N,8845,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627083,,Half-life in male mice after 1 mg/kg intravenous dose
A,Mus musculus,10090.0,,,1,Intermediate,,17731,,N,8847,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL627085,,Half life in mice plasma
A,Mus musculus,10090.0,,,1,Intermediate,,17592,,N,8848,1,,,50594,,,,BAO_0000218,CHEMBL627086,,Half life in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,3132,,N,8849,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627087,,Half life in mouse plasma at dose 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,8850,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627088,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,8851,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627089,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined
A,Mus musculus,10090.0,,,1,Intermediate,,17729,,N,8852,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627090,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined
A,Mus musculus,10090.0,,,1,Intermediate,,3277,,N,8853,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627091,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,8854,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627092,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,3760,,N,8855,1,,,50594,,,In vivo,BAO_0000218,CHEMBL876785,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice"
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,8856,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627093,,Half-life by iv administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2862,,N,8857,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627094,,Half-life by oral administration in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,5980,,N,8858,1,,,50594,,,,BAO_0000218,CHEMBL627095,,Half-life in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6159,,N,8859,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL627096,,Half-life using mouse brain homogenate
A,Mus musculus,10090.0,,,1,Intermediate,,6254,,N,8860,1,,,50594,,,,BAO_0000218,CHEMBL627097,,Half-life was measured in mice
A,Mus musculus,10090.0,,,1,Intermediate,,6062,,N,8861,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627098,,Half-life was measured in mouse after an iv dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,1574,,N,8862,1,,,50594,Blood,178.0,,BAO_0000218,CHEMBL627099,,Half-life period was determined in mouse blood
A,Mus musculus,10090.0,,,1,Intermediate,,56,,N,8863,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL627100,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain"
A,Mus musculus,10090.0,,,1,Intermediate,,993,,N,8864,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL627101,,Plasma half life in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,6652,,N,8865,1,,,50594,,,,BAO_0000218,CHEMBL627102,,Stability of the peptide in the presence of mouse serum
A,Mus musculus,10090.0,,,1,Intermediate,,17852,,N,8866,1,,,50594,,,,BAO_0000218,CHEMBL627103,,Terminal half life of compound was determined in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,8867,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627104,,Terminal half life was evaluated in mice after intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,2675,,N,8868,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627105,,Terminal half life was evaluated in mice after oral administration
A,Mus musculus,10090.0,,,1,Intermediate,,499,,N,8869,1,,,50594,,,,BAO_0000218,CHEMBL876786,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.
A,Mus musculus,10090.0,,,1,Intermediate,,499,,N,8870,1,,,50594,,,,BAO_0000218,CHEMBL873825,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.
A,Mus musculus,10090.0,,,1,Intermediate,,499,,N,8871,1,,,50594,,,,BAO_0000218,CHEMBL627106,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,8872,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626336,,half life period is evaluated by administering intravenously at 25 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,8873,1,,,50594,,,In vivo,BAO_0000218,CHEMBL877462,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice"
A,Mus musculus,10090.0,,,1,Intermediate,,5506,,N,8874,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626337,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable"
A,Mus musculus,10090.0,,,1,Intermediate,,17734,,N,8875,1,,,50594,,,,BAO_0000218,CHEMBL626338,,Half life after intraperitoneal administration of 100 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8876,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626339,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8877,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626340,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8878,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625377,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8879,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625378,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration
A,Mus musculus,10090.0,,,1,Intermediate,,17728,,N,8880,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625379,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration
A,Sus scrofa,9823.0,,,1,Autocuration,Microsomes,14294,,U,8881,0,,,22224,,,,BAO_0000251,CHEMBL625380,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak)
A,Sus scrofa,9823.0,,,1,Autocuration,Microsomes,14294,,U,8882,0,,,22224,,,,BAO_0000251,CHEMBL625381,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak)
A,Sus scrofa,9823.0,,,1,Autocuration,,6056,,U,8883,0,,,22224,,,,BAO_0000019,CHEMBL625382,,Stability to porcine renal DHP-I
A,Sus scrofa,9823.0,,,1,Autocuration,,1317,,U,8884,0,,,22224,,,In vivo,BAO_0000218,CHEMBL873828,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg
A,Sus scrofa,9823.0,,,1,Autocuration,,1317,,U,8885,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625383,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg
A,Sus scrofa,9823.0,,,1,Autocuration,,5229,,U,8886,0,,,22224,,,,BAO_0000019,CHEMBL625384,,Half-life of the parent prodrug in porcine esterase solution
A,Sus scrofa,9823.0,,,1,Autocuration,,4231,,U,8887,0,,,22224,,,,BAO_0000019,CHEMBL625385,,"First order rate constant, k was determined in in pig liver Esterase"
A,Sus scrofa,9823.0,,,1,Autocuration,,4231,,U,8888,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL625386,,Half life of the in pig liver Esterase
A,Sus scrofa,9823.0,,,1,Autocuration,,5318,,U,8889,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623571,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase
A,Sus scrofa,9823.0,,,1,Autocuration,,5318,,U,8890,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623572,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase
A,Sus scrofa,9823.0,,,1,Autocuration,,5318,,U,8891,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623573,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase
A,Sus scrofa,9823.0,,,1,Autocuration,,3305,,U,8892,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623574,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay
A,Sus scrofa,9823.0,,,1,Autocuration,,3305,,U,8893,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623575,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined
A,Sus scrofa,9823.0,,,1,Autocuration,,2842,,U,8894,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623749,,Half-life in the presence of pig liver esterase(PLE) was evaluated.
A,Sus scrofa,9823.0,,,1,Autocuration,,2842,,U,8895,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623750,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable
A,Sus scrofa,9823.0,,,1,Autocuration,,889,,U,8896,0,,,22224,Liver,2107.0,In vitro,BAO_0000221,CHEMBL623751,,Half-life in vitro in pig liver
A,Sus scrofa,9823.0,,,1,Autocuration,,1904,,U,8897,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL623752,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,8898,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623753,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2774,,N,8899,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623754,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1742,,N,8900,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623755,,Maximum concentration in rat plasma was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,8901,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623756,,Maximum concentration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,8902,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623757,,Maximum concentration in rats at 1-2 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2081,,N,8903,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623758,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3307,,N,8904,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623759,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,8905,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623760,,Maximum concentration at the dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,8906,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623761,,Maximum concentration was evaluated in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,8907,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623762,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,8908,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL877594,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,8909,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623763,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,8910,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623764,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,8911,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623765,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2591,,N,8912,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623766,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2591,,N,8913,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623767,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2591,,N,8914,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623768,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8915,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623769,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8916,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623770,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8917,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623771,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8918,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623772,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8919,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623773,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8920,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623774,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,8921,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623775,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14465,,N,8922,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623776,,Cmax in rat (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,8923,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622191,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,8924,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622192,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,8925,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622193,,Maximum plasma concentration determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,8926,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622194,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,8927,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622195,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6824,,N,8928,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622196,,Maximum plasma concentration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,8929,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622197,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2932,,N,8930,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622198,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2932,,N,8931,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622199,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,8932,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622200,,Maximum plasma concentration of compound was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2864,,N,8933,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622201,,Maximum plasma concentration after 20 mg/kg oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,8934,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623990,,Maximum plasma concentration after oral administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,8935,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623991,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,8936,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623992,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,8937,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623993,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,8938,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623994,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control
F,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,8939,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623995,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration
F,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,8940,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623996,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration
F,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,8941,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623997,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4516,,N,8942,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623998,,Maximum plasma concentration dosed orally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4516,,N,8943,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623999,,Maximum plasma concentration dosed orally in rats after 6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4516,,N,8944,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624000,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,8945,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624001,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,8946,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624002,,Maximum plasma concentration in rat after po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8947,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624003,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,8948,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624004,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8949,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624005,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8950,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624006,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8951,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624007,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8952,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624008,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8953,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624009,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8954,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL874387,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8955,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624010,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8956,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624011,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8957,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624012,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8958,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624013,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8959,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624736,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8960,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624737,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8961,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624738,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8962,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624739,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8963,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624740,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8964,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624896,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8965,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624897,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8966,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624108,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8967,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624109,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8968,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624110,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8969,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624111,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8970,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624112,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8971,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624113,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8972,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL619709,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8973,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL619710,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8974,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619711,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8975,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619712,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8976,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619713,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8977,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619714,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8978,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619715,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8979,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619716,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8980,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619717,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8981,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619718,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8982,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619719,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8983,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL875329,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8984,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619720,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8985,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619721,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8986,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619722,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8987,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619723,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8988,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619724,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8989,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619725,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8990,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619726,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8991,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619727,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,8992,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619728,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,8993,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL619729,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8994,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619730,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8995,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619731,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8996,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619732,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8997,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619733,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8998,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL619734,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,8999,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL619735,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9000,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL875330,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9001,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL628465,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9002,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL628466,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9003,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL628467,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9004,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628468,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9005,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628469,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9006,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628470,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9007,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628471,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9008,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628472,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9009,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL625191,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9010,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL625192,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9011,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL875337,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9012,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL626341,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9013,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL626342,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9014,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL621943,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3748,,N,9015,1,,,50597,,,,BAO_0000218,CHEMBL621944,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,9016,1,,,50597,,,,BAO_0000218,CHEMBL621945,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4871,,N,9017,1,,,50597,,,,BAO_0000218,CHEMBL621946,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4871,,N,9018,1,,,50597,,,,BAO_0000218,CHEMBL621947,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4872,,N,9019,1,,,50597,,,,BAO_0000218,CHEMBL621948,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4872,,N,9020,1,,,50597,,,,BAO_0000218,CHEMBL621949,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5413,,N,9021,1,,,50597,,,,BAO_0000218,CHEMBL621950,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5413,,N,9022,1,,,50597,,,,BAO_0000218,CHEMBL621951,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15272,,N,9023,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL621952,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,9024,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL621953,,Stability (%) in rat liver microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,9025,1,,,50597,,,,BAO_0000218,CHEMBL621954,,Area under curve was calculated after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,9026,1,,,50597,,,,BAO_0000218,CHEMBL621955,,Area under the curve was calculated after iv administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,9027,1,,,50597,,,,BAO_0000218,CHEMBL621956,,Area under the curve was calculated in rat after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6211,,N,9028,1,,,50597,,,,BAO_0000218,CHEMBL621957,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,9029,1,,,50597,,,,BAO_0000218,CHEMBL621958,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,9030,1,,,50597,,,,BAO_0000218,CHEMBL621959,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,9031,1,,,50597,,,,BAO_0000218,CHEMBL621960,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,9032,1,,,50597,,,,BAO_0000218,CHEMBL621961,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,9033,1,,,50597,,,,BAO_0000218,CHEMBL621962,,p value of the compound
F,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,9034,1,,,50597,,,,BAO_0000218,CHEMBL876787,,p value of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,9035,1,,,50597,,,,BAO_0000218,CHEMBL621963,,p value of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9036,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL622637,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9037,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL622638,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9038,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL626561,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
F,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,7991,,U,9039,0,,,22224,,,,BAO_0000019,CHEMBL626562,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9040,0,,,22224,,,,BAO_0000218,CHEMBL626563,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr )
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9041,0,,,22224,,,,BAO_0000218,CHEMBL626564,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr )
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,6253,,U,9042,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626565,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,6253,,U,9043,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626566,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3615,,U,9044,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626567,,Clearance rate in rabbits
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,4059,,U,9045,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626568,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9046,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626569,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9047,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626570,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9048,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626571,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9049,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626572,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,4059,,U,9050,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626573,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,Microsomes,9659,,U,9051,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL626574,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,Microsomes,9659,,U,9052,0,,,22224,Liver,2107.0,,BAO_0000251,CHEMBL626575,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3639,,U,9053,0,,,22224,,,,BAO_0000218,CHEMBL626576,,Dose at which bioavailability of intravenously administered compound was tested in rabbit
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3639,,U,9054,0,,,22224,,,,BAO_0000218,CHEMBL626577,,Dose at which bioavailability of perorally administered compound was tested in rabbit
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3639,,U,9055,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626578,,The compound was tested for its bioavailability in rabbit (by oral dosage).
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9056,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625263,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9057,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625264,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9058,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625265,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,Microsomes,14294,,U,9059,0,,,22224,,,,BAO_0000251,CHEMBL625266,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak)
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,Microsomes,14294,,U,9060,0,,,22224,,,,BAO_0000251,CHEMBL876796,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak)
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9061,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625267,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9062,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625268,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9063,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625269,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,5124,,U,9064,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL624689,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9065,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624690,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9066,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL624691,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr )
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,429,,U,9067,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL624692,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr)
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,4059,,U,9068,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624693,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,4137,,U,9069,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624694,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,11672,,U,9070,0,,,22224,,,In vitro,BAO_0000221,CHEMBL877596,,In vitro Biological half-life in crude homogenate of rabbit renal cortex
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,12886,,U,9071,0,,,22224,,,,BAO_0000019,CHEMBL624695,,Time within which only 10% of the drug was degraded
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3853,,U,9072,0,,,22224,Liver,2107.0,,BAO_0000221,CHEMBL624696,,Half life period in rabbit liver homogenate
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,3615,,U,9073,0,,,22224,,,,BAO_0000019,CHEMBL624697,,Half life value in rabbits
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,6253,,U,9074,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL624698,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,6253,,U,9075,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL624699,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample
A,Oryctolagus cuniculus,9986.0,,,1,Autocuration,,6077,,U,9076,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624700,,Half-life period in rabbits following intravenous administration at 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17617,,N,9077,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622903,,AUC 0-8 hr value in rats at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,9078,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622904,,AUC after administration at 2000 mg/kg/day in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6149,,N,9079,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622905,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,9080,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622906,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,9081,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622907,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9082,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622908,,AUC in rat after oral administration at 10.5 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9083,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622909,,AUC in rat after oral administration at 11.2 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9084,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622910,,AUC in rat after oral administration at 9.7 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,9085,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622911,,AUC in rat brain after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6504,,N,9086,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622912,,AUC in rat p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,9087,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622913,,AUC in rat p.o. at 20 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,9088,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622914,,AUC in rat plasma after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,216,,N,9089,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622915,,AUC in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,9090,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622916,,AUC value after IV dose at a dose of 5 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,9091,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622917,,AUC value after oral dose at a dose of 10 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,9092,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622918,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,216,,N,9093,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622919,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6049,,N,9094,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622920,,Maximum plasma concentration was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2463,,N,9095,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622921,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6679,,N,9096,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622922,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6681,,N,9097,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622923,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,9098,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL877604,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9099,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622924,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9100,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622925,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,9101,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622926,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6227,,N,9102,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623625,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,9103,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623626,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1465,,N,9104,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623627,,Maximum plasma drug concentration was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4368,,N,9105,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623628,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9106,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623629,,Mean peak plasma concentration was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9107,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623630,,Mean peak plasma concentration was observed after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9108,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623804,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9109,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623805,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1567,,N,9110,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623806,,Peak oral plasma concentration was determined in rats by oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,9111,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623807,,Peak plasma concentration (Cmax) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6193,,N,9112,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623808,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,9113,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623809,,Peak plasma concentration (Cmax) in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6485,,N,9114,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623810,,Peak plasma concentration at 1 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,9115,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623811,,Peak plasma concentration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,9116,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623812,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5394,,N,9117,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877605,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4408,,N,9118,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623813,,Pharmacokinetic property (Cmax) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,9119,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623814,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4878,,N,9120,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623815,,Cmax in rat after 3mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5862,Sprague-Dawley,N,9121,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623816,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4517,,N,9122,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623145,,Cmax in rats after 20 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,9123,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623146,,Cmax in rat plasma after 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5436,,N,9124,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623147,,Plasma concentration after oral administration of 100 mg/kg to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9125,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623042,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4950,,N,9126,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623043,,Tested for the Cmax in rat at 10 mg/kg per orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9127,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623044,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9128,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623045,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3360,,N,9129,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623046,,Bioavailability as oral Cmax in rats at 30 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3360,,N,9130,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623226,,Bioavailability as oral Cmax in rats at 6hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9131,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623227,,The maximum concentration of compound was measured at the dose of 100 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9132,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623228,,The maximum concentration of compound was measured at the dose of 300 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9133,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623229,,The maximum concentration of compound was measured at the dose of 30 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5160,,N,9134,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623230,,The maximum plasma levels for the compounds were determined by LC-MS.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9135,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623231,,mean peak plasma concentration was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9136,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623232,,mean peak plasma concentration was observed after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,9137,1,,,50597,,,,BAO_0000218,CHEMBL623233,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9138,1,,,50597,,,,BAO_0000218,CHEMBL623234,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9139,1,,,50597,,,,BAO_0000218,CHEMBL623235,,Concentration in plasma (portal) following oral dose in rats at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9140,1,,,50597,,,,BAO_0000218,CHEMBL623236,,Concentration in plasma (portal) following oral dose in rats at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9141,1,,,50597,,,,BAO_0000218,CHEMBL623237,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9142,1,,,50597,,,,BAO_0000218,CHEMBL623238,,Concentration in plasma (systemic) following oral dose in rats at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3535,,N,9143,1,,,50597,,,,BAO_0000218,CHEMBL623239,,Concentration in plasma (systemic) following oral dose in rats at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,9144,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623240,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6326,,N,9145,1,,,50597,Hypothalamus,1898.0,,BAO_0000218,CHEMBL623241,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6326,,N,9146,1,,,50597,Hypothalamus,1898.0,,BAO_0000218,CHEMBL623242,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6326,,N,9147,1,,,50597,,,,BAO_0000218,CHEMBL874394,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6326,,N,9148,1,,,50597,,,,BAO_0000218,CHEMBL623243,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9149,1,,,50597,,,,BAO_0000218,CHEMBL623244,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9150,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623245,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9151,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623246,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9152,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623247,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9153,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623248,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9154,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623249,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9155,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625072,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9156,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625073,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9157,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625074,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9158,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625075,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9159,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625076,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9160,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625077,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9161,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625078,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9162,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL874395,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9163,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625079,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9164,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625080,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9165,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625081,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9166,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625082,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9167,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625083,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9168,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625084,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9169,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625085,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9170,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625086,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9171,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625087,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9172,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625088,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9173,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622205,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9174,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622206,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9175,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622207,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9176,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622366,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9177,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622367,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9178,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL875331,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9179,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622368,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9180,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622369,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9181,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622370,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9182,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622371,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9183,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622372,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9184,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622373,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9185,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622374,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9186,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622375,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9187,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622376,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9188,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622377,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9189,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622378,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9190,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622379,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9191,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622380,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9192,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622381,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9193,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622382,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9194,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622383,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9195,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL875332,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9196,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL622384,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9197,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL622385,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6175,,N,9198,1,,,50597,Stomach,945.0,,BAO_0000218,CHEMBL622386,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9199,1,,,50597,,,,BAO_0000218,CHEMBL622387,,The compound was tested for the plasma binding in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9200,1,,,50597,,,,BAO_0000218,CHEMBL622388,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9201,1,,,50597,,,,BAO_0000218,CHEMBL622389,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9202,1,,,50597,,,,BAO_0000218,CHEMBL622390,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9203,1,,,50597,,,,BAO_0000218,CHEMBL622391,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9204,1,,,50597,,,,BAO_0000218,CHEMBL622392,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16459,,N,9205,1,,,50597,,,,BAO_0000218,CHEMBL622393,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3278,,N,9206,1,,,50597,,,,BAO_0000218,CHEMBL622394,,Plasma level at 2 hr after administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3278,,N,9207,1,,,50597,,,,BAO_0000218,CHEMBL622395,,plasma level at 2 hr after administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9208,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL622396,,Stability in rat serum measured as % recovery at 1 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9209,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624894,,Stability in rat serum measured as % recovery at 10 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9210,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624895,,Stability in rat serum measured as % recovery at 10 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9211,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624058,,Stability in rat serum measured as % recovery at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9212,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624059,,Stability in rat serum measured as % recovery at 3 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9213,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624060,,Stability in rat serum measured as % recovery at 3 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9214,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624061,,Stability in rat serum measured as % recovery at 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4684,,N,9215,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL624062,,Stability in rat serum measured as % recovery at 5 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16456,,N,9216,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624063,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16456,,N,9217,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624064,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,723,,N,9218,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL624065,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,723,,N,9219,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL624066,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5160,,N,9220,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877490,,Half life tested in mature male rat at a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,9221,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874442,,Half life after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5633,,N,9222,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626890,,Half life period after administration (30 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,9223,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626891,,Half life period in rat after 5 mg/Kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,9224,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626892,,Half life period in rat after 5 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9225,1,,,50597,,,,BAO_0000218,CHEMBL626893,,Half life period was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9226,1,,,50597,,,,BAO_0000218,CHEMBL626894,,Half life period was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9227,1,,,50597,,,,BAO_0000218,CHEMBL626895,,Half life period was evaluated in rat; 0.5-1.0
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9228,1,,,50597,,,,BAO_0000218,CHEMBL626896,,Half life period was evaluated in rat; 5.9-7.5
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14512,,N,9229,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626897,,Half-life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6230,,N,9230,1,,,50597,,,,BAO_0000218,CHEMBL626898,,Half-life time in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3364,,N,9231,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626899,,Terminal half-life after iv administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6874,,N,9232,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626900,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,857,,N,9233,1,,,50597,,,,BAO_0000218,CHEMBL626901,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,858,,N,9234,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626902,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,858,,N,9235,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626903,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9236,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874443,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9237,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626904,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6305,,N,9238,1,,,50597,,,,BAO_0000218,CHEMBL626905,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13501,,N,9239,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL873830,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,9240,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626906,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,9241,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631076,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2932,,N,9242,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631077,,Biological half-life was measured in plasma of rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,9243,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631078,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,9244,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631079,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2713,,N,9245,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631080,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9246,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631081,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9247,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631239,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,740,,N,9248,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631240,,Compound was evaluated for plasma half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,9249,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631241,,AUC value at a dose of 5 mg/kg (p.o.) in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,9250,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631242,,AUC value after administration of 20 mg/Kg oral dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,9251,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631243,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,9252,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL874444,,AUC0-96 after administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,9253,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631244,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3293,,N,9254,1,,,50597,,,,BAO_0000218,CHEMBL631245,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,9255,1,,,50597,,,,BAO_0000218,CHEMBL627162,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,9256,1,,,50597,,,,BAO_0000218,CHEMBL627163,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6757,,N,9257,1,,,50597,,,,BAO_0000218,CHEMBL627164,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,9258,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL627165,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,9259,1,,,50597,,,,BAO_0000218,CHEMBL627166,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5979,,N,9260,1,,,50597,,,,BAO_0000218,CHEMBL627167,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,9261,1,,,50597,,,,BAO_0000218,CHEMBL627822,,Area under curve (AUC) at a dose of 30 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9262,1,,,50597,,,,BAO_0000218,CHEMBL627823,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9263,1,,,50597,,,,BAO_0000218,CHEMBL627824,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5355,,N,9264,1,,,50597,,,,BAO_0000218,CHEMBL627825,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5633,,N,9265,1,,,50597,,,,BAO_0000218,CHEMBL627826,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1716,,N,9266,1,,,50597,,,,BAO_0000218,CHEMBL627827,,Area under curve (Pharmacokinetic property) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1716,,N,9267,1,,,50597,,,,BAO_0000218,CHEMBL627828,,Area under curve (Pharmacokinetic property) of the compound; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,9268,1,,,50597,,,,BAO_0000218,CHEMBL627829,,Area under curve after intravenous administration (1 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,9269,1,,,50597,,,,BAO_0000218,CHEMBL627830,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,9270,1,,,50597,,,,BAO_0000218,CHEMBL627831,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9271,1,,,50597,,,,BAO_0000218,CHEMBL627832,,Area under curve in male SD rats was observed after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4413,,N,9272,1,,,50597,,,,BAO_0000218,CHEMBL627833,,Area under curve of compound after iv administration of 20 mg/kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,9273,1,,,50597,,,,BAO_0000218,CHEMBL627834,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,9274,1,,,50597,,,,BAO_0000218,CHEMBL628004,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,9275,1,,,50597,,,,BAO_0000218,CHEMBL628005,,Area under curve at 5 mg/kg po was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,9276,1,,,50597,,,,BAO_0000218,CHEMBL628006,,Area under curve in Rat at a oral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4186,,N,9277,1,,,50597,,,,BAO_0000218,CHEMBL628007,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,9278,1,,,50597,,,,BAO_0000218,CHEMBL625676,,Area under curve was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17858,,N,9279,1,,,50597,,,,BAO_0000218,CHEMBL631309,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,9280,1,,,50597,,,,BAO_0000218,CHEMBL631310,,Area under curve after intravenous administration at 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6106,,N,9281,1,,,50597,,,,BAO_0000218,CHEMBL631311,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,9282,1,,,50597,,,,BAO_0000218,CHEMBL631312,,Area under curve at 4 hr in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,9283,1,,,50597,,,,BAO_0000218,CHEMBL631313,,Area under curve at a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,9284,1,,,50597,,,,BAO_0000218,CHEMBL631314,,Area under curve at the dose of 2 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,9285,1,,,50597,,,,BAO_0000218,CHEMBL631315,,Area under curve at the dose of 5 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5862,,N,9286,1,,,50597,,,,BAO_0000218,CHEMBL631316,,Area under curve for a 2-mpk po dose in SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5862,,N,9287,1,,,50597,,,,BAO_0000218,CHEMBL631317,,Area under curve in SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9288,1,,,50597,,,,BAO_0000218,CHEMBL874471,,Area under curve in rat after oral administration at 13 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5871,,N,9289,1,,,50597,,,,BAO_0000218,CHEMBL631318,,Area under curve in rat by po administration at 0-24 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5919,,N,9290,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631319,,Area under curve in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,9291,1,,,50597,,,,BAO_0000218,CHEMBL631320,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,9292,1,,,50597,,,,BAO_0000218,CHEMBL631321,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10,,N,9293,1,,,50597,,,,BAO_0000218,CHEMBL631322,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,9294,1,,,50597,,,,BAO_0000218,CHEMBL631323,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,9295,1,,,50597,,,,BAO_0000218,CHEMBL631324,,Area under curve value in rat at a dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,9296,1,,,50597,,,,BAO_0000218,CHEMBL631325,,Area under curve was determined after oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,9297,1,,,50597,,,,BAO_0000218,CHEMBL631326,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,9298,1,,,50597,,,,BAO_0000218,CHEMBL631327,,Area under curve was determined after peroral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5375,,N,9299,1,,,50597,,,,BAO_0000218,CHEMBL631328,,Area under curve was determined at a dose 30 mpk administered orally.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,9300,1,,,50597,,,,BAO_0000218,CHEMBL631329,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4368,,N,9301,1,,,50597,,,,BAO_0000218,CHEMBL627217,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5610,,N,9302,1,,,50597,,,,BAO_0000218,CHEMBL626352,,Area under curve was determined in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5833,,N,9303,1,,,50597,,,,BAO_0000218,CHEMBL626353,,Area under curve was determined in rat after PO administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4257,,N,9304,1,,,50597,,,,BAO_0000218,CHEMBL626354,,Area under curve was determined in rat after a 3 mg/kg of oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5937,,N,9305,1,,,50597,,,,BAO_0000218,CHEMBL626355,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,9306,1,,,50597,,,,BAO_0000218,CHEMBL626356,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,9307,1,,,50597,,,,BAO_0000218,CHEMBL626357,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9308,1,,,50597,,,,BAO_0000218,CHEMBL626358,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9309,1,,,50597,,,,BAO_0000218,CHEMBL626359,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17771,,N,9310,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626360,,Peak plasma concentration in rat at a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1628,,N,9311,1,,,50597,,,,BAO_0000218,CHEMBL626361,,Plasma concentration at 2 hr in rats was evaluated.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1628,,N,9312,1,,,50597,,,,BAO_0000218,CHEMBL626362,,Plasma concentration at 2 hr in rats was evaluated; Not available
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9313,1,,,50597,,,,BAO_0000218,CHEMBL626363,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9314,1,,,50597,,,,BAO_0000218,CHEMBL626970,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9315,1,,,50597,,,,BAO_0000218,CHEMBL626971,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9316,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626972,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9317,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626973,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9318,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626974,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9319,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL874592,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,9320,1,,,50597,,,,BAO_0000218,CHEMBL626975,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,9321,1,,,50597,,,,BAO_0000218,CHEMBL626976,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,9322,1,,,50597,,,,BAO_0000218,CHEMBL626977,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,9323,1,,,50597,,,,BAO_0000218,CHEMBL626978,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16427,,N,9324,1,,,50597,,,,BAO_0000218,CHEMBL626979,,PK study was carried to determine the relative absorption ranking in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,9325,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626980,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9326,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626981,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9327,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626982,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9328,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626983,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9329,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622522,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9330,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622523,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9331,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622524,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9332,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622525,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9333,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622526,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9334,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL619849,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9335,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL619850,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9336,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL623864,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9337,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL623865,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9338,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL623866,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9339,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL623867,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9340,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL877615,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9341,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL623868,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9342,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL623869,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9343,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL623870,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9344,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL623871,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9345,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL623872,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9346,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622129,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9347,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622130,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9348,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622131,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9349,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622132,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9350,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622133,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9351,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622134,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9352,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622135,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9353,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622136,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9354,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL622137,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9355,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL622138,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9356,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623017,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9357,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623018,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9358,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623019,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9359,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623020,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9360,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623021,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9361,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623022,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9362,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623023,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9363,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623024,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9364,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623025,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9365,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620545,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9366,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620546,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9367,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620547,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9368,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620548,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9369,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620549,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9370,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620550,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9371,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620551,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9372,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620552,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9373,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620553,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9374,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620554,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9375,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL875845,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9376,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620555,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9377,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620556,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9378,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620557,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9379,1,,,50597,,,,BAO_0000218,CHEMBL620558,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9380,1,,,50597,,,,BAO_0000218,CHEMBL620559,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9381,1,,,50597,,,,BAO_0000218,CHEMBL622939,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9382,1,,,50597,,,,BAO_0000218,CHEMBL622940,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9383,1,,,50597,,,,BAO_0000218,CHEMBL622941,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9384,1,,,50597,,,,BAO_0000218,CHEMBL622942,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9385,1,,,50597,,,,BAO_0000218,CHEMBL622943,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9386,1,,,50597,,,,BAO_0000218,CHEMBL622944,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9387,1,,,50597,,,,BAO_0000218,CHEMBL622945,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9388,1,,,50597,,,,BAO_0000218,CHEMBL622946,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3341,,N,9389,1,,,50597,,,,BAO_0000218,CHEMBL622947,,Compound was evaluated for terminal half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3634,,N,9390,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622948,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3634,,N,9391,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622949,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4839,,N,9392,1,,,50597,,,,BAO_0000218,CHEMBL622950,,Compound was tested for its half life in rat
A,Macaca mulatta,9544.0,,,1,Intermediate,,5005,,U,9393,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622951,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,9394,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL622952,,Compound was tested for its plasma half life in Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,9395,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL622953,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1094,,N,9396,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL873818,,Compound was tested for plasma half-life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5031,,N,9397,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622954,,Elimination half life after i.v. administration of compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,9398,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622955,,Elimination half-life after IV dosing at 0.5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,9399,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875229,,Elimination half-life after IV dosing at 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,9400,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622956,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,9401,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622957,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9402,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622958,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9403,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622959,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9404,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622960,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9405,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622961,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4687,,N,9406,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622962,,Evaluated for the half life in rat (in vivo)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,9407,1,,,50597,,,,BAO_0000218,CHEMBL622963,,Hafl life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,9408,1,,,50597,,,,BAO_0000218,CHEMBL622964,,Hafl life rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,9409,1,,,50597,,,,BAO_0000218,CHEMBL622965,,Hafl life rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,9410,1,,,50597,,,,BAO_0000218,CHEMBL622966,,Hafl life rat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,9411,1,,,50597,,,,BAO_0000218,CHEMBL622967,,Hafl life rat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9412,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622968,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9413,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622969,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9414,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL875327,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,9415,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628638,,Half life in rat after 1 mg/kg i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,9416,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628639,,Half life in rat after 2 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9417,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625840,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4722,,N,9418,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625841,,Half life of 10 mg/kg oral dose determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9419,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625842,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9420,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625843,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9421,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625844,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9422,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873822,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9423,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625845,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9424,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627059,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9425,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627060,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,9426,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627061,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4762,,N,9427,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627709,,Half life of compound at 5 mg/kg after po administration was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5327,,N,9428,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627710,,Half life of compound determined after intravenous administration to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4847,,N,9429,1,,,50597,,,,BAO_0000218,CHEMBL627711,,Half life of compound was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,9430,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627712,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9431,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627713,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9432,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627714,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Macaca fascicularis,9541.0,,,1,Intermediate,,4256,,U,9433,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627889,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4256,,U,9434,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627890,,Half life determined in rat by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4722,,N,9435,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627891,,Half life determined in rats after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,9436,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627892,,Half life in rat plasma after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,9437,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627893,,Half life in rat plasma after administration of 2 mg/kg iv
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1435,,N,9438,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627894,,Half life in rat plasma was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1435,,N,9439,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627895,,Half life in rat plasma was determined; NA means not applicable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5206,,N,9440,1,,,50597,,,,BAO_0000218,CHEMBL627896,,Half life in rat was tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6080,,N,9441,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627897,,Half life measured in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4449,,N,9442,1,,,50597,,,,BAO_0000218,CHEMBL627898,,Half life recorded in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,9443,1,,,50597,,,,BAO_0000218,CHEMBL627899,,Half life was calculated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,9444,1,,,50597,,,,BAO_0000218,CHEMBL873823,,Half life was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3747,,N,9445,1,,,50597,,,,BAO_0000218,CHEMBL627900,,Half life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17858,,N,9446,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627901,,Half life after 10 mg/kg oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9447,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627902,,Half life after administering orally a dose of 10 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9448,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627903,,Half life after administering orally a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5031,,N,9449,1,,,50597,,,,BAO_0000218,CHEMBL627904,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4722,,N,9450,1,,,50597,,,,BAO_0000218,CHEMBL627905,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,9451,1,,,50597,,,,BAO_0000218,CHEMBL627906,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,9452,1,,,50597,,,,BAO_0000218,CHEMBL627907,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,9453,1,,,50597,,,,BAO_0000218,CHEMBL876783,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,9454,1,,,50597,,,,BAO_0000218,CHEMBL627908,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,9455,1,,,50597,,,,BAO_0000218,CHEMBL627909,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1353,,N,9456,1,,,50597,,,,BAO_0000218,CHEMBL627910,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1353,,N,9457,1,,,50597,,,,BAO_0000218,CHEMBL627911,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1353,,N,9458,1,,,50597,,,,BAO_0000218,CHEMBL627912,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1353,,N,9459,1,,,50597,,,,BAO_0000218,CHEMBL627913,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1353,,N,9460,1,,,50597,,,,BAO_0000218,CHEMBL627914,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,9461,1,,,50597,,,,BAO_0000218,CHEMBL627915,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,9462,1,,,50597,,,,BAO_0000218,CHEMBL627916,,Area under the curve was evaluated after 20 uM/kg of peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6062,,N,9463,1,,,50597,,,,BAO_0000218,CHEMBL627917,,Area under the curve was measured in rat after an iv dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6056,,N,9464,1,,,50597,,,,BAO_0000218,CHEMBL627918,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,9465,1,,,50597,,,,BAO_0000218,CHEMBL627919,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9466,1,,,50597,,,,BAO_0000218,CHEMBL627920,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9467,1,,,50597,,,,BAO_0000218,CHEMBL627921,,Area under the curve was evaluated at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9468,1,,,50597,,,,BAO_0000218,CHEMBL627922,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9469,1,,,50597,,,,BAO_0000218,CHEMBL876784,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9470,1,,,50597,,,,BAO_0000218,CHEMBL627923,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9471,1,,,50597,,,,BAO_0000218,CHEMBL626208,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9472,1,,,50597,,,,BAO_0000218,CHEMBL626209,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,9473,1,,,50597,,,,BAO_0000218,CHEMBL626210,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2463,,N,9474,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627994,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,9475,1,,,50597,,,,BAO_0000218,CHEMBL627995,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4075,,N,9476,1,,,50597,,,,BAO_0000218,CHEMBL627996,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5394,,N,9477,1,,,50597,,,,BAO_0000218,CHEMBL627997,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9478,1,,,50597,,,,BAO_0000218,CHEMBL627998,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9479,1,,,50597,,,,BAO_0000218,CHEMBL628640,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9480,1,,,50597,,,,BAO_0000218,CHEMBL628641,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,9481,1,,,50597,,,,BAO_0000218,CHEMBL628642,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9482,1,,,50597,,,,BAO_0000218,CHEMBL628643,,Compound was evaluated for area under the curve expressed as (h*ug/ml)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2591,,N,9483,1,,,50597,,,,BAO_0000218,CHEMBL628644,,Compound was tested for area under curve in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6567,,N,9484,1,,,50597,,,,BAO_0000218,CHEMBL628645,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6211,,N,9485,1,,,50597,,,,BAO_0000218,CHEMBL628646,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5529,,N,9486,1,,,50597,,,,BAO_0000218,CHEMBL628647,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9487,1,,,50597,,,,BAO_0000218,CHEMBL628648,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9488,1,,,50597,,,,BAO_0000218,CHEMBL625358,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9489,1,,,50597,,,,BAO_0000218,CHEMBL625359,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5408,,N,9490,1,,,50597,,,,BAO_0000218,CHEMBL625360,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,9491,1,,,50597,,,,BAO_0000218,CHEMBL625361,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,9492,1,,,50597,,,,BAO_0000218,CHEMBL625362,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,9493,1,,,50597,,,,BAO_0000218,CHEMBL625363,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4796,,N,9494,1,,,50597,,,,BAO_0000218,CHEMBL625364,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,9495,1,,,50597,,,,BAO_0000218,CHEMBL625365,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,9496,1,,,50597,,,,BAO_0000218,CHEMBL625366,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,9497,1,,,50597,,,,BAO_0000218,CHEMBL625367,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9498,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625368,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9499,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625369,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9500,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625370,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9501,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625371,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9502,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625372,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9503,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625373,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9504,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625374,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9505,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL877593,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9506,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625375,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9507,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625376,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9508,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL621973,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9509,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL621974,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9510,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL621975,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9511,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622166,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9512,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622167,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9513,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622168,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9514,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622169,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9515,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL622170,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9516,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622171,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9517,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622172,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9518,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622173,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9519,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622174,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9520,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622175,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9521,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622176,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9522,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622177,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9523,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622178,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9524,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622179,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9525,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622180,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9526,1,,,50597,,,,BAO_0000218,CHEMBL622181,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9527,1,,,50597,,,,BAO_0000218,CHEMBL622182,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9528,1,,,50597,,,,BAO_0000218,CHEMBL622183,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9529,1,,,50597,,,,BAO_0000218,CHEMBL622184,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9530,1,,,50597,,,,BAO_0000218,CHEMBL622185,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9531,1,,,50597,,,,BAO_0000218,CHEMBL622186,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9532,1,,,50597,,,,BAO_0000218,CHEMBL622187,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9533,1,,,50597,,,,BAO_0000218,CHEMBL625002,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9534,1,,,50597,,,,BAO_0000218,CHEMBL622090,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9535,1,,,50597,,,,BAO_0000218,CHEMBL622091,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9536,1,,,50597,,,,BAO_0000218,CHEMBL622092,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9537,1,,,50597,,,,BAO_0000218,CHEMBL622093,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9538,1,,,50597,,,,BAO_0000218,CHEMBL622094,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9539,1,,,50597,,,,BAO_0000218,CHEMBL622095,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9540,1,,,50597,,,,BAO_0000218,CHEMBL622264,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9541,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL622265,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9542,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL622266,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9543,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL622267,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9544,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL622268,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9545,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL622269,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9546,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625071,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9547,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621621,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9548,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621622,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9549,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621623,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9550,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621624,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9551,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621625,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9552,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621626,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9553,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621627,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9554,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621628,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9555,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL875328,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9556,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621629,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9557,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621630,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9558,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621631,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9559,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621632,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9560,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621633,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9561,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621634,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9562,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621635,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9563,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621636,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9564,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621637,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9565,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL621638,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9566,1,,,50597,,,,BAO_0000218,CHEMBL618883,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9567,1,,,50597,,,,BAO_0000218,CHEMBL618884,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9568,1,,,50597,,,,BAO_0000218,CHEMBL628627,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9569,1,,,50597,,,,BAO_0000218,CHEMBL628628,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9570,1,,,50597,,,,BAO_0000218,CHEMBL628629,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9571,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628630,,Half life after administering orally a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9572,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628631,,Half life after administering orally a dose of 3 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9573,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628632,,Half life after administering intravenously a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,526,,N,9574,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628633,,Half life after oral dosing in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9575,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628634,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4368,,N,9576,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627789,,Half life by intravenous administration of 3.4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3371,,N,9577,1,,,50597,,,,BAO_0000218,CHEMBL627790,,Half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,9578,1,,,50597,,,,BAO_0000218,CHEMBL627791,,Half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6453,,N,9579,1,,,50597,,,,BAO_0000218,CHEMBL627792,,Half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9580,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627793,,Half life in rat after intravenous administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9581,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627794,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9582,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627795,,Half life in rat after po administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9583,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627796,,Half life in rat after po administration of the compound; ND means Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9584,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875335,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,9585,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627797,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5789,,N,9586,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627798,,Half life in rat i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,9587,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627799,,Half life in rat i.v. at 2 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,9588,1,,,50597,,,,BAO_0000218,CHEMBL627800,,Half life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,484,,N,9589,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627801,,Half life in rats after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,9590,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627802,,Half life in rats at the dose of 1.0 mpk by i.v. administration
A,Rattus norvegicus,10116.0,,,1,Expert,,6642,,N,9591,1,,,50597,,,,BAO_0000218,CHEMBL627803,,Half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,9592,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873820,,Half life was evaluated after intravenous administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1369,,N,9593,1,,,50597,,,,BAO_0000218,CHEMBL627804,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,9594,1,,,50597,,,,BAO_0000218,CHEMBL627805,,Half life was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6049,,N,9595,1,,,50597,,,,BAO_0000218,CHEMBL627806,,Half life was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,9596,1,,,50597,,,,BAO_0000218,CHEMBL627107,,Half life was evaluated in rat; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,9597,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627108,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,9598,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627109,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11149,,N,9599,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627110,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats
A,Primates,9443.0,,,1,Intermediate,,2891,,U,9600,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627111,,Half life was measured in monkey at dose of 10 mg/kg by po administration
A,Primates,9443.0,,,1,Intermediate,,2891,,U,9601,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627112,,Half life was measured in monkey at dose of 10 mg/kg by po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2891,,U,9602,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627113,,Half life was measured in rat at dose of 30 mg/kg by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2891,,U,9603,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627114,,Half life was measured in rat at dose of 30 mg/kg by po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,9604,1,,,50597,,,,BAO_0000218,CHEMBL627115,,Half life (t1/2) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,9605,1,,,50597,,,,BAO_0000218,CHEMBL627116,,Half life period at a dose of 10 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,9606,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627117,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5503,,N,9607,1,,,50597,,,,BAO_0000218,CHEMBL627118,,Half life period was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,9608,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627119,,Half life period after intravenous administration at 20 mpk in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,9609,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627120,,Half life period after intravenous administration at 20 mpk in rats; Not performed.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6109,,N,9610,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626922,,Half life period after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,9611,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626923,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,9612,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626924,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4755,,N,9613,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626925,,Half life period in 80% rat plasma at 37 degree Centigrade
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5862,,N,9614,1,,,50597,,,,BAO_0000218,CHEMBL626926,,Half life period in SD rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9615,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626927,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9616,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626928,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9617,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626929,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9618,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626930,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,9619,1,,,50597,,,,BAO_0000218,CHEMBL626931,,Half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6103,,N,9620,1,,,50597,,,,BAO_0000218,CHEMBL626932,,Half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6317,,N,9621,1,,,50597,,,,BAO_0000218,CHEMBL626933,,Half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9622,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873826,,Half life period in rat after oral administration at 10.5 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9623,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626934,,Half life period in rat after oral administration at 11.2 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9624,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626935,,Half life period in rat after oral administration at 13 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,9625,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626936,,Half life period in rat after oral administration at 9.7 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,9626,1,,,50597,,,,BAO_0000218,CHEMBL626937,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6295,,N,9627,1,,,50597,,,,BAO_0000218,CHEMBL625906,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6296,,N,9628,1,,,50597,,,,BAO_0000218,CHEMBL625907,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16427,,N,9629,1,,,50597,,,,BAO_0000218,CHEMBL625908,,PK study was carried to determine AUC (area under curve) value in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,9630,1,,,50597,,,,BAO_0000218,CHEMBL625909,,Pharmacokinetic parameter AUC after intravenous administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,9631,1,,,50597,,,,BAO_0000218,CHEMBL625910,,Pharmacokinetic parameter AUC after oral administration to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9632,1,,,50597,,,,BAO_0000218,CHEMBL625911,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9633,1,,,50597,,,,BAO_0000218,CHEMBL625912,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9634,1,,,50597,,,,BAO_0000218,CHEMBL626538,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9635,1,,,50597,,,,BAO_0000218,CHEMBL876794,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9636,1,,,50597,,,,BAO_0000218,CHEMBL626539,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,9637,1,,,50597,,,,BAO_0000218,CHEMBL626540,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5394,,N,9638,1,,,50597,,,,BAO_0000218,CHEMBL626541,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5394,,N,9639,1,,,50597,,,,BAO_0000218,CHEMBL626542,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,9640,1,,,50597,,,,BAO_0000218,CHEMBL626543,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,9641,1,,,50597,,,,BAO_0000218,CHEMBL626544,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,9642,1,,,50597,,,,BAO_0000218,CHEMBL626545,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,9643,1,,,50597,,,,BAO_0000218,CHEMBL626546,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,9644,1,,,50597,,,,BAO_0000218,CHEMBL626547,,Pharmacokinetic parameter area under curve was reported
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4408,,N,9645,1,,,50597,,,,BAO_0000218,CHEMBL626548,,Pharmacokinetic property (AUC) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,9646,1,,,50597,,,,BAO_0000218,CHEMBL626549,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4397,,N,9647,1,,,50597,,,,BAO_0000218,CHEMBL626550,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4397,,N,9648,1,,,50597,,,,BAO_0000218,CHEMBL626551,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5491,,N,9649,1,,,50597,,,,BAO_0000218,CHEMBL623777,,Pharmacokinetic property was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5491,,N,9650,1,,,50597,,,,BAO_0000218,CHEMBL623778,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5491,,N,9651,1,,,50597,,,,BAO_0000218,CHEMBL623779,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,9652,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL623780,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,9653,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622015,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,9654,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622016,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5173,,N,9655,1,,,50597,,,,BAO_0000218,CHEMBL622017,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5173,,N,9656,1,,,50597,,,,BAO_0000218,CHEMBL622018,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5173,,N,9657,1,,,50597,,,,BAO_0000218,CHEMBL622019,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5173,,N,9658,1,,,50597,,,,BAO_0000218,CHEMBL622020,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,9659,1,,,50597,,,,BAO_0000218,CHEMBL622021,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,9660,1,,,50597,,,,BAO_0000218,CHEMBL622022,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5327,,N,9661,1,,,50597,,,,BAO_0000218,CHEMBL622023,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6681,,N,9662,1,,,50597,,,,BAO_0000218,CHEMBL622024,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,9663,1,,,50597,,,,BAO_0000218,CHEMBL622693,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,9664,1,,,50597,,,,BAO_0000218,CHEMBL622694,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,9665,1,,,50597,,,,BAO_0000218,CHEMBL622695,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,9666,1,,,50597,,,,BAO_0000218,CHEMBL622696,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,9667,1,,,50597,,,,BAO_0000218,CHEMBL622697,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6619,,N,9668,1,,,50597,,,,BAO_0000218,CHEMBL622874,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6619,,N,9669,1,,,50597,,,,BAO_0000218,CHEMBL622875,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10363,,N,9670,1,,,50597,,,,BAO_0000218,CHEMBL622876,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4796,,N,9671,1,,,50597,,,,BAO_0000218,CHEMBL622877,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9672,1,,,50597,,,,BAO_0000218,CHEMBL622878,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9673,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622879,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4839,,N,9674,1,,,50597,,,,BAO_0000218,CHEMBL877602,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9675,1,,,50597,,,,BAO_0000218,CHEMBL622880,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9676,1,,,50597,,,,BAO_0000218,CHEMBL622881,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9677,1,,,50597,,,,BAO_0000218,CHEMBL622882,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9678,1,,,50597,,,,BAO_0000218,CHEMBL622883,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9679,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622884,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11450,,N,9680,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL622885,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,9681,1,,,50597,,,,BAO_0000218,CHEMBL622886,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,9682,1,,,50597,,,,BAO_0000218,CHEMBL622887,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,9683,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622888,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9684,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622889,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9685,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622890,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9686,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622891,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9687,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL877603,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9688,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622892,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9689,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622893,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9690,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622894,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9691,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622895,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9692,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622896,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9693,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622897,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9694,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622898,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9695,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622899,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9696,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622900,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9697,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL624114,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9698,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL624115,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9699,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL624116,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9700,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624117,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9701,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624118,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9702,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624119,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9703,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624120,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9704,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624121,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9705,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624122,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9706,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624123,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9707,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624124,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9708,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624125,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9709,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624126,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9710,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624127,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9711,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624128,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9712,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL624129,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9713,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL624130,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9714,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL622340,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9715,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL622341,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9716,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622342,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9717,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622343,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9718,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622344,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9719,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622345,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9720,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622346,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9721,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622347,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9722,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622348,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9723,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622349,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9724,1,,,50597,,,,BAO_0000218,CHEMBL622350,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9725,1,,,50597,,,,BAO_0000218,CHEMBL622351,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9726,1,,,50597,,,,BAO_0000218,CHEMBL622352,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9727,1,,,50597,,,,BAO_0000218,CHEMBL622353,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9728,1,,,50597,,,,BAO_0000218,CHEMBL622354,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9729,1,,,50597,,,,BAO_0000218,CHEMBL622355,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9730,1,,,50597,,,,BAO_0000218,CHEMBL622356,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9731,1,,,50597,,,,BAO_0000218,CHEMBL622357,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9732,1,,,50597,,,,BAO_0000218,CHEMBL622358,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9733,1,,,50597,,,,BAO_0000218,CHEMBL622359,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9734,1,,,50597,,,,BAO_0000218,CHEMBL874393,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9735,1,,,50597,,,,BAO_0000218,CHEMBL622872,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9736,1,,,50597,,,,BAO_0000218,CHEMBL622873,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9737,1,,,50597,,,,BAO_0000218,CHEMBL623047,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9738,1,,,50597,,,,BAO_0000218,CHEMBL623048,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9739,1,,,50597,,,,BAO_0000218,CHEMBL623049,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9740,1,,,50597,,,,BAO_0000218,CHEMBL623050,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9741,1,,,50597,,,,BAO_0000218,CHEMBL623051,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9742,1,,,50597,,,,BAO_0000218,CHEMBL623052,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9743,1,,,50597,,,,BAO_0000218,CHEMBL626343,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9744,1,,,50597,,,,BAO_0000218,CHEMBL626344,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9745,1,,,50597,,,,BAO_0000218,CHEMBL626345,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9746,1,,,50597,,,,BAO_0000218,CHEMBL626346,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9747,1,,,50597,,,,BAO_0000218,CHEMBL626347,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9748,1,,,50597,,,,BAO_0000218,CHEMBL626348,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16434,,N,9749,1,,,50597,,,,BAO_0000218,CHEMBL626349,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
F,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9750,1,,,50597,,,,BAO_0000218,CHEMBL626350,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9751,1,,,50597,,,,BAO_0000218,CHEMBL626351,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9752,1,,,50597,,,,BAO_0000218,CHEMBL627650,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
F,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9753,1,,,50597,,,,BAO_0000218,CHEMBL627651,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9754,1,,,50597,,,,BAO_0000218,CHEMBL627652,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16435,,N,9755,1,,,50597,,,,BAO_0000218,CHEMBL627653,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9756,1,,,50597,,,,BAO_0000218,CHEMBL627654,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9757,1,,,50597,,,,BAO_0000218,CHEMBL627835,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9758,1,,,50597,,,,BAO_0000218,CHEMBL627836,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9759,1,,,50597,,,,BAO_0000218,CHEMBL627837,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9760,1,,,50597,,,,BAO_0000218,CHEMBL627838,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9761,1,,,50597,,,,BAO_0000218,CHEMBL875338,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9762,1,,,50597,,,,BAO_0000218,CHEMBL627839,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9763,1,,,50597,,,,BAO_0000218,CHEMBL627840,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9764,1,,,50597,,,,BAO_0000218,CHEMBL627841,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9765,1,,,50597,,,,BAO_0000218,CHEMBL627842,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9766,1,,,50597,,,,BAO_0000218,CHEMBL627843,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9767,1,,,50597,,,,BAO_0000218,CHEMBL627844,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9768,1,,,50597,,,,BAO_0000218,CHEMBL627845,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,9769,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627846,,Half life period in rat by iv administration at a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9770,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627847,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9771,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL873821,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9772,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626079,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1515,,N,9773,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626080,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5491,,N,9774,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626081,,Half life period was evaluated in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5491,,N,9775,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL875344,,Half life period was evaluated in rat plasma; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1918,,N,9776,1,,,50597,,,,BAO_0000218,CHEMBL626082,,Half life period was evaluated in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1918,,N,9777,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626250,,"Half life period was evaluated in rats, iv"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6113,,N,9778,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626251,,Half life period after intravenous administration at 5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5546,,N,9779,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626252,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5553,,N,9780,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626253,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4188,,N,9781,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626254,,Half life stability of compound was evaluated in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6215,,N,9782,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626255,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6141,,N,9783,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626256,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,9784,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626257,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,9785,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626258,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,9786,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626259,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5789,,N,9787,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626260,,Half in rat i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,9788,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875345,,Half period in rat after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17594,,N,9789,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626261,,Half-life after repeated oral dose of compound at 1 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12357,,N,9790,1,,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL626262,,Half-life measured in in vitro Cathepsin B assay in rat liver
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5210,,N,9791,1,,,50597,,,,BAO_0000218,CHEMBL626263,,Half-life of compound was determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,9792,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625270,,Half-life at 10 mg/kg in rat upon intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6672,,N,9793,1,,,50597,,,,BAO_0000218,CHEMBL625271,,Half-life determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6673,,N,9794,1,,,50597,,,,BAO_0000218,CHEMBL625272,,Half-life determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9795,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625273,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3741,,N,9796,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625274,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,9797,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625275,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,9798,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625276,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17537,,N,9799,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625277,,Half-life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4965,,N,9800,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625278,,Half-life in rat plasma was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17537,,N,9801,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625279,,Half-life in rat plasma; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6124,,N,9802,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL625280,,Half-life in rat serum
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6124,,N,9803,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL876797,,Half-life in rat serum; na is not available
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,9804,1,,,50597,,,,BAO_0000218,CHEMBL625281,,Half-life was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17668,,N,9805,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL873827,,Half-life was calculated in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3185,,N,9806,1,,,50597,,,,BAO_0000218,CHEMBL625282,,Half-life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,9807,1,,,50597,,,,BAO_0000218,CHEMBL625283,,Half-life was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,9808,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625284,,Half-life after administration of 20 mg/Kg oral dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4029,,N,9809,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625285,,Half-life after administration of 3.2 mg/kg intravenously in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4029,,N,9810,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625286,,Half-life after intravenous administration in female rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4029,,N,9811,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625287,,Half-life after intravenous administration in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6180,,N,9812,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625288,,Half-life after intravenous dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1557,,N,9813,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625289,,Half-life in a rat liver homogenate preparation
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,9814,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625290,,Half-life in plasma of rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,9815,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL876798,,Half-life in plasma of rat at dose of 3-10 mgkg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5064,,N,9816,1,,,50597,,,,BAO_0000218,CHEMBL625291,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5145,,N,9817,1,,,50597,,,,BAO_0000218,CHEMBL625292,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5147,,N,9818,1,,,50597,,,,BAO_0000218,CHEMBL625293,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5833,,N,9819,1,,,50597,,,,BAO_0000218,CHEMBL622832,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6596,,N,9820,1,,,50597,,,,BAO_0000218,CHEMBL622833,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,9821,1,,,50597,,,,BAO_0000218,CHEMBL622834,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,9822,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622835,,Half-life in rat after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,9823,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622836,,Half-life in rat after po administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,9824,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622837,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10,,N,9825,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622838,,Half-life in rat at 3 mg/kg dose administered intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17669,,N,9826,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622839,,Half-life in rat brain homogenate
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17065,,N,9827,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622840,,Half-life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4333,,N,9828,1,,,50597,,,,BAO_0000218,CHEMBL622841,,Half-life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6827,,N,9829,1,,,50597,,,,BAO_0000218,CHEMBL622842,,Half-life in Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,889,,N,9830,1,,,50597,Plasma,1969.0,In vitro,BAO_0000218,CHEMBL622843,,Half-life in vitro in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,889,,N,9831,1,,,50597,Plasma,1969.0,In vitro,BAO_0000218,CHEMBL622844,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3747,,N,9832,1,,,50597,,,,BAO_0000218,CHEMBL622845,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9833,1,,,50597,,,,BAO_0000218,CHEMBL622846,,The area under the curve of compound was measured at the dose of 100 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9834,1,,,50597,,,,BAO_0000218,CHEMBL622847,,The area under the curve of compound was measured at the dose of 300 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,9835,1,,,50597,,,,BAO_0000218,CHEMBL622848,,The area under the curve of compound was measured at the dose of 30 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3360,,N,9836,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622849,,Bioavailability as oral AUC in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,9837,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622850,,The plasma concentration versus time curve (AUC) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9838,1,,,50597,,,,BAO_0000218,CHEMBL876807,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9839,1,,,50597,,,,BAO_0000218,CHEMBL622851,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9840,1,,,50597,,,,BAO_0000218,CHEMBL622852,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,9841,1,,,50597,,,,BAO_0000218,CHEMBL622853,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,9842,1,,,50597,,,,BAO_0000218,CHEMBL622854,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17411,,N,9843,1,,,50597,,,,BAO_0000218,CHEMBL622855,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,9844,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622856,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,9845,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622857,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,9846,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622858,,AUC in rat after po administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,9847,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622859,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,9848,1,,,50597,,,,BAO_0000218,CHEMBL622860,,Area under curve value 24 hr after 10 mg/kg iv administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,9849,1,,,50597,,,,BAO_0000218,CHEMBL622861,,Area under curve value 24 hr after 10 mg/kg oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,9850,1,,,50597,,,,BAO_0000218,CHEMBL622862,,Area under curve value 24 hr after 2 mg/kg iv administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,9851,1,,,50597,,,,BAO_0000218,CHEMBL622863,,Area under curve value 24 hr after 2 mg/kg oral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,9852,1,,,50597,,,,BAO_0000218,CHEMBL623817,,Area under curve value 6 hr after po administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,9853,1,,,50597,,,,BAO_0000218,CHEMBL623818,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,9854,1,,,50597,,,,BAO_0000218,CHEMBL623819,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,9855,1,,,50597,,,,BAO_0000218,CHEMBL623820,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,9856,1,,,50597,,,,BAO_0000218,CHEMBL623821,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6642,,N,9857,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL623822,,AUC normalized for dose (AUCN) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,9858,1,,,50597,,,,BAO_0000218,CHEMBL623823,,Area under curve in rat after p.o. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,9859,1,,,50597,,,,BAO_0000218,CHEMBL623824,,Area under curve in rat after p.o. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,9860,1,,,50597,,,,BAO_0000218,CHEMBL623825,,Area under curve in rat after p.o. administration; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,9861,1,,,50597,,,,BAO_0000218,CHEMBL622070,,Area under curve in rat after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3603,,N,9862,1,,,50597,,,,BAO_0000218,CHEMBL622071,,Area under curve (carotid artery) value of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3550,,N,9863,1,,,50597,,,,BAO_0000218,CHEMBL622072,,Bioavailability expressed as the area under curve of rat carotid artery
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,9864,1,,,50597,,,,BAO_0000218,CHEMBL622073,,Area under curve in male SD rats was observed after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,9865,1,,,50597,,,,BAO_0000218,CHEMBL622074,,Area under curve of the compound was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5407,,N,9866,1,,,50597,,,,BAO_0000218,CHEMBL622075,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,9867,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622076,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,9868,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622077,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3603,,N,9869,1,,,50597,,,,BAO_0000218,CHEMBL622078,,Area under curve (portal vein) value of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3550,,N,9870,1,,,50597,,,,BAO_0000218,CHEMBL622079,,Bioavailability expressed as the area under curve of rat portal vein
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,9871,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622080,,Area Under plasma concentration time curve in rat upon peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,9872,1,,,50597,,,,BAO_0000218,CHEMBL877612,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,9873,1,,,50597,,,,BAO_0000218,CHEMBL622081,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9874,1,,,50597,,,,BAO_0000218,CHEMBL622082,,Compound was evaluated for oral bioavailability in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9875,1,,,50597,,,,BAO_0000218,CHEMBL622083,,Compound was evaluated for oral bioavailability in rats after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9876,1,,,50597,,,,BAO_0000218,CHEMBL622084,,Compound was evaluated for oral bioavailability in rats; 30-80
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9877,1,,,50597,,,,BAO_0000218,CHEMBL622085,,Compound was evaluated for oral bioavailability in rats; 50-60
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9878,1,,,50597,,,,BAO_0000218,CHEMBL622086,,Compound was evaluated for oral bioavailability in rats; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17791,,N,9879,1,,,50597,,,,BAO_0000218,CHEMBL622087,,Compound was evaluated for oral bioavailability in rats; peptide
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,9880,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622088,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,9881,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622089,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,9882,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL623685,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,9883,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL623686,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9884,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL623687,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9885,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL623688,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9886,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL623689,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9887,1,,,50597,Stomach,945.0,In vivo,BAO_0000218,CHEMBL622485,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9888,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622486,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9889,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL877613,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9890,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622487,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9891,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622488,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9892,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622489,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9893,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622490,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9894,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622491,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9895,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622492,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9896,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622493,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9897,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622494,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8677,,N,9898,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL622495,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9899,1,,,50597,,,,BAO_0000218,CHEMBL622496,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6899,,N,9900,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622497,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2189,,N,9901,1,,,50597,,,,BAO_0000218,CHEMBL622498,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2189,,N,9902,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624918,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2189,,N,9903,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624919,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9904,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624920,,Biodistribution of compound in rat blood after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9905,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624921,,Biodistribution of compound in rat blood after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9906,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL624922,,Biodistribution of compound in rat brain after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9907,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL624923,,Biodistribution of compound in rat heart after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9908,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL624924,,Biodistribution of compound in rat heart after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9909,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL624925,,Biodistribution of compound in rat kidney after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9910,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL624926,,Biodistribution of compound in rat kidney after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9911,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL624927,,Biodistribution of compound in rat liver after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9912,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL874402,,Biodistribution of compound in rat liver after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9913,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624928,,Biodistribution of compound in rat lung after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9914,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624929,,Biodistribution of compound in rat lung after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9915,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624930,,Biodistribution of compound in rat muscle after 5 min of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10839,,N,9916,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624931,,Biodistribution of compound in rat muscle after 5 min of administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9917,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624932,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9918,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624933,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9919,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624934,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9920,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624935,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9921,1,,,50597,,,,BAO_0000218,CHEMBL624936,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9922,1,,,50597,,,,BAO_0000218,CHEMBL624937,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9923,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL624938,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9924,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL624939,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9925,1,,,50597,,,,BAO_0000218,CHEMBL624940,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4043,,N,9926,1,,,50597,,,,BAO_0000218,CHEMBL874403,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,9927,1,,,50597,,,,BAO_0000218,CHEMBL624941,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9971,,N,9928,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624942,,Dose required to lower urine osmolality to 300 mOsm/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9971,,N,9929,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624943,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5765,,N,9930,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624944,,% Bioavailability after 1 day of the drug administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5765,,N,9931,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624945,,% Bioavailability after 4 day of the drug administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4257,,N,9932,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624946,,Absolute bioavailability was evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9933,1,,,50597,,,,BAO_0000218,CHEMBL624947,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9934,1,,,50597,,,,BAO_0000218,CHEMBL624948,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9935,1,,,50597,,,,BAO_0000218,CHEMBL624949,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9936,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622025,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9937,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622026,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9938,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622027,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9939,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622028,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9940,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622029,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9941,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622208,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9942,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622209,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9943,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622210,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9944,1,,,50597,,,,BAO_0000218,CHEMBL622211,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9945,1,,,50597,,,,BAO_0000218,CHEMBL622212,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9946,1,,,50597,,,,BAO_0000218,CHEMBL622213,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9947,1,,,50597,,,,BAO_0000218,CHEMBL874404,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9948,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620452,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9949,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620453,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9950,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL620454,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9951,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624067,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9952,1,,,50597,,,,BAO_0000218,CHEMBL624068,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9953,1,,,50597,Female gonad,992.0,,BAO_0000218,CHEMBL624069,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9954,1,,,50597,Female gonad,992.0,,BAO_0000218,CHEMBL624070,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9955,1,,,50597,Female gonad,992.0,,BAO_0000218,CHEMBL624071,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9956,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL624072,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9957,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL624073,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9958,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL624788,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9959,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL624789,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9960,1,,,50597,,,,BAO_0000218,CHEMBL624790,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9961,1,,,50597,,,,BAO_0000218,CHEMBL624791,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9962,1,,,50597,,,,BAO_0000218,CHEMBL624792,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9963,1,,,50597,,,,BAO_0000218,CHEMBL624793,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9964,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL877491,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9965,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624957,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9966,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624958,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13091,,N,9967,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624959,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11977,,N,9968,1,,,50597,,,,BAO_0000218,CHEMBL624960,,Dissociation constant was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,9969,1,,,50597,,,,BAO_0000218,CHEMBL624961,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9970,1,,,50597,,,,BAO_0000218,CHEMBL624962,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,9971,1,,,50597,,,,BAO_0000218,CHEMBL624963,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4755,,N,9972,1,,,50597,,,,BAO_0000218,CHEMBL624964,,Observed rate constant in 80% rat plasma at 37 degree Centigrade
A,Rattus norvegicus,10116.0,,,1,Intermediate,,589,,N,9973,1,,,50597,,,,BAO_0000218,CHEMBL624965,,LogP value was evaluated in the in situ rat gut perfusion assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,9974,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624966,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5031,,N,9975,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624967,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,9976,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624968,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,9977,1,,,50597,,,,BAO_0000218,CHEMBL624969,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration
F,Rattus norvegicus,10116.0,,,1,Expert,,2862,,N,9978,1,,,50597,,,,BAO_0000218,CHEMBL624970,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,9979,1,,,50597,,,,BAO_0000218,CHEMBL624971,,Half-life was evaluated after 10 uM/kg of intra arterial administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,9980,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624972,,Half-life was evaluated after 20 uM/kg of peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6005,,N,9981,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624973,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2938,,N,9982,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL624974,,Half-life was evaluated in plasma of rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9983,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624975,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,9984,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877492,,Half-life was evaluated in rats at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6062,,N,9985,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624976,,Half-life was measured in rat after an iv dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,9986,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624977,,Half-life period of compound in rats after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3136,,N,9987,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626848,,Half-life period of compound was measured in rat plasma.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3136,,N,9988,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626849,,Half-life period of compound was measured in rat plasma; ND is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3136,,N,9989,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626850,,Half-life period of compound was measured in rat plasma; not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4521,,N,9990,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626851,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5871,,N,9991,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626852,,Half-life period in rat by iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6077,,N,9992,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626853,,Half-life period in rats following intravenous administration at 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6679,,N,9993,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626854,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5144,,N,9994,1,,,50597,,,,BAO_0000218,CHEMBL627486,,Half-life period was determined for the compound in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4498,,N,9995,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627487,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4498,,N,9996,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627488,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,9997,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627489,,Half-life value after IV dose at a dose of 5 mg/kg in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6211,,N,9998,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627490,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5529,,N,9999,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873829,,Half-life was determined in rat after intravenous administration (0.5 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,10000,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627655,,Half-life was determined in rat at a dose of 1 mpk i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,10001,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625994,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6444,,N,10002,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625995,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5207,,N,10003,1,,,50597,,,,BAO_0000218,CHEMBL625996,,Half-life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,530,,N,10004,1,,,50597,Plasma,1969.0,In vitro,BAO_0000218,CHEMBL625850,,In vitro half life in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1116,,N,10005,1,,,50597,Plasma,1969.0,In vitro,BAO_0000218,CHEMBL625851,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3219,,N,10006,1,,,50597,,,In vitro,BAO_0000218,CHEMBL625852,,In vitro half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6109,,N,10007,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625853,,In vivo half life period after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,10008,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625854,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,10009,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874450,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10010,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625855,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10011,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625856,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10012,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625857,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10013,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873831,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,10014,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625858,,Longer half-life in rat (i.v.) at 0.5 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,10015,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625859,,Longer half-life in rat (p.o.) at 2.0 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3457,,N,10016,1,,,50597,,,,BAO_0000218,CHEMBL625860,,Pharmacokinetic property (half life) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,10017,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625861,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,10018,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625862,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,10019,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625863,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,10020,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625864,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5739,,N,10021,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625865,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,10022,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625866,,Pharmacokinetic half time was determined intravenously in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6567,,N,10023,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625867,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2448,,N,10024,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625868,,Plasma half life of hydrolysis of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5423,,N,10025,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625869,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10026,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL874451,,Plasma half life period was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10027,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625870,,Plasma half-life in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10028,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625871,,Plasma half-life in Sprague-Dawley rats; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,10029,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625872,,Plasma half-life in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,10030,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625873,,Plasma half-life in rats; <MQL
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10031,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625874,,Plasma half-life period (0-8 h) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10032,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL625875,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10033,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625876,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10034,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631258,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4956,,N,10035,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631259,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4956,,N,10036,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL631260,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10037,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631261,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10038,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631262,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10039,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631263,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10040,1,,,50597,,,,BAO_0000218,CHEMBL631264,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10041,1,,,50597,,,,BAO_0000218,CHEMBL631265,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10042,1,,,50597,,,,BAO_0000218,CHEMBL631266,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10043,1,,,50597,,,,BAO_0000218,CHEMBL631267,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10044,1,,,50597,,,,BAO_0000218,CHEMBL631268,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10045,1,,,50597,,,,BAO_0000218,CHEMBL631269,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10046,1,,,50597,,,,BAO_0000218,CHEMBL631270,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10047,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631271,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10048,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631272,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10049,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631273,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10050,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631274,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10051,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631275,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10052,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626984,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10053,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626985,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10054,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626986,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10055,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626987,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10056,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626988,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10057,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626989,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10058,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626990,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10059,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626991,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10060,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626992,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10061,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626993,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10062,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL874593,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10063,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626994,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10064,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626995,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10065,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626190,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10066,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626191,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10067,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626364,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10068,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626365,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10069,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626366,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10070,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626367,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10071,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626368,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10072,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626369,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10073,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626370,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4498,,N,10074,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626371,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4498,,N,10075,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626372,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3603,,N,10076,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626373,,Bioavailability after a dose of 10 mg/kg p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6215,,N,10077,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626374,,Bioavailability after peroral administration (10 mg/kg) was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,10078,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626375,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5710,,N,10079,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626376,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5676,,N,10080,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626377,,Bioavailability in rat po was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17667,,N,10081,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626378,,Bioavailability of compound at 10 mg/kg in rat after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17667,,N,10082,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626379,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6848,,N,10083,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626380,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6848,,N,10084,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626381,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17267,,N,10085,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626382,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6362,,N,10086,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626383,,Bioavailability in rat (Sprague-Dawley) (female)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,10087,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874652,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17671,,N,10088,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626384,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4333,,N,10089,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626385,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6077,,N,10090,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626386,,Bioavailability in rat at an oral dose of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3278,,N,10091,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626387,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5964,,N,10092,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626388,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4884,,N,10093,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626389,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4905,,N,10094,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626390,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4884,,N,10095,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626391,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6850,,N,10096,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626392,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2864,,N,10097,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626393,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5780,,N,10098,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623026,,Bioavailability was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1465,,N,10099,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623027,,Bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5199,,N,10100,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623028,,Bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5765,,N,10101,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623029,,Bioavailability in rat after 1 day dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5765,,N,10102,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623030,,Bioavailability in rat after 4 day dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,10103,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623031,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,10104,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623032,,Bioavailability after IV dosing at 1 mg/kg in rat; no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,10105,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623033,,Bioavailability after oral administration at a dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6518,,N,10106,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623034,,Bioavailability after oral administration at a dose of 4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2083,,N,10107,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623035,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17260,,N,10108,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623036,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4956,,N,10109,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623037,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4368,,N,10110,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623038,,Bioavailability by intravenous administration of 3.4 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17752,,N,10111,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL874385,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,10112,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623039,,Bioavailability in rat (Fisher) (fasted)
A,Primates,9443.0,,,1,Intermediate,,2891,,U,10113,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623040,,Bioavailability in monkey after po administration of 10 mg/kg dose
A,Primates,9443.0,,,1,Intermediate,,2891,,U,10114,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623041,,Oral bioavailability in monkey (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6672,,N,10115,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623741,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6673,,N,10116,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623742,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,10117,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623743,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,10118,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623744,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17853,,N,10119,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623745,,Bioavailability in rat (dose 2.0 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4521,,N,10120,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623746,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4940,,N,10121,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623747,,Oral bioavailability in rat (dose 5 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2891,,U,10122,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623748,,Bioavailability in rat after po administration of 30 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2891,,U,10123,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623916,,Bioavailability in rat after po administration of 30 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4521,,N,10124,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623917,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17686,,N,10125,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623918,,Bioavailability in rat (dose 2 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,10126,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874386,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,10127,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623919,,Bioavailability in rat; Only traces detected in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5064,,N,10128,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623920,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5147,,N,10129,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623148,,Bioavailability upon oral administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1916,,N,10130,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623149,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6049,,N,10131,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623150,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1445,,N,10132,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623151,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1445,,N,10133,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623152,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state"
F,Rattus norvegicus,10116.0,,,1,Expert,,2862,,N,10134,1,,,50597,,,,BAO_0000218,CHEMBL623153,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose
F,Rattus norvegicus,10116.0,,,1,Expert,,2862,,N,10135,1,,,50597,,,,BAO_0000218,CHEMBL623154,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4194,,N,10136,1,,,50597,,,,BAO_0000218,CHEMBL623155,,In vitro and metabolic stability was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4194,,N,10137,1,,,50597,,,,BAO_0000218,CHEMBL623156,,In vitro metabolic stability in rat hepatocytes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5486,,N,10138,1,,,50597,,,,BAO_0000218,CHEMBL623157,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein
A,Rattus norvegicus,10116.0,,Hepatocyte,1,Intermediate,,17582,,N,10139,1,401.0,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL623158,,Metabolic rate for compound was observed in rat hepatocytes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5600,,N,10140,1,,,50597,,,,BAO_0000218,CHEMBL623159,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14294,,N,10141,1,,,50597,,,,BAO_0000218,CHEMBL874390,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14294,,N,10142,1,,,50597,,,,BAO_0000218,CHEMBL623160,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14294,,N,10143,1,,,50597,,,,BAO_0000218,CHEMBL623161,,Metabolism of compound in rat S9 microsomes; Trace
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17847,,N,10144,1,,,50597,,,,BAO_0000218,CHEMBL623162,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10145,1,,,50597,,,,BAO_0000218,CHEMBL623163,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10146,1,,,50597,,,,BAO_0000218,CHEMBL623164,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10147,1,,,50597,,,,BAO_0000218,CHEMBL623165,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10148,1,,,50597,,,,BAO_0000218,CHEMBL623166,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10149,1,,,50597,,,,BAO_0000218,CHEMBL624983,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10150,1,,,50597,,,,BAO_0000218,CHEMBL624984,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10151,1,,,50597,,,,BAO_0000218,CHEMBL624985,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10152,1,,,50597,,,,BAO_0000218,CHEMBL622970,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10153,1,,,50597,,,,BAO_0000218,CHEMBL622971,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10154,1,,,50597,,,,BAO_0000218,CHEMBL622972,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10155,1,,,50597,,,,BAO_0000218,CHEMBL622973,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10156,1,,,50597,,,,BAO_0000218,CHEMBL622974,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10157,1,,,50597,,,,BAO_0000218,CHEMBL622975,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10158,1,,,50597,,,,BAO_0000218,CHEMBL622976,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10159,1,,,50597,,,,BAO_0000218,CHEMBL622977,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10160,1,,,50597,,,,BAO_0000218,CHEMBL624351,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10161,1,,,50597,,,,BAO_0000218,CHEMBL624352,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10162,1,,,50597,,,,BAO_0000218,CHEMBL624353,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10163,1,,,50597,,,,BAO_0000218,CHEMBL622397,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10164,1,,,50597,,,,BAO_0000218,CHEMBL622398,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10165,1,,,50597,,,,BAO_0000218,CHEMBL622399,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10166,1,,,50597,,,,BAO_0000218,CHEMBL622400,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10167,1,,,50597,,,,BAO_0000218,CHEMBL628428,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10168,1,,,50597,,,,BAO_0000218,CHEMBL628590,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10169,1,,,50597,,,,BAO_0000218,CHEMBL628591,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10170,1,,,50597,,,,BAO_0000218,CHEMBL628592,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10171,1,,,50597,,,,BAO_0000218,CHEMBL628593,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10172,1,,,50597,,,,BAO_0000218,CHEMBL875333,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10173,1,,,50597,,,,BAO_0000218,CHEMBL628594,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4969,,N,10174,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628595,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6737,,N,10175,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628596,,Stability in rat plasma was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6737,,N,10176,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628597,,Stability in rat plasma was determined; ND= no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,10177,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628598,,Tested for plasma half life period in rat (0-8 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,10178,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628599,,Tested for plasma half life period in rat (0-8 hr); Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,10179,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628600,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,10180,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628601,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4950,,N,10181,1,,,50597,,,,BAO_0000218,CHEMBL628602,,Tested for the half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2412,,N,10182,1,,,50597,,,In vitro,BAO_0000218,CHEMBL628603,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2412,,N,10183,1,,,50597,,,In vitro,BAO_0000218,CHEMBL628604,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2412,,N,10184,1,,,50597,,,In vitro,BAO_0000218,CHEMBL628605,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2412,,N,10185,1,,,50597,,,In vitro,BAO_0000218,CHEMBL628606,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2412,,N,10186,1,,,50597,,,In vitro,BAO_0000218,CHEMBL628607,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,10187,1,,,50597,,,,BAO_0000218,CHEMBL628608,,The biological half life the compound was measured at the dose of 100 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15022,,N,10188,1,,,50597,,,,BAO_0000218,CHEMBL628609,,The biological half life the compound was measured at the dose of 30 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,406,,N,10189,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628610,,The compound was evaluated for plasma half life period in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,10190,1,,,50597,,,In vivo,BAO_0000218,CHEMBL873819,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,10191,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628611,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5247,,N,10192,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628612,,The pharmacokinetic parameter half-life period in vivo in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10193,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628613,,"The pharmacokinetic property, Half-life was determined"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10194,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628614,,"The pharmacokinetic property, Half-life in rat in vivo"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10195,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628615,,"The pharmacokinetic property, Half-life was determined; ND denotes no data"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10196,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628616,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3918,,N,10197,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627924,,The plasma half life period in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2906,,N,10198,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL627925,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6467,,N,10199,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627926,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,10200,1,,,50597,,,,BAO_0000218,CHEMBL627927,,t1/2 (apparent elimination)of the compound was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3788,,N,10201,1,,,50597,,,,BAO_0000218,CHEMBL627928,,t1/2 value in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17796,,N,10202,1,,,50597,,,,BAO_0000218,CHEMBL627539,,Half life in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,10203,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL876790,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,10204,1,,,50597,,,In vivo,BAO_0000218,CHEMBL858186,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,10205,1,,,50597,,,,BAO_0000218,CHEMBL627540,,Half-life period in fasted rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,10206,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627541,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,10207,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627715,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,429,,N,10208,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627716,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,10209,1,,,50597,,,,BAO_0000218,CHEMBL627717,,Maximum time required to achieve Cmax was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10210,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627718,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10211,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627719,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10212,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627720,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,10213,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627721,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,10214,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627722,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10215,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627723,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10216,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626058,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10217,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626059,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10218,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626060,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,10219,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626061,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,10220,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876791,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4723,,N,10221,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626062,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,10222,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626063,,Tmax at the dose of 2 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,10223,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626064,,Tmax at the dose of 5 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,10224,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626065,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17720,,N,10225,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626066,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,10226,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626067,,tmax upon peroral administration of 10.0 mg/Kg dose in rat
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10227,1,,,50597,,,,BAO_0000218,CHEMBL626068,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10228,1,,,50597,,,,BAO_0000218,CHEMBL626069,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10229,1,,,50597,,,,BAO_0000218,CHEMBL626070,,Percent total excretion of 3-methoxyacetaminophen glucuronide
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10230,1,,,50597,,,,BAO_0000218,CHEMBL626071,,Percent total excretion of N-methoxyacetaminophen glucuronide
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10231,1,,,50597,,,,BAO_0000218,CHEMBL626072,,Percent total excretion of N-methoxyacetaminophen sulfate
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10232,1,,,50597,,,,BAO_0000218,CHEMBL626073,,Percent total excretion of acetaminophen
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7768,,N,10233,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626741,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17655,,N,10234,1,,,50597,,,,BAO_0000218,CHEMBL626742,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17735,,N,10235,1,,,50597,,,,BAO_0000218,CHEMBL626743,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,10236,1,,,50597,,,,BAO_0000218,CHEMBL876792,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17735,,N,10237,1,,,50597,,,,BAO_0000218,CHEMBL626744,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7116,,N,10238,1,,,50597,,,,BAO_0000218,CHEMBL626745,,Compound was tested for antidiuretic activity in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4878,,N,10239,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626746,,AUC in rat after 3mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,10240,1,,,50597,,,,BAO_0000218,CHEMBL626747,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,10241,1,,,50597,,,,BAO_0000218,CHEMBL626748,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16367,,N,10242,1,,,50597,,,,BAO_0000218,CHEMBL626749,,Bioavailability administered orally at a dose of 10 mg/kg to rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16366,,N,10243,1,,,50597,,,,BAO_0000218,CHEMBL626750,,Oral Bioavailability was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,10244,1,,,50597,,,,BAO_0000218,CHEMBL626751,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4426,,N,10245,1,,,50597,,,,BAO_0000218,CHEMBL626913,,Oral bioavailability in rat; Not performed.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10246,1,,,50597,,,,BAO_0000218,CHEMBL626914,,Bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5041,,N,10247,1,,,50597,,,,BAO_0000218,CHEMBL626915,,Bioavailability was determined; ND denotes no data
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,10248,1,,,50597,,,,BAO_0000218,CHEMBL626916,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1500,,N,10249,1,,,50597,,,,BAO_0000218,CHEMBL626917,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17409,,N,10250,1,,,50597,,,,BAO_0000218,CHEMBL626918,,Binding towards rat plasma protein at 10 uM
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17409,,N,10251,1,,,50597,,,,BAO_0000218,CHEMBL626919,,Binding towards rat plasma protein at 100 uM
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,10252,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626920,,Bioavailability in rat (dose 20 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13501,,N,10253,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621976,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6567,,N,10254,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877599,,Bioavailability in rat after 5 mg/kg oral gavage
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6571,,N,10255,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621977,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6715,,N,10256,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621978,,Bioavailability in rat (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6715,,N,10257,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621979,,Bioavailability in rat (dose 3 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2932,,N,10258,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621980,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4171,,N,10259,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621981,,Bioavailability of the compound in rats after administration of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,10260,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621982,,Bioavailability after administration of 10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17509,,N,10261,1,,,50597,,,In vivo,BAO_0000218,CHEMBL882953,,Bioavailability after administration of 2 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4527,,N,10262,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621983,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,10263,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621984,,Bioavailability in dogs was determined; high
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10264,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621985,,Bioavailability in monkey after intravenous administration at 1 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10265,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621986,,Bioavailability in monkey after peroral administration at 10 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10266,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621987,,Bioavailability in rat after intravenous administration at 1 mpk
F,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10267,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877600,,Bioavailability in rat after intravenous administration at 2 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10268,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621988,,Bioavailability in rat after peroral administration at 30 mpk
F,Rattus norvegicus,10116.0,,,1,Intermediate,,6659,,N,10269,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621989,,Bioavailability in rat after peroral administration at at 100 mpk
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6597,,N,10270,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621990,,Bioavailability in rats was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1202,,N,10271,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621991,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1202,,N,10272,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621992,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1202,,N,10273,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621993,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1202,,N,10274,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621994,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5207,,N,10275,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621995,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5970,,N,10276,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621996,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,10277,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621997,,Oral bioavailability in rat (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17538,,N,10278,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621998,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1466,,N,10279,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621999,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,10280,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622000,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,10281,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622001,,Bioavailability was measured in rat after oral administration; 2-4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2879,,N,10282,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622002,,Bioavailability was measured in rat after oral administration; 3-7
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3777,,N,10283,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622003,,Bioavailability in rat (intraduodenal administration)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3777,,N,10284,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877601,,Bioavailability in rat (intraduodenal administration)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3777,,N,10285,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624871,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3777,,N,10286,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622004,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5423,,N,10287,1,,,50597,,,In vivo,BAO_0000218,CHEMBL882954,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,10288,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622005,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16365,,N,10289,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622006,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4239,,N,10290,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622007,,Bioavailability was measured in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5438,,N,10291,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622008,,Bioavailability was reported
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10292,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622009,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10293,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622010,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,10294,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622011,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,10295,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622012,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4199,,N,10296,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622013,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4890,,N,10297,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622014,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2792,,N,10298,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624749,,Bioavailability was determined at 3 mg/kg po dose in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5529,,N,10299,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624750,,Oral bioavailability in rat (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,10300,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624751,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,10301,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624752,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6685,,N,10302,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624753,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6005,,N,10303,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624754,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,10304,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624755,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,10305,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624756,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6103,,N,10306,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624757,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,10307,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624758,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6410,,N,10308,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622270,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5353,,N,10309,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622271,,Bioavailability in rat (Sprague-Dawley)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,10310,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622272,,Bioavailability in rat at the dose of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,10311,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622273,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5809,,N,10312,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622274,,Bioavailability in rat (cannulated) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,10313,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622275,,Bioavailability value of compound in rats was determined after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3634,,N,10314,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622276,,Oral bioavailability in rat (dose 20 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3341,,N,10315,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622277,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2690,,N,10316,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622278,,Oral bioavailability in rat (dose 5 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3184,,N,10317,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622279,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,740,,N,10318,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622280,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1806,,N,10319,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624083,,Compound was evaluated for oral bioavailability in rats; 15-27 %
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4891,,N,10320,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624084,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3634,,N,10321,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624085,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,64,,N,10322,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624086,,Compound was tested for bioavailability in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4839,,N,10323,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624087,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1094,,N,10324,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624088,,Oral bioavailability in rat
A,Macaca mulatta,9544.0,,,1,Intermediate,,5005,,U,10325,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624089,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5005,,U,10326,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624090,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4687,,N,10327,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624091,,Evaluated for the bioavailability in rat (in vivo)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17804,,N,10328,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624092,,F value of compound in rats was determined after peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10329,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624093,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10330,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624094,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10331,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624095,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5974,,N,10332,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624096,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1088,,N,10333,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624097,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1742,,N,10334,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624098,,Maximum fall in carotid flow in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4689,,N,10335,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874392,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2463,,N,10336,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624099,,Oral bioavailability in rat (dose 5 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,10337,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624100,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5654,,N,10338,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624101,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6874,,N,10339,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624102,,Oral bioavailability in rat (male Wistar)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5633,,N,10340,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624103,,Oral bioavailability after administration (30 mg/kg) in rat; good
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5496,,N,10341,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624104,,Oral bioavailability at the dose of 2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2358,,N,10342,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624105,,Oral bioavailability determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16456,,N,10343,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624106,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,10344,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624107,,Oral bioavailability in rat (dose single 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,10345,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623943,,Oral bioavailability in rat (dose single 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5302,,N,10346,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623944,,Oral bioavailability in rat (dose 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10347,1,,,50597,,,,BAO_0000218,CHEMBL623945,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10348,1,,,50597,,,,BAO_0000218,CHEMBL623946,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10349,1,,,50597,,,,BAO_0000218,CHEMBL623947,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10350,1,,,50597,,,,BAO_0000218,CHEMBL623948,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10351,1,,,50597,,,,BAO_0000218,CHEMBL623949,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10352,1,,,50597,,,,BAO_0000218,CHEMBL623950,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10353,1,,,50597,,,,BAO_0000218,CHEMBL874398,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10354,1,,,50597,,,,BAO_0000218,CHEMBL623951,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10355,1,,,50597,,,,BAO_0000218,CHEMBL623952,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10356,1,,,50597,,,,BAO_0000218,CHEMBL623953,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10357,1,,,50597,,,,BAO_0000218,CHEMBL623954,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10358,1,,,50597,,,,BAO_0000218,CHEMBL623955,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10359,1,,,50597,,,,BAO_0000218,CHEMBL623956,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10360,1,,,50597,,,,BAO_0000218,CHEMBL627807,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10361,1,,,50597,,,,BAO_0000218,CHEMBL627808,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10362,1,,,50597,,,,BAO_0000218,CHEMBL627809,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10363,1,,,50597,,,,BAO_0000218,CHEMBL627810,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10364,1,,,50597,,,,BAO_0000218,CHEMBL627811,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10365,1,,,50597,,,,BAO_0000218,CHEMBL627812,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10366,1,,,50597,,,,BAO_0000218,CHEMBL627813,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10367,1,,,50597,,,,BAO_0000218,CHEMBL627814,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10368,1,,,50597,,,,BAO_0000218,CHEMBL875336,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10369,1,,,50597,,,,BAO_0000218,CHEMBL627815,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10370,1,,,50597,,,,BAO_0000218,CHEMBL627816,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10371,1,,,50597,,,,BAO_0000218,CHEMBL627817,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10372,1,,,50597,,,,BAO_0000218,CHEMBL627818,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10373,1,,,50597,,,,BAO_0000218,CHEMBL627819,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10374,1,,,50597,,,,BAO_0000218,CHEMBL627820,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10375,1,,,50597,,,,BAO_0000218,CHEMBL627821,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10376,1,,,50597,,,,BAO_0000218,CHEMBL628464,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10377,1,,,50597,,,,BAO_0000218,CHEMBL626239,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10378,1,,,50597,,,,BAO_0000218,CHEMBL626240,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10379,1,,,50597,,,,BAO_0000218,CHEMBL626241,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10380,1,,,50597,,,,BAO_0000218,CHEMBL626242,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10381,1,,,50597,,,,BAO_0000218,CHEMBL626243,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10382,1,,,50597,,,,BAO_0000218,CHEMBL626244,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10383,1,,,50597,,,,BAO_0000218,CHEMBL626907,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10384,1,,,50597,,,,BAO_0000218,CHEMBL626908,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10385,1,,,50597,,,,BAO_0000218,CHEMBL626909,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10386,1,,,50597,,,,BAO_0000218,CHEMBL626910,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10387,1,,,50597,,,,BAO_0000218,CHEMBL875342,,Percent total excretion of acetaminophen cysteine conjugate
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10388,1,,,50597,,,,BAO_0000218,CHEMBL626911,,Percent total excretion of acetaminophen glucuronide
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10389,1,,,50597,,,,BAO_0000218,CHEMBL626912,,Percent total excretion of acetaminophen sulfate
F,Rattus norvegicus,10116.0,,,1,Intermediate,,7449,,N,10390,1,,,50597,,,,BAO_0000218,CHEMBL627065,,Percent total excretion of acetaminophen-mercapturic acid
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3172,,N,10391,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627066,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16456,,N,10392,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627067,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
A,ratrat,8656.0,,,1,Autocuration,,10839,,U,10393,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627068,,Biodistribution of compound in rat muscle after 5 min of administration
A,ratrat,8656.0,,,1,Autocuration,,10839,,U,10394,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627069,,Biodistribution of compound in rat muscle after 5 min of administration.
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10395,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627070,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10396,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627071,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10397,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627072,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10398,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627073,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10399,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625387,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10400,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625388,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10401,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625389,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female)
A,Ovis aries,9940.0,,,1,Autocuration,,5334,,U,10402,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875343,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female)
A,Serpentes,8570.0,,,1,Intermediate,,1735,,N,10403,1,,,50497,,,,BAO_0000218,CHEMBL876795,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE)
A,Serpentes,8570.0,,,1,Intermediate,,1469,,N,10404,1,,,50497,,,,BAO_0000218,CHEMBL626552,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg
A,Serpentes,8570.0,,,1,Intermediate,,1336,,N,10405,1,,,50497,,,,BAO_0000218,CHEMBL626553,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase
A,Homo sapiens,9606.0,,,1,Autocuration,,12403,,U,10406,0,,,22224,Plasma,1969.0,,BAO_0000366,CHEMBL626554,,The human biological plasma half life of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,10407,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626555,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10408,1,,,50597,,,,BAO_0000218,CHEMBL626556,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10409,1,,,50597,,,,BAO_0000218,CHEMBL626557,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10410,1,,,50597,,,,BAO_0000218,CHEMBL626558,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10411,1,,,50597,,,,BAO_0000218,CHEMBL626559,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10412,1,,,50597,,,,BAO_0000218,CHEMBL626560,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10413,1,,,50597,,,,BAO_0000218,CHEMBL876803,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10414,1,,,50597,,,,BAO_0000218,CHEMBL627964,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10415,1,,,50597,,,,BAO_0000218,CHEMBL627965,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10416,1,,,50597,,,,BAO_0000218,CHEMBL627966,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10417,1,,,50597,,,,BAO_0000218,CHEMBL627967,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10418,1,,,50597,,,,BAO_0000218,CHEMBL627968,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10419,1,,,50597,,,,BAO_0000218,CHEMBL627969,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10420,1,,,50597,,,,BAO_0000218,CHEMBL627970,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10421,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627971,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8004,,N,10422,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627972,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound
B,Homo sapiens,9606.0,,,1,Expert,,15917,,D,10423,9,,,180,,,,BAO_0000357,CHEMBL856029,,Dissociation constant against binding to human cyclophilin A
B,Bos taurus,9913.0,,,1,Expert,,12396,,H,10424,8,,,11591,,,,BAO_0000019,CHEMBL627973,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II
A,,,,,1,Autocuration,,7065,,U,10425,0,,,22224,,,,BAO_0000019,CHEMBL627974,,-Log C was determined by performing the electroshock minimum test
A,,,,,1,Autocuration,,7065,,U,10426,0,,,22224,,,,BAO_0000019,CHEMBL627975,,-Log C was determined by performing the foot shock test
A,,,,,1,Autocuration,,7065,,U,10427,0,,,22224,,,,BAO_0000019,CHEMBL627976,,-Log C was determined by performing the incl screen test
A,,,,,1,Autocuration,,7065,,U,10428,0,,,22224,,,,BAO_0000019,CHEMBL627977,,-Log C was determined by performing the maximum electroshock test
A,,,,,1,Autocuration,,7065,,U,10429,0,,,22224,,,,BAO_0000019,CHEMBL627978,,-Log C was determined by performing the pentylenetetrazole test
A,,,,,1,Autocuration,,12415,,U,10430,0,,,22224,,,,BAO_0000019,CHEMBL627979,,Tested for experimental arotinoid inhibitory dose
A,,,,,1,Autocuration,,10256,,U,10431,0,,,22224,,,,BAO_0000019,CHEMBL876804,,Negative log transformed activity
A,,,,,1,Autocuration,,7991,,U,10432,0,,,22224,,,,BAO_0000019,CHEMBL627980,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)"
A,Cavia porcellus,10141.0,,,1,Intermediate,,14342,,N,10433,1,,,50512,,,,BAO_0000218,CHEMBL627981,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor
A,Cavia porcellus,10141.0,,,1,Intermediate,,14342,,N,10434,1,,,50512,,,,BAO_0000218,CHEMBL627982,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor
A,Cavia porcellus,10141.0,,,1,Intermediate,,14342,,N,10435,1,,,50512,,,,BAO_0000218,CHEMBL627983,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor
A,Cavia porcellus,10141.0,,,1,Intermediate,,14342,,N,10436,1,,,50512,Ileum,2116.0,,BAO_0000218,CHEMBL627984,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor
P,,,,,1,Autocuration,,6047,,U,10437,0,,,22229,,,,BAO_0000100,CHEMBL627985,,Solubility in water was determined; values expressed as -log
A,,,,,1,Autocuration,,17269,,U,10438,0,,,22224,,,,BAO_0000019,CHEMBL627986,,Ratio of Kcat to that of Km was determined
A,,,,,1,Autocuration,,10026,,U,10439,0,,,22224,,,,BAO_0000019,CHEMBL627987,,Observed first order rate constant
A,,,,,1,Autocuration,,14583,,U,10440,0,,,22224,,,,BAO_0000019,CHEMBL627988,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,10441,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627989,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2661,,N,10442,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627990,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4029,,N,10443,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876805,,Oral Bioavailability after administration of 10 mg/kg in male rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17735,,N,10444,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627991,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4576,,N,10445,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627992,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17582,,N,10446,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627993,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,10447,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622817,,Oral bioavailability at 1 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17651,,N,10448,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622818,,Oral bioavailability at 10 mg/kg was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17670,,N,10449,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622819,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5045,,N,10450,1,,,50597,,,In vivo,BAO_0000218,CHEMBL872267,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1696,,N,10451,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622820,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17764,,N,10452,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622821,,Oral bioavailability after intravenous administration in rats at 24 uM/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,10453,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622822,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6596,,N,10454,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622823,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17547,,N,10455,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622824,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17771,,N,10456,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622825,,Oral bioavailability in rat at a dose of 3 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,10457,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622901,,Oral bioavailability in rat after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4558,,N,10458,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622902,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,10459,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621844,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6827,,N,10460,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621845,,Oral bioavailability in Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4026,,N,10461,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621846,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10,,N,10462,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621847,,Oral bioavailability in rat (dose 30 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10463,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877609,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10464,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621848,,Bioavailability in rat (dose 3 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10465,1,,,50597,,,In vivo,BAO_0000218,CHEMBL621849,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10466,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622030,,Oral bioavailability in rat (dose 60 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4796,,N,10467,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622031,,Percent oral bioavailability determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,10468,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622032,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2137,,N,10469,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622033,,The compound was evaluated for bioavailability in rats; 32-51
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2959,,N,10470,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622034,,Bioavailability in rat (dose 20 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1361,,N,10471,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622035,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4727,,N,10472,1,,,50597,,,In vivo,BAO_0000218,CHEMBL882966,,Bioavailability percent in rat at the dose of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16423,,N,10473,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622036,,Bioavailability was evaluated after 20 uM/kg of peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5206,,N,10474,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622037,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,10475,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622038,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17723,,N,10476,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622039,,Bioavailability in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10477,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622040,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10478,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622041,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10479,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622042,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10480,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622043,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10481,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622044,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10482,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL622045,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10483,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL622046,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10484,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL622047,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10485,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL877610,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10486,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622048,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10487,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622049,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10488,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622050,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10489,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622051,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10490,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622052,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10491,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622053,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10492,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622054,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10493,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622055,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5237,,N,10494,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622056,,Oral bioavailability in rats was determined; High
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5503,,N,10495,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622057,,Oral bioavailability in the rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15765,,N,10496,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628008,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15660,,N,10497,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622058,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10498,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622059,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10499,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622060,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10500,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622061,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5978,,N,10501,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622062,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,10502,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622063,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat
A,Rattus norvegicus,10116.0,,,1,Expert,,3598,,N,10503,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877611,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4216,,N,10504,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622064,,Oral bioavailability of compound in Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17839,,N,10505,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622065,,Oral bioavailability of compound in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6570,,N,10506,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622066,,Oral bioavailability in rat (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5334,,N,10507,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622067,,Oral bioavailability of compound in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6886,,N,10508,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622068,,Oral bioavailability of compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5210,,N,10509,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622069,,Oral bioavailability of compound was determined in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4170,,N,10510,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624796,,Oral bioavailability at a dose of 30 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6028,,N,10511,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624797,,Oral bioavailability in rat (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6028,,N,10512,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623053,,Oral bioavailability in rat (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,10513,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623054,,Oral bioavailability evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6168,,N,10514,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623055,,Oral bioavailability in fasted rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6168,,N,10515,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623056,,Oral bioavailability in fed rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5160,,N,10516,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623057,,Oral bioavailability in rat (mature male) (dose 30 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,10517,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623058,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,10518,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623059,,Oral bioavailability in rat (dose 10 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6535,,N,10519,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623060,,Oral bioavailability in rat after administration of 10 mg/kg po
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4194,,N,10520,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623061,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6230,,N,10521,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623062,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6619,,N,10522,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623063,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17607,,N,10523,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623064,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4942,,N,10524,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623065,,Oral bioavailability in ratrs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4942,,N,10525,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623066,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6646,,N,10526,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623067,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5237,,N,10527,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623068,,Oral bioavailability in rats was determined; High
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6646,,N,10528,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623069,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4449,,N,10529,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623070,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6057,,N,10530,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623071,,Oral bioavailability was calculated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2552,,N,10531,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623072,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5496,,N,10532,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623073,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6484,,N,10533,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623074,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6485,,N,10534,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623075,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6616,,N,10535,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623076,,Oral bioavailability after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4969,,N,10536,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623077,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5862,,N,10537,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623078,,Oral bioavailability in rat (Sprague-Dawley)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10538,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623079,,Oral bioavailability in Sprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10539,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623080,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10540,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623081,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5546,,N,10541,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623082,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6168,,N,10542,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874400,,Oral bioavailability in fasted rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6168,,N,10543,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623083,,Oral bioavailability in fed rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3624,,N,10544,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623084,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5213,,N,10545,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623085,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5496,,N,10546,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623086,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5553,,N,10547,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623087,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5833,,N,10548,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623088,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5836,,N,10549,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623089,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5865,,N,10550,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623090,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5960,,N,10551,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623091,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6249,,N,10552,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623092,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6448,,N,10553,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623093,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6453,,N,10554,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874401,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,10555,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623094,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17607,,N,10556,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623095,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,10557,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623096,,Oral bioavailability in rat after peroral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5939,,N,10558,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624913,,Oral bioavailability in rat after peroral administration at 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6281,,N,10559,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624914,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5874,,N,10560,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624915,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5213,,N,10561,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624916,,Oral bioavailability in rat; Not measured
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4964,,N,10562,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624917,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11020,,N,10563,1,,,50597,,,,BAO_0000218,CHEMBL625157,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6251,,N,10564,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625158,,In vitro metabolic potential in rat liver microsomes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1568,,N,10565,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625159,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3032,,N,10566,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625160,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3748,,N,10567,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625161,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,401,,N,10568,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625162,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6512,,N,10569,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625163,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17617,,N,10570,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625164,,Oral bioavailability in rats at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6679,,N,10571,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625165,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6742,,N,10572,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625166,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,589,,N,10573,1,,,50597,,,,BAO_0000218,CHEMBL625167,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis
A,Rattus norvegicus,10116.0,,,1,Intermediate,,589,,N,10574,1,,,50597,,,,BAO_0000218,CHEMBL625168,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3185,,N,10575,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625169,,Plasma clearance of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17596,,N,10576,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626264,,Plasma clearance at 10 mg/kg in rat upon intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2713,,N,10577,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626265,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,10578,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626266,,The compound was tested for plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12500,,N,10579,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626267,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2713,,N,10580,1,,,50597,,,,BAO_0000218,CHEMBL626268,,Plasma concentration upon oral administration of 1 mg/Kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,10581,1,,,50597,,,,BAO_0000218,CHEMBL626269,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6227,,N,10582,1,,,50597,,,,BAO_0000218,CHEMBL626270,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4709,,N,10583,1,,,50597,,,,BAO_0000218,CHEMBL626271,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,10584,1,,,50597,,,,BAO_0000218,CHEMBL626272,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,10585,1,,,50597,,,,BAO_0000218,CHEMBL626273,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,10586,1,,,50597,,,,BAO_0000218,CHEMBL875346,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5510,,N,10587,1,,,50597,,,,BAO_0000218,CHEMBL626274,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4514,,N,10588,1,,,50597,,,,BAO_0000218,CHEMBL626275,,Compound was tested for protein binding in rat plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2713,,N,10589,1,,,50597,,,,BAO_0000218,CHEMBL624646,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. 
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2713,,N,10590,1,,,50597,,,,BAO_0000218,CHEMBL624647,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5340,,N,10591,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624648,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12058,,N,10592,1,,,50597,,,,BAO_0000218,CHEMBL624649,,Area under curve ratio was determined (po/iv) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10593,1,,,50597,,,,BAO_0000218,CHEMBL624650,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10594,1,,,50597,,,,BAO_0000218,CHEMBL624651,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10595,1,,,50597,,,,BAO_0000218,CHEMBL624652,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6495,,N,10596,1,,,50597,,,,BAO_0000218,CHEMBL624653,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6078,,N,10597,1,,,50597,,,,BAO_0000218,CHEMBL624654,,Ratio of AUCbrain to AUCplasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5656,,N,10598,1,,,50597,,,,BAO_0000218,CHEMBL624655,,Ratio of brain to plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10599,1,,,50597,,,,BAO_0000218,CHEMBL624656,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10600,1,,,50597,,,,BAO_0000218,CHEMBL624657,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10601,1,,,50597,,,,BAO_0000218,CHEMBL624658,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,10602,1,,,50597,,,,BAO_0000218,CHEMBL624659,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,10603,1,,,50597,,,,BAO_0000218,CHEMBL624660,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10130,,N,10604,1,,,50597,,,,BAO_0000218,CHEMBL624661,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5213,,N,10605,1,,,50597,,,,BAO_0000218,CHEMBL624662,,Steady state brain :blood ratio was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10606,1,,,50597,,,,BAO_0000218,CHEMBL625199,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10607,1,,,50597,,,,BAO_0000218,CHEMBL625200,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10608,1,,,50597,,,,BAO_0000218,CHEMBL625201,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4910,,N,10609,1,,,50597,,,,BAO_0000218,CHEMBL625202,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2083,,N,10610,1,,,50597,,,,BAO_0000218,CHEMBL625203,,Percentage recovery after 3h incubation with rat hapatocytes was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2082,,N,10611,1,,,50597,,,,BAO_0000218,CHEMBL625204,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2082,,N,10612,1,,,50597,,,,BAO_0000218,CHEMBL625205,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6351,,N,10613,1,,,50597,,,,BAO_0000218,CHEMBL625206,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats
A,,,,,1,Autocuration,,14583,,U,10614,0,,,22224,,,,BAO_0000019,CHEMBL625207,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation."
A,,,,,1,Autocuration,,14583,,U,10615,0,,,22224,,,,BAO_0000019,CHEMBL625208,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.
A,Homo sapiens,9606.0,,Caco-2,1,Intermediate,,4608,,N,10616,1,495.0,,50587,,,,BAO_0000218,CHEMBL625209,,In vivo absorption in Caco-2 cell line monolayers was determined
P,,,,,1,Autocuration,,13668,,U,10617,0,,,22229,,,,BAO_0000100,CHEMBL625210,,Calculated partition coefficient (clogP)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,10618,1,,,50597,,,,BAO_0000218,CHEMBL625211,,Area under curve was determine after peroral administration at 10 mpk in Rat
A,Macaca mulatta,9544.0,,,1,Intermediate,,5669,,N,10619,1,,,50797,,,,BAO_0000218,CHEMBL625212,,Area under curve was determine after peroral administration at 10 mpk in Rhesus
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,10620,1,,,50597,,,,BAO_0000218,CHEMBL625213,,Area under curve was determine after peroral administration at 160 mpk in Rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,10621,1,,,50597,,,,BAO_0000218,CHEMBL625214,,Area under curve was determine after peroral administration at 20 mpk in Rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,10622,1,,,50597,,,,BAO_0000218,CHEMBL874542,,Area under curve was determine after peroral administration at 50 mpk in Rat
P,,,,,1,Autocuration,,6472,,U,10623,0,,,22229,,,,BAO_0000100,CHEMBL625215,,Calculated partition coefficient (clogP) (AlogP)
A,,,,,1,Autocuration,,15106,,U,10624,0,,,22224,,,,BAO_0000019,CHEMBL625216,,Activated partial thromboplastin time measured
P,,,,,1,Autocuration,,15207,,U,10625,0,,,22224,,,,BAO_0000100,CHEMBL625217,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4)
P,,,,,1,Autocuration,,15207,,U,10626,0,,,22224,,,,BAO_0000100,CHEMBL625218,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13941,,N,10627,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL622864,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13941,,N,10628,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622865,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13941,,N,10629,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622866,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13941,,N,10630,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL622867,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog
A,Cavia porcellus,10141.0,,,1,Intermediate,,15240,,N,10631,1,,,50512,Plasma,1969.0,,BAO_0000218,CHEMBL876808,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.
A,,,,,1,Autocuration,,10655,,U,10632,0,,,22224,Brain,955.0,,BAO_0000019,CHEMBL627725,,AUC in brain
A,,,,,1,Autocuration,,10655,,U,10633,0,,,22224,Serum,1977.0,,BAO_0000019,CHEMBL627726,,AUC in serum
A,,,,,1,Autocuration,,6504,,U,10634,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627727,,AUC was determined
A,,,,,1,Autocuration,,10615,,U,10635,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627728,,AUC of the compound.
A,,,,,1,Autocuration,,10353,,U,10636,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627729,,AUC value (0-4 hr)
A,,,,,1,Autocuration,,14907,,U,10637,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627730,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,"
A,,,,,1,Autocuration,,14907,,U,10638,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627731,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg
A,,,,,1,Autocuration,,14907,,U,10639,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627732,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,"
A,,,,,1,Autocuration,,14907,,U,10640,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL627733,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16359,,N,10641,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627734,,AUC(area under curve) was determined after intravenous administration in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16359,,N,10642,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL627735,,AUC(area under curve) was determined after oral administration in rats
A,Cavia porcellus,10141.0,,,1,Intermediate,,15240,,N,10643,1,,,50512,Plasma,1969.0,,BAO_0000218,CHEMBL627736,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15240,,N,10644,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL876809,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.
A,,,,,1,Autocuration,,15469,,U,10645,0,,,22224,,,,BAO_0000019,CHEMBL627737,,Area Under Curve after oral dosing of 100 uM/Kg
A,,,,,1,Autocuration,,15469,,U,10646,0,,,22224,,,,BAO_0000019,CHEMBL627738,,Area Under Curve after oral dosing of 30 uM/Kg
A,,,,,1,Autocuration,,13520,,U,10647,0,,,22224,,,,BAO_0000019,CHEMBL627739,,Area Under Curve was measured by ploting the graph between concentration verses time
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17025,,N,10648,1,,,50588,,,,BAO_0000218,CHEMBL626143,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally
A,Simiiformes,314293.0,,,1,Autocuration,,17025,,U,10649,0,,,22224,,,,BAO_0000218,CHEMBL626144,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,10650,1,,,50592,,,,BAO_0000218,CHEMBL626145,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17025,,N,10651,1,,,50597,,,,BAO_0000218,CHEMBL626146,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12032,,N,10652,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626147,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time
A,,,,,1,Autocuration,,10291,,U,10653,0,,,22224,,,,BAO_0000019,CHEMBL626148,,Area under curve (AUC) was determined
A,,,,,1,Autocuration,,5767,,U,10654,0,,,22224,,,,BAO_0000218,CHEMBL626149,,Area under curve (AUC) following ip administration at 1 mg/kg
A,,,,,1,Autocuration,,1434,,U,10655,0,,,22224,,,,BAO_0000019,CHEMBL626150,,Area under curve (AUC) was determined; ND is Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,10656,1,,,50588,,,,BAO_0000218,CHEMBL626151,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,10657,1,,,50588,,,,BAO_0000218,CHEMBL626152,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,10658,1,,,50588,,,,BAO_0000218,CHEMBL626153,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound
A,,,,,1,Autocuration,,1434,,U,10659,0,,,22224,,,,BAO_0000019,CHEMBL626154,,Area under curve (AUR) was determined
A,,,,,1,Autocuration,,11883,,U,10660,0,,,22224,,,,BAO_0000019,CHEMBL626155,,Area under curve at 1 uM/dg administered intravenously
A,,,,,1,Autocuration,,11883,,U,10661,0,,,22224,,,,BAO_0000019,CHEMBL626156,,Area under curve at 10 uM/dg administered perorally
A,,,,,1,Autocuration,,11883,,U,10662,0,,,22224,,,,BAO_0000019,CHEMBL626157,,Area under curve at 2 uM/dg administered intravenously
A,,,,,1,Autocuration,,11883,,U,10663,0,,,22224,,,,BAO_0000019,CHEMBL626158,,Area under curve at 20 uM/dg administered perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15233,,N,10664,1,,,50588,,,,BAO_0000218,CHEMBL626159,,Area under curve at a peroral dose of 3 mg/kg in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15233,,N,10665,1,,,50597,,,,BAO_0000218,CHEMBL626160,,Area under curve at a peroral dose of 3 mg/kg in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15233,,N,10666,1,,,50588,,,,BAO_0000218,CHEMBL626161,,Area under curve at an iv dose of 1 mg/kg in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15233,,N,10667,1,,,50597,,,,BAO_0000218,CHEMBL626162,,Area under curve at an iv dose of 1 mg/kg in rat
A,,,,,1,Autocuration,,12978,,U,10668,0,,,22224,,,,BAO_0000019,CHEMBL626163,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.
A,,,,,1,Autocuration,,12978,,U,10669,0,,,22224,,,,BAO_0000019,CHEMBL626164,,Area under curve gives the effective duration for the angiotensin II antagonist effect.
A,Mus musculus,10090.0,,,1,Intermediate,,11355,,N,10670,1,,,50594,,,,BAO_0000218,CHEMBL626165,,Area under curve measured as conc vs time after intravenous administration to mice.
A,Mus musculus,10090.0,,,1,Intermediate,,11355,,N,10671,1,,,50594,,,,BAO_0000218,CHEMBL626166,,Area under curve measured as conc vs time after peroral administration to mice.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12923,,N,10672,1,,,50588,,,,BAO_0000218,CHEMBL626167,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12923,,N,10673,1,,,50588,,,,BAO_0000218,CHEMBL626168,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12923,,N,10674,1,,,50588,,,,BAO_0000218,CHEMBL877463,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12923,,N,10675,1,,,50588,,,,BAO_0000218,CHEMBL626169,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10676,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626170,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10677,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626171,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10678,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626172,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10679,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL626173,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10680,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626174,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10681,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626175,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10682,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626176,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10683,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626177,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10684,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622499,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10685,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622500,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10686,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622501,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10687,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622502,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10688,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622503,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10689,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL877614,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10690,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624839,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10691,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624840,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10692,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624841,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10693,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL624842,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10694,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624843,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10695,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624844,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10696,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL624845,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17738,,N,10697,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL621904,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10698,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL621905,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10699,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL874382,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10700,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL621906,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10701,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL621907,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10702,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622096,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10703,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL622097,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10704,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622098,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10705,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622099,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10706,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622100,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10707,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622101,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10708,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622102,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10709,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622103,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10710,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622104,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10711,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622105,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10712,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622106,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10713,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622107,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10714,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622108,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10715,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622109,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10716,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL622110,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10717,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL622111,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10718,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL874383,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10719,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL622112,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10720,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL622113,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10721,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL622114,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10722,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622115,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11195,,N,10723,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622116,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6193,,N,10724,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622117,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6803,,N,10725,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622118,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,10726,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622119,,Oral bioavailability in rats at 6 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,10727,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622120,,Oral bioavailability in rat (dose 6 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6647,,N,10728,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622121,,Oral bioavailability in rats at 6 mg/kg dose; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6640,,N,10729,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622122,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,10730,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622123,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6641,,N,10731,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622124,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6642,,N,10732,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622125,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,10733,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622126,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6141,,N,10734,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620455,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4390,,N,10735,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620456,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,10736,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620457,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5472,,N,10737,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620458,,Oral bioavailability was evaluated; Not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5438,,N,10738,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620459,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4883,,N,10739,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620460,,Oral bioavailability in rat by oral dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1908,,N,10740,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620461,,Oral bioavailability in rat (dose 10 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10741,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620462,,Oral bioavailability in rat (Sprague-Dawley)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10742,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620463,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10743,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620464,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10744,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620465,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10745,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620466,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10746,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620467,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4853,,N,10747,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620468,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,10748,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620469,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12873,,N,10749,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620470,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3169,,N,10750,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620471,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6305,,N,10751,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620472,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4762,,N,10752,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620473,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17847,,N,10753,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620474,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6211,,N,10754,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620475,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6011,,N,10755,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620476,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6317,,N,10756,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620477,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,10757,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620478,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,10758,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618768,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,10759,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618769,,Oral bioavailability in rat after oral administration at 13 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6644,,N,10760,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618770,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6113,,N,10761,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618771,,Oral bioavailability (dose 20 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5937,,N,10762,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618772,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5711,,N,10763,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618773,,Oral bioavailability in rat at 10 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10764,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875842,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10765,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618774,,Bioavailability in rat (dose 3 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10766,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618775,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17717,,N,10767,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618776,,Oral bioavailability in rat (dose 60 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4722,,N,10768,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618777,,Percent bioavailability (F) in rats after iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4722,,N,10769,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618778,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4353,,N,10770,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618779,,Bioavailability in rat (dose 5 uM/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15662,,N,10771,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618780,,Oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,10772,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618781,,Bioavailability in rat (dose 2 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,4756,,N,10773,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618782,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3436,,N,10774,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618783,,Oral bioavailability in rat (dose 20 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17800,,N,10775,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618784,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15762,,N,10776,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618785,,Percent oral bioavailability evaluated in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,10777,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618786,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5089,,N,10778,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618787,,Percent oral bioavailability in rat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3185,,N,10779,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618788,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5145,,N,10780,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618789,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3457,,N,10781,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618790,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3457,,N,10782,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618791,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5983,,N,10783,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875843,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5739,,N,10784,1,,,50597,,,In vivo,BAO_0000218,CHEMBL618792,,Oral bioavailability in rat (dose 20 mg/kg p.o.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,3579,,N,10785,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623395,,Cmax at a dose of 30 mg/kg in rat
A,Simiiformes,314293.0,,,1,Autocuration,,17788,,U,10786,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623396,,Cmax in monkeys at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14956,,N,10787,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623397,,Cmax in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17788,,N,10788,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623398,,Cmax in rats at a dose of 1 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,9750,,N,10789,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623399,,Cmax was measured in mice after an oral dose of 50 mg/kg.
A,,,,,1,Autocuration,,12767,,U,10790,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623400,,"Cmax value at a dose of 12.7 uM/kg, po"
A,,,,,1,Autocuration,,12767,,U,10791,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623401,,"Cmax value at a dose of 6.3 uM/kg, iv"
A,,,,,1,Autocuration,,12767,,U,10792,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623402,,"Cmax value at a dose of 7.1 uM/kg, iv"
A,,,,,1,Autocuration,,12703,,U,10793,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623403,,Cmax value of compound was determined after 1 hr
A,,,,,1,Autocuration,,15778,,U,10794,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623404,,Cmax value of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12818,,N,10795,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625997,,Cmax value administered intraintestinal in rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14964,,N,10796,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625998,,Cmax value administered perorally was determined in rat; Not determined
A,,,,,1,Autocuration,,15808,,U,10797,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625999,,Cmax value at the dose of 2.3 mg/kg
A,,,,,1,Autocuration,,15808,,U,10798,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626000,,Cmax value at the dose of 5 mg/kg
A,,,,,1,Autocuration,,15778,,U,10799,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626001,,Cmax value in the period of 8 hr after dosing. 
A,,,,,1,Autocuration,,3715,,U,10800,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626002,,Cmax value at a oral dose of 20 mg/kg; Not tested
A,,,,,1,Autocuration,,3715,,U,10801,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626003,,Cmax value at a oral dose of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,1446,,N,10802,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626004,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500
A,Cavia porcellus,10141.0,,,1,Intermediate,,15240,,N,10803,1,,,50512,,,In vivo,BAO_0000218,CHEMBL626005,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15240,,N,10804,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626006,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14810,,N,10805,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626007,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported
A,Mus musculus,10090.0,,,1,Intermediate,,14239,,N,10806,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626008,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12555,,N,10807,1,,,50588,Liver,2107.0,In vivo,BAO_0000218,CHEMBL626009,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,10754,,N,10808,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626010,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,10809,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626011,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,10810,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626012,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,10811,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626013,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,10812,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL626014,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice
A,Mus musculus,10090.0,,,1,Intermediate,,10754,,N,10813,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL877496,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.
F,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10814,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626015,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs
F,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10815,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626016,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs
F,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10816,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626017,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13543,,N,10817,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626018,,Bioavailability as maximal plasma concentration in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13543,,N,10818,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626692,,Bioavailability as maximal plasma concentration in dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13543,,N,10819,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626693,,Bioavailability as maximal plasma concentration in rats
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13543,,U,10820,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626694,,Bioavailability as maximal plasma concentration in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10821,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626695,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10822,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626696,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10823,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626697,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10824,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626859,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10825,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626860,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14600,,N,10826,1,,,50588,Blood,178.0,In vivo,BAO_0000218,CHEMBL626861,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14681,,N,10827,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626296,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose
A,,,,,1,Autocuration,,15905,,U,10828,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626297,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg
A,,,,,1,Autocuration,,15905,,U,10829,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626298,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13304,,N,10830,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626299,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,10831,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626300,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,10832,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626301,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,10833,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626962,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,10834,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626963,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,10835,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626964,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10836,1,,,100710,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626965,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10837,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626966,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10838,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626967,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10839,1,,,100710,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626968,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10840,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626969,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10841,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL627126,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10842,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631276,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10843,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631277,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10844,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631278,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10845,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL874457,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10846,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631279,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10847,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631280,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10848,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631281,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10849,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631968,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10850,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631969,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10851,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631970,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10852,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631971,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10853,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL631972,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10854,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL630435,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10855,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL630436,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10856,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL630437,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10857,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL630438,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10858,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL630439,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10859,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630440,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10860,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630441,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10861,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630442,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10862,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625234,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10863,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625235,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10864,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625236,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10865,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625237,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10866,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626125,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10867,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626126,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10868,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626127,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10869,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626128,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10870,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626129,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10871,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626130,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10872,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626131,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10873,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626132,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10874,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626752,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10875,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626753,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10876,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626754,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10877,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626755,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10878,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626756,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10879,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626757,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10880,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626758,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10881,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626759,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,10882,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626760,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10883,1,,,50588,,,,BAO_0000218,CHEMBL626394,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10884,1,,,50588,,,,BAO_0000218,CHEMBL626395,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10885,1,,,50588,,,,BAO_0000218,CHEMBL626396,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10886,1,,,50588,,,,BAO_0000218,CHEMBL626397,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10887,1,,,50588,,,,BAO_0000218,CHEMBL626398,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10888,1,,,50588,,,,BAO_0000218,CHEMBL626399,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10889,1,,,50597,,,,BAO_0000218,CHEMBL874653,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10890,1,,,50597,,,,BAO_0000218,CHEMBL626400,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10891,1,,,50597,,,,BAO_0000218,CHEMBL626401,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10892,1,,,50597,,,,BAO_0000218,CHEMBL626402,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10893,1,,,50597,,,,BAO_0000218,CHEMBL626403,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10894,1,,,50597,,,,BAO_0000218,CHEMBL626404,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10895,1,,,50597,,,,BAO_0000218,CHEMBL626405,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10896,1,,,50597,,,,BAO_0000218,CHEMBL625529,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10897,1,,,50597,,,,BAO_0000218,CHEMBL625530,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10898,1,,,50597,,,,BAO_0000218,CHEMBL625531,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10899,1,,,50597,,,,BAO_0000218,CHEMBL625532,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10900,1,,,50597,,,,BAO_0000218,CHEMBL625533,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10901,1,,,50597,,,,BAO_0000218,CHEMBL875474,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10902,1,,,50597,,,,BAO_0000218,CHEMBL625534,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10903,1,,,50597,,,,BAO_0000218,CHEMBL625535,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10904,1,,,50597,,,,BAO_0000218,CHEMBL625536,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10905,1,,,50597,,,,BAO_0000218,CHEMBL625537,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10906,1,,,50597,,,,BAO_0000218,CHEMBL625538,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10907,1,,,50597,,,,BAO_0000218,CHEMBL625539,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10908,1,,,50597,,,,BAO_0000218,CHEMBL625540,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10909,1,,,50597,,,,BAO_0000218,CHEMBL625541,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10910,1,,,50597,,,,BAO_0000218,CHEMBL625542,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10911,1,,,50597,,,,BAO_0000218,CHEMBL625543,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,10912,1,,,50597,,,,BAO_0000218,CHEMBL625544,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10913,1,,,50588,,,,BAO_0000218,CHEMBL625545,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10914,1,,,50588,,,,BAO_0000218,CHEMBL625546,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10915,1,,,50588,,,,BAO_0000218,CHEMBL625547,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10916,1,,,50588,,,,BAO_0000218,CHEMBL625548,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10917,1,,,50588,,,,BAO_0000218,CHEMBL625549,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10918,1,,,50588,,,,BAO_0000218,CHEMBL625550,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10919,1,,,50588,,,,BAO_0000218,CHEMBL625551,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10920,1,,,50588,,,,BAO_0000218,CHEMBL875475,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10921,1,,,50588,,,,BAO_0000218,CHEMBL625552,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10922,1,,,50588,,,,BAO_0000218,CHEMBL625553,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10923,1,,,50588,,,,BAO_0000218,CHEMBL625554,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10924,1,,,50588,,,,BAO_0000218,CHEMBL625555,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10925,1,,,50588,,,,BAO_0000218,CHEMBL625556,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10926,1,,,50588,,,,BAO_0000218,CHEMBL624986,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10927,1,,,50588,,,,BAO_0000218,CHEMBL624987,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,10928,1,,,50588,,,,BAO_0000218,CHEMBL624988,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10929,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624989,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10930,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624990,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10931,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL874391,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10932,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624991,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10933,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624992,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10934,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624993,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10935,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624994,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10936,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624995,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10937,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624996,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10938,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624997,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10939,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624998,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10940,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624999,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10941,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL882955,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10942,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625000,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10943,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625001,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10944,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625089,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10945,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625090,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10946,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625091,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10947,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625092,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10948,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625093,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10949,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625094,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,10950,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL625095,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,2249,,N,10951,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625096,,Compound was evaluated for its bioavailability in the dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2249,,N,10952,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625097,,Compound was evaluated for its bioavailability in the rats
A,,,,,1,Autocuration,,17515,,U,10953,0,,,22224,,,In vivo,BAO_0000218,CHEMBL882956,,Compound was evaluated for oral bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14541,,N,10954,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625098,,Compound was evaluated for percentage of Oral bioavailability in rats
A,Cavia porcellus,10141.0,,,1,Autocuration,,12797,,U,10955,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625099,,Bioavailability in guinea pig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12797,,N,10956,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625100,,Compound was evaluated for the oral bioavailability in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12797,,N,10957,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625101,,Compound was evaluated for the oral bioavailability in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12797,,N,10958,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874396,,Compound was evaluated for the oral bioavailability in rat
F,Canis lupus familiaris,9615.0,,,1,Autocuration,,11727,,U,10959,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625102,,Bioavailability in dog (dosed i.v.)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13249,,N,10960,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625103,,Compound was tested for in vivo bioavailability in dog
A,Cricetinae,10026.0,,,1,Intermediate,,13249,,N,10961,1,,,100712,,,In vivo,BAO_0000218,CHEMBL625104,,Compound was tested for in vivo bioavailability in hamsters
A,Simiiformes,314293.0,,,1,Autocuration,,13249,,U,10962,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625105,,Compound was tested for in vivo bioavailability in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13249,,N,10963,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625106,,Compound was tested for in vivo bioavailability in rat
A,Mus musculus,10090.0,,,1,Autocuration,,9552,,U,10964,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625107,,Oral bioavailability in mouse
A,Mus musculus,10090.0,,,1,Intermediate,,9552,,N,10965,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625108,,Compound was tested for percent of oral bioavailability in mice; 56-74
A,Mus musculus,10090.0,,,1,Autocuration,,14839,,U,10966,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625109,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg)
A,Macaca fascicularis,9541.0,,,1,Autocuration,,14839,,U,10967,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625110,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.)
A,Macaca fascicularis,9541.0,,,1,Autocuration,,14839,,U,10968,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625111,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.)
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10969,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625112,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.)
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10970,1,,,50594,,,In vivo,BAO_0000218,CHEMBL875334,,Oral bioavailability in nude mice
A,Primates,9443.0,,,1,Autocuration,,11219,,U,10971,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628617,,Bioavailability in monkey (i.d. dosing)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9552,,U,10972,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628618,,Bioavailability in rat
A,,,,,1,Autocuration,,11732,,U,10973,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628619,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%
A,,,,,1,Autocuration,,11732,,U,10974,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628620,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10975,1,,,100710,,,In vivo,BAO_0000218,CHEMBL628621,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10976,1,,,100710,,,In vivo,BAO_0000218,CHEMBL628622,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10977,1,,,100710,,,In vivo,BAO_0000218,CHEMBL628623,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10978,1,,,100710,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628624,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10979,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628625,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14839,,N,10980,1,,,100710,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628626,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10981,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627041,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10982,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627042,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,10983,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627043,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose
A,,,,,1,Autocuration,,13932,,U,10984,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627044,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,11637,,N,10985,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627045,,Cmax in mouse plasma
A,,,,,1,Autocuration,,11637,,U,10986,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627046,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13960,,N,10987,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627047,,Maximal plasma concentration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15905,,N,10988,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627048,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10989,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627049,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10990,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627050,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10991,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627051,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10992,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627052,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10993,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627053,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,10994,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627054,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,10995,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627055,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,10996,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627056,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,10997,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627057,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample)
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,10998,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627058,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,10999,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626211,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg
A,,,,,1,Autocuration,,10291,,U,11000,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626212,,Maximum Concentration of the compound.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,11001,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626213,,Maximum Concentration was measured after iv administration into Beagle dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,11002,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626214,,Maximum Concentration was measured after iv administration into Beagle dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,11003,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626215,,Maximum Concentration was measured after po administration into Beagle dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14599,,N,11004,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626216,,Maximum Concentration was measured after po administration into Beagle dog.
A,,,,,1,Autocuration,,12767,,U,11005,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626217,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously
A,,,,,1,Autocuration,,12767,,U,11006,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626218,,Maximum blood level reached after an iv dose of 12.2 uM/kg
A,,,,,1,Autocuration,,12767,,U,11007,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626219,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route
A,,,,,1,Autocuration,,12767,,U,11008,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626220,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route
A,,,,,1,Autocuration,,12767,,U,11009,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626221,,Maximum blood level reached after an oral dose of 5.0 mg/kg
A,,,,,1,Autocuration,,12767,,U,11010,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626222,,Maximum blood level reached at dose of 10.6 uM/kg orally
A,Cavia porcellus,10141.0,,,1,Intermediate,,14706,,N,11011,1,,,50512,,,In vivo,BAO_0000218,CHEMBL626223,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration
A,Cavia porcellus,10141.0,,,1,Intermediate,,14706,,N,11012,1,,,50512,,,In vivo,BAO_0000218,CHEMBL626224,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11013,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL626225,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11014,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL626226,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11015,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL626227,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11016,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL626228,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11017,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626229,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11018,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626921,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11019,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876793,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,11020,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625309,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg
A,Bacillus subtilis,1423.0,,,1,Intermediate,,10524,,N,11021,1,,,50278,,,In vivo,BAO_0000218,CHEMBL625310,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
A,Simiiformes,314293.0,,,1,Autocuration,,11871,,U,11022,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625311,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11871,,N,11023,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625312,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg
A,,,,,1,Autocuration,,3437,,U,11024,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625313,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally
A,Mus musculus,10090.0,,,1,Intermediate,,12038,,N,11025,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625314,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12038,,N,11026,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625315,,Maximum concentration in male rats after iv administration of 20 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11027,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625316,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11028,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625317,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11029,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625318,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11030,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625319,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11031,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625320,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11032,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625321,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11033,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625322,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11034,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL876801,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11035,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625323,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11036,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625324,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11037,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625325,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11038,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625326,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11039,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625327,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11040,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625328,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11041,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625329,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11042,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625330,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11043,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627774,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11044,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627775,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11045,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627949,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11046,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627950,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11047,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627951,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11048,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627952,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11049,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627953,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11050,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627954,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11051,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627955,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11052,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627956,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11053,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL876802,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11054,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627957,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11055,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627958,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11056,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627959,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11057,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627960,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11058,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627961,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,11059,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627962,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11060,1,,,50597,,,,BAO_0000218,CHEMBL627963,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11061,1,,,50597,,,,BAO_0000218,CHEMBL624759,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11062,1,,,50597,,,,BAO_0000218,CHEMBL624760,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11063,1,,,50597,,,,BAO_0000218,CHEMBL624761,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11064,1,,,50597,,,,BAO_0000218,CHEMBL877607,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11065,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624762,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11066,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624763,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11067,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624764,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11068,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624765,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11069,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624766,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11070,1,,,50588,,,,BAO_0000218,CHEMBL624767,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11071,1,,,50588,,,,BAO_0000218,CHEMBL624768,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11072,1,,,50588,,,,BAO_0000218,CHEMBL624769,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11073,1,,,50588,,,,BAO_0000218,CHEMBL624770,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11074,1,,,50588,,,,BAO_0000218,CHEMBL624771,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11075,1,,,50588,,,,BAO_0000218,CHEMBL624772,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11076,1,,,50597,,,,BAO_0000218,CHEMBL624773,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11077,1,,,50597,,,,BAO_0000218,CHEMBL624774,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11078,1,,,50597,,,,BAO_0000218,CHEMBL624775,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11079,1,,,50597,,,,BAO_0000218,CHEMBL624776,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11080,1,,,50597,,,,BAO_0000218,CHEMBL624777,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11081,1,,,50597,,,,BAO_0000218,CHEMBL624778,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11082,1,,,50597,,,,BAO_0000218,CHEMBL624779,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11083,1,,,50597,,,,BAO_0000218,CHEMBL624780,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11084,1,,,50597,,,,BAO_0000218,CHEMBL624781,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11085,1,,,50597,,,,BAO_0000218,CHEMBL877608,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11086,1,,,50597,,,,BAO_0000218,CHEMBL624782,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11087,1,,,50597,,,,BAO_0000218,CHEMBL624783,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11088,1,,,50597,,,,BAO_0000218,CHEMBL624784,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11089,1,,,50597,,,,BAO_0000218,CHEMBL624785,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11090,1,,,50597,,,,BAO_0000218,CHEMBL624786,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11091,1,,,50597,,,,BAO_0000218,CHEMBL624787,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11092,1,,,50597,,,,BAO_0000218,CHEMBL628676,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11093,1,,,50597,,,,BAO_0000218,CHEMBL621842,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11094,1,,,50597,,,,BAO_0000218,CHEMBL621843,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11095,1,,,50597,,,,BAO_0000218,CHEMBL623873,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11096,1,,,50597,,,,BAO_0000218,CHEMBL623874,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11097,1,,,50597,,,,BAO_0000218,CHEMBL623875,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,11098,1,,,50597,,,,BAO_0000218,CHEMBL623876,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11099,1,,,50588,,,,BAO_0000218,CHEMBL623877,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11100,1,,,50588,,,,BAO_0000218,CHEMBL623878,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11101,1,,,50588,,,,BAO_0000218,CHEMBL623879,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11102,1,,,50588,,,,BAO_0000218,CHEMBL623880,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11103,1,,,50588,,,,BAO_0000218,CHEMBL623881,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11104,1,,,50588,,,,BAO_0000218,CHEMBL623957,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11105,1,,,50588,,,,BAO_0000218,CHEMBL623958,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11106,1,,,50588,,,,BAO_0000218,CHEMBL623959,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11107,1,,,50588,,,,BAO_0000218,CHEMBL623960,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11108,1,,,50588,,,,BAO_0000218,CHEMBL623961,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11109,1,,,50588,,,,BAO_0000218,CHEMBL623962,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11110,1,,,50588,,,,BAO_0000218,CHEMBL624676,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11111,1,,,50588,,,,BAO_0000218,CHEMBL624677,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11112,1,,,50588,,,,BAO_0000218,CHEMBL624678,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11113,1,,,50588,,,,BAO_0000218,CHEMBL624679,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11114,1,,,50588,,,,BAO_0000218,CHEMBL624680,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr)
A,,,,,1,Autocuration,,11732,,U,11115,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624849,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%
A,,,,,1,Autocuration,,11732,,U,11116,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624850,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%
A,,,,,1,Autocuration,,11732,,U,11117,0,,,22224,,,In vivo,BAO_0000218,CHEMBL874399,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%
A,,,,,1,Autocuration,,11732,,U,11118,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624851,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%
A,,,,,1,Autocuration,,11732,,U,11119,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624852,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13359,,U,11120,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624853,,Oral bioavailability in rat (dose 10 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,16618,,U,11121,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624854,,Oral bioavailability in rat (Sprague-Dawley)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13960,,U,11122,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624855,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13917,,U,11123,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624856,,Oral bioavailability in rats was determined in vivo
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,14266,,U,11124,0,,,22224,,,In vivo,BAO_0000218,CHEMBL882957,,Oral bioavailability in dog
A,Simiiformes,314293.0,,,1,Autocuration,,12359,,U,11125,0,,,22224,,,In vivo,BAO_0000218,CHEMBL624857,,Oral bioavailability of compound in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12359,,N,11126,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622202,,Oral bioavailability of compound in rat
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12359,,U,11127,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622203,,Bioavailability in rat of PMEA prodrug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12359,,N,11128,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625522,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility
A,Macaca mulatta,9544.0,,,1,Autocuration,,10791,,U,11129,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622868,,Serum conc at 3 hours following 25 mg/kg dose
A,Macaca mulatta,9544.0,,,1,Autocuration,,10791,,U,11130,0,,,22224,Urine,1088.0,In vivo,BAO_0000218,CHEMBL622869,,Urine conc 0-5 hours following 25 mg/kg dose
A,Macaca mulatta,9544.0,,,1,Autocuration,,10791,,U,11131,0,,,22224,Urine,1088.0,In vivo,BAO_0000218,CHEMBL622870,,Urine conc 0-24 hours following 25 mg/kg dose
A,Chlorocebus aethiops,9534.0,,,1,Autocuration,,138,,U,11132,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622871,,Oral bioavailability in African green monkeys; 20-25
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14521,,N,11133,1,,,100710,,,In vivo,BAO_0000218,CHEMBL620560,,Oral bioavailability in cynomolgus monkey.
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,13953,,U,11134,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620561,,Oral bioavailability in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12836,,N,11135,1,,,50588,,,In vivo,BAO_0000218,CHEMBL620562,,Oral bioavailability in dog at 10 mg/kg oral dose
A,Cricetinae,10026.0,,,1,Intermediate,,12836,,N,11136,1,,,100712,,,In vivo,BAO_0000218,CHEMBL620563,,Oral bioavailability in hamster at 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12836,,N,11137,1,,,50597,,,In vivo,BAO_0000218,CHEMBL620564,,Oral bioavailability in rat at 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Autocuration,,14521,,U,11138,0,,,22224,,,In vivo,BAO_0000218,CHEMBL872265,,Oral bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13953,,U,11139,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620565,,Oral bioavailability in rat
A,Eutheria,9347.0,,,1,Autocuration,,6799,,U,11140,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620566,,Oral bioavailability
A,,,,,1,Autocuration,,11311,,U,11141,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620567,,Oral bioavailability was determined; range 49-102%
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,4013,,N,11142,1,,,50588,,,In vivo,BAO_0000218,CHEMBL620568,,Oral bioavailability was determined in dogs
A,Rattus norvegicus,10116.0,,,1,Autocuration,,4013,,U,11143,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620569,,Oral bioavailability in rat
A,Eutheria,9347.0,,,1,Autocuration,,17591,,U,11144,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620570,,Oral bioavailability
A,,,,,1,Autocuration,,17591,,U,11145,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620571,,Oral bioavailability was determined; Not orally available
A,Mus musculus,10090.0,,,1,Intermediate,,15011,,N,11146,1,,,50594,,,In vivo,BAO_0000218,CHEMBL620572,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample)
A,Mus musculus,10090.0,,,1,Autocuration,,15011,,U,11147,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620573,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg)
A,Mus musculus,10090.0,,,1,Autocuration,,15011,,U,11148,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620574,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg
A,Macaca mulatta,9544.0,,,1,Autocuration,,9552,,U,11149,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620575,,Oral bioavailability in Rhesus monkey
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,9552,,U,11150,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620576,,Oral bioavailability in dog (female mongrel)
A,,,,,1,Autocuration,,3639,,U,11151,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875846,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,13397,,U,11152,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620577,,Oral bioavailability in dog
A,,,,,1,Autocuration,,3031,,U,11153,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620578,,Percentage Bioavailability was evaluated.
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12818,,U,11154,0,,,22224,,,In vivo,BAO_0000218,CHEMBL620579,,Bioavailability in rat administered i.d.
A,Eutheria,9347.0,,,1,Autocuration,,4847,,U,11155,0,,,22224,,,In vivo,BAO_0000218,CHEMBL621248,,Bioavailability
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,12421,,U,11156,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625390,,Bioavailability in dog (male Beagle) i.v. administration
A,Rattus norvegicus,10116.0,,,1,Autocuration,,11966,,U,11157,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625391,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)"
A,Primates,9443.0,,,1,Autocuration,,11218,,U,11158,0,,,22224,,,In vivo,BAO_0000218,CHEMBL872266,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,13129,,U,11159,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625392,,Oral bioavailability in rat (Sprague-Dawley) (male)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12350,,N,11160,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625393,,The oral bioavailability was measured on rats after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2231,,N,11161,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625394,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg
A,Macaca mulatta,9544.0,,,1,Intermediate,,2231,,N,11162,1,,,50797,,,In vivo,BAO_0000218,CHEMBL625395,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12187,,U,11163,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625396,,Bioavailability in rat (dose 10 mg/kg i.d.)
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,12421,,U,11164,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625397,,Bioavailability in dog (male Beagle) i.v. administration
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11165,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625398,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11166,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL625399,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11167,1,,,50594,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL626074,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11168,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626075,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2231,,N,11169,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626076,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg
A,Macaca mulatta,9544.0,,,1,Intermediate,,2231,,N,11170,1,,,50797,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626077,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12178,,N,11171,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL626078,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose)
A,,,,,1,Autocuration,,12178,,U,11172,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL625846,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose)
A,,,,,1,Autocuration,,12178,,U,11173,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL625847,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose)
A,Rattus norvegicus,10116.0,,,1,Expert,,15633,,N,11174,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625848,,Maximum concentration observed in rats at an oral dose of 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14258,,N,11175,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625849,,Maximum concentration of compound in plasma administered orally to rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,11176,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626023,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,11177,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626024,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,11178,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626025,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs"
A,,,,,1,Autocuration,,5566,,U,11179,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626026,,Maximum concentration after 10 mg/kg by oral administration
A,,,,,1,Autocuration,,16935,,U,11180,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626027,,Maximum concentration at a dose of 1.5 mg/kg
A,,,,,1,Autocuration,,16935,,U,11181,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626028,,Maximum concentration at a dose of 2.0 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,11182,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626029,,Maximum concentration in dog plasma
A,,,,,1,Autocuration,,12536,,U,11183,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626030,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally
A,,,,,1,Autocuration,,12536,,U,11184,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626031,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously
A,,,,,1,Autocuration,,12536,,U,11185,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626032,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously
A,,,,,1,Autocuration,,12536,,U,11186,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626033,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally
A,,,,,1,Autocuration,,12536,,U,11187,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626034,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9994,,N,11188,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626035,,Maximum concentration in plasma after oral administration in dog (25 mg/kg)
A,,,,,1,Autocuration,,1434,,U,11189,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626036,,Maximum concentration in plasma at Tmax
A,Canis lupus familiaris,9615.0,,,1,Expert,,12836,,N,11190,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626037,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose
A,Cricetinae,10026.0,,,1,Intermediate,,12836,,N,11191,1,,,100712,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626038,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12836,,N,11192,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626039,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12545,,N,11193,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626040,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,13856,,N,11194,1,,,50592,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626041,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg
A,,,,,1,Autocuration,,3550,,U,11195,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626042,,Maximum concentration was calculated
A,,,,,1,Autocuration,,2632,,U,11196,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626043,,Maximum concentration was calculated.
A,,,,,1,Autocuration,,5566,,U,11197,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626044,,Maximum concentration at a peroral dose of 10 mg/kg
A,,,,,1,Autocuration,,11883,,U,11198,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626045,,Maximum concentration of the drug at 10 uM/dg administered perorally
A,,,,,1,Autocuration,,11883,,U,11199,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626046,,Maximum concentration of the drug at 2 uM/dg administered intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14122,,N,11200,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626047,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose."
A,Cricetinae,10026.0,,,1,Intermediate,,14122,,N,11201,1,,,100712,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626048,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14122,,N,11202,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626049,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12542,,N,11203,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626050,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12542,,N,11204,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL874541,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose
A,Cricetinae,10026.0,,,1,Intermediate,,12542,,N,11205,1,,,100712,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622826,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose
A,Cricetinae,10026.0,,,1,Intermediate,,12542,,N,11206,1,,,100712,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622827,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12542,,N,11207,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622828,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14080,,N,11208,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622829,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11911,,N,11209,1,,,50597,,,In vivo,BAO_0000218,CHEMBL876806,,Maximum concentration reached following intravenous administration in male rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13204,,N,11210,1,,,50588,,,In vivo,BAO_0000218,CHEMBL622830,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13204,,N,11211,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622831,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,11212,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626794,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,11213,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626795,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,11214,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626796,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,11215,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626797,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14127,,N,11216,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626798,,Maximum drug concentration is determined after oral dosing in rats.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14339,,N,11217,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626799,,Maximum observed concentration in oral (5 mg/kg) fasted dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14339,,N,11218,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626800,,Maximum observed concentration in oral (5 mg/kg) fed dogs
A,,,,,1,Autocuration,,13494,,U,11219,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626801,,Maximum plasma concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14925,,N,11220,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL876816,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14474,,N,11221,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626802,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14474,,N,11222,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626803,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog
A,,,,,1,Autocuration,,13917,,U,11223,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626804,,Maximum plasma concentration following oral administration of 30 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11224,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626805,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11225,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626309,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11226,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626310,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11227,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626311,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11228,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626312,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11229,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL626313,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11230,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL626314,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11231,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL626315,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11232,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL626316,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9796,,N,11233,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL626317,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11234,1,,,50597,,,,BAO_0000218,CHEMBL626318,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11235,1,,,50597,,,,BAO_0000218,CHEMBL626319,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11236,1,,,50597,,,,BAO_0000218,CHEMBL626320,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11237,1,,,50597,,,,BAO_0000218,CHEMBL875053,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11238,1,,,50597,,,,BAO_0000218,CHEMBL626321,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11239,1,,,50597,,,,BAO_0000218,CHEMBL626322,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11240,1,,,50597,,,,BAO_0000218,CHEMBL626323,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11241,1,,,50597,,,,BAO_0000218,CHEMBL626324,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11242,1,,,50597,,,,BAO_0000218,CHEMBL626325,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11243,1,,,50597,,,,BAO_0000218,CHEMBL626326,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11244,1,,,50597,,,,BAO_0000218,CHEMBL626327,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8363,,N,11245,1,,,50597,,,,BAO_0000218,CHEMBL626328,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11246,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626329,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11247,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626330,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11248,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626331,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11249,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626332,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11250,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626333,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11251,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626334,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11252,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626335,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11253,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624798,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11254,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624799,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11255,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624800,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11256,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624801,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11257,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624802,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11258,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624803,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11259,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624804,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11260,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624805,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11261,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL624806,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11262,1,,,50597,,,,BAO_0000218,CHEMBL624807,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11263,1,,,50597,,,,BAO_0000218,CHEMBL624808,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11264,1,,,50597,,,,BAO_0000218,CHEMBL624809,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11265,1,,,50597,,,,BAO_0000218,CHEMBL624810,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11266,1,,,50597,,,,BAO_0000218,CHEMBL877618,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11267,1,,,50597,,,,BAO_0000218,CHEMBL624811,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11268,1,,,50597,,,,BAO_0000218,CHEMBL624812,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11269,1,,,50597,,,,BAO_0000218,CHEMBL624813,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11270,1,,,50597,,,,BAO_0000218,CHEMBL624814,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11271,1,,,50597,,,,BAO_0000218,CHEMBL624815,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11272,1,,,50597,,,,BAO_0000218,CHEMBL624816,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11273,1,,,50597,,,,BAO_0000218,CHEMBL624817,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11274,1,,,50588,,,,BAO_0000218,CHEMBL624818,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11275,1,,,50588,,,,BAO_0000218,CHEMBL624819,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11276,1,,,50588,,,,BAO_0000218,CHEMBL624820,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11277,1,,,50588,,,,BAO_0000218,CHEMBL624821,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11278,1,,,50588,,,,BAO_0000218,CHEMBL624822,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,11279,1,,,50588,,,,BAO_0000218,CHEMBL624823,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr)
A,Escherichia coli,562.0,,,1,Intermediate,,15599,,N,11280,1,,,50212,,,,BAO_0000218,CHEMBL624824,,Observed diffusion coefficient in organic solvent for Escherichia coli
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11281,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624825,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11282,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624826,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11283,1,,,50597,Cardiac atrium,2081.0,,BAO_0000218,CHEMBL876817,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11284,1,,,50597,Cardiac atrium,2081.0,,BAO_0000218,CHEMBL624827,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11285,1,,,50597,,,,BAO_0000218,CHEMBL624828,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11286,1,,,50597,,,,BAO_0000218,CHEMBL624829,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11287,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624830,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11288,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624831,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11289,1,,,50597,Cardiac atrium,2081.0,,BAO_0000218,CHEMBL624832,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11290,1,,,50597,Cardiac atrium,2081.0,,BAO_0000218,CHEMBL624833,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11291,1,,,50597,,,,BAO_0000218,CHEMBL624834,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11292,1,,,50597,,,,BAO_0000218,CHEMBL624835,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11293,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL624836,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9614,,N,11294,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL624837,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11295,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL624838,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11296,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL622188,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11297,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL622189,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11298,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL622190,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11299,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL625170,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11300,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625171,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11301,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625172,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11302,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL625173,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11303,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625174,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11304,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625175,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11305,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL625176,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11306,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625177,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11307,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625178,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11308,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625179,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9071,,N,11309,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL625180,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration
A,,,,,1,Autocuration,,10677,,U,11310,0,,,22224,,,,BAO_0000218,CHEMBL625181,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration"
A,Mus musculus,10090.0,,,1,Intermediate,,9750,,N,11311,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL625182,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11312,1,,,50597,,,,BAO_0000218,CHEMBL625183,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11313,1,,,50597,,,,BAO_0000218,CHEMBL875848,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11314,1,,,50597,,,,BAO_0000218,CHEMBL622260,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11315,1,,,50597,,,,BAO_0000218,CHEMBL622261,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11316,1,,,50597,,,,BAO_0000218,CHEMBL622262,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11317,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622263,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11318,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL622418,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11319,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622419,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11320,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623388,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11321,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623389,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11322,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623390,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11323,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623391,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11324,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL623392,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11325,1,,,50594,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL623393,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11326,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623394,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11327,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618885,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11328,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL618886,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11329,1,,,50594,,,In vivo,BAO_0000218,CHEMBL618887,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11330,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619535,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11331,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL619536,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11332,1,,,50594,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL619537,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11333,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619705,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11334,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619706,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11335,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL619707,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11336,1,,,50594,,,In vivo,BAO_0000218,CHEMBL619708,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11337,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625219,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11338,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL625220,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11339,1,,,50594,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625221,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11340,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625222,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11341,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625223,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11342,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625224,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Mus musculus,10090.0,,,1,Intermediate,,13256,,N,11343,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625225,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11344,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625226,,Biodistribution in Rat blood after 24 hours of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11345,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625227,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11346,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625228,,Biodistribution in Rat blood after 30 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11347,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL875354,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11348,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625229,,Biodistribution in Rat blood after 5 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11349,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625230,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11350,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625231,,Biodistribution in Rat heart after 24 hours of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11351,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625900,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11352,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625901,,Biodistribution in Rat heart after 30 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11353,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625902,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11354,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625903,,Biodistribution in Rat heart after 5 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11355,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625904,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11356,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625905,,Biodistribution in Rat liver after 24 hours of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11357,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627861,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11358,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627862,,Biodistribution in Rat liver after 30 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11359,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627863,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11360,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627769,,Biodistribution in Rat liver after 30 minutes of iv administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13249,,N,11361,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627770,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered
A,Macaca fascicularis,9541.0,,,1,Intermediate,,13622,,N,11362,1,,,100710,,,In vivo,BAO_0000218,CHEMBL627771,,Cmax in cynomolgus monkey (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13622,,N,11363,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627772,,Cmax in rat (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13622,,N,11364,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627773,,Cmax in rat (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13494,,N,11365,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621922,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12170,,N,11366,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621923,,Cmax in rat plasma after oral dose (10 mg/kg)
A,,,,,1,Autocuration,,12170,,U,11367,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621924,,Cmax in plasma after oral dose (10 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17025,,N,11368,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621925,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally
A,Simiiformes,314293.0,,,1,Autocuration,,17025,,U,11369,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621926,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,11370,1,,,50592,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621927,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17025,,N,11371,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621928,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14187,,N,11372,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621929,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.
A,Mus musculus,10090.0,,,1,Intermediate,,14816,,N,11373,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621930,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17820,,N,11374,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621931,,Maximum plasma concentration after oral dosing in rat
A,,,,,1,Autocuration,,14380,,U,11375,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621932,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11376,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621933,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14691,,N,11377,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621934,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14691,,N,11378,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621935,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13375,,N,11379,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621936,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg
A,,,,,1,Autocuration,,6236,,U,11380,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621937,,Maximum plasma concentration was determined
A,,,,,1,Autocuration,,14380,,U,11381,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621938,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11382,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621939,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11383,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621940,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11384,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621941,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11385,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL621942,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11386,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626178,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11387,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626179,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11388,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626180,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13622,,N,11389,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626181,,Plasma Cmax in rat (PO dose)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,11390,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626182,,Maximum serum concentration after po dose of 5.22 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,11391,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626183,,Maximum serum concentration after po dose of 5.46 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,11392,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626184,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,11393,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626185,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,11394,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626186,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,11395,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL877589,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.
A,,,,,1,Autocuration,,11883,,U,11396,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626187,,Maximum concentration of the drug at 1 uM/dg administered intravenously
A,,,,,1,Autocuration,,11883,,U,11397,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626188,,Maximum concentration of the drug at 20 uM/dg administered perorally
A,,,,,1,Autocuration,,13391,,U,11398,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626189,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg
A,,,,,1,Autocuration,,13391,,U,11399,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL626855,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM
A,,,,,1,Autocuration,,13391,,U,11400,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL623781,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM
A,,,,,1,Autocuration,,13391,,U,11401,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL623782,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16360,,N,11402,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623783,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3673,,N,11403,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623784,,Cmax in dog plasma after 1mg/kg oral dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14431,,N,11404,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623785,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14431,,N,11405,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623786,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14964,,N,11406,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623787,,Oral maximum concentration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14964,,N,11407,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623788,,Oral maximum concentration in rat
A,Mus musculus,10090.0,,,1,Intermediate,,14209,,N,11408,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623789,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.
A,Mus musculus,10090.0,,,1,Intermediate,,11355,,N,11409,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL623790,,Peak concentration in blood after intravenous administration to mice
A,Mus musculus,10090.0,,,1,Intermediate,,11355,,N,11410,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL623791,,Peak concentration in blood after peroral administration to mice
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11966,,N,11411,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623792,,Peak concentration in rat plasma was determined
A,Simiiformes,314293.0,,,1,Autocuration,,8918,,U,11412,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623793,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg
A,Mus musculus,10090.0,,,1,Intermediate,,8918,,N,11413,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623794,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8918,,N,11414,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623795,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11415,1,,,50597,,,,BAO_0000218,CHEMBL623796,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11416,1,,,50597,,,,BAO_0000218,CHEMBL623797,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11417,1,,,50597,,,,BAO_0000218,CHEMBL623798,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11418,1,,,50597,,,,BAO_0000218,CHEMBL623799,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11419,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624490,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11420,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624491,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11421,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624492,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11422,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624493,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11423,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL877595,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11424,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624494,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11425,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624495,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11426,1,,,50597,Intestine,160.0,,BAO_0000218,CHEMBL624681,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11427,1,,,50597,,,,BAO_0000218,CHEMBL624682,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11428,1,,,50597,,,,BAO_0000218,CHEMBL624683,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11429,1,,,50597,,,,BAO_0000218,CHEMBL624684,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11430,1,,,50597,,,,BAO_0000218,CHEMBL624685,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11431,1,,,50597,,,,BAO_0000218,CHEMBL624686,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11432,1,,,50597,,,,BAO_0000218,CHEMBL624687,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11433,1,,,50597,,,,BAO_0000218,CHEMBL624688,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11434,1,,,50597,,,,BAO_0000218,CHEMBL627161,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11435,1,,,50597,,,,BAO_0000218,CHEMBL622127,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11436,1,,,50597,,,,BAO_0000218,CHEMBL622128,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11437,1,,,50597,,,,BAO_0000218,CHEMBL874384,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11438,1,,,50597,,,,BAO_0000218,CHEMBL624898,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11439,1,,,50597,,,,BAO_0000218,CHEMBL624899,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11440,1,,,50597,,,,BAO_0000218,CHEMBL624900,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11441,1,,,50597,,,,BAO_0000218,CHEMBL624901,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11442,1,,,50597,,,,BAO_0000218,CHEMBL624902,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11443,1,,,50597,,,,BAO_0000218,CHEMBL624903,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11444,1,,,50597,,,,BAO_0000218,CHEMBL624904,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11445,1,,,50597,,,,BAO_0000218,CHEMBL624905,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11446,1,,,50597,,,,BAO_0000218,CHEMBL624906,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11447,1,,,50597,,,,BAO_0000218,CHEMBL624907,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11448,1,,,50597,,,,BAO_0000218,CHEMBL624908,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11449,1,,,50597,,,,BAO_0000218,CHEMBL624909,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11450,1,,,50597,,,,BAO_0000218,CHEMBL624910,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11451,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624911,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11452,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL874388,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11453,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624912,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11454,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL622930,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11455,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623121,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11456,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623122,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11457,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623123,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11458,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623124,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11459,1,,,50597,,,,BAO_0000218,CHEMBL623125,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11460,1,,,50597,,,,BAO_0000218,CHEMBL623126,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11461,1,,,50597,,,,BAO_0000218,CHEMBL623127,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11462,1,,,50597,,,,BAO_0000218,CHEMBL623128,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11463,1,,,50597,,,,BAO_0000218,CHEMBL623129,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11464,1,,,50597,,,,BAO_0000218,CHEMBL623130,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11465,1,,,50597,,,,BAO_0000218,CHEMBL623131,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11466,1,,,50597,,,,BAO_0000218,CHEMBL623132,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11467,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623133,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11468,1,,,50597,,,,BAO_0000218,CHEMBL623134,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11469,1,,,50597,,,,BAO_0000218,CHEMBL874389,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11470,1,,,50597,,,,BAO_0000218,CHEMBL623135,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11471,1,,,50597,,,,BAO_0000218,CHEMBL623136,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11472,1,,,50597,,,,BAO_0000218,CHEMBL623137,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11473,1,,,50597,,,,BAO_0000218,CHEMBL623138,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11474,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623139,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11475,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL623140,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11476,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623141,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11477,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623142,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11478,1,,,50597,,,,BAO_0000218,CHEMBL623143,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ
A,Mus musculus,10090.0,,,1,Intermediate,,14571,,N,11479,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL623144,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14571,,N,11480,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623405,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11481,1,,,50597,,,,BAO_0000218,CHEMBL624074,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11482,1,,,50597,,,,BAO_0000218,CHEMBL624075,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11483,1,,,50597,,,,BAO_0000218,CHEMBL624076,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11484,1,,,50597,,,,BAO_0000218,CHEMBL624077,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11485,1,,,50597,,,,BAO_0000218,CHEMBL624078,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11486,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624079,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11487,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624261,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11488,1,,,50597,,,,BAO_0000218,CHEMBL624262,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11489,1,,,50597,,,,BAO_0000218,CHEMBL624263,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11490,1,,,50597,,,,BAO_0000218,CHEMBL624264,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11491,1,,,50597,,,,BAO_0000218,CHEMBL624265,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11492,1,,,50597,,,,BAO_0000218,CHEMBL624266,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11493,1,,,50597,,,,BAO_0000218,CHEMBL624267,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11494,1,,,50597,,,,BAO_0000218,CHEMBL624268,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11495,1,,,50597,,,,BAO_0000218,CHEMBL875227,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11496,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624269,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11497,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624270,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11498,1,,,50597,,,,BAO_0000218,CHEMBL624271,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11499,1,,,50597,,,,BAO_0000218,CHEMBL624272,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8319,,N,11500,1,,,50597,,,,BAO_0000218,CHEMBL624273,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11501,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624274,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11502,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624275,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11503,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624276,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12038,,N,11504,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624277,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg
A,,,,,1,Autocuration,,14314,,U,11505,0,,,22224,,,,BAO_0000019,CHEMBL624278,,% dose converted to 2-amino-5-chlorophenyl sulfate
A,,,,,1,Autocuration,,14314,,U,11506,0,,,22224,,,,BAO_0000019,CHEMBL624279,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,11507,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL624280,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,11508,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL624281,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,11509,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL622933,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,11510,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL622934,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11511,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622935,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11512,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL622936,,Biodistribution in Rat liver after 5 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11513,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL875228,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11514,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622937,,Biodistribution in Rat lung after 24 hours of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11515,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622938,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11516,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL619736,,Biodistribution in Rat lung after 30 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11517,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625117,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11518,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625118,,Biodistribution in Rat lung after 5 minutes of iv administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8829,,N,11519,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625119,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14972,,N,11520,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625120,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14972,,N,11521,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625121,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14972,,N,11522,1,,,50597,Thalamus,10000006.0,In vivo,BAO_0000218,CHEMBL625122,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11523,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL622204,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11524,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL877503,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11525,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627127,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,,,,,1,Autocuration,,14608,,U,11526,0,,,22224,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL627128,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,,,,,1,Autocuration,,14608,,U,11527,0,,,22224,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL627129,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,,,,,1,Autocuration,,14608,,U,11528,0,,,22224,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL627130,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11529,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL627131,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11530,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL627132,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11531,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL627133,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11532,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL627134,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11533,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL627135,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11534,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL627136,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11535,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628435,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11536,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628436,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11537,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628437,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11538,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL628438,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11539,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL628439,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11540,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL628440,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11541,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628441,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11542,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628442,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11543,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628443,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11544,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628444,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11545,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628445,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11546,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL877504,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11547,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL628446,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11548,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL626874,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11549,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL626875,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11550,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL626876,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11551,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL626877,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11552,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL626878,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11553,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL626879,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Simiiformes,314293.0,,,1,Autocuration,,8918,,U,11554,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626880,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg
A,Mus musculus,10090.0,,,1,Intermediate,,8918,,N,11555,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626881,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8918,,N,11556,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626882,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14470,,N,11557,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626883,,Peak plasma concentration was measured in dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,11558,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626884,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,11559,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626885,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,11560,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626886,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,11561,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626887,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,11562,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626888,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11563,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626889,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog
A,Simiiformes,314293.0,,,1,Autocuration,,13465,,U,11564,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626761,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11565,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626762,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11566,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626763,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13465,,N,11567,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626764,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13465,,N,11568,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626765,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11569,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626766,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13465,,N,11570,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626767,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13465,,N,11571,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626768,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11572,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626769,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13465,,N,11573,1,,,50588,,,In vivo,BAO_0000218,CHEMBL874463,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog
A,Simiiformes,314293.0,,,1,Autocuration,,13465,,U,11574,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626770,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey
A,Simiiformes,314293.0,,,1,Autocuration,,13465,,U,11575,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626771,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13465,,N,11576,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626772,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14731,,N,11577,1,,,100710,,,In vivo,BAO_0000218,CHEMBL626773,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. 
A,Mus musculus,10090.0,,,1,Intermediate,,14731,,N,11578,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626774,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. 
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13376,,N,11579,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626775,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13376,,N,11580,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626776,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14443,,N,11581,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626777,,Maximum concentration (Cmax) in rat when administered orally
A,Simiiformes,314293.0,,,1,Autocuration,,13465,,U,11582,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626778,,Maximal concentration in monkey plasma after 25 mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Autocuration,,16359,,U,11583,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626779,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)"
A,Rattus norvegicus,10116.0,,,1,Autocuration,,16359,,U,11584,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626780,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)"
A,,,,,1,Autocuration,,15618,,U,11585,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626781,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14554,,N,11586,1,,,50597,,,In vivo,BAO_0000218,CHEMBL632164,,Pharmacokinetic profile Cmax was evaluated in rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11537,,N,11587,1,,,50588,,,In vivo,BAO_0000218,CHEMBL632165,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg)
A,Mus musculus,10090.0,,,1,Intermediate,,11537,,N,11588,1,,,50594,,,In vivo,BAO_0000218,CHEMBL632166,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11537,,N,11589,1,,,50588,,,In vivo,BAO_0000218,CHEMBL632167,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg)
A,Mus musculus,10090.0,,,1,Intermediate,,11537,,N,11590,1,,,50594,,,In vivo,BAO_0000218,CHEMBL632168,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,2021,,U,11591,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632169,,Cmax in rat plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5932,,N,11592,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632170,,Cmax in dog plasma after 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,11593,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632171,,Cmax in rat plasma after 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17320,,N,11594,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632172,,Plasma level in rats at 30 mg/kg
A,Mus musculus,10090.0,,,1,Intermediate,,15831,,N,11595,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632173,,Tested for maximum plasma concentration in mice
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,11596,1,,,50597,,,In vivo,BAO_0000218,CHEMBL632174,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,11597,1,,,50597,,,In vivo,BAO_0000218,CHEMBL632175,,The Cmax values in female wistar rats.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15343,,N,11598,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632176,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15343,,N,11599,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632177,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14856,,N,11600,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL632178,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13129,,N,11601,1,,,50597,,,In vivo,BAO_0000218,CHEMBL632179,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13098,,N,11602,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL632180,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13098,,N,11603,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL632181,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13098,,N,11604,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL632182,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.
A,Mus musculus,10090.0,,,1,Autocuration,,15478,,U,11605,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL632183,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15341,,N,11606,1,,,50588,,,In vivo,BAO_0000218,CHEMBL632184,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,11607,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874470,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11608,1,,,50597,,,,BAO_0000218,CHEMBL631302,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11609,1,,,50597,,,,BAO_0000218,CHEMBL631303,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11610,1,,,50597,,,,BAO_0000218,CHEMBL631304,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11611,1,,,50597,,,,BAO_0000218,CHEMBL631305,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11612,1,,,50597,,,,BAO_0000218,CHEMBL631306,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11613,1,,,50597,,,,BAO_0000218,CHEMBL631307,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11614,1,,,50597,,,,BAO_0000218,CHEMBL631308,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11615,1,,,50597,,,,BAO_0000218,CHEMBL625557,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11616,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625558,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11617,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625559,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11618,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625560,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11619,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625561,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11620,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625562,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11621,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL875320,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11622,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625563,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11623,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL625564,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11624,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL625565,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11625,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL625566,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11626,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL625567,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11627,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL625568,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11628,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL628217,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11629,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL628218,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11630,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL628219,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8684,,N,11631,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL628220,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm"
A,,,,,1,Autocuration,,8926,,U,11632,0,,,22224,,,,BAO_0000019,CHEMBL628221,,Distribution in the blood after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11633,0,,,22224,,,,BAO_0000019,CHEMBL628222,,Distribution in the blood after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11634,0,,,22224,,,,BAO_0000019,CHEMBL628223,,Distribution in the blood after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11635,0,,,22224,,,,BAO_0000019,CHEMBL628224,,Distribution in the blood after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11636,0,,,22224,,,,BAO_0000019,CHEMBL628225,,Distribution in the blood after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11637,0,,,22224,,,,BAO_0000019,CHEMBL628226,,Distribution in the blood after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11638,0,,,22224,,,,BAO_0000019,CHEMBL628227,,Distribution in the bone after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11639,0,,,22224,,,,BAO_0000019,CHEMBL875481,,Distribution in the bone after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11640,0,,,22224,,,,BAO_0000019,CHEMBL628228,,Distribution in the bone after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11641,0,,,22224,,,,BAO_0000019,CHEMBL628229,,Distribution in the bone after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11642,0,,,22224,,,,BAO_0000019,CHEMBL628230,,Distribution in the bone after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11643,0,,,22224,,,,BAO_0000019,CHEMBL628231,,Distribution in the bone after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11644,0,,,22224,,,,BAO_0000019,CHEMBL628232,,Distribution in the heart after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11645,0,,,22224,,,,BAO_0000019,CHEMBL628233,,Distribution in the heart after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11646,0,,,22224,,,,BAO_0000019,CHEMBL628234,,Distribution in the heart after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11647,0,,,22224,,,,BAO_0000019,CHEMBL628235,,Distribution in the heart after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11648,0,,,22224,,,,BAO_0000019,CHEMBL628236,,Distribution in the heart after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11649,0,,,22224,,,,BAO_0000019,CHEMBL628237,,Distribution in the heart after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11650,0,,,22224,,,,BAO_0000019,CHEMBL628238,,Distribution in the kidneys after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11651,0,,,22224,,,,BAO_0000019,CHEMBL628239,,Distribution in the kidneys after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11652,0,,,22224,,,,BAO_0000019,CHEMBL628240,,Distribution in the kidneys after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11653,0,,,22224,,,,BAO_0000019,CHEMBL628241,,Distribution in the kidneys after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11654,0,,,22224,,,,BAO_0000019,CHEMBL628242,,Distribution in the kidneys after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11655,0,,,22224,,,,BAO_0000019,CHEMBL875482,,Distribution in the kidneys after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11656,0,,,22224,,,,BAO_0000019,CHEMBL628243,,Distribution in the liver after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11657,0,,,22224,,,,BAO_0000019,CHEMBL628244,,Distribution in the liver after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11658,0,,,22224,,,,BAO_0000019,CHEMBL628245,,Distribution in the liver after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11659,0,,,22224,,,,BAO_0000019,CHEMBL628246,,Distribution in the liver after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11660,0,,,22224,,,,BAO_0000019,CHEMBL628247,,Distribution in the liver after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11661,0,,,22224,,,,BAO_0000019,CHEMBL628248,,Distribution in the liver after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11662,0,,,22224,,,,BAO_0000019,CHEMBL628249,,Distribution in the lung after 120 min of intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,11663,1,,,50594,,,,BAO_0000218,CHEMBL625452,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,11664,1,,,50594,,,,BAO_0000218,CHEMBL625453,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,11665,1,,,50594,,,,BAO_0000218,CHEMBL625454,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)"
A,Mus musculus,10090.0,,,1,Intermediate,,14839,,N,11666,1,,,50594,,,,BAO_0000218,CHEMBL623844,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12178,,N,11667,1,,,50597,,,,BAO_0000218,CHEMBL623845,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12178,,N,11668,1,,,50597,,,,BAO_0000218,CHEMBL623846,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat
A,,,,,1,Autocuration,,12178,,U,11669,0,,,22224,,,,BAO_0000218,CHEMBL623847,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,11670,1,,,100710,,,,BAO_0000218,CHEMBL623848,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,11671,1,,,100710,,,,BAO_0000218,CHEMBL623849,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,11672,1,,,100710,,,,BAO_0000218,CHEMBL623850,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,11673,1,,,100710,,,,BAO_0000218,CHEMBL623851,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,11674,0,,,22224,,,,BAO_0000218,CHEMBL623852,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12187,,N,11675,1,,,50506,,,,BAO_0000218,CHEMBL624551,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12187,,N,11676,1,,,50506,,,,BAO_0000218,CHEMBL624552,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay"
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,11677,0,,,22224,,,,BAO_0000218,CHEMBL624553,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,11678,0,,,22224,,,,BAO_0000218,CHEMBL624554,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12187,,N,11679,1,,,50597,,,,BAO_0000218,CHEMBL624555,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12187,,N,11680,1,,,50597,,,,BAO_0000218,CHEMBL624741,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14122,,N,11681,1,,,50588,,,,BAO_0000218,CHEMBL624742,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma"
A,Cricetinae,10026.0,,,1,Intermediate,,14122,,N,11682,1,,,100712,,,,BAO_0000218,CHEMBL624743,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14122,,N,11683,1,,,50597,,,,BAO_0000218,CHEMBL877606,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma"
A,,,,,1,Autocuration,,13391,,U,11684,0,,,22224,,,,BAO_0000218,CHEMBL624744,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg
A,,,,,1,Autocuration,,13391,,U,11685,0,,,22224,Blood,178.0,,BAO_0000218,CHEMBL624745,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM
A,,,,,1,Autocuration,,13391,,U,11686,0,,,22224,Blood,178.0,,BAO_0000218,CHEMBL624746,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM
A,,,,,1,Autocuration,,13391,,U,11687,0,,,22224,Blood,178.0,,BAO_0000218,CHEMBL624747,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM
A,,,,,1,Autocuration,,16360,,U,11688,0,,,22224,,,,BAO_0000019,CHEMBL624748,,Oral absorption expressed as Area under curve was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,3673,,N,11689,1,,,50588,,,,BAO_0000218,CHEMBL622504,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14122,,N,11690,1,,,50588,,,,BAO_0000218,CHEMBL622505,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma"
A,Cricetinae,10026.0,,,1,Intermediate,,14122,,N,11691,1,,,100712,,,,BAO_0000218,CHEMBL622506,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma"
A,Cricetinae,10026.0,,,1,Intermediate,,14122,,N,11692,1,,,100712,,,,BAO_0000218,CHEMBL622507,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14122,,N,11693,1,,,50597,,,,BAO_0000218,CHEMBL622508,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma"
A,,,,,1,Autocuration,,13889,,U,11694,0,,,22224,,,,BAO_0000019,CHEMBL622509,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,11695,1,,,50597,,,,BAO_0000218,CHEMBL622510,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17279,,N,11696,1,,,50597,,,,BAO_0000218,CHEMBL622511,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer)
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14548,,N,11697,1,,,100710,,,,BAO_0000218,CHEMBL622512,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14548,,N,11698,1,,,100710,,,,BAO_0000218,CHEMBL622513,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14548,,N,11699,1,,,100710,,,,BAO_0000218,CHEMBL622514,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14548,,N,11700,1,,,50588,,,,BAO_0000218,CHEMBL622515,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14548,,N,11701,1,,,50588,,,,BAO_0000218,CHEMBL622516,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14548,,N,11702,1,,,50597,,,,BAO_0000218,CHEMBL622517,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14548,,N,11703,1,,,50597,,,,BAO_0000218,CHEMBL622518,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14548,,N,11704,1,,,50597,,,,BAO_0000218,CHEMBL622519,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11705,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL622520,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11706,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL622521,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Mus musculus,10090.0,,,1,Intermediate,,14608,,N,11707,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL625113,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11708,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL625114,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11709,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL874397,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11710,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625115,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11711,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625116,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11712,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL623932,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11713,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL623933,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11714,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL623934,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11715,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL623935,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11716,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL623936,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11717,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL623937,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14608,,N,11718,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL623938,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11719,1,,,50594,,,,BAO_0000218,CHEMBL623939,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11720,1,,,50594,,,,BAO_0000218,CHEMBL623940,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11721,1,,,50594,,,,BAO_0000218,CHEMBL623941,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11722,1,,,50594,,,,BAO_0000218,CHEMBL627216,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11723,1,,,50594,,,,BAO_0000218,CHEMBL623942,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11724,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL618793,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11725,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL618794,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11726,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL618795,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11727,1,,,50594,,,,BAO_0000218,CHEMBL618796,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11728,1,,,50594,,,,BAO_0000218,CHEMBL618797,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11729,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618798,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11730,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618799,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11731,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618800,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11732,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618801,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11733,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618802,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11734,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL618803,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11735,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618804,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11736,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618805,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11737,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618806,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11738,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618807,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11739,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618808,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11740,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL618809,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11741,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL618810,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11742,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL618811,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11743,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL875844,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11744,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL618812,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11745,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL618813,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11746,1,,,50594,,,,BAO_0000218,CHEMBL618814,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11747,1,,,50594,,,,BAO_0000218,CHEMBL618815,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11748,1,,,50594,,,,BAO_0000218,CHEMBL618816,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11749,1,,,50594,,,,BAO_0000218,CHEMBL618817,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11750,1,,,50594,,,,BAO_0000218,CHEMBL620544,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,11751,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626230,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,11752,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626231,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,11753,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626232,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14906,,N,11754,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626233,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14906,,N,11755,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626234,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14906,,N,11756,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL875341,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,11757,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626235,,The maximum plasma concentration (100 mg/kg) administered orally in human
A,Callithrix,9481.0,,,1,Autocuration,,14215,,U,11758,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626236,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset
A,Simiiformes,314293.0,,,1,Autocuration,,14215,,U,11759,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626237,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14215,,N,11760,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626238,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,11761,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622412,,The maximum plasma concentration (200 mg/kg) administered orally in human
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,11762,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623114,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat
A,Callithrix,9481.0,,,1,Autocuration,,14215,,U,11763,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623115,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset
A,Simiiformes,314293.0,,,1,Autocuration,,14215,,U,11764,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623116,,The maximum plasma concentration (25 mg/kg) administered orally in monkey
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,14215,,U,11765,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623117,,The maximum plasma concentration (30 mg/kg) administered orally in dog
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,11766,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623118,,The maximum plasma concentration (400 mg/kg) administered orally in human
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,11767,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623119,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,11768,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623120,,The maximum plasma concentration (50 mg/kg) administered orally in rat
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,11769,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623286,,The maximum plasma concentration (800 mg/kg) administered orally in human
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14067,,N,11770,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623287,,The maximum plasma concentration was measured on rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12350,,N,11771,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623288,,The maximum plasma concentration was measured on rats after oral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14813,,N,11772,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623289,,Plasma drug Cmax in rat (PO dose)
A,,,,,1,Autocuration,,12536,,U,11773,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623290,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14169,,N,11774,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623291,,maximum Plasma concentration in Dog was determined after Peroral administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14169,,N,11775,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623292,,maximum Plasma concentration in Rats was determined after Peroral administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15604,,N,11776,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623293,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog
A,Simiiformes,314293.0,,,1,Autocuration,,15604,,U,11777,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623294,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15604,,N,11778,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623295,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat
A,Mus musculus,10090.0,,,1,Intermediate,,14387,,N,11779,1,,,50594,,,In vivo,BAO_0000218,CHEMBL623296,,maximum concentration was measured when administered through oral route in mice
A,Mus musculus,10090.0,,,1,Intermediate,,15115,,N,11780,1,,,50594,,,,BAO_0000218,CHEMBL875349,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1
A,Simiiformes,314293.0,,,1,Autocuration,,15115,,U,11781,0,,,22224,,,,BAO_0000019,CHEMBL623297,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1
A,Simiiformes,314293.0,,,1,Autocuration,,15115,,U,11782,0,,,22224,,,,BAO_0000019,CHEMBL623298,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6
A,Simiiformes,314293.0,,,1,Autocuration,,15115,,U,11783,0,,,22224,,,,BAO_0000019,CHEMBL623299,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16359,,N,11784,1,,,50597,,,,BAO_0000218,CHEMBL623300,,Pharmacokinetic parameter was evaluated in rats
A,Mus musculus,10090.0,,,1,Intermediate,,12829,,N,11785,1,,,50594,,,,BAO_0000218,CHEMBL623301,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle
A,Mus musculus,10090.0,,,1,Intermediate,,12829,,N,11786,1,,,50594,,,,BAO_0000218,CHEMBL623302,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle
A,Mus musculus,10090.0,,,1,Intermediate,,12829,,N,11787,1,,,50594,,,,BAO_0000218,CHEMBL623303,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle
A,Mus musculus,10090.0,,,1,Intermediate,,12829,,N,11788,1,,,50594,,,,BAO_0000218,CHEMBL623304,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle
A,Mus musculus,10090.0,,,1,Intermediate,,12829,,N,11789,1,,,50594,,,,BAO_0000218,CHEMBL623305,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,11790,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL623306,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,11791,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL623307,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15137,,N,11792,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL623308,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.
A,Mus musculus,10090.0,,,1,Intermediate,,15137,,N,11793,1,,,50594,Plasma,1969.0,,BAO_0000218,CHEMBL623309,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.
A,Mus musculus,10090.0,,,1,Intermediate,,13509,,N,11794,1,,,50594,,,,BAO_0000218,CHEMBL623310,,Plasma Concentration after 120 min of oral administration to mice
A,Mus musculus,10090.0,,,1,Intermediate,,13509,,N,11795,1,,,50594,,,,BAO_0000218,CHEMBL623311,,Plasma Concentration after 30 min of oral administration to mice
A,Macaca fascicularis,9541.0,,,1,Intermediate,,13509,,N,11796,1,,,100710,,,,BAO_0000218,CHEMBL623312,,Plasma Concentration after 60 min of oral administration to mice
A,Mus musculus,10090.0,,,1,Intermediate,,13509,,N,11797,1,,,50594,,,,BAO_0000218,CHEMBL875350,,Plasma Concentration after 60 min of oral administration to mice; Not determined
A,Mus musculus,10090.0,,,1,Intermediate,,13509,,N,11798,1,,,50594,,,,BAO_0000218,CHEMBL628635,,Plasma Concentration after 90 min of oral administration to mice
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11799,1,,,50597,,,,BAO_0000218,CHEMBL628636,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11800,1,,,50597,,,,BAO_0000218,CHEMBL628637,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12064,,N,11801,1,,,50597,,,,BAO_0000218,CHEMBL628058,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11802,1,,,50597,,,,BAO_0000218,CHEMBL628059,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11803,1,,,50597,,,,BAO_0000218,CHEMBL628060,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time
A,,,,,1,Autocuration,,8926,,U,11804,0,,,22224,,,,BAO_0000019,CHEMBL628061,,Distribution in the lung after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11805,0,,,22224,,,,BAO_0000019,CHEMBL628062,,Distribution in the lung after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11806,0,,,22224,,,,BAO_0000019,CHEMBL628063,,Distribution in the lung after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11807,0,,,22224,,,,BAO_0000019,CHEMBL628064,,Distribution in the lung after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11808,0,,,22224,,,,BAO_0000019,CHEMBL628065,,Distribution in the lung after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11809,0,,,22224,Muscle tissue,2385.0,,BAO_0000019,CHEMBL628066,,Distribution in the muscle after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11810,0,,,22224,Muscle tissue,2385.0,,BAO_0000019,CHEMBL628067,,Distribution in the muscle after 15 min of intravenous administration
A,Mus musculus,10090.0,,,1,Intermediate,,8926,,N,11811,1,,,50594,Muscle tissue,2385.0,,BAO_0000218,CHEMBL874646,,Distribution in the muscle after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11812,0,,,22224,Muscle tissue,2385.0,,BAO_0000019,CHEMBL628068,,Distribution in the muscle after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11813,0,,,22224,Muscle tissue,2385.0,,BAO_0000019,CHEMBL628069,,Distribution in the muscle after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11814,0,,,22224,Muscle tissue,2385.0,,BAO_0000019,CHEMBL628070,,Distribution in the muscle after 90 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11815,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628071,,Distribution in the spleen after 120 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11816,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628072,,Distribution in the spleen after 15 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11817,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628073,,Distribution in the spleen after 30 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11818,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628074,,Distribution in the spleen after 5 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11819,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628075,,Distribution in the spleen after 60 min of intravenous administration
A,,,,,1,Autocuration,,8926,,U,11820,0,,,22224,Spleen,2106.0,,BAO_0000019,CHEMBL628076,,Distribution in the spleen after 90 min of intravenous administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11821,1,,,50597,Adrenal cortex,1235.0,,BAO_0000218,CHEMBL628077,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11822,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628078,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11823,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628079,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11824,1,,,50597,Female gonad,992.0,,BAO_0000218,CHEMBL628080,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11825,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL628081,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11826,1,,,50597,Adrenal cortex,1235.0,,BAO_0000218,CHEMBL628082,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11827,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL874647,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11828,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL626406,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11829,1,,,50597,Female gonad,992.0,,BAO_0000218,CHEMBL626407,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7570,,N,11830,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626408,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11831,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626409,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11832,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626410,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11833,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626411,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11834,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626412,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11835,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626413,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11836,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626414,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11837,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626415,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11838,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626416,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11839,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627062,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11840,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627063,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11841,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627064,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11842,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627227,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11843,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627228,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11844,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627229,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11845,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625792,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11846,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625793,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11847,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625794,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11848,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625795,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21"
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,11849,1,,,50594,,,,BAO_0000218,CHEMBL625796,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13376,,N,11850,1,,,50588,,,,BAO_0000218,CHEMBL625797,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13376,,N,11851,1,,,50588,,,,BAO_0000218,CHEMBL625798,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg
A,,,,,1,Autocuration,,14380,,U,11852,0,,,22224,,,,BAO_0000218,CHEMBL875613,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11853,0,,,22224,,,,BAO_0000218,CHEMBL625799,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11854,0,,,22224,,,,BAO_0000218,CHEMBL625800,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11855,0,,,22224,,,,BAO_0000218,CHEMBL625801,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11856,0,,,22224,,,,BAO_0000218,CHEMBL625802,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11857,0,,,22224,,,,BAO_0000218,CHEMBL625803,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally
A,,,,,1,Autocuration,,14380,,U,11858,0,,,22224,,,,BAO_0000019,CHEMBL625804,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution
A,,,,,1,Autocuration,,14380,,U,11859,0,,,22224,,,,BAO_0000218,CHEMBL622530,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11860,1,,,50594,,,,BAO_0000218,CHEMBL622531,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11861,1,,,50594,,,,BAO_0000218,CHEMBL622532,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11862,1,,,50594,,,,BAO_0000218,CHEMBL623176,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11863,1,,,50594,,,,BAO_0000218,CHEMBL623177,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11864,1,,,50594,,,,BAO_0000218,CHEMBL623178,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11865,1,,,50594,,,,BAO_0000218,CHEMBL623179,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11866,1,,,50594,,,,BAO_0000218,CHEMBL623180,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11867,1,,,50594,,,,BAO_0000218,CHEMBL623181,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11868,1,,,50594,,,,BAO_0000218,CHEMBL624131,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11869,1,,,50594,,,,BAO_0000218,CHEMBL624132,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11870,1,,,50594,,,,BAO_0000218,CHEMBL624133,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11871,1,,,50594,,,,BAO_0000218,CHEMBL624846,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11872,1,,,50594,,,,BAO_0000218,CHEMBL624847,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11873,1,,,50594,,,,BAO_0000218,CHEMBL624848,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11874,1,,,50594,,,,BAO_0000218,CHEMBL625012,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11875,1,,,50594,,,,BAO_0000218,CHEMBL625013,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11876,1,,,50594,,,,BAO_0000218,CHEMBL625014,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11877,1,,,50594,,,,BAO_0000218,CHEMBL625015,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11878,1,,,50594,,,,BAO_0000218,CHEMBL625016,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11879,1,,,50594,,,,BAO_0000218,CHEMBL625017,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11880,1,,,50594,,,,BAO_0000218,CHEMBL625018,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11881,1,,,50594,,,,BAO_0000218,CHEMBL625019,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11882,1,,,50594,,,,BAO_0000218,CHEMBL625020,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,11883,1,,,50594,,,,BAO_0000218,CHEMBL625021,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,11884,1,,,50597,,,,BAO_0000218,CHEMBL625022,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Mus musculus,10090.0,,,1,Intermediate,,14731,,N,11885,1,,,50594,,,,BAO_0000218,CHEMBL625023,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. 
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14731,,N,11886,1,,,100710,,,,BAO_0000218,CHEMBL625024,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14731,,N,11887,1,,,100710,,,,BAO_0000218,CHEMBL627626,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. 
A,,,,,1,Autocuration,,13758,,U,11888,0,,,22224,Brain,955.0,,BAO_0000218,CHEMBL627627,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain
A,,,,,1,Autocuration,,13758,,U,11889,0,,,22224,Serum,1977.0,,BAO_0000218,CHEMBL627628,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum
A,,,,,1,Autocuration,,13758,,U,11890,0,,,22224,Brain,955.0,,BAO_0000218,CHEMBL627629,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain
A,,,,,1,Autocuration,,13758,,U,11891,0,,,22224,Serum,1977.0,,BAO_0000218,CHEMBL627630,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum
A,,,,,1,Autocuration,,16359,,U,11892,0,,,22224,,,,BAO_0000019,CHEMBL627631,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35)
A,,,,,1,Autocuration,,16359,,U,11893,0,,,22224,,,,BAO_0000218,CHEMBL629515,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3)
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11894,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL629516,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11895,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL629517,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11896,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL629518,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11897,1,,,50594,,,,BAO_0000218,CHEMBL877499,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11898,1,,,50594,,,,BAO_0000218,CHEMBL629519,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11899,1,,,50594,,,,BAO_0000218,CHEMBL629520,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,15383,,N,11900,1,,,50594,,,,BAO_0000218,CHEMBL629521,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11901,1,,,50594,,,,BAO_0000218,CHEMBL629522,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11902,1,,,50594,,,,BAO_0000218,CHEMBL629523,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11903,1,,,50594,,,,BAO_0000218,CHEMBL629524,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11904,1,,,50594,,,,BAO_0000218,CHEMBL629525,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11905,1,,,50594,,,,BAO_0000218,CHEMBL629526,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11906,1,,,50594,,,,BAO_0000218,CHEMBL629527,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11907,1,,,50594,,,,BAO_0000218,CHEMBL629528,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11908,1,,,50594,,,,BAO_0000218,CHEMBL629529,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11909,1,,,50594,,,,BAO_0000218,CHEMBL629530,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11910,1,,,50594,,,,BAO_0000218,CHEMBL629531,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11911,1,,,50594,,,,BAO_0000218,CHEMBL628656,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,11912,1,,,50594,,,,BAO_0000218,CHEMBL628657,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11913,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628658,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11914,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628659,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11915,1,,,50597,,,In vivo,BAO_0000218,CHEMBL877500,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11916,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628660,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11917,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628661,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11918,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628662,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11919,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628663,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11920,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628664,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11921,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628665,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11922,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628666,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11923,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628667,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11924,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628668,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11925,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628669,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11926,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628670,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11927,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL628671,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11928,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL628672,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11929,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL630300,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11930,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL629787,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11931,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL629788,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11932,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629789,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11933,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629790,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11934,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629791,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11935,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629792,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11936,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629793,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,11937,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629794,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11938,1,,,50597,,,,BAO_0000218,CHEMBL874459,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11939,1,,,50597,,,,BAO_0000218,CHEMBL629795,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11940,1,,,50597,,,,BAO_0000218,CHEMBL629796,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11941,1,,,50597,,,,BAO_0000218,CHEMBL629797,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10677,,N,11942,1,,,50597,,,,BAO_0000218,CHEMBL629798,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11943,1,,,50597,Adrenal gland,2369.0,In vivo,BAO_0000218,CHEMBL629799,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11944,1,,,50597,Adrenal gland,2369.0,In vivo,BAO_0000218,CHEMBL629800,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11945,1,,,50597,Adrenal gland,2369.0,In vivo,BAO_0000218,CHEMBL629801,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11946,1,,,50597,Adrenal gland,2369.0,In vivo,BAO_0000218,CHEMBL629802,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11947,1,,,50597,Adrenal gland,2369.0,In vivo,BAO_0000218,CHEMBL629803,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11948,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL629804,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11949,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL629805,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11950,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL629806,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11951,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL629807,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11952,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL629808,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11953,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629809,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11954,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629810,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11955,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629811,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11956,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629812,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11957,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629813,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11958,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL874460,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11959,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629814,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11960,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629815,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11961,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629816,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11962,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629817,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11963,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626643,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11964,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626644,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11965,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626806,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11966,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL626807,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11967,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627261,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11968,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627262,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11969,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627263,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11970,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627264,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11971,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627265,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11972,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627266,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11973,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627267,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11974,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627268,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11975,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627269,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,11976,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627270,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11977,1,,,50597,,,,BAO_0000218,CHEMBL627271,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11978,1,,,50597,,,,BAO_0000218,CHEMBL627946,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11979,1,,,50597,,,,BAO_0000218,CHEMBL875472,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11980,1,,,50597,,,,BAO_0000218,CHEMBL627947,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11981,1,,,50597,,,,BAO_0000218,CHEMBL627948,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11982,1,,,50597,,,,BAO_0000218,CHEMBL628113,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11983,1,,,50597,,,,BAO_0000218,CHEMBL628114,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11984,1,,,50597,,,,BAO_0000218,CHEMBL628115,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11985,1,,,50597,,,,BAO_0000218,CHEMBL628116,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11986,1,,,50597,,,,BAO_0000218,CHEMBL628117,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11987,1,,,50597,,,,BAO_0000218,CHEMBL628118,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11988,1,,,50597,,,,BAO_0000218,CHEMBL628119,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11989,1,,,50597,,,,BAO_0000218,CHEMBL628120,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11990,1,,,50597,,,,BAO_0000218,CHEMBL628121,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11991,1,,,50597,,,,BAO_0000218,CHEMBL628122,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11992,1,,,50597,,,,BAO_0000218,CHEMBL627297,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11993,1,,,50597,,,,BAO_0000218,CHEMBL627298,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11994,1,,,50597,,,,BAO_0000218,CHEMBL627299,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11995,1,,,50597,,,,BAO_0000218,CHEMBL627300,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11996,1,,,50597,,,,BAO_0000218,CHEMBL627301,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11997,1,,,50597,,,,BAO_0000218,CHEMBL627302,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11998,1,,,50597,,,,BAO_0000218,CHEMBL627303,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,11999,1,,,50597,,,,BAO_0000218,CHEMBL627304,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12000,1,,,50597,,,,BAO_0000218,CHEMBL627305,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12001,1,,,50597,,,,BAO_0000218,CHEMBL627306,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12002,1,,,50597,,,,BAO_0000218,CHEMBL623982,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12003,1,,,50597,,,,BAO_0000218,CHEMBL623983,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12004,1,,,50597,,,,BAO_0000218,CHEMBL623984,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12005,1,,,50597,,,,BAO_0000218,CHEMBL623985,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12006,1,,,50597,,,,BAO_0000218,CHEMBL623986,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12007,1,,,50597,,,,BAO_0000218,CHEMBL623987,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12008,1,,,50597,,,,BAO_0000218,CHEMBL623988,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12009,1,,,50597,,,,BAO_0000218,CHEMBL623989,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12010,1,,,50597,,,,BAO_0000218,CHEMBL622215,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12011,1,,,50597,,,,BAO_0000218,CHEMBL622216,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12012,1,,,50597,,,,BAO_0000218,CHEMBL877481,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41"
A,,,,,1,Autocuration,,16359,,U,12013,0,,,22224,,,,BAO_0000218,CHEMBL622217,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8)
A,Mus musculus,10090.0,,,1,Intermediate,,13701,,N,12014,1,,,50594,,,,BAO_0000218,CHEMBL622218,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14554,,N,12015,1,,,50597,,,,BAO_0000218,CHEMBL622219,,Pharmacokinetic profile AUC was evaluated in rats
A,,,,,1,Autocuration,,6241,,U,12016,0,,,22224,,,,BAO_0000019,CHEMBL622220,,Pharmacokinetic property (Area under curve)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11537,,N,12017,1,,,50588,,,,BAO_0000218,CHEMBL622221,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg)."
A,Mus musculus,10090.0,,,1,Intermediate,,11537,,N,12018,1,,,50594,,,,BAO_0000218,CHEMBL622222,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg)."
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11537,,N,12019,1,,,50588,,,,BAO_0000218,CHEMBL622223,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg)."
A,Mus musculus,10090.0,,,1,Intermediate,,11537,,N,12020,1,,,50594,,,,BAO_0000218,CHEMBL622224,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg)."
A,,,,,1,Autocuration,,13118,,U,12021,0,,,22224,,,,BAO_0000019,CHEMBL622225,,Plasma concentration (AUC) was determined
A,,,,,1,Autocuration,,13118,,U,12022,0,,,22224,,,,BAO_0000019,CHEMBL622226,,Plasma concentration (AUC) was determined; Not detectable
A,Cavia porcellus,10141.0,,,1,Intermediate,,9562,,N,12023,1,,,50512,,,,BAO_0000218,CHEMBL624154,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10363,,N,12024,1,,,50597,,,,BAO_0000218,CHEMBL624155,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10363,,N,12025,1,,,50597,,,,BAO_0000218,CHEMBL624156,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10363,,N,12026,1,,,50597,,,,BAO_0000218,CHEMBL624157,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10363,,N,12027,1,,,50597,,,,BAO_0000218,CHEMBL624158,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,12028,1,,,50597,,,,BAO_0000218,CHEMBL624159,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,12029,1,,,50597,,,,BAO_0000218,CHEMBL624160,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,12030,1,,,50597,,,,BAO_0000218,CHEMBL624161,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,12031,1,,,50597,,,,BAO_0000218,CHEMBL624162,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13317,,N,12032,1,,,50588,,,,BAO_0000218,CHEMBL624163,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,12033,1,,,50597,,,,BAO_0000218,CHEMBL624164,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,12034,1,,,50597,,,,BAO_0000218,CHEMBL624165,,The AUC(0-infinity) values in female wistar rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,12035,1,,,50597,,,,BAO_0000218,CHEMBL624166,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,12036,1,,,50597,,,,BAO_0000218,CHEMBL624167,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,12037,1,,,50597,,,,BAO_0000218,CHEMBL624168,,The AUC(0-t)values in female wistar rats.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14067,,N,12038,1,,,50597,,,,BAO_0000218,CHEMBL624169,,The Area under the concentration time curve of compound was measured on rats
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,12039,1,,,50587,,,,BAO_0000218,CHEMBL624170,,The area under curve (100 mg/kg) administered orally in humans
A,Callithrix,9481.0,,,1,Autocuration,,14215,,U,12040,0,,,22224,,,,BAO_0000218,CHEMBL624171,,The area under curve (12.5 mg/kg) administered intravenously in marmoset
A,Simiiformes,314293.0,,,1,Autocuration,,14215,,U,12041,0,,,22224,,,,BAO_0000218,CHEMBL624172,,The area under curve (12.5 mg/kg) administered intravenously in monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14215,,N,12042,1,,,50588,,,,BAO_0000218,CHEMBL624173,,The area under curve (15 mg/kg) administered intravenously in dog
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,12043,1,,,50587,,,,BAO_0000218,CHEMBL877488,,The area under curve (200 mg/kg) administered orally in humans
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,12044,1,,,50597,,,,BAO_0000218,CHEMBL624174,,The area under curve (25 mg/kg) administered intravenously in rat
A,Callithrix,9481.0,,,1,Autocuration,,14215,,U,12045,0,,,22224,,,,BAO_0000218,CHEMBL624175,,The area under curve (25 mg/kg) administered orally in marmoset
A,Simiiformes,314293.0,,,1,Autocuration,,14215,,U,12046,0,,,22224,,,,BAO_0000218,CHEMBL624176,,The area under curve (25 mg/kg) administered orally in monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14215,,N,12047,1,,,50588,,,,BAO_0000218,CHEMBL624177,,The area under curve (30 mg/kg) administered orally in dog
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,12048,1,,,50587,,,,BAO_0000218,CHEMBL624178,,The area under curve (400 mg/kg) administered orally in humans
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,12049,1,,,50597,,,,BAO_0000218,CHEMBL624179,,The area under curve (50 mg/kg) administered orally in fasted rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14215,,N,12050,1,,,50597,,,,BAO_0000218,CHEMBL627689,,The area under curve (50 mg/kg) administered orally in rat
A,Homo sapiens,9606.0,,,1,Intermediate,,14215,,N,12051,1,,,50587,,,,BAO_0000218,CHEMBL627690,,The area under curve (800 mg/kg) administered orally in humans
A,,,,,1,Autocuration,,11324,,U,12052,0,,,22224,,,,BAO_0000019,CHEMBL627691,,The compound was evaluated for area under the curve
A,Callithrix,9481.0,,,1,Autocuration,,11324,,U,12053,0,,,22224,,,,BAO_0000019,CHEMBL627692,,The compound was evaluated for area under the curve in marmosets
A,Callithrix,9481.0,,,1,Autocuration,,11324,,U,12054,0,,,22224,,,,BAO_0000019,CHEMBL627693,,The compound was evaluated for area under the curve in marmosets
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13875,,N,12055,1,,,50597,,,,BAO_0000218,CHEMBL627694,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13875,,N,12056,1,,,50597,,,,BAO_0000218,CHEMBL627695,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat
A,,,,,1,Autocuration,,13875,,U,12057,0,,,22224,,,,BAO_0000218,CHEMBL627696,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13875,,N,12058,1,,,50597,,,,BAO_0000218,CHEMBL627697,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13875,,N,12059,1,,,50597,,,,BAO_0000218,CHEMBL627698,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13875,,N,12060,1,,,50597,,,,BAO_0000218,CHEMBL627699,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13807,,N,12061,1,,,50597,,,,BAO_0000218,CHEMBL627700,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14127,,N,12062,1,,,50597,,,,BAO_0000218,CHEMBL627701,,Total drug exposure is determined after oral dosing in rats.
A,,,,,1,Autocuration,,15116,,U,12063,0,,,22224,,,,BAO_0000218,CHEMBL627702,,Total drug exposure (5 mg/kg) when administered intravenously
A,,,,,1,Autocuration,,15116,,U,12064,0,,,22224,,,,BAO_0000218,CHEMBL627703,,Total drug exposure (5 mg/kg) when administered orally
A,Simiiformes,314293.0,,,1,Autocuration,,15604,,U,12065,0,,,22224,,,,BAO_0000218,CHEMBL626873,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15604,,N,12066,1,,,50597,,,,BAO_0000218,CHEMBL629583,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15604,,N,12067,1,,,50588,,,,BAO_0000218,CHEMBL629584,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15604,,N,12068,1,,,50588,,,,BAO_0000218,CHEMBL629585,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12069,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629586,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12070,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL629587,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12071,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629588,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12072,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629589,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12073,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629590,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12074,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629591,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12075,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629592,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12076,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629593,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12077,1,,,50597,,,In vivo,BAO_0000218,CHEMBL629594,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12078,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL629595,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12079,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL630290,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12080,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627137,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12081,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627138,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12082,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627139,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12083,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627140,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12084,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627141,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12085,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627142,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12086,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627143,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12087,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL874449,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12088,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627144,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12089,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627145,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12090,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627146,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12091,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627147,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12092,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627148,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12093,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627149,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12094,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL632160,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12095,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL632161,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12096,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL632162,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12097,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL632163,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12098,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL874469,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12099,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627182,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12100,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627183,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12101,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627184,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12102,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627185,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12103,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627186,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12104,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627187,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12105,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627188,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12106,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627189,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12107,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627190,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12108,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627191,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12109,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627192,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12110,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627193,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12111,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL874590,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12112,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627194,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12113,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627195,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12114,1,,,50597,Female gonad,992.0,In vivo,BAO_0000218,CHEMBL627196,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12115,1,,,50597,Female gonad,992.0,In vivo,BAO_0000218,CHEMBL627197,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12116,1,,,50597,Female gonad,992.0,In vivo,BAO_0000218,CHEMBL627198,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12117,1,,,50597,Female gonad,992.0,In vivo,BAO_0000218,CHEMBL627199,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12118,1,,,50597,Female gonad,992.0,In vivo,BAO_0000218,CHEMBL627200,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12119,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627201,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12120,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627202,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12121,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627203,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12122,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627204,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12123,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627205,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12124,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627206,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12125,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627207,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12126,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627208,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12127,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL627209,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12128,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL627210,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12129,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL627211,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12130,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL627212,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12131,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL627213,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12132,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL626599,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12133,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL626600,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10911,,N,12134,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL626601,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram
A,,,,,1,Autocuration,,8081,,U,12135,0,,,22224,,,,BAO_0000019,CHEMBL627484,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound
A,Macaca fascicularis,9541.0,,,1,Intermediate,,17248,,N,12136,1,,,100710,Plasma,1969.0,,BAO_0000218,CHEMBL627485,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg)
A,Macaca fascicularis,9541.0,,,1,Intermediate,,17248,,N,12137,1,,,100710,Plasma,1969.0,,BAO_0000218,CHEMBL628147,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable
A,Macaca fascicularis,9541.0,,,1,Intermediate,,17248,,N,12138,1,,,100710,Plasma,1969.0,,BAO_0000218,CHEMBL628148,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,12139,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL628149,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,12140,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL628150,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,12141,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL628318,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17248,,N,12142,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL628319,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,12143,1,,,50588,,,,BAO_0000218,CHEMBL875609,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )"
A,,,,,1,Autocuration,,7040,,U,12144,0,,,22224,,,,BAO_0000019,CHEMBL628320,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10
A,,,,,1,Autocuration,,7040,,U,12145,0,,,22224,,,,BAO_0000019,CHEMBL628321,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5
A,,,,,1,Autocuration,,7040,,U,12146,0,,,22224,,,,BAO_0000019,CHEMBL628322,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8
A,,,,,1,Autocuration,,7040,,U,12147,0,,,22224,,,,BAO_0000019,CHEMBL628323,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2
A,,,,,1,Autocuration,,7040,,U,12148,0,,,22224,,,,BAO_0000019,CHEMBL628324,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6
A,,,,,1,Autocuration,,7040,,U,12149,0,,,22224,,,,BAO_0000019,CHEMBL628325,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2
A,,,,,1,Autocuration,,7040,,U,12150,0,,,22224,,,,BAO_0000019,CHEMBL628326,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12151,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL628327,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12152,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL628328,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12153,1,,,50588,Blood,178.0,,BAO_0000218,CHEMBL628329,,"Concentration of compound in blood of dog 1, after administering intravenously"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12154,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628330,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12155,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628331,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12156,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628332,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12157,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628333,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12158,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628334,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12159,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628335,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12160,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628336,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12161,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628337,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12162,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628338,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12163,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL875610,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12164,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628339,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12165,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628340,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12166,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628341,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12167,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622214,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12168,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623167,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12169,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623168,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12170,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623169,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12171,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL623170,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12172,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627224,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12173,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL875634,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12174,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627225,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12175,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627226,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12176,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626083,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12177,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626084,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12178,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626085,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12179,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626086,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12180,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626087,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12181,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626088,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12182,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626089,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12183,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626090,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12184,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626091,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12185,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626092,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12186,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626093,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12187,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626094,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12188,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626095,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12189,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL626096,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26"
A,Simiiformes,314293.0,,,1,Autocuration,,15604,,U,12190,0,,,22224,,,,BAO_0000218,CHEMBL626097,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15604,,N,12191,1,,,50597,,,,BAO_0000218,CHEMBL626098,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat
A,,,,,1,Autocuration,,1806,,U,12192,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL626099,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv
A,,,,,1,Autocuration,,1806,,U,12193,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL626100,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17237,,N,12194,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL626101,,AUC 0-inf in dog
A,Cavia porcellus,10141.0,,,1,Intermediate,,17237,,N,12195,1,,,50512,Plasma,1969.0,,BAO_0000218,CHEMBL626102,,AUC 0-inf in guinea pig
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17237,,N,12196,1,,,50588,Plasma,1969.0,,BAO_0000218,CHEMBL626103,,AUC 0-t in dog
A,Cavia porcellus,10141.0,,,1,Intermediate,,17237,,N,12197,1,,,50512,Plasma,1969.0,,BAO_0000218,CHEMBL628391,,AUC 0-t in guinea pig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15194,,N,12198,1,,,50597,,,,BAO_0000218,CHEMBL628392,,The compound was tested for brain to plasma partition in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15194,,N,12199,1,,,50597,,,,BAO_0000218,CHEMBL628393,,The compound was tested for brain to plasma partition in rat.
A,,,,,1,Autocuration,,8787,,U,12200,0,,,22224,Blood,178.0,,BAO_0000019,CHEMBL628394,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17025,,N,12201,1,,,50588,,,,BAO_0000218,CHEMBL628395,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.
A,Simiiformes,314293.0,,,1,Autocuration,,17025,,U,12202,0,,,22224,,,,BAO_0000218,CHEMBL628396,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,12203,1,,,50592,,,,BAO_0000218,CHEMBL628397,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17025,,N,12204,1,,,50597,,,,BAO_0000218,CHEMBL628398,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.
A,Macaca mulatta,9544.0,,,1,Intermediate,,4236,,N,12205,1,,,50797,,,,BAO_0000218,CHEMBL628399,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15343,,N,12206,1,,,50588,,,,BAO_0000218,CHEMBL628400,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15343,,N,12207,1,,,50597,,,,BAO_0000218,CHEMBL874907,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose
A,,,,,1,Autocuration,,17720,,U,12208,0,,,22224,,,,BAO_0000019,CHEMBL628401,,Area under curve of the compound was determined
A,Simiiformes,314293.0,,,1,Autocuration,,17788,,U,12209,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL628402,,AUC in monkeys at a dose of 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17788,,N,12210,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628403,,AUC in rats at a dose of 1 mg/kg
A,,,,,1,Autocuration,,8778,,U,12211,0,,,22224,,,,BAO_0000019,CHEMBL628404,,Compound was evaluated for the overall absorbance loss at pH of 2
A,,,,,1,Autocuration,,8778,,U,12212,0,,,22224,,,,BAO_0000019,CHEMBL628405,,Compound was evaluated for the overall absorbance loss at pH of 4
A,,,,,1,Autocuration,,8778,,U,12213,0,,,22224,,,,BAO_0000019,CHEMBL628406,,Compound was evaluated for the overall absorbance loss at pH of 7
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2249,,N,12214,1,,,50597,,,,BAO_0000218,CHEMBL628407,,Compound was evaluated for its absorption in the rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8881,,N,12215,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628408,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8881,,N,12216,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629171,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8881,,N,12217,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629172,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8881,,N,12218,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629173,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12219,1,,,50597,,,,BAO_0000218,CHEMBL629174,,In vitro percent permeability into rat ileum
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12220,1,,,50597,,,,BAO_0000218,CHEMBL629175,,In vitro percent permeability into rat ileum; Range is 10-17
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12221,1,,,50597,,,,BAO_0000218,CHEMBL629176,,In vitro percent permeability into rat ileum; Range is 10-18
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12222,1,,,50597,,,,BAO_0000218,CHEMBL629177,,In vitro percent permeability into rat ileum; Range is 10-19
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12223,1,,,50597,,,,BAO_0000218,CHEMBL629178,,In vitro percent permeability into rat ileum; Range is 12-15
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12224,1,,,50597,,,,BAO_0000218,CHEMBL631869,,In vitro percent permeability into rat ileum; Range is 13-19
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12225,1,,,50597,,,,BAO_0000218,CHEMBL631870,,In vitro percent permeability into rat ileum; Range is 14-17
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12226,1,,,50597,,,,BAO_0000218,CHEMBL631871,,In vitro percent permeability into rat ileum; Range is 15-18
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12227,1,,,50597,,,,BAO_0000218,CHEMBL631872,,In vitro percent permeability into rat ileum; Range is 2-5
A,,,,,1,Autocuration,,15286,,U,12228,0,,,22224,Ileum,2116.0,,BAO_0000221,CHEMBL875775,,In vitro percent permeability into rat ileum; Range is 23-42
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12229,1,,,50597,,,,BAO_0000218,CHEMBL631873,,In vitro percent permeability into rat ileum; Range is 28-36
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12230,1,,,50597,,,,BAO_0000218,CHEMBL631874,,In vitro percent permeability into rat ileum; Range is 29-35
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12231,1,,,50597,,,,BAO_0000218,CHEMBL631875,,In vitro percent permeability into rat ileum; Range is 46-66
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12232,1,,,50597,,,,BAO_0000218,CHEMBL631876,,In vitro percent permeability into rat ileum; Range is 50-68
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12233,1,,,50597,,,,BAO_0000218,CHEMBL631877,,In vitro percent permeability into rat ileum; Range is 78-81
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12234,1,,,50597,,,,BAO_0000218,CHEMBL631878,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12235,1,,,50597,,,,BAO_0000218,CHEMBL631879,,In vitro percent permeability into rat ileum; nd indicates not detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12236,1,,,50597,,,,BAO_0000218,CHEMBL631880,,In vitro percent permeability into rat ileum; nt indicates not detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15286,,N,12237,1,,,50597,,,,BAO_0000218,CHEMBL631881,,In vitro percent permeability into rat ileum; nt indicates not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13770,,N,12238,1,,,50597,,,,BAO_0000218,CHEMBL631882,,Compound was tested for oral absorption in bile-duct cannulated rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13770,,N,12239,1,,,50597,,,,BAO_0000218,CHEMBL630749,,Compound was tested for oral absorption in bile-duct cannulated rats.
A,Homo sapiens,9606.0,,,1,Intermediate,,5202,,N,12240,1,,,50587,,,,BAO_0000218,CHEMBL630750,,Oral absorption using Caco-2 cell monolayers.
A,Homo sapiens,9606.0,,,1,Intermediate,,14920,,N,12241,1,,,50587,,,,BAO_0000218,CHEMBL630253,,Percent of the drug absorbed after administration to humans was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12242,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL630254,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12243,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL630255,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12244,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL630256,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12245,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL875781,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12246,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630257,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13751,,N,12247,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630258,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15807,,N,12248,1,,,50597,,,,BAO_0000218,CHEMBL630259,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15807,,N,12249,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL630260,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15807,,N,12250,1,,,50597,Striatum,2435.0,,BAO_0000218,CHEMBL630261,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12251,1,,,50597,,,,BAO_0000218,CHEMBL630262,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12252,1,,,50597,,,,BAO_0000218,CHEMBL630263,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12253,1,,,50597,,,,BAO_0000218,CHEMBL630264,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12254,1,,,50597,,,,BAO_0000218,CHEMBL630265,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12255,1,,,50597,,,,BAO_0000218,CHEMBL630266,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12256,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630267,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12257,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630268,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12258,1,,,50597,,,,BAO_0000218,CHEMBL630269,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12259,1,,,50597,,,,BAO_0000218,CHEMBL630270,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12260,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL630141,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12261,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL630142,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12262,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL630143,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12263,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL630144,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12264,1,,,50597,Prostate gland,2367.0,,BAO_0000218,CHEMBL630145,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12265,1,,,50597,Prostate gland,2367.0,,BAO_0000218,CHEMBL630146,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12266,1,,,50597,,,,BAO_0000218,CHEMBL630147,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12267,1,,,50597,,,,BAO_0000218,CHEMBL630148,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12268,1,,,50597,,,,BAO_0000218,CHEMBL630149,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12269,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL630150,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12270,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL630151,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12271,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL632031,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12272,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL632032,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12273,1,,,50597,,,,BAO_0000218,CHEMBL632033,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12274,1,,,50597,,,,BAO_0000218,CHEMBL632034,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12275,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL632035,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12276,1,,,50597,,,,BAO_0000218,CHEMBL632036,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14950,,N,12277,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL632037,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12278,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL632038,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12279,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL632039,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12280,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL632040,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12281,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL632041,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12282,1,,,50588,Blood,178.0,,BAO_0000218,CHEMBL632042,,"Concentration of compound in blood of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12283,1,,,50588,,,,BAO_0000218,CHEMBL632043,,"Concentration of compound in left ventricle of dog 1, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12284,1,,,50588,,,,BAO_0000218,CHEMBL632044,,"Concentration of compound in left ventricle of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12285,1,,,50588,Liver,2107.0,,BAO_0000218,CHEMBL632045,,"Concentration of compound in liver of dog 1, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12286,1,,,50588,Liver,2107.0,,BAO_0000218,CHEMBL632046,,"Concentration of compound in liver of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12287,1,,,50588,Lung,2048.0,,BAO_0000218,CHEMBL632047,,"Concentration of compound in lung of dog 1, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12288,1,,,50588,Lung,2048.0,,BAO_0000218,CHEMBL632048,,"Concentration of compound in lung of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12289,1,,,50588,Muscle tissue,2385.0,,BAO_0000218,CHEMBL632049,,"Concentration of compound in muscle of dog 1, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12290,1,,,50588,Muscle tissue,2385.0,,BAO_0000218,CHEMBL876418,,"Concentration of compound in muscle of dog 2, after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12291,1,,,50588,Spleen,2106.0,,BAO_0000218,CHEMBL632050,,"Concentration of compound in spleen of dog 1,after administering intravenously"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9614,,N,12292,1,,,50588,Spleen,2106.0,,BAO_0000218,CHEMBL632051,,"Concentration of compound in spleen of dog 2, after administering intravenously"
F,,,,,1,Autocuration,,10353,,U,12293,0,,,22224,,,,BAO_0000218,CHEMBL632052,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).
F,,,,,1,Autocuration,,10353,,U,12294,0,,,22224,,,,BAO_0000218,CHEMBL632053,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).
A,,,,,1,Autocuration,,10353,,U,12295,0,,,22224,,,,BAO_0000218,CHEMBL632054,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).
F,,,,,1,Autocuration,,10353,,U,12296,0,,,22224,,,,BAO_0000218,CHEMBL632055,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).
F,,,,,1,Autocuration,,10353,,U,12297,0,,,22224,,,,BAO_0000218,CHEMBL631181,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).
A,,,,,1,Autocuration,,9196,,U,12298,0,,,22224,,,,BAO_0000218,CHEMBL631182,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12299,0,,,22224,,,,BAO_0000218,CHEMBL631183,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr
A,,,,,1,Autocuration,,9196,,U,12300,0,,,22224,,,,BAO_0000218,CHEMBL631184,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12301,0,,,22224,,,,BAO_0000218,CHEMBL629774,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12302,0,,,22224,,,,BAO_0000218,CHEMBL629775,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12303,0,,,22224,,,,BAO_0000218,CHEMBL876549,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12304,0,,,22224,,,,BAO_0000218,CHEMBL628172,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12305,0,,,22224,,,,BAO_0000218,CHEMBL628173,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12306,0,,,22224,,,,BAO_0000218,CHEMBL628174,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12307,0,,,22224,,,,BAO_0000218,CHEMBL628175,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12308,0,,,22224,,,,BAO_0000218,CHEMBL628176,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12309,0,,,22224,,,,BAO_0000218,CHEMBL628177,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12310,0,,,22224,,,,BAO_0000218,CHEMBL628178,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12311,0,,,22224,,,,BAO_0000218,CHEMBL628179,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12312,0,,,22224,,,,BAO_0000218,CHEMBL628180,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced
A,,,,,1,Autocuration,,9196,,U,12313,0,,,22224,,,,BAO_0000218,CHEMBL628181,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr
A,,,,,1,Autocuration,,9196,,U,12314,0,,,22224,,,,BAO_0000218,CHEMBL628182,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12315,0,,,22224,,,,BAO_0000218,CHEMBL628183,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12316,0,,,22224,,,,BAO_0000218,CHEMBL628184,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined
A,,,,,1,Autocuration,,9196,,U,12317,0,,,22224,,,,BAO_0000218,CHEMBL628185,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12318,0,,,22224,,,,BAO_0000218,CHEMBL875617,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12319,0,,,22224,,,,BAO_0000218,CHEMBL628186,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined
A,,,,,1,Autocuration,,9196,,U,12320,0,,,22224,,,,BAO_0000218,CHEMBL628187,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12321,0,,,22224,,,,BAO_0000218,CHEMBL628188,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12322,0,,,22224,,,,BAO_0000218,CHEMBL628189,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12323,0,,,22224,,,,BAO_0000218,CHEMBL628190,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined
A,,,,,1,Autocuration,,9196,,U,12324,0,,,22224,,,,BAO_0000218,CHEMBL628191,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12325,0,,,22224,,,,BAO_0000218,CHEMBL626513,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12326,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626514,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12327,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626515,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12328,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626516,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12329,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626517,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12330,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626518,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12331,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626519,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12332,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626520,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12333,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626521,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12334,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626522,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12335,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626523,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12336,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626524,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12337,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626688,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12338,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626689,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12339,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626690,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12340,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626691,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12341,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL627319,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12342,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL624052,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8608,,N,12343,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL624053,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12344,1,,,50597,,,,BAO_0000218,CHEMBL624054,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12345,1,,,50597,,,,BAO_0000218,CHEMBL624055,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12346,1,,,50597,,,,BAO_0000218,CHEMBL624056,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12347,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL624057,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12348,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622281,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12349,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622282,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12350,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622283,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12351,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622284,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12352,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622285,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8085,,N,12353,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL622286,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats
P,,,,,1,Autocuration,,7657,,U,12354,0,,,22224,,,,BAO_0000100,CHEMBL622287,,Distribution coefficient (D %) between octanol and buffer of pH 7.4
A,Mus musculus,10090.0,,,1,Intermediate,,8935,,N,12355,1,,,50594,,,,BAO_0000218,CHEMBL622288,,Partition coefficient (logD7.4)
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12356,1,,,50594,,,,BAO_0000218,CHEMBL622289,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection"
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12357,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL622290,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection"
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12358,1,,,50594,,,,BAO_0000218,CHEMBL622291,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12359,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL622292,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12360,1,,,50594,,,,BAO_0000218,CHEMBL622293,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection"
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12361,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL622294,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection"
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,12362,1,,,50594,,,,BAO_0000218,CHEMBL622295,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13792,,N,12363,1,,,50597,Brain,955.0,,BAO_0000218,CHEMBL622296,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12364,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL874409,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12365,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622297,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12366,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622298,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12367,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622299,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12368,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622300,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12369,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622301,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12370,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622302,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12371,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622303,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12372,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622304,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12373,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622305,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12374,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL622306,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12375,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626864,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12376,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626865,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12377,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626866,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12378,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626867,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12379,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626868,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12380,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626869,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12381,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626870,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12382,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626871,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12383,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626872,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12384,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL632185,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14103,,N,12385,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL632186,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined
A,,,,,1,Autocuration,,12904,,U,12386,0,,,22224,,,,BAO_0000019,CHEMBL629310,,Amount of acetic acid produced by the compound
A,,,,,1,Autocuration,,12904,,U,12387,0,,,22224,,,,BAO_0000019,CHEMBL629311,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9663,,N,12388,1,,,50597,,,,BAO_0000218,CHEMBL629312,,Log of (Cbrain/Cblood) in rats
A,,,,,1,Autocuration,,7652,,U,12389,0,,,22224,,,,BAO_0000221,CHEMBL629313,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12390,0,,,22224,,,,BAO_0000221,CHEMBL629314,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12391,0,,,22224,,,,BAO_0000221,CHEMBL629315,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng)
B,,,,,1,Autocuration,,7652,,U,12392,0,,,22224,,,,BAO_0000219,CHEMBL629316,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12393,0,,,22224,,,,BAO_0000221,CHEMBL629317,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12394,0,,,22224,,,,BAO_0000019,CHEMBL629318,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12395,0,,,22224,,,,BAO_0000019,CHEMBL877497,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12396,0,,,22224,,,,BAO_0000019,CHEMBL629319,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12397,0,,,22224,,,,BAO_0000019,CHEMBL629320,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12398,0,,,22224,,,,BAO_0000019,CHEMBL629496,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12399,0,,,22224,,,,BAO_0000019,CHEMBL629497,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12400,0,,,22224,,,,BAO_0000019,CHEMBL629498,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12401,0,,,22224,,,,BAO_0000019,CHEMBL629499,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12402,0,,,22224,,,,BAO_0000019,CHEMBL629500,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12403,0,,,22224,,,,BAO_0000019,CHEMBL629501,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng)
A,,,,,1,Autocuration,,7652,,U,12404,0,,,22224,,,,BAO_0000019,CHEMBL629502,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng)
F,,,,,1,Autocuration,,8267,,U,12405,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629503,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8267,,N,12406,1,,,50588,,,,BAO_0000218,CHEMBL629504,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs
A,,,,,1,Autocuration,,14479,,U,12407,0,,,22224,,,,BAO_0000019,CHEMBL629505,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.
A,,,,,1,Autocuration,,17515,,U,12408,0,,,22224,,,,BAO_0000019,CHEMBL629506,,Compound was evaluated for total body clearance
A,,,,,1,Autocuration,,17515,,U,12409,0,,,22224,,,,BAO_0000019,CHEMBL629507,,Compound was evaluated for volume of distribution at steady state
A,,,,,1,Autocuration,,8142,,U,12410,0,,,22224,,,,BAO_0000019,CHEMBL877498,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.
A,,,,,1,Autocuration,,14849,,U,12411,0,,,22224,,,,BAO_0000019,CHEMBL629508,,Percentage of the diamine which is monoprotonated at pH 7.4
A,,,,,1,Autocuration,,7653,,U,12412,0,,,22224,,,,BAO_0000019,CHEMBL629509,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12413,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629510,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12414,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629511,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12415,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629512,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12416,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629513,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12417,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629514,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12418,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628447,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12419,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628448,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12420,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628449,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12421,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631119,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12422,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631120,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12423,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631121,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12424,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL874458,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12425,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631122,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12426,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631123,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12427,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631124,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12428,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631125,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12429,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631290,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12430,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631291,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12431,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631292,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12432,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631293,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12433,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631294,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12434,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631295,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12435,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631296,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8631,,N,12436,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631297,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes
A,,,,,1,Autocuration,,10263,,U,12437,0,,,22224,,,,BAO_0000218,CHEMBL631298,,Maximum biodistribution (Bmax) was determined.
A,Mus musculus,10090.0,,,1,Intermediate,,12364,,N,12438,1,,,50594,,,,BAO_0000218,CHEMBL631299,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice
A,Mus musculus,10090.0,,,1,Intermediate,,12364,,N,12439,1,,,50594,,,,BAO_0000218,CHEMBL631300,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice
A,Mus musculus,10090.0,,,1,Intermediate,,12364,,N,12440,1,,,50594,,,,BAO_0000218,CHEMBL631301,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice
A,Mus musculus,10090.0,,,1,Intermediate,,12364,,N,12441,1,,,50594,,,,BAO_0000218,CHEMBL630291,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice
A,,,,,1,Autocuration,,14793,,U,12442,0,,,22224,,,,BAO_0000218,CHEMBL630292,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally
A,,,,,1,Autocuration,,14793,,U,12443,0,,,22224,,,,BAO_0000218,CHEMBL630293,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously
A,,,,,1,Autocuration,,14793,,U,12444,0,,,22224,,,,BAO_0000218,CHEMBL630294,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12445,0,,,22224,,,,BAO_0000218,CHEMBL630295,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally
A,,,,,1,Autocuration,,14793,,U,12446,0,,,22224,,,,BAO_0000218,CHEMBL630296,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously
A,,,,,1,Autocuration,,14793,,U,12447,0,,,22224,,,,BAO_0000218,CHEMBL626782,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12448,0,,,22224,,,,BAO_0000218,CHEMBL626783,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12449,0,,,22224,,,,BAO_0000218,CHEMBL626784,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally
A,,,,,1,Autocuration,,14793,,U,12450,0,,,22224,,,,BAO_0000218,CHEMBL626785,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously
A,,,,,1,Autocuration,,14793,,U,12451,0,,,22224,,,,BAO_0000218,CHEMBL626786,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally
A,,,,,1,Autocuration,,9196,,U,12452,0,,,22224,,,,BAO_0000218,CHEMBL626787,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12453,0,,,22224,,,,BAO_0000218,CHEMBL626788,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined
A,,,,,1,Autocuration,,9196,,U,12454,0,,,22224,,,,BAO_0000218,CHEMBL625927,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12455,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625928,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12456,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625929,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12457,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625930,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12458,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625931,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12459,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627230,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12460,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627231,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12461,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627232,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12462,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627233,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12463,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL875470,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12464,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627234,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12465,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627235,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12466,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627236,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12467,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627237,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12468,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627238,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12469,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627239,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12470,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627240,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12471,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627241,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12472,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627242,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12473,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627243,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12474,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627244,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12475,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627245,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12476,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627246,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12477,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627247,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12478,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627248,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12479,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627249,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12480,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625569,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12481,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625570,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12482,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625571,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12483,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625572,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12484,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625573,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12485,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625574,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12486,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626245,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12487,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626246,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,,,,,1,Autocuration,,9196,,U,12488,0,,,22224,,,,BAO_0000218,CHEMBL626247,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12489,0,,,22224,,,,BAO_0000218,CHEMBL626248,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12490,0,,,22224,,,,BAO_0000218,CHEMBL626249,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12491,0,,,22224,,,,BAO_0000218,CHEMBL626420,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12492,0,,,22224,,,,BAO_0000218,CHEMBL626421,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr
A,,,,,1,Autocuration,,9196,,U,12493,0,,,22224,,,,BAO_0000218,CHEMBL626422,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12494,0,,,22224,,,,BAO_0000218,CHEMBL626423,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12495,0,,,22224,,,,BAO_0000218,CHEMBL626424,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12023,,N,12496,1,,,50588,,,,BAO_0000218,CHEMBL626425,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12023,,N,12497,1,,,50597,,,,BAO_0000218,CHEMBL875476,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12023,,N,12498,1,,,100710,,,,BAO_0000218,CHEMBL626426,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously
P,,,,,1,Autocuration,,10580,,U,12499,0,,,22224,,,,BAO_0000100,CHEMBL626427,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol
P,,,,,1,Autocuration,,10580,,U,12500,0,,,22224,,,,BAO_0000100,CHEMBL626428,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol
A,,,,,1,Autocuration,,16032,,U,12501,0,,,22224,,,,BAO_0000019,CHEMBL626429,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg
A,,,,,1,Autocuration,,16032,,U,12502,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL625025,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12503,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625026,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12504,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625027,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12505,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL874410,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12506,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625028,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12507,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625029,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12508,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625030,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12509,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625031,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12510,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625032,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12511,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625033,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12512,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL625034,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12513,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624872,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12514,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624873,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12515,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624874,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12516,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624875,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12517,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624876,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12518,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624877,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12519,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624878,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12520,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624879,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12521,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624880,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12522,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624881,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12523,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL624882,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12524,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624883,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12525,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624884,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12526,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624885,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12527,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624886,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12528,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624887,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12529,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624888,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12530,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624889,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12531,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL624890,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12532,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL621964,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12533,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL621965,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12534,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL621966,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12535,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL621967,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12536,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL622164,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,,,,,1,Autocuration,,7653,,U,12537,0,,,22224,,,,BAO_0000019,CHEMBL623097,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids)
A,,,,,1,Autocuration,,7653,,U,12538,0,,,22224,,,,BAO_0000019,CHEMBL623098,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein)
A,,,,,1,Autocuration,,7653,,U,12539,0,,,22224,,,,BAO_0000019,CHEMBL623099,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble
A,,,,,1,Autocuration,,7653,,U,12540,0,,,22224,,,,BAO_0000019,CHEMBL623100,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12541,1,,,50597,,,,BAO_0000218,CHEMBL628673,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12542,1,,,50597,,,,BAO_0000218,CHEMBL628674,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12543,1,,,50597,,,,BAO_0000218,CHEMBL628675,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12544,1,,,50597,,,,BAO_0000218,CHEMBL627644,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12545,1,,,50597,,,,BAO_0000218,CHEMBL627645,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12546,1,,,50597,,,,BAO_0000218,CHEMBL627646,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12547,1,,,50597,,,,BAO_0000218,CHEMBL627647,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9104,,N,12548,1,,,50597,,,,BAO_0000218,CHEMBL627648,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12902,,N,12549,1,,,50597,,,,BAO_0000218,CHEMBL627649,,Free level in rat plasma
A,,,,,1,Autocuration,,6614,,U,12550,0,,,22224,,,,BAO_0000019,CHEMBL628313,,Level reaching in blood plasma of rat or human was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9663,,N,12551,1,,,50597,,,,BAO_0000218,CHEMBL628314,,Log (Cbrain/Cblood) in rats
A,,,,,1,Autocuration,,17658,,U,12552,0,,,22224,,,,BAO_0000019,CHEMBL628315,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity
A,,,,,1,Autocuration,,17658,,U,12553,0,,,22224,,,,BAO_0000019,CHEMBL628316,,Mean percentage of compound transport through membrane; expressed as membrane transport
A,,,,,1,Autocuration,,14314,,U,12554,0,,,22224,,,,BAO_0000218,CHEMBL628317,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound
A,,,,,1,Autocuration,,7385,,U,12555,0,,,22224,,,,BAO_0000019,CHEMBL628473,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5
A,,,,,1,Autocuration,,7385,,U,12556,0,,,22224,,,,BAO_0000019,CHEMBL628474,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined"
A,,,,,1,Autocuration,,7385,,U,12557,0,,,22224,,,,BAO_0000019,CHEMBL628475,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5
A,,,,,1,Autocuration,,1329,,U,12558,0,,,22224,,,,BAO_0000019,CHEMBL628476,,Net water uptake by a carrier mediated transport (%cm) mechanism
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,12559,0,,,22224,,,,BAO_0000218,CHEMBL628477,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12187,,N,12560,1,,,50506,,,,BAO_0000218,CHEMBL628478,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret
A,Mustela putorius furo,9669.0,,,1,Intermediate,,12187,,N,12561,1,,,50506,,,,BAO_0000218,CHEMBL628479,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay"
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,12562,0,,,22224,,,,BAO_0000218,CHEMBL628480,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,12563,0,,,22224,,,,BAO_0000218,CHEMBL628481,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12187,,N,12564,1,,,50597,,,,BAO_0000218,CHEMBL628482,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12187,,N,12565,1,,,50597,,,,BAO_0000218,CHEMBL628483,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9278,,N,12566,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628484,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9278,,N,12567,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628485,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,9278,,N,12568,1,,,100710,Plasma,1969.0,,BAO_0000218,CHEMBL628486,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)"
A,Homo sapiens,9606.0,,,1,Intermediate,,9278,,N,12569,1,,,50587,Plasma,1969.0,,BAO_0000218,CHEMBL628487,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9278,,N,12570,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628488,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9278,,N,12571,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628489,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9278,,N,12572,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628490,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,12573,1,,,100710,,,,BAO_0000218,CHEMBL628491,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,12574,1,,,100710,,,,BAO_0000218,CHEMBL877507,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay
A,,,,,1,Autocuration,,12186,,U,12575,0,,,22224,,,,BAO_0000218,CHEMBL628492,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay
A,Simiiformes,314293.0,,,1,Autocuration,,12041,,U,12576,0,,,22224,,,,BAO_0000019,CHEMBL628493,,% metabolized in monkey S-9 after 2 hours (10 ug/mL)
A,Simiiformes,314293.0,,,1,Autocuration,,12041,,U,12577,0,,,22224,,,,BAO_0000019,CHEMBL628494,,% metabolized in monkey S-9 after 2 hours (1 ug/ml)
A,Simiiformes,314293.0,,,1,Autocuration,,12041,,U,12578,0,,,22224,,,,BAO_0000019,CHEMBL628495,,% metabolized in monkey S-9 after 2 hours (10 ug/ml)
A,Homo sapiens,9606.0,,,1,Intermediate,,6737,,N,12579,1,,,50587,,,,BAO_0000218,CHEMBL628496,,Permeability in Caco-2 assay at 10E-6
A,,,,,1,Autocuration,,13758,,U,12580,0,,,22224,Brain,955.0,,BAO_0000218,CHEMBL628497,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain
A,,,,,1,Autocuration,,13758,,U,12581,0,,,22224,Brain,955.0,,BAO_0000218,CHEMBL628498,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain
A,,,,,1,Autocuration,,5676,,U,12582,0,,,22224,,,,BAO_0000019,CHEMBL628499,,Plasma protein binding was determined
A,,,,,1,Autocuration,,14793,,U,12583,0,,,22224,,,,BAO_0000218,CHEMBL627656,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12584,0,,,22224,,,,BAO_0000218,CHEMBL627657,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally
A,,,,,1,Autocuration,,14793,,U,12585,0,,,22224,,,,BAO_0000218,CHEMBL626808,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously
A,,,,,1,Autocuration,,14793,,U,12586,0,,,22224,,,,BAO_0000218,CHEMBL626809,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12587,0,,,22224,,,,BAO_0000218,CHEMBL626810,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12588,0,,,22224,,,,BAO_0000218,CHEMBL626811,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally
A,,,,,1,Autocuration,,14793,,U,12589,0,,,22224,,,,BAO_0000218,CHEMBL874465,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously
A,,,,,1,Autocuration,,14793,,U,12590,0,,,22224,,,,BAO_0000218,CHEMBL626812,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12591,0,,,22224,,,,BAO_0000218,CHEMBL626813,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally
A,,,,,1,Autocuration,,14793,,U,12592,0,,,22224,,,,BAO_0000218,CHEMBL626814,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally
A,,,,,1,Autocuration,,14000,,U,12593,0,,,22224,,,,BAO_0000019,CHEMBL626815,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.
A,,,,,1,Autocuration,,5948,,U,12594,0,,,22224,,,,BAO_0000019,CHEMBL628566,,Partition coefficient (logP)
P,,,,,1,Autocuration,,13824,,U,12595,0,,,22229,,,,BAO_0000100,CHEMBL628567,,Calculated partition coefficient (clogP) (CLOGP3 V3.4)
P,,,,,1,Autocuration,,10778,,U,12596,0,,,22229,,,,BAO_0000100,CHEMBL628568,,Calculated partition coefficient (clogP)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17237,,N,12597,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628569,,C max in dog
A,Cavia porcellus,10141.0,,,1,Intermediate,,17237,,N,12598,1,,,50512,,,In vivo,BAO_0000218,CHEMBL628570,,C max in guinea pig
A,,,,,1,Autocuration,,2809,,U,12599,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628571,,C max value was evaluated
A,,,,,1,Autocuration,,11954,,U,12600,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628572,,Cmax value after oral dose of 0.1 mg//kg
A,,,,,1,Autocuration,,11954,,U,12601,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628573,,Cmax value after oral dose of 0.3 mg/kg
A,,,,,1,Autocuration,,11954,,U,12602,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628574,,Cmax value after oral dose of 1 mg/kg
A,,,,,1,Autocuration,,11954,,U,12603,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628575,,Cmax value after oral dose of 10 mg/kg
A,,,,,1,Autocuration,,11954,,U,12604,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628576,,Cmax value after oral dose of 23.4 mg/kg
A,,,,,1,Autocuration,,11954,,U,12605,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628577,,Cmax value after oral dose of 3 mg/kg
A,,,,,1,Autocuration,,11954,,U,12606,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628578,,Cmax value after oral dose of 3.87 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12768,,N,12607,1,,,50588,,,In vivo,BAO_0000218,CHEMBL874466,,Cmax value in female Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12768,,N,12608,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628579,,Cmax value in male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12780,,N,12609,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628580,,Cmax value in rat plasma when administered 20 mg/kg perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,12610,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628581,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,12611,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL628582,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17025,,N,12612,1,,,50588,,,,BAO_0000218,CHEMBL628583,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.
A,Simiiformes,314293.0,,,1,Autocuration,,17025,,U,12613,0,,,22224,,,,BAO_0000218,CHEMBL625782,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,12614,1,,,50592,,,,BAO_0000218,CHEMBL625783,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17025,,N,12615,1,,,50597,,,,BAO_0000218,CHEMBL625784,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.
A,Macaca mulatta,9544.0,,,1,Intermediate,,4236,,N,12616,1,,,50797,Plasma,1969.0,,BAO_0000218,CHEMBL625785,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15791,,N,12617,1,,,50597,,,,BAO_0000218,CHEMBL625786,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg
A,,,,,1,Autocuration,,11149,,U,12618,0,,,22224,,,,BAO_0000019,CHEMBL874467,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,12619,1,,,50588,,,,BAO_0000218,CHEMBL625787,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )"
A,Human immunodeficiency virus,12721.0,,,1,Intermediate,,15778,,N,12620,1,,,50677,,,,BAO_0000218,CHEMBL625964,,cytotoxicity against HIV protease enzyme.
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,12621,1,,,50594,,,,BAO_0000218,CHEMBL625965,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose
A,Mus musculus,10090.0,,,1,Intermediate,,12745,,N,12622,1,,,50594,,,,BAO_0000218,CHEMBL625966,,Apparent clearance in mice after oral administration of 100 mg/kg of dose
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13941,,N,12623,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625967,,The plasma clearance in dog.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13941,,N,12624,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625968,,The plasma clearance in rat.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16449,,N,12625,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625969,,Clearance from plasma in male Sprague-Dawley rats
A,Macaca fascicularis,9541.0,,,1,Intermediate,,16449,,N,12626,1,,,100710,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625970,,Clearance from plasma in male cynomolgus monkeys
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,12627,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625971,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,12628,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625972,,Clearance of compound in dog plasma
A,Homo sapiens,9606.0,,,1,Intermediate,,14224,,N,12629,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625973,,Clearance of compound in human plasma
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14317,,N,12630,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625974,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14317,,N,12631,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625975,,Clearance of compound when administered intravenously as an individual dose to a single dog.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14224,,N,12632,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625976,,"Clearance (10 mg/kg, intravenously) in dog plasma"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17237,,N,12633,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625977,,Clearance value in dog
A,Cavia porcellus,10141.0,,,1,Intermediate,,17237,,N,12634,1,,,50512,,,In vivo,BAO_0000218,CHEMBL625978,,Clearance value in guinea pig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14187,,N,12635,1,,,50597,,,In vivo,BAO_0000218,CHEMBL874468,,Clearance values in rats after iv administration.
A,,,,,1,Autocuration,,4806,,U,12636,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625421,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,15025,,N,12637,1,,,50592,,,In vivo,BAO_0000218,CHEMBL625422,,In vivo clearance (5 mg/kg) was determined in rabbits
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13197,,N,12638,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625423,,Plasma Clearance rate was determined for the compound in rats
A,Saimiri,9520.0,,,1,Autocuration,,13197,,U,12639,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625424,,Plasma Clearance rate was determined for the compound in squirrel monkeys
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13960,,N,12640,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625425,,Plasma clearance in rat
A,,,,,1,Autocuration,,17820,,U,12641,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625426,,Plasma clearance of the compound
A,Cavia porcellus,10141.0,,,1,Intermediate,,14706,,N,12642,1,,,50512,,,In vivo,BAO_0000218,CHEMBL625427,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration
A,Cavia porcellus,10141.0,,,1,Intermediate,,14706,,N,12643,1,,,50512,,,In vivo,BAO_0000218,CHEMBL625428,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration
A,,,,,1,Autocuration,,6504,,U,12644,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625429,,Plasma clearance was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14925,,N,12645,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625430,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13197,,N,12646,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625431,,Plasma clearance rate was determined for the compound in rats
A,Saimiri,9520.0,,,1,Autocuration,,13197,,U,12647,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627307,,Plasma clearance rate was determined for the compound in squirrel monkeys
A,,,,,1,Autocuration,,3437,,U,12648,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627308,,Slow clearance (CL) was determined
A,,,,,1,Autocuration,,9196,,U,12649,0,,,22224,,,,BAO_0000218,CHEMBL627309,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12650,0,,,22224,,,,BAO_0000218,CHEMBL627310,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced
A,,,,,1,Autocuration,,9196,,U,12651,0,,,22224,,,,BAO_0000218,CHEMBL627311,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12652,0,,,22224,,,,BAO_0000218,CHEMBL627312,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12653,0,,,22224,,,,BAO_0000218,CHEMBL627313,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr
A,,,,,1,Autocuration,,9196,,U,12654,0,,,22224,,,,BAO_0000218,CHEMBL627314,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12655,0,,,22224,,,,BAO_0000218,CHEMBL627315,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12656,0,,,22224,,,,BAO_0000218,CHEMBL627316,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12657,0,,,22224,,,,BAO_0000218,CHEMBL627317,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr
A,,,,,1,Autocuration,,9196,,U,12658,0,,,22224,,,,BAO_0000218,CHEMBL627318,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12659,0,,,22224,,,,BAO_0000218,CHEMBL627999,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12660,0,,,22224,,,,BAO_0000218,CHEMBL628000,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr
A,,,,,1,Autocuration,,9196,,U,12661,0,,,22224,,,,BAO_0000218,CHEMBL628001,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr
A,,,,,1,Autocuration,,9196,,U,12662,0,,,22224,,,,BAO_0000218,CHEMBL628002,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12663,0,,,22224,,,,BAO_0000218,CHEMBL625610,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12664,0,,,22224,,,,BAO_0000218,CHEMBL625611,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12665,0,,,22224,,,,BAO_0000218,CHEMBL625612,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr
A,,,,,1,Autocuration,,9196,,U,12666,0,,,22224,,,,BAO_0000218,CHEMBL625613,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr
A,,,,,1,Autocuration,,9196,,U,12667,0,,,22224,,,,BAO_0000218,CHEMBL875479,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr
A,,,,,1,Autocuration,,9196,,U,12668,0,,,22224,,,,BAO_0000218,CHEMBL625614,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr
A,,,,,1,Autocuration,,9196,,U,12669,0,,,22224,,,,BAO_0000218,CHEMBL625615,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr
A,,,,,1,Autocuration,,9196,,U,12670,0,,,22224,,,,BAO_0000218,CHEMBL626302,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12671,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626303,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8374,,N,12672,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL627420,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12673,1,,,50597,,,,BAO_0000218,CHEMBL627421,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12674,1,,,50597,,,,BAO_0000218,CHEMBL625695,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12675,1,,,50597,,,,BAO_0000218,CHEMBL625696,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12676,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL875606,,Distribution of compound in mice brain was measured after 1 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12677,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL625697,,Distribution of compound in mice brain was measured after 24 hr r
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12678,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL625698,,Distribution of compound in mice brain was measured after 2 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12679,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL625699,,Distribution of compound in mice brain was measured after 3 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12680,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL625700,,Distribution of compound in mice brain was measured after 6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12681,1,,,50594,,,,BAO_0000218,CHEMBL625701,,Distribution of compound in mice liver was measured after 1 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12682,1,,,50594,,,,BAO_0000218,CHEMBL625702,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12683,1,,,50594,,,,BAO_0000218,CHEMBL625703,,Distribution of compound in mice liver was measured after 2 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12684,1,,,50594,,,,BAO_0000218,CHEMBL625704,,Distribution of compound in mice liver was measured after 3 hr
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,12685,1,,,50594,,,,BAO_0000218,CHEMBL625705,,Distribution of compound in mice liver was measured after 6 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12686,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL625706,,Distribution in dog adrenal medulla 30 min after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12687,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL625707,,Distribution in dog adrenal medulla 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12688,1,,,50588,,,,BAO_0000218,CHEMBL625708,,Distribution in female dog Ovary 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12689,1,,,50588,,,,BAO_0000218,CHEMBL625709,,Distribution in female dog Ovary 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12690,1,,,50588,,,,BAO_0000218,CHEMBL624180,,Distribution in female dog adipose 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12691,1,,,50588,,,,BAO_0000218,CHEMBL624181,,Distribution in female dog adipose 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12692,1,,,50588,Adrenal cortex,1235.0,,BAO_0000218,CHEMBL624182,,Distribution in female dog adrenal cortex 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12693,1,,,50588,Adrenal cortex,1235.0,,BAO_0000218,CHEMBL624183,,Distribution in female dog adrenal cortex 72 hours after administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12694,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624184,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12695,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL877489,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12696,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624185,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12697,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624186,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12698,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624187,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12699,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL624188,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12700,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624189,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12701,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624190,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12702,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624191,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12703,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624192,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12704,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624193,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12705,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624194,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12706,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624891,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12707,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624892,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12708,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL624893,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12709,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL627632,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12710,1,,,50597,,,,BAO_0000218,CHEMBL627633,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12711,1,,,50597,,,,BAO_0000218,CHEMBL627634,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12712,1,,,50597,,,,BAO_0000218,CHEMBL627635,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12713,1,,,50597,,,,BAO_0000218,CHEMBL627636,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12714,1,,,50597,,,,BAO_0000218,CHEMBL626816,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12715,1,,,50597,,,,BAO_0000218,CHEMBL626817,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12716,1,,,50597,,,,BAO_0000218,CHEMBL626818,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12717,1,,,50597,,,,BAO_0000218,CHEMBL626819,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12718,1,,,50597,,,,BAO_0000218,CHEMBL626820,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12719,1,,,50597,,,,BAO_0000218,CHEMBL626821,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12720,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626822,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12721,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626823,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12722,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626824,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12723,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626825,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12724,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626826,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12725,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626827,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12726,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626828,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12727,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626829,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12728,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL626830,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12729,1,,,50597,,,,BAO_0000218,CHEMBL627150,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12730,1,,,50597,,,,BAO_0000218,CHEMBL627151,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12731,1,,,50597,,,,BAO_0000218,CHEMBL627152,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12732,1,,,50597,,,,BAO_0000218,CHEMBL627153,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-
A,,,,,1,Autocuration,,12904,,U,12733,0,,,22224,,,,BAO_0000019,CHEMBL627154,,Rate of acetate production by the compound was determined
A,,,,,1,Autocuration,,12904,,U,12734,0,,,22224,,,,BAO_0000019,CHEMBL627155,,Rate of acetate production by the compound was determined; Not determined
A,,,,,1,Autocuration,,3730,,U,12735,0,,,22224,,,,BAO_0000019,CHEMBL627156,,Rate of hydrolysis of nitrocefin by compound was evaluated in water
A,,,,,1,Autocuration,,3627,,U,12736,0,,,22224,,,,BAO_0000019,CHEMBL627157,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,13799,,N,12737,1,,,50592,,,,BAO_0000218,CHEMBL627158,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,13799,,N,12738,1,,,50592,Plasma,1969.0,,BAO_0000218,CHEMBL627159,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration
A,Mus musculus,10090.0,,,1,Intermediate,,13799,,N,12739,1,,,50594,,,,BAO_0000218,CHEMBL627160,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13799,,N,12740,1,,,50597,,,,BAO_0000218,CHEMBL628540,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13799,,N,12741,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628541,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13799,,N,12742,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628542,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration
P,,,,,1,Autocuration,,6629,,U,12743,0,,,22229,,,,BAO_0000100,CHEMBL628543,,Solubility after at a pH 1.2
P,,,,,1,Autocuration,,6629,,U,12744,0,,,22229,,,,BAO_0000100,CHEMBL628544,,Solubility after at pH 1.2
P,,,,,1,Autocuration,,6629,,U,12745,0,,,22229,,,,BAO_0000100,CHEMBL628545,,Solubility after injection of water
A,,,,,1,Autocuration,,14000,,U,12746,0,,,22224,,,,BAO_0000019,CHEMBL628546,,Statistical significance of IC 50 values; Expressed as R value
A,,,,,1,Autocuration,,8267,,U,12747,0,,,22224,,,,BAO_0000019,CHEMBL874455,,Systemic availability with respect to methyldopa was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13799,,N,12748,1,,,50597,,,,BAO_0000218,CHEMBL628547,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13799,,N,12749,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL628548,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12750,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628549,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12751,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628550,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12752,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628551,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12753,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628552,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12754,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628553,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12755,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628554,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12756,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628555,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12757,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628556,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12758,1,,,50592,Kidney,2113.0,,BAO_0000218,CHEMBL628557,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12759,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628558,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12760,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628559,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12761,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628560,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12762,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL874456,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12763,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628561,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12764,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL628562,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12765,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628563,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12766,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628564,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12767,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL628565,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12768,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL631248,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12769,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL631249,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12770,1,,,50592,Kidney,2113.0,,BAO_0000218,CHEMBL627214,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12771,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL874591,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12772,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL627215,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12773,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL625471,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12774,1,,,50592,,,,BAO_0000218,CHEMBL625472,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12775,1,,,50592,,,,BAO_0000218,CHEMBL625473,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13317,,N,12776,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625474,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15341,,N,12777,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625475,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,12778,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625476,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,12779,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625477,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15341,,N,12780,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625478,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12801,,N,12781,1,,,50597,esophageal tunica muscularis mucosae,,In vitro,BAO_0000218,CHEMBL625479,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12801,,N,12782,1,,,50597,esophageal tunica muscularis mucosae,,In vitro,BAO_0000218,CHEMBL625480,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14856,,N,12783,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625481,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,12784,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625482,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,12785,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625483,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,12786,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625484,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14062,,N,12787,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625485,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,12788,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625486,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,12789,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625487,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,12790,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625488,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,12791,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625489,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,12792,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625490,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14346,,N,12793,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625491,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14346,,N,12794,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625492,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats
A,Homo sapiens,9606.0,,,1,Intermediate,,15711,,N,12795,1,,,50587,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625493,,plasma clearance in human
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,12796,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625494,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,12797,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625495,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14886,,N,12798,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625496,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg
P,,,,,1,Autocuration,,4115,,U,12799,0,,,22229,,,,BAO_0000100,CHEMBL625497,,1-Octanol/water partition coefficient measured at 7.4
P,,,,,1,Autocuration,,13733,,U,12800,0,,,22229,,,,BAO_0000100,CHEMBL625498,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,12102,,U,12801,0,,,22224,,,,BAO_0000019,CHEMBL625499,,Partition coefficient (logP)
P,,,,,1,Autocuration,,12676,,U,12802,0,,,22229,,,,BAO_0000100,CHEMBL625500,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13733,,U,12803,0,,,22229,,,,BAO_0000100,CHEMBL625501,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13740,,U,12804,0,,,22229,,,,BAO_0000100,CHEMBL625502,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,12766,,U,12805,0,,,22229,,,,BAO_0000100,CHEMBL625503,,Calculated partition coefficient (clogP) (relative to BAY K 8644)
P,,,,,1,Autocuration,,2764,,U,12806,0,,,22229,,,,BAO_0000100,CHEMBL625504,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,12355,,U,12807,0,,,22229,,,,BAO_0000100,CHEMBL625505,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,11314,,U,12808,0,,,22229,,,,BAO_0000100,CHEMBL625506,,Calculated partition coefficient of the compound
A,,,,,1,Autocuration,,12706,,U,12809,0,,,22224,,,,BAO_0000019,CHEMBL625507,,Partition coefficient (logP)
P,,,,,1,Autocuration,,12645,,U,12810,0,,,22229,,,,BAO_0000100,CHEMBL625508,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13668,,U,12811,0,,,22229,,,,BAO_0000100,CHEMBL625509,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,12819,,U,12812,0,,,22229,,,,BAO_0000100,CHEMBL625510,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13668,,U,12813,0,,,22229,,,,BAO_0000100,CHEMBL883125,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13017,,U,12814,0,,,22229,,,,BAO_0000100,CHEMBL625511,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,2448,,U,12815,0,,,22224,,,,BAO_0000019,CHEMBL874650,,Partition coefficient of the compound
A,,,,,1,Autocuration,,11526,,U,12816,0,,,22224,,,,BAO_0000019,CHEMBL625512,,Partition coefficient of the compound
A,,,,,1,Autocuration,,12426,,U,12817,0,,,22224,,,,BAO_0000019,CHEMBL625513,,Partition coefficient of compound was determined
A,,,,,1,Autocuration,,2448,,U,12818,0,,,22224,,,,BAO_0000019,CHEMBL625514,,Partition coefficient was determined
P,,,,,1,Autocuration,,12001,,U,12819,0,,,22229,,,,BAO_0000100,CHEMBL625515,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,12426,,U,12820,0,,,22229,,,,BAO_0000100,CHEMBL625516,,partition coefficient of compound was determined
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13204,,N,12821,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625517,,The total body administered intravenously in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13204,,N,12822,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625518,,The total body administered intravenously in rats
A,Mus musculus,10090.0,,,1,Intermediate,,13889,,N,12823,1,,,50594,,,,BAO_0000218,CHEMBL625519,,Time taken for the administration to female NIH mice weighing 25-30 g.
A,,,,,1,Autocuration,,13889,,U,12824,0,,,22224,,,,BAO_0000019,CHEMBL625520,,Time taken for the administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,17025,,N,12825,1,,,50588,,,In vivo,BAO_0000218,CHEMBL874651,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.
A,Simiiformes,314293.0,,,1,Autocuration,,17025,,U,12826,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625521,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,12827,1,,,50592,,,In vivo,BAO_0000218,CHEMBL623171,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,17025,,N,12828,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623853,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.
A,,,,,1,Autocuration,,15067,,U,12829,0,,,22224,,,,BAO_0000019,CHEMBL623854,,Plasma clearance for the compound was determined.
P,,,,,1,Autocuration,,3091,,U,12830,0,,,22224,,,,BAO_0000100,CHEMBL874405,,CLog P value of the compound
P,,,,,1,Autocuration,,15592,,U,12831,0,,,22229,,,,BAO_0000100,CHEMBL623855,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14738,,U,12832,0,,,22229,,,,BAO_0000100,CHEMBL623856,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14738,,U,12833,0,,,22224,,,,BAO_0000100,CHEMBL623857,,ClogP value of the compound; nd ='no data'
P,,,,,1,Autocuration,,14738,,U,12834,0,,,22224,,,,BAO_0000100,CHEMBL623858,,ClogP value of the compound; nd ='not determined'
P,,,,,1,Autocuration,,6076,,U,12835,0,,,22224,,,,BAO_0000100,CHEMBL623859,,CLog P was determined
P,,,,,1,Autocuration,,17840,,U,12836,0,,,22229,,,,BAO_0000100,CHEMBL839829,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,13589,,U,12837,0,,,22224,,,,BAO_0000019,CHEMBL623860,,CLogP was calculated
A,,,,,1,Autocuration,,17655,,U,12838,0,,,22224,,,,BAO_0000019,CHEMBL623861,,CLogP value was determined
A,,,,,1,Autocuration,,5867,,U,12839,0,,,22224,,,,BAO_0000019,CHEMBL623862,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.
P,,,,,1,Autocuration,,5867,,U,12840,0,,,22229,,,,BAO_0000100,CHEMBL874406,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,10783,,U,12841,0,,,22229,,,,BAO_0000100,CHEMBL623863,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14849,,U,12842,0,,,22229,,,,BAO_0000100,CHEMBL624021,,Calculated partition coefficient (clogP)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12843,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL624022,,Distribution in female dog adrenal medulla 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12844,1,,,50588,Adrenal medulla,1236.0,,BAO_0000218,CHEMBL624023,,Distribution in female dog adrenal medulla 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12845,1,,,50588,,,,BAO_0000218,CHEMBL624024,,Distribution in female dog bile 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12846,1,,,50588,,,,BAO_0000218,CHEMBL624025,,Distribution in female dog bile 72 hr after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12847,1,,,50588,,,,BAO_0000218,CHEMBL624026,,Distribution in female dog blood 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12848,1,,,50588,,,,BAO_0000218,CHEMBL624027,,Distribution in female dog blood 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12849,1,,,50588,,,,BAO_0000218,CHEMBL624028,,Distribution in female dog heart 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12850,1,,,50588,,,,BAO_0000218,CHEMBL624029,,Distribution in female dog heart 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12851,1,,,50588,,,,BAO_0000218,CHEMBL624030,,Distribution in female dog kidney 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12852,1,,,50588,,,,BAO_0000218,CHEMBL624031,,Distribution in female dog kidney 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12853,1,,,50588,Intestine,160.0,,BAO_0000218,CHEMBL624032,,Distribution in female dog large intestine 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12854,1,,,50588,Intestine,160.0,,BAO_0000218,CHEMBL874407,,Distribution in female dog large intestine 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12855,1,,,50588,,,,BAO_0000218,CHEMBL624033,,Distribution in female dog liver 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12856,1,,,50588,,,,BAO_0000218,CHEMBL624034,,Distribution in female dog liver 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12857,1,,,50588,,,,BAO_0000218,CHEMBL624035,,Distribution in female dog lung 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12858,1,,,50588,,,,BAO_0000218,CHEMBL624036,,Distribution in female dog lung 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12859,1,,,50588,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624037,,Distribution in female dog muscle 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12860,1,,,50588,Muscle tissue,2385.0,,BAO_0000218,CHEMBL624038,,Distribution in female dog muscle 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12861,1,,,50588,,,,BAO_0000218,CHEMBL624039,,Distribution in female dog pancreas 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12862,1,,,50588,,,,BAO_0000218,CHEMBL624040,,Distribution in female dog pancreas 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12863,1,,,50588,Intestine,160.0,,BAO_0000218,CHEMBL624041,,Distribution in female dog small intestine 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12864,1,,,50588,Intestine,160.0,,BAO_0000218,CHEMBL624042,,Distribution in female dog small intestine 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12865,1,,,50588,Spleen,2106.0,,BAO_0000218,CHEMBL624043,,Distribution in female dog spleen 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12866,1,,,50588,Spleen,2106.0,,BAO_0000218,CHEMBL624044,,Distribution in female dog spleen 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12867,1,,,50588,Stomach,945.0,,BAO_0000218,CHEMBL624045,,Distribution in female dog stomach 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12868,1,,,50588,Stomach,945.0,,BAO_0000218,CHEMBL624046,,Distribution in female dog stomach 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12869,1,,,50588,Thyroid gland,2046.0,,BAO_0000218,CHEMBL624047,,Distribution in female dog thyroid 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12870,1,,,50588,Thyroid gland,2046.0,,BAO_0000218,CHEMBL624048,,Distribution in female dog thyroid 72 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12871,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL874408,,Distribution in female dog urine 24 hours after administration.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8170,,N,12872,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL624049,,Distribution in female dog urine 72 hr after administration.
A,,,,,1,Autocuration,,14283,,U,12873,0,,,22224,Plasma,1969.0,,BAO_0000218,CHEMBL624050,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg
A,,,,,1,Autocuration,,5623,,U,12874,0,,,22224,,,,BAO_0000019,CHEMBL624051,,Plasma concentration at 7 hr after intravenous dosing
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12875,1,,,50597,,,,BAO_0000218,CHEMBL623278,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12876,1,,,50597,,,,BAO_0000218,CHEMBL623279,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12877,1,,,50597,,,,BAO_0000218,CHEMBL623280,,Plasma concentration of 3 mg/kg iv after 1 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12878,1,,,50597,,,,BAO_0000218,CHEMBL623963,,Plasma concentration of 3 mg/kg iv after 2 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12879,1,,,50597,,,,BAO_0000218,CHEMBL623964,,Plasma concentration of 3 mg/kg iv after 4 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12880,1,,,50597,,,,BAO_0000218,CHEMBL623965,,Plasma concentration of 3 mg/kg iv after 6 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12881,1,,,50597,,,,BAO_0000218,CHEMBL623966,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12882,1,,,50597,,,,BAO_0000218,CHEMBL874415,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12883,1,,,50597,,,,BAO_0000218,CHEMBL623967,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12884,1,,,50597,,,,BAO_0000218,CHEMBL623968,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12885,1,,,50597,,,,BAO_0000218,CHEMBL623969,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12886,1,,,50597,,,,BAO_0000218,CHEMBL628409,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12887,1,,,50597,,,,BAO_0000218,CHEMBL628410,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12888,1,,,50597,,,,BAO_0000218,CHEMBL628411,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,12889,1,,,50597,,,,BAO_0000218,CHEMBL628412,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr
A,,,,,1,Autocuration,,12553,,U,12890,0,,,22224,,,,BAO_0000019,CHEMBL628413,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts
A,,,,,1,Autocuration,,14548,,U,12891,0,,,22224,Plasma,1969.0,,BAO_0000019,CHEMBL628414,,The concentration in plasmat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12892,1,,,50597,,,,BAO_0000218,CHEMBL628415,,Tissue level at 10 mg/kg/po in wistar rats in blood
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12893,1,,,50597,,,,BAO_0000218,CHEMBL628416,,Tissue level at 10 mg/kg/po in wistar rats in brown fat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12894,1,,,50597,,,,BAO_0000218,CHEMBL628417,,Tissue level at 10 mg/kg/po in wistar rats in heart
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12895,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL874908,,Tissue level at 10 mg/kg/po in wistar rats in liver
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12896,1,,,50597,,,,BAO_0000218,CHEMBL628418,,Tissue level at 10 mg/kg/po in wistar rats in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12897,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL628419,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,12898,1,,,50597,,,,BAO_0000218,CHEMBL628420,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat
A,,,,,1,Autocuration,,1629,,U,12899,0,,,22224,,,,BAO_0000019,CHEMBL628421,,Water solubility at 37 degree C.
P,,,,,1,Autocuration,,8194,,U,12900,0,,,22229,,,,BAO_0000100,CHEMBL626726,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr
P,,,,,1,Autocuration,,8194,,U,12901,0,,,22229,,,,BAO_0000100,CHEMBL626727,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12902,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626728,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12903,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626729,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12904,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626730,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12905,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626731,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12906,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL626732,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12907,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626733,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12908,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626734,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12909,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626735,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12910,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL874909,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12911,1,,,50597,Heart,948.0,,BAO_0000218,CHEMBL626736,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12912,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL626737,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12913,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL630999,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12914,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL631000,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12915,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL631001,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12916,1,,,50597,Kidney,2113.0,,BAO_0000218,CHEMBL631002,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12917,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631003,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12918,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631004,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12919,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631005,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12920,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631006,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12921,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631007,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12922,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL631008,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12923,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL631009,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12924,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL631010,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12925,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL631011,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12926,1,,,50597,Lung,2048.0,,BAO_0000218,CHEMBL631012,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12927,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL630271,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12928,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL630272,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12929,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL630273,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12930,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL630274,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12931,1,,,50597,Thyroid gland,2046.0,,BAO_0000218,CHEMBL630275,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12932,1,,,50597,,,,BAO_0000218,CHEMBL875782,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12933,1,,,50597,,,,BAO_0000218,CHEMBL630276,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12934,1,,,50597,,,,BAO_0000218,CHEMBL630277,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12935,1,,,50597,,,,BAO_0000218,CHEMBL630278,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8594,,N,12936,1,,,50597,,,,BAO_0000218,CHEMBL630279,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-
A,,,,,1,Autocuration,,8151,,U,12937,0,,,22224,,,,BAO_0000019,CHEMBL630280,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg
A,,,,,1,Autocuration,,8151,,U,12938,0,,,22224,,,,BAO_0000019,CHEMBL630281,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12939,1,,,50592,,,,BAO_0000218,CHEMBL630282,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,12940,1,,,50592,,,,BAO_0000218,CHEMBL630283,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2
A,,,,,1,Autocuration,,5797,,U,12941,0,,,22224,,,,BAO_0000019,CHEMBL630284,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug)
A,,,,,1,Autocuration,,7849,,U,12942,0,,,22224,,,,BAO_0000019,CHEMBL630285,,Alkylating activity was determined
A,,,,,1,Autocuration,Microsomes,14220,,U,12943,0,,,22224,,,,BAO_0000251,CHEMBL630286,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM)
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,8650,,N,12944,1,,,50592,,,,BAO_0000218,CHEMBL630069,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,8650,,N,12945,1,,,50592,,,,BAO_0000218,CHEMBL630070,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,8650,,N,12946,1,,,50592,,,,BAO_0000218,CHEMBL630071,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,8650,,N,12947,1,,,50592,,,,BAO_0000218,CHEMBL630072,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,8650,,N,12948,1,,,50592,,,,BAO_0000218,CHEMBL875110,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7116,,N,12949,1,,,50597,,,,BAO_0000218,CHEMBL630073,,Compound was tested for antidiuretic activity in rats
A,,,,,1,Autocuration,,14131,,U,12950,0,,,22224,,,,BAO_0000019,CHEMBL630074,,Compound was tested for inactivation kinetic values
A,,,,,1,Autocuration,,7415,,U,12951,0,,,22224,,,In vivo,BAO_0000218,CHEMBL630075,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route
A,,,,,1,Autocuration,,13178,,U,12952,0,,,22224,,,,BAO_0000019,CHEMBL630076,,Dissociation rate calculated from the first-order equation using the t1/2 value
P,,,,,1,Autocuration,,8815,,U,12953,0,,,22229,,,,BAO_0000100,CHEMBL630077,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water
P,,,,,1,Autocuration,,1450,,U,12954,0,,,22229,,,,BAO_0000100,CHEMBL630078,,Aqueous solubility was measured
P,,,,,1,Autocuration,,1450,,U,12955,0,,,22229,,,,BAO_0000100,CHEMBL630079,,Aqueous solubility was measured at a pH 4
P,,,,,1,Autocuration,,1450,,U,12956,0,,,22229,,,,BAO_0000100,CHEMBL630080,,Aqueous solubility (pH 7)
P,,,,,1,Autocuration,,1450,,U,12957,0,,,22229,,,,BAO_0000100,CHEMBL630081,,Aqueous solubility was measured at a pH 9
A,,,,,1,Autocuration,,12711,,U,12958,0,,,22224,,,,BAO_0000019,CHEMBL630082,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents"
A,,,,,1,Autocuration,,12711,,U,12959,0,,,22224,,,,BAO_0000019,CHEMBL630083,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents."
A,,,,,1,Autocuration,,12711,,U,12960,0,,,22224,,,,BAO_0000019,CHEMBL630084,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents."
P,,,,,1,Autocuration,,15032,,U,12961,0,,,22229,,,,BAO_0000100,CHEMBL629198,,Aqueous solubility of the compound
P,,,,,1,Autocuration,,9964,,U,12962,0,,,22229,,,,BAO_0000100,CHEMBL629199,,Aqueous solubility at 37 degree Celsius at pH 7.38
P,,,,,1,Autocuration,,14962,,U,12963,0,,,22229,,,,BAO_0000100,CHEMBL629200,,Aqueous solubility in pH 7.4 phosphate buffer
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12487,,N,12964,1,,,50588,,,,BAO_0000218,CHEMBL629201,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12487,,N,12965,1,,,50588,,,,BAO_0000218,CHEMBL629202,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog
A,Homo sapiens,9606.0,,,1,Intermediate,,10026,,N,12966,1,,,50587,,,,BAO_0000218,CHEMBL875111,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius
A,Homo sapiens,9606.0,,,1,Intermediate,,10026,,N,12967,1,,,50587,,,,BAO_0000218,CHEMBL629203,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius
A,Homo sapiens,9606.0,,,1,Intermediate,,10026,,N,12968,1,,,50587,,,,BAO_0000218,CHEMBL629204,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius
A,Homo sapiens,9606.0,,,1,Intermediate,,10026,,N,12969,1,,,50587,,,,BAO_0000218,CHEMBL629205,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius
A,Homo sapiens,9606.0,,,1,Intermediate,,10026,,N,12970,1,,,50587,,,,BAO_0000218,CHEMBL629206,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius
A,,,,,1,Autocuration,,10026,,U,12971,0,,,22224,,,,BAO_0000019,CHEMBL631185,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,12972,1,,,50597,,,,BAO_0000218,CHEMBL631186,,Compound was evaluated for the average bile flow rat in rats
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,12973,1,,,50592,,,,BAO_0000218,CHEMBL631187,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,17025,,N,12974,1,,,50592,,,,BAO_0000218,CHEMBL631188,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg"
A,,,,,1,Autocuration,,10184,,U,12975,0,,,22224,,,,BAO_0000019,CHEMBL876419,,Average half life period was determined
A,,,,,1,Autocuration,,10184,,U,12976,0,,,22224,,,,BAO_0000019,CHEMBL631189,,Average half life period was determined
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12977,1,,,50602,,,,BAO_0000218,CHEMBL631190,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12978,1,,,50602,,,,BAO_0000218,CHEMBL631191,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12979,1,,,50602,,,,BAO_0000218,CHEMBL631192,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12980,1,,,50602,,,,BAO_0000218,CHEMBL632400,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12981,1,,,50602,,,,BAO_0000218,CHEMBL630564,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12982,1,,,50602,,,,BAO_0000218,CHEMBL630565,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12983,1,,,50602,,,,BAO_0000218,CHEMBL630566,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12984,1,,,50602,,,,BAO_0000218,CHEMBL631229,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,12985,1,,,50602,,,,BAO_0000218,CHEMBL631230,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.
P,,,,,1,Autocuration,,6030,,U,12986,0,,,22229,,,,BAO_0000100,CHEMBL876428,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6147,,U,12987,0,,,22229,,,,BAO_0000100,CHEMBL631231,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14556,,U,12988,0,,,22229,,,,BAO_0000100,CHEMBL631232,,Calculated partition coefficient (clogP) (MacLogP)
A,,,,,1,Autocuration,,768,,U,12989,0,,,22224,,,,BAO_0000019,CHEMBL631233,,Hydrophilicity was determined
P,,,,,1,Autocuration,,14452,,U,12990,0,,,22229,,,,BAO_0000100,CHEMBL631234,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,5237,,U,12991,0,,,22224,,,,BAO_0000019,CHEMBL883126,,Increased absorption was determined
P,,,,,1,Autocuration,,14378,,U,12992,0,,,22224,,,,BAO_0000100,CHEMBL631235,,Lipophilicity value was evaluated
P,,,,,1,Autocuration,,14418,,U,12993,0,,,22224,,,,BAO_0000100,CHEMBL631236,,Log P value of the compound.
A,,,,,1,Autocuration,,5249,,U,12994,0,,,22224,,,,BAO_0000019,CHEMBL631237,,Partition coefficient of compound was determined
P,,,,,1,Autocuration,,14621,,U,12995,0,,,22229,,,,BAO_0000100,CHEMBL631238,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,12542,,U,12996,0,,,22229,,,,BAO_0000100,CHEMBL876429,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,12542,,U,12997,0,,,22224,,,,BAO_0000019,CHEMBL631414,,Partition coefficient was measured by medchem software; Not calculated
P,,,,,1,Autocuration,,12542,,U,12998,0,,,22224,,,,BAO_0000100,CHEMBL631415,,Partition coefficient was measured by octanol-water using standard shake-flask method
P,,,,,1,Autocuration,,15462,,U,12999,0,,,22229,,,,BAO_0000100,CHEMBL631416,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,14884,,U,13000,0,,,22224,,,,BAO_0000019,CHEMBL631417,,Partition coefficient (logP)
P,,,,,1,Autocuration,,16526,,U,13001,0,,,22229,,,,BAO_0000100,CHEMBL631418,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13693,,U,13002,0,,,22229,,,,BAO_0000100,CHEMBL631419,,The Octanol/Water partition coefficient CLogP
A,,,,,1,Autocuration,,13693,,U,13003,0,,,22224,,,,BAO_0000019,CHEMBL631420,,The pharmacokinetic parameter C Log p was reported
P,,,,,1,Autocuration,,13779,,U,13004,0,,,22229,,,,BAO_0000100,CHEMBL631421,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14772,,U,13005,0,,,22229,,,,BAO_0000100,CHEMBL631422,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14393,,U,13006,0,,,22229,,,,BAO_0000100,CHEMBL631423,,Calculated partition coefficient (clogP)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,13007,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL876430,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,13008,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631424,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13744,,N,13009,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631425,,Compound was administered intravenously in dog to evaluate plasma clearance values
A,Simiiformes,314293.0,,,1,Autocuration,,13744,,U,13010,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631426,,Compound was administered intravenously in monkey to evaluate plasma clearance values
A,Mus musculus,10090.0,,,1,Intermediate,,13744,,N,13011,1,,,50594,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631427,,Compound was administered intravenously in mouse to evaluate plasma clearance values
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13207,,N,13012,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631428,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg
A,Macaca mulatta,9544.0,,,1,Intermediate,Microsomes,5669,,N,13013,1,,,50797,Liver,2107.0,In vitro,BAO_0000218,CHEMBL631429,,Intrinsic clearance in Rhesus liver microsome
A,Canis lupus familiaris,9615.0,,,1,Intermediate,Microsomes,5669,,N,13014,1,,,50588,Liver,2107.0,In vitro,BAO_0000218,CHEMBL631430,,Intrinsic clearance in dog liver microsome
A,Rattus norvegicus,10116.0,,,1,Intermediate,Microsomes,5669,,N,13015,1,,,50597,Liver,2107.0,In vitro,BAO_0000218,CHEMBL631431,,Intrinsic clearance in rat liver microsome
A,Macaca mulatta,9544.0,,,1,Intermediate,,4853,,N,13016,1,,,50797,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL631432,,Low plasma clearance was calculated in rhesus monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,16452,,N,13017,1,,,50588,,,In vivo,BAO_0000218,CHEMBL631433,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
A,,,,,1,Autocuration,,11954,,U,13018,0,,,22224,,,In vivo,BAO_0000218,CHEMBL631434,,Plasma clearance after intravenous dose of 0.3 mg/kg
A,,,,,1,Autocuration,,11954,,U,13019,0,,,22224,,,In vivo,BAO_0000218,CHEMBL631435,,Plasma clearance after intravenous dose of 1 mg/kg
A,,,,,1,Autocuration,,11954,,U,13020,0,,,22224,,,In vivo,BAO_0000218,CHEMBL631436,,Plasma clearance after intravenous dose of 3 mg/kg
A,,,,,1,Autocuration,,11954,,U,13021,0,,,22224,,,In vivo,BAO_0000218,CHEMBL631437,,Plasma clearance after intravenous dose of 3.87 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,13022,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631438,,Plasma clearance after peroral administration at 10 mpk in Rat
A,Macaca mulatta,9544.0,,,1,Intermediate,,5669,,N,13023,1,,,50797,,,In vivo,BAO_0000218,CHEMBL876431,,Plasma clearance after peroral administration at 10 mpk in Rhesus
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5669,,N,13024,1,,,50588,,,In vivo,BAO_0000218,CHEMBL631439,,Plasma clearance after peroral administration at 10 mpk in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13662,,N,13025,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631440,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat
A,,,,,1,Autocuration,,8272,,U,13026,0,,,22224,,,,BAO_0000019,CHEMBL631441,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC)
A,,,,,1,Autocuration,,13410,,U,13027,0,,,22224,,,,BAO_0000019,CHEMBL631442,,Critical Micellar concentration was determined
A,,,,,1,Autocuration,,13410,,U,13028,0,,,22224,,,,BAO_0000019,CHEMBL626525,,Critical Micellar concentration of the compound. was determined
A,,,,,1,Autocuration,,12628,,U,13029,0,,,22224,,,,BAO_0000019,CHEMBL627168,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration
A,,,,,1,Autocuration,,9675,,U,13030,0,,,22224,,,,BAO_0000019,CHEMBL875618,,Critical micellar concentration was measured in water by the dye solubilization method
B,,,,,1,Autocuration,,12628,,U,13031,0,,,22224,,,,BAO_0000019,CHEMBL626612,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC
A,,,,,1,Autocuration,,12766,,U,13032,0,,,22224,,,,BAO_0000019,CHEMBL626613,,CMR value (relative to BAY K 8644)
A,,,,,1,Autocuration,,7849,,U,13033,0,,,22224,,,,BAO_0000019,CHEMBL626614,,Carbamoylating activity was determined
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,13034,0,,,22224,,,,BAO_0000218,CHEMBL626615,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey
A,,,,,1,Autocuration,,2040,,U,13035,0,,,22224,,,,BAO_0000019,CHEMBL626616,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.
A,,,,,1,Autocuration,,2040,,U,13036,0,,,22224,,,,BAO_0000019,CHEMBL626617,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14180,,N,13037,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626618,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14180,,N,13038,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626619,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14474,,N,13039,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626620,,"Clearance rate at 0.46 mg/kg, iv, in dogs"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14474,,N,13040,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626621,,"Clearance rate at 5.5 mg/kg, iv, in rat"
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14548,,N,13041,1,,,100710,,,In vivo,BAO_0000218,CHEMBL626622,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14548,,N,13042,1,,,100710,,,In vivo,BAO_0000218,CHEMBL626623,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,14548,,N,13043,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626624,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14548,,N,13044,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626625,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6125,,N,13045,1,,,50597,Liver,2107.0,Ex vivo,BAO_0000218,CHEMBL626626,,Clearance rate constant using isolated perfused rat liver (IPRL) assay
A,,,,,1,Autocuration,,6874,,U,13046,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626627,,Tested for the total clearance of the compound
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15343,,N,13047,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626628,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose
A,,,,,1,Autocuration,,6236,,U,13048,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626629,,Total body clearance was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13049,1,,,50597,,,,BAO_0000218,CHEMBL626630,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13050,1,,,50597,,,,BAO_0000218,CHEMBL626631,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg
P,,,,,1,Autocuration,,8194,,U,13051,0,,,22229,,,,BAO_0000100,CHEMBL626632,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr
P,,,,,1,Autocuration,,8194,,U,13052,0,,,22229,,,,BAO_0000100,CHEMBL626633,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr
P,,,,,1,Autocuration,,8194,,U,13053,0,,,22229,,,,BAO_0000100,CHEMBL626634,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr
P,,,,,1,Autocuration,,8194,,U,13054,0,,,22229,,,,BAO_0000100,CHEMBL626635,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr
P,,,,,1,Autocuration,,8194,,U,13055,0,,,22229,,,,BAO_0000100,CHEMBL626636,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr
P,,,,,1,Autocuration,,8194,,U,13056,0,,,22229,,,,BAO_0000100,CHEMBL626637,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13057,1,,,50339,,,,BAO_0000218,CHEMBL626638,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13058,1,,,50339,,,,BAO_0000218,CHEMBL626639,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13059,1,,,50339,,,,BAO_0000218,CHEMBL626640,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13060,1,,,50339,,,,BAO_0000218,CHEMBL626641,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13061,1,,,50339,,,,BAO_0000218,CHEMBL627272,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13062,1,,,50339,,,,BAO_0000218,CHEMBL627273,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13063,1,,,50339,,,,BAO_0000218,CHEMBL627441,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13064,1,,,50339,,,,BAO_0000218,CHEMBL628355,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13065,1,,,50339,,,,BAO_0000218,CHEMBL628356,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13066,1,,,50339,,,,BAO_0000218,CHEMBL628357,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13067,1,,,50339,,,,BAO_0000218,CHEMBL628358,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day)
A,Pneumocystis carinii,4754.0,,,1,Intermediate,,13273,,N,13068,1,,,50339,,,,BAO_0000218,CHEMBL622307,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day)
A,,,,,1,Autocuration,,13118,,U,13069,0,,,22224,,,,BAO_0000019,CHEMBL622527,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0
A,,,,,1,Autocuration,,13118,,U,13070,0,,,22224,,,,BAO_0000019,CHEMBL622528,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable
A,,,,,1,Autocuration,,13118,,U,13071,0,,,22224,,,,BAO_0000019,CHEMBL622529,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4
A,,,,,1,Autocuration,,13118,,U,13072,0,,,22224,,,,BAO_0000019,CHEMBL622992,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable
A,,,,,1,Autocuration,,13118,,U,13073,0,,,22224,,,,BAO_0000019,CHEMBL622993,,Conversion rate by hydrolysis of compound in plasma after 6 hr. 
A,,,,,1,Autocuration,,13118,,U,13074,0,,,22224,,,,BAO_0000019,CHEMBL622994,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10633,,N,13075,1,,,50597,,,,BAO_0000218,CHEMBL622995,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10633,,N,13076,1,,,50597,,,,BAO_0000218,CHEMBL622996,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood."
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10633,,N,13077,1,,,50597,,,,BAO_0000218,CHEMBL622997,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10633,,N,13078,1,,,50597,,,,BAO_0000218,CHEMBL622998,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate"
A,,,,,1,Autocuration,,5767,,U,13079,0,,,22224,,,,BAO_0000218,CHEMBL622999,,Cp max following ip administration at 1 mg/kg
A,,,,,1,Autocuration,,3302,,U,13080,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623000,,Maximum concentration in plasma was reported at 0.5 hour
A,,,,,1,Autocuration,,3302,,U,13081,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL623001,,Maximum concentration in plasma was reported at 2 hour
A,Mus musculus,10090.0,,,1,Intermediate,,12467,,N,13082,1,,,50594,,,,BAO_0000218,CHEMBL623002,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells
P,,,,,1,Autocuration,,11778,,U,13083,0,,,22229,,,,BAO_0000100,CHEMBL623003,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8)
A,,,,,1,Autocuration,,4321,,U,13084,0,,,22224,,,,BAO_0000019,CHEMBL623004,,Steady state concentration was evaluated
A,,,,,1,Autocuration,,14884,,U,13085,0,,,22224,,,,BAO_0000019,CHEMBL623005,,Partition coefficient (logP)
A,,,,,1,Autocuration,,15234,,U,13086,0,,,22224,,,,BAO_0000019,CHEMBL623006,,Partition coefficient (logD7.4)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13087,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623007,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13088,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL623008,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13089,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL876654,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13090,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623009,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13091,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623010,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13092,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL623011,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13093,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL623012,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats
A,,,,,1,Autocuration,,8151,,U,13094,0,,,22224,,,,BAO_0000019,CHEMBL623013,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg
A,,,,,1,Autocuration,,8151,,U,13095,0,,,22224,,,,BAO_0000019,CHEMBL623014,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg
A,,,,,1,Autocuration,,8151,,U,13096,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623015,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg
A,,,,,1,Autocuration,,8151,,U,13097,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL623016,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg
A,,,,,1,Autocuration,,8151,,U,13098,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL624858,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13099,1,,,50597,,,,BAO_0000218,CHEMBL624859,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13100,1,,,50597,,,,BAO_0000218,CHEMBL624860,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13101,1,,,50597,,,,BAO_0000218,CHEMBL624861,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13102,1,,,50597,,,,BAO_0000218,CHEMBL624862,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13103,1,,,50597,,,,BAO_0000218,CHEMBL624863,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8151,,N,13104,1,,,50597,,,,BAO_0000218,CHEMBL876655,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13105,1,,,50588,,,,BAO_0000218,CHEMBL624864,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13106,1,,,50588,,,,BAO_0000218,CHEMBL624865,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13107,1,,,50588,,,,BAO_0000218,CHEMBL624866,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249
F,Canis lupus familiaris,9615.0,,,1,Expert,,6996,,N,13108,1,,,50588,,,,BAO_0000218,CHEMBL624867,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13109,1,,,50588,,,,BAO_0000218,CHEMBL624868,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13110,1,,,50588,,,,BAO_0000218,CHEMBL628450,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13111,1,,,50588,,,,BAO_0000218,CHEMBL628451,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13112,1,,,50588,,,,BAO_0000218,CHEMBL628452,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13113,1,,,50588,,,,BAO_0000218,CHEMBL628453,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13114,1,,,50588,,,,BAO_0000218,CHEMBL628454,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13115,1,,,50588,,,,BAO_0000218,CHEMBL628455,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13116,1,,,50588,,,,BAO_0000218,CHEMBL628456,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13117,1,,,50588,,,,BAO_0000218,CHEMBL628457,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13118,1,,,50588,,,,BAO_0000218,CHEMBL877505,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13119,1,,,50588,,,,BAO_0000218,CHEMBL628458,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13120,1,,,50588,,,,BAO_0000218,CHEMBL628459,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13121,1,,,50588,,,,BAO_0000218,CHEMBL628460,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13122,1,,,50588,,,,BAO_0000218,CHEMBL628461,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899
B,,,,,1,Autocuration,,6996,,U,13123,0,,,22224,,,,BAO_0000218,CHEMBL628462,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13124,1,,,50588,,,,BAO_0000218,CHEMBL628463,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat
F,Rattus norvegicus,10116.0,,,1,Expert,,6996,,N,13125,1,,,50597,,,,BAO_0000218,CHEMBL625666,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg"
B,,,,,1,Autocuration,,6996,,U,13126,0,,,22224,,,,BAO_0000218,CHEMBL625667,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat
A,Rattus norvegicus,10116.0,,,1,Expert,,6996,,N,13127,1,,,50597,,,,BAO_0000218,CHEMBL625668,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13128,1,,,50597,,,,BAO_0000218,CHEMBL625669,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat
A,,,,,1,Autocuration,,7114,,U,13129,0,,,22224,,,,BAO_0000019,CHEMBL625670,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7114,,N,13130,1,,,50597,,,,BAO_0000218,CHEMBL625671,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13131,1,,,50602,,,,BAO_0000218,CHEMBL625672,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13132,1,,,50602,,,,BAO_0000218,CHEMBL625673,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13133,1,,,50602,,,,BAO_0000218,CHEMBL625674,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13134,1,,,50602,,,,BAO_0000218,CHEMBL625675,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13135,1,,,50602,,,,BAO_0000218,CHEMBL627637,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13136,1,,,50602,,,,BAO_0000218,CHEMBL627638,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13137,1,,,50602,,,,BAO_0000218,CHEMBL627639,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13138,1,,,50602,,,,BAO_0000218,CHEMBL627640,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13139,1,,,50602,,,,BAO_0000218,CHEMBL627641,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13140,1,,,50602,,,,BAO_0000218,CHEMBL627642,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,13141,1,,,50602,,,,BAO_0000218,CHEMBL877506,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.
A,Mus musculus,10090.0,,,1,Intermediate,,8613,,N,13142,1,,,50594,,,,BAO_0000218,CHEMBL627275,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13143,1,,,50506,,,,BAO_0000218,CHEMBL627643,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets."
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13144,1,,,50506,,,,BAO_0000218,CHEMBL631246,,"Average area under curve value dosed at 10 mg/kg, id in ferrets."
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13145,1,,,50506,,,,BAO_0000218,CHEMBL631247,,"Average area under curve value dosed at 10 mg/kg, id in ferrets."
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13146,1,,,50506,,,,BAO_0000218,CHEMBL629532,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13147,1,,,50506,,,,BAO_0000218,CHEMBL629533,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13148,1,,,50506,,,,BAO_0000218,CHEMBL629534,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).
A,Mustela putorius furo,9669.0,,,1,Intermediate,,11219,,N,13149,1,,,50506,,,,BAO_0000218,CHEMBL629535,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.
A,,,,,1,Autocuration,,14837,,U,13150,0,,,22224,,,,BAO_0000019,CHEMBL625932,,Pharmacokinetic parameter :drug bound to plasma was reported
A,,,,,1,Autocuration,,14837,,U,13151,0,,,22224,,,,BAO_0000019,CHEMBL625933,,compound was evaluated for drug bound in plasma
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15343,,N,13152,1,,,50597,,,,BAO_0000218,CHEMBL625934,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose
A,Eutheria,9347.0,,,1,Autocuration,,13761,,U,13153,0,,,22224,,,,BAO_0000218,CHEMBL625935,,Bioavailability
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14810,,N,13154,1,,,50597,,,,BAO_0000218,CHEMBL625936,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14810,,N,13155,1,,,50597,,,,BAO_0000218,CHEMBL625937,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13249,,N,13156,1,,,50588,,,,BAO_0000218,CHEMBL625938,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13157,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL625939,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13158,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL625940,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13159,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL874464,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13160,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL625941,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13161,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL625942,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9267,,N,13162,1,,,50597,Bile,1970.0,,BAO_0000218,CHEMBL625943,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.
A,Homo sapiens,9606.0,,,1,Intermediate,,15549,,N,13163,1,,,50587,Serum,1977.0,,BAO_0000218,CHEMBL625944,,In vitro protein binding in human serum at 5 ug/ml
A,,,,,1,Autocuration,,10929,,U,13164,0,,,22224,,,,BAO_0000019,CHEMBL625945,,Serum protein binding ability was measured
A,,,,,1,Autocuration,,15444,,U,13165,0,,,22224,,,,BAO_0000019,CHEMBL625946,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,12860,,U,13166,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625947,,Oral bioavailability in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12170,,N,13167,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625948,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.
A,,,,,1,Autocuration,,15173,,U,13168,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625949,,Absolute oral bioavailability at an iv dose of 14 mg/kg
A,,,,,1,Autocuration,,15173,,U,13169,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625950,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg
A,Eutheria,9347.0,,,1,Autocuration,,15173,,U,13170,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625951,,Oral bioavailability (dose 15 mg/kg i.v.)
A,,,,,1,Autocuration,,15173,,U,13171,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625952,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.
A,,,,,1,Autocuration,,15173,,U,13172,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625953,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally
A,,,,,1,Autocuration,,15173,,U,13173,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625954,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.
A,,,,,1,Autocuration,,15173,,U,13174,0,,,22224,,,In vivo,BAO_0000218,CHEMBL882959,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,11767,,N,13175,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625955,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen
A,Mustela putorius furo,9669.0,,,1,Autocuration,,11219,,U,13176,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625956,,Bioavailability in ferret
A,Macaca fascicularis,9541.0,,,1,Intermediate,,12186,,N,13177,1,,,100710,,,In vivo,BAO_0000218,CHEMBL625957,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13178,1,,,50597,,,,BAO_0000218,CHEMBL625958,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13179,1,,,50597,,,,BAO_0000218,CHEMBL625959,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13180,1,,,50597,,,,BAO_0000218,CHEMBL626642,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13181,1,,,50597,,,,BAO_0000218,CHEMBL631330,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13182,1,,,50597,,,,BAO_0000218,CHEMBL631331,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13183,1,,,50597,,,,BAO_0000218,CHEMBL631332,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13184,1,,,50597,,,,BAO_0000218,CHEMBL631333,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13185,1,,,50597,,,,BAO_0000218,CHEMBL632018,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13186,1,,,50597,,,,BAO_0000218,CHEMBL632019,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13187,1,,,50597,,,,BAO_0000218,CHEMBL632020,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13188,1,,,50597,,,,BAO_0000218,CHEMBL632021,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13189,1,,,50597,,,,BAO_0000218,CHEMBL632022,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13190,1,,,50597,,,,BAO_0000218,CHEMBL632023,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13191,1,,,50597,,,,BAO_0000218,CHEMBL632024,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13192,1,,,50597,,,,BAO_0000218,CHEMBL874472,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13193,1,,,50597,,,,BAO_0000218,CHEMBL632025,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13194,1,,,50597,,,,BAO_0000218,CHEMBL632026,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13195,1,,,50597,,,,BAO_0000218,CHEMBL632027,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13196,1,,,50597,,,,BAO_0000218,CHEMBL632028,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13197,1,,,50597,,,,BAO_0000218,CHEMBL626430,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13198,1,,,50597,,,,BAO_0000218,CHEMBL626431,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13199,1,,,50597,,,,BAO_0000218,CHEMBL626432,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13200,1,,,50597,,,,BAO_0000218,CHEMBL626433,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13201,1,,,50597,,,,BAO_0000218,CHEMBL626434,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13202,1,,,50597,,,,BAO_0000218,CHEMBL627280,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13203,1,,,50597,,,,BAO_0000218,CHEMBL627281,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13204,1,,,50597,,,,BAO_0000218,CHEMBL627282,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg
A,,,,,1,Autocuration,,7199,,U,13205,0,,,22224,,,,BAO_0000019,CHEMBL627283,,Total body clearance was measured at given dose
A,,,,,1,Autocuration,,7199,,U,13206,0,,,22224,,,,BAO_0000218,CHEMBL627284,,Total body clearance was measured at given dose.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7095,,N,13207,1,,,50597,,,,BAO_0000218,CHEMBL627285,,Metabolic clearance from the body in rat
A,,,,,1,Autocuration,,7095,,U,13208,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627286,,Renal clearance from the body
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7095,,N,13209,1,,,50597,,,In vivo,BAO_0000218,CHEMBL875477,,Renal clearance from the body in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12528,,N,13210,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627287,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12528,,N,13211,1,,,50588,,,In vivo,BAO_0000218,CHEMBL627288,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7095,,N,13212,1,,,50597,,,,BAO_0000218,CHEMBL627289,,Total clearance from the body in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14223,,N,13213,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627290,,Clearance into cortex from rat plasma or PBS
A,,,,,1,Autocuration,,13569,,U,13214,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627291,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg
A,,,,,1,Autocuration,,13569,,U,13215,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627292,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg
A,,,,,1,Autocuration,,13569,,U,13216,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627293,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg
A,,,,,1,Autocuration,,13569,,U,13217,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627294,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg
A,,,,,1,Autocuration,,13569,,U,13218,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875478,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg
A,,,,,1,Autocuration,,13979,,U,13219,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627295,,Clearance was determined
A,Mus musculus,10090.0,,,1,Intermediate,,14315,,N,13220,1,,,50594,,,In vivo,BAO_0000218,CHEMBL627296,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,14315,,N,13221,1,,,50592,,,In vivo,BAO_0000218,CHEMBL626119,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14315,,N,13222,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626120,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12174,,N,13223,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626121,,Clearance in rat after iv dose (100 ug/kg)
A,Cavia porcellus,10141.0,,,1,Autocuration,,12797,,U,13224,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626122,,Clearance in guinea pig
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12797,,N,13225,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626123,,Compound was evaluated for clearance in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12797,,N,13226,1,,,50588,,,In vivo,BAO_0000218,CHEMBL623456,,Compound was evaluated for the clearance in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12797,,N,13227,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623457,,Compound was evaluated for the clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11500,,N,13228,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623458,,Compound was tested in vivo for clearance after iv administration in the rat
A,,,,,1,Autocuration,,15173,,U,13229,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623459,,IV clearance determined at an iv dose of 14 mg/kg
A,,,,,1,Autocuration,,15173,,U,13230,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875484,,IV clearance determined at an iv dose of 15.2 mg/kg
A,,,,,1,Autocuration,,15173,,U,13231,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623460,,IV clearance determined at an iv dose of 15 mg/kg
A,,,,,1,Autocuration,,15173,,U,13232,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623461,,IV clearance determined at an peroral dose of 30 mg/kg.
A,,,,,1,Autocuration,,15173,,U,13233,0,,,22224,,,In vivo,BAO_0000218,CHEMBL623462,,IV clearance determined at an peroral dose of 30.2 mg/kg.
A,,,,,1,Autocuration,,15173,,U,13234,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627386,,IV clearance determined at an peroral dose of 30.3 mg/kg.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13235,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627387,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13236,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627388,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13237,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627389,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13238,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627390,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13239,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627391,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13240,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627392,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13241,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627393,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13242,1,,,50597,Trachea,3126.0,In vivo,BAO_0000218,CHEMBL627394,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13243,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627395,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13244,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL875485,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13245,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627396,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13246,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627397,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13247,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL627398,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13248,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL627399,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13249,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627400,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13250,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627401,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13251,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627402,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13252,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627403,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13253,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL627404,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13254,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623101,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13255,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL877480,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13256,1,,,50597,Trachea,3126.0,In vivo,BAO_0000218,CHEMBL623102,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13257,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL623103,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13258,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL623104,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13259,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623105,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13260,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623106,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13261,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL623107,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13262,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL623108,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13263,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL623109,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13264,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL623110,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13265,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL623111,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13266,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625060,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13267,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625061,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13268,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625062,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13269,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625063,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13270,1,,,50597,Trachea,3126.0,In vivo,BAO_0000218,CHEMBL625064,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13271,1,,,50597,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL625065,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13272,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625066,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13273,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625067,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13274,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625068,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13275,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL622159,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13276,1,,,50597,Intestine,160.0,In vivo,BAO_0000218,CHEMBL622160,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13277,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL622161,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13278,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL622162,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13279,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL622163,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13280,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622313,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13281,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622314,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13282,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622315,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14198,,N,13283,1,,,50597,Trachea,3126.0,In vivo,BAO_0000218,CHEMBL622316,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats
A,Escherichia coli,562.0,,,1,Intermediate,,15599,,N,13284,1,,,50212,,,,BAO_0000218,CHEMBL877486,,Normal diffusion coefficient in water for Escherichia coli
A,,,,,1,Autocuration,,8204,,U,13285,0,,,22224,,,,BAO_0000019,CHEMBL622317,,Average max percent decrease in RVR (renal vascular resistance) was determined
A,,,,,1,Autocuration,,8204,,U,13286,0,,,22224,,,,BAO_0000019,CHEMBL622318,,Average max percent decrease in RVR (renal vascular resistance) was determined.
A,,,,,1,Autocuration,,6154,,U,13287,0,,,22224,,,,BAO_0000019,CHEMBL622319,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13288,0,,,22224,,,,BAO_0000019,CHEMBL622320,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13289,0,,,22224,,,,BAO_0000019,CHEMBL622321,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time
A,,,,,1,Autocuration,,6154,,U,13290,0,,,22224,,,,BAO_0000019,CHEMBL622322,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time
A,,,,,1,Autocuration,,7114,,U,13291,0,,,22224,,,,BAO_0000019,CHEMBL622323,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7114,,N,13292,1,,,50597,,,,BAO_0000218,CHEMBL622324,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13293,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622325,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13294,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622326,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13295,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL877487,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13296,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622327,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13297,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622328,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13298,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622329,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13299,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622330,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13300,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622331,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13301,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622332,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13302,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622333,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13303,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL627658,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13304,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL630428,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13305,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL630429,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13306,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL630430,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13307,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL630431,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13308,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL630432,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13309,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL630433,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13310,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL630434,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13311,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629372,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13312,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629553,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13313,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629554,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13314,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL874447,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13315,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629555,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13316,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629556,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13317,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629557,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13318,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629558,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13319,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629559,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13320,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629560,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13321,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629561,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13322,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629562,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13323,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629563,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13324,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629564,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13325,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629565,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13326,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629566,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13327,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629567,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13328,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629568,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13329,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629569,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13330,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL629570,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13331,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL629571,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12170,,U,13332,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629572,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12170,,U,13333,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629573,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.
A,Eutheria,9347.0,,,1,Autocuration,,4985,,U,13334,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629574,,Bioavailability (dose 20 mg/kg)
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,15145,,U,13335,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629575,,Bioavailability in dog
A,Rattus norvegicus,10116.0,,,1,Autocuration,,14080,,U,13336,0,,,22224,,,In vivo,BAO_0000218,CHEMBL874448,,Bioavailability in rat (Sprague-Dawley) (male)
A,Primates,9443.0,,,1,Autocuration,,11219,,U,13337,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629576,,Bioavailability in monkey (dose 10 mg/kg i.d.)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,15145,,U,13338,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629577,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Autocuration,,15145,,U,13339,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629578,,Bioavailability in rat
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,1202,,U,13340,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629579,,Bioavailability in dog (dose 3.0 mg/kg p.o.)
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,1202,,U,13341,0,,,22224,,,In vivo,BAO_0000218,CHEMBL882958,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr
A,Pan troglodytes,9598.0,,,1,Intermediate,,1202,,N,13342,1,,,50505,,,In vivo,BAO_0000218,CHEMBL629580,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp
A,Eutheria,9347.0,,,1,Autocuration,,4026,,U,13343,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629581,,Bioavailability
A,Saimiri,9520.0,,,1,Autocuration,,1492,,U,13344,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629582,,Bioavailability in squirrel monkey
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12793,,N,13345,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628522,,Bioavailability was evaluated in dog
A,Cricetinae,10026.0,,,1,Intermediate,,12793,,N,13346,1,,,100712,,,In vivo,BAO_0000218,CHEMBL625432,,Bioavailability was evaluated in hamster
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12793,,U,13347,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625433,,Bioavailability in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,13348,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625434,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14793,,N,13349,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL625435,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>
A,Rattus norvegicus,10116.0,,,1,Autocuration,,14793,,U,13350,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625436,,Bioavailability in rat (dose 10 mg/kg p.o.)
A,Macaca fascicularis,9541.0,,,1,Intermediate,,14731,,N,13351,1,,,100710,,,In vivo,BAO_0000218,CHEMBL874588,,Bioavailability was measured in cynomolgus monkeys.
A,Mus musculus,10090.0,,,1,Intermediate,,14731,,N,13352,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625437,,Bioavailability was measured in nude mice.
A,Mustela putorius furo,9669.0,,,1,Autocuration,,12187,,U,13353,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625438,,Bioavailability in ferret (dose 10 mg/kg i.d.)
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,13354,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625439,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose)
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,13355,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625440,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay"
A,Simiiformes,314293.0,,,1,Autocuration,,12187,,U,13356,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625441,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose)
A,Rattus norvegicus,10116.0,,,1,Autocuration,,12187,,U,13357,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625442,,Bioavailability in rat (dose 10 mg/kg i.d.)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12187,,N,13358,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625443,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay"
A,,,,,1,Autocuration,,17431,,U,13359,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625444,,Bioavailability was determined; extremely poor
A,Mus musculus,10090.0,,,1,Intermediate,,13318,,N,13360,1,,,50594,,,In vivo,BAO_0000218,CHEMBL625445,,% bioavailability in mice after oral administration of prodrug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13361,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625446,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13362,1,,,50588,,,In vivo,BAO_0000218,CHEMBL882960,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13363,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625447,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13364,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625448,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13365,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625449,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13366,1,,,50588,,,In vivo,BAO_0000218,CHEMBL874589,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13367,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625450,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13368,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625451,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13369,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626584,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13370,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626585,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13371,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626586,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13372,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626587,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13373,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626588,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13374,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626589,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13375,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626590,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13376,1,,,50588,,,In vivo,BAO_0000218,CHEMBL626591,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13377,1,,,50588,,,In vivo,BAO_0000218,CHEMBL627181,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13378,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628083,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47
A,,,,,1,Autocuration,,15173,,U,13379,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628084,,IV clearance determined at an peroral dose of 15 mg/kg.
F,Hymenolepis nana,102285.0,,,1,Expert,,7732,,N,13380,1,,,50064,,,In vivo,BAO_0000218,CHEMBL628085,,Mouse oral clearance was measured against Hymenolepiasis nana.
F,Heligmosomoides polygyrus,6339.0,,,1,Expert,,7732,,N,13381,1,,,50545,,,In vivo,BAO_0000218,CHEMBL628086,,Mouse oral clearance was measured against Nematospiroides dubius
F,,,,,1,Autocuration,,7732,,U,13382,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628087,,Mouse oral clearance was measured against N. dubius; NT is Not Tested
A,Mus musculus,10090.0,,,1,Intermediate,,7732,,N,13383,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628088,,Mouse oral clearance was measured against N. nana; NT is Not Tested
B,,,,,1,Autocuration,,7732,,U,13384,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628089,,Mouse oral clearance was measured against N. nana; NT is Not Tested
A,,,,,1,Autocuration,,8328,,U,13385,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628090,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13386,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628091,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13387,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628092,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13388,0,,,22224,,,In vivo,BAO_0000218,CHEMBL628093,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13389,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875607,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13390,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625710,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13391,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625711,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13392,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625712,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation
A,,,,,1,Autocuration,,8328,,U,13393,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625713,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,13376,,N,13394,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625714,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg
A,Macaca mulatta,9544.0,,,1,Intermediate,,13477,,N,13395,1,,,50797,,,In vivo,BAO_0000218,CHEMBL625715,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,13396,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625716,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13477,,N,13397,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625717,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13313,,N,13398,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625718,,Plasma clearance was determined for the compound in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,13399,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625719,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,13400,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625720,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,13401,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625721,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12504,,N,13402,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625722,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13129,,N,13403,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625723,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.
A,Heligmosomoides polygyrus,6339.0,,,1,Intermediate,,7732,,N,13404,1,,,50545,,,In vivo,BAO_0000218,CHEMBL625724,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.
A,Heligmosomoides polygyrus,6339.0,,,1,Intermediate,,7732,,N,13405,1,,,50545,,,In vivo,BAO_0000218,CHEMBL625725,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.
A,Heligmosomoides polygyrus,6339.0,,,1,Intermediate,,7732,,N,13406,1,,,50545,,,In vivo,BAO_0000218,CHEMBL625726,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.
A,Heligmosomoides polygyrus,6339.0,,,1,Intermediate,,7732,,N,13407,1,,,50545,,,In vivo,BAO_0000218,CHEMBL875608,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.
A,Heligmosomoides polygyrus,6339.0,,,1,Intermediate,,7732,,N,13408,1,,,50545,,,In vivo,BAO_0000218,CHEMBL625727,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9278,,U,13409,0,,,22224,Urine,1088.0,In vivo,BAO_0000218,CHEMBL625728,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9278,,U,13410,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625729,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9278,,U,13411,0,,,22224,,,In vivo,BAO_0000218,CHEMBL625730,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9278,,U,13412,0,,,22224,Urine,1088.0,In vivo,BAO_0000218,CHEMBL625731,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage
A,Rattus norvegicus,10116.0,,,1,Autocuration,,9278,,U,13413,0,,,22224,Urine,1088.0,In vivo,BAO_0000218,CHEMBL626417,,Urinary clearance was determined in rat at 25 mg/kg os dosage
A,Homo sapiens,9606.0,,,1,Intermediate,,9278,,N,13414,1,,,50587,Urine,1088.0,In vivo,BAO_0000218,CHEMBL626418,,Urinary clearance was determined at 100 mg/kg oral dosage in human
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9278,,N,13415,1,,,50588,Urine,1088.0,In vivo,BAO_0000218,CHEMBL626419,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5932,,N,13416,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626592,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5932,,N,13417,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626593,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5182,,N,13418,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626594,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,10499,,N,13419,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625035,,Clearance rate in dogs
A,,,,,1,Autocuration,,6051,,U,13420,0,,,22224,,,In vitro,BAO_0000019,CHEMBL625036,,Compound was measured for intrinsic clearance
P,,,,,1,Autocuration,,17508,,U,13421,0,,,22229,,,,BAO_0000100,CHEMBL625037,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6228,,U,13422,0,,,22229,,,,BAO_0000100,CHEMBL625038,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6231,,U,13423,0,,,22229,,,,BAO_0000100,CHEMBL625039,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,17740,,U,13424,0,,,22229,,,,BAO_0000100,CHEMBL625040,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6495,,U,13425,0,,,22229,,,,BAO_0000100,CHEMBL625041,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,2171,,U,13426,0,,,22229,,,,BAO_0000100,CHEMBL625042,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,3255,,U,13427,0,,,22224,,,,BAO_0000019,CHEMBL874411,,Partition coefficient of the compound
A,,,,,1,Autocuration,,6821,,U,13428,0,,,22224,,,,BAO_0000019,CHEMBL625043,,Permeability
P,,,,,1,Autocuration,,2685,,U,13429,0,,,22229,,,,BAO_0000100,CHEMBL625044,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,17584,,U,13430,0,,,22224,,,,BAO_0000019,CHEMBL625045,,Partition coefficient (logD)
P,,,,,1,Autocuration,,13824,,U,13431,0,,,22229,,,,BAO_0000100,CHEMBL625046,,Calculated partition coefficient (clogP) (CLOGP3 V3.4)
P,,,,,1,Autocuration,,13824,,U,13432,0,,,22229,,,,BAO_0000100,CHEMBL625047,,Calculated partition coefficient (clogP) (CLOGP3 V3.4)
P,,,,,1,Autocuration,,16479,,U,13433,0,,,22229,,,,BAO_0000100,CHEMBL625048,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,11997,,U,13434,0,,,22229,,,,BAO_0000100,CHEMBL625049,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,2988,,U,13435,0,,,22229,,,,BAO_0000100,CHEMBL625050,,Calculated logarithm of partition coefficient (P) was determined
P,,,,,1,Autocuration,,931,,U,13436,0,,,22229,,,,BAO_0000100,CHEMBL625051,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,4381,,U,13437,0,,,22229,,,,BAO_0000100,CHEMBL874412,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,4397,,U,13438,0,,,22229,,,,BAO_0000100,CHEMBL625052,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,5889,,U,13439,0,,,22229,,,,BAO_0000100,CHEMBL625053,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,6154,,U,13440,0,,,22224,,,,BAO_0000019,CHEMBL623250,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13441,0,,,22224,,,,BAO_0000019,CHEMBL623251,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13442,0,,,22224,,,,BAO_0000019,CHEMBL623252,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13443,0,,,22224,,,,BAO_0000019,CHEMBL623253,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time
A,,,,,1,Autocuration,,6154,,U,13444,0,,,22224,,,,BAO_0000019,CHEMBL623254,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time
A,,,,,1,Autocuration,,6154,,U,13445,0,,,22224,,,,BAO_0000019,CHEMBL623255,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time
A,,,,,1,Autocuration,,6887,,U,13446,0,,,22224,,,,BAO_0000019,CHEMBL626831,,Percent degradation of compound at a pH of 1 over a 18 hr period
A,,,,,1,Autocuration,,6887,,U,13447,0,,,22224,,,,BAO_0000019,CHEMBL877494,,Percent degradation of compound at pH of 1 over an 18 hr period
A,,,,,1,Autocuration,,14116,,U,13448,0,,,22224,,,,BAO_0000019,CHEMBL626832,,Delta Logarithm of Partition Coefficient value was determined.
A,,,,,1,Autocuration,,11137,,U,13449,0,,,22224,,,,BAO_0000019,CHEMBL626833,,Delta logPoct-cyc
P,,,,,1,Autocuration,,7230,,U,13450,0,,,22224,,,,BAO_0000100,CHEMBL626834,,Lipophilicity estimated on reversed phase TLC
A,,,,,1,Autocuration,,15741,,U,13451,0,,,22224,,,,BAO_0000019,CHEMBL626835,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.
A,,,,,1,Autocuration,,9663,,U,13452,0,,,22224,,,,BAO_0000019,CHEMBL626836,,Delta logPoct-cyc
P,,,,,1,Autocuration,,9663,,U,13453,0,,,22229,,,,BAO_0000100,CHEMBL626837,,Change in logarithm of partition coefficient of the compound
A,,,,,1,Autocuration,,13807,,U,13454,0,,,22224,,,,BAO_0000019,CHEMBL626838,,Delta logD (pH 6.5)
P,,,,,1,Autocuration,,13807,,U,13455,0,,,22224,,,,BAO_0000100,CHEMBL626839,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane"
A,,,,,1,Autocuration,,17425,,U,13456,0,,,22224,,,,BAO_0000019,CHEMBL626840,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb
A,,,,,1,Autocuration,,12143,,U,13457,0,,,22224,,,,BAO_0000019,CHEMBL626841,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound)
A,,,,,1,Autocuration,,12608,,U,13458,0,,,22224,,,,BAO_0000219,CHEMBL626842,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells
A,,,,,1,Autocuration,,12608,,U,13459,0,,,22224,,,,BAO_0000219,CHEMBL626843,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13460,1,,,50597,,,,BAO_0000218,CHEMBL626844,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13461,1,,,50597,,,,BAO_0000218,CHEMBL877495,,Amount of deuterium retained was reported after normal workup in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13462,1,,,50597,,,,BAO_0000218,CHEMBL626845,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13463,1,,,50597,,,,BAO_0000218,CHEMBL626846,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13464,1,,,50597,,,,BAO_0000218,CHEMBL626847,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13465,1,,,50597,,,,BAO_0000218,CHEMBL628677,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8649,,N,13466,1,,,50597,,,,BAO_0000218,CHEMBL628678,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup
A,,,,,1,Autocuration,,9659,,U,13467,0,,,22224,,,,BAO_0000019,CHEMBL628679,,Compound was subjected to electrochemical oxidation
A,,,,,1,Autocuration,,9659,,U,13468,0,,,22224,,,,BAO_0000019,CHEMBL628680,,Compound was subjected to photochemical oxidation
A,,,,,1,Autocuration,,9659,,U,13469,0,,,22224,,,,BAO_0000019,CHEMBL628681,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide
A,,,,,1,Autocuration,,9659,,U,13470,0,,,22224,,,,BAO_0000019,CHEMBL628682,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide
A,,,,,1,Autocuration,,9659,,U,13471,0,,,22224,,,,BAO_0000019,CHEMBL628683,,Oxidation of compound by methemoglobin in presence of hydroperoxide
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9607,,N,13472,1,,,50597,,,,BAO_0000218,CHEMBL628684,,Percent diffusion through fuzzy rat skin after 48 h of incubation
P,,,,,1,Autocuration,,7057,,U,13473,0,,,22229,,,,BAO_0000100,CHEMBL877501,,Dissociation constant (pKa)
P,,,,,1,Autocuration,,7057,,U,13474,0,,,22224,,,,BAO_0000100,CHEMBL628685,,Dissociation constant value of the compound; ND means not determined.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13475,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628686,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13476,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL628687,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13477,1,,,50597,,,,BAO_0000218,CHEMBL628688,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13478,1,,,50597,,,,BAO_0000218,CHEMBL628689,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13479,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL628690,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13480,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL629363,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13481,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL629364,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13482,1,,,50597,Spleen,2106.0,,BAO_0000218,CHEMBL629365,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13483,1,,,50597,,,,BAO_0000218,CHEMBL629366,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13484,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629367,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13485,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL629368,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7911,,N,13486,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL877502,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13487,1,,,50594,Cerebellum,2037.0,,BAO_0000218,CHEMBL629369,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13488,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL629370,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13489,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL629371,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13490,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL626276,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13491,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL626277,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13492,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL631250,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13493,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631251,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13494,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631252,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13495,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631253,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13496,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631254,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13497,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631255,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13498,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631256,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13499,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631257,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13500,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628009,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13501,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628010,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13502,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628011,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13503,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628012,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13504,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628013,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13505,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628014,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13506,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628015,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13507,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628016,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13508,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL874461,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13509,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628017,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13510,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628018,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13511,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628019,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13512,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628020,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13513,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628021,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13514,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628022,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8133,,N,13515,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL628023,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13516,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628024,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13517,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628025,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13518,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628026,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13519,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628027,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po"
A,Simiiformes,314293.0,,,1,Autocuration,,8133,,U,13520,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628028,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13521,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628029,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13522,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628030,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13523,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628031,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13524,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628032,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13525,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628033,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13526,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628034,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13527,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628035,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13528,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628036,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13529,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL874462,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13530,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628037,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13531,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628123,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13532,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628124,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13533,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628125,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13534,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628126,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13535,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628127,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13536,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628128,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13537,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628129,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13538,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628130,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13539,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628131,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13540,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628132,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13541,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628133,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13542,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628134,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13543,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628135,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13544,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628136,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13545,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628137,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13546,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628138,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13547,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628139,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13548,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628140,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13549,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628141,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13550,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628142,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13551,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628143,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13552,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628144,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13553,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628145,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13554,1,,,50588,,,In vivo,BAO_0000218,CHEMBL628146,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13555,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625355,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13556,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625356,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13557,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625357,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13558,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625527,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13559,1,,,50588,,,In vivo,BAO_0000218,CHEMBL875473,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13560,1,,,50588,,,In vivo,BAO_0000218,CHEMBL625528,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9025,,N,13561,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626304,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,9025,,N,13562,1,,,50588,Artery,1637.0,In vivo,BAO_0000218,CHEMBL624138,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11
P,,,,,1,Autocuration,,6448,,U,13563,0,,,22229,,,,BAO_0000100,CHEMBL624139,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,17221,,U,13564,0,,,22229,,,,BAO_0000100,CHEMBL624140,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6545,,U,13565,0,,,22229,,,,BAO_0000100,CHEMBL624141,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,577,,U,13566,0,,,22229,,,,BAO_0000100,CHEMBL624142,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6285,,U,13567,0,,,22229,,,,BAO_0000100,CHEMBL624143,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6500,,U,13568,0,,,22229,,,,BAO_0000100,CHEMBL624144,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6716,,U,13569,0,,,22229,,,,BAO_0000100,CHEMBL624145,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,13658,,U,13570,0,,,22229,,,,BAO_0000100,CHEMBL624146,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6549,,U,13571,0,,,22229,,,,BAO_0000100,CHEMBL624147,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,14685,,U,13572,0,,,22229,,,,BAO_0000100,CHEMBL883123,,Calculated partition coefficient (clogP) (MacLogP)
A,,,,,1,Autocuration,,6893,,U,13573,0,,,22224,,,,BAO_0000019,CHEMBL624148,,Partition coefficient (logP)
A,,,,,1,Autocuration,,3687,,U,13574,0,,,22224,,,,BAO_0000019,CHEMBL874416,,Kinetic parameter was determined
P,,,,,1,Autocuration,,4207,,U,13575,0,,,22229,,,,BAO_0000100,CHEMBL624149,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,4626,,U,13576,0,,,22229,,,,BAO_0000100,CHEMBL624150,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,1021,,U,13577,0,,,22224,,,,BAO_0000100,CHEMBL624151,,Lipophilicity was determined
P,,,,,1,Autocuration,,3777,,U,13578,0,,,22224,,,,BAO_0000100,CHEMBL624152,,Lipophilicity was determined
P,,,,,1,Autocuration,,17533,,U,13579,0,,,22224,,,,BAO_0000100,CHEMBL622139,,Lipophilicity was determined
P,,,,,1,Autocuration,,6524,,U,13580,0,,,22229,,,,BAO_0000100,CHEMBL622140,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,17533,,U,13581,0,,,22224,,,,BAO_0000100,CHEMBL622141,,Lipophilicity was determined
P,,,,,1,Autocuration,,6480,,U,13582,0,,,22224,,,,BAO_0000100,CHEMBL622142,,Lipophilicity in octanol-water
P,,,,,1,Autocuration,,17606,,U,13583,0,,,22229,,,,BAO_0000100,CHEMBL622143,,Calculated partition coefficient (clogP)
P,,,,,1,Autocuration,,6863,,U,13584,0,,,22229,,,,BAO_0000100,CHEMBL622144,,Octanol-water partition coefficient was determined
A,,,,,1,Autocuration,,1356,,U,13585,0,,,22224,,,,BAO_0000019,CHEMBL877473,,Partition coefficient (logP)
P,,,,,1,Autocuration,,3326,,U,13586,0,,,22229,,,,BAO_0000100,CHEMBL622145,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,1356,,U,13587,0,,,22224,,,,BAO_0000019,CHEMBL622146,,Partition coefficient was determined; ND means not determined
P,,,,,1,Autocuration,,12984,,U,13588,0,,,22229,,,,BAO_0000100,CHEMBL622147,,Calculated partition coefficient (clogP)
A,,,,,1,Autocuration,,17363,,U,13589,0,,,22224,,,,BAO_0000019,CHEMBL622148,,Partition coefficient of the compound
A,,,,,1,Autocuration,,6827,,U,13590,0,,,22224,,,,BAO_0000019,CHEMBL883124,,Permeability was determined
P,,,,,1,Autocuration,,261,,U,13591,0,,,22229,,,,BAO_0000100,CHEMBL622149,,The compound was evaluated for the partition coefficient
A,,,,,1,Autocuration,,2685,,U,13592,0,,,22224,,,,BAO_0000019,CHEMBL622150,,Partition coefficient (logP)
P,,,,,1,Autocuration,,414,,U,13593,0,,,22224,,,,BAO_0000100,CHEMBL622151,,The lipophilicity was reported
P,,,,,1,Autocuration,,15769,,U,13594,0,,,22229,,,,BAO_0000100,CHEMBL622152,,logarithm of the octanol-water partition coefficient for the compound
A,,,,,1,Autocuration,,17248,,U,13595,0,,,22224,,,,BAO_0000019,CHEMBL622153,,Clogp value was determined
A,,,,,1,Autocuration,,16935,,U,13596,0,,,22224,,,In vivo,BAO_0000218,CHEMBL877474,,Clp at a dose of 1.5 mg/kg
A,,,,,1,Autocuration,,16935,,U,13597,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622154,,Clp at a dose of 2.0 mg/kg
A,,,,,1,Autocuration,,14832,,U,13598,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622155,,"Clp, plasma clearance at a dose of 10 mg/kg"
A,,,,,1,Autocuration,,14832,,U,13599,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622156,,"Clp, plasma clearance at a dose of 50 mg/kg"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2399,,N,13600,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622157,,Compound was tested for plasma clearance in rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,2399,,N,13601,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622158,,Compound was tested for plasma clearance in rat; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6227,,N,13602,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622807,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg
A,Macaca mulatta,9544.0,,,1,Intermediate,,6227,,N,13603,1,,,50797,,,In vivo,BAO_0000218,CHEMBL622808,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg
A,,,,,1,Autocuration,,5623,,U,13604,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622809,,Plasma clearance by iv administration at a dose 0.003 ug/mL
A,,,,,1,Autocuration,,4854,,U,13605,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622810,,Plasma clearance determined
A,Cricetinae,10026.0,,,1,Intermediate,,4493,,N,13606,1,,,100712,,,In vivo,BAO_0000218,CHEMBL876653,,Plasma clearance after iv administration at 3 mg/kg in hamster
A,Cricetinae,10026.0,,,1,Intermediate,,4493,,N,13607,1,,,100712,,,In vivo,BAO_0000218,CHEMBL622811,,Plasma clearance after iv administration at 4 mg/kg in hamster
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14956,,N,13608,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622986,,Rate of clearance in rat was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,13609,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622987,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,13610,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622988,,Total plasma clearance after iv dose of 5.10 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,13611,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622989,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15372,,N,13612,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622990,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats
A,Simiiformes,314293.0,,,1,Autocuration,,15604,,U,13613,0,,,22224,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622991,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15604,,N,13614,1,,,50597,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622227,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15604,,N,13615,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL622228,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14964,,N,13616,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622229,,Clpl value in rat
A,Cavia porcellus,10141.0,,,1,Intermediate,,15240,,N,13617,1,,,50512,,,In vivo,BAO_0000218,CHEMBL622230,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16449,,N,13618,1,,,50597,,,In vivo,BAO_0000218,CHEMBL622231,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats
A,Macaca fascicularis,9541.0,,,1,Intermediate,,16449,,N,13619,1,,,100710,,,In vivo,BAO_0000218,CHEMBL622232,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys
A,,,,,1,Autocuration,,12902,,U,13620,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622233,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13621,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622234,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13622,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622235,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13623,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622236,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13624,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622237,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13625,0,,,22224,,,In vivo,BAO_0000218,CHEMBL877482,,Cmax in minutes at a po dose of 10.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13626,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622238,,Cmax in minutes at a po dose of 20.0(pmol/g/h).
A,,,,,1,Autocuration,,12902,,U,13627,0,,,22224,,,In vivo,BAO_0000218,CHEMBL622239,,Cmax in minutes at a po dose of 40.0(pmol/g/h).
A,,,,,1,Autocuration,,11149,,U,13628,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL622240,,Cmax was calculated as maximum concentration reached in the blood
A,,,,,1,Autocuration,,11149,,U,13629,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL622241,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,13630,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631013,,Cmax was determine after peroral administration at 10 mpk in Rat
A,Macaca mulatta,9544.0,,,1,Intermediate,,5669,,N,13631,1,,,50797,,,In vivo,BAO_0000218,CHEMBL631014,,Cmax was determine after peroral administration at 10 mpk in Rhesus
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,5669,,N,13632,1,,,50588,,,In vivo,BAO_0000218,CHEMBL631015,,Cmax was determine after peroral administration at 10 mpk in dog
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,13633,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631016,,Cmax was determine after peroral administration at 160 mpk in Rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,13634,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631017,,Cmax was determine after peroral administration at 20 mpk in Rat
A,Rattus norvegicus,10116.0,,,1,Intermediate,,5669,,N,13635,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631018,,Cmax was determine after peroral administration at 50 mpk in Rat
A,,,,,1,Autocuration,,4236,,U,13636,0,,,22224,,,In vivo,BAO_0000218,CHEMBL631019,,Cmax was determined
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13637,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL875761,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13638,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL631020,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13639,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL631669,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13640,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL631670,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain
A,Mus musculus,10090.0,,,1,Intermediate,,13792,,N,13641,1,,,50594,Striatum,2435.0,,BAO_0000218,CHEMBL631671,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13642,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631672,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13643,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631673,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13644,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631856,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13645,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631857,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13646,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631858,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13647,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631859,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13648,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631860,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13649,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631861,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13650,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631862,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13651,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631863,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13652,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631864,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13653,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631865,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13654,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL631866,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13655,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629360,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13656,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629361,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13657,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL629362,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13658,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL630740,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13659,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL630741,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13660,1,,,50597,Blood,178.0,,BAO_0000218,CHEMBL630742,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13661,1,,,50597,,,,BAO_0000218,CHEMBL630743,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13662,1,,,50597,,,,BAO_0000218,CHEMBL630744,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13663,1,,,50597,,,,BAO_0000218,CHEMBL630745,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13664,1,,,50597,,,,BAO_0000218,CHEMBL630746,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13665,1,,,50597,,,,BAO_0000218,CHEMBL630747,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13666,1,,,50597,,,,BAO_0000218,CHEMBL630748,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13667,1,,,50597,,,,BAO_0000218,CHEMBL632056,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13668,1,,,50597,,,,BAO_0000218,CHEMBL632057,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13669,1,,,50597,,,,BAO_0000218,CHEMBL632058,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13670,1,,,50597,,,,BAO_0000218,CHEMBL632059,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13671,1,,,50597,,,,BAO_0000218,CHEMBL632060,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13672,1,,,50597,,,,BAO_0000218,CHEMBL632061,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13673,1,,,50597,,,,BAO_0000218,CHEMBL629207,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13674,1,,,50597,,,,BAO_0000218,CHEMBL629208,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13675,1,,,50597,,,,BAO_0000218,CHEMBL629209,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13676,1,,,50597,,,,BAO_0000218,CHEMBL629210,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13677,1,,,50597,,,,BAO_0000218,CHEMBL629211,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13678,1,,,50597,,,,BAO_0000218,CHEMBL629212,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8418,,N,13679,1,,,50597,,,,BAO_0000218,CHEMBL629213,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13680,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629214,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13681,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629215,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8133,,N,13682,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL635154,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13683,1,,,50597,,,,BAO_0000218,CHEMBL629216,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13684,1,,,50597,,,,BAO_0000218,CHEMBL629217,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13685,1,,,50597,,,,BAO_0000218,CHEMBL629218,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13686,1,,,50597,,,,BAO_0000218,CHEMBL629219,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13687,1,,,50597,,,,BAO_0000218,CHEMBL629220,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13688,1,,,50597,,,,BAO_0000218,CHEMBL629221,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13689,1,,,50597,,,,BAO_0000218,CHEMBL631127,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13690,1,,,50597,,,,BAO_0000218,CHEMBL631128,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13691,1,,,50597,,,,BAO_0000218,CHEMBL631129,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13692,1,,,50597,,,,BAO_0000218,CHEMBL631130,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13693,1,,,50597,,,,BAO_0000218,CHEMBL631131,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13694,1,,,50597,,,,BAO_0000218,CHEMBL631132,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13695,1,,,50597,,,,BAO_0000218,CHEMBL631133,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13696,1,,,50597,,,,BAO_0000218,CHEMBL631134,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13697,1,,,50597,,,,BAO_0000218,CHEMBL875120,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13698,1,,,50597,,,,BAO_0000218,CHEMBL631135,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13699,1,,,50597,,,,BAO_0000218,CHEMBL631136,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13700,1,,,50597,,,,BAO_0000218,CHEMBL631137,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13701,1,,,50597,,,,BAO_0000218,CHEMBL631138,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13702,1,,,50597,,,,BAO_0000218,CHEMBL631139,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13703,1,,,50597,,,,BAO_0000218,CHEMBL631140,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13704,1,,,50597,,,,BAO_0000218,CHEMBL631141,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13705,1,,,50597,,,,BAO_0000218,CHEMBL631142,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13706,1,,,50597,,,,BAO_0000218,CHEMBL631143,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr )
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6996,,N,13707,1,,,50597,,,,BAO_0000218,CHEMBL631144,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13708,1,,,50588,,,,BAO_0000218,CHEMBL631145,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13709,1,,,50588,,,,BAO_0000218,CHEMBL631146,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13710,1,,,50588,,,,BAO_0000218,CHEMBL631147,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13711,1,,,50588,,,,BAO_0000218,CHEMBL631148,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13712,1,,,50588,,,,BAO_0000218,CHEMBL631149,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13713,1,,,50588,,,,BAO_0000218,CHEMBL631150,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13714,1,,,50588,,,,BAO_0000218,CHEMBL631151,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13715,1,,,50588,,,,BAO_0000218,CHEMBL631152,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13716,1,,,50588,,,,BAO_0000218,CHEMBL631443,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13717,1,,,50588,,,,BAO_0000218,CHEMBL631444,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13718,1,,,50588,,,,BAO_0000218,CHEMBL631445,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13719,1,,,50588,,,,BAO_0000218,CHEMBL631446,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr )
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13720,1,,,50588,,,,BAO_0000218,CHEMBL631447,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13721,1,,,50588,,,,BAO_0000218,CHEMBL631448,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13722,1,,,50588,,,,BAO_0000218,CHEMBL631449,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13723,1,,,50588,,,,BAO_0000218,CHEMBL631450,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,6996,,N,13724,1,,,50588,,,,BAO_0000218,CHEMBL629724,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr)
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13725,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL629725,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13726,1,,,50594,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL629726,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13727,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL629727,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13728,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630404,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13729,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630405,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13730,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630406,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13731,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL630407,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13732,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL630573,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13733,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL630574,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13734,1,,,50594,Stomach,945.0,In vivo,BAO_0000218,CHEMBL630575,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13735,1,,,50594,,,In vivo,BAO_0000218,CHEMBL630576,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13736,1,,,50594,,,In vivo,BAO_0000218,CHEMBL630577,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13737,1,,,50594,,,In vivo,BAO_0000218,CHEMBL630578,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,9716,,N,13738,1,,,50594,,,In vivo,BAO_0000218,CHEMBL630579,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)"
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13739,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL630580,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered)
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13740,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL630581,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13741,1,,,50594,Kidney,2113.0,,BAO_0000218,CHEMBL630582,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered)
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13742,1,,,50594,,,,BAO_0000218,CHEMBL630583,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13743,1,,,50594,,,,BAO_0000218,CHEMBL630584,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered)
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13744,1,,,50594,,,,BAO_0000218,CHEMBL630585,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13745,1,,,50594,,,,BAO_0000218,CHEMBL630586,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered)
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13746,1,,,50594,,,,BAO_0000218,CHEMBL630587,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13747,1,,,50594,,,,BAO_0000218,CHEMBL630588,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered)
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13748,1,,,50594,,,,BAO_0000218,CHEMBL630589,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h
A,Mus musculus,10090.0,,,1,Intermediate,,12192,,N,13749,1,,,50594,,,,BAO_0000218,CHEMBL630590,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13750,0,,,22224,Feces,1988.0,,BAO_0000019,CHEMBL630591,,Removal of 238-Plutonium(IV) in feces at 24 h
A,,,,,1,Autocuration,,12192,,U,13751,0,,,22224,Feces,1988.0,,BAO_0000019,CHEMBL630592,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13752,0,,,22224,,,,BAO_0000019,CHEMBL630593,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h
A,,,,,1,Autocuration,,12192,,U,13753,0,,,22224,,,,BAO_0000019,CHEMBL630594,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13754,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630595,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered)
A,,,,,1,Autocuration,,12192,,U,13755,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630596,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13756,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630597,,Removal of 238-Plutonium(IV) in urine after 0-24 h
A,,,,,1,Autocuration,,12192,,U,13757,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630598,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13758,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630599,,Removal of 238-Plutonium(IV) in urine after 0-4 h
A,,,,,1,Autocuration,,12192,,U,13759,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630600,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13760,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630601,,Removal of 238-Plutonium(IV) in urine after 4-24 h
A,,,,,1,Autocuration,,12192,,U,13761,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630602,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13762,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630603,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered)
A,,,,,1,Autocuration,,12192,,U,13763,0,,,22224,Urine,1088.0,,BAO_0000019,CHEMBL630604,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13764,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624869,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13765,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL624870,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13766,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623189,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13767,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623190,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13768,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623191,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13769,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623192,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13770,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623193,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13771,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623194,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13772,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623195,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13773,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623196,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13774,1,,,50597,,,,BAO_0000218,CHEMBL623197,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13775,1,,,50597,,,,BAO_0000218,CHEMBL623198,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13776,1,,,50597,,,,BAO_0000218,CHEMBL623199,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13777,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623200,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13778,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623201,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13779,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623202,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13780,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623203,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13781,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623204,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13782,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623205,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13783,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623206,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13784,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623207,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13785,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623208,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13786,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623209,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13787,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL623210,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13788,1,,,50597,,,,BAO_0000218,CHEMBL623211,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11836,,N,13789,1,,,50597,Uterus,995.0,,BAO_0000218,CHEMBL623212,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline
A,,,,,1,Autocuration,,12640,,U,13790,0,,,22224,,,,BAO_0000019,CHEMBL623213,,Tested in vitro for intrinsic activity relative to quinpirole
A,,,,,1,Autocuration,,14218,,U,13791,0,,,22224,,,,BAO_0000019,CHEMBL623214,,"Relative ion enhancement, determined in pulsed ultrafiltration"
A,,,,,1,Autocuration,,11296,,U,13792,0,,,22224,,,,BAO_0000019,CHEMBL623215,,% ionization at the pH 7.4 at 37 degree Centigrade
A,,,,,1,Autocuration,,10929,,U,13793,0,,,22224,,,,BAO_0000019,CHEMBL623216,,Percentage ionization was measured
A,Bos taurus,9913.0,,,1,Intermediate,,13841,,N,13794,1,,,50591,,,,BAO_0000218,CHEMBL623217,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.
A,,,,,1,Autocuration,,10431,,U,13795,0,,,22224,,,,BAO_0000019,CHEMBL623218,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant
A,,,,,1,Autocuration,,10431,,U,13796,0,,,22224,,,,BAO_0000019,CHEMBL623913,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant
A,,,,,1,Autocuration,,10431,,U,13797,0,,,22224,,,,BAO_0000019,CHEMBL623914,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA
P,,,,,1,Autocuration,,8826,,U,13798,0,,,22229,,,,BAO_0000100,CHEMBL623915,,Compound was evaluated for the partition coefficient in octanol/water
P,,,,,1,Autocuration,,8826,,U,13799,0,,,22229,,,,BAO_0000100,CHEMBL624080,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4)
A,,,,,1,Autocuration,,9884,,U,13800,0,,,22224,,,,BAO_0000019,CHEMBL624081,,Equilibrium constant measured by the pulse radiolysis at pH 7
A,Homo sapiens,9606.0,,,1,Intermediate,,9827,,N,13801,1,,,50587,,,,BAO_0000218,CHEMBL624082,,In vitro hydrolytic rate constant determined in human blood
A,Homo sapiens,9606.0,,,1,Intermediate,,10009,,N,13802,1,,,50587,,,,BAO_0000218,CHEMBL625054,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma
A,,,,,1,Autocuration,,10009,,U,13803,0,,,22224,,,,BAO_0000019,CHEMBL877485,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,13804,1,,,50594,,,,BAO_0000218,CHEMBL625055,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,13805,1,,,50594,,,,BAO_0000218,CHEMBL625056,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate
A,Homo sapiens,9606.0,,,1,Intermediate,,10009,,N,13806,1,,,50587,,,,BAO_0000218,CHEMBL625057,,In vitro oxidation of compound in presence of human plasma
A,,,,,1,Autocuration,,10009,,U,13807,0,,,22224,,,,BAO_0000019,CHEMBL625058,,In vitro oxidation of compound in presence of hydrogen peroxide
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,13808,1,,,50594,,,,BAO_0000218,CHEMBL625059,,In vitro oxidation of compound in presence of mouse brain homogenate
A,Mus musculus,10090.0,,,1,Intermediate,,10009,,N,13809,1,,,50594,,,,BAO_0000218,CHEMBL629536,,In vitro oxidation of compound in presence of mouse liver homogenate
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13810,1,,,50597,,,,BAO_0000218,CHEMBL629537,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13811,1,,,50597,,,,BAO_0000218,CHEMBL629538,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13812,1,,,50597,,,,BAO_0000218,CHEMBL629539,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13813,1,,,50597,,,,BAO_0000218,CHEMBL874445,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13814,1,,,50597,,,,BAO_0000218,CHEMBL629540,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13815,1,,,50597,,,,BAO_0000218,CHEMBL629541,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13816,1,,,50597,,,,BAO_0000218,CHEMBL629542,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13817,1,,,50597,,,,BAO_0000218,CHEMBL630243,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13818,1,,,50597,,,,BAO_0000218,CHEMBL630244,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13819,1,,,50597,,,,BAO_0000218,CHEMBL630245,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13820,1,,,50597,,,,BAO_0000218,CHEMBL630246,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13821,1,,,50597,,,,BAO_0000218,CHEMBL630247,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13822,1,,,50597,,,,BAO_0000218,CHEMBL630248,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13823,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL630249,,Biodistribution in rat blood at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13824,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL630250,,Biodistribution in rat blood at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13825,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL630251,,Biodistribution in rat blood at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13826,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL630252,,Biodistribution in rat blood at 3 hr after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13827,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL630408,,Biodistribution in rat blood at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13828,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630409,,Biodistribution in rat cerebellum at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13829,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL874446,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13830,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630410,,Biodistribution in rat cerebellum at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13831,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630411,,Biodistribution in rat cerebellum at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13832,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630412,,Biodistribution in rat cerebellum at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13833,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630413,,Biodistribution in rat cerebellum at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13834,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630414,,Biodistribution in rat cerebellum at 3 hr after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13835,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL630415,,Biodistribution in rat cerebellum at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13836,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630416,,Biodistribution in rat cortex at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13837,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630417,,Biodistribution in rat cortex at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13838,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630418,,Biodistribution in rat cortex at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13839,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630419,,Biodistribution in rat cortex at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13840,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630420,,Biodistribution in rat cortex at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13841,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630421,,Biodistribution in rat cortex at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13842,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630422,,Biodistribution in rat cortex at 3 hr after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13843,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630423,,Biodistribution in rat cortex at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13844,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL630424,,Biodistribution in rat heart at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13845,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL630425,,Biodistribution in rat heart at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13846,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL629462,,Biodistribution in rat heart at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13847,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL630426,,Biodistribution in rat heart at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13848,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL630427,,Biodistribution in rat heart at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13849,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625877,,Biodistribution in rat heart at 3 hr after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13850,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625878,,Biodistribution in rat heart at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13851,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625879,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13852,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625880,,Biodistribution in rat hippocampus at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13853,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625881,,Biodistribution in rat hippocampus at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13854,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625882,,Biodistribution in rat hippocampus at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13855,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625883,,Biodistribution in rat hippocampus at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13856,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625884,,Biodistribution in rat kidney at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13857,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625885,,Biodistribution in rat kidney at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13858,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628649,,Biodistribution in rat kidney at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13859,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628650,,Biodistribution in rat kidney at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13860,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628651,,Biodistribution in rat kidney at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13861,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628652,,Biodistribution in rat kidney at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13862,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL628653,,Biodistribution in rat kidney at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13863,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL628654,,Biodistribution in rat liver at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13864,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL628655,,Biodistribution in rat liver at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13865,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625238,,Biodistribution in rat liver at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13866,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625239,,Biodistribution in rat liver at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13867,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625240,,Biodistribution in rat liver at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13868,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625241,,Biodistribution in rat liver at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13869,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625242,,Biodistribution in rat liver at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13870,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL874587,,Biodistribution in rat lung at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13871,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625405,,Biodistribution in rat lung at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13872,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625406,,Biodistribution in rat lung at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13873,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625407,,Biodistribution in rat lung at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13874,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625408,,Biodistribution in rat lung at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,13875,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625409,,Biodistribution in rat lung at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13876,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625410,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13877,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625411,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13878,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625412,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13879,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625413,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13880,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625414,,Percent of maximal contractile response to compound in rat thoracic aorta strips v
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13881,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625415,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12361,,N,13882,1,,,50597,Thoracic aorta,1515.0,,BAO_0000218,CHEMBL625416,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12712,,N,13883,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625417,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13884,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL625418,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13885,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625419,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13886,1,,,50597,,,,BAO_0000218,CHEMBL625420,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13887,1,,,50597,,,,BAO_0000218,CHEMBL626996,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13888,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL626997,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13889,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626998,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,13890,1,,,50597,,,,BAO_0000218,CHEMBL626999,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion"
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13891,1,,,50594,,,,BAO_0000218,CHEMBL627000,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13892,1,,,50594,,,,BAO_0000218,CHEMBL627001,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13893,1,,,50594,,,,BAO_0000218,CHEMBL627002,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13894,1,,,50594,,,,BAO_0000218,CHEMBL627003,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13895,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627004,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13896,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627005,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13897,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL874594,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13898,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627006,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13899,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627007,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13900,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627884,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13901,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627885,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13902,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627886,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13903,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627887,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13904,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627888,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13905,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL628057,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8050,,N,13906,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627405,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13907,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627406,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13908,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627407,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13909,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627408,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13910,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627409,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13911,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL875486,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13912,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627410,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13913,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627411,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13914,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627412,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13915,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627413,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13916,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627414,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13917,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627415,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13918,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627416,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13919,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627417,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13920,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627418,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13921,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627419,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13922,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627320,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,13923,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627321,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13924,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627322,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13925,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627323,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13926,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627491,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13927,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627492,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13928,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627493,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13929,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627494,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13930,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627495,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13931,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627496,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13932,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627497,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13933,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627498,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13934,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627499,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13935,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627500,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13936,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627501,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13937,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625616,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13938,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625617,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13939,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625618,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13940,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625619,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13941,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625620,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13942,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625621,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13943,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625622,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13944,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625788,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13945,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625789,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13946,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625790,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13947,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625791,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13948,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL622334,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13949,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622335,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13950,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622336,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13951,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622337,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13952,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622338,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13953,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL622339,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13954,1,,,50597,,,In vivo,BAO_0000218,CHEMBL624153,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13955,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628430,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13956,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628431,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13957,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628432,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13958,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628433,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13959,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL628434,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13960,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626789,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13961,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626790,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13962,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626791,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13963,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626792,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,13964,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL626793,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13965,1,,,50597,,,,BAO_0000218,CHEMBL627436,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13966,1,,,50597,,,,BAO_0000218,CHEMBL627437,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13967,1,,,50597,,,,BAO_0000218,CHEMBL627438,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13968,1,,,50597,,,,BAO_0000218,CHEMBL627439,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13969,1,,,50597,,,,BAO_0000218,CHEMBL627440,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13970,1,,,50597,,,,BAO_0000218,CHEMBL627602,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13971,1,,,50597,,,,BAO_0000218,CHEMBL627603,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13972,1,,,50597,,,,BAO_0000218,CHEMBL627604,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13973,1,,,50597,,,,BAO_0000218,CHEMBL627605,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13974,1,,,50597,,,,BAO_0000218,CHEMBL627606,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13975,1,,,50597,,,,BAO_0000218,CHEMBL627607,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13976,1,,,50597,,,,BAO_0000218,CHEMBL627608,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13977,1,,,50597,,,,BAO_0000218,CHEMBL627609,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13978,1,,,50597,,,,BAO_0000218,CHEMBL627610,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13979,1,,,50597,,,,BAO_0000218,CHEMBL627611,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,13980,1,,,50597,,,,BAO_0000218,CHEMBL627612,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg
P,,,,,1,Autocuration,,8362,,U,13981,0,,,22229,,,,BAO_0000100,CHEMBL627613,,Octanol:water partition coefficient is evaluated
P,,,,,1,Autocuration,,8257,,U,13982,0,,,22224,,,,BAO_0000100,CHEMBL627614,,Partition coefficient in 1-octanol/water system
P,,,,,1,Autocuration,,8257,,U,13983,0,,,22224,,,,BAO_0000100,CHEMBL627615,,Partition coefficient in 1-octanol/water system measured using radio active compounds
P,,,,,1,Autocuration,,9468,,U,13984,0,,,22224,,,,BAO_0000100,CHEMBL627616,,Partition coefficient in octanol/water system was determined
P,,,,,1,Autocuration,,9468,,U,13985,0,,,22224,,,,BAO_0000100,CHEMBL627617,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.
A,,,,,1,Autocuration,,10568,,U,13986,0,,,22224,,,,BAO_0000019,CHEMBL627618,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade
A,,,,,1,Autocuration,,10568,,U,13987,0,,,22224,,,,BAO_0000019,CHEMBL627619,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade"
A,,,,,1,Autocuration,,15359,,U,13988,0,,,22224,,,,BAO_0000019,CHEMBL627620,,Pseudo-first-order rate constant of the compound
A,,,,,1,Autocuration,,15359,,U,13989,0,,,22224,,,,BAO_0000019,CHEMBL627621,,Pseudo-first-order rate constant with 1-min time point
A,,,,,1,Autocuration,,15359,,U,13990,0,,,22224,,,,BAO_0000019,CHEMBL627622,,Pseudo-first-order rate constant without 1-min time point
A,,,,,1,Autocuration,,10431,,U,13991,0,,,22224,,,,BAO_0000019,CHEMBL627623,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA
A,,,,,1,Autocuration,,10431,,U,13992,0,,,22224,,,,BAO_0000019,CHEMBL627624,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA
A,,,,,1,Autocuration,,10431,,U,13993,0,,,22224,,,,BAO_0000019,CHEMBL627625,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA
A,,,,,1,Autocuration,,15704,,U,13994,0,,,22224,,,,BAO_0000019,CHEMBL628523,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade
A,,,,,1,Autocuration,,15287,,U,13995,0,,,22224,,,,BAO_0000019,CHEMBL628524,,The alkaline hydrolysis second order rate constant(K OH) of the compound
A,,,,,1,Autocuration,,7516,,U,13996,0,,,22224,,,,BAO_0000019,CHEMBL628525,,The efflux rate constant of the compound
A,,,,,1,Autocuration,,12973,,U,13997,0,,,22224,,,,BAO_0000019,CHEMBL625732,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine
A,,,,,1,Autocuration,,12973,,U,13998,0,,,22224,,,,BAO_0000019,CHEMBL625733,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine
F,,,,,1,Autocuration,,12973,,U,13999,0,,,22224,,,,BAO_0000019,CHEMBL625734,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine
A,,,,,1,Autocuration,,12973,,U,14000,0,,,22224,,,,BAO_0000019,CHEMBL625913,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined
A,,,,,1,Autocuration,,8696,,U,14001,0,,,22224,,,,BAO_0000019,CHEMBL625914,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala
A,,,,,1,Autocuration,,15052,,U,14002,0,,,22224,,,,BAO_0000019,CHEMBL625915,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C
A,,,,,1,Autocuration,,15052,,U,14003,0,,,22224,,,,BAO_0000019,CHEMBL625916,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C
A,,,,,1,Autocuration,,10503,,U,14004,0,,,22224,,,,BAO_0000019,CHEMBL625917,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H)
A,,,,,1,Autocuration,,8354,,U,14005,0,,,22224,,,,BAO_0000019,CHEMBL625918,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14006,0,,,22224,,,,BAO_0000019,CHEMBL625919,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14007,0,,,22224,,,,BAO_0000019,CHEMBL625920,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14008,0,,,22224,,,,BAO_0000019,CHEMBL874453,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14009,0,,,22224,,,,BAO_0000019,CHEMBL625921,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,10503,,U,14010,0,,,22224,,,,BAO_0000019,CHEMBL625922,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay
A,,,,,1,Autocuration,,8354,,U,14011,0,,,22224,,,,BAO_0000019,CHEMBL625923,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14012,0,,,22224,,,,BAO_0000019,CHEMBL625924,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14013,0,,,22224,,,,BAO_0000019,CHEMBL625925,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,14014,0,,,22224,,,,BAO_0000019,CHEMBL625926,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14015,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627704,,Biodistribution in rat lung at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14016,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627705,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14017,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627706,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14018,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627707,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14019,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627708,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14020,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628361,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14021,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628362,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14022,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628363,,Biodistribution in rat striatum at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14023,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628364,,Biodistribution in rat striatum at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14024,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628365,,Biodistribution in rat striatum at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14025,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL874454,,Biodistribution in rat striatum at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14026,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628531,,Biodistribution in rat striatum at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14027,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628532,,Biodistribution in rat striatum at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14028,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628533,,Biodistribution in rat striatum at 3 hr after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14029,1,,,50597,Striatum,2435.0,In vivo,BAO_0000218,CHEMBL628534,,Biodistribution in rat striatum at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14030,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL628535,,Biodistribution in rat thyroid at 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14031,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL628536,,Biodistribution in rat thyroid at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14032,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL628537,,Biodistribution in rat thyroid at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14033,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL628538,,Biodistribution in rat thyroid at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14034,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL628539,,Biodistribution in rat thyroid at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14035,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL630297,,Biodistribution in rat thyroid at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14036,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL630298,,Biodistribution in rat thyroid at 60 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14037,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL630299,,Biodistribution in rest of brain of rat 120 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14038,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL628094,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14039,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL628095,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14040,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL874648,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14041,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL628096,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14042,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL628097,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13100,,N,14043,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL628098,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.
A,,,,,1,Autocuration,,13331,,U,14044,0,,,22224,,,,BAO_0000019,CHEMBL628099,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)"
A,,,,,1,Autocuration,,13331,,U,14045,0,,,22224,,,,BAO_0000019,CHEMBL628100,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)"
A,,,,,1,Autocuration,,13331,,U,14046,0,,,22224,,,,BAO_0000019,CHEMBL628101,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!)
A,,,,,1,Autocuration,,13331,,U,14047,0,,,22224,,,,BAO_0000019,CHEMBL628102,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)"
A,,,,,1,Autocuration,,13331,,U,14048,0,,,22224,,,,BAO_0000019,CHEMBL628103,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)"
A,,,,,1,Autocuration,,13331,,U,14049,0,,,22224,,,,BAO_0000019,CHEMBL628104,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)"
A,,,,,1,Autocuration,,13331,,U,14050,0,,,22224,,,,BAO_0000019,CHEMBL628105,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)"
A,,,,,1,Autocuration,,13331,,U,14051,0,,,22224,,,,BAO_0000019,CHEMBL628106,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14052,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628107,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally
F,,,,,1,Autocuration,,10086,,U,14053,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL628108,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14054,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628109,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally
F,,,,,1,Autocuration,,10086,,U,14055,0,,,22224,Urine,1088.0,,BAO_0000218,CHEMBL625299,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14056,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625300,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14057,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625301,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14058,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625302,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10086,,N,14059,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL874649,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13248,,N,14060,1,,,50597,,,,BAO_0000218,CHEMBL625303,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13248,,N,14061,1,,,50597,,,,BAO_0000218,CHEMBL625463,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested
A,Homo sapiens,9606.0,,,1,Intermediate,,14527,,N,14062,1,,,50587,Liver,2107.0,,BAO_0000218,CHEMBL625464,,In vitro metabolism in human liver microsomes
A,Homo sapiens,9606.0,,,1,Intermediate,,3008,,N,14063,1,,,50587,,,,BAO_0000218,CHEMBL625465,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14064,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625466,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14065,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625467,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14066,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625468,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14067,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625469,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14068,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625470,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14069,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL632418,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14070,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627250,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14071,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627251,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14072,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627252,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14073,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627253,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14074,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627254,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14075,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875471,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14076,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627255,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14077,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627256,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14078,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627257,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14079,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627258,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14080,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627259,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14081,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627260,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14082,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623256,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14083,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL874413,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14084,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623257,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14085,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623258,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14086,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623259,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14087,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623260,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14088,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623261,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14089,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623262,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14090,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623263,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14091,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623264,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14092,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623265,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14093,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623266,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14094,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623267,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14095,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623268,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14096,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623269,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14097,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623270,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14098,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623271,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14099,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623272,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14100,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623273,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14101,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623274,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14102,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL874414,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14103,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623275,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14104,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629150,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14105,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623276,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14106,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623277,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14107,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623112,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14108,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623113,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14109,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623800,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14110,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623801,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14111,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL623802,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14112,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL623803,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14113,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL623970,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14114,1,,,50597,Uterus,995.0,In vivo,BAO_0000218,CHEMBL623971,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14115,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623972,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14116,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623973,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14117,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623974,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14118,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL623975,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14119,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623976,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14120,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623977,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14121,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623978,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14122,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL623979,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14123,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623980,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14124,1,,,50597,,,In vivo,BAO_0000218,CHEMBL623981,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14125,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626278,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14045,,N,14126,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626279,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals)
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14127,1,,,50594,,,In vivo,BAO_0000218,CHEMBL626280,,Biodistribution in mice bladder plus excreted urine was determined
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14128,1,,,50594,,,,BAO_0000218,CHEMBL626281,,"Percentage biodistribution in mouse blood, 10 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14129,1,,,50594,,,,BAO_0000218,CHEMBL626282,,"Percentage biodistribution in mouse blood, 30 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14130,1,,,50594,,,,BAO_0000218,CHEMBL626283,,"Percentage biodistribution in mouse blood, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14131,1,,,50594,,,,BAO_0000218,CHEMBL626284,,"Percentage biodistribution in mouse blood, 60 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14132,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL626285,,"Percentage biodistribution in mouse brain, 10 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14133,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL626286,,"Percentage biodistribution in mouse brain, 30 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14134,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL626287,,"Percentage biodistribution in mouse brain, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14135,1,,,50594,Brain,955.0,,BAO_0000218,CHEMBL626288,,"Percentage biodistribution in mouse brain, 60 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14136,1,,,50594,,,,BAO_0000218,CHEMBL626289,,"Percentage biodistribution in mouse heart, 10 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14137,1,,,50594,,,,BAO_0000218,CHEMBL626290,,"Percentage biodistribution in mouse heart, 30 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14138,1,,,50594,,,,BAO_0000218,CHEMBL626291,,"Percentage biodistribution in mouse heart, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14139,1,,,50594,,,,BAO_0000218,CHEMBL839888,,"Percentage biodistribution in mouse heart, 60 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14140,1,,,50594,Intestine,160.0,,BAO_0000218,CHEMBL626292,,"Percentage biodistribution in mouse intestine, 10 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14141,1,,,50594,Intestine,160.0,,BAO_0000218,CHEMBL626293,,"Percentage biodistribution in mouse intestine, 30 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14142,1,,,50594,Intestine,160.0,,BAO_0000218,CHEMBL626294,,"Percentage biodistribution in mouse intestine, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14143,1,,,50594,Intestine,160.0,,BAO_0000218,CHEMBL626295,,"Percentage biodistribution in mouse intestine, 60 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14144,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL627659,,"Percentage biodistribution in mouse liver, 10 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14145,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL627660,,"Percentage biodistribution in mouse liver, 30 minutes of post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14146,1,,,50594,Liver,2107.0,,BAO_0000218,CHEMBL627661,,"Percentage biodistribution in mouse liver, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14147,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627662,,Biodistribution in mice liver at 60 minutes of post injection
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14148,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627663,,Biodistribution in mice lungs at 10 min of post injection
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14149,1,,,50594,,,,BAO_0000218,CHEMBL627664,,"Percentage biodistribution in mouse lung, 30 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14150,1,,,50594,,,,BAO_0000218,CHEMBL627665,,"Percentage biodistribution in mousee lung, 5 minutes post injection"
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14151,1,,,50594,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627666,,Biodistribution in mice lungs at 60 min of post injection
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14152,1,,,50594,Spleen,2106.0,,BAO_0000218,CHEMBL627667,,Percentage biodistribution in mouse spleen
A,Mus musculus,10090.0,,,1,Intermediate,,14045,,N,14153,1,,,50594,Stomach,945.0,,BAO_0000218,CHEMBL627668,,Percentage biodistribution in mouse stomach
A,Mus musculus,10090.0,,,1,Intermediate,,11745,,N,14154,1,,,50594,Urine,1088.0,,BAO_0000218,CHEMBL627669,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.
A,,,,,1,Autocuration,,13257,,U,14155,0,,,22224,Urinary bladder,1255.0,In vivo,BAO_0000218,CHEMBL627670,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder
A,,,,,1,Autocuration,,13257,,U,14156,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL627671,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood
A,,,,,1,Autocuration,,13257,,U,14157,0,,,22224,Bone element,1474.0,In vivo,BAO_0000218,CHEMBL627672,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone
A,,,,,1,Autocuration,,13257,,U,14158,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627673,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat
A,,,,,1,Autocuration,,13257,,U,14159,0,,,22224,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627674,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney
A,,,,,1,Autocuration,,13257,,U,14160,0,,,22224,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627675,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver
A,,,,,1,Autocuration,,13257,,U,14161,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627676,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung
A,,,,,1,Autocuration,,13257,,U,14162,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627677,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle
A,,,,,1,Autocuration,,8354,,U,14163,0,,,22224,,,,BAO_0000019,CHEMBL627678,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7095,,N,14164,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL627679,,Affinity for protein binding expressed as association constant in fresh rat serum
A,,,,,1,Autocuration,,12185,,U,14165,0,,,22224,,,,BAO_0000019,CHEMBL627680,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation
A,,,,,1,Autocuration,,12185,,U,14166,0,,,22224,,,,BAO_0000019,CHEMBL627681,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive
A,,,,,1,Autocuration,,12185,,U,14167,0,,,22224,,,,BAO_0000019,CHEMBL627682,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation
A,,,,,1,Autocuration,,12185,,U,14168,0,,,22224,,,,BAO_0000019,CHEMBL627683,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive
A,,,,,1,Autocuration,,12686,,U,14169,0,,,22224,,,,BAO_0000019,CHEMBL627684,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4
A,,,,,1,Autocuration,,12686,,U,14170,0,,,22224,,,,BAO_0000019,CHEMBL874441,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants"
A,,,,,1,Autocuration,,12686,,U,14171,0,,,22224,,,,BAO_0000019,CHEMBL627685,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h
A,,,,,1,Autocuration,,12686,,U,14172,0,,,22224,,,,BAO_0000019,CHEMBL627686,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants"
A,,,,,1,Autocuration,,8057,,U,14173,0,,,22224,,,,BAO_0000019,CHEMBL627687,,Apparent rate constant Koff for inactivation of dTMP synthase.
A,,,,,1,Autocuration,,15778,,U,14174,0,,,22224,,,,BAO_0000019,CHEMBL627688,,The irreversible inhibitor activity by second order rate equation.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12375,,N,14175,1,,,50597,,,,BAO_0000218,CHEMBL628038,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12375,,N,14176,1,,,50597,,,,BAO_0000218,CHEMBL628039,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12375,,N,14177,1,,,50597,,,,BAO_0000218,CHEMBL628040,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration
A,,,,,1,Autocuration,,13588,,U,14178,0,,,22224,,,,BAO_0000019,CHEMBL628041,,Dissociation rate calculated from the first-order equation using t1/2 value
A,,,,,1,Autocuration,,15039,,U,14179,0,,,22224,,,,BAO_0000019,CHEMBL630226,,The compound was tested for Binding constant against DNA
A,,,,,1,Autocuration,,9500,,U,14180,0,,,22224,,,,BAO_0000019,CHEMBL628042,,First order rate constant for cyclization of the compound
A,,,,,1,Autocuration,,10014,,U,14181,0,,,22224,,,,BAO_0000019,CHEMBL625232,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius
A,,,,,1,Autocuration,,10014,,U,14182,0,,,22224,,,,BAO_0000019,CHEMBL625233,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius
A,,,,,1,Autocuration,,568,,U,14183,0,,,22224,,,,BAO_0000019,CHEMBL625979,,Hydrolysis rate constant was determined
A,,,,,1,Autocuration,,10026,,U,14184,0,,,22224,,,,BAO_0000019,CHEMBL625980,,Observed first order rate constant
A,,,,,1,Autocuration,,10281,,U,14185,0,,,22224,,,,BAO_0000019,CHEMBL625981,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4
A,,,,,1,Autocuration,,10281,,U,14186,0,,,22224,,,,BAO_0000019,CHEMBL625982,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4
A,,,,,1,Autocuration,,9680,,U,14187,0,,,22224,,,,BAO_0000019,CHEMBL625983,,Second-order rate constant for attack on PNPA at 25 degree Centigrade
A,,,,,1,Autocuration,,13028,,U,14188,0,,,22224,,,,BAO_0000019,CHEMBL625984,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14189,0,,,22224,,,,BAO_0000019,CHEMBL625985,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14190,0,,,22224,,,,BAO_0000019,CHEMBL625986,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14191,0,,,22224,,,,BAO_0000019,CHEMBL625987,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14192,0,,,22224,,,,BAO_0000019,CHEMBL625988,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14193,0,,,22224,,,,BAO_0000019,CHEMBL625989,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14194,0,,,22224,,,,BAO_0000019,CHEMBL625990,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14195,0,,,22224,,,,BAO_0000019,CHEMBL625991,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14196,0,,,22224,,,,BAO_0000019,CHEMBL625992,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14197,0,,,22224,,,,BAO_0000019,CHEMBL625993,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14198,0,,,22224,,,,BAO_0000019,CHEMBL631973,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14199,0,,,22224,,,,BAO_0000019,CHEMBL632143,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14200,0,,,22224,,,,BAO_0000019,CHEMBL632144,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14201,0,,,22224,,,,BAO_0000019,CHEMBL632145,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14202,0,,,22224,,,,BAO_0000019,CHEMBL632146,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14203,0,,,22224,,,,BAO_0000019,CHEMBL632147,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14204,0,,,22224,,,,BAO_0000019,CHEMBL632148,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14205,0,,,22224,,,,BAO_0000019,CHEMBL632149,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14206,0,,,22224,,,,BAO_0000019,CHEMBL632150,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14207,0,,,22224,,,,BAO_0000019,CHEMBL632151,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,Homo sapiens,9606.0,,,1,Intermediate,,3008,,N,14208,1,,,50587,,,,BAO_0000218,CHEMBL632152,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected
A,Homo sapiens,9606.0,,,1,Intermediate,,4509,,N,14209,1,,,50587,,,,BAO_0000218,CHEMBL632153,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM
A,Homo sapiens,9606.0,,,1,Intermediate,,4509,,N,14210,1,,,50587,,,,BAO_0000218,CHEMBL632154,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14211,1,,,50602,,,,BAO_0000218,CHEMBL632155,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14212,1,,,50602,,,,BAO_0000218,CHEMBL632156,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14213,1,,,50602,,,,BAO_0000218,CHEMBL632157,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14214,1,,,50602,,,,BAO_0000218,CHEMBL632158,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14215,1,,,50602,,,,BAO_0000218,CHEMBL632159,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14216,1,,,50602,,,,BAO_0000218,CHEMBL626305,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14217,1,,,50602,,,,BAO_0000218,CHEMBL626306,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14218,1,,,50602,,,,BAO_0000218,CHEMBL626307,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14219,1,,,50602,,,,BAO_0000218,CHEMBL626308,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14220,1,,,50602,,,,BAO_0000218,CHEMBL626479,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10
A,Human herpesvirus 1,10298.0,,,1,Intermediate,,8613,,N,14221,1,,,50602,,,,BAO_0000218,CHEMBL626480,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10
P,,,,,1,Autocuration,,6021,,U,14222,0,,,22229,,,,BAO_0000100,CHEMBL626481,,Calculated partition coefficient (clogP) (MlogP)
A,,,,,1,Autocuration,,9348,,U,14223,0,,,22224,,,,BAO_0000019,CHEMBL626482,,Equipotent potent ratio relative to carbachol (nicotinic activity)
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,14224,1,,,50588,,,,BAO_0000218,CHEMBL626483,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available"
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,14225,1,,,50588,,,,BAO_0000218,CHEMBL626484,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available"
P,,,,,1,Autocuration,,15592,,U,14226,0,,,22229,,,,BAO_0000100,CHEMBL626485,,Solubility at pH 7.4 in micro g/mL;NA denotes available
P,,,,,1,Autocuration,,15592,,U,14227,0,,,22229,,,,BAO_0000100,CHEMBL626486,,Solubility at pH 7.4 in micro g/mL;NA denotes not available
P,,,,,1,Autocuration,,15592,,U,14228,0,,,22229,,,,BAO_0000100,CHEMBL626487,,Solubility at pH 7.4 in ug/mL;NA denotes not available
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,15592,,N,14229,1,,,50588,Plasma,1969.0,In vivo,BAO_0000218,CHEMBL626488,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7095,,N,14230,1,,,50597,Serum,1977.0,,BAO_0000218,CHEMBL626489,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.
A,,,,,1,Autocuration,,16618,,U,14231,0,,,22224,,,,BAO_0000019,CHEMBL626490,,Area under the MAP curve measured over 5 min; ND means Not determined
P,,,,,1,Autocuration,,16835,,U,14232,0,,,22224,,,,BAO_0000100,CHEMBL626491,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.
P,,,,,1,Autocuration,,15284,,U,14233,0,,,22229,,,,BAO_0000100,CHEMBL626492,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined
A,,,,,1,Autocuration,,15750,,U,14234,0,,,22224,,,,BAO_0000019,CHEMBL626493,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16618,,N,14235,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626494,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested
A,,,,,1,Autocuration,,16618,,U,14236,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626495,,Half life after oral tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15812,,N,14237,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626496,,Half life was determined in plasma of rat; NT indicates not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,16618,,N,14238,1,,,50597,,,In vivo,BAO_0000218,CHEMBL626497,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested
A,,,,,1,Autocuration,,16618,,U,14239,0,,,22224,,,In vivo,BAO_0000218,CHEMBL626498,,Oral bioavailability after oral tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13098,,N,14240,1,,,50597,,,,BAO_0000218,CHEMBL626499,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13098,,N,14241,1,,,50597,,,,BAO_0000218,CHEMBL626500,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15812,,N,14242,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626501,,half life was determined in plasma of rat; NT indicates not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15812,,N,14243,1,,,50597,Plasma,1969.0,,BAO_0000218,CHEMBL626502,,half life was determined in plasma of rat; NT means not tested
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14244,1,,,50597,,,,BAO_0000218,CHEMBL626503,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14245,1,,,50597,,,,BAO_0000218,CHEMBL626504,,Mean sodium excretion in rats (Control/Drug treatment value); inactive
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14246,1,,,50597,,,,BAO_0000218,CHEMBL626505,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14247,1,,,50597,,,,BAO_0000218,CHEMBL626506,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14248,1,,,50597,,,,BAO_0000218,CHEMBL626507,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14249,1,,,50597,,,,BAO_0000218,CHEMBL626508,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14250,1,,,50597,,,,BAO_0000218,CHEMBL626509,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14251,1,,,50597,,,,BAO_0000218,CHEMBL875480,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14252,1,,,50597,,,,BAO_0000218,CHEMBL626510,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14253,1,,,50597,,,,BAO_0000218,CHEMBL626511,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14254,1,,,50597,,,,BAO_0000218,CHEMBL626512,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14255,1,,,50597,,,,BAO_0000218,CHEMBL628208,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14256,1,,,50597,,,,BAO_0000218,CHEMBL628209,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14257,1,,,50597,,,,BAO_0000218,CHEMBL628210,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14258,1,,,50597,,,,BAO_0000218,CHEMBL628211,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14259,1,,,50597,,,,BAO_0000218,CHEMBL628212,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14260,1,,,50597,,,,BAO_0000218,CHEMBL628213,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14261,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628214,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14262,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628215,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14263,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628216,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14264,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626595,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14265,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626596,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14266,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626597,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14267,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626598,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14268,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622242,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14269,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622243,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14270,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622244,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14271,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622245,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14272,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622246,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14273,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622247,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14274,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622248,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14275,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL877483,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14276,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL622249,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14277,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622250,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14278,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622251,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14279,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622252,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14280,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622253,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14281,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622254,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14282,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622255,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14283,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622256,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14284,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622257,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14285,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622258,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14286,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622259,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14287,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622927,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14288,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622928,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14289,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL622929,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14290,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL623182,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14291,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL623183,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14292,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623184,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14293,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623185,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14294,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL877484,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14295,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL627274,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14296,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623186,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14297,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623187,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14298,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL623188,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14299,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628055,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14300,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628056,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14301,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628200,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14302,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628201,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14303,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628202,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14304,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628203,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14305,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628204,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14306,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628205,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14307,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628206,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug
A,,,,,1,Autocuration,,13257,,U,14308,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL628207,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)
A,,,,,1,Autocuration,,13257,,U,14309,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627220,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood
A,,,,,1,Autocuration,,13257,,U,14310,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627221,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle
A,,,,,1,Autocuration,,13257,,U,14311,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627222,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)
A,,,,,1,Autocuration,,13257,,U,14312,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627223,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood
A,,,,,1,Autocuration,,13257,,U,14313,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL632062,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle
A,,,,,1,Autocuration,,13257,,U,14314,0,,,22224,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL632063,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen
A,,,,,1,Autocuration,,13257,,U,14315,0,,,22224,Urinary bladder,1255.0,In vivo,BAO_0000218,CHEMBL632064,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder
A,,,,,1,Autocuration,,13257,,U,14316,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL632065,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood
A,,,,,1,Autocuration,,13257,,U,14317,0,,,22224,Bone element,1474.0,In vivo,BAO_0000218,CHEMBL632066,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone
A,,,,,1,Autocuration,,13257,,U,14318,0,,,22224,,,In vivo,BAO_0000218,CHEMBL632067,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat
A,,,,,1,Autocuration,,13257,,U,14319,0,,,22224,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629188,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney
A,,,,,1,Autocuration,,13257,,U,14320,0,,,22224,Liver,2107.0,In vivo,BAO_0000218,CHEMBL629189,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver
A,,,,,1,Autocuration,,13257,,U,14321,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL629190,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung
A,,,,,1,Autocuration,,13257,,U,14322,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629191,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle
A,,,,,1,Autocuration,,13257,,U,14323,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629192,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)
A,,,,,1,Autocuration,,13257,,U,14324,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629193,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle
A,,,,,1,Autocuration,,13257,,U,14325,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629194,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)
A,,,,,1,Autocuration,,13257,,U,14326,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629195,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood
A,,,,,1,Autocuration,,13257,,U,14327,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629373,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle
A,,,,,1,Autocuration,,13257,,U,14328,0,,,22224,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL629374,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen
A,,,,,1,Autocuration,,13257,,U,14329,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629375,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood
A,,,,,1,Autocuration,,13257,,U,14330,0,,,22224,Urinary bladder,1255.0,In vivo,BAO_0000218,CHEMBL629376,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder
A,,,,,1,Autocuration,,13257,,U,14331,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL629377,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood
A,,,,,1,Autocuration,,13257,,U,14332,0,,,22224,Bone element,1474.0,In vivo,BAO_0000218,CHEMBL629378,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone
A,,,,,1,Autocuration,,13257,,U,14333,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629379,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat
A,,,,,1,Autocuration,,13257,,U,14334,0,,,22224,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629151,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney
A,,,,,1,Autocuration,,13257,,U,14335,0,,,22224,Liver,2107.0,In vivo,BAO_0000218,CHEMBL629152,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver
A,,,,,1,Autocuration,,13257,,U,14336,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL629153,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung
A,,,,,1,Autocuration,,13257,,U,14337,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629154,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle
A,,,,,1,Autocuration,,13257,,U,14338,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629155,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)
A,,,,,1,Autocuration,,13257,,U,14339,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629156,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood
A,,,,,1,Autocuration,,13257,,U,14340,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629157,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle
A,,,,,1,Autocuration,,13257,,U,14341,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL629158,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)
A,,,,,1,Autocuration,,13257,,U,14342,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629159,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood
A,,,,,1,Autocuration,,13257,,U,14343,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629160,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle
A,,,,,1,Autocuration,,13257,,U,14344,0,,,22224,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL629161,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen
A,,,,,1,Autocuration,,13257,,U,14345,0,,,22224,Urinary bladder,1255.0,In vivo,BAO_0000218,CHEMBL629162,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder
A,,,,,1,Autocuration,,13257,,U,14346,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL629163,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood
A,,,,,1,Autocuration,,13257,,U,14347,0,,,22224,Bone element,1474.0,In vivo,BAO_0000218,CHEMBL629164,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone
A,,,,,1,Autocuration,,13257,,U,14348,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629165,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat
A,,,,,1,Autocuration,,13257,,U,14349,0,,,22224,Liver,2107.0,In vivo,BAO_0000218,CHEMBL629166,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver
A,,,,,1,Autocuration,,13257,,U,14350,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL629167,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung
A,,,,,1,Autocuration,,13257,,U,14351,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL629168,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle
A,,,,,1,Autocuration,,2193,,U,14352,0,,,22224,,,,BAO_0000019,CHEMBL629169,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM
A,,,,,1,Autocuration,,2193,,U,14353,0,,,22224,,,,BAO_0000019,CHEMBL629170,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration
A,,,,,1,Autocuration,,2193,,U,14354,0,,,22224,,,,BAO_0000019,CHEMBL631153,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM
A,,,,,1,Autocuration,,2193,,U,14355,0,,,22224,,,,BAO_0000019,CHEMBL875121,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed
A,,,,,1,Autocuration,,2193,,U,14356,0,,,22224,,,,BAO_0000019,CHEMBL631154,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM
A,,,,,1,Autocuration,,2193,,U,14357,0,,,22224,,,,BAO_0000019,CHEMBL631155,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed
A,,,,,1,Autocuration,,568,,U,14358,0,,,22224,,,,BAO_0000019,CHEMBL631156,,Hydrolysis rate constant was determined
A,,,,,1,Autocuration,,9680,,U,14359,0,,,22224,,,,BAO_0000019,CHEMBL631157,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade"
A,,,,,1,Autocuration,,9680,,U,14360,0,,,22224,,,,BAO_0000019,CHEMBL631158,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade"
A,,,,,1,Autocuration,,9680,,U,14361,0,,,22224,,,,BAO_0000019,CHEMBL631159,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade"
A,,,,,1,Autocuration,,10026,,U,14362,0,,,22224,,,,BAO_0000019,CHEMBL631160,,Observed second order rate constant
A,,,,,1,Autocuration,,10281,,U,14363,0,,,22224,,,,BAO_0000019,CHEMBL631161,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4
A,,,,,1,Autocuration,,10014,,U,14364,0,,,22224,,,,BAO_0000019,CHEMBL631162,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius
A,,,,,1,Autocuration,,10014,,U,14365,0,,,22224,,,,BAO_0000019,CHEMBL630313,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius
A,,,,,1,Autocuration,,9680,,U,14366,0,,,22224,,,,BAO_0000019,CHEMBL630314,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade"
A,,,,,1,Autocuration,,9680,,U,14367,0,,,22224,,,,BAO_0000019,CHEMBL630315,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade"
A,,,,,1,Autocuration,,13028,,U,14368,0,,,22224,,,,BAO_0000019,CHEMBL630316,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14369,0,,,22224,,,,BAO_0000019,CHEMBL630986,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14370,0,,,22224,,,,BAO_0000019,CHEMBL630987,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14371,0,,,22224,,,,BAO_0000019,CHEMBL630988,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14372,0,,,22224,,,,BAO_0000019,CHEMBL630989,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14373,0,,,22224,,,,BAO_0000019,CHEMBL630990,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14374,0,,,22224,,,,BAO_0000019,CHEMBL630991,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14375,0,,,22224,,,,BAO_0000019,CHEMBL630992,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14376,0,,,22224,,,,BAO_0000019,CHEMBL630993,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,,,,,1,Autocuration,,13028,,U,14377,0,,,22224,,,,BAO_0000019,CHEMBL630994,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10014,,N,14378,1,,,50597,,,,BAO_0000218,CHEMBL630995,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex
A,,,,,1,Autocuration,,9962,,U,14379,0,,,22224,,,,BAO_0000019,CHEMBL629252,,Association constant for compound at 31 degree C was determined
A,,,,,1,Autocuration,,12029,,U,14380,0,,,22224,,,,BAO_0000019,CHEMBL629253,,Calculated antagonist equilibrium dissociation constant of the compound
A,,,,,1,Autocuration,,12029,,U,14381,0,,,22224,,,,BAO_0000019,CHEMBL629944,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed
A,Cavia porcellus,10141.0,,,1,Intermediate,,10583,,N,14382,1,,,50512,Trachea,3126.0,,BAO_0000218,CHEMBL629945,,Dissociation constants vs LTE4 on guinea pig trachea
A,,,,,1,Autocuration,,568,,U,14383,0,,,22224,,,,BAO_0000019,CHEMBL629946,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8"
A,,,,,1,Autocuration,,568,,U,14384,0,,,22224,,,,BAO_0000019,CHEMBL629947,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5"
A,,,,,1,Autocuration,,568,,U,14385,0,,,22224,,,,BAO_0000019,CHEMBL629948,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5"
A,,,,,1,Autocuration,,568,,U,14386,0,,,22224,,,,BAO_0000019,CHEMBL856024,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5"
A,,,,,1,Autocuration,,7493,,U,14387,0,,,22224,,,,BAO_0000019,CHEMBL629949,,Affinity constant KD value was derived from TMP
A,,,,,1,Autocuration,,8371,,U,14388,0,,,22224,,,,BAO_0000019,CHEMBL629950,,Apparent dissociation (binding) rate constant was evaluated
P,,,,,1,Autocuration,,13114,,U,14389,0,,,22224,,,,BAO_0000100,CHEMBL630127,,Dissociation constant (KD) of the compound
P,,,,,1,Autocuration,,15515,,U,14390,0,,,22224,,,,BAO_0000100,CHEMBL630128,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy
P,,,,,1,Autocuration,,522,,U,14391,0,,,22224,,,,BAO_0000100,CHEMBL630129,,Dissociation constant from ESR titration experiments
,,,,,1,Autocuration,,13888,,U,14392,0,,,22224,,,,BAO_0000019,CHEMBL630130,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant)
P,,,,,1,Autocuration,,2616,,U,14393,0,,,22224,,,,BAO_0000100,CHEMBL875234,,Dissociation constant was evaluated.
P,,,,,1,Autocuration,,3798,,U,14394,0,,,22224,,,,BAO_0000100,CHEMBL630131,,Dissociation constant was reported
A,Rattus norvegicus,10116.0,,,1,Intermediate,,8731,,N,14395,1,,,50597,,,,BAO_0000218,CHEMBL630132,,Dissociation constant was determined in rat pituitary cells.
A,,,,,1,Autocuration,,11892,,U,14396,0,,,22224,,,,BAO_0000019,CHEMBL630133,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound
A,,,,,1,Autocuration,,11892,,U,14397,0,,,22224,,,,BAO_0000019,CHEMBL630134,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound
A,,,,,1,Autocuration,,2582,,U,14398,0,,,22224,,,,BAO_0000019,CHEMBL630135,,Equilibrium dissociation constant of the compound
A,,,,,1,Autocuration,,11892,,U,14399,0,,,22224,,,,BAO_0000019,CHEMBL630136,,Equilibrium dissociation constant was determined
A,,,,,1,Autocuration,,13396,,U,14400,0,,,22224,,,,BAO_0000019,CHEMBL630137,,Kinetic constant KD was evaluated
A,,,,,1,Autocuration,,603,,U,14401,0,,,22224,,,,BAO_0000019,CHEMBL630138,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3
A,,,,,1,Autocuration,,15673,,U,14402,0,,,22224,,,,BAO_0000019,CHEMBL630139,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4
A,,,,,1,Autocuration,,10368,,U,14403,0,,,22224,,,,BAO_0000019,CHEMBL630140,,Rate constant for hydrolysis in aqueous acetone.
A,,,,,1,Autocuration,,14228,,U,14404,0,,,22224,,,,BAO_0000019,CHEMBL875235,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14405,1,,,50597,,,,BAO_0000218,CHEMBL876439,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14406,1,,,50597,,,,BAO_0000218,CHEMBL630605,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14407,1,,,50597,,,,BAO_0000218,CHEMBL630606,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14408,1,,,50597,,,,BAO_0000218,CHEMBL630607,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14409,1,,,50597,,,,BAO_0000218,CHEMBL630608,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14410,1,,,50597,,,,BAO_0000218,CHEMBL630609,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14411,1,,,50597,,,,BAO_0000218,CHEMBL630610,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14412,1,,,50597,,,,BAO_0000218,CHEMBL630611,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14413,1,,,50597,,,,BAO_0000218,CHEMBL629552,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14414,1,,,50597,,,,BAO_0000218,CHEMBL629733,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14415,1,,,50597,,,,BAO_0000218,CHEMBL629734,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14416,1,,,50597,,,,BAO_0000218,CHEMBL629735,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14417,1,,,50597,,,,BAO_0000218,CHEMBL629736,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14418,1,,,50597,,,,BAO_0000218,CHEMBL629737,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14419,1,,,50597,,,,BAO_0000218,CHEMBL629738,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14420,1,,,50597,,,,BAO_0000218,CHEMBL629739,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14421,1,,,50597,,,,BAO_0000218,CHEMBL629740,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14422,1,,,50597,,,,BAO_0000218,CHEMBL629741,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14423,1,,,50597,,,,BAO_0000218,CHEMBL629742,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14424,1,,,50597,,,,BAO_0000218,CHEMBL629743,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14425,1,,,50597,,,,BAO_0000218,CHEMBL629744,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14426,1,,,50597,,,,BAO_0000218,CHEMBL629745,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14427,1,,,50597,,,,BAO_0000218,CHEMBL629746,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14428,1,,,50597,,,,BAO_0000218,CHEMBL629747,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14429,1,,,50597,,,,BAO_0000218,CHEMBL629748,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14430,1,,,50597,,,,BAO_0000218,CHEMBL629749,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14431,1,,,50597,,,,BAO_0000218,CHEMBL629750,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14432,1,,,50597,,,,BAO_0000218,CHEMBL629751,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14433,1,,,50597,,,,BAO_0000218,CHEMBL629752,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14434,1,,,50597,,,,BAO_0000218,CHEMBL629753,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14435,1,,,50597,,,,BAO_0000218,CHEMBL629754,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14436,1,,,50597,,,,BAO_0000218,CHEMBL629755,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14437,1,,,50597,,,,BAO_0000218,CHEMBL629756,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14438,1,,,50597,,,,BAO_0000218,CHEMBL629757,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14439,1,,,50597,,,,BAO_0000218,CHEMBL629758,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14440,1,,,50597,,,,BAO_0000218,CHEMBL629759,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14441,1,,,50597,,,,BAO_0000218,CHEMBL629760,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11510,,N,14442,1,,,50597,,,,BAO_0000218,CHEMBL876443,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8310,,N,14443,1,,,50588,,,,BAO_0000218,CHEMBL629761,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8310,,N,14444,1,,,50588,,,,BAO_0000218,CHEMBL629762,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14445,1,,,50594,,,,BAO_0000218,CHEMBL629763,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14446,1,,,50594,,,,BAO_0000218,CHEMBL629764,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14447,1,,,50594,,,,BAO_0000218,CHEMBL629765,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14448,1,,,50594,,,,BAO_0000218,CHEMBL629766,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14449,1,,,50594,,,,BAO_0000218,CHEMBL629767,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8310,,N,14450,1,,,50588,,,,BAO_0000218,CHEMBL629768,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14451,1,,,50594,,,,BAO_0000218,CHEMBL629769,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8310,,N,14452,1,,,50588,,,,BAO_0000218,CHEMBL629770,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,8310,,N,14453,1,,,50588,,,,BAO_0000218,CHEMBL629771,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14454,1,,,50594,,,,BAO_0000218,CHEMBL629772,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14455,1,,,50594,,,,BAO_0000218,CHEMBL629773,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14456,1,,,50594,,,,BAO_0000218,CHEMBL625455,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14457,1,,,50594,,,,BAO_0000218,CHEMBL625456,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally
A,Mus musculus,10090.0,,,1,Intermediate,,8310,,N,14458,1,,,50594,,,,BAO_0000218,CHEMBL625457,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14459,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625458,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14460,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625459,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14461,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875483,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14462,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL634779,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14463,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625460,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14464,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626117,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14465,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626118,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14466,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628342,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14467,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628343,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14468,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628344,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14469,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628345,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14470,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628346,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14471,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628347,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14472,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628348,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14473,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628349,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14474,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875611,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14475,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628350,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14476,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628351,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14477,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628352,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14478,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628353,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14479,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628354,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14480,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626667,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14481,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626668,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14482,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626669,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14483,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626670,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14484,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626671,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14485,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626672,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14486,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626673,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14487,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626674,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14488,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626675,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14489,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626676,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14490,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626677,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14491,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626678,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14492,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626679,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14493,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875612,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14494,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626680,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14495,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626681,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14496,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626682,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14497,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626683,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14498,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626684,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14499,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626685,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14500,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626686,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14501,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626687,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14502,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624978,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14503,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624979,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14504,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624980,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14505,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL624981,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14506,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL624982,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug
A,,,,,1,Autocuration,,13257,,U,14507,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627564,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)
A,,,,,1,Autocuration,,13257,,U,14508,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627565,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)
A,,,,,1,Autocuration,,13257,,U,14509,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627566,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood
A,,,,,1,Autocuration,,13257,,U,14510,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627567,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle
A,,,,,1,Autocuration,,13257,,U,14511,0,,,22224,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627568,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen
A,,,,,1,Autocuration,,13257,,U,14512,0,,,22224,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627569,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney
A,,,,,1,Autocuration,,13257,,U,14513,0,,,22224,Urinary bladder,1255.0,In vivo,BAO_0000218,CHEMBL627570,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder
A,,,,,1,Autocuration,,13257,,U,14514,0,,,22224,Blood,178.0,In vivo,BAO_0000218,CHEMBL627571,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood
A,,,,,1,Autocuration,,13257,,U,14515,0,,,22224,Bone element,1474.0,In vivo,BAO_0000218,CHEMBL627572,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone
A,,,,,1,Autocuration,,13257,,U,14516,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627573,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat
A,,,,,1,Autocuration,,13257,,U,14517,0,,,22224,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL627574,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney
A,,,,,1,Autocuration,,13257,,U,14518,0,,,22224,Liver,2107.0,In vivo,BAO_0000218,CHEMBL627575,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver
A,,,,,1,Autocuration,,13257,,U,14519,0,,,22224,Lung,2048.0,In vivo,BAO_0000218,CHEMBL627576,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung
A,,,,,1,Autocuration,,13257,,U,14520,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627577,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle
A,,,,,1,Autocuration,,13257,,U,14521,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627578,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)
A,,,,,1,Autocuration,,13257,,U,14522,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627579,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood
A,,,,,1,Autocuration,,13257,,U,14523,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627580,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle
A,,,,,1,Autocuration,,13257,,U,14524,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627581,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)
A,,,,,1,Autocuration,,13257,,U,14525,0,,,22224,,,In vivo,BAO_0000218,CHEMBL627582,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood
A,,,,,1,Autocuration,,13257,,U,14526,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627583,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle
A,,,,,1,Autocuration,,13257,,U,14527,0,,,22224,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL627584,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen
A,,,,,1,Autocuration,,13257,,U,14528,0,,,22224,Prostate gland,2367.0,In vivo,BAO_0000218,CHEMBL627585,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood
A,,,,,1,Autocuration,,13257,,U,14529,0,,,22224,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL627586,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14530,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627587,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14531,1,,,50597,,,In vivo,BAO_0000218,CHEMBL627588,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14532,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628250,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14533,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628251,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14534,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628252,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14535,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628253,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14536,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL628254,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14537,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL877493,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14538,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628255,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14539,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628256,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14540,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL628257,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14541,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL628258,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14542,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628259,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14543,1,,,50597,,,In vivo,BAO_0000218,CHEMBL628429,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14544,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL626862,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14545,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL626863,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14546,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625886,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14547,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625887,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14548,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625888,,Biodistribution of the [11C]-radiolabeled compound in rat cortex
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14549,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625889,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14550,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625890,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14551,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL625891,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14552,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL625892,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14553,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL625893,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14554,1,,,50597,Cerebellum,2037.0,In vivo,BAO_0000218,CHEMBL625894,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14555,1,,,50597,,,In vivo,BAO_0000218,CHEMBL625895,,Biodistribution of the [18F]-radiolabeled compound in rat cortex
A,,,,,1,Autocuration,,12404,,U,14556,0,,,22224,,,,BAO_0000019,CHEMBL625896,,Reaction rate parameter value for phosphate with transfer with respect to ATP
A,,,,,1,Autocuration,,568,,U,14557,0,,,22224,,,,BAO_0000019,CHEMBL625897,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)"
A,,,,,1,Autocuration,,568,,U,14558,0,,,22224,,,,BAO_0000019,CHEMBL625898,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)"
A,,,,,1,Autocuration,,568,,U,14559,0,,,22224,,,,BAO_0000019,CHEMBL625899,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)"
A,,,,,1,Autocuration,,12404,,U,14560,0,,,22224,,,,BAO_0000019,CHEMBL626124,,Reaction rate parameter value for phosphate with transfer with respect to ATP
A,Escherichia coli,562.0,,,1,Intermediate,,7624,,N,14561,1,,,50212,,,,BAO_0000218,CHEMBL628500,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7624,,N,14562,1,,,50597,,,,BAO_0000218,CHEMBL857856,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7624,,N,14563,1,,,50597,,,,BAO_0000218,CHEMBL628501,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity"
A,,,,,1,Autocuration,,4643,,U,14564,0,,,22224,,,,BAO_0000019,CHEMBL628502,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system"
A,,,,,1,Autocuration,,11532,,U,14565,0,,,22224,,,,BAO_0000019,CHEMBL628503,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.
A,,,,,1,Autocuration,,11018,,U,14566,0,,,22224,,,,BAO_0000019,CHEMBL628504,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade
A,,,,,1,Autocuration,,2276,,U,14567,0,,,22224,,,,BAO_0000019,CHEMBL628505,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined"
A,,,,,1,Autocuration,,2276,,U,14568,0,,,22224,,,,BAO_0000019,CHEMBL874452,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM"
A,,,,,1,Autocuration,,2276,,U,14569,0,,,22224,,,,BAO_0000019,CHEMBL628506,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined"
A,,,,,1,Autocuration,,2276,,U,14570,0,,,22224,,,,BAO_0000019,CHEMBL628507,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined"
A,,,,,1,Autocuration,,2276,,U,14571,0,,,22224,,,,BAO_0000019,CHEMBL628508,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM"
A,,,,,1,Autocuration,,8949,,U,14572,0,,,22224,,,,BAO_0000019,CHEMBL628509,,Michaelis constant (KM) was evaluated
A,,,,,1,Autocuration,,12404,,U,14573,0,,,22224,,,,BAO_0000019,CHEMBL628510,,Reaction rate parameter value for phosphate with transfer with respect to ATP
B,,,,,1,Autocuration,,7625,,U,14574,0,,,22224,,,,BAO_0000019,CHEMBL628511,,Substrate concentration for half maximal velocity was reported for rat hexokinase I
B,,,,,1,Autocuration,,7625,,U,14575,0,,,22224,,,,BAO_0000019,CHEMBL628512,,Substrate concentration for half maximal velocity was reported for rat hexokinase II
B,,,,,1,Autocuration,,7625,,U,14576,0,,,22224,,,,BAO_0000019,CHEMBL628513,,Substrate concentration for half maximal velocity was reported for rat hexokinase III
B,,,,,1,Autocuration,,7625,,U,14577,0,,,22224,,,,BAO_0000019,CHEMBL628514,,Substrate concentration for half maximal velocity was reported for yeast hexokinase
A,,,,,1,Autocuration,,12908,,U,14578,0,,,22224,,,,BAO_0000019,CHEMBL628515,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.
A,,,,,1,Autocuration,,10368,,U,14579,0,,,22224,,,,BAO_0000019,CHEMBL628516,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine
A,,,,,1,Autocuration,,13108,,U,14580,0,,,22224,,,,BAO_0000019,CHEMBL628517,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5)
A,,,,,1,Autocuration,,13108,,U,14581,0,,,22224,,,,BAO_0000019,CHEMBL628518,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5)
A,,,,,1,Autocuration,,15217,,U,14582,0,,,22224,,,,BAO_0000019,CHEMBL628519,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer
A,,,,,1,Autocuration,,15217,,U,14583,0,,,22224,,,,BAO_0000019,CHEMBL628520,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available
A,,,,,1,Autocuration,,10933,,U,14584,0,,,22224,,,,BAO_0000019,CHEMBL628521,,Binding constant was determined
A,,,,,1,Autocuration,,2363,,U,14585,0,,,22224,,,,BAO_0000019,CHEMBL630443,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade
A,,,,,1,Autocuration,,2363,,U,14586,0,,,22224,,,,BAO_0000019,CHEMBL630444,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined
A,,,,,1,Autocuration,,2276,,U,14587,0,,,22224,,,,BAO_0000019,CHEMBL857732,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine
P,,,,,1,Autocuration,,14915,,U,14588,0,,,22224,,,,BAO_0000100,CHEMBL630445,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.
A,,,,,1,Autocuration,,8847,,U,14589,0,,,22224,,,,BAO_0000019,CHEMBL630446,,Catalytic rate constant of the compound
B,,,,,1,Autocuration,,15357,,U,14590,0,,,22224,,,,BAO_0000019,CHEMBL630447,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition
A,,,,,1,Autocuration,,2869,,U,14591,0,,,22224,,,,BAO_0000019,CHEMBL630448,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His)
A,,,,,1,Autocuration,,3484,,U,14592,0,,,22224,,,,BAO_0000019,CHEMBL630449,,Catalytic rate constant against phospholipase A2 was determined
A,,,,,1,Autocuration,,1373,,U,14593,0,,,22224,,,,BAO_0000019,CHEMBL630450,,"Compound was evaluated for catalytic constant, Kcat"
A,,,,,1,Autocuration,,8142,,U,14594,0,,,22224,,,,BAO_0000019,CHEMBL630451,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined
A,,,,,1,Autocuration,,14131,,U,14595,0,,,22224,,,,BAO_0000019,CHEMBL630452,,Kcat calculated from 0.693/T1/2
A,,,,,1,Autocuration,,17269,,U,14596,0,,,22224,,,,BAO_0000019,CHEMBL630453,,Kcat was determined
A,,,,,1,Autocuration,,3485,,U,14597,0,,,22224,,,,BAO_0000019,CHEMBL630454,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis
A,,,,,1,Autocuration,,3485,,U,14598,0,,,22224,,,,BAO_0000019,CHEMBL630455,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis
A,,,,,1,Autocuration,,3485,,U,14599,0,,,22224,,,,BAO_0000019,CHEMBL631487,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis
A,,,,,1,Autocuration,,5962,,U,14600,0,,,22224,,,,BAO_0000019,CHEMBL631488,,Kcat value was determined
A,,,,,1,Autocuration,,3133,,U,14601,0,,,22224,,,,BAO_0000019,CHEMBL876440,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated
A,,,,,1,Autocuration,,3133,,U,14602,0,,,22224,,,,BAO_0000019,CHEMBL631489,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated
A,,,,,1,Autocuration,,2276,,U,14603,0,,,22224,,,,BAO_0000019,CHEMBL857742,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined"
A,,,,,1,Autocuration,,2276,,U,14604,0,,,22224,,,,BAO_0000019,CHEMBL631490,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat"
A,,,,,1,Autocuration,,2276,,U,14605,0,,,22224,,,,BAO_0000019,CHEMBL631491,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined"
A,,,,,1,Autocuration,,2276,,U,14606,0,,,22224,,,,BAO_0000019,CHEMBL631492,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined"
A,,,,,1,Autocuration,,2276,,U,14607,0,,,22224,,,,BAO_0000019,CHEMBL631493,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat"
A,,,,,1,Autocuration,,4892,,U,14608,0,,,22224,,,,BAO_0000019,CHEMBL631494,,Kinetic parameter for rate of conversion to PABA was determined
A,,,,,1,Autocuration,,3133,,U,14609,0,,,22224,,,,BAO_0000019,CHEMBL631495,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14610,1,,,50597,Feces,1988.0,,BAO_0000218,CHEMBL631496,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14611,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631497,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14612,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631498,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14613,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629776,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14614,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629777,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14615,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL629778,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14616,1,,,50597,,,,BAO_0000218,CHEMBL630456,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14617,1,,,50597,,,,BAO_0000218,CHEMBL630457,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14618,1,,,50597,,,,BAO_0000218,CHEMBL630458,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14619,1,,,50597,,,,BAO_0000218,CHEMBL630459,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14620,1,,,50597,,,,BAO_0000218,CHEMBL630460,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14621,1,,,50597,,,,BAO_0000218,CHEMBL876550,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14622,1,,,50597,,,,BAO_0000218,CHEMBL630461,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14623,1,,,50597,,,,BAO_0000218,CHEMBL630462,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14624,1,,,50597,,,,BAO_0000218,CHEMBL630463,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14625,1,,,50597,,,,BAO_0000218,CHEMBL630464,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14626,1,,,50597,,,,BAO_0000218,CHEMBL630465,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14627,1,,,50597,,,,BAO_0000218,CHEMBL630466,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14628,1,,,50597,,,,BAO_0000218,CHEMBL630467,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14629,1,,,50597,,,,BAO_0000218,CHEMBL630633,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14630,1,,,50597,,,,BAO_0000218,CHEMBL630634,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14631,1,,,50597,,,,BAO_0000218,CHEMBL630635,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14632,1,,,50597,,,,BAO_0000218,CHEMBL630636,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,11488,,N,14633,1,,,50597,,,,BAO_0000218,CHEMBL630637,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14634,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL630638,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14635,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL630639,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14636,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL630640,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14637,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL876551,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14638,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL630641,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14639,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL630642,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14640,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL630643,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14641,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL630644,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14642,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL630645,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14643,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL625599,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14644,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL625600,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14645,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL625601,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14646,1,,,50592,Feces,1988.0,,BAO_0000218,CHEMBL625602,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14647,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL627470,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14648,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL627471,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14649,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL627472,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14650,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL627473,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h"
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,7132,,N,14651,1,,,50592,Urine,1088.0,,BAO_0000218,CHEMBL627474,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14652,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627475,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14653,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL627476,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14654,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627477,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14655,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627478,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14656,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627479,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14657,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627480,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14658,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627481,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14659,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627482,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14660,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL627483,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14661,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL875636,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14662,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625764,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14663,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625765,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14664,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625766,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14665,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625767,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14666,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625768,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14667,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625769,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14668,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625770,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14669,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625771,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14670,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625772,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug
A,Canis lupus familiaris,9615.0,,,1,Intermediate,,12582,,N,14671,1,,,50588,Urine,1088.0,,BAO_0000218,CHEMBL625773,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14672,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625774,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14673,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625775,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14674,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625776,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14675,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625777,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14676,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625778,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14677,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625779,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14678,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625780,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14679,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL625781,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14680,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875637,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14681,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626473,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14682,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626474,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14683,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626475,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14684,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626476,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14685,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL634397,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14686,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL626477,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14687,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631069,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14688,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631070,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14689,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631071,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14690,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631072,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14691,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631073,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14692,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631074,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14693,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631075,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14694,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631725,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14695,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631726,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14696,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631727,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14697,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631728,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14698,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631729,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14699,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631730,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14700,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631731,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14701,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631910,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14702,1,,,50597,Hippocampus,10000000.0,In vivo,BAO_0000218,CHEMBL631911,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14703,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL631912,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15413,,N,14704,1,,,50597,Hypothalamus,1898.0,In vivo,BAO_0000218,CHEMBL631913,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14705,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631914,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14706,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631915,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14707,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL875778,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14708,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631916,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14709,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631917,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14710,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631918,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14711,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631919,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14712,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631920,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14713,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631921,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14714,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631922,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14715,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL631923,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14716,1,,,50597,,,In vivo,BAO_0000218,CHEMBL631924,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14717,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630234,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14718,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630235,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14719,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630236,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14720,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630237,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14721,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630238,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14722,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630239,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14723,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630303,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14724,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630304,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14725,1,,,50597,,,In vivo,BAO_0000218,CHEMBL630305,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14726,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630306,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14727,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630307,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14728,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630308,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14729,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630309,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14730,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629309,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14731,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629993,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14732,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629994,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14733,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL629995,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14734,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL631993,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14735,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL631994,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14736,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL631995,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14737,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL631996,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14738,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL631997,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14739,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL631998,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14740,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL631999,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14741,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL632000,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14742,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL632001,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14743,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL874424,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14744,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL632002,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14745,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL632003,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,,,,,1,Autocuration,,3133,,U,14746,0,,,22224,,,,BAO_0000019,CHEMBL632004,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated
A,,,,,1,Autocuration,,2742,,U,14747,0,,,22224,,,,BAO_0000019,CHEMBL632005,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme
A,,,,,1,Autocuration,,2742,,U,14748,0,,,22224,,,,BAO_0000019,CHEMBL632006,,Compound was tested for amidase rate in the presence of N62C screen enzyme
A,,,,,1,Autocuration,,2742,,U,14749,0,,,22224,,,,BAO_0000019,CHEMBL632007,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme
A,,,,,1,Autocuration,,2742,,U,14750,0,,,22224,,,,BAO_0000019,CHEMBL632008,,Compound was tested for amidase rate in the presence of S166C screen enzyme
A,,,,,1,Autocuration,,2742,,U,14751,0,,,22224,,,,BAO_0000019,CHEMBL632009,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme
A,,,,,1,Autocuration,,2742,,U,14752,0,,,22224,,,,BAO_0000019,CHEMBL632010,,Compound was tested for esterase rate in the presence of N62C screen enzyme
A,,,,,1,Autocuration,,2742,,U,14753,0,,,22224,,,,BAO_0000019,CHEMBL857750,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme
A,,,,,1,Autocuration,,2742,,U,14754,0,,,22224,,,,BAO_0000019,CHEMBL632011,,Compound was tested for esterase rate in the presence of S166C screen enzyme
A,,,,,1,Autocuration,,2276,,U,14755,0,,,22224,,,,BAO_0000019,CHEMBL632012,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM"
A,,,,,1,Autocuration,,2276,,U,14756,0,,,22224,,,,BAO_0000019,CHEMBL632013,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM"
A,,,,,1,Autocuration,,2276,,U,14757,0,,,22224,,,,BAO_0000019,CHEMBL632014,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM"
A,,,,,1,Autocuration,,2276,,U,14758,0,,,22224,,,,BAO_0000019,CHEMBL629622,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM"
A,,,,,1,Autocuration,,2276,,U,14759,0,,,22224,,,,BAO_0000019,CHEMBL629623,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM"
A,,,,,1,Autocuration,,2276,,U,14760,0,,,22224,,,,BAO_0000019,CHEMBL629624,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM"
A,,,,,1,Autocuration,,17269,,U,14761,0,,,22224,,,,BAO_0000019,CHEMBL629625,,Ratio of Kcat to that of Km was determined
A,,,,,1,Autocuration,,2276,,U,14762,0,,,22224,,,,BAO_0000019,CHEMBL629626,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat"
A,,,,,1,Autocuration,,2276,,U,14763,0,,,22224,,,,BAO_0000019,CHEMBL629627,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat"
A,,,,,1,Autocuration,,15917,,U,14764,0,,,22224,,,,BAO_0000019,CHEMBL629628,,"Compound was evaluated for constant, Kd"
A,,,,,1,Autocuration,,10933,,U,14765,0,,,22224,,,,BAO_0000019,CHEMBL629629,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay
A,,,,,1,Autocuration,,10933,,U,14766,0,,,22224,,,,BAO_0000019,CHEMBL629630,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay
A,,,,,1,Autocuration,,14293,,U,14767,0,,,22224,,,,BAO_0000019,CHEMBL856030,,Dissociation Constant of compound determined
B,,,,,1,Autocuration,,6698,,U,14768,0,,,22224,,,,BAO_0000019,CHEMBL629631,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined
B,,,,,1,Autocuration,,6698,,U,14769,0,,,22224,,,,BAO_0000019,CHEMBL629632,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data
P,,,,,1,Autocuration,,4318,,U,14770,0,,,22224,,,,BAO_0000100,CHEMBL629633,,Dissociation constant of compound with Fructose was determined
P,,,,,1,Autocuration,,4318,,U,14771,0,,,22224,,,,BAO_0000100,CHEMBL629634,,Dissociation constant of compound with Fructose was determined; Not determined
P,,,,,1,Autocuration,,4318,,U,14772,0,,,22224,,,,BAO_0000100,CHEMBL629635,,Dissociation constant of compound with Lactulose was determined
P,,,,,1,Autocuration,,4318,,U,14773,0,,,22224,,,,BAO_0000100,CHEMBL629636,,Dissociation constant of compound with Lactulose was determined; Not determined
P,,,,,1,Autocuration,,14959,,U,14774,0,,,22224,,,,BAO_0000100,CHEMBL629637,,Dissociation constant of the Compound
P,,,,,1,Autocuration,,5913,,U,14775,0,,,22224,,,,BAO_0000100,CHEMBL629638,,Dissociation constant by non-linear regression analysis
P,,,,,1,Autocuration,,14218,,U,14776,0,,,22224,,,,BAO_0000100,CHEMBL629639,,Dissociation constant was determined
P,,,,,1,Autocuration,,10689,,U,14777,0,,,22224,,,,BAO_0000100,CHEMBL629640,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM
P,,,,,1,Autocuration,,13925,,U,14778,0,,,22224,,,,BAO_0000100,CHEMBL629641,,Dissociation constant was determined
P,,,,,1,Autocuration,,16359,,U,14779,0,,,22224,,,,BAO_0000100,CHEMBL631344,,Dissociation constant was determined
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10944,,N,14780,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL631345,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle
A,,,,,1,Autocuration,,11080,,U,14781,0,,,22224,,,,BAO_0000019,CHEMBL631346,,The dissociation constant determined by fluorescence displacement assay
A,,,,,1,Autocuration,,17805,,U,14782,0,,,22224,,,,BAO_0000019,CHEMBL631524,,kd value surface plasmon resonance (SPR) method
A,Rattus norvegicus,10116.0,,,1,Intermediate,,10944,,N,14783,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL631525,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle
F,,,,,1,Autocuration,,16645,,U,14784,0,,,22224,,,,BAO_0000019,CHEMBL631526,,First dissociation constant of the binding of compound to V30M TTR
F,,,,,1,Autocuration,,16645,,U,14785,0,,,22224,,,,BAO_0000019,CHEMBL631527,,Second dissociation constant of the binding of compound to V30M TTR
A,,,,,1,Autocuration,,7793,,U,14786,0,,,22224,,,,BAO_0000019,CHEMBL631528,,"Compound was evaluated for equilibrium constant, Ke"
A,,,,,1,Autocuration,,12199,,U,14787,0,,,22224,Hypothalamus,1898.0,,BAO_0000019,CHEMBL631529,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus
A,,,,,1,Autocuration,,12199,,U,14788,0,,,22224,Hypothalamus,1898.0,,BAO_0000019,CHEMBL631530,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive
A,,,,,1,Autocuration,,9680,,U,14789,0,,,22224,,,,BAO_0000019,CHEMBL631531,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade
A,,,,,1,Autocuration,,9680,,U,14790,0,,,22224,,,,BAO_0000019,CHEMBL631532,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade
A,,,,,1,Autocuration,,9680,,U,14791,0,,,22224,,,,BAO_0000019,CHEMBL631533,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14792,1,,,50594,,,,BAO_0000218,CHEMBL876552,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14793,1,,,50594,,,,BAO_0000218,CHEMBL631534,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14794,1,,,50594,,,,BAO_0000218,CHEMBL631535,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14795,1,,,50594,,,,BAO_0000218,CHEMBL631536,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14796,1,,,50594,,,,BAO_0000218,CHEMBL631537,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14797,1,,,50594,,,,BAO_0000218,CHEMBL631538,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14798,1,,,50594,,,,BAO_0000218,CHEMBL631539,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte
A,Mus musculus,10090.0,,,1,Intermediate,,13758,,N,14799,1,,,50594,,,,BAO_0000218,CHEMBL631540,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,14800,1,,,50597,,,,BAO_0000218,CHEMBL625637,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14393,,N,14801,1,,,50597,,,,BAO_0000218,CHEMBL625638,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,15078,,N,14802,1,,,50597,,,,BAO_0000218,CHEMBL625639,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose"
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14803,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625640,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14804,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625641,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14805,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625642,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14806,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625643,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14807,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625644,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14808,1,,,50597,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL625645,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14809,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625646,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14810,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625647,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14811,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625648,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14812,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL625649,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14813,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625650,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14814,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL625651,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14815,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL625652,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14816,1,,,50597,Zone of skin,14.0,In vivo,BAO_0000218,CHEMBL625653,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14817,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625654,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14818,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL625655,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14819,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625656,,Biodistribution of Compound in rat blood after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14820,1,,,50597,Blood,178.0,In vivo,BAO_0000218,CHEMBL625657,,Biodistribution of Compound in rat blood after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14821,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625658,,Biodistribution of Compound in rat brain after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14822,1,,,50597,Brain,955.0,In vivo,BAO_0000218,CHEMBL625659,,Biodistribution of Compound in rat brain after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14823,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625660,,Biodistribution of Compound in rat heart after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14824,1,,,50597,Heart,948.0,In vivo,BAO_0000218,CHEMBL625661,,Biodistribution of Compound in rat heart after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14825,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625662,,Biodistribution of Compound in rat liver after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14826,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL625663,,Biodistribution of Compound in rat liver after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14827,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL875621,,Biodistribution of Compound in rat lung after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14828,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL628382,,Biodistribution of Compound in rat lung after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14829,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL628383,,Biodistribution of Compound in rat muscle after 15 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,9712,,N,14830,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL628384,,Biodistribution of Compound in rat muscle after 2 minutes of administration
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14831,1,,,50597,,,,BAO_0000218,CHEMBL628385,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14832,1,,,50597,,,,BAO_0000218,CHEMBL875753,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,13925,,N,14833,1,,,50597,,,,BAO_0000218,CHEMBL628386,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14834,1,,,50597,,,,BAO_0000218,CHEMBL628387,,Organ distribution in rat blood 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14835,1,,,50597,,,,BAO_0000218,CHEMBL628388,,Organ distribution in rat blood 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14836,1,,,50597,,,,BAO_0000218,CHEMBL628389,,Organ distribution in rat blood 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14837,1,,,50597,,,,BAO_0000218,CHEMBL632756,,Organ distribution in rat blood 30 min after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14838,1,,,50597,,,,BAO_0000218,CHEMBL628390,,Organ distribution in rat brain 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14839,1,,,50597,,,,BAO_0000218,CHEMBL631811,,Organ distribution in rat brain 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14840,1,,,50597,,,,BAO_0000218,CHEMBL631812,,Organ distribution in rat brain 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14841,1,,,50597,,,,BAO_0000218,CHEMBL631813,,Organ distribution in rat heart 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14842,1,,,50597,,,,BAO_0000218,CHEMBL631814,,Organ distribution in rat heart 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14843,1,,,50597,,,,BAO_0000218,CHEMBL631815,,Organ distribution in rat heart 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14844,1,,,50597,,,,BAO_0000218,CHEMBL631816,,Organ distribution in rat kidney 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14845,1,,,50597,,,,BAO_0000218,CHEMBL875758,,Organ distribution in rat kidney 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14846,1,,,50597,,,,BAO_0000218,CHEMBL631817,,Organ distribution in rat kidney 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14847,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631818,,Organ distribution in rat liver 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14848,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631819,,Organ distribution in rat liver 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14849,1,,,50597,Liver,2107.0,,BAO_0000218,CHEMBL631820,,Organ distribution in rat liver 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14850,1,,,50597,,,,BAO_0000218,CHEMBL631821,,Organ distribution in rat lung 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14851,1,,,50597,,,,BAO_0000218,CHEMBL631822,,Organ distribution in rat lung 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14852,1,,,50597,,,,BAO_0000218,CHEMBL631823,,Organ distribution in rat lung 30 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14853,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL631824,,Organ distribution in rat muscle 2 minutes after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14854,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL631825,,Organ distribution in rat muscle 2 hr after intravenous injection
A,Rattus norvegicus,10116.0,,,1,Intermediate,,6941,,N,14855,1,,,50597,Muscle tissue,2385.0,,BAO_0000218,CHEMBL631826,,Organ distribution in rat muscle 30 minutes after intravenous injection
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,14856,1,,,50594,,,In vivo,BAO_0000218,CHEMBL631827,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,14857,1,,,50594,,,In vivo,BAO_0000218,CHEMBL631828,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,14858,1,,,50594,,,In vivo,BAO_0000218,CHEMBL631829,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14859,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875759,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14860,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631830,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14861,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631831,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14862,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631832,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14863,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631833,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14864,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631834,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14865,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631835,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14866,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631836,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14867,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631837,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14868,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631838,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14869,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631839,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14870,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631840,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14871,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631841,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14872,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631842,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14873,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631843,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14874,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631844,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14875,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631845,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14876,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631846,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14877,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL875760,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14878,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL632199,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14879,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631847,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14880,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL631848,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14881,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628707,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14882,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628708,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14883,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628709,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14884,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628710,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14885,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628711,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14886,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628712,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14887,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628713,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12582,,N,14888,1,,,50597,Urine,1088.0,,BAO_0000218,CHEMBL628714,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug
A,Rattus norvegicus,10116.0,,,1,Intermediate,,7415,,N,14889,1,,,50597,,,,BAO_0000218,CHEMBL628715,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h"
A,,,,,1,Autocuration,,7313,,U,14890,0,,,22224,,,,BAO_0000019,CHEMBL629179,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM
A,,,,,1,Autocuration,,7313,,U,14891,0,,,22224,,,,BAO_0000019,CHEMBL629180,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM
A,,,,,1,Autocuration,,7313,,U,14892,0,,,22224,,,,BAO_0000019,CHEMBL875108,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM
A,,,,,1,Autocuration,,7570,,U,14893,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629181,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14894,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629182,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14895,0,,,22224,,,,BAO_0000019,CHEMBL629183,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14896,0,,,22224,,,,BAO_0000019,CHEMBL629184,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14897,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629185,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14898,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629186,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14899,0,,,22224,,,,BAO_0000019,CHEMBL629187,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14900,0,,,22224,,,,BAO_0000019,CHEMBL629887,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14901,0,,,22224,,,,BAO_0000019,CHEMBL629888,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14902,0,,,22224,,,,BAO_0000019,CHEMBL629889,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14903,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629890,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14904,0,,,22224,,,,BAO_0000019,CHEMBL629891,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14905,0,,,22224,,,,BAO_0000019,CHEMBL629892,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14906,0,,,22224,Adrenal cortex,1235.0,,BAO_0000019,CHEMBL629893,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14907,0,,,22224,,,,BAO_0000019,CHEMBL629894,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.
A,,,,,1,Autocuration,,7570,,U,14908,0,,,22224,,,,BAO_0000019,CHEMBL629895,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.
A,Canis lupus familiaris,9615.0,,,1,Autocuration,,14122,,U,14909,0,,,22224,,,In vivo,BAO_0000218,CHEMBL875109,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma"
A,Macaca fascicularis,9541.0,,,1,Autocuration,,16449,,U,14910,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629896,,Absolute bioavailability in male cynomolgus monkeys
A,Rattus norvegicus,10116.0,,,1,Autocuration,,16449,,U,14911,0,,,22224,,,In vivo,BAO_0000218,CHEMBL629897,,Absolute bioavailability in maleSprague-Dawley rats
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14912,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL629898,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14913,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630057,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14914,1,,,50597,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630058,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14915,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630059,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14916,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630060,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14917,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630061,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14918,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630062,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14919,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630063,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14920,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630064,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14921,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630065,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14922,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630066,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14923,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630067,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14924,1,,,50597,Lung,2048.0,In vivo,BAO_0000218,CHEMBL630068,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14925,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL631113,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14926,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL631114,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14927,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL631115,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14928,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL631116,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14929,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630528,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14930,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630529,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14931,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630530,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14932,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630531,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14933,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630532,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14934,1,,,50597,Muscle tissue,2385.0,In vivo,BAO_0000218,CHEMBL630533,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14935,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL630534,,Biodistribution in normal mice blood after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14936,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL630535,,Biodistribution in normal mice blood after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14937,1,,,50594,Blood,178.0,In vivo,BAO_0000218,CHEMBL630536,,Biodistribution in normal mice blood after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14938,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL630537,,Biodistribution in normal mice bone after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14939,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL630538,,Biodistribution in normal mice bone after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14940,1,,,50594,Bone,10000001.0,In vivo,BAO_0000218,CHEMBL630539,,Biodistribution in normal mice bone after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14941,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL630540,,Biodistribution in normal mice heart after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14942,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL630541,,Biodistribution in normal mice heart after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14943,1,,,50594,Heart,948.0,In vivo,BAO_0000218,CHEMBL630542,,Biodistribution in normal mice heart after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14944,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630543,,Biodistribution in normal mice kidney after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14945,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630544,,Biodistribution in normal mice kidney after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14946,1,,,50594,Kidney,2113.0,In vivo,BAO_0000218,CHEMBL630545,,Biodistribution in normal mice kidney after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14947,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630546,,Biodistribution in normal mice liver after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14948,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630547,,Biodistribution in normal mice liver after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14949,1,,,50594,Liver,2107.0,In vivo,BAO_0000218,CHEMBL630548,,Biodistribution in normal mice liver after 4 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14950,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630549,,Biodistribution in normal mice spleen after 120 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14951,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630550,,Biodistribution in normal mice spleen after 24 hr
A,Mus musculus,10090.0,,,1,Intermediate,,15045,,N,14952,1,,,50594,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL876426,,Biodistribution in normal mice spleen after 4 hr
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14953,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630551,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14954,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630552,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14955,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630553,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14956,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630554,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14957,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630555,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14958,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630556,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14959,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630557,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14960,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630558,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14961,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630559,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14962,1,,,50597,Spleen,2106.0,In vivo,BAO_0000218,CHEMBL630560,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,12017,,N,14963,1,,,50597,Thyroid gland,2046.0,In vivo,BAO_0000218,CHEMBL876427,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol
A,Rattus norvegicus,10116.0,,,1,Intermediate,,14941,,N,14964,1,,,50597,,,,BAO_0000218,CHEMBL630561,,The Kel values in female wistar rats.
A,,,,,1,Autocuration,,4646,,U,14965,0,,,22224,,,,BAO_0000019,CHEMBL630562,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade
A,,,,,1,Autocuration,,8847,,U,14966,0,,,22224,,,,BAO_0000019,CHEMBL630563,,Hydrolysis rate constant of the compound
P,,,,,1,Autocuration,,11778,,U,14967,0,,,22229,,,,BAO_0000100,CHEMBL629673,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer
A,,,,,1,Autocuration,,2363,,U,14968,0,,,22224,,,,BAO_0000019,CHEMBL629674,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade"
A,,,,,1,Autocuration,,2363,,U,14969,0,,,22224,,,,BAO_0000019,CHEMBL629675,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade"
A,,,,,1,Autocuration,,2363,,U,14970,0,,,22224,,,,BAO_0000019,CHEMBL629676,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data"
A,,,,,1,Autocuration,,2363,,U,14971,0,,,22224,,,,BAO_0000019,CHEMBL629677,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined"
A,,,,,1,Autocuration,,8371,,U,14972,0,,,22224,,,,BAO_0000019,CHEMBL629678,,Apparent inactivation rate constant was evaluated
A,,,,,1,Autocuration,,14883,,U,14973,0,,,22224,,,,BAO_0000019,CHEMBL629679,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.
A,,,,,1,Autocuration,,14883,,U,14974,0,,,22224,,,,BAO_0000019,CHEMBL629680,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade
A,,,,,1,Autocuration,,4643,,U,14975,0,,,22224,,,,BAO_0000019,CHEMBL629681,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5
A,,,,,1,Autocuration,,3519,,U,14976,0,,,22224,,,,BAO_0000019,CHEMBL629682,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.
A,,,,,1,Autocuration,,10600,,U,14977,0,,,22224,,,,BAO_0000019,CHEMBL629683,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine
F,,,,,1,Autocuration,,8501,,U,14978,0,,,22224,,,,BAO_0000019,CHEMBL629684,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events
P,,,,,1,Autocuration,,8505,,U,14979,0,,,22224,,,,BAO_0000100,CHEMBL629685,,Dissociation constant was determined
P,,,,,1,Autocuration,,9778,,U,14980,0,,,22224,,,,BAO_0000100,CHEMBL629686,,Dissociation constant was determined
P,,,,,1,Autocuration,,9778,,U,14981,0,,,22224,,,,BAO_0000100,CHEMBL872932,,Dissociation constant at pH 7.4
P,,,,,1,Autocuration,,9778,,U,14982,0,,,22224,,,,BAO_0000100,CHEMBL629687,,Dissociation constant in presence of 1 mM dithiothreitol
A,,,,,1,Autocuration,,13007,,U,14983,0,,,22224,,,,BAO_0000019,CHEMBL872931,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase
A,,,,,1,Autocuration,,13007,,U,14984,0,,,22224,,,,BAO_0000019,CHEMBL628151,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase
A,,,,,1,Autocuration,,13007,,U,14985,0,,,22224,,,,BAO_0000019,CHEMBL628152,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase
A,,,,,1,Autocuration,,13007,,U,14986,0,,,22224,,,,BAO_0000019,CHEMBL628153,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase
A,,,,,1,Autocuration,,11482,,U,14987,0,,,22224,,,,BAO_0000019,CHEMBL628154,,Kinetic constant for aromatization of androstenedione
A,,,,,1,Autocuration,,11482,,U,14988,0,,,22224,,,,BAO_0000019,CHEMBL628155,,Kinetic constant for aromatization of testosterone
A,,,,,1,Autocuration,,2303,,U,14989,0,,,22224,,,,BAO_0000019,CHEMBL628156,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12
A,,,,,1,Autocuration,,11964,,U,14990,0,,,22224,,,,BAO_0000019,CHEMBL628157,,Local inhibition constant was determined
A,Saccharomyces cerevisiae,4932.0,,,1,Intermediate,,3140,,N,14991,1,,,50347,,,,BAO_0000218,CHEMBL857533,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor
P,,,,,1,Autocuration,,10650,,U,14992,0,,,22224,,,,BAO_0000100,CHEMBL628158,,Dissociation constant value of the compound
A,,,,,1,Autocuration,,4667,,U,14993,0,,,22224,Cornea,964.0,,BAO_0000019,CHEMBL628159,,In vitro permeability through cornea without epithelium
A,,,,,1,Autocuration,,4667,,U,14994,0,,,22224,Cornea,964.0,,BAO_0000019,CHEMBL875616,,In vitro permeability through intact cornea
A,Oryctolagus cuniculus,9986.0,,,1,Intermediate,,9199,,N,14995,1,,,50592,Cornea,964.0,,BAO_0000218,CHEMBL628160,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits
A,,,,,1,Autocuration,,11966,,U,14996,0,,,22224,,,,BAO_0000019,CHEMBL628161,,Rate of enzyme inactivation for the compound was determined
A,,,,,1,Autocuration,,4667,,U,14997,0,,,22224,Cornea,964.0,,BAO_0000019,CHEMBL628162,,In vitro permeability through cornea without epithelium
A,,,,,1,Autocuration,,4667,,U,14998,0,,,22224,Cornea,964.0,,BAO_0000019,CHEMBL628163,,In vitro permeability through intact cornea
A,,,,,1,Autocuration,,8354,,U,14999,0,,,22224,,,,BAO_0000019,CHEMBL628164,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15000,0,,,22224,,,,BAO_0000019,CHEMBL628165,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15001,0,,,22224,,,,BAO_0000019,CHEMBL628166,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15002,0,,,22224,,,,BAO_0000019,CHEMBL628167,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15003,0,,,22224,,,,BAO_0000019,CHEMBL628168,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15004,0,,,22224,,,,BAO_0000019,CHEMBL628169,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15005,0,,,22224,,,,BAO_0000019,CHEMBL628170,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15006,0,,,22224,,,,BAO_0000019,CHEMBL628171,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15007,0,,,22224,,,,BAO_0000019,CHEMBL627434,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15008,0,,,22224,,,,BAO_0000019,CHEMBL627435,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15009,0,,,22224,,,,BAO_0000019,CHEMBL628110,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15010,0,,,22224,,,,BAO_0000019,CHEMBL628111,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15011,0,,,22224,,,,BAO_0000019,CHEMBL628112,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15012,0,,,22224,,,,BAO_0000019,CHEMBL628260,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,,,,,1,Autocuration,,8354,,U,15013,0,,,22224,,,,BAO_0000019,CHEMBL628261,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6"
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15014,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628262,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M)
A,Homo sapiens,9606.0,,,1,Intermediate,,14439,,N,15015,1,,,50587,,,In vivo,BAO_0000218,CHEMBL628263,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15016,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628264,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15017,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628265,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15018,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628266,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15019,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628267,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15020,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628268,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15021,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628269,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15022,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628270,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15023,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628271,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L)
A,Mus musculus,10090.0,,,1,Intermediate,,14439,,N,15024,1,,,50594,,,In vivo,BAO_0000218,CHEMBL628272,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M)
